DRUG_ID;Name;ligand_name;ChEMBLID;DrugBankID;PubChemCID;CAS;UNII;InChiKey;SMILES;MolecularWeight;XLogP;TPSA;Complexity;Charge;HBondDonorCount;HBondAceptorCount;RotableBondCount;HeavyAtomCount;Max_Phase;Drug_Status;Approval_Year;Drug_Type;Action;TargetProteinID;entry_name;receptor_class;receptor_family;ligand_type;ICD_Code;ICD_Title;IndicationMaxPhase;IndicationStatus;URI;PubMedID
1;cetirizine;cetirizine;CHEMBL1000;DB00341;2678;83881-51-0;YO7261ME24;ZKLPARSLTMPFCP-UHFFFAOYSA-N;C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3889;17;53;443;0;1;5;8;27;4;Approved;1995;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;31747183, 30000569, 35951890
1;cetirizine;cetirizine;CHEMBL1000;DB00341;2678;83881-51-0;YO7261ME24;ZKLPARSLTMPFCP-UHFFFAOYSA-N;C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3889;17;53;443;0;1;5;8;27;4;Approved;1995;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;8A43.Z;Neuromyelitis optica, unspecified;1;Inactive;744293382/unspecified;31747183, 30000569, 35951890
1;cetirizine;cetirizine;CHEMBL1000;DB00341;2678;83881-51-0;YO7261ME24;ZKLPARSLTMPFCP-UHFFFAOYSA-N;C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3889;17;53;443;0;1;5;8;27;4;Approved;1995;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;31747183, 30000569, 35951890
1;cetirizine;cetirizine;CHEMBL1000;DB00341;2678;83881-51-0;YO7261ME24;ZKLPARSLTMPFCP-UHFFFAOYSA-N;C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3889;17;53;443;0;1;5;8;27;4;Approved;1995;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31747183, 30000569, 35951890
1;cetirizine;cetirizine;CHEMBL1000;DB00341;2678;83881-51-0;YO7261ME24;ZKLPARSLTMPFCP-UHFFFAOYSA-N;C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3889;17;53;443;0;1;5;8;27;4;Approved;1995;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.03;Other allergic rhinitis;3;Inactive;941478759;31747183, 30000569, 35951890
1;cetirizine;cetirizine;CHEMBL1000;DB00341;2678;83881-51-0;YO7261ME24;ZKLPARSLTMPFCP-UHFFFAOYSA-N;C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3889;17;53;443;0;1;5;8;27;4;Approved;1995;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;31747183, 30000569, 35951890
1;cetirizine;cetirizine;CHEMBL1000;DB00341;2678;83881-51-0;YO7261ME24;ZKLPARSLTMPFCP-UHFFFAOYSA-N;C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3889;17;53;443;0;1;5;8;27;4;Approved;1995;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA09.0;Chronic rhinitis;2;Inactive;1346915097;31747183, 30000569, 35951890
1;cetirizine;cetirizine;CHEMBL1000;DB00341;2678;83881-51-0;YO7261ME24;ZKLPARSLTMPFCP-UHFFFAOYSA-N;C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3889;17;53;443;0;1;5;8;27;4;Approved;1995;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;3;Unknown;215767047/unspecified;31747183, 30000569, 35951890
1;cetirizine;cetirizine;CHEMBL1000;DB00341;2678;83881-51-0;YO7261ME24;ZKLPARSLTMPFCP-UHFFFAOYSA-N;C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3889;17;53;443;0;1;5;8;27;4;Approved;1995;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA8Z;Dermatitis or eczema, unspecified;3;Inactive;1887882424/unspecified;31747183, 30000569, 35951890
1;cetirizine;cetirizine;CHEMBL1000;DB00341;2678;83881-51-0;YO7261ME24;ZKLPARSLTMPFCP-UHFFFAOYSA-N;C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3889;17;53;443;0;1;5;8;27;4;Approved;1995;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;31747183, 30000569, 35951890
1;cetirizine;cetirizine;CHEMBL1000;DB00341;2678;83881-51-0;YO7261ME24;ZKLPARSLTMPFCP-UHFFFAOYSA-N;C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3889;17;53;443;0;1;5;8;27;4;Approved;1995;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;3;Unknown;1729106757/unspecified;31747183, 30000569, 35951890
1;cetirizine;cetirizine;CHEMBL1000;DB00341;2678;83881-51-0;YO7261ME24;ZKLPARSLTMPFCP-UHFFFAOYSA-N;C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3889;17;53;443;0;1;5;8;27;4;Approved;1995;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;ED70.Z;Alopecia, unspecified;2;Inactive;1313926062/unspecified;31747183, 30000569, 35951890
1;cetirizine;cetirizine;CHEMBL1000;DB00341;2678;83881-51-0;YO7261ME24;ZKLPARSLTMPFCP-UHFFFAOYSA-N;C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3889;17;53;443;0;1;5;8;27;4;Approved;1995;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;RA01;COVID-19;3;Active;1730556128;31747183, 30000569, 35951890
2;pentazocine;pentazocine;CHEMBL100116;DB00652;441278;359-83-1;RP4A60D26L;VOKSWYLNZZRQPF-GDIGMMSISA-N;CC1C2CC3=C(C1(CCN2CC=C(C)C)C)C=C(C=C3)O;2854;33;235;414;0;1;2;2;21;4;Approved;1964;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Inactive;1456478153/unspecified;30000307, 31643817, 3888578
2;pentazocine;pentazocine;CHEMBL100116;DB00652;441278;359-83-1;RP4A60D26L;VOKSWYLNZZRQPF-GDIGMMSISA-N;CC1C2CC3=C(C1(CCN2CC=C(C)C)C)C=C(C=C3)O;2854;33;235;414;0;1;2;2;21;4;Approved;1964;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000307, 31643817, 3888578
2;pentazocine;pentazocine;CHEMBL100116;DB00652;441278;359-83-1;RP4A60D26L;VOKSWYLNZZRQPF-GDIGMMSISA-N;CC1C2CC3=C(C1(CCN2CC=C(C)C)C)C=C(C=C3)O;2854;33;235;414;0;1;2;2;21;4;Approved;1964;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Inactive;1456478153/unspecified;30000307, 31643817, 3888578
2;pentazocine;pentazocine;CHEMBL100116;DB00652;441278;359-83-1;RP4A60D26L;VOKSWYLNZZRQPF-GDIGMMSISA-N;CC1C2CC3=C(C1(CCN2CC=C(C)C)C)C=C(C=C3)O;2854;33;235;414;0;1;2;2;21;4;Approved;1964;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000307, 31643817, 3888578
3;levosalbutamol;levosalbutamol;CHEMBL1002;DB13139;123600;34391-04-3;EDN2NBH5SS;NDAUXUAQIAJITI-LBPRGKRZSA-N;CC(C)(C)NC[C@@H](C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1999;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;3;Unknown;133207228/unspecified;18031154, 11236808, 33867777
3;levosalbutamol;levosalbutamol;CHEMBL1002;DB13139;123600;34391-04-3;EDN2NBH5SS;NDAUXUAQIAJITI-LBPRGKRZSA-N;CC(C)(C)NC[C@@H](C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1999;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;18031154, 11236808, 33867777
3;levosalbutamol;levosalbutamol;CHEMBL1002;DB13139;123600;34391-04-3;EDN2NBH5SS;NDAUXUAQIAJITI-LBPRGKRZSA-N;CC(C)(C)NC[C@@H](C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1999;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;3;Inactive;850824593/other;18031154, 11236808, 33867777
4;doxylamine;doxylamine;CHEMBL1004;DB00366;3162;469-21-6;95QB77JKPL;HCFDWZZGGLSKEP-UHFFFAOYSA-N;CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C;27037;25;254;276;0;0;3;6;20;4;Approved;1948;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;1H0Z;Infection, unspecified;1;Inactive;1435254666/unspecified;29999680, 31869110, 31644135
4;doxylamine;doxylamine;CHEMBL1004;DB00366;3162;469-21-6;95QB77JKPL;HCFDWZZGGLSKEP-UHFFFAOYSA-N;CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C;27037;25;254;276;0;0;3;6;20;4;Approved;1948;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;1;Inactive;1711769234/unspecified;29999680, 31869110, 31644135
4;doxylamine;doxylamine;CHEMBL1004;DB00366;3162;469-21-6;95QB77JKPL;HCFDWZZGGLSKEP-UHFFFAOYSA-N;CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C;27037;25;254;276;0;0;3;6;20;4;Approved;1948;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;29999680, 31869110, 31644135
5;remifentanil;remifentanil;CHEMBL1005;DB00899;60815;132875-61-7;P10582JYYK;ZTVQQQVZCWLTDF-UHFFFAOYSA-N;CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC;3764;19;762;523;0;0;6;9;27;4;Approved;1996;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;1E91.5;Postherpetic polyneuropathy;3;Unknown;321057933;30000312, 29958225, 29594514
5;remifentanil;remifentanil;CHEMBL1005;DB00899;60815;132875-61-7;P10582JYYK;ZTVQQQVZCWLTDF-UHFFFAOYSA-N;CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC;3764;19;762;523;0;0;6;9;27;4;Approved;1996;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;5B81.01;Obesity in adults;3;Unknown;2062927079;30000312, 29958225, 29594514
5;remifentanil;remifentanil;CHEMBL1005;DB00899;60815;132875-61-7;P10582JYYK;ZTVQQQVZCWLTDF-UHFFFAOYSA-N;CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC;3764;19;762;523;0;0;6;9;27;4;Approved;1996;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;7A41;Obstructive sleep apnoea;1;Inactive;1919233290;30000312, 29958225, 29594514
5;remifentanil;remifentanil;CHEMBL1005;DB00899;60815;132875-61-7;P10582JYYK;ZTVQQQVZCWLTDF-UHFFFAOYSA-N;CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC;3764;19;762;523;0;0;6;9;27;4;Approved;1996;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8B20;Stroke not known if ischaemic or haemorrhagic;3;Inactive;1442995018;30000312, 29958225, 29594514
5;remifentanil;remifentanil;CHEMBL1005;DB00899;60815;132875-61-7;P10582JYYK;ZTVQQQVZCWLTDF-UHFFFAOYSA-N;CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC;3764;19;762;523;0;0;6;9;27;4;Approved;1996;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD11.5;Dyspnoea;2;Inactive;960305085;30000312, 29958225, 29594514
5;remifentanil;remifentanil;CHEMBL1005;DB00899;60815;132875-61-7;P10582JYYK;ZTVQQQVZCWLTDF-UHFFFAOYSA-N;CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC;3764;19;762;523;0;0;6;9;27;4;Approved;1996;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000312, 29958225, 29594514
6;gonadorelin;gonadorelin;CHEMBL1007;DB00644;638793;"33515-09-2;71447-49-9;9034-40-6";9O7312W37G;XLXSAKCOAKORKW-AQJXLSMYSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;11823;-24;475;2390;0;16;15;31;85;4;Approved;1982;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;3;Active;1047754165/unspecified;7006547, 31731249, 24431404
6;gonadorelin;gonadorelin;CHEMBL1007;DB00644;638793;"33515-09-2;71447-49-9;9034-40-6";9O7312W37G;XLXSAKCOAKORKW-AQJXLSMYSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;11823;-24;475;2390;0;16;15;31;85;4;Approved;1982;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.0;Adenocarcinoma of prostate;3;Active;1510677183;7006547, 31731249, 24431404
6;gonadorelin;gonadorelin;CHEMBL1007;DB00644;638793;"33515-09-2;71447-49-9;9034-40-6";9O7312W37G;XLXSAKCOAKORKW-AQJXLSMYSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;11823;-24;475;2390;0;16;15;31;85;4;Approved;1982;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;3;Active;1552457716/unspecified;7006547, 31731249, 24431404
6;gonadorelin;gonadorelin;CHEMBL1007;DB00644;638793;"33515-09-2;71447-49-9;9034-40-6";9O7312W37G;XLXSAKCOAKORKW-AQJXLSMYSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;11823;-24;475;2390;0;16;15;31;85;4;Approved;1982;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;5A61.2;Gonadotropin deficiency;4;Approved;1409526590;7006547, 31731249, 24431404
6;gonadorelin;gonadorelin;CHEMBL1007;DB00644;638793;"33515-09-2;71447-49-9;9034-40-6";9O7312W37G;XLXSAKCOAKORKW-AQJXLSMYSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;11823;-24;475;2390;0;16;15;31;85;4;Approved;1982;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;5A61.Y;Other specified hypofunction or disorders of pituitary gland;3;Inactive;292840069/other;7006547, 31731249, 24431404
6;gonadorelin;gonadorelin;CHEMBL1007;DB00644;638793;"33515-09-2;71447-49-9;9034-40-6";9O7312W37G;XLXSAKCOAKORKW-AQJXLSMYSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;11823;-24;475;2390;0;16;15;31;85;4;Approved;1982;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;FB83.1Z;Osteoporosis, unspecified;3;Inactive;2113001430/unspecified;7006547, 31731249, 24431404
6;gonadorelin;gonadorelin;CHEMBL1007;DB00644;638793;"33515-09-2;71447-49-9;9034-40-6";9O7312W37G;XLXSAKCOAKORKW-AQJXLSMYSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;11823;-24;475;2390;0;16;15;31;85;4;Approved;1982;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GC8Y;Other specified diseases of the genitourinary system;3;Inactive;30659757/other;7006547, 31731249, 24431404
6;gonadorelin;gonadorelin;CHEMBL1007;DB00644;638793;"33515-09-2;71447-49-9;9034-40-6";9O7312W37G;XLXSAKCOAKORKW-AQJXLSMYSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;11823;-24;475;2390;0;16;15;31;85;4;Approved;1982;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;X2;Diagnostis;4;Approved;NA;7006547, 31731249, 24431404
6;gonadorelin;gonadorelin diacetate;CHEMBL1981292;DB00644;36523;"33515-09-2;71447-49-9;9034-40-6";9O7312W37G;XLXSAKCOAKORKW-UHFFFAOYSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;11823;-24;475;2390;0;16;15;31;85;4;Approved;1982;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;3;Active;1047754165/unspecified;7006547, 31731249, 24431404
6;gonadorelin;gonadorelin diacetate;CHEMBL1981292;DB00644;36523;"33515-09-2;71447-49-9;9034-40-6";9O7312W37G;XLXSAKCOAKORKW-UHFFFAOYSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;11823;-24;475;2390;0;16;15;31;85;4;Approved;1982;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.0;Adenocarcinoma of prostate;3;Active;1510677183;7006547, 31731249, 24431404
6;gonadorelin;gonadorelin diacetate;CHEMBL1981292;DB00644;36523;"33515-09-2;71447-49-9;9034-40-6";9O7312W37G;XLXSAKCOAKORKW-UHFFFAOYSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;11823;-24;475;2390;0;16;15;31;85;4;Approved;1982;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;3;Active;1552457716/unspecified;7006547, 31731249, 24431404
6;gonadorelin;gonadorelin diacetate;CHEMBL1981292;DB00644;36523;"33515-09-2;71447-49-9;9034-40-6";9O7312W37G;XLXSAKCOAKORKW-UHFFFAOYSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;11823;-24;475;2390;0;16;15;31;85;4;Approved;1982;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;5A61.2;Gonadotropin deficiency;4;Approved;1409526590;7006547, 31731249, 24431404
6;gonadorelin;gonadorelin diacetate;CHEMBL1981292;DB00644;36523;"33515-09-2;71447-49-9;9034-40-6";9O7312W37G;XLXSAKCOAKORKW-UHFFFAOYSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;11823;-24;475;2390;0;16;15;31;85;4;Approved;1982;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;5A61.Y;Other specified hypofunction or disorders of pituitary gland;3;Inactive;292840069/other;7006547, 31731249, 24431404
6;gonadorelin;gonadorelin diacetate;CHEMBL1981292;DB00644;36523;"33515-09-2;71447-49-9;9034-40-6";9O7312W37G;XLXSAKCOAKORKW-UHFFFAOYSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;11823;-24;475;2390;0;16;15;31;85;4;Approved;1982;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;FB83.1Z;Osteoporosis, unspecified;3;Inactive;2113001430/unspecified;7006547, 31731249, 24431404
6;gonadorelin;gonadorelin diacetate;CHEMBL1981292;DB00644;36523;"33515-09-2;71447-49-9;9034-40-6";9O7312W37G;XLXSAKCOAKORKW-UHFFFAOYSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;11823;-24;475;2390;0;16;15;31;85;4;Approved;1982;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GC8Y;Other specified diseases of the genitourinary system;3;Inactive;30659757/other;7006547, 31731249, 24431404
6;gonadorelin;gonadorelin diacetate;CHEMBL1981292;DB00644;36523;"33515-09-2;71447-49-9;9034-40-6";9O7312W37G;XLXSAKCOAKORKW-UHFFFAOYSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;11823;-24;475;2390;0;16;15;31;85;4;Approved;1982;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;X2;Diagnostis;4;Approved;NA;7006547, 31731249, 24431404
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Active;437815624/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Active;2070699808;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;3;Inactive;1254916765;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;1;Inactive;119340957;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;3;Active;1442995018;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;1;Active;1982355687;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9B70;Inherited retinal dystrophies;2;Unknown;1060480722;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9B71.0Z;Diabetic retinopathy, unspecified;1;Active;1006882070/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9B75.0Z;Age-related macular degeneration, unspecified;2;Inactive;1514301548/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9D46;Impairment of binocular functions;3;Inactive;296599996;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;CA23;Asthma;1;Inactive;1656445230;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;EC23.20;Oculocutaneous albinism;2;Inactive;1189424097;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;LD90.0;Angelman syndrome;3;Inactive;1106558408;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MA80.0;Aphasia;3;Inactive;1167055901;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;ME84.Z;Spinal pain, unspecified;2;Unknown;2051065876/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Active;661232217/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;1;Unknown;277610609/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;ND51.2;Injury of spinal cord, level unspecified;3;Active;2131180445;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Active;437815624/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Active;2070699808;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;3;Inactive;1254916765;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;1;Inactive;119340957;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;3;Active;1442995018;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;1;Active;1982355687;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9B70;Inherited retinal dystrophies;2;Unknown;1060480722;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9B71.0Z;Diabetic retinopathy, unspecified;1;Active;1006882070/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9B75.0Z;Age-related macular degeneration, unspecified;2;Inactive;1514301548/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9D46;Impairment of binocular functions;3;Inactive;296599996;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;CA23;Asthma;1;Inactive;1656445230;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;EC23.20;Oculocutaneous albinism;2;Inactive;1189424097;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;LD90.0;Angelman syndrome;3;Inactive;1106558408;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MA80.0;Aphasia;3;Inactive;1167055901;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;ME84.Z;Spinal pain, unspecified;2;Unknown;2051065876/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Active;661232217/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;1;Unknown;277610609/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;ND51.2;Injury of spinal cord, level unspecified;3;Active;2131180445;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Active;437815624/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Active;2070699808;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;3;Inactive;1254916765;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;1;Inactive;119340957;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;3;Active;1442995018;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;1;Active;1982355687;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9B70;Inherited retinal dystrophies;2;Unknown;1060480722;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9B71.0Z;Diabetic retinopathy, unspecified;1;Active;1006882070/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9B75.0Z;Age-related macular degeneration, unspecified;2;Inactive;1514301548/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9D46;Impairment of binocular functions;3;Inactive;296599996;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;CA23;Asthma;1;Inactive;1656445230;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;EC23.20;Oculocutaneous albinism;2;Inactive;1189424097;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;LD90.0;Angelman syndrome;3;Inactive;1106558408;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MA80.0;Aphasia;3;Inactive;1167055901;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;ME84.Z;Spinal pain, unspecified;2;Unknown;2051065876/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Active;661232217/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;1;Unknown;277610609/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;ND51.2;Injury of spinal cord, level unspecified;3;Active;2131180445;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Active;437815624/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Active;2070699808;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;3;Inactive;1254916765;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;1;Inactive;119340957;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;3;Active;1442995018;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;1;Active;1982355687;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9B70;Inherited retinal dystrophies;2;Unknown;1060480722;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9B71.0Z;Diabetic retinopathy, unspecified;1;Active;1006882070/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9B75.0Z;Age-related macular degeneration, unspecified;2;Inactive;1514301548/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9D46;Impairment of binocular functions;3;Inactive;296599996;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;CA23;Asthma;1;Inactive;1656445230;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;EC23.20;Oculocutaneous albinism;2;Inactive;1189424097;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;LD90.0;Angelman syndrome;3;Inactive;1106558408;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MA80.0;Aphasia;3;Inactive;1167055901;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;ME84.Z;Spinal pain, unspecified;2;Unknown;2051065876/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Active;661232217/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;1;Unknown;277610609/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;ND51.2;Injury of spinal cord, level unspecified;3;Active;2131180445;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Active;437815624/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Active;2070699808;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;3;Inactive;1254916765;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;1;Inactive;119340957;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;3;Active;1442995018;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;1;Active;1982355687;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9B70;Inherited retinal dystrophies;2;Unknown;1060480722;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9B71.0Z;Diabetic retinopathy, unspecified;1;Active;1006882070/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9B75.0Z;Age-related macular degeneration, unspecified;2;Inactive;1514301548/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;9D46;Impairment of binocular functions;3;Inactive;296599996;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;CA23;Asthma;1;Inactive;1656445230;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;EC23.20;Oculocutaneous albinism;2;Inactive;1189424097;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;LD90.0;Angelman syndrome;3;Inactive;1106558408;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MA80.0;Aphasia;3;Inactive;1167055901;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;ME84.Z;Spinal pain, unspecified;2;Unknown;2051065876/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Active;661232217/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;1;Unknown;277610609/unspecified;30000396, 31644043, 29489269
7;levodopa;levodopa;CHEMBL1009;DB01235;6047;59-92-7;46627O600J;WTDRDQBEARUVNC-LURJTMIESA-N;C1=CC(=C(C=C1CC(C(=O)O)N)O)O;19719;-27;104;209;0;4;5;3;14;4;Approved;1970;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;ND51.2;Injury of spinal cord, level unspecified;3;Active;2131180445;30000396, 31644043, 29489269
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;1E51.1;Chronic hepatitis C;2;Unknown;1615937473;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;6A60.Z;Bipolar type I disorder, unspecified;1;Unknown;1456478153/unspecified;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;1;Inactive;2016549355/unspecified;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;8A80.0;Migraine without aura;3;Inactive;2048783472;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;8A80.1Z;Migraine with aura, unspecified;3;Inactive;525744634/unspecified;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;8A80.Z;Migraine, unspecified;2;Active;669367341/unspecified;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;8C0Z;Polyneuropathy, unspecified;2;Inactive;58868923/unspecified;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;9B71.0Z;Diabetic retinopathy, unspecified;3;Unknown;1006882070/unspecified;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BC43.0Z;Dilated cardiomyopathy, unspecified;3;Active;1916294688/unspecified;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BC43.1Z;Hypertrophic cardiomyopathy, unspecified;2;Unknown;1830681485/unspecified;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BC45;Cardiomegaly;3;Unknown;273368763;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BC4Z;Diseases of the myocardium or cardiac chambers, unspecified;3;Unknown;2135151223/unspecified;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BC81.3Z;Atrial fibrillation, unspecified;3;Inactive;171698302/unspecified;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BD10;Congestive heart failure;3;Inactive;2136808878;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BD1Z;Heart failure, unspecified;3;Inactive;1458683894/unspecified;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;DB94.Z;Alcoholic liver disease, unspecified;2;Inactive;469481605/unspecified;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;LA8A.3;Congenital supravalvar aortic stenosis;3;Unknown;1066595728;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;2;Inactive;1282135070/unspecified;30137786, 30000686, 31643728
9;candesartan;candesartan;CHEMBL1016;DB13919;2541;139481-59-7;S8Q36MD2XX;HTQMVQVXFRQIKW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O;4405;41;119;660;0;2;7;7;33;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;RA01;COVID-19;3;Unknown;1730556128;30137786, 30000686, 31643728
10;telmisartan;telmisartan;CHEMBL1017;DB00966;65999;144701-48-4;U5SYW473RQ;RMMXLENWKUUMAY-UHFFFAOYSA-N;CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C;5146;69;729;831;0;1;4;7;39;4;Approved;1998;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;1C62.Z;Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified;2;Inactive;1508081745/unspecified;30000691, 31643373, 26051689
10;telmisartan;telmisartan;CHEMBL1017;DB00966;65999;144701-48-4;U5SYW473RQ;RMMXLENWKUUMAY-UHFFFAOYSA-N;CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C;5146;69;729;831;0;1;4;7;39;4;Approved;1998;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;5C52.Z;Inborn errors of lipid metabolism, unspecified;3;Inactive;182578312/unspecified;30000691, 31643373, 26051689
10;telmisartan;telmisartan;CHEMBL1017;DB00966;65999;144701-48-4;U5SYW473RQ;RMMXLENWKUUMAY-UHFFFAOYSA-N;CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C;5146;69;729;831;0;1;4;7;39;4;Approved;1998;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;7A41;Obstructive sleep apnoea;1;Unknown;1919233290;30000691, 31643373, 26051689
10;telmisartan;telmisartan;CHEMBL1017;DB00966;65999;144701-48-4;U5SYW473RQ;RMMXLENWKUUMAY-UHFFFAOYSA-N;CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C;5146;69;729;831;0;1;4;7;39;4;Approved;1998;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;8A20;Alzheimer disease;2;Active;1611724421;30000691, 31643373, 26051689
10;telmisartan;telmisartan;CHEMBL1017;DB00966;65999;144701-48-4;U5SYW473RQ;RMMXLENWKUUMAY-UHFFFAOYSA-N;CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C;5146;69;729;831;0;1;4;7;39;4;Approved;1998;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;30000691, 31643373, 26051689
10;telmisartan;telmisartan;CHEMBL1017;DB00966;65999;144701-48-4;U5SYW473RQ;RMMXLENWKUUMAY-UHFFFAOYSA-N;CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C;5146;69;729;831;0;1;4;7;39;4;Approved;1998;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;8E43.0Z;Neuropathic pain, unspecified;2;Active;1339785363/unspecified;30000691, 31643373, 26051689
10;telmisartan;telmisartan;CHEMBL1017;DB00966;65999;144701-48-4;U5SYW473RQ;RMMXLENWKUUMAY-UHFFFAOYSA-N;CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C;5146;69;729;831;0;1;4;7;39;4;Approved;1998;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000691, 31643373, 26051689
10;telmisartan;telmisartan;CHEMBL1017;DB00966;65999;144701-48-4;U5SYW473RQ;RMMXLENWKUUMAY-UHFFFAOYSA-N;CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C;5146;69;729;831;0;1;4;7;39;4;Approved;1998;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;30000691, 31643373, 26051689
10;telmisartan;telmisartan;CHEMBL1017;DB00966;65999;144701-48-4;U5SYW473RQ;RMMXLENWKUUMAY-UHFFFAOYSA-N;CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C;5146;69;729;831;0;1;4;7;39;4;Approved;1998;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;GB61.Z;Chronic kidney disease, stage unspecified;3;Inactive;412389819/unspecified;30000691, 31643373, 26051689
10;telmisartan;telmisartan;CHEMBL1017;DB00966;65999;144701-48-4;U5SYW473RQ;RMMXLENWKUUMAY-UHFFFAOYSA-N;CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C;5146;69;729;831;0;1;4;7;39;4;Approved;1998;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;LA8A.22;Bicuspid aortic valve;3;Unknown;1328968452;30000691, 31643373, 26051689
10;telmisartan;telmisartan;CHEMBL1017;DB00966;65999;144701-48-4;U5SYW473RQ;RMMXLENWKUUMAY-UHFFFAOYSA-N;CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C;5146;69;729;831;0;1;4;7;39;4;Approved;1998;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;MF96.Z;Proteinuria, unspecified;3;Inactive;930895737/unspecified;30000691, 31643373, 26051689
10;telmisartan;telmisartan;CHEMBL1017;DB00966;65999;144701-48-4;U5SYW473RQ;RMMXLENWKUUMAY-UHFFFAOYSA-N;CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C;5146;69;729;831;0;1;4;7;39;4;Approved;1998;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;RA01;COVID-19;3;Active;1730556128;30000691, 31643373, 26051689
11;idazoxan;idazoxan;CHEMBL10316;DB12551;54459;"79944-58-4;84720-37-6";NA;HPMRFMKYPGXPEP-UHFFFAOYSA-N;C1CN=C(N1)C2COC3=CC=CC=C3O2;20422;7;428;267;0;1;3;1;15;2;Active;NA;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;2;Active;1683919430/unspecified;2875218, 33668888, 25833022
11;idazoxan;idazoxan;CHEMBL10316;DB12551;54459;"79944-58-4;84720-37-6";NA;HPMRFMKYPGXPEP-UHFFFAOYSA-N;C1CN=C(N1)C2COC3=CC=CC=C3O2;20422;7;428;267;0;1;3;1;15;2;Active;NA;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A20;Alzheimer disease;2;Active;1611724421;2875218, 33668888, 25833022
11;idazoxan;idazoxan;CHEMBL10316;DB12551;54459;"79944-58-4;84720-37-6";NA;HPMRFMKYPGXPEP-UHFFFAOYSA-N;C1CN=C(N1)C2COC3=CC=CC=C3O2;20422;7;428;267;0;1;3;1;15;2;Active;NA;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;2;Active;1683919430/unspecified;2875218, 33668888, 25833022
11;idazoxan;idazoxan;CHEMBL10316;DB12551;54459;"79944-58-4;84720-37-6";NA;HPMRFMKYPGXPEP-UHFFFAOYSA-N;C1CN=C(N1)C2COC3=CC=CC=C3O2;20422;7;428;267;0;1;3;1;15;2;Active;NA;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A20;Alzheimer disease;2;Active;1611724421;2875218, 33668888, 25833022
11;idazoxan;idazoxan;CHEMBL10316;DB12551;54459;"79944-58-4;84720-37-6";NA;HPMRFMKYPGXPEP-UHFFFAOYSA-N;C1CN=C(N1)C2COC3=CC=CC=C3O2;20422;7;428;267;0;1;3;1;15;2;Active;NA;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;2;Active;1683919430/unspecified;2875218, 33668888, 25833022
11;idazoxan;idazoxan;CHEMBL10316;DB12551;54459;"79944-58-4;84720-37-6";NA;HPMRFMKYPGXPEP-UHFFFAOYSA-N;C1CN=C(N1)C2COC3=CC=CC=C3O2;20422;7;428;267;0;1;3;1;15;2;Active;NA;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A20;Alzheimer disease;2;Active;1611724421;2875218, 33668888, 25833022
12;latanoprost;latanoprost;CHEMBL1051;DB00654;5311221;130209-82-4;6Z5B6HVF6O;GGXICVAJURFBLW-CEYXHVGTSA-N;CC(C)OC(=O)CCCC=CCC1C(CC(C1CCC(CCC2=CC=CC=C2)O)O)O;4326;43;87;526;0;3;5;14;31;4;Approved;1996;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C61.01;Ocular hypertension;4;Approved;535283437;31082022, 30000735, 31695162
12;latanoprost;latanoprost;CHEMBL1051;DB00654;5311221;130209-82-4;6Z5B6HVF6O;GGXICVAJURFBLW-CEYXHVGTSA-N;CC(C)OC(=O)CCCC=CCC1C(CC(C1CCC(CCC2=CC=CC=C2)O)O)O;4326;43;87;526;0;3;5;14;31;4;Approved;1996;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;31082022, 30000735, 31695162
12;latanoprost;latanoprost;CHEMBL1051;DB00654;5311221;130209-82-4;6Z5B6HVF6O;GGXICVAJURFBLW-CEYXHVGTSA-N;CC(C)OC(=O)CCCC=CCC1C(CC(C1CCC(CCC2=CC=CC=C2)O)O)O;4326;43;87;526;0;3;5;14;31;4;Approved;1996;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;31082022, 30000735, 31695162
12;latanoprost;latanoprost;CHEMBL1051;DB00654;5311221;130209-82-4;6Z5B6HVF6O;GGXICVAJURFBLW-CEYXHVGTSA-N;CC(C)OC(=O)CCCC=CCC1C(CC(C1CCC(CCC2=CC=CC=C2)O)O)O;4326;43;87;526;0;3;5;14;31;4;Approved;1996;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;AB31.0;Meniere disease;2;Unknown;683932278;31082022, 30000735, 31695162
12;latanoprost;latanoprost;CHEMBL1051;DB00654;5311221;130209-82-4;6Z5B6HVF6O;GGXICVAJURFBLW-CEYXHVGTSA-N;CC(C)OC(=O)CCCC=CCC1C(CC(C1CCC(CCC2=CC=CC=C2)O)O)O;4326;43;87;526;0;3;5;14;31;4;Approved;1996;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;ED63.0;Vitiligo;3;Unknown;1894744640;31082022, 30000735, 31695162
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;5A11;Type 2 diabetes mellitus;3;Inactive;119724091;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;5C52.Z;Inborn errors of lipid metabolism, unspecified;3;Inactive;182578312/unspecified;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;5C80.0Z;Hypercholesterolaemia, unspecified;3;Inactive;875976032/unspecified;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA41.0;Acute ST elevation myocardial infarction;3;Active;391388807;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA4Z;Acute ischaemic heart disease, unspecified;2;Inactive;1829545371/unspecified;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BB01.Z;Pulmonary hypertension, unspecified;3;Inactive;1496633964/unspecified;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BB71.Z;Aortic valve insufficiency, unspecified;2;Active;1548485475/unspecified;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BC42.1;Infectious myocarditis;3;Unknown;654702340;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BC43.1Z;Hypertrophic cardiomyopathy, unspecified;3;Active;1830681485/unspecified;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BC81.3Z;Atrial fibrillation, unspecified;3;Inactive;171698302/unspecified;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BD10;Congestive heart failure;4;Approved;2136808878;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BD5Z;Diseases of arteries or arterioles, unspecified;2;Inactive;1164983645/unspecified;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;GC2Z;Diseases of the urinary system, unspecified;3;Unknown;1932345217/unspecified;33004114, 29939681, 30000690
13;valsartan;valsartan;CHEMBL1069;DB00177;60846;137862-53-4;80M03YXJ7I;ACWBQPMHZXGDFX-QFIPXVFZSA-N;CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O;4355;44;112;608;0;2;6;10;32;4;Approved;1996;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;LD2H.Y;Other specified syndromic genetic deafness;2;Inactive;186534168/other;33004114, 29939681, 30000690
14;propiverine;propiverine;CHEMBL1078261;DB12278;4942;60569-19-9;468GE2241L;QPCVHQBVMYCJOM-UHFFFAOYSA-N;CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C;3675;47;388;429;0;0;4;8;27;4;Approved;2017;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;3;Inactive;1118102209;30516934, 30516930, 27011567
14;propiverine;propiverine;CHEMBL1078261;DB12278;4942;60569-19-9;468GE2241L;QPCVHQBVMYCJOM-UHFFFAOYSA-N;CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C;3675;47;388;429;0;0;4;8;27;4;Approved;2017;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;30516934, 30516930, 27011567
14;propiverine;propiverine;CHEMBL1078261;DB12278;4942;60569-19-9;468GE2241L;QPCVHQBVMYCJOM-UHFFFAOYSA-N;CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C;3675;47;388;429;0;0;4;8;27;4;Approved;2017;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;3;Inactive;1118102209;30516934, 30516930, 27011567
14;propiverine;propiverine;CHEMBL1078261;DB12278;4942;60569-19-9;468GE2241L;QPCVHQBVMYCJOM-UHFFFAOYSA-N;CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C;3675;47;388;429;0;0;4;8;27;4;Approved;2017;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;30516934, 30516930, 27011567
14;propiverine;propiverine;CHEMBL1078261;DB12278;4942;60569-19-9;468GE2241L;QPCVHQBVMYCJOM-UHFFFAOYSA-N;CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C;3675;47;388;429;0;0;4;8;27;4;Approved;2017;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;3;Inactive;1118102209;30516934, 30516930, 27011567
14;propiverine;propiverine;CHEMBL1078261;DB12278;4942;60569-19-9;468GE2241L;QPCVHQBVMYCJOM-UHFFFAOYSA-N;CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C;3675;47;388;429;0;0;4;8;27;4;Approved;2017;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;30516934, 30516930, 27011567
14;propiverine;propiverine;CHEMBL1078261;DB12278;4942;60569-19-9;468GE2241L;QPCVHQBVMYCJOM-UHFFFAOYSA-N;CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C;3675;47;388;429;0;0;4;8;27;4;Approved;2017;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;3;Inactive;1118102209;30516934, 30516930, 27011567
14;propiverine;propiverine;CHEMBL1078261;DB12278;4942;60569-19-9;468GE2241L;QPCVHQBVMYCJOM-UHFFFAOYSA-N;CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C;3675;47;388;429;0;0;4;8;27;4;Approved;2017;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;30516934, 30516930, 27011567
14;propiverine;propiverine;CHEMBL1078261;DB12278;4942;60569-19-9;468GE2241L;QPCVHQBVMYCJOM-UHFFFAOYSA-N;CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C;3675;47;388;429;0;0;4;8;27;4;Approved;2017;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;3;Inactive;1118102209;30516934, 30516930, 27011567
14;propiverine;propiverine;CHEMBL1078261;DB12278;4942;60569-19-9;468GE2241L;QPCVHQBVMYCJOM-UHFFFAOYSA-N;CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C;3675;47;388;429;0;0;4;8;27;4;Approved;2017;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;30516934, 30516930, 27011567
14;propiverine;propiverine;CHEMBL1078261;DB12278;4942;60569-19-9;468GE2241L;QPCVHQBVMYCJOM-UHFFFAOYSA-N;CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C;3675;47;388;429;0;0;4;8;27;4;Approved;2017;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC50.0;Overactive bladder;3;Inactive;1118102209;30516934, 30516930, 27011567
14;propiverine;propiverine;CHEMBL1078261;DB12278;4942;60569-19-9;468GE2241L;QPCVHQBVMYCJOM-UHFFFAOYSA-N;CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C;3675;47;388;429;0;0;4;8;27;4;Approved;2017;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;30516934, 30516930, 27011567
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C30.Z;Melanoma of skin, unspecified;1;Inactive;488336723/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.0;Migraine without aura;3;Active;2048783472;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;3;Active;525744634/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;1;Inactive;277610609/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C30.Z;Melanoma of skin, unspecified;1;Inactive;488336723/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.0;Migraine without aura;3;Active;2048783472;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;3;Active;525744634/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;1;Inactive;277610609/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C30.Z;Melanoma of skin, unspecified;1;Inactive;488336723/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.0;Migraine without aura;3;Active;2048783472;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;3;Active;525744634/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;1;Inactive;277610609/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C30.Z;Melanoma of skin, unspecified;1;Inactive;488336723/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.0;Migraine without aura;3;Active;2048783472;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;3;Active;525744634/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;1;Inactive;277610609/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C30.Z;Melanoma of skin, unspecified;1;Inactive;488336723/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.0;Migraine without aura;3;Active;2048783472;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;3;Active;525744634/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;1;Inactive;277610609/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C30.Z;Melanoma of skin, unspecified;1;Inactive;488336723/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.0;Migraine without aura;3;Active;2048783472;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;3;Active;525744634/unspecified;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;30137790, 31643379, 21754121
15;tizanidine;tizanidine;CHEMBL1079;DB00697;5487;51322-75-9;6AI06C00GW;XFYDIVBRZNQMJC-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl;25371;11;904;300;0;2;4;2;16;4;Approved;1996;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;1;Inactive;277610609/unspecified;30137790, 31643379, 21754121
16;methscopolamine;methscopolamine bromide;CHEMBL1354199;DB00462;23724781;"13265-10-6;155-41-9";RTN51LK7WL;CXYRUNPLKGGUJF-JIRGPDKYSA-M;C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C.[Br-];3983;;591;454;0;1;5;5;24;4;Approved;1953;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;30000727, 32992345, 490316
16;methscopolamine;methscopolamine;"CHEMBL107979;CHEMBL293927;CHEMBL3140030;CHEMBL376897";DB11315;71183;"13265-10-6;155-41-9";RTN51LK7WL;LZCOQTDXKCNBEE-JVPPMCEKSA-N;C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C;3184;13;591;454;1;1;4;5;23;4;Approved;1953;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;30000727, 32992345, 490316
16;methscopolamine;methscopolamine bromide;CHEMBL1354199;DB00462;23724781;"13265-10-6;155-41-9";RTN51LK7WL;CXYRUNPLKGGUJF-JIRGPDKYSA-M;C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C.[Br-];3983;;591;454;0;1;5;5;24;4;Approved;1953;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;30000727, 32992345, 490316
16;methscopolamine;methscopolamine;"CHEMBL107979;CHEMBL293927;CHEMBL3140030;CHEMBL376897";DB11315;71183;"13265-10-6;155-41-9";RTN51LK7WL;LZCOQTDXKCNBEE-JVPPMCEKSA-N;C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C;3184;13;591;454;1;1;4;5;23;4;Approved;1953;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;30000727, 32992345, 490316
16;methscopolamine;methscopolamine bromide;CHEMBL1354199;DB00462;23724781;"13265-10-6;155-41-9";RTN51LK7WL;CXYRUNPLKGGUJF-JIRGPDKYSA-M;C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C.[Br-];3983;;591;454;0;1;5;5;24;4;Approved;1953;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;30000727, 32992345, 490316
16;methscopolamine;methscopolamine;"CHEMBL107979;CHEMBL293927;CHEMBL3140030;CHEMBL376897";DB11315;71183;"13265-10-6;155-41-9";RTN51LK7WL;LZCOQTDXKCNBEE-JVPPMCEKSA-N;C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C;3184;13;591;454;1;1;4;5;23;4;Approved;1953;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;30000727, 32992345, 490316
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;2;Active;111507461/unspecified;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Active;1699574100/unspecified;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Active;897917531/unspecified;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A41;Obstructive sleep apnoea;1;Inactive;1919233290;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A80;Restless legs syndrome;2;Unknown;1254916765;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7B2Z;Sleep-wake disorders, unspecified;2;Active;274880002/unspecified;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;8A20;Alzheimer disease;2;Active;1611724421;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;2;Active;111507461/unspecified;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Active;1699574100/unspecified;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Active;897917531/unspecified;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A41;Obstructive sleep apnoea;1;Inactive;1919233290;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A80;Restless legs syndrome;2;Unknown;1254916765;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7B2Z;Sleep-wake disorders, unspecified;2;Active;274880002/unspecified;36897120, 34958536, 31643236
17;suvorexant;suvorexant;CHEMBL1083659;DB09034;24965990;1030377-33-3;081L192FO9;JYTNQNCOQXFQPK-MRXNPFEDSA-N;CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl;4509;49;803;664;0;0;6;3;32;4;Approved;2014;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;8A20;Alzheimer disease;2;Active;1611724421;36897120, 34958536, 31643236
19;acetophenazine;acetophenazine;CHEMBL1085;DB01063;17676;2751-68-0;8620H6K4QH;WNTYBHLDCKXEOT-UHFFFAOYSA-N;CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO;4116;26;723;540;0;1;6;7;29;4;Approved;1961;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;14045146, 14211419, 5100621
20;agomelatine;agomelatine;CHEMBL10878;DB06594;82148;138112-76-2;137R1N49AD;YJYPHIXNFHFHND-UHFFFAOYSA-N;CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC;2433;27;383;280;0;1;2;4;18;4;Approved;2009;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;34165944, 24033095, 21271795
20;agomelatine;agomelatine;CHEMBL10878;DB06594;82148;138112-76-2;137R1N49AD;YJYPHIXNFHFHND-UHFFFAOYSA-N;CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC;2433;27;383;280;0;1;2;4;18;4;Approved;2009;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;34165944, 24033095, 21271795
20;agomelatine;agomelatine;CHEMBL10878;DB06594;82148;138112-76-2;137R1N49AD;YJYPHIXNFHFHND-UHFFFAOYSA-N;CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC;2433;27;383;280;0;1;2;4;18;4;Approved;2009;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Inactive;1582741816/unspecified;34165944, 24033095, 21271795
20;agomelatine;agomelatine;CHEMBL10878;DB06594;82148;138112-76-2;137R1N49AD;YJYPHIXNFHFHND-UHFFFAOYSA-N;CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC;2433;27;383;280;0;1;2;4;18;4;Approved;2009;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;34165944, 24033095, 21271795
20;agomelatine;agomelatine;CHEMBL10878;DB06594;82148;138112-76-2;137R1N49AD;YJYPHIXNFHFHND-UHFFFAOYSA-N;CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC;2433;27;383;280;0;1;2;4;18;4;Approved;2009;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;34165944, 24033095, 21271795
20;agomelatine;agomelatine;CHEMBL10878;DB06594;82148;138112-76-2;137R1N49AD;YJYPHIXNFHFHND-UHFFFAOYSA-N;CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC;2433;27;383;280;0;1;2;4;18;4;Approved;2009;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;34165944, 24033095, 21271795
20;agomelatine;agomelatine;CHEMBL10878;DB06594;82148;138112-76-2;137R1N49AD;YJYPHIXNFHFHND-UHFFFAOYSA-N;CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC;2433;27;383;280;0;1;2;4;18;4;Approved;2009;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Inactive;1582741816/unspecified;34165944, 24033095, 21271795
20;agomelatine;agomelatine;CHEMBL10878;DB06594;82148;138112-76-2;137R1N49AD;YJYPHIXNFHFHND-UHFFFAOYSA-N;CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC;2433;27;383;280;0;1;2;4;18;4;Approved;2009;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;MB24.3;Anxiety;3;Inactive;2027043655;34165944, 24033095, 21271795
20;agomelatine;agomelatine;CHEMBL10878;DB06594;82148;138112-76-2;137R1N49AD;YJYPHIXNFHFHND-UHFFFAOYSA-N;CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC;2433;27;383;280;0;1;2;4;18;4;Approved;2009;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;34165944, 24033095, 21271795
20;agomelatine;agomelatine;CHEMBL10878;DB06594;82148;138112-76-2;137R1N49AD;YJYPHIXNFHFHND-UHFFFAOYSA-N;CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC;2433;27;383;280;0;1;2;4;18;4;Approved;2009;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;34165944, 24033095, 21271795
20;agomelatine;agomelatine;CHEMBL10878;DB06594;82148;138112-76-2;137R1N49AD;YJYPHIXNFHFHND-UHFFFAOYSA-N;CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC;2433;27;383;280;0;1;2;4;18;4;Approved;2009;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Inactive;1582741816/unspecified;34165944, 24033095, 21271795
20;agomelatine;agomelatine;CHEMBL10878;DB06594;82148;138112-76-2;137R1N49AD;YJYPHIXNFHFHND-UHFFFAOYSA-N;CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC;2433;27;383;280;0;1;2;4;18;4;Approved;2009;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;MB24.3;Anxiety;3;Inactive;2027043655;34165944, 24033095, 21271795
21;mesoridazine;mesoridazine;CHEMBL1088;DB00933;4078;5588-33-0;5XE4NWM740;SLVMESMUVMCQIY-UHFFFAOYSA-N;CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C;3866;45;681;502;0;0;5;4;26;4;Approved;1970;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000077, 24732149, 184805
21;mesoridazine;mesoridazine;CHEMBL1088;DB00933;4078;5588-33-0;5XE4NWM740;SLVMESMUVMCQIY-UHFFFAOYSA-N;CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C;3866;45;681;502;0;0;5;4;26;4;Approved;1970;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000077, 24732149, 184805
22;pirbuterol;pirbuterol;CHEMBL1094966;DB01291;4845;38677-81-5;OG645J8RVW;VQDBNKDJNJQRDG-UHFFFAOYSA-N;CC(C)(C)NCC(C1=NC(=C(C=C1)O)CO)O;2403;-1;856;230;0;4;5;5;17;4;Approved;1986;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;30000129, 7053311, 6143112
22;pirbuterol;pirbuterol;CHEMBL1094966;DB01291;4845;38677-81-5;OG645J8RVW;VQDBNKDJNJQRDG-UHFFFAOYSA-N;CC(C)(C)NCC(C1=NC(=C(C=C1)O)CO)O;2403;-1;856;230;0;4;5;5;17;4;Approved;1986;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;30000129, 7053311, 6143112
23;reproterol;reproterol;CHEMBL1095607;DB12846;25654;54063-54-6;NA;WVLAAKXASPCBGT-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCCNCC(C3=CC(=CC(=C3)O)O)O;3894;-5;131;569;0;4;7;7;28;4;Approved;1977;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;22198635, 10364735, 15219266
23;reproterol;reproterol;CHEMBL1095607;DB12846;25654;54063-54-6;NA;WVLAAKXASPCBGT-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCCNCC(C3=CC(=CC(=C3)O)O)O;3894;-5;131;569;0;4;7;7;28;4;Approved;1977;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;22198635, 10364735, 15219266
24;indacaterol;indacaterol;CHEMBL1095777;DB05039;6918554;312753-06-3;8OR09251MQ;QZZUEBNBZAPZLX-QFIPXVFZSA-N;CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC;3925;33;816;589;0;4;4;6;29;4;Approved;2011;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;3;Inactive;1458683894/unspecified;27181606, 30000976, 33871819
24;indacaterol;indacaterol;CHEMBL1095777;DB05039;6918554;312753-06-3;8OR09251MQ;QZZUEBNBZAPZLX-QFIPXVFZSA-N;CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC;3925;33;816;589;0;4;4;6;29;4;Approved;2011;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;27181606, 30000976, 33871819
24;indacaterol;indacaterol;CHEMBL1095777;DB05039;6918554;312753-06-3;8OR09251MQ;QZZUEBNBZAPZLX-QFIPXVFZSA-N;CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC;3925;33;816;589;0;4;4;6;29;4;Approved;2011;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;27181606, 30000976, 33871819
24;indacaterol;indacaterol;CHEMBL1095777;DB05039;6918554;312753-06-3;8OR09251MQ;QZZUEBNBZAPZLX-QFIPXVFZSA-N;CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC;3925;33;816;589;0;4;4;6;29;4;Approved;2011;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;27181606, 30000976, 33871819
24;indacaterol;indacaterol;CHEMBL1095777;DB05039;6918554;312753-06-3;8OR09251MQ;QZZUEBNBZAPZLX-QFIPXVFZSA-N;CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC;3925;33;816;589;0;4;4;6;29;4;Approved;2011;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;3;Inactive;1656445230;27181606, 30000976, 33871819
25;ponesimod;ponesimod;CHEMBL1096146;DB12016;11363176;854107-55-4;5G7AKV2MKP;LPAUOXUZGSBGDU-ULCCENQXSA-N;CCCN=C1N(C(=O)C(=CC2=CC(=C(C=C2)OCC(CO)O)Cl)S1)C3=CC=CC=C3C;461;46;108;674;0;2;6;8;31;4;Approved;2021;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.Z;Multiple sclerosis, unspecified;4;Approved;1298865187/unspecified;34383396, 34813253, 33779698
25;ponesimod;ponesimod;CHEMBL1096146;DB12016;11363176;854107-55-4;5G7AKV2MKP;LPAUOXUZGSBGDU-ULCCENQXSA-N;CCCN=C1N(C(=O)C(=CC2=CC(=C(C=C2)OCC(CO)O)Cl)S1)C3=CC=CC=C3C;461;46;108;674;0;2;6;8;31;4;Approved;2021;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;EA90.Z;Psoriasis of unspecified type;2;Inactive;63698555/unspecified;34383396, 34813253, 33779698
26;clazosentan;clazosentan;CHEMBL109648;DB06677;6433095;180384-56-9;3DRR0X4728;LFWCJABOXHSRGC-UHFFFAOYSA-N;CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC(=NC=C3)C4=NNN=N4)OCCO)OC5=CC=CC=C5OC;5776;16;209;917;0;3;14;11;41;4;Approved;2022;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;8B01;Subarachnoid haemorrhage;4;Approved;1363253283;35362854, 35364589, 30508597
27;biperiden;biperiden;CHEMBL1101;DB00810;2381;514-65-8;0FRP6G56LD;YSXKPIUOCJLQIE-UHFFFAOYSA-N;C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O;3115;43;235;422;0;1;2;5;23;4;Approved;1959;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;31643581, 28785576, 33346074
27;biperiden;biperiden;CHEMBL1101;DB00810;2381;514-65-8;0FRP6G56LD;YSXKPIUOCJLQIE-UHFFFAOYSA-N;C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O;3115;43;235;422;0;1;2;5;23;4;Approved;1959;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;31643581, 28785576, 33346074
27;biperiden;biperiden;CHEMBL1101;DB00810;2381;514-65-8;0FRP6G56LD;YSXKPIUOCJLQIE-UHFFFAOYSA-N;C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O;3115;43;235;422;0;1;2;5;23;4;Approved;1959;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A6Z;Epilepsy or seizures, unspecified;3;Active;1397288146/unspecified;31643581, 28785576, 33346074
28;epinastine;epinastine;CHEMBL1106;DB00751;3241;80012-43-7;Q13WX941EF;WHWZLSFABNNENI-UHFFFAOYSA-N;C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N;24931;35;416;378;0;1;1;0;19;4;Approved;2003;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000206, 32491470, 38150534
28;epinastine;epinastine;CHEMBL1106;DB00751;3241;80012-43-7;Q13WX941EF;WHWZLSFABNNENI-UHFFFAOYSA-N;C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N;24931;35;416;378;0;1;1;0;19;4;Approved;2003;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000206, 32491470, 38150534
28;epinastine;epinastine;CHEMBL1106;DB00751;3241;80012-43-7;Q13WX941EF;WHWZLSFABNNENI-UHFFFAOYSA-N;C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N;24931;35;416;378;0;1;1;0;19;4;Approved;2003;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;3;Inactive;1565925107;30000206, 32491470, 38150534
28;epinastine;epinastine;CHEMBL1106;DB00751;3241;80012-43-7;Q13WX941EF;WHWZLSFABNNENI-UHFFFAOYSA-N;C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N;24931;35;416;378;0;1;1;0;19;4;Approved;2003;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.03;Other allergic rhinitis;3;Unknown;941478759;30000206, 32491470, 38150534
28;epinastine;epinastine;CHEMBL1106;DB00751;3241;80012-43-7;Q13WX941EF;WHWZLSFABNNENI-UHFFFAOYSA-N;C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N;24931;35;416;378;0;1;1;0;19;4;Approved;2003;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;3;Inactive;1711769234/unspecified;30000206, 32491470, 38150534
28;epinastine;epinastine;CHEMBL1106;DB00751;3241;80012-43-7;Q13WX941EF;WHWZLSFABNNENI-UHFFFAOYSA-N;C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N;24931;35;416;378;0;1;1;0;19;4;Approved;2003;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000206, 32491470, 38150534
28;epinastine;epinastine;CHEMBL1106;DB00751;3241;80012-43-7;Q13WX941EF;WHWZLSFABNNENI-UHFFFAOYSA-N;C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N;24931;35;416;378;0;1;1;0;19;4;Approved;2003;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000206, 32491470, 38150534
28;epinastine;epinastine;CHEMBL1106;DB00751;3241;80012-43-7;Q13WX941EF;WHWZLSFABNNENI-UHFFFAOYSA-N;C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N;24931;35;416;378;0;1;1;0;19;4;Approved;2003;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;3;Inactive;1565925107;30000206, 32491470, 38150534
28;epinastine;epinastine;CHEMBL1106;DB00751;3241;80012-43-7;Q13WX941EF;WHWZLSFABNNENI-UHFFFAOYSA-N;C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N;24931;35;416;378;0;1;1;0;19;4;Approved;2003;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.03;Other allergic rhinitis;3;Unknown;941478759;30000206, 32491470, 38150534
28;epinastine;epinastine;CHEMBL1106;DB00751;3241;80012-43-7;Q13WX941EF;WHWZLSFABNNENI-UHFFFAOYSA-N;C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N;24931;35;416;378;0;1;1;0;19;4;Approved;2003;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;3;Inactive;1711769234/unspecified;30000206, 32491470, 38150534
29;droperidol;droperidol;CHEMBL1108;DB00450;3168;548-73-2;O9U0F09D5X;RMEDXOLNCUSCGS-UHFFFAOYSA-N;C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F;3794;35;526;615;0;1;4;6;28;4;Approved;1970;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000664, 34185452, 35063889
29;droperidol;droperidol;CHEMBL1108;DB00450;3168;548-73-2;O9U0F09D5X;RMEDXOLNCUSCGS-UHFFFAOYSA-N;C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F;3794;35;526;615;0;1;4;6;28;4;Approved;1970;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000664, 34185452, 35063889
29;droperidol;droperidol;CHEMBL1108;DB00450;3168;548-73-2;O9U0F09D5X;RMEDXOLNCUSCGS-UHFFFAOYSA-N;C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F;3794;35;526;615;0;1;4;6;28;4;Approved;1970;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;30000664, 34185452, 35063889
29;droperidol;droperidol;CHEMBL1108;DB00450;3168;548-73-2;O9U0F09D5X;RMEDXOLNCUSCGS-UHFFFAOYSA-N;C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F;3794;35;526;615;0;1;4;6;28;4;Approved;1970;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000664, 34185452, 35063889
29;droperidol;droperidol;CHEMBL1108;DB00450;3168;548-73-2;O9U0F09D5X;RMEDXOLNCUSCGS-UHFFFAOYSA-N;C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F;3794;35;526;615;0;1;4;6;28;4;Approved;1970;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000664, 34185452, 35063889
29;droperidol;droperidol;CHEMBL1108;DB00450;3168;548-73-2;O9U0F09D5X;RMEDXOLNCUSCGS-UHFFFAOYSA-N;C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F;3794;35;526;615;0;1;4;6;28;4;Approved;1970;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;30000664, 34185452, 35063889
29;droperidol;droperidol;CHEMBL1108;DB00450;3168;548-73-2;O9U0F09D5X;RMEDXOLNCUSCGS-UHFFFAOYSA-N;C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F;3794;35;526;615;0;1;4;6;28;4;Approved;1970;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000664, 34185452, 35063889
29;droperidol;droperidol;CHEMBL1108;DB00450;3168;548-73-2;O9U0F09D5X;RMEDXOLNCUSCGS-UHFFFAOYSA-N;C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F;3794;35;526;615;0;1;4;6;28;4;Approved;1970;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000664, 34185452, 35063889
29;droperidol;droperidol;CHEMBL1108;DB00450;3168;548-73-2;O9U0F09D5X;RMEDXOLNCUSCGS-UHFFFAOYSA-N;C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F;3794;35;526;615;0;1;4;6;28;4;Approved;1970;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;30000664, 34185452, 35063889
29;droperidol;droperidol;CHEMBL1108;DB00450;3168;548-73-2;O9U0F09D5X;RMEDXOLNCUSCGS-UHFFFAOYSA-N;C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F;3794;35;526;615;0;1;4;6;28;4;Approved;1970;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000664, 34185452, 35063889
29;droperidol;droperidol;CHEMBL1108;DB00450;3168;548-73-2;O9U0F09D5X;RMEDXOLNCUSCGS-UHFFFAOYSA-N;C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F;3794;35;526;615;0;1;4;6;28;4;Approved;1970;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000664, 34185452, 35063889
29;droperidol;droperidol;CHEMBL1108;DB00450;3168;548-73-2;O9U0F09D5X;RMEDXOLNCUSCGS-UHFFFAOYSA-N;C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F;3794;35;526;615;0;1;4;6;28;4;Approved;1970;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;30000664, 34185452, 35063889
29;droperidol;droperidol;CHEMBL1108;DB00450;3168;548-73-2;O9U0F09D5X;RMEDXOLNCUSCGS-UHFFFAOYSA-N;C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F;3794;35;526;615;0;1;4;6;28;4;Approved;1970;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000664, 34185452, 35063889
29;droperidol;droperidol;CHEMBL1108;DB00450;3168;548-73-2;O9U0F09D5X;RMEDXOLNCUSCGS-UHFFFAOYSA-N;C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F;3794;35;526;615;0;1;4;6;28;4;Approved;1970;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000664, 34185452, 35063889
29;droperidol;droperidol;CHEMBL1108;DB00450;3168;548-73-2;O9U0F09D5X;RMEDXOLNCUSCGS-UHFFFAOYSA-N;C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F;3794;35;526;615;0;1;4;6;28;4;Approved;1970;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;30000664, 34185452, 35063889
30;ambrisentan;ambrisentan;CHEMBL1111;DB06403;6918493;177036-94-1;HW6NV07QEC;OUJTZYPIHDYQMC-LJQANCHMSA-N;CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C;3784;38;815;475;0;1;6;7;28;4;Approved;2007;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31643986, 26308684, 21623643
30;ambrisentan;ambrisentan;CHEMBL1111;DB06403;6918493;177036-94-1;HW6NV07QEC;OUJTZYPIHDYQMC-LJQANCHMSA-N;CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C;3784;38;815;475;0;1;6;7;28;4;Approved;2007;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;31643986, 26308684, 21623643
30;ambrisentan;ambrisentan;CHEMBL1111;DB06403;6918493;177036-94-1;HW6NV07QEC;OUJTZYPIHDYQMC-LJQANCHMSA-N;CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C;3784;38;815;475;0;1;6;7;28;4;Approved;2007;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BB01.Z;Pulmonary hypertension, unspecified;4;Approved;1496633964/unspecified;31643986, 26308684, 21623643
30;ambrisentan;ambrisentan;CHEMBL1111;DB06403;6918493;177036-94-1;HW6NV07QEC;OUJTZYPIHDYQMC-LJQANCHMSA-N;CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C;3784;38;815;475;0;1;6;7;28;4;Approved;2007;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;CA23;Asthma;2;Unknown;1656445230;31643986, 26308684, 21623643
30;ambrisentan;ambrisentan;CHEMBL1111;DB06403;6918493;177036-94-1;HW6NV07QEC;OUJTZYPIHDYQMC-LJQANCHMSA-N;CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C;3784;38;815;475;0;1;6;7;28;4;Approved;2007;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;CB03.4;Idiopathic pulmonary fibrosis;3;Inactive;1074069640;31643986, 26308684, 21623643
30;ambrisentan;ambrisentan;CHEMBL1111;DB06403;6918493;177036-94-1;HW6NV07QEC;OUJTZYPIHDYQMC-LJQANCHMSA-N;CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C;3784;38;815;475;0;1;6;7;28;4;Approved;2007;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;LA89.3;Hypoplastic left heart syndrome;2;Inactive;1811800027;31643986, 26308684, 21623643
30;ambrisentan;ambrisentan;CHEMBL1111;DB06403;6918493;177036-94-1;HW6NV07QEC;OUJTZYPIHDYQMC-LJQANCHMSA-N;CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C;3784;38;815;475;0;1;6;7;28;4;Approved;2007;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;NF04.Y;Other specified effects of air pressure or water pressure;2;Inactive;1098633535/other;31643986, 26308684, 21623643
30;ambrisentan;ambrisentan;CHEMBL1111;DB06403;6918493;177036-94-1;HW6NV07QEC;OUJTZYPIHDYQMC-LJQANCHMSA-N;CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C;3784;38;815;475;0;1;6;7;28;4;Approved;2007;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;RA01;COVID-19;2;Active;1730556128;31643986, 26308684, 21623643
30;ambrisentan;ambrisentan;CHEMBL1111;DB06403;6918493;177036-94-1;HW6NV07QEC;OUJTZYPIHDYQMC-LJQANCHMSA-N;CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C;3784;38;815;475;0;1;6;7;28;4;Approved;2007;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31643986, 26308684, 21623643
30;ambrisentan;ambrisentan;CHEMBL1111;DB06403;6918493;177036-94-1;HW6NV07QEC;OUJTZYPIHDYQMC-LJQANCHMSA-N;CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C;3784;38;815;475;0;1;6;7;28;4;Approved;2007;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;31643986, 26308684, 21623643
30;ambrisentan;ambrisentan;CHEMBL1111;DB06403;6918493;177036-94-1;HW6NV07QEC;OUJTZYPIHDYQMC-LJQANCHMSA-N;CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C;3784;38;815;475;0;1;6;7;28;4;Approved;2007;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BB01.Z;Pulmonary hypertension, unspecified;4;Approved;1496633964/unspecified;31643986, 26308684, 21623643
30;ambrisentan;ambrisentan;CHEMBL1111;DB06403;6918493;177036-94-1;HW6NV07QEC;OUJTZYPIHDYQMC-LJQANCHMSA-N;CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C;3784;38;815;475;0;1;6;7;28;4;Approved;2007;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;CA23;Asthma;2;Unknown;1656445230;31643986, 26308684, 21623643
30;ambrisentan;ambrisentan;CHEMBL1111;DB06403;6918493;177036-94-1;HW6NV07QEC;OUJTZYPIHDYQMC-LJQANCHMSA-N;CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C;3784;38;815;475;0;1;6;7;28;4;Approved;2007;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;CB03.4;Idiopathic pulmonary fibrosis;3;Inactive;1074069640;31643986, 26308684, 21623643
30;ambrisentan;ambrisentan;CHEMBL1111;DB06403;6918493;177036-94-1;HW6NV07QEC;OUJTZYPIHDYQMC-LJQANCHMSA-N;CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C;3784;38;815;475;0;1;6;7;28;4;Approved;2007;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;LA89.3;Hypoplastic left heart syndrome;2;Inactive;1811800027;31643986, 26308684, 21623643
30;ambrisentan;ambrisentan;CHEMBL1111;DB06403;6918493;177036-94-1;HW6NV07QEC;OUJTZYPIHDYQMC-LJQANCHMSA-N;CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C;3784;38;815;475;0;1;6;7;28;4;Approved;2007;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;NF04.Y;Other specified effects of air pressure or water pressure;2;Inactive;1098633535/other;31643986, 26308684, 21623643
30;ambrisentan;ambrisentan;CHEMBL1111;DB06403;6918493;177036-94-1;HW6NV07QEC;OUJTZYPIHDYQMC-LJQANCHMSA-N;CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C;3784;38;815;475;0;1;6;7;28;4;Approved;2007;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;RA01;COVID-19;2;Active;1730556128;31643986, 26308684, 21623643
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.0;Autism spectrum disorder without disorder of intellectual development and with mild or no impairment of functional language;2;Inactive;120443468;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;4;Approved;437815624/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Active;1582741816/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Inactive;2070699808;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;3;Unknown;263852475/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;3;Unknown;546689346/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6E20;Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium, without psychotic symptoms;3;Inactive;1124422593;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A20;Alzheimer disease;3;Inactive;1611724421;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;LD55;Fragile X chromosome;2;Inactive;1524287677;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB23.0;Aggressive behaviour;4;Approved;501393848;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.0;Autism spectrum disorder without disorder of intellectual development and with mild or no impairment of functional language;2;Inactive;120443468;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;4;Approved;437815624/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Active;1582741816/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Inactive;2070699808;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;3;Unknown;263852475/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;3;Unknown;546689346/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6E20;Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium, without psychotic symptoms;3;Inactive;1124422593;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A20;Alzheimer disease;3;Inactive;1611724421;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;LD55;Fragile X chromosome;2;Inactive;1524287677;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB23.0;Aggressive behaviour;4;Approved;501393848;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.0;Autism spectrum disorder without disorder of intellectual development and with mild or no impairment of functional language;2;Inactive;120443468;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;4;Approved;437815624/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Active;1582741816/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Inactive;2070699808;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;3;Unknown;263852475/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;3;Unknown;546689346/unspecified;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6E20;Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium, without psychotic symptoms;3;Inactive;1124422593;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A20;Alzheimer disease;3;Inactive;1611724421;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;LD55;Fragile X chromosome;2;Inactive;1524287677;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB23.0;Aggressive behaviour;4;Approved;501393848;31613519, 33064050, 30000075
31;aripiprazole;aripiprazole;CHEMBL1112;DB01238;60795;129722-12-9;82VFR53I78;CEUORZQYGODEFX-UHFFFAOYSA-N;C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl;4484;46;448;559;0;1;4;7;30;4;Approved;2002;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;31613519, 33064050, 30000075
32;amoxapine;amoxapine;CHEMBL1113;DB00543;2170;14028-44-5;NA;QWGDMFLQWFTERH-UHFFFAOYSA-N;C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3138;26;369;424;0;1;3;1;22;4;Approved;1980;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;31082024, 30000242, 31643838
32;amoxapine;amoxapine;CHEMBL1113;DB00543;2170;14028-44-5;NA;QWGDMFLQWFTERH-UHFFFAOYSA-N;C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3138;26;369;424;0;1;3;1;22;4;Approved;1980;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;31082024, 30000242, 31643838
32;amoxapine;amoxapine;CHEMBL1113;DB00543;2170;14028-44-5;NA;QWGDMFLQWFTERH-UHFFFAOYSA-N;C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3138;26;369;424;0;1;3;1;22;4;Approved;1980;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;31082024, 30000242, 31643838
32;amoxapine;amoxapine;CHEMBL1113;DB00543;2170;14028-44-5;NA;QWGDMFLQWFTERH-UHFFFAOYSA-N;C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3138;26;369;424;0;1;3;1;22;4;Approved;1980;Small molecule;Antagonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;31082024, 30000242, 31643838
32;amoxapine;amoxapine;CHEMBL1113;DB00543;2170;14028-44-5;NA;QWGDMFLQWFTERH-UHFFFAOYSA-N;C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3138;26;369;424;0;1;3;1;22;4;Approved;1980;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;31082024, 30000242, 31643838
33;dicyclomine;dicyclomine;CHEMBL1123;DB00804;3042;77-19-0;4KV4X8IF6V;CURUTKGFNZGFSE-UHFFFAOYSA-N;CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2;3095;55;295;326;0;0;3;8;22;4;Approved;1950;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;30000514, 31644199, 32847457
33;dicyclomine;dicyclomine;CHEMBL1123;DB00804;3042;77-19-0;4KV4X8IF6V;CURUTKGFNZGFSE-UHFFFAOYSA-N;CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2;3095;55;295;326;0;0;3;8;22;4;Approved;1950;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;30000514, 31644199, 32847457
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6C40.2Z;Alcohol dependence, unspecified;1;Inactive;1580466198/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;7A20.Z;Narcolepsy, unspecified;2;Inactive;1201727099/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A00.0Z;Parkinson disease, unspecified;3;Inactive;296066191/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8B1Z;Cerebral ischaemia, unspecified;1;Active;1427441570/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8E47;Encephalopathy, not elsewhere classified;2;Active;1375895174;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;9B71.3;Retinopathy of prematurity;2;Inactive;947283385;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BD40.0;Lower limb atherosclerosis;3;Inactive;897545836;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DA0A.Y;Other specified disorders of teeth and supporting structures;3;Active;1767358557/other;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DA93.0;Paralytic ileus;2;Inactive;1868011045;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;3;Active;1282135070/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB4D;Headache, not elsewhere classified;3;Unknown;1405405864;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MD11.0;Apnoea;4;Approved;992235907;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MD11.1;Asphyxia;3;Active;2008663041;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ME84.0;Cervical spine pain;3;Inactive;534629524;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ME84.2Z;Low back pain, unspecified;3;Unknown;1815305992/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ME84.Z;Spinal pain, unspecified;3;Inactive;2051065876/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ND51.2;Injury of spinal cord, level unspecified;2;Active;2131180445;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6C40.2Z;Alcohol dependence, unspecified;1;Inactive;1580466198/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;7A20.Z;Narcolepsy, unspecified;2;Inactive;1201727099/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A00.0Z;Parkinson disease, unspecified;3;Inactive;296066191/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8B1Z;Cerebral ischaemia, unspecified;1;Active;1427441570/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8E47;Encephalopathy, not elsewhere classified;2;Active;1375895174;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;9B71.3;Retinopathy of prematurity;2;Inactive;947283385;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BD40.0;Lower limb atherosclerosis;3;Inactive;897545836;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DA0A.Y;Other specified disorders of teeth and supporting structures;3;Active;1767358557/other;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DA93.0;Paralytic ileus;2;Inactive;1868011045;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;3;Active;1282135070/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB4D;Headache, not elsewhere classified;3;Unknown;1405405864;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MD11.0;Apnoea;4;Approved;992235907;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MD11.1;Asphyxia;3;Active;2008663041;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ME84.0;Cervical spine pain;3;Inactive;534629524;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ME84.2Z;Low back pain, unspecified;3;Unknown;1815305992/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ME84.Z;Spinal pain, unspecified;3;Inactive;2051065876/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ND51.2;Injury of spinal cord, level unspecified;2;Active;2131180445;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6C40.2Z;Alcohol dependence, unspecified;1;Inactive;1580466198/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;7A20.Z;Narcolepsy, unspecified;2;Inactive;1201727099/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A00.0Z;Parkinson disease, unspecified;3;Inactive;296066191/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8B1Z;Cerebral ischaemia, unspecified;1;Active;1427441570/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8E47;Encephalopathy, not elsewhere classified;2;Active;1375895174;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;9B71.3;Retinopathy of prematurity;2;Inactive;947283385;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BD40.0;Lower limb atherosclerosis;3;Inactive;897545836;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DA0A.Y;Other specified disorders of teeth and supporting structures;3;Active;1767358557/other;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DA93.0;Paralytic ileus;2;Inactive;1868011045;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;3;Active;1282135070/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB4D;Headache, not elsewhere classified;3;Unknown;1405405864;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MD11.0;Apnoea;4;Approved;992235907;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MD11.1;Asphyxia;3;Active;2008663041;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ME84.0;Cervical spine pain;3;Inactive;534629524;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ME84.2Z;Low back pain, unspecified;3;Unknown;1815305992/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ME84.Z;Spinal pain, unspecified;3;Inactive;2051065876/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ND51.2;Injury of spinal cord, level unspecified;2;Active;2131180445;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6C40.2Z;Alcohol dependence, unspecified;1;Inactive;1580466198/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;7A20.Z;Narcolepsy, unspecified;2;Inactive;1201727099/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A00.0Z;Parkinson disease, unspecified;3;Inactive;296066191/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8B1Z;Cerebral ischaemia, unspecified;1;Active;1427441570/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8E47;Encephalopathy, not elsewhere classified;2;Active;1375895174;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;9B71.3;Retinopathy of prematurity;2;Inactive;947283385;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BD40.0;Lower limb atherosclerosis;3;Inactive;897545836;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DA0A.Y;Other specified disorders of teeth and supporting structures;3;Active;1767358557/other;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DA93.0;Paralytic ileus;2;Inactive;1868011045;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;3;Active;1282135070/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB4D;Headache, not elsewhere classified;3;Unknown;1405405864;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MD11.0;Apnoea;4;Approved;992235907;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MD11.1;Asphyxia;3;Active;2008663041;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ME84.0;Cervical spine pain;3;Inactive;534629524;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ME84.2Z;Low back pain, unspecified;3;Unknown;1815305992/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ME84.Z;Spinal pain, unspecified;3;Inactive;2051065876/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30977054, 32706535, 28756014
34;caffeine;caffeine;CHEMBL113;DB00201;2519;58-08-2;3G6A5W338E;RYYVLZVUVIJVGH-UHFFFAOYSA-N;CN1C=NC2=C1C(=O)N(C(=O)N2C)C;19419;-1;584;293;0;0;3;0;14;4;Approved;1948;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ND51.2;Injury of spinal cord, level unspecified;2;Active;2131180445;30977054, 32706535, 28756014
35;epoprostenol;epoprostenol;CHEMBL1139;DB01240;5282411;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-OZUDYXHBSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;8B01;Subarachnoid haemorrhage;2;Inactive;1363253283;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol;CHEMBL1139;DB01240;5282411;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-OZUDYXHBSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol;CHEMBL1139;DB01240;5282411;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-OZUDYXHBSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;NA07.Z;Intracranial injury, unspecified;1;Inactive;277610609/unspecified;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol;CHEMBL1139;DB01240;5282411;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-OZUDYXHBSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;NE84;Failure or rejection of transplanted organs or tissues;2;Inactive;129221830;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol;CHEMBL1139;DB01240;5282411;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-OZUDYXHBSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;RA01;COVID-19;2;Inactive;1730556128;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol (TN);CHEMBL1139;DB01240;5280427;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-VVUHWYTRSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)O)O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;8B01;Subarachnoid haemorrhage;2;Inactive;1363253283;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol (TN);CHEMBL1139;DB01240;5280427;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-VVUHWYTRSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)O)O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol (TN);CHEMBL1139;DB01240;5280427;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-VVUHWYTRSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)O)O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;NA07.Z;Intracranial injury, unspecified;1;Inactive;277610609/unspecified;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol (TN);CHEMBL1139;DB01240;5280427;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-VVUHWYTRSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)O)O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;NE84;Failure or rejection of transplanted organs or tissues;2;Inactive;129221830;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol (TN);CHEMBL1139;DB01240;5280427;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-VVUHWYTRSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)O)O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;RA01;COVID-19;2;Inactive;1730556128;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol;CHEMBL1139;DB01240;5282411;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-OZUDYXHBSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;8B01;Subarachnoid haemorrhage;2;Inactive;1363253283;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol;CHEMBL1139;DB01240;5282411;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-OZUDYXHBSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol;CHEMBL1139;DB01240;5282411;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-OZUDYXHBSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;NA07.Z;Intracranial injury, unspecified;1;Inactive;277610609/unspecified;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol;CHEMBL1139;DB01240;5282411;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-OZUDYXHBSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;NE84;Failure or rejection of transplanted organs or tissues;2;Inactive;129221830;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol;CHEMBL1139;DB01240;5282411;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-OZUDYXHBSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;RA01;COVID-19;2;Inactive;1730556128;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol (TN);CHEMBL1139;DB01240;5280427;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-VVUHWYTRSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)O)O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;8B01;Subarachnoid haemorrhage;2;Inactive;1363253283;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol (TN);CHEMBL1139;DB01240;5280427;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-VVUHWYTRSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)O)O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol (TN);CHEMBL1139;DB01240;5280427;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-VVUHWYTRSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)O)O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;NA07.Z;Intracranial injury, unspecified;1;Inactive;277610609/unspecified;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol (TN);CHEMBL1139;DB01240;5280427;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-VVUHWYTRSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)O)O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;NE84;Failure or rejection of transplanted organs or tissues;2;Inactive;129221830;38163334, 26101188, 34030557
35;epoprostenol;epoprostenol (TN);CHEMBL1139;DB01240;5280427;35121-78-9;DCR9Z582X0;KAQKFAOMNZTLHT-VVUHWYTRSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)O)O2)O)O;3525;29;87;485;0;3;5;10;25;4;Approved;1995;Small molecule;Agonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;RA01;COVID-19;2;Inactive;1730556128;38163334, 26101188, 34030557
36;tulobuterol;tulobuterol;CHEMBL1159717;DB12248;5606;41570-61-0;591I9SU0F7;YREYLAVBNPACJM-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC=CC=C1Cl)O;22773;23;323;191;0;2;2;4;15;4;Approved;1998;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;29021505, 22270072, 33175639
36;tulobuterol;tulobuterol;CHEMBL1159717;DB12248;5606;41570-61-0;591I9SU0F7;YREYLAVBNPACJM-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC=CC=C1Cl)O;22773;23;323;191;0;2;2;4;15;4;Approved;1998;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;29021505, 22270072, 33175639
37;desloratadine;desloratadine;CHEMBL1172;DB00967;124087;100643-71-8;FVF865388R;JAUOIFJMECXRGI-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4;3108;45;249;425;0;1;2;0;22;4;Approved;2001;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000785, 18336052, 11398910
37;desloratadine;desloratadine;CHEMBL1172;DB00967;124087;100643-71-8;FVF865388R;JAUOIFJMECXRGI-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4;3108;45;249;425;0;1;2;0;22;4;Approved;2001;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA00;Acute nasopharyngitis;3;Unknown;2066255370;30000785, 18336052, 11398910
37;desloratadine;desloratadine;CHEMBL1172;DB00967;124087;100643-71-8;FVF865388R;JAUOIFJMECXRGI-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4;3108;45;249;425;0;1;2;0;22;4;Approved;2001;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000785, 18336052, 11398910
37;desloratadine;desloratadine;CHEMBL1172;DB00967;124087;100643-71-8;FVF865388R;JAUOIFJMECXRGI-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4;3108;45;249;425;0;1;2;0;22;4;Approved;2001;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.03;Other allergic rhinitis;3;Inactive;941478759;30000785, 18336052, 11398910
37;desloratadine;desloratadine;CHEMBL1172;DB00967;124087;100643-71-8;FVF865388R;JAUOIFJMECXRGI-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4;3108;45;249;425;0;1;2;0;22;4;Approved;2001;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000785, 18336052, 11398910
37;desloratadine;desloratadine;CHEMBL1172;DB00967;124087;100643-71-8;FVF865388R;JAUOIFJMECXRGI-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4;3108;45;249;425;0;1;2;0;22;4;Approved;2001;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;3;Inactive;215767047/unspecified;30000785, 18336052, 11398910
37;desloratadine;desloratadine;CHEMBL1172;DB00967;124087;100643-71-8;FVF865388R;JAUOIFJMECXRGI-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4;3108;45;249;425;0;1;2;0;22;4;Approved;2001;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA8Z;Dermatitis or eczema, unspecified;3;Inactive;1887882424/unspecified;30000785, 18336052, 11398910
37;desloratadine;desloratadine;CHEMBL1172;DB00967;124087;100643-71-8;FVF865388R;JAUOIFJMECXRGI-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4;3108;45;249;425;0;1;2;0;22;4;Approved;2001;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;30000785, 18336052, 11398910
37;desloratadine;desloratadine;CHEMBL1172;DB00967;124087;100643-71-8;FVF865388R;JAUOIFJMECXRGI-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4;3108;45;249;425;0;1;2;0;22;4;Approved;2001;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;3;Inactive;1729106757/unspecified;30000785, 18336052, 11398910
38;prucalopride;prucalopride;CHEMBL117287;DB06480;3052762;179474-81-8;0A09IUW5TP;ZPMNHBXQOOVQJL-UHFFFAOYSA-N;COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl;3679;2;768;445;0;2;5;6;25;4;Approved;2018;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DA93.0;Paralytic ileus;3;Unknown;1868011045;31643961, 30694627, 35952195
38;prucalopride;prucalopride;CHEMBL117287;DB06480;3052762;179474-81-8;0A09IUW5TP;ZPMNHBXQOOVQJL-UHFFFAOYSA-N;COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl;3679;2;768;445;0;2;5;6;25;4;Approved;2018;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;3;Unknown;1158238623/unspecified;31643961, 30694627, 35952195
38;prucalopride;prucalopride;CHEMBL117287;DB06480;3052762;179474-81-8;0A09IUW5TP;ZPMNHBXQOOVQJL-UHFFFAOYSA-N;COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl;3679;2;768;445;0;2;5;6;25;4;Approved;2018;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DD9Z;Functional gastrointestinal disorders, unspecified;4;Approved;132592466/unspecified;31643961, 30694627, 35952195
38;prucalopride;prucalopride;CHEMBL117287;DB06480;3052762;179474-81-8;0A09IUW5TP;ZPMNHBXQOOVQJL-UHFFFAOYSA-N;COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl;3679;2;768;445;0;2;5;6;25;4;Approved;2018;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD92;Dyspepsia;2;Active;869622187;31643961, 30694627, 35952195
38;prucalopride;prucalopride;CHEMBL117287;DB06480;3052762;179474-81-8;0A09IUW5TP;ZPMNHBXQOOVQJL-UHFFFAOYSA-N;COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl;3679;2;768;445;0;2;5;6;25;4;Approved;2018;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD93;Dysphagia;2;Inactive;968461848;31643961, 30694627, 35952195
38;prucalopride;prucalopride;CHEMBL117287;DB06480;3052762;179474-81-8;0A09IUW5TP;ZPMNHBXQOOVQJL-UHFFFAOYSA-N;COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl;3679;2;768;445;0;2;5;6;25;4;Approved;2018;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;ME05.0;Constipation;4;Approved;502284069;31643961, 30694627, 35952195
39;propantheline;propantheline;CHEMBL1180725;DB00782;4934;298-50-0;1306V2B0Q8;VVWYOYDLCMFIEM-UHFFFAOYSA-N;CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C;3685;42;355;474;1;0;3;7;27;4;Approved;1953;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;30000726, 31643394, 7655132
39;propantheline;propantheline;CHEMBL1180725;DB00782;4934;298-50-0;1306V2B0Q8;VVWYOYDLCMFIEM-UHFFFAOYSA-N;CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C;3685;42;355;474;1;0;3;7;27;4;Approved;1953;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;1;Unknown;1118102209;30000726, 31643394, 7655132
39;propantheline;propantheline;CHEMBL1180725;DB00782;4934;298-50-0;1306V2B0Q8;VVWYOYDLCMFIEM-UHFFFAOYSA-N;CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C;3685;42;355;474;1;0;3;7;27;4;Approved;1953;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;30000726, 31643394, 7655132
39;propantheline;propantheline;CHEMBL1180725;DB00782;4934;298-50-0;1306V2B0Q8;VVWYOYDLCMFIEM-UHFFFAOYSA-N;CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C;3685;42;355;474;1;0;3;7;27;4;Approved;1953;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;1;Unknown;1118102209;30000726, 31643394, 7655132
39;propantheline;propantheline;CHEMBL1180725;DB00782;4934;298-50-0;1306V2B0Q8;VVWYOYDLCMFIEM-UHFFFAOYSA-N;CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C;3685;42;355;474;1;0;3;7;27;4;Approved;1953;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;30000726, 31643394, 7655132
39;propantheline;propantheline;CHEMBL1180725;DB00782;4934;298-50-0;1306V2B0Q8;VVWYOYDLCMFIEM-UHFFFAOYSA-N;CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C;3685;42;355;474;1;0;3;7;27;4;Approved;1953;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;1;Unknown;1118102209;30000726, 31643394, 7655132
40;zolmitriptan;zolmitriptan;CHEMBL1185;DB00315;60857;139264-17-8;2FS66TH3YW;ULSDMUVEXKOYBU-ZDUSSCGKSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3;28736;22;574;375;0;2;3;5;21;4;Approved;1997;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000523, 32491581, 10386213
40;zolmitriptan;zolmitriptan;CHEMBL1185;DB00315;60857;139264-17-8;2FS66TH3YW;ULSDMUVEXKOYBU-ZDUSSCGKSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3;28736;22;574;375;0;2;3;5;21;4;Approved;1997;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000523, 32491581, 10386213
40;zolmitriptan;zolmitriptan;CHEMBL1185;DB00315;60857;139264-17-8;2FS66TH3YW;ULSDMUVEXKOYBU-ZDUSSCGKSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3;28736;22;574;375;0;2;3;5;21;4;Approved;1997;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000523, 32491581, 10386213
41;methylnaltrexone;methylnaltrexone;CHEMBL1186579;DB06800;5361918;916055-93-1;0RK7M7IABE;JVLBPIPGETUEET-GAAHOAFPSA-O;C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6;3564;16;668;664;1;2;4;2;26;4;Approved;2008;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;2C10.Y;Other specified malignant neoplasms of pancreas;3;Unknown;542147910/other;33226751, 20426500, 19605844
41;methylnaltrexone;methylnaltrexone;CHEMBL1186579;DB06800;5361918;916055-93-1;0RK7M7IABE;JVLBPIPGETUEET-GAAHOAFPSA-O;C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6;3564;16;668;664;1;2;4;2;26;4;Approved;2008;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DA41.00;Gastroparesis;2;Inactive;598423727;33226751, 20426500, 19605844
41;methylnaltrexone;methylnaltrexone;CHEMBL1186579;DB06800;5361918;916055-93-1;0RK7M7IABE;JVLBPIPGETUEET-GAAHOAFPSA-O;C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6;3564;16;668;664;1;2;4;2;26;4;Approved;2008;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DA93.0;Paralytic ileus;3;Inactive;1868011045;33226751, 20426500, 19605844
41;methylnaltrexone;methylnaltrexone;CHEMBL1186579;DB06800;5361918;916055-93-1;0RK7M7IABE;JVLBPIPGETUEET-GAAHOAFPSA-O;C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6;3564;16;668;664;1;2;4;2;26;4;Approved;2008;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DB30.Y;Other specified obstruction of large intestine;1;Inactive;320939116/other;33226751, 20426500, 19605844
41;methylnaltrexone;methylnaltrexone;CHEMBL1186579;DB06800;5361918;916055-93-1;0RK7M7IABE;JVLBPIPGETUEET-GAAHOAFPSA-O;C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6;3564;16;668;664;1;2;4;2;26;4;Approved;2008;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DC31.Z;Acute pancreatitis, unspecified;3;Active;698285441/unspecified;33226751, 20426500, 19605844
41;methylnaltrexone;methylnaltrexone;CHEMBL1186579;DB06800;5361918;916055-93-1;0RK7M7IABE;JVLBPIPGETUEET-GAAHOAFPSA-O;C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6;3564;16;668;664;1;2;4;2;26;4;Approved;2008;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME05.0;Constipation;4;Approved;502284069;33226751, 20426500, 19605844
41;methylnaltrexone;methylnaltrexone [VANDF];CHEMBL1186579;DB06800;16089915;916055-93-1;0RK7M7IABE;JVLBPIPGETUEET-WIXLDOGYSA-O;C[N@@+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6;3564;16;668;664;1;2;4;2;26;4;Approved;2008;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;2C10.Y;Other specified malignant neoplasms of pancreas;3;Unknown;542147910/other;33226751, 20426500, 19605844
41;methylnaltrexone;methylnaltrexone [VANDF];CHEMBL1186579;DB06800;16089915;916055-93-1;0RK7M7IABE;JVLBPIPGETUEET-WIXLDOGYSA-O;C[N@@+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6;3564;16;668;664;1;2;4;2;26;4;Approved;2008;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DA41.00;Gastroparesis;2;Inactive;598423727;33226751, 20426500, 19605844
41;methylnaltrexone;methylnaltrexone [VANDF];CHEMBL1186579;DB06800;16089915;916055-93-1;0RK7M7IABE;JVLBPIPGETUEET-WIXLDOGYSA-O;C[N@@+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6;3564;16;668;664;1;2;4;2;26;4;Approved;2008;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DA93.0;Paralytic ileus;3;Inactive;1868011045;33226751, 20426500, 19605844
41;methylnaltrexone;methylnaltrexone [VANDF];CHEMBL1186579;DB06800;16089915;916055-93-1;0RK7M7IABE;JVLBPIPGETUEET-WIXLDOGYSA-O;C[N@@+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6;3564;16;668;664;1;2;4;2;26;4;Approved;2008;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DB30.Y;Other specified obstruction of large intestine;1;Inactive;320939116/other;33226751, 20426500, 19605844
41;methylnaltrexone;methylnaltrexone [VANDF];CHEMBL1186579;DB06800;16089915;916055-93-1;0RK7M7IABE;JVLBPIPGETUEET-WIXLDOGYSA-O;C[N@@+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6;3564;16;668;664;1;2;4;2;26;4;Approved;2008;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DC31.Z;Acute pancreatitis, unspecified;3;Active;698285441/unspecified;33226751, 20426500, 19605844
41;methylnaltrexone;methylnaltrexone [VANDF];CHEMBL1186579;DB06800;16089915;916055-93-1;0RK7M7IABE;JVLBPIPGETUEET-WIXLDOGYSA-O;C[N@@+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6;3564;16;668;664;1;2;4;2;26;4;Approved;2008;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME05.0;Constipation;4;Approved;502284069;33226751, 20426500, 19605844
42;umeclidinium;umeclidinium;CHEMBL1187833;DB09076;11519070;869185-19-3;GE2T1418SV;FVTWTVQXNAJTQP-UHFFFAOYSA-N;C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5;4286;47;295;543;1;1;2;8;32;4;Approved;2013;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;35849317, 29999790, 32162970
42;umeclidinium;umeclidinium;CHEMBL1187833;DB09076;11519070;869185-19-3;GE2T1418SV;FVTWTVQXNAJTQP-UHFFFAOYSA-N;C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5;4286;47;295;543;1;1;2;8;32;4;Approved;2013;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;35849317, 29999790, 32162970
42;umeclidinium;umeclidinium;CHEMBL1187833;DB09076;11519070;869185-19-3;GE2T1418SV;FVTWTVQXNAJTQP-UHFFFAOYSA-N;C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5;4286;47;295;543;1;1;2;8;32;4;Approved;2013;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;35849317, 29999790, 32162970
42;umeclidinium;umeclidinium;CHEMBL1187833;DB09076;11519070;869185-19-3;GE2T1418SV;FVTWTVQXNAJTQP-UHFFFAOYSA-N;C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5;4286;47;295;543;1;1;2;8;32;4;Approved;2013;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;3;Active;1656445230;35849317, 29999790, 32162970
42;umeclidinium;umeclidinium;CHEMBL1187833;DB09076;11519070;869185-19-3;GE2T1418SV;FVTWTVQXNAJTQP-UHFFFAOYSA-N;C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5;4286;47;295;543;1;1;2;8;32;4;Approved;2013;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;2;Inactive;1416949107/unspecified;35849317, 29999790, 32162970
42;umeclidinium;umeclidinium;CHEMBL1187833;DB09076;11519070;869185-19-3;GE2T1418SV;FVTWTVQXNAJTQP-UHFFFAOYSA-N;C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5;4286;47;295;543;1;1;2;8;32;4;Approved;2013;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;35849317, 29999790, 32162970
42;umeclidinium;umeclidinium;CHEMBL1187833;DB09076;11519070;869185-19-3;GE2T1418SV;FVTWTVQXNAJTQP-UHFFFAOYSA-N;C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5;4286;47;295;543;1;1;2;8;32;4;Approved;2013;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;35849317, 29999790, 32162970
42;umeclidinium;umeclidinium;CHEMBL1187833;DB09076;11519070;869185-19-3;GE2T1418SV;FVTWTVQXNAJTQP-UHFFFAOYSA-N;C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5;4286;47;295;543;1;1;2;8;32;4;Approved;2013;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;35849317, 29999790, 32162970
42;umeclidinium;umeclidinium;CHEMBL1187833;DB09076;11519070;869185-19-3;GE2T1418SV;FVTWTVQXNAJTQP-UHFFFAOYSA-N;C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5;4286;47;295;543;1;1;2;8;32;4;Approved;2013;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;3;Active;1656445230;35849317, 29999790, 32162970
42;umeclidinium;umeclidinium;CHEMBL1187833;DB09076;11519070;869185-19-3;GE2T1418SV;FVTWTVQXNAJTQP-UHFFFAOYSA-N;C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5;4286;47;295;543;1;1;2;8;32;4;Approved;2013;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;2;Inactive;1416949107/unspecified;35849317, 29999790, 32162970
43;olopatadine;olopatadine;CHEMBL1189432;DB00768;5281071;113806-05-6;D27V6190PM;JBIMVDZLSHOPLA-LSCVHKIXSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O;3374;15;498;488;0;1;4;5;25;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000577, 36651792, 28656804
43;olopatadine;olopatadine;CHEMBL1189432;DB00768;5281071;113806-05-6;D27V6190PM;JBIMVDZLSHOPLA-LSCVHKIXSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O;3374;15;498;488;0;1;4;5;25;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000577, 36651792, 28656804
43;olopatadine;olopatadine;CHEMBL1189432;DB00768;5281071;113806-05-6;D27V6190PM;JBIMVDZLSHOPLA-LSCVHKIXSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O;3374;15;498;488;0;1;4;5;25;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.03;Other allergic rhinitis;3;Inactive;941478759;30000577, 36651792, 28656804
43;olopatadine;olopatadine;CHEMBL1189432;DB00768;5281071;113806-05-6;D27V6190PM;JBIMVDZLSHOPLA-LSCVHKIXSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O;3374;15;498;488;0;1;4;5;25;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000577, 36651792, 28656804
43;olopatadine;olopatadine;CHEMBL1189432;DB00768;5281071;113806-05-6;D27V6190PM;JBIMVDZLSHOPLA-LSCVHKIXSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O;3374;15;498;488;0;1;4;5;25;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000577, 36651792, 28656804
45;pheniramine;pheniramine;CHEMBL1193;DB01620;4761;86-21-5;134FM9ZZ6M;IJHNSHDBIRRJRN-UHFFFAOYSA-N;CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2;24034;28;161;221;0;0;2;5;18;4;Approved;1994;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;1E32;Influenza, virus not identified;3;Inactive;1235618695;35952175, 7906008, 4698679
45;pheniramine;pheniramine;CHEMBL1193;DB01620;4761;86-21-5;134FM9ZZ6M;IJHNSHDBIRRJRN-UHFFFAOYSA-N;CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2;24034;28;161;221;0;0;2;5;18;4;Approved;1994;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;35952175, 7906008, 4698679
45;pheniramine;pheniramine;CHEMBL1193;DB01620;4761;86-21-5;134FM9ZZ6M;IJHNSHDBIRRJRN-UHFFFAOYSA-N;CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2;24034;28;161;221;0;0;2;5;18;4;Approved;1994;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA00;Acute nasopharyngitis;3;Inactive;2066255370;35952175, 7906008, 4698679
45;pheniramine;pheniramine;CHEMBL1193;DB01620;4761;86-21-5;134FM9ZZ6M;IJHNSHDBIRRJRN-UHFFFAOYSA-N;CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2;24034;28;161;221;0;0;2;5;18;4;Approved;1994;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA07.0;Acute upper respiratory infection, site unspecified;3;Unknown;819139656;35952175, 7906008, 4698679
45;pheniramine;pheniramine;CHEMBL1193;DB01620;4761;86-21-5;134FM9ZZ6M;IJHNSHDBIRRJRN-UHFFFAOYSA-N;CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2;24034;28;161;221;0;0;2;5;18;4;Approved;1994;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;35952175, 7906008, 4698679
45;pheniramine;pheniramine;CHEMBL1193;DB01620;4761;86-21-5;134FM9ZZ6M;IJHNSHDBIRRJRN-UHFFFAOYSA-N;CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2;24034;28;161;221;0;0;2;5;18;4;Approved;1994;Small molecule;Inverse agonist;Q9H3N8;hrh4_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;1E32;Influenza, virus not identified;3;Inactive;1235618695;35952175, 7906008, 4698679
45;pheniramine;pheniramine;CHEMBL1193;DB01620;4761;86-21-5;134FM9ZZ6M;IJHNSHDBIRRJRN-UHFFFAOYSA-N;CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2;24034;28;161;221;0;0;2;5;18;4;Approved;1994;Small molecule;Inverse agonist;Q9H3N8;hrh4_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;35952175, 7906008, 4698679
45;pheniramine;pheniramine;CHEMBL1193;DB01620;4761;86-21-5;134FM9ZZ6M;IJHNSHDBIRRJRN-UHFFFAOYSA-N;CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2;24034;28;161;221;0;0;2;5;18;4;Approved;1994;Small molecule;Inverse agonist;Q9H3N8;hrh4_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA00;Acute nasopharyngitis;3;Inactive;2066255370;35952175, 7906008, 4698679
45;pheniramine;pheniramine;CHEMBL1193;DB01620;4761;86-21-5;134FM9ZZ6M;IJHNSHDBIRRJRN-UHFFFAOYSA-N;CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2;24034;28;161;221;0;0;2;5;18;4;Approved;1994;Small molecule;Inverse agonist;Q9H3N8;hrh4_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA07.0;Acute upper respiratory infection, site unspecified;3;Unknown;819139656;35952175, 7906008, 4698679
45;pheniramine;pheniramine;CHEMBL1193;DB01620;4761;86-21-5;134FM9ZZ6M;IJHNSHDBIRRJRN-UHFFFAOYSA-N;CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2;24034;28;161;221;0;0;2;5;18;4;Approved;1994;Small molecule;Inverse agonist;Q9H3N8;hrh4_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;35952175, 7906008, 4698679
46;aclidinium;aclidinium;CHEMBL1194325;DB08897;11434515;727649-81-2;K17VY42F6C;ASMXXROZKSBQIH-VITNCHFBSA-N;C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5;4847;47;112;647;1;1;6;10;33;4;Approved;2012;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;29999631, 31644139, 34137664
46;aclidinium;aclidinium;CHEMBL1194325;DB08897;11434515;727649-81-2;K17VY42F6C;ASMXXROZKSBQIH-VITNCHFBSA-N;C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5;4847;47;112;647;1;1;6;10;33;4;Approved;2012;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;29999631, 31644139, 34137664
46;aclidinium;aclidinium;CHEMBL1194325;DB08897;11434515;727649-81-2;K17VY42F6C;ASMXXROZKSBQIH-VITNCHFBSA-N;C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5;4847;47;112;647;1;1;6;10;33;4;Approved;2012;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;29999631, 31644139, 34137664
46;aclidinium;aclidinium;CHEMBL1194325;DB08897;11434515;727649-81-2;K17VY42F6C;ASMXXROZKSBQIH-VITNCHFBSA-N;C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5;4847;47;112;647;1;1;6;10;33;4;Approved;2012;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;29999631, 31644139, 34137664
46;aclidinium;aclidinium;CHEMBL1194325;DB08897;11434515;727649-81-2;K17VY42F6C;ASMXXROZKSBQIH-VITNCHFBSA-N;C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5;4847;47;112;647;1;1;6;10;33;4;Approved;2012;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;29999631, 31644139, 34137664
46;aclidinium;aclidinium;CHEMBL1194325;DB08897;11434515;727649-81-2;K17VY42F6C;ASMXXROZKSBQIH-VITNCHFBSA-N;C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5;4847;47;112;647;1;1;6;10;33;4;Approved;2012;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;29999631, 31644139, 34137664
46;aclidinium;aclidinium;CHEMBL1194325;DB08897;11434515;727649-81-2;K17VY42F6C;ASMXXROZKSBQIH-VITNCHFBSA-N;C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5;4847;47;112;647;1;1;6;10;33;4;Approved;2012;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;29999631, 31644139, 34137664
46;aclidinium;aclidinium;CHEMBL1194325;DB08897;11434515;727649-81-2;K17VY42F6C;ASMXXROZKSBQIH-VITNCHFBSA-N;C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5;4847;47;112;647;1;1;6;10;33;4;Approved;2012;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;29999631, 31644139, 34137664
46;aclidinium;aclidinium;CHEMBL1194325;DB08897;11434515;727649-81-2;K17VY42F6C;ASMXXROZKSBQIH-VITNCHFBSA-N;C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5;4847;47;112;647;1;1;6;10;33;4;Approved;2012;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;29999631, 31644139, 34137664
46;aclidinium;aclidinium;CHEMBL1194325;DB08897;11434515;727649-81-2;K17VY42F6C;ASMXXROZKSBQIH-VITNCHFBSA-N;C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5;4847;47;112;647;1;1;6;10;33;4;Approved;2012;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;29999631, 31644139, 34137664
46;aclidinium;aclidinium;CHEMBL1194325;DB08897;11434515;727649-81-2;K17VY42F6C;ASMXXROZKSBQIH-VITNCHFBSA-N;C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5;4847;47;112;647;1;1;6;10;33;4;Approved;2012;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;29999631, 31644139, 34137664
46;aclidinium;aclidinium;CHEMBL1194325;DB08897;11434515;727649-81-2;K17VY42F6C;ASMXXROZKSBQIH-VITNCHFBSA-N;C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5;4847;47;112;647;1;1;6;10;33;4;Approved;2012;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;29999631, 31644139, 34137664
46;aclidinium;aclidinium;CHEMBL1194325;DB08897;11434515;727649-81-2;K17VY42F6C;ASMXXROZKSBQIH-VITNCHFBSA-N;C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5;4847;47;112;647;1;1;6;10;33;4;Approved;2012;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;29999631, 31644139, 34137664
46;aclidinium;aclidinium;CHEMBL1194325;DB08897;11434515;727649-81-2;K17VY42F6C;ASMXXROZKSBQIH-VITNCHFBSA-N;C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5;4847;47;112;647;1;1;6;10;33;4;Approved;2012;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;29999631, 31644139, 34137664
46;aclidinium;aclidinium;CHEMBL1194325;DB08897;11434515;727649-81-2;K17VY42F6C;ASMXXROZKSBQIH-VITNCHFBSA-N;C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5;4847;47;112;647;1;1;6;10;33;4;Approved;2012;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;29999631, 31644139, 34137664
47;ergometrine;ergometrine;CHEMBL119443;DB01253;443884;60-79-7;WH41D8433D;WVVSZNPYNCNODU-XTQGRXLLSA-N;CC(CO)NC(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3254;18;684;535;0;3;3;3;24;4;Approved;1959;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA43.Z;Postpartum haemorrhage, unspecified;4;Approved;820245648/unspecified;16147681, 5435196, 18610393
48;vilanterol;vilanterol;CHEMBL1198857;DB09082;10184665;503068-34-6;028LZY775B;DAFYYTQWSAWIGS-DEOSSOPVSA-N;C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl;4864;38;912;466;0;4;6;16;32;4;Approved;2013;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;35849317, 29999792, 32162970
48;vilanterol;vilanterol;CHEMBL1198857;DB09082;10184665;503068-34-6;028LZY775B;DAFYYTQWSAWIGS-DEOSSOPVSA-N;C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl;4864;38;912;466;0;4;6;16;32;4;Approved;2013;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;35849317, 29999792, 32162970
49;fosaprepitant;fosaprepitant;CHEMBL1199324;DB06717;135413538;172673-20-0;NA;BARDROPHSZEBKC-OITMNORJSA-N;CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NN(C(=O)N3)P(=O)(O)O)C4=CC=C(C=C4)F;6144;1;124;997;0;3;14;7;41;4;Approved;2008;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;MD90;Nausea or vomiting;4;Approved;677319549;28470980, 34793245, 27510503
49;fosaprepitant;fosaprepitant;CHEMBL1199324;DB06717;135413538;172673-20-0;NA;BARDROPHSZEBKC-OITMNORJSA-N;CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NN(C(=O)N3)P(=O)(O)O)C4=CC=C(C=C4)F;6144;1;124;997;0;3;14;7;41;4;Approved;2008;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;NA07.Z;Intracranial injury, unspecified;1;Unknown;277610609/unspecified;28470980, 34793245, 27510503
50;dimenhydrinate;dimenhydrinate+;CHEMBL1200406;DB00985;441281;523-87-5;JB937PER5C;KKRAMGIVRBZVCD-UHFFFAOYSA-N;CN1C(=C2C(=NC(=N2)Cl)N(C1=O)C)[O-].C[NH+](C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;470;;85;623;0;1;4;6;33;4;Approved;1972;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MB48.0Z;Vertigo, unspecified;4;Approved;1398634694/unspecified;30000927, 31643540, 33911336
50;dimenhydrinate;dimenhydrinate+;CHEMBL1200406;DB00985;441281;523-87-5;JB937PER5C;KKRAMGIVRBZVCD-UHFFFAOYSA-N;CN1C(=C2C(=NC(=N2)Cl)N(C1=O)C)[O-].C[NH+](C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;470;;85;623;0;1;4;6;33;4;Approved;1972;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90;Nausea or vomiting;2;Unknown;677319549;30000927, 31643540, 33911336
50;dimenhydrinate;dimenhydrinate+;CHEMBL1200406;DB00985;441281;523-87-5;JB937PER5C;KKRAMGIVRBZVCD-UHFFFAOYSA-N;CN1C(=C2C(=NC(=N2)Cl)N(C1=O)C)[O-].C[NH+](C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;470;;85;623;0;1;4;6;33;4;Approved;1972;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90.1;Vomiting;4;Approved;447658033;30000927, 31643540, 33911336
50;dimenhydrinate;dimenhydrinate;CHEMBL1200406;DB00985;10660;523-87-5;JB937PER5C;NFLLKCVHYJRNRH-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;470;;818;509;0;1;5;6;33;4;Approved;1972;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MB48.0Z;Vertigo, unspecified;4;Approved;1398634694/unspecified;30000927, 31643540, 33911336
50;dimenhydrinate;dimenhydrinate;CHEMBL1200406;DB00985;10660;523-87-5;JB937PER5C;NFLLKCVHYJRNRH-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;470;;818;509;0;1;5;6;33;4;Approved;1972;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90;Nausea or vomiting;2;Unknown;677319549;30000927, 31643540, 33911336
50;dimenhydrinate;dimenhydrinate;CHEMBL1200406;DB00985;10660;523-87-5;JB937PER5C;NFLLKCVHYJRNRH-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;470;;818;509;0;1;5;6;33;4;Approved;1972;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90.1;Vomiting;4;Approved;447658033;30000927, 31643540, 33911336
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B33.4;Leukaemia, unspecified;2;Unknown;1385484871;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;5A50.1;Pseudohypoparathyroidism;2;Active;1225154856;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A7Z;Depressive disorders, unspecified;1;Unknown;1563440232/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA23;Asthma;4;Approved;1656445230;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CB41;Respiratory failure;3;Inactive;370028006;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB60.Z;Acute kidney failure, stage unspecified;3;Active;476391827/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GC2Z;Diseases of the urinary system, unspecified;2;Unknown;1932345217/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MC82.Z;Cardiac arrest, unspecified;2;Inactive;395422191/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NF04.Y;Other specified effects of air pressure or water pressure;3;Inactive;1098633535/other;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B33.4;Leukaemia, unspecified;2;Unknown;1385484871;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;5A50.1;Pseudohypoparathyroidism;2;Active;1225154856;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A7Z;Depressive disorders, unspecified;1;Unknown;1563440232/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA23;Asthma;4;Approved;1656445230;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CB41;Respiratory failure;3;Inactive;370028006;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB60.Z;Acute kidney failure, stage unspecified;3;Active;476391827/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GC2Z;Diseases of the urinary system, unspecified;2;Unknown;1932345217/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MC82.Z;Cardiac arrest, unspecified;2;Inactive;395422191/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NF04.Y;Other specified effects of air pressure or water pressure;3;Inactive;1098633535/other;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B33.4;Leukaemia, unspecified;2;Unknown;1385484871;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;5A50.1;Pseudohypoparathyroidism;2;Active;1225154856;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A7Z;Depressive disorders, unspecified;1;Unknown;1563440232/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA23;Asthma;4;Approved;1656445230;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CB41;Respiratory failure;3;Inactive;370028006;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB60.Z;Acute kidney failure, stage unspecified;3;Active;476391827/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GC2Z;Diseases of the urinary system, unspecified;2;Unknown;1932345217/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MC82.Z;Cardiac arrest, unspecified;2;Inactive;395422191/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NF04.Y;Other specified effects of air pressure or water pressure;3;Inactive;1098633535/other;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B33.4;Leukaemia, unspecified;2;Unknown;1385484871;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;5A50.1;Pseudohypoparathyroidism;2;Active;1225154856;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A7Z;Depressive disorders, unspecified;1;Unknown;1563440232/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA23;Asthma;4;Approved;1656445230;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CB41;Respiratory failure;3;Inactive;370028006;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB60.Z;Acute kidney failure, stage unspecified;3;Active;476391827/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GC2Z;Diseases of the urinary system, unspecified;2;Unknown;1932345217/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MC82.Z;Cardiac arrest, unspecified;2;Inactive;395422191/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NF04.Y;Other specified effects of air pressure or water pressure;3;Inactive;1098633535/other;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B33.4;Leukaemia, unspecified;2;Unknown;1385484871;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;5A50.1;Pseudohypoparathyroidism;2;Active;1225154856;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A7Z;Depressive disorders, unspecified;1;Unknown;1563440232/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA23;Asthma;4;Approved;1656445230;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CB41;Respiratory failure;3;Inactive;370028006;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB60.Z;Acute kidney failure, stage unspecified;3;Active;476391827/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GC2Z;Diseases of the urinary system, unspecified;2;Unknown;1932345217/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MC82.Z;Cardiac arrest, unspecified;2;Inactive;395422191/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NF04.Y;Other specified effects of air pressure or water pressure;3;Inactive;1098633535/other;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B33.4;Leukaemia, unspecified;2;Unknown;1385484871;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;5A50.1;Pseudohypoparathyroidism;2;Active;1225154856;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A7Z;Depressive disorders, unspecified;1;Unknown;1563440232/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA23;Asthma;4;Approved;1656445230;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CB41;Respiratory failure;3;Inactive;370028006;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB60.Z;Acute kidney failure, stage unspecified;3;Active;476391827/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GC2Z;Diseases of the urinary system, unspecified;2;Unknown;1932345217/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MC82.Z;Cardiac arrest, unspecified;2;Inactive;395422191/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NF04.Y;Other specified effects of air pressure or water pressure;3;Inactive;1098633535/other;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B33.4;Leukaemia, unspecified;2;Unknown;1385484871;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;5A50.1;Pseudohypoparathyroidism;2;Active;1225154856;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A7Z;Depressive disorders, unspecified;1;Unknown;1563440232/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA23;Asthma;4;Approved;1656445230;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CB41;Respiratory failure;3;Inactive;370028006;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB60.Z;Acute kidney failure, stage unspecified;3;Active;476391827/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GC2Z;Diseases of the urinary system, unspecified;2;Unknown;1932345217/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MC82.Z;Cardiac arrest, unspecified;2;Inactive;395422191/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NF04.Y;Other specified effects of air pressure or water pressure;3;Inactive;1098633535/other;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B33.4;Leukaemia, unspecified;2;Unknown;1385484871;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;5A50.1;Pseudohypoparathyroidism;2;Active;1225154856;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A7Z;Depressive disorders, unspecified;1;Unknown;1563440232/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA23;Asthma;4;Approved;1656445230;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CB41;Respiratory failure;3;Inactive;370028006;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB60.Z;Acute kidney failure, stage unspecified;3;Active;476391827/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GC2Z;Diseases of the urinary system, unspecified;2;Unknown;1932345217/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MC82.Z;Cardiac arrest, unspecified;2;Inactive;395422191/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NF04.Y;Other specified effects of air pressure or water pressure;3;Inactive;1098633535/other;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B33.4;Leukaemia, unspecified;2;Unknown;1385484871;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;5A50.1;Pseudohypoparathyroidism;2;Active;1225154856;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A7Z;Depressive disorders, unspecified;1;Unknown;1563440232/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA23;Asthma;4;Approved;1656445230;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CB41;Respiratory failure;3;Inactive;370028006;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB60.Z;Acute kidney failure, stage unspecified;3;Active;476391827/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GC2Z;Diseases of the urinary system, unspecified;2;Unknown;1932345217/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MC82.Z;Cardiac arrest, unspecified;2;Inactive;395422191/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NF04.Y;Other specified effects of air pressure or water pressure;3;Inactive;1098633535/other;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B33.4;Leukaemia, unspecified;2;Unknown;1385484871;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;5A50.1;Pseudohypoparathyroidism;2;Active;1225154856;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A7Z;Depressive disorders, unspecified;1;Unknown;1563440232/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA23;Asthma;4;Approved;1656445230;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CB41;Respiratory failure;3;Inactive;370028006;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB60.Z;Acute kidney failure, stage unspecified;3;Active;476391827/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GC2Z;Diseases of the urinary system, unspecified;2;Unknown;1932345217/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MC82.Z;Cardiac arrest, unspecified;2;Inactive;395422191/unspecified;30000168, 30422557, 30085566
51;theophylline;aminophylline;CHEMBL1370561;DB01223;9433;317-34-0;27Y3KJK423;FQPFAHBPWDRTLU-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N;42043;;191;273;0;4;8;1;30;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NF04.Y;Other specified effects of air pressure or water pressure;3;Inactive;1098633535/other;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B33.4;Leukaemia, unspecified;2;Unknown;1385484871;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;5A50.1;Pseudohypoparathyroidism;2;Active;1225154856;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A7Z;Depressive disorders, unspecified;1;Unknown;1563440232/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA23;Asthma;4;Approved;1656445230;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CB41;Respiratory failure;3;Inactive;370028006;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB60.Z;Acute kidney failure, stage unspecified;3;Active;476391827/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GC2Z;Diseases of the urinary system, unspecified;2;Unknown;1932345217/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MC82.Z;Cardiac arrest, unspecified;2;Inactive;395422191/unspecified;30000168, 30422557, 30085566
51;theophylline;oxtriphylline;CHEMBL1200434;DB01303;656652;4499-40-5;3K045XR58X;SOELXOBIIIBLRJ-UHFFFAOYSA-M;CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO;28333;;916;415;0;1;4;2;20;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NF04.Y;Other specified effects of air pressure or water pressure;3;Inactive;1098633535/other;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B33.4;Leukaemia, unspecified;2;Unknown;1385484871;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;5A50.1;Pseudohypoparathyroidism;2;Active;1225154856;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A7Z;Depressive disorders, unspecified;1;Unknown;1563440232/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA23;Asthma;4;Approved;1656445230;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CB41;Respiratory failure;3;Inactive;370028006;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB60.Z;Acute kidney failure, stage unspecified;3;Active;476391827/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GC2Z;Diseases of the urinary system, unspecified;2;Unknown;1932345217/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MC82.Z;Cardiac arrest, unspecified;2;Inactive;395422191/unspecified;30000168, 30422557, 30085566
51;theophylline;theophylline;CHEMBL190;DB00277;2153;58-55-9;0I55128JYK;ZFXYFBGIUFBOJW-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)NC=N2;18016;0;693;267;0;1;3;0;13;4;Approved;1940;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NF04.Y;Other specified effects of air pressure or water pressure;3;Inactive;1098633535/other;30000168, 30422557, 30085566
52;cetrorelix;cetrorelix;CHEMBL1200490;DB00050;25074887;120287-85-6;OON1HFZ4BA;SBNPWPIBESPSIF-MHWMIDJBSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCNC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C;1431;23;496;2830;0;17;16;39;102;4;Approved;2000;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;5A80.1;Polycystic ovary syndrome;3;Inactive;1213633323;37223762, 19761413, 32863284
52;cetrorelix;cetrorelix;CHEMBL1200490;DB00050;25074887;120287-85-6;OON1HFZ4BA;SBNPWPIBESPSIF-MHWMIDJBSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCNC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C;1431;23;496;2830;0;17;16;39;102;4;Approved;2000;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;FA20.Z;Rheumatoid arthritis, serology unspecified;2;Inactive;576319925/unspecified;37223762, 19761413, 32863284
52;cetrorelix;cetrorelix;CHEMBL1200490;DB00050;25074887;120287-85-6;OON1HFZ4BA;SBNPWPIBESPSIF-MHWMIDJBSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCNC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C;1431;23;496;2830;0;17;16;39;102;4;Approved;2000;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA10.Z;Endometriosis of unspecified site;2;Inactive;1838213761/unspecified;37223762, 19761413, 32863284
52;cetrorelix;cetrorelix;CHEMBL1200490;DB00050;25074887;120287-85-6;OON1HFZ4BA;SBNPWPIBESPSIF-MHWMIDJBSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCNC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C;1431;23;496;2830;0;17;16;39;102;4;Approved;2000;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA32.0;Ovarian hyperstimulation syndrome;4;Approved;1216664013;37223762, 19761413, 32863284
52;cetrorelix;cetrorelix;CHEMBL1200490;DB00050;25074887;120287-85-6;OON1HFZ4BA;SBNPWPIBESPSIF-MHWMIDJBSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCNC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C;1431;23;496;2830;0;17;16;39;102;4;Approved;2000;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA90;Hyperplasia of prostate;3;Inactive;978159279;37223762, 19761413, 32863284
52;cetrorelix;cetrorelix;CHEMBL1200490;DB00050;25074887;120287-85-6;OON1HFZ4BA;SBNPWPIBESPSIF-MHWMIDJBSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCNC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C;1431;23;496;2830;0;17;16;39;102;4;Approved;2000;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GC8Y;Other specified diseases of the genitourinary system;4;Approved;30659757/other;37223762, 19761413, 32863284
53;tropicamide;tropicamide;CHEMBL1200604;DB00809;5593;1508-75-4;N0A3Z5XTC6;BGDKAVGWHJFAGW-UHFFFAOYSA-N;CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2;28435;15;534;310;0;1;3;6;21;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.3;Presbyopia;2;Inactive;22794400;30000733, 31082113, 35739063
53;tropicamide;tropicamide;CHEMBL1200604;DB00809;5593;1508-75-4;N0A3Z5XTC6;BGDKAVGWHJFAGW-UHFFFAOYSA-N;CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2;28435;15;534;310;0;1;3;6;21;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;2;Inactive;1739126837;30000733, 31082113, 35739063
53;tropicamide;tropicamide;CHEMBL1200604;DB00809;5593;1508-75-4;N0A3Z5XTC6;BGDKAVGWHJFAGW-UHFFFAOYSA-N;CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2;28435;15;534;310;0;1;3;6;21;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;30000733, 31082113, 35739063
53;tropicamide;tropicamide;CHEMBL1200604;DB00809;5593;1508-75-4;N0A3Z5XTC6;BGDKAVGWHJFAGW-UHFFFAOYSA-N;CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2;28435;15;534;310;0;1;3;6;21;4;Approved;1960;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.3;Presbyopia;2;Inactive;22794400;30000733, 31082113, 35739063
53;tropicamide;tropicamide;CHEMBL1200604;DB00809;5593;1508-75-4;N0A3Z5XTC6;BGDKAVGWHJFAGW-UHFFFAOYSA-N;CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2;28435;15;534;310;0;1;3;6;21;4;Approved;1960;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;2;Inactive;1739126837;30000733, 31082113, 35739063
53;tropicamide;tropicamide;CHEMBL1200604;DB00809;5593;1508-75-4;N0A3Z5XTC6;BGDKAVGWHJFAGW-UHFFFAOYSA-N;CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2;28435;15;534;310;0;1;3;6;21;4;Approved;1960;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;30000733, 31082113, 35739063
53;tropicamide;tropicamide;CHEMBL1200604;DB00809;5593;1508-75-4;N0A3Z5XTC6;BGDKAVGWHJFAGW-UHFFFAOYSA-N;CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2;28435;15;534;310;0;1;3;6;21;4;Approved;1960;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.3;Presbyopia;2;Inactive;22794400;30000733, 31082113, 35739063
53;tropicamide;tropicamide;CHEMBL1200604;DB00809;5593;1508-75-4;N0A3Z5XTC6;BGDKAVGWHJFAGW-UHFFFAOYSA-N;CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2;28435;15;534;310;0;1;3;6;21;4;Approved;1960;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;2;Inactive;1739126837;30000733, 31082113, 35739063
53;tropicamide;tropicamide;CHEMBL1200604;DB00809;5593;1508-75-4;N0A3Z5XTC6;BGDKAVGWHJFAGW-UHFFFAOYSA-N;CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2;28435;15;534;310;0;1;3;6;21;4;Approved;1960;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;30000733, 31082113, 35739063
53;tropicamide;tropicamide;CHEMBL1200604;DB00809;5593;1508-75-4;N0A3Z5XTC6;BGDKAVGWHJFAGW-UHFFFAOYSA-N;CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2;28435;15;534;310;0;1;3;6;21;4;Approved;1960;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.3;Presbyopia;2;Inactive;22794400;30000733, 31082113, 35739063
53;tropicamide;tropicamide;CHEMBL1200604;DB00809;5593;1508-75-4;N0A3Z5XTC6;BGDKAVGWHJFAGW-UHFFFAOYSA-N;CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2;28435;15;534;310;0;1;3;6;21;4;Approved;1960;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;2;Inactive;1739126837;30000733, 31082113, 35739063
53;tropicamide;tropicamide;CHEMBL1200604;DB00809;5593;1508-75-4;N0A3Z5XTC6;BGDKAVGWHJFAGW-UHFFFAOYSA-N;CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2;28435;15;534;310;0;1;3;6;21;4;Approved;1960;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;30000733, 31082113, 35739063
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6B8Z;Feeding or eating disorders, unspecified;2;Inactive;1412387537/unspecified;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;7A20.0;Narcolepsy, Type 1;4;Approved;1851015159;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;7A20.Z;Narcolepsy, unspecified;4;Approved;1201727099/unspecified;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;7A21;Idiopathic hypersomnia;4;Approved;631826564;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;7B2Z;Sleep-wake disorders, unspecified;2;Inactive;274880002/unspecified;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;8A04.1;Essential tremor or related tremors;2;Inactive;1036027657;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;8A04.Y;Other specified disorders associated with tremor;2;Inactive;645263329/other;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;CA0H.Y;Other specified diseases of vocal cords or larynx, not elsewhere classified;2;Inactive;1914646281/other;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MB4D;Headache, not elsewhere classified;3;Unknown;1405405864;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MB53.0;Alternating hemiplegia;2;Inactive;774373615;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MG30.01;Chronic widespread pain;3;Inactive;849253504;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6B8Z;Feeding or eating disorders, unspecified;2;Inactive;1412387537/unspecified;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;7A20.0;Narcolepsy, Type 1;4;Approved;1851015159;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;7A20.Z;Narcolepsy, unspecified;4;Approved;1201727099/unspecified;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;7A21;Idiopathic hypersomnia;4;Approved;631826564;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;7B2Z;Sleep-wake disorders, unspecified;2;Inactive;274880002/unspecified;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;8A04.1;Essential tremor or related tremors;2;Inactive;1036027657;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;8A04.Y;Other specified disorders associated with tremor;2;Inactive;645263329/other;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;CA0H.Y;Other specified diseases of vocal cords or larynx, not elsewhere classified;2;Inactive;1914646281/other;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MB4D;Headache, not elsewhere classified;3;Unknown;1405405864;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MB53.0;Alternating hemiplegia;2;Inactive;774373615;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MG30.01;Chronic widespread pain;3;Inactive;849253504;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6B8Z;Feeding or eating disorders, unspecified;2;Inactive;1412387537/unspecified;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;7A20.0;Narcolepsy, Type 1;4;Approved;1851015159;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;7A20.Z;Narcolepsy, unspecified;4;Approved;1201727099/unspecified;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;7A21;Idiopathic hypersomnia;4;Approved;631826564;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;7B2Z;Sleep-wake disorders, unspecified;2;Inactive;274880002/unspecified;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;8A04.1;Essential tremor or related tremors;2;Inactive;1036027657;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;8A04.Y;Other specified disorders associated with tremor;2;Inactive;645263329/other;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;CA0H.Y;Other specified diseases of vocal cords or larynx, not elsewhere classified;2;Inactive;1914646281/other;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MB4D;Headache, not elsewhere classified;3;Unknown;1405405864;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MB53.0;Alternating hemiplegia;2;Inactive;774373615;29999861, 31643903, 32965954
54;oxybate;4-Hydroxybutanoic acid;CHEMBL1342;DB01440;10413;502-85-2;7G33012534;SJZRECIVHVDYJC-UHFFFAOYSA-N;C(CC(=O)O)CO;1041;-6;575;60;0;2;3;3;7;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MG30.01;Chronic widespread pain;3;Inactive;849253504;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6B8Z;Feeding or eating disorders, unspecified;2;Inactive;1412387537/unspecified;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;7A20.0;Narcolepsy, Type 1;4;Approved;1851015159;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;7A20.Z;Narcolepsy, unspecified;4;Approved;1201727099/unspecified;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;7A21;Idiopathic hypersomnia;4;Approved;631826564;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;7B2Z;Sleep-wake disorders, unspecified;2;Inactive;274880002/unspecified;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;8A04.1;Essential tremor or related tremors;2;Inactive;1036027657;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;8A04.Y;Other specified disorders associated with tremor;2;Inactive;645263329/other;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;CA0H.Y;Other specified diseases of vocal cords or larynx, not elsewhere classified;2;Inactive;1914646281/other;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MB4D;Headache, not elsewhere classified;3;Unknown;1405405864;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MB53.0;Alternating hemiplegia;2;Inactive;774373615;29999861, 31643903, 32965954
54;oxybate;sodium oxybate;CHEMBL1200682;DB09072;23663870;502-85-2;7G33012534;XYGBKMMCQDZQOZ-UHFFFAOYSA-M;C(CC(=O)[O-])CO.[Na+];12609;;604;54;0;1;3;2;8;4;Approved;2002;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MG30.01;Chronic widespread pain;3;Inactive;849253504;29999861, 31643903, 32965954
55;olmesartan medoxomil;olmesartan medoxomil;CHEMBL1200692;NA;130881;144689-63-4;NA;UQGKUQLKSCSZGY-UHFFFAOYSA-N;CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O;5586;38;154;969;0;2;10;11;41;4;Approved;2002;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;19405551, 12076183, 21275446
55;olmesartan medoxomil;olmesartan medoxomil;CHEMBL1200692;NA;130881;144689-63-4;NA;UQGKUQLKSCSZGY-UHFFFAOYSA-N;CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O;5586;38;154;969;0;2;10;11;41;4;Approved;2002;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;19405551, 12076183, 21275446
55;olmesartan medoxomil;olmesartan medoxomil;CHEMBL1200692;NA;130881;144689-63-4;NA;UQGKUQLKSCSZGY-UHFFFAOYSA-N;CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O;5586;38;154;969;0;2;10;11;41;4;Approved;2002;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;19405551, 12076183, 21275446
55;olmesartan medoxomil;olmesartan medoxomil;CHEMBL1200692;NA;130881;144689-63-4;NA;UQGKUQLKSCSZGY-UHFFFAOYSA-N;CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O;5586;38;154;969;0;2;10;11;41;4;Approved;2002;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;19405551, 12076183, 21275446
55;olmesartan medoxomil;olmesartan medoxomil;CHEMBL1200692;NA;130881;144689-63-4;NA;UQGKUQLKSCSZGY-UHFFFAOYSA-N;CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O;5586;38;154;969;0;2;10;11;41;4;Approved;2002;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BD40.Z;Atherosclerotic chronic arterial occlusive disease, unspecified;3;Inactive;109367356/unspecified;19405551, 12076183, 21275446
55;olmesartan medoxomil;olmesartan medoxomil;CHEMBL1200692;NA;130881;144689-63-4;NA;UQGKUQLKSCSZGY-UHFFFAOYSA-N;CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O;5586;38;154;969;0;2;10;11;41;4;Approved;2002;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;GB40;Nephritic syndrome;2;Inactive;1783829886;19405551, 12076183, 21275446
55;olmesartan medoxomil;olmesartan medoxomil;CHEMBL1200692;NA;130881;144689-63-4;NA;UQGKUQLKSCSZGY-UHFFFAOYSA-N;CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O;5586;38;154;969;0;2;10;11;41;4;Approved;2002;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;GB61.Z;Chronic kidney disease, stage unspecified;3;Inactive;412389819/unspecified;19405551, 12076183, 21275446
55;olmesartan medoxomil;olmesartan medoxomil;CHEMBL1200692;NA;130881;144689-63-4;NA;UQGKUQLKSCSZGY-UHFFFAOYSA-N;CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O;5586;38;154;969;0;2;10;11;41;4;Approved;2002;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;GC2Z;Diseases of the urinary system, unspecified;3;Inactive;1932345217/unspecified;19405551, 12076183, 21275446
55;olmesartan medoxomil;olmesartan medoxomil;CHEMBL1200692;NA;130881;144689-63-4;NA;UQGKUQLKSCSZGY-UHFFFAOYSA-N;CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O;5586;38;154;969;0;2;10;11;41;4;Approved;2002;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;MF96.Z;Proteinuria, unspecified;3;Inactive;930895737/unspecified;19405551, 12076183, 21275446
56;travoprost;travoprost;CHEMBL1200799;DB00287;5282226;157283-68-6;WJ68R08KX9;MKPLKVHSHYCHOC-AHTXBMBWSA-N;CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O;5005;41;962;693;0;3;9;13;35;4;Approved;2001;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C61.01;Ocular hypertension;4;Approved;535283437;30000736, 16930087, 18377347
56;travoprost;travoprost;CHEMBL1200799;DB00287;5282226;157283-68-6;WJ68R08KX9;MKPLKVHSHYCHOC-AHTXBMBWSA-N;CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O;5005;41;962;693;0;3;9;13;35;4;Approved;2001;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C61.20;Pseudoexfoliative open-angle glaucoma;3;Inactive;1391393460;30000736, 16930087, 18377347
56;travoprost;travoprost;CHEMBL1200799;DB00287;5282226;157283-68-6;WJ68R08KX9;MKPLKVHSHYCHOC-AHTXBMBWSA-N;CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O;5005;41;962;693;0;3;9;13;35;4;Approved;2001;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000736, 16930087, 18377347
56;travoprost;travoprost;CHEMBL1200799;DB00287;5282226;157283-68-6;WJ68R08KX9;MKPLKVHSHYCHOC-AHTXBMBWSA-N;CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O;5005;41;962;693;0;3;9;13;35;4;Approved;2001;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000736, 16930087, 18377347
57;homatropine methylbromide;methylhomatropine bromide;"CHEMBL1200851;CHEMBL1201235;CHEMBL1615437";DB00725;6646;80-49-9;68JRS2HC1C;FUFVKLQESJNNAN-UHFFFAOYSA-M;C[N+]1(C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C.[Br-];3703;;465;374;0;1;4;4;22;4;Approved;1943;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD12;Cough;4;Approved;2027526159;14928219, 576237, 5416194
57;homatropine methylbromide;homatropine methylbromide;"CHEMBL1200851;CHEMBL1201235;CHEMBL1615437";DB00725;5282592;80-49-9;68JRS2HC1C;WKWOJBUWWZTUQV-PJPHBNEVSA-N;C[N+]1(C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C;2904;24;465;374;1;1;3;4;21;4;Approved;1943;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD12;Cough;4;Approved;2027526159;14928219, 576237, 5416194
57;homatropine methylbromide;methylhomatropine bromide;"CHEMBL1200851;CHEMBL1201235;CHEMBL1615437";DB00725;6646;80-49-9;68JRS2HC1C;FUFVKLQESJNNAN-UHFFFAOYSA-M;C[N+]1(C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C.[Br-];3703;;465;374;0;1;4;4;22;4;Approved;1943;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD12;Cough;4;Approved;2027526159;14928219, 576237, 5416194
57;homatropine methylbromide;homatropine methylbromide;"CHEMBL1200851;CHEMBL1201235;CHEMBL1615437";DB00725;5282592;80-49-9;68JRS2HC1C;WKWOJBUWWZTUQV-PJPHBNEVSA-N;C[N+]1(C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C;2904;24;465;374;1;1;3;4;21;4;Approved;1943;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD12;Cough;4;Approved;2027526159;14928219, 576237, 5416194
57;homatropine methylbromide;methylhomatropine bromide;"CHEMBL1200851;CHEMBL1201235;CHEMBL1615437";DB00725;6646;80-49-9;68JRS2HC1C;FUFVKLQESJNNAN-UHFFFAOYSA-M;C[N+]1(C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C.[Br-];3703;;465;374;0;1;4;4;22;4;Approved;1943;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD12;Cough;4;Approved;2027526159;14928219, 576237, 5416194
57;homatropine methylbromide;homatropine methylbromide;"CHEMBL1200851;CHEMBL1201235;CHEMBL1615437";DB00725;5282592;80-49-9;68JRS2HC1C;WKWOJBUWWZTUQV-PJPHBNEVSA-N;C[N+]1(C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C;2904;24;465;374;1;1;3;4;21;4;Approved;1943;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD12;Cough;4;Approved;2027526159;14928219, 576237, 5416194
57;homatropine methylbromide;methylhomatropine bromide;"CHEMBL1200851;CHEMBL1201235;CHEMBL1615437";DB00725;6646;80-49-9;68JRS2HC1C;FUFVKLQESJNNAN-UHFFFAOYSA-M;C[N+]1(C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C.[Br-];3703;;465;374;0;1;4;4;22;4;Approved;1943;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD12;Cough;4;Approved;2027526159;14928219, 576237, 5416194
57;homatropine methylbromide;homatropine methylbromide;"CHEMBL1200851;CHEMBL1201235;CHEMBL1615437";DB00725;5282592;80-49-9;68JRS2HC1C;WKWOJBUWWZTUQV-PJPHBNEVSA-N;C[N+]1(C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C;2904;24;465;374;1;1;3;4;21;4;Approved;1943;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD12;Cough;4;Approved;2027526159;14928219, 576237, 5416194
57;homatropine methylbromide;methylhomatropine bromide;"CHEMBL1200851;CHEMBL1201235;CHEMBL1615437";DB00725;6646;80-49-9;68JRS2HC1C;FUFVKLQESJNNAN-UHFFFAOYSA-M;C[N+]1(C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C.[Br-];3703;;465;374;0;1;4;4;22;4;Approved;1943;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD12;Cough;4;Approved;2027526159;14928219, 576237, 5416194
57;homatropine methylbromide;homatropine methylbromide;"CHEMBL1200851;CHEMBL1201235;CHEMBL1615437";DB00725;5282592;80-49-9;68JRS2HC1C;WKWOJBUWWZTUQV-PJPHBNEVSA-N;C[N+]1(C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C;2904;24;465;374;1;1;3;4;21;4;Approved;1943;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD12;Cough;4;Approved;2027526159;14928219, 576237, 5416194
58;fluphenazine decanoate;fluphenazine decanoate;CHEMBL1200854;NA;3388;5002-47-1;NA;VIQCGTZFEYDQMR-UHFFFAOYSA-N;CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;5918;9;613;765;0;0;9;16;41;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;35373519, 25654768, 15674872
58;fluphenazine decanoate;fluphenazine decanoate;CHEMBL1200854;NA;3388;5002-47-1;NA;VIQCGTZFEYDQMR-UHFFFAOYSA-N;CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;5918;9;613;765;0;0;9;16;41;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;EA90.Z;Psoriasis of unspecified type;2;Inactive;63698555/unspecified;35373519, 25654768, 15674872
59;dexchlorpheniramine;dexchlorpheniramine maleate;CHEMBL1200927;DB09555;5281070;2438-32-6;B10YD955QW;DBAKFASWICGISY-DASCVMRKSA-N;CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=CC(=O)O)C(=O)O;3909;;907;368;0;2;6;7;27;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine maleate;CHEMBL1200927;DB09555;5281070;2438-32-6;B10YD955QW;DBAKFASWICGISY-DASCVMRKSA-N;CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=CC(=O)O)C(=O)O;3909;;907;368;0;2;6;7;27;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine maleate;CHEMBL1200927;DB09555;5281070;2438-32-6;B10YD955QW;DBAKFASWICGISY-DASCVMRKSA-N;CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=CC(=O)O)C(=O)O;3909;;907;368;0;2;6;7;27;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine maleate;CHEMBL1200927;DB09555;5281070;2438-32-6;B10YD955QW;DBAKFASWICGISY-DASCVMRKSA-N;CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=CC(=O)O)C(=O)O;3909;;907;368;0;2;6;7;27;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.03;Other allergic rhinitis;4;Approved;941478759;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine maleate;CHEMBL1200927;DB09555;5281070;2438-32-6;B10YD955QW;DBAKFASWICGISY-DASCVMRKSA-N;CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=CC(=O)O)C(=O)O;3909;;907;368;0;2;6;7;27;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine maleate;CHEMBL1200927;DB09555;5281070;2438-32-6;B10YD955QW;DBAKFASWICGISY-DASCVMRKSA-N;CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=CC(=O)O)C(=O)O;3909;;907;368;0;2;6;7;27;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.3;Vasomotor rhinitis;4;Approved;1286636442;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine maleate;CHEMBL1200927;DB09555;5281070;2438-32-6;B10YD955QW;DBAKFASWICGISY-DASCVMRKSA-N;CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=CC(=O)O)C(=O)O;3909;;907;368;0;2;6;7;27;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB04;Idiopathic angioedema;4;Approved;330898059;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine maleate;CHEMBL1200927;DB09555;5281070;2438-32-6;B10YD955QW;DBAKFASWICGISY-DASCVMRKSA-N;CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=CC(=O)O)C(=O)O;3909;;907;368;0;2;6;7;27;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine maleate;CHEMBL1200927;DB09555;5281070;2438-32-6;B10YD955QW;DBAKFASWICGISY-DASCVMRKSA-N;CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=CC(=O)O)C(=O)O;3909;;907;368;0;2;6;7;27;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EJ40.Z;Sunburn, unspecified;3;Unknown;318744822/unspecified;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine;CHEMBL1201353;DB13679;33036;2438-32-6;B10YD955QW;SOYKEARSMXGVTM-HNNXBMFYSA-N;CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2;27479;34;161;249;0;0;2;5;19;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine;CHEMBL1201353;DB13679;33036;2438-32-6;B10YD955QW;SOYKEARSMXGVTM-HNNXBMFYSA-N;CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2;27479;34;161;249;0;0;2;5;19;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine;CHEMBL1201353;DB13679;33036;2438-32-6;B10YD955QW;SOYKEARSMXGVTM-HNNXBMFYSA-N;CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2;27479;34;161;249;0;0;2;5;19;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine;CHEMBL1201353;DB13679;33036;2438-32-6;B10YD955QW;SOYKEARSMXGVTM-HNNXBMFYSA-N;CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2;27479;34;161;249;0;0;2;5;19;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.03;Other allergic rhinitis;4;Approved;941478759;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine;CHEMBL1201353;DB13679;33036;2438-32-6;B10YD955QW;SOYKEARSMXGVTM-HNNXBMFYSA-N;CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2;27479;34;161;249;0;0;2;5;19;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine;CHEMBL1201353;DB13679;33036;2438-32-6;B10YD955QW;SOYKEARSMXGVTM-HNNXBMFYSA-N;CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2;27479;34;161;249;0;0;2;5;19;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.3;Vasomotor rhinitis;4;Approved;1286636442;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine;CHEMBL1201353;DB13679;33036;2438-32-6;B10YD955QW;SOYKEARSMXGVTM-HNNXBMFYSA-N;CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2;27479;34;161;249;0;0;2;5;19;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB04;Idiopathic angioedema;4;Approved;330898059;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine;CHEMBL1201353;DB13679;33036;2438-32-6;B10YD955QW;SOYKEARSMXGVTM-HNNXBMFYSA-N;CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2;27479;34;161;249;0;0;2;5;19;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;30000848, 29976533, 16390354
59;dexchlorpheniramine;dexchlorpheniramine;CHEMBL1201353;DB13679;33036;2438-32-6;B10YD955QW;SOYKEARSMXGVTM-HNNXBMFYSA-N;CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2;27479;34;161;249;0;0;2;5;19;4;Approved;1958;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EJ40.Z;Sunburn, unspecified;3;Unknown;318744822/unspecified;30000848, 29976533, 16390354
61;methdilazine;methdilazine;CHEMBL1200959;DB00902;14677;1982-37-2;4Q13LY9Z8X;HTMIBDQKFHUPSX-UHFFFAOYSA-N;CN1CCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42;2964;52;318;339;0;0;3;2;21;4;Approved;1982;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;14080889, 8975609, 15782943
61;methdilazine;methdilazine;CHEMBL1200959;DB00902;14677;1982-37-2;4Q13LY9Z8X;HTMIBDQKFHUPSX-UHFFFAOYSA-N;CN1CCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42;2964;52;318;339;0;0;3;2;21;4;Approved;1982;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;14080889, 8975609, 15782943
61;methdilazine;methdilazine;CHEMBL1200959;DB00902;14677;1982-37-2;4Q13LY9Z8X;HTMIBDQKFHUPSX-UHFFFAOYSA-N;CN1CCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42;2964;52;318;339;0;0;3;2;21;4;Approved;1982;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB04;Idiopathic angioedema;4;Approved;330898059;14080889, 8975609, 15782943
61;methdilazine;methdilazine;CHEMBL1200959;DB00902;14677;1982-37-2;4Q13LY9Z8X;HTMIBDQKFHUPSX-UHFFFAOYSA-N;CN1CCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42;2964;52;318;339;0;0;3;2;21;4;Approved;1982;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;14080889, 8975609, 15782943
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C61.01;Ocular hypertension;4;Approved;535283437;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C82.3;Restrictive ophthalmopathy;3;Active;1291786130;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;EC21.2;Hereditary alopecia or hypotrichosis;4;Approved;384451022;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;ED70.Z;Alopecia, unspecified;2;Inactive;1313926062/unspecified;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C61.01;Ocular hypertension;4;Approved;535283437;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C82.3;Restrictive ophthalmopathy;3;Active;1291786130;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;EC21.2;Hereditary alopecia or hypotrichosis;4;Approved;384451022;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;ED70.Z;Alopecia, unspecified;2;Inactive;1313926062/unspecified;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C61.01;Ocular hypertension;4;Approved;535283437;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C82.3;Restrictive ophthalmopathy;3;Active;1291786130;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;EC21.2;Hereditary alopecia or hypotrichosis;4;Approved;384451022;30000734, 32447639, 32544560
62;bimatoprost;bimatoprost;CHEMBL1200963;DB00905;5311027;155206-00-1;QXS94885MZ;AQOKCDNYWBIDND-FTOWTWDKSA-N;CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O;4156;28;898;541;0;4;4;12;30;4;Approved;2001;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;ED70.Z;Alopecia, unspecified;2;Inactive;1313926062/unspecified;30000734, 32447639, 32544560
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Inverse agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Inverse agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Inverse agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Inverse agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Inverse agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Inverse agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Inverse agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Inverse agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Inverse agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Inverse agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Inverse agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Inverse agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Inverse agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Inverse agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;38022280, 3545764, 2897276
63;haloperidol decanoate;haloperidol decanoate;CHEMBL1200986;NA;52919;74050-97-8;NA;GUTXTARXLVFHDK-UHFFFAOYSA-N;CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl;5301;79;466;665;0;0;5;16;37;4;Approved;1986;Small molecule;Inverse agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;38022280, 3545764, 2897276
64;thiothixene;thiothixene;CHEMBL1201;DB01623;941651;3313-26-6;7318FJ13YJ;GFBKORZTTCHDGY-UWVJOHFNSA-N;CN1CCN(CC1)CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4436;38;775;711;0;0;6;5;30;4;Approved;1967;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000171, 4433190, 6055751
64;thiothixene;thiothixene;CHEMBL1201;DB01623;941651;3313-26-6;7318FJ13YJ;GFBKORZTTCHDGY-UWVJOHFNSA-N;CN1CCN(CC1)CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4436;38;775;711;0;0;6;5;30;4;Approved;1967;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000171, 4433190, 6055751
64;thiothixene;thiothixene;CHEMBL1201;DB01623;941651;3313-26-6;7318FJ13YJ;GFBKORZTTCHDGY-UWVJOHFNSA-N;CN1CCN(CC1)CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4436;38;775;711;0;0;6;5;30;4;Approved;1967;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000171, 4433190, 6055751
65;cabergoline;cabergoline;CHEMBL1201087;DB00248;54746;81409-90-7;LL60K9J05T;KORNTPPJEAJQIU-KJXAQDMKSA-N;CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C;4516;34;717;713;0;2;4;8;33;4;Approved;1996;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;2A00.5;Primary neoplasm of brain of unknown or unspecified type;4;Approved;677986724;30000386, 28025719, 35670988
65;cabergoline;cabergoline;CHEMBL1201087;DB00248;54746;81409-90-7;LL60K9J05T;KORNTPPJEAJQIU-KJXAQDMKSA-N;CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C;4516;34;717;713;0;2;4;8;33;4;Approved;1996;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;2C6Z;Malignant neoplasms of breast, unspecified;1;Inactive;1047754165/unspecified;30000386, 28025719, 35670988
65;cabergoline;cabergoline;CHEMBL1201087;DB00248;54746;81409-90-7;LL60K9J05T;KORNTPPJEAJQIU-KJXAQDMKSA-N;CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C;4516;34;717;713;0;2;4;8;33;4;Approved;1996;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A14;Diabetes mellitus, type unspecified;3;Unknown;1697306310;30000386, 28025719, 35670988
65;cabergoline;cabergoline;CHEMBL1201087;DB00248;54746;81409-90-7;LL60K9J05T;KORNTPPJEAJQIU-KJXAQDMKSA-N;CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C;4516;34;717;713;0;2;4;8;33;4;Approved;1996;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A70.0;Pituitary-dependent Cushing disease;2;Inactive;380861892;30000386, 28025719, 35670988
65;cabergoline;cabergoline;CHEMBL1201087;DB00248;54746;81409-90-7;LL60K9J05T;KORNTPPJEAJQIU-KJXAQDMKSA-N;CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C;4516;34;717;713;0;2;4;8;33;4;Approved;1996;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A80.1;Polycystic ovary syndrome;2;Unknown;1213633323;30000386, 28025719, 35670988
65;cabergoline;cabergoline;CHEMBL1201087;DB00248;54746;81409-90-7;LL60K9J05T;KORNTPPJEAJQIU-KJXAQDMKSA-N;CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C;4516;34;717;713;0;2;4;8;33;4;Approved;1996;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;30000386, 28025719, 35670988
65;cabergoline;cabergoline;CHEMBL1201087;DB00248;54746;81409-90-7;LL60K9J05T;KORNTPPJEAJQIU-KJXAQDMKSA-N;CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C;4516;34;717;713;0;2;4;8;33;4;Approved;1996;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C4Z;Disorders due to substance use, unspecified;2;Inactive;590211325/unspecified;30000386, 28025719, 35670988
65;cabergoline;cabergoline;CHEMBL1201087;DB00248;54746;81409-90-7;LL60K9J05T;KORNTPPJEAJQIU-KJXAQDMKSA-N;CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C;4516;34;717;713;0;2;4;8;33;4;Approved;1996;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;3;Inactive;1254916765;30000386, 28025719, 35670988
65;cabergoline;cabergoline;CHEMBL1201087;DB00248;54746;81409-90-7;LL60K9J05T;KORNTPPJEAJQIU-KJXAQDMKSA-N;CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C;4516;34;717;713;0;2;4;8;33;4;Approved;1996;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;GA32.0;Ovarian hyperstimulation syndrome;3;Inactive;1216664013;30000386, 28025719, 35670988
65;cabergoline;cabergoline;CHEMBL1201087;DB00248;54746;81409-90-7;LL60K9J05T;KORNTPPJEAJQIU-KJXAQDMKSA-N;CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C;4516;34;717;713;0;2;4;8;33;4;Approved;1996;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;GC8Y;Other specified diseases of the genitourinary system;3;Inactive;30659757/other;30000386, 28025719, 35670988
65;cabergoline;cabergoline;CHEMBL1201087;DB00248;54746;81409-90-7;LL60K9J05T;KORNTPPJEAJQIU-KJXAQDMKSA-N;CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C;4516;34;717;713;0;2;4;8;33;4;Approved;1996;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG30.Z;Chronic pain, unspecified;2;Unknown;1581976053/unspecified;30000386, 28025719, 35670988
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.02;Hepatocellular carcinoma of liver;2;Inactive;1294035808;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C34;Cutaneous neuroendocrine carcinoma;2;Inactive;680322043;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;3;Inactive;1552457716/unspecified;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;4;Approved;1594217552/other;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F37.Y;Other specified benign neoplasm of endocrine glands;3;Unknown;1290583069/other;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F9A;Neoplasms of unknown behaviour of endocrine glands;3;Inactive;1442164144;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;3;Inactive;1844086508/unspecified;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5B10;Carcinoid syndrome;4;Approved;111763187;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;9C82.3;Restrictive ophthalmopathy;2;Inactive;1291786130;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DA22.1;Erosive gastro-oesophageal reflux disease;2;Unknown;417695496;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DB30.Y;Other specified obstruction of large intestine;2;Inactive;320939116/other;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DE11;Dumping syndrome;2;Inactive;237191235;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;GB81;Autosomal dominant polycystic kidney disease;3;Inactive;91220434;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.1;Diarrhoea;3;Inactive;116759077;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.02;Hepatocellular carcinoma of liver;2;Inactive;1294035808;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C34;Cutaneous neuroendocrine carcinoma;2;Inactive;680322043;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;3;Inactive;1552457716/unspecified;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;4;Approved;1594217552/other;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F37.Y;Other specified benign neoplasm of endocrine glands;3;Unknown;1290583069/other;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F9A;Neoplasms of unknown behaviour of endocrine glands;3;Inactive;1442164144;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;3;Inactive;1844086508/unspecified;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5B10;Carcinoid syndrome;4;Approved;111763187;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;9C82.3;Restrictive ophthalmopathy;2;Inactive;1291786130;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DA22.1;Erosive gastro-oesophageal reflux disease;2;Unknown;417695496;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DB30.Y;Other specified obstruction of large intestine;2;Inactive;320939116/other;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DE11;Dumping syndrome;2;Inactive;237191235;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;GB81;Autosomal dominant polycystic kidney disease;3;Inactive;91220434;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.1;Diarrhoea;3;Inactive;116759077;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.02;Hepatocellular carcinoma of liver;2;Inactive;1294035808;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C34;Cutaneous neuroendocrine carcinoma;2;Inactive;680322043;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;3;Inactive;1552457716/unspecified;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;4;Approved;1594217552/other;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F37.Y;Other specified benign neoplasm of endocrine glands;3;Unknown;1290583069/other;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F9A;Neoplasms of unknown behaviour of endocrine glands;3;Inactive;1442164144;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;3;Inactive;1844086508/unspecified;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5B10;Carcinoid syndrome;4;Approved;111763187;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;9C82.3;Restrictive ophthalmopathy;2;Inactive;1291786130;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DA22.1;Erosive gastro-oesophageal reflux disease;2;Unknown;417695496;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DB30.Y;Other specified obstruction of large intestine;2;Inactive;320939116/other;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DE11;Dumping syndrome;2;Inactive;237191235;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;GB81;Autosomal dominant polycystic kidney disease;3;Inactive;91220434;31145576, 25014687, 31643689
66;lanreotide;S-lanreotide;CHEMBL2079626;DB06791;10796238;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-HUZRFOFRSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.1;Diarrhoea;3;Inactive;116759077;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.02;Hepatocellular carcinoma of liver;2;Inactive;1294035808;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C34;Cutaneous neuroendocrine carcinoma;2;Inactive;680322043;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;3;Inactive;1552457716/unspecified;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;4;Approved;1594217552/other;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F37.Y;Other specified benign neoplasm of endocrine glands;3;Unknown;1290583069/other;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F9A;Neoplasms of unknown behaviour of endocrine glands;3;Inactive;1442164144;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;3;Inactive;1844086508/unspecified;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5B10;Carcinoid syndrome;4;Approved;111763187;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;9C82.3;Restrictive ophthalmopathy;2;Inactive;1291786130;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DA22.1;Erosive gastro-oesophageal reflux disease;2;Unknown;417695496;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DB30.Y;Other specified obstruction of large intestine;2;Inactive;320939116/other;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DE11;Dumping syndrome;2;Inactive;237191235;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;GB81;Autosomal dominant polycystic kidney disease;3;Inactive;91220434;31145576, 25014687, 31643689
66;lanreotide;lanreotide;CHEMBL1201185;DB06791;6918011;108736-35-2;0G3DE8943Y;PUDHBTGHUJUUFI-SCTWWAJVSA-N;C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O;10963;25;406;2000;0;13;14;17;77;4;Approved;2007;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.1;Diarrhoea;3;Inactive;116759077;31145576, 25014687, 31643689
67;maraviroc;maraviroc;CHEMBL1201187;DB04835;3002977;376348-65-1;MD6P741W8A;GSNHKUDZZFZSJB-HLMSNRGBSA-N;CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C;5137;51;63;751;0;1;6;8;37;4;Approved;2007;Small molecule;Antagonist;P51681;ccr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;1C62.Z;Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified;4;Approved;1508081745/unspecified;30000615, 31643590, 18174962
67;maraviroc;maraviroc;CHEMBL1201187;DB04835;3002977;376348-65-1;MD6P741W8A;GSNHKUDZZFZSJB-HLMSNRGBSA-N;CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C;5137;51;63;751;0;1;6;8;37;4;Approved;2007;Small molecule;Antagonist;P51681;ccr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2B57.Z;Kaposi sarcoma of unspecified primary site;2;Inactive;2131977134/unspecified;30000615, 31643590, 18174962
67;maraviroc;maraviroc;CHEMBL1201187;DB04835;3002977;376348-65-1;MD6P741W8A;GSNHKUDZZFZSJB-HLMSNRGBSA-N;CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C;5137;51;63;751;0;1;6;8;37;4;Approved;2007;Small molecule;Antagonist;P51681;ccr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;4B24.Z;Graft-versus-host disease, unspecified;2;Inactive;437372167/unspecified;30000615, 31643590, 18174962
67;maraviroc;maraviroc;CHEMBL1201187;DB04835;3002977;376348-65-1;MD6P741W8A;GSNHKUDZZFZSJB-HLMSNRGBSA-N;CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C;5137;51;63;751;0;1;6;8;37;4;Approved;2007;Small molecule;Antagonist;P51681;ccr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;4B4Z;Diseases of the immune system, unspecified;4;Approved;1954798891/unspecified;30000615, 31643590, 18174962
67;maraviroc;maraviroc;CHEMBL1201187;DB04835;3002977;376348-65-1;MD6P741W8A;GSNHKUDZZFZSJB-HLMSNRGBSA-N;CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C;5137;51;63;751;0;1;6;8;37;4;Approved;2007;Small molecule;Antagonist;P51681;ccr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;5C80.1;Hypertriglyceridaemia;1;Inactive;1820945441;30000615, 31643590, 18174962
67;maraviroc;maraviroc;CHEMBL1201187;DB04835;3002977;376348-65-1;MD6P741W8A;GSNHKUDZZFZSJB-HLMSNRGBSA-N;CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C;5137;51;63;751;0;1;6;8;37;4;Approved;2007;Small molecule;Antagonist;P51681;ccr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;6D8Z;Dementia, unknown or unspecified cause;2;Unknown;546689346/unspecified;30000615, 31643590, 18174962
67;maraviroc;maraviroc;CHEMBL1201187;DB04835;3002977;376348-65-1;MD6P741W8A;GSNHKUDZZFZSJB-HLMSNRGBSA-N;CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C;5137;51;63;751;0;1;6;8;37;4;Approved;2007;Small molecule;Antagonist;P51681;ccr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;8B20;Stroke not known if ischaemic or haemorrhagic;3;Active;1442995018;30000615, 31643590, 18174962
67;maraviroc;maraviroc;CHEMBL1201187;DB04835;3002977;376348-65-1;MD6P741W8A;GSNHKUDZZFZSJB-HLMSNRGBSA-N;CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C;5137;51;63;751;0;1;6;8;37;4;Approved;2007;Small molecule;Antagonist;P51681;ccr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;FA20.Z;Rheumatoid arthritis, serology unspecified;2;Inactive;576319925/unspecified;30000615, 31643590, 18174962
67;maraviroc;maraviroc;CHEMBL1201187;DB04835;3002977;376348-65-1;MD6P741W8A;GSNHKUDZZFZSJB-HLMSNRGBSA-N;CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C;5137;51;63;751;0;1;6;8;37;4;Approved;2007;Small molecule;Antagonist;P51681;ccr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;2;Active;1282135070/unspecified;30000615, 31643590, 18174962
67;maraviroc;maraviroc;CHEMBL1201187;DB04835;3002977;376348-65-1;MD6P741W8A;GSNHKUDZZFZSJB-HLMSNRGBSA-N;CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C;5137;51;63;751;0;1;6;8;37;4;Approved;2007;Small molecule;Antagonist;P51681;ccr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;RA01;COVID-19;2;Active;1730556128;30000615, 31643590, 18174962
69;leuprolide;leuprolide;CHEMBL1201199;DB00007;657181;53714-56-0;EFY6W0M8TG;GFIJNRVAKGFPGQ-LIJARHBVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12094;7;432;2390;0;15;14;32;87;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;3;Active;1047754165/unspecified;17970643, 31869126, 31643987
69;leuprolide;leuprolide;CHEMBL1201199;DB00007;657181;53714-56-0;EFY6W0M8TG;GFIJNRVAKGFPGQ-LIJARHBVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12094;7;432;2390;0;15;14;32;87;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.0;Adenocarcinoma of prostate;4;Approved;1510677183;17970643, 31869126, 31643987
69;leuprolide;leuprolide;CHEMBL1201199;DB00007;657181;53714-56-0;EFY6W0M8TG;GFIJNRVAKGFPGQ-LIJARHBVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12094;7;432;2390;0;15;14;32;87;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.Y;Other specified malignant neoplasms of prostate;4;Approved;1552457716/other;17970643, 31869126, 31643987
69;leuprolide;leuprolide;CHEMBL1201199;DB00007;657181;53714-56-0;EFY6W0M8TG;GFIJNRVAKGFPGQ-LIJARHBVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12094;7;432;2390;0;15;14;32;87;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;4;Approved;1552457716/unspecified;17970643, 31869126, 31643987
69;leuprolide;leuprolide;CHEMBL1201199;DB00007;657181;53714-56-0;EFY6W0M8TG;GFIJNRVAKGFPGQ-LIJARHBVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12094;7;432;2390;0;15;14;32;87;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2E86.0;Leiomyoma of uterus;4;Approved;455734276;17970643, 31869126, 31643987
69;leuprolide;leuprolide;CHEMBL1201199;DB00007;657181;53714-56-0;EFY6W0M8TG;GFIJNRVAKGFPGQ-LIJARHBVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12094;7;432;2390;0;15;14;32;87;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;5A60.3;Central precocious puberty;4;Approved;1749914533;17970643, 31869126, 31643987
69;leuprolide;leuprolide;CHEMBL1201199;DB00007;657181;53714-56-0;EFY6W0M8TG;GFIJNRVAKGFPGQ-LIJARHBVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12094;7;432;2390;0;15;14;32;87;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;5A80.0;Clinical hyperandrogenism;2;Unknown;1023132628;17970643, 31869126, 31643987
69;leuprolide;leuprolide;CHEMBL1201199;DB00007;657181;53714-56-0;EFY6W0M8TG;GFIJNRVAKGFPGQ-LIJARHBVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12094;7;432;2390;0;15;14;32;87;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;5A92;Peripheral precocious puberty;4;Approved;1495024153;17970643, 31869126, 31643987
69;leuprolide;leuprolide;CHEMBL1201199;DB00007;657181;53714-56-0;EFY6W0M8TG;GFIJNRVAKGFPGQ-LIJARHBVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12094;7;432;2390;0;15;14;32;87;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;8A20;Alzheimer disease;2;Active;1611724421;17970643, 31869126, 31643987
69;leuprolide;leuprolide;CHEMBL1201199;DB00007;657181;53714-56-0;EFY6W0M8TG;GFIJNRVAKGFPGQ-LIJARHBVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12094;7;432;2390;0;15;14;32;87;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA10.Z;Endometriosis of unspecified site;4;Approved;1838213761/unspecified;17970643, 31869126, 31643987
69;leuprolide;leuprolide;CHEMBL1201199;DB00007;657181;53714-56-0;EFY6W0M8TG;GFIJNRVAKGFPGQ-LIJARHBVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12094;7;432;2390;0;15;14;32;87;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GC8Y;Other specified diseases of the genitourinary system;3;Unknown;30659757/other;17970643, 31869126, 31643987
69;leuprolide;leuprolide;CHEMBL1201199;DB00007;657181;53714-56-0;EFY6W0M8TG;GFIJNRVAKGFPGQ-LIJARHBVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12094;7;432;2390;0;15;14;32;87;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;2;Active;1282135070/unspecified;17970643, 31869126, 31643987
69;leuprolide;leuprolide;CHEMBL1201199;DB00007;657181;53714-56-0;EFY6W0M8TG;GFIJNRVAKGFPGQ-LIJARHBVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12094;7;432;2390;0;15;14;32;87;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;MG3Z;Pain, unspecified;3;Unknown;661232217/unspecified;17970643, 31869126, 31643987
69;leuprolide;leuprolide;CHEMBL1201199;DB00007;657181;53714-56-0;EFY6W0M8TG;GFIJNRVAKGFPGQ-LIJARHBVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12094;7;432;2390;0;15;14;32;87;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;NE84;Failure or rejection of transplanted organs or tissues;2;Unknown;129221830;17970643, 31869126, 31643987
70;benztropine;benztropine;CHEMBL1201203;DB00245;1201549;86-13-5;1NHL2J4X8K;GIJXKZJWITVLHI-YOFSQIOKSA-N;CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4;3074;45;125;340;0;0;2;4;23;4;Approved;1954;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;32809468, 30000721, 31643727
70;benztropine;benztropine;CHEMBL1201203;DB00245;1201549;86-13-5;1NHL2J4X8K;GIJXKZJWITVLHI-YOFSQIOKSA-N;CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4;3074;45;125;340;0;0;2;4;23;4;Approved;1954;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;32809468, 30000721, 31643727
70;benztropine;benztropine;CHEMBL1201203;DB00245;1201549;86-13-5;1NHL2J4X8K;GIJXKZJWITVLHI-YOFSQIOKSA-N;CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4;3074;45;125;340;0;0;2;4;23;4;Approved;1954;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;ME84.3;Sciatica;2;Inactive;2056651014;32809468, 30000721, 31643727
70;benztropine;benztropine;CHEMBL1201203;DB00245;1201549;86-13-5;1NHL2J4X8K;GIJXKZJWITVLHI-YOFSQIOKSA-N;CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4;3074;45;125;340;0;0;2;4;23;4;Approved;1954;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;ME84.Z;Spinal pain, unspecified;2;Inactive;2051065876/unspecified;32809468, 30000721, 31643727
70;benztropine;benztropine;CHEMBL1201203;DB00245;1201549;86-13-5;1NHL2J4X8K;GIJXKZJWITVLHI-YOFSQIOKSA-N;CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4;3074;45;125;340;0;0;2;4;23;4;Approved;1954;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Unknown;661232217/unspecified;32809468, 30000721, 31643727
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G40;Sepsis without septic shock;1;Inactive;622600769;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Active;1683090852;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;2;Unknown;761947693/unspecified;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;4;Approved;56009591;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;3;Inactive;1663360295/unspecified;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DB99.4;Hepatopulmonary syndrome;1;Inactive;866605228;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME04.Z;Ascites, unspecified;3;Unknown;1133729855/unspecified;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ND51.2;Injury of spinal cord, level unspecified;3;Inactive;2131180445;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G40;Sepsis without septic shock;1;Inactive;622600769;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Active;1683090852;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;2;Unknown;761947693/unspecified;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;4;Approved;56009591;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;3;Inactive;1663360295/unspecified;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DB99.4;Hepatopulmonary syndrome;1;Inactive;866605228;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME04.Z;Ascites, unspecified;3;Unknown;1133729855/unspecified;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ND51.2;Injury of spinal cord, level unspecified;3;Inactive;2131180445;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G40;Sepsis without septic shock;1;Inactive;622600769;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Active;1683090852;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;2;Unknown;761947693/unspecified;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;4;Approved;56009591;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;3;Inactive;1663360295/unspecified;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DB99.4;Hepatopulmonary syndrome;1;Inactive;866605228;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME04.Z;Ascites, unspecified;3;Unknown;1133729855/unspecified;32885276, 25644760, 35002029
71;midodrine;midodrine;CHEMBL1201212;DB00211;4195;42794-76-3;6YE7PBM15H;PTKSEFOSCHHMPD-UHFFFAOYSA-N;COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O;25428;-6;938;263;0;3;5;6;18;4;Approved;1996;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ND51.2;Injury of spinal cord, level unspecified;3;Inactive;2131180445;32885276, 25644760, 35002029
72;isoetharine;isoetharine [MI];CHEMBL1201213;DB00221;71466;79490-84-9;YV0SN3276Q;HUYWAWARQUIQLE-MFKMUULPSA-N;CC[C@H]([C@H](C1=CC(=C(C=C1)O)O)O)NC(C)C;23931;17;727;223;0;4;4;5;17;4;Approved;1979;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;30000052, 6855843, 8629678
72;isoetharine;isoetharine [MI];CHEMBL1201213;DB00221;71466;79490-84-9;YV0SN3276Q;HUYWAWARQUIQLE-MFKMUULPSA-N;CC[C@H]([C@H](C1=CC(=C(C=C1)O)O)O)NC(C)C;23931;17;727;223;0;4;4;5;17;4;Approved;1979;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;30000052, 6855843, 8629678
72;isoetharine;isoetharine [MI];CHEMBL1201213;DB00221;71466;79490-84-9;YV0SN3276Q;HUYWAWARQUIQLE-MFKMUULPSA-N;CC[C@H]([C@H](C1=CC(=C(C=C1)O)O)O)NC(C)C;23931;17;727;223;0;4;4;5;17;4;Approved;1979;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;30000052, 6855843, 8629678
72;isoetharine;isoetharine;CHEMBL1201213;DB00221;3762;79490-84-9;YV0SN3276Q;HUYWAWARQUIQLE-UHFFFAOYSA-N;CCC(C(C1=CC(=C(C=C1)O)O)O)NC(C)C;23931;17;727;223;0;4;4;5;17;4;Approved;1979;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;30000052, 6855843, 8629678
72;isoetharine;isoetharine;CHEMBL1201213;DB00221;3762;79490-84-9;YV0SN3276Q;HUYWAWARQUIQLE-UHFFFAOYSA-N;CCC(C(C1=CC(=C(C=C1)O)O)O)NC(C)C;23931;17;727;223;0;4;4;5;17;4;Approved;1979;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;30000052, 6855843, 8629678
72;isoetharine;isoetharine;CHEMBL1201213;DB00221;3762;79490-84-9;YV0SN3276Q;HUYWAWARQUIQLE-UHFFFAOYSA-N;CCC(C(C1=CC(=C(C=C1)O)O)O)NC(C)C;23931;17;727;223;0;4;4;5;17;4;Approved;1979;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;30000052, 6855843, 8629678
72;isoetharine;isoetharine [MI];CHEMBL1201213;DB00221;71466;79490-84-9;YV0SN3276Q;HUYWAWARQUIQLE-MFKMUULPSA-N;CC[C@H]([C@H](C1=CC(=C(C=C1)O)O)O)NC(C)C;23931;17;727;223;0;4;4;5;17;4;Approved;1979;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;30000052, 6855843, 8629678
72;isoetharine;isoetharine [MI];CHEMBL1201213;DB00221;71466;79490-84-9;YV0SN3276Q;HUYWAWARQUIQLE-MFKMUULPSA-N;CC[C@H]([C@H](C1=CC(=C(C=C1)O)O)O)NC(C)C;23931;17;727;223;0;4;4;5;17;4;Approved;1979;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;30000052, 6855843, 8629678
72;isoetharine;isoetharine [MI];CHEMBL1201213;DB00221;71466;79490-84-9;YV0SN3276Q;HUYWAWARQUIQLE-MFKMUULPSA-N;CC[C@H]([C@H](C1=CC(=C(C=C1)O)O)O)NC(C)C;23931;17;727;223;0;4;4;5;17;4;Approved;1979;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;30000052, 6855843, 8629678
72;isoetharine;isoetharine;CHEMBL1201213;DB00221;3762;79490-84-9;YV0SN3276Q;HUYWAWARQUIQLE-UHFFFAOYSA-N;CCC(C(C1=CC(=C(C=C1)O)O)O)NC(C)C;23931;17;727;223;0;4;4;5;17;4;Approved;1979;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;30000052, 6855843, 8629678
72;isoetharine;isoetharine;CHEMBL1201213;DB00221;3762;79490-84-9;YV0SN3276Q;HUYWAWARQUIQLE-UHFFFAOYSA-N;CCC(C(C1=CC(=C(C=C1)O)O)O)NC(C)C;23931;17;727;223;0;4;4;5;17;4;Approved;1979;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;30000052, 6855843, 8629678
72;isoetharine;isoetharine;CHEMBL1201213;DB00221;3762;79490-84-9;YV0SN3276Q;HUYWAWARQUIQLE-UHFFFAOYSA-N;CCC(C(C1=CC(=C(C=C1)O)O)O)NC(C)C;23931;17;727;223;0;4;4;5;17;4;Approved;1979;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;30000052, 6855843, 8629678
73;dapiprazole;dapiprazole;CHEMBL1201216;DB00298;3033538;72822-12-9;5RNZ8GJO7K;RFWZESUMWJKKRN-UHFFFAOYSA-N;CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4;3255;24;372;395;0;0;4;4;24;4;Approved;1990;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;8539022, 7902553, 1350669
73;dapiprazole;dapiprazole;CHEMBL1201216;DB00298;3033538;72822-12-9;5RNZ8GJO7K;RFWZESUMWJKKRN-UHFFFAOYSA-N;CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4;3255;24;372;395;0;0;4;4;24;4;Approved;1990;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;8539022, 7902553, 1350669
73;dapiprazole;dapiprazole;CHEMBL1201216;DB00298;3033538;72822-12-9;5RNZ8GJO7K;RFWZESUMWJKKRN-UHFFFAOYSA-N;CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4;3255;24;372;395;0;0;4;4;24;4;Approved;1990;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;8539022, 7902553, 1350669
74;lisdexamfetamine;lisdexamfetamine;CHEMBL1201222;DB01255;11597698;608137-32-2;H645GUL8KJ;VOBHXZCDAVEXEY-JSGCOSHPSA-N;CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N;26338;12;811;252;0;3;3;8;19;4;Approved;2007;Small molecule;Agonist;Q96RJ0;taar1_human;Class A (Rhodopsin);Trace amine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;4;Approved;821852937/unspecified;30000800, 24788672, 32932388
74;lisdexamfetamine;lisdexamfetamine;CHEMBL1201222;DB01255;11597698;608137-32-2;H645GUL8KJ;VOBHXZCDAVEXEY-JSGCOSHPSA-N;CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N;26338;12;811;252;0;3;3;8;19;4;Approved;2007;Small molecule;Agonist;Q96RJ0;taar1_human;Class A (Rhodopsin);Trace amine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;3;Inactive;1683919430/unspecified;30000800, 24788672, 32932388
74;lisdexamfetamine;lisdexamfetamine;CHEMBL1201222;DB01255;11597698;608137-32-2;H645GUL8KJ;VOBHXZCDAVEXEY-JSGCOSHPSA-N;CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N;26338;12;811;252;0;3;3;8;19;4;Approved;2007;Small molecule;Agonist;Q96RJ0;taar1_human;Class A (Rhodopsin);Trace amine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Inactive;1456478153/unspecified;30000800, 24788672, 32932388
74;lisdexamfetamine;lisdexamfetamine;CHEMBL1201222;DB01255;11597698;608137-32-2;H645GUL8KJ;VOBHXZCDAVEXEY-JSGCOSHPSA-N;CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N;26338;12;811;252;0;3;3;8;19;4;Approved;2007;Small molecule;Agonist;Q96RJ0;taar1_human;Class A (Rhodopsin);Trace amine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;30000800, 24788672, 32932388
74;lisdexamfetamine;lisdexamfetamine;CHEMBL1201222;DB01255;11597698;608137-32-2;H645GUL8KJ;VOBHXZCDAVEXEY-JSGCOSHPSA-N;CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N;26338;12;811;252;0;3;3;8;19;4;Approved;2007;Small molecule;Agonist;Q96RJ0;taar1_human;Class A (Rhodopsin);Trace amine receptors;Aminergic receptors;6B81;Bulimia Nervosa;2;Inactive;509381842;30000800, 24788672, 32932388
74;lisdexamfetamine;lisdexamfetamine;CHEMBL1201222;DB01255;11597698;608137-32-2;H645GUL8KJ;VOBHXZCDAVEXEY-JSGCOSHPSA-N;CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N;26338;12;811;252;0;3;3;8;19;4;Approved;2007;Small molecule;Agonist;Q96RJ0;taar1_human;Class A (Rhodopsin);Trace amine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;30000800, 24788672, 32932388
74;lisdexamfetamine;lisdexamfetamine;CHEMBL1201222;DB01255;11597698;608137-32-2;H645GUL8KJ;VOBHXZCDAVEXEY-JSGCOSHPSA-N;CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N;26338;12;811;252;0;3;3;8;19;4;Approved;2007;Small molecule;Agonist;Q96RJ0;taar1_human;Class A (Rhodopsin);Trace amine receptors;Aminergic receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;1;Inactive;2016549355/unspecified;30000800, 24788672, 32932388
74;lisdexamfetamine;lisdexamfetamine;CHEMBL1201222;DB01255;11597698;608137-32-2;H645GUL8KJ;VOBHXZCDAVEXEY-JSGCOSHPSA-N;CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N;26338;12;811;252;0;3;3;8;19;4;Approved;2007;Small molecule;Agonist;Q96RJ0;taar1_human;Class A (Rhodopsin);Trace amine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;2;Inactive;1038292737/unspecified;30000800, 24788672, 32932388
74;lisdexamfetamine;lisdexamfetamine;CHEMBL1201222;DB01255;11597698;608137-32-2;H645GUL8KJ;VOBHXZCDAVEXEY-JSGCOSHPSA-N;CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N;26338;12;811;252;0;3;3;8;19;4;Approved;2007;Small molecule;Agonist;Q96RJ0;taar1_human;Class A (Rhodopsin);Trace amine receptors;Aminergic receptors;8A40.Z;Multiple sclerosis, unspecified;2;Inactive;1298865187/unspecified;30000800, 24788672, 32932388
74;lisdexamfetamine;lisdexamfetamine;CHEMBL1201222;DB01255;11597698;608137-32-2;H645GUL8KJ;VOBHXZCDAVEXEY-JSGCOSHPSA-N;CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N;26338;12;811;252;0;3;3;8;19;4;Approved;2007;Small molecule;Agonist;Q96RJ0;taar1_human;Class A (Rhodopsin);Trace amine receptors;Aminergic receptors;MB29.1;Binge eating;4;Approved;1535148777;30000800, 24788672, 32932388
75;isopropamide;isopropamide;CHEMBL1201232;DB01625;3775;7492-32-2;8B9I31H724;JTPUMZTWMWIVPA-UHFFFAOYSA-O;CC(C)[N+](C)(CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N)C(C)C;3535;43;431;419;1;1;1;8;26;4;Approved;1957;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;13549220, 11104, 21951
75;isopropamide;isopropamide;CHEMBL1201232;DB01625;3775;7492-32-2;8B9I31H724;JTPUMZTWMWIVPA-UHFFFAOYSA-O;CC(C)[N+](C)(CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N)C(C)C;3535;43;431;419;1;1;1;8;26;4;Approved;1957;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;13549220, 11104, 21951
76;mephentermine;mephentermine;CHEMBL1201234;DB01365;3677;100-92-5;TEZ91L71V4;RXQCGGRTAILOIN-UHFFFAOYSA-N;CC(C)(CC1=CC=CC=C1)NC;16326;24;12;123;0;1;1;3;12;4;Approved;1951;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;34456355, 23759255, 32404042
76;mephentermine;mephentermine;CHEMBL1201234;DB01365;3677;100-92-5;TEZ91L71V4;RXQCGGRTAILOIN-UHFFFAOYSA-N;CC(C)(CC1=CC=CC=C1)NC;16326;24;12;123;0;1;1;3;12;4;Approved;1951;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;34456355, 23759255, 32404042
76;mephentermine;mephentermine;CHEMBL1201234;DB01365;3677;100-92-5;TEZ91L71V4;RXQCGGRTAILOIN-UHFFFAOYSA-N;CC(C)(CC1=CC=CC=C1)NC;16326;24;12;123;0;1;1;3;12;4;Approved;1951;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;34456355, 23759255, 32404042
76;mephentermine;mephentermine;CHEMBL1201234;DB01365;3677;100-92-5;TEZ91L71V4;RXQCGGRTAILOIN-UHFFFAOYSA-N;CC(C)(CC1=CC=CC=C1)NC;16326;24;12;123;0;1;1;3;12;4;Approved;1951;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;34456355, 23759255, 32404042
76;mephentermine;mephentermine;CHEMBL1201234;DB01365;3677;100-92-5;TEZ91L71V4;RXQCGGRTAILOIN-UHFFFAOYSA-N;CC(C)(CC1=CC=CC=C1)NC;16326;24;12;123;0;1;1;3;12;4;Approved;1951;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;34456355, 23759255, 32404042
76;mephentermine;mephentermine;CHEMBL1201234;DB01365;3677;100-92-5;TEZ91L71V4;RXQCGGRTAILOIN-UHFFFAOYSA-N;CC(C)(CC1=CC=CC=C1)NC;16326;24;12;123;0;1;1;3;12;4;Approved;1951;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;34456355, 23759255, 32404042
76;mephentermine;mephentermine;CHEMBL1201234;DB01365;3677;100-92-5;TEZ91L71V4;RXQCGGRTAILOIN-UHFFFAOYSA-N;CC(C)(CC1=CC=CC=C1)NC;16326;24;12;123;0;1;1;3;12;4;Approved;1951;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;34456355, 23759255, 32404042
76;mephentermine;mephentermine;CHEMBL1201234;DB01365;3677;100-92-5;TEZ91L71V4;RXQCGGRTAILOIN-UHFFFAOYSA-N;CC(C)(CC1=CC=CC=C1)NC;16326;24;12;123;0;1;1;3;12;4;Approved;1951;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;34456355, 23759255, 32404042
76;mephentermine;mephentermine;CHEMBL1201234;DB01365;3677;100-92-5;TEZ91L71V4;RXQCGGRTAILOIN-UHFFFAOYSA-N;CC(C)(CC1=CC=CC=C1)NC;16326;24;12;123;0;1;1;3;12;4;Approved;1951;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;34456355, 23759255, 32404042
77;levobunolol;levobunolol;CHEMBL1201237;DB01210;39468;47141-42-4;G6317AOI7K;IXHBTMCLRNMKHZ-LBPRGKRZSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CCCC2=O)O;2914;24;586;350;0;2;4;6;21;4;Approved;1985;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.01;Ocular hypertension;4;Approved;535283437;30000211, 37861808, 3019819
77;levobunolol;levobunolol;CHEMBL1201237;DB01210;39468;47141-42-4;G6317AOI7K;IXHBTMCLRNMKHZ-LBPRGKRZSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CCCC2=O)O;2914;24;586;350;0;2;4;6;21;4;Approved;1985;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.01;Ocular hypertension;4;Approved;535283437;30000211, 37861808, 3019819
78;rocuronium;rocuronium;CHEMBL1201244;DB00728;441290;143558-00-3;WRE554RFEZ;YXRDKMPIGHSVRX-OOJCLDBCSA-N;CC(=O)OC1C(CC2C1(CCC3C2CCC4C3(CC(C(C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C;5298;5;59;898;1;1;5;6;38;4;Approved;1994;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;26512948, 29999741, 30969710
78;rocuronium;rocuronium;CHEMBL1201244;DB00728;441290;143558-00-3;WRE554RFEZ;YXRDKMPIGHSVRX-OOJCLDBCSA-N;CC(=O)OC1C(CC2C1(CCC3C2CCC4C3(CC(C(C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C;5298;5;59;898;1;1;5;6;38;4;Approved;1994;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;26512948, 29999741, 30969710
79;bromodiphenhydramine;bromodiphenhydramine;CHEMBL1201245;DB01237;2444;118-23-0;T032BI7727;NUNIWXHYABYXKF-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=C(C=C2)Br;3342;4;125;258;0;0;2;6;20;4;Approved;1954;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;1973150, 1194397, 14377226
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2B6Y;Other specified malignant neoplasms of lip, oral cavity or pharynx;2;Active;794095161/other;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C51.Z;Malignant neoplasms of peritoneum, unspecified;2;Inactive;315445782/unspecified;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C6Y;Other specified malignant neoplasms of breast;4;Approved;1047754165/other;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C6Z;Malignant neoplasms of breast, unspecified;4;Approved;1047754165/unspecified;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C73.Z;Malignant neoplasms of ovary, unspecified;2;Active;685124533/unspecified;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C74.Z;Malignant neoplasms of fallopian tube, unspecified;2;Inactive;459381514/unspecified;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C82.0;Adenocarcinoma of prostate;4;Approved;1510677183;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C82.Y;Other specified malignant neoplasms of prostate;4;Approved;1552457716/other;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;4;Approved;1552457716/unspecified;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GA10.Z;Endometriosis of unspecified site;4;Approved;1838213761/unspecified;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GA11;Adenomyosis;2;Inactive;171294592;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GA30.0Z;Menopause, unspecified;3;Inactive;1965418440/unspecified;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GA30.6;Premature ovarian failure;2;Active;756899519;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GC8Y;Other specified diseases of the genitourinary system;3;Inactive;30659757/other;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2B6Y;Other specified malignant neoplasms of lip, oral cavity or pharynx;2;Active;794095161/other;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C51.Z;Malignant neoplasms of peritoneum, unspecified;2;Inactive;315445782/unspecified;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C6Y;Other specified malignant neoplasms of breast;4;Approved;1047754165/other;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C6Z;Malignant neoplasms of breast, unspecified;4;Approved;1047754165/unspecified;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C73.Z;Malignant neoplasms of ovary, unspecified;2;Active;685124533/unspecified;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C74.Z;Malignant neoplasms of fallopian tube, unspecified;2;Inactive;459381514/unspecified;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C82.0;Adenocarcinoma of prostate;4;Approved;1510677183;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C82.Y;Other specified malignant neoplasms of prostate;4;Approved;1552457716/other;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;4;Approved;1552457716/unspecified;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GA10.Z;Endometriosis of unspecified site;4;Approved;1838213761/unspecified;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GA11;Adenomyosis;2;Inactive;171294592;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GA30.0Z;Menopause, unspecified;3;Inactive;1965418440/unspecified;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GA30.6;Premature ovarian failure;2;Active;756899519;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GC8Y;Other specified diseases of the genitourinary system;3;Inactive;30659757/other;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2B6Y;Other specified malignant neoplasms of lip, oral cavity or pharynx;2;Active;794095161/other;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C51.Z;Malignant neoplasms of peritoneum, unspecified;2;Inactive;315445782/unspecified;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C6Y;Other specified malignant neoplasms of breast;4;Approved;1047754165/other;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;4;Approved;1047754165/unspecified;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C73.Z;Malignant neoplasms of ovary, unspecified;2;Active;685124533/unspecified;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C74.Z;Malignant neoplasms of fallopian tube, unspecified;2;Inactive;459381514/unspecified;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.0;Adenocarcinoma of prostate;4;Approved;1510677183;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.Y;Other specified malignant neoplasms of prostate;4;Approved;1552457716/other;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;4;Approved;1552457716/unspecified;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA10.Z;Endometriosis of unspecified site;4;Approved;1838213761/unspecified;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA11;Adenomyosis;2;Inactive;171294592;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA30.0Z;Menopause, unspecified;3;Inactive;1965418440/unspecified;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA30.6;Premature ovarian failure;2;Active;756899519;31644049, 25738668, 31294133
80;goserelin;S-goserelin;CHEMBL1201247;DB00014;90474525;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-ORFGIKFDSA-N;[2H][C@]1(C(C(C(=O)N1)([2H])[2H])([2H])[2H])C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N6CCC[C@H]6C(=O)NNC(=O)N;12744;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GC8Y;Other specified diseases of the genitourinary system;3;Inactive;30659757/other;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2B6Y;Other specified malignant neoplasms of lip, oral cavity or pharynx;2;Active;794095161/other;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C51.Z;Malignant neoplasms of peritoneum, unspecified;2;Inactive;315445782/unspecified;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C6Y;Other specified malignant neoplasms of breast;4;Approved;1047754165/other;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;4;Approved;1047754165/unspecified;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C73.Z;Malignant neoplasms of ovary, unspecified;2;Active;685124533/unspecified;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C74.Z;Malignant neoplasms of fallopian tube, unspecified;2;Inactive;459381514/unspecified;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.0;Adenocarcinoma of prostate;4;Approved;1510677183;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.Y;Other specified malignant neoplasms of prostate;4;Approved;1552457716/other;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;4;Approved;1552457716/unspecified;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA10.Z;Endometriosis of unspecified site;4;Approved;1838213761/unspecified;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA11;Adenomyosis;2;Inactive;171294592;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA30.0Z;Menopause, unspecified;3;Inactive;1965418440/unspecified;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA30.6;Premature ovarian failure;2;Active;756899519;31644049, 25738668, 31294133
80;goserelin;goserelin;CHEMBL1201247;DB00014;5311128;65807-02-5;0F65R8P09N;BLCLNMBMMGCOAS-URPVMXJPSA-N;CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6;12694;-15;496;2560;0;17;16;32;91;4;Approved;1989;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GC8Y;Other specified diseases of the genitourinary system;3;Inactive;30659757/other;31644049, 25738668, 31294133
81;arbutamine;arbutamine;CHEMBL1201251;DB01102;60789;128470-16-6;B07L15YAEV;IIRWWTKISYTTBL-SFHVURJKSA-N;C1=CC(=CC=C1CCCCNCC(C2=CC(=C(C=C2)O)O)O)O;3174;9;93;320;0;5;5;8;23;4;Approved;1997;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;9183607, 8960948, 10453293
82;histrelin;histrelin;CHEMBL1201255;NA;25077993;76712-82-8;NA;HHXHVIJIIXKSOE-QILQGKCVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC2=CN(C=N2)CC3=CC=CC=C3)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13235;11;447;2650;0;16;15;35;96;4;Approved;1991;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.0;Adenocarcinoma of prostate;4;Approved;1510677183;31643395, 26683629, 7684676
82;histrelin;histrelin;CHEMBL1201255;NA;25077993;76712-82-8;NA;HHXHVIJIIXKSOE-QILQGKCVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC2=CN(C=N2)CC3=CC=CC=C3)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13235;11;447;2650;0;16;15;35;96;4;Approved;1991;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;4;Approved;1552457716/unspecified;31643395, 26683629, 7684676
82;histrelin;histrelin;CHEMBL1201255;NA;25077993;76712-82-8;NA;HHXHVIJIIXKSOE-QILQGKCVSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC2=CN(C=N2)CC3=CC=CC=C3)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13235;11;447;2650;0;16;15;35;96;4;Approved;1991;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;5A60.3;Central precocious puberty;4;Approved;1749914533;31643395, 26683629, 7684676
83;bethanidine;bethanidine;CHEMBL1201260;DB00217;2368;55-73-2;W8S3YM7AUU;NIVZHWNOUVJHKV-UHFFFAOYSA-N;CNC(=NC)NCC1=CC=CC=C1;17725;9;364;160;0;2;1;4;13;4;Approved;1981;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;34748762, 6017482, 5634708
83;bethanidine;bethanidine;CHEMBL1201260;DB00217;2368;55-73-2;W8S3YM7AUU;NIVZHWNOUVJHKV-UHFFFAOYSA-N;CNC(=NC)NCC1=CC=CC=C1;17725;9;364;160;0;2;1;4;13;4;Approved;1981;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;34748762, 6017482, 5634708
83;bethanidine;bethanidine;CHEMBL1201260;DB00217;2368;55-73-2;W8S3YM7AUU;NIVZHWNOUVJHKV-UHFFFAOYSA-N;CNC(=NC)NCC1=CC=CC=C1;17725;9;364;160;0;2;1;4;13;4;Approved;1981;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;34748762, 6017482, 5634708
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;7004425, 2049823, 3291837
84;dipivefrin;dipivefrin;CHEMBL1201262;DB00449;3105;52365-63-6;8Q1PVL543G;OCUJLLGVOUDECM-UHFFFAOYSA-N;CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C;3514;29;849;463;0;2;6;9;25;4;Approved;1980;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;7004425, 2049823, 3291837
85;methantheline;methantheline;CHEMBL1201264;DB00940;4097;5818-17-7;36EI79TX7I;GZHFODJQISUKAY-UHFFFAOYSA-N;CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13;3404;33;355;426;1;0;3;7;25;4;Approved;1951;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;22527350, 8750900, 19279
85;methantheline;methantheline;CHEMBL1201264;DB00940;4097;5818-17-7;36EI79TX7I;GZHFODJQISUKAY-UHFFFAOYSA-N;CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13;3404;33;355;426;1;0;3;7;25;4;Approved;1951;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;4;Approved;1416949107/unspecified;22527350, 8750900, 19279
86;buclizine;buclizine;CHEMBL1201271;DB00354;6729;82-95-1;0C94V6X681;MOYGZHXDRJNJEP-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl;433;71;65;514;0;0;2;6;31;4;Approved;1982;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;22469258, 32890657, 26663906
86;buclizine;buclizine;CHEMBL1201271;DB00354;6729;82-95-1;0C94V6X681;MOYGZHXDRJNJEP-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl;433;71;65;514;0;0;2;6;31;4;Approved;1982;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;22469258, 32890657, 26663906
86;buclizine;buclizine;CHEMBL1201271;DB00354;6729;82-95-1;0C94V6X681;MOYGZHXDRJNJEP-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl;433;71;65;514;0;0;2;6;31;4;Approved;1982;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;22469258, 32890657, 26663906
86;buclizine;buclizine;CHEMBL1201271;DB00354;6729;82-95-1;0C94V6X681;MOYGZHXDRJNJEP-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl;433;71;65;514;0;0;2;6;31;4;Approved;1982;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;22469258, 32890657, 26663906
87;levobetaxolol;levobetaxolol;CHEMBL1201274;DB09351;60657;93221-48-8;75O9XHA4TU;NWIUTZDMDHAVTP-KRWDZBQOSA-N;CC(C)NC[C@@H](COC1=CC=C(C=C1)CCOCC2CC2)O;3074;28;507;286;0;2;4;11;22;4;Approved;2000;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.01;Ocular hypertension;4;Approved;535283437;15036567, 18289898, 11572462
87;levobetaxolol;levobetaxolol;CHEMBL1201274;DB09351;60657;93221-48-8;75O9XHA4TU;NWIUTZDMDHAVTP-KRWDZBQOSA-N;CC(C)NC[C@@H](COC1=CC=C(C=C1)CCOCC2CC2)O;3074;28;507;286;0;2;4;11;22;4;Approved;2000;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;15036567, 18289898, 11572462
88;cinacalcet;cinacalcet;CHEMBL1201284;DB01012;156419;226256-56-0;UAZ6V7728S;VDHAWDNDOKGFTD-MRXNPFEDSA-N;CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F;3574;61;12;422;0;1;4;6;26;4;Approved;2004;Small molecule;PAM;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;2C82.0;Adenocarcinoma of prostate;2;Inactive;1510677183;37603675, 35277957, 32491590
88;cinacalcet;cinacalcet;CHEMBL1201284;DB01012;156419;226256-56-0;UAZ6V7728S;VDHAWDNDOKGFTD-MRXNPFEDSA-N;CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F;3574;61;12;422;0;1;4;6;26;4;Approved;2004;Small molecule;PAM;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;2D12.Y;Other specified malignant neoplasms of other endocrine glands or related structures;4;Approved;202249350/other;37603675, 35277957, 32491590
88;cinacalcet;cinacalcet;CHEMBL1201284;DB01012;156419;226256-56-0;UAZ6V7728S;VDHAWDNDOKGFTD-MRXNPFEDSA-N;CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F;3574;61;12;422;0;1;4;6;26;4;Approved;2004;Small molecule;PAM;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;5A51.0;Primary hyperparathyroidism;4;Approved;817194045;37603675, 35277957, 32491590
88;cinacalcet;cinacalcet;CHEMBL1201284;DB01012;156419;226256-56-0;UAZ6V7728S;VDHAWDNDOKGFTD-MRXNPFEDSA-N;CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F;3574;61;12;422;0;1;4;6;26;4;Approved;2004;Small molecule;PAM;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;5A51.1;Secondary hyperparathyroidism;4;Approved;1442752937;37603675, 35277957, 32491590
88;cinacalcet;cinacalcet;CHEMBL1201284;DB01012;156419;226256-56-0;UAZ6V7728S;VDHAWDNDOKGFTD-MRXNPFEDSA-N;CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F;3574;61;12;422;0;1;4;6;26;4;Approved;2004;Small molecule;PAM;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;5A51.Z;Hyperparathyroidism, unspecified;4;Approved;9633776/unspecified;37603675, 35277957, 32491590
88;cinacalcet;cinacalcet;CHEMBL1201284;DB01012;156419;226256-56-0;UAZ6V7728S;VDHAWDNDOKGFTD-MRXNPFEDSA-N;CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F;3574;61;12;422;0;1;4;6;26;4;Approved;2004;Small molecule;PAM;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;5C63.22;Hypophosphataemic rickets;1;Inactive;1010293846;37603675, 35277957, 32491590
88;cinacalcet;cinacalcet;CHEMBL1201284;DB01012;156419;226256-56-0;UAZ6V7728S;VDHAWDNDOKGFTD-MRXNPFEDSA-N;CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F;3574;61;12;422;0;1;4;6;26;4;Approved;2004;Small molecule;PAM;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;GB61.Z;Chronic kidney disease, stage unspecified;4;Approved;412389819/unspecified;37603675, 35277957, 32491590
89;oxyphenonium;oxyphenonium;CHEMBL1201286;DB00219;5749;14214-84-7;D2G5508Y7I;GFRUPHOKLBPHTQ-UHFFFAOYSA-N;CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3485;41;465;409;1;1;3;9;25;4;Approved;1982;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA60.Z;Gastric ulcer, unspecified;4;Approved;1437411258/unspecified;13462727, 18170611, 6085901
89;oxyphenonium;oxyphenonium;CHEMBL1201286;DB00219;5749;14214-84-7;D2G5508Y7I;GFRUPHOKLBPHTQ-UHFFFAOYSA-N;CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3485;41;465;409;1;1;3;9;25;4;Approved;1982;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA63.Z;Duodenal ulcer, unspecified;4;Approved;553678663/unspecified;13462727, 18170611, 6085901
89;oxyphenonium;oxyphenonium;CHEMBL1201286;DB00219;5749;14214-84-7;D2G5508Y7I;GFRUPHOKLBPHTQ-UHFFFAOYSA-N;CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3485;41;465;409;1;1;3;9;25;4;Approved;1982;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA60.Z;Gastric ulcer, unspecified;4;Approved;1437411258/unspecified;13462727, 18170611, 6085901
89;oxyphenonium;oxyphenonium;CHEMBL1201286;DB00219;5749;14214-84-7;D2G5508Y7I;GFRUPHOKLBPHTQ-UHFFFAOYSA-N;CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3485;41;465;409;1;1;3;9;25;4;Approved;1982;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA63.Z;Duodenal ulcer, unspecified;4;Approved;553678663/unspecified;13462727, 18170611, 6085901
90;dexbrompheniramine;dexbrompheniramine;CHEMBL1201287;DB00405;16960;132-21-8;75T64B71RP;ZDIGNSYAACHWNL-HNNXBMFYSA-N;CN(C)CC[C@@H](C1=CC=C(C=C1)Br)C2=CC=CC=N2;31924;35;161;249;0;0;2;5;19;4;Approved;1963;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000837, 19085565, 3981411
90;dexbrompheniramine;dexbrompheniramine;CHEMBL1201287;DB00405;16960;132-21-8;75T64B71RP;ZDIGNSYAACHWNL-HNNXBMFYSA-N;CN(C)CC[C@@H](C1=CC=C(C=C1)Br)C2=CC=CC=N2;31924;35;161;249;0;0;2;5;19;4;Approved;1963;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000837, 19085565, 3981411
91;acamprosate;acamprosate;CHEMBL1201293;DB00659;71158;77337-76-9;N4K14YGM3J;AFCGFAGUEYAMAO-UHFFFAOYSA-N;CC(=O)NCCCS(=O)(=O)O;18121;-12;918;215;0;2;4;4;11;4;Approved;2004;Small molecule;Antagonist;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;6A02.Z;Autism spectrum disorder, unspecified;1;Inactive;437815624/unspecified;36153940, 31643988, 20163323
91;acamprosate;acamprosate;CHEMBL1201293;DB00659;71158;77337-76-9;N4K14YGM3J;AFCGFAGUEYAMAO-UHFFFAOYSA-N;CC(=O)NCCCS(=O)(=O)O;18121;-12;918;215;0;2;4;4;11;4;Approved;2004;Small molecule;Antagonist;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;6B8Z;Feeding or eating disorders, unspecified;2;Inactive;1412387537/unspecified;36153940, 31643988, 20163323
91;acamprosate;acamprosate;CHEMBL1201293;DB00659;71158;77337-76-9;N4K14YGM3J;AFCGFAGUEYAMAO-UHFFFAOYSA-N;CC(=O)NCCCS(=O)(=O)O;18121;-12;918;215;0;2;4;4;11;4;Approved;2004;Small molecule;Antagonist;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;36153940, 31643988, 20163323
91;acamprosate;acamprosate;CHEMBL1201293;DB00659;71158;77337-76-9;N4K14YGM3J;AFCGFAGUEYAMAO-UHFFFAOYSA-N;CC(=O)NCCCS(=O)(=O)O;18121;-12;918;215;0;2;4;4;11;4;Approved;2004;Small molecule;Antagonist;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;36153940, 31643988, 20163323
91;acamprosate;acamprosate;CHEMBL1201293;DB00659;71158;77337-76-9;N4K14YGM3J;AFCGFAGUEYAMAO-UHFFFAOYSA-N;CC(=O)NCCCS(=O)(=O)O;18121;-12;918;215;0;2;4;4;11;4;Approved;2004;Small molecule;Antagonist;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Inactive;2016549355/unspecified;36153940, 31643988, 20163323
91;acamprosate;acamprosate;CHEMBL1201293;DB00659;71158;77337-76-9;N4K14YGM3J;AFCGFAGUEYAMAO-UHFFFAOYSA-N;CC(=O)NCCCS(=O)(=O)O;18121;-12;918;215;0;2;4;4;11;4;Approved;2004;Small molecule;Antagonist;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;LD55;Fragile X chromosome;2;Inactive;1524287677;36153940, 31643988, 20163323
91;acamprosate;acamprosate;CHEMBL1201293;DB00659;71158;77337-76-9;N4K14YGM3J;AFCGFAGUEYAMAO-UHFFFAOYSA-N;CC(=O)NCCCS(=O)(=O)O;18121;-12;918;215;0;2;4;4;11;4;Approved;2004;Small molecule;Antagonist;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;MC41;Tinnitus;1;Inactive;1089305710;36153940, 31643988, 20163323
91;acamprosate;acamprosate;CHEMBL1201293;DB00659;71158;77337-76-9;N4K14YGM3J;AFCGFAGUEYAMAO-UHFFFAOYSA-N;CC(=O)NCCCS(=O)(=O)O;18121;-12;918;215;0;2;4;4;11;4;Approved;2004;Small molecule;Inhibitor;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6A02.Z;Autism spectrum disorder, unspecified;1;Inactive;437815624/unspecified;36153940, 31643988, 20163323
91;acamprosate;acamprosate;CHEMBL1201293;DB00659;71158;77337-76-9;N4K14YGM3J;AFCGFAGUEYAMAO-UHFFFAOYSA-N;CC(=O)NCCCS(=O)(=O)O;18121;-12;918;215;0;2;4;4;11;4;Approved;2004;Small molecule;Inhibitor;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6B8Z;Feeding or eating disorders, unspecified;2;Inactive;1412387537/unspecified;36153940, 31643988, 20163323
91;acamprosate;acamprosate;CHEMBL1201293;DB00659;71158;77337-76-9;N4K14YGM3J;AFCGFAGUEYAMAO-UHFFFAOYSA-N;CC(=O)NCCCS(=O)(=O)O;18121;-12;918;215;0;2;4;4;11;4;Approved;2004;Small molecule;Inhibitor;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;36153940, 31643988, 20163323
91;acamprosate;acamprosate;CHEMBL1201293;DB00659;71158;77337-76-9;N4K14YGM3J;AFCGFAGUEYAMAO-UHFFFAOYSA-N;CC(=O)NCCCS(=O)(=O)O;18121;-12;918;215;0;2;4;4;11;4;Approved;2004;Small molecule;Inhibitor;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;36153940, 31643988, 20163323
91;acamprosate;acamprosate;CHEMBL1201293;DB00659;71158;77337-76-9;N4K14YGM3J;AFCGFAGUEYAMAO-UHFFFAOYSA-N;CC(=O)NCCCS(=O)(=O)O;18121;-12;918;215;0;2;4;4;11;4;Approved;2004;Small molecule;Inhibitor;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Inactive;2016549355/unspecified;36153940, 31643988, 20163323
91;acamprosate;acamprosate;CHEMBL1201293;DB00659;71158;77337-76-9;N4K14YGM3J;AFCGFAGUEYAMAO-UHFFFAOYSA-N;CC(=O)NCCCS(=O)(=O)O;18121;-12;918;215;0;2;4;4;11;4;Approved;2004;Small molecule;Inhibitor;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;LD55;Fragile X chromosome;2;Inactive;1524287677;36153940, 31643988, 20163323
91;acamprosate;acamprosate;CHEMBL1201293;DB00659;71158;77337-76-9;N4K14YGM3J;AFCGFAGUEYAMAO-UHFFFAOYSA-N;CC(=O)NCCCS(=O)(=O)O;18121;-12;918;215;0;2;4;4;11;4;Approved;2004;Small molecule;Inhibitor;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MC41;Tinnitus;1;Inactive;1089305710;36153940, 31643988, 20163323
92;bitolterol;bitolterol;CHEMBL1201295;DB00901;35330;30392-40-6;NA;FZGVEKPRDOIXJY-UHFFFAOYSA-N;CC1=CC=C(C=C1)C(=O)OC2=C(C=C(C=C2)C(CNC(C)(C)C)O)OC(=O)C3=CC=C(C=C3)C;4615;52;849;658;0;2;6;10;34;4;Approved;1984;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30000241, 3895171, 3278878
92;bitolterol;bitolterol;CHEMBL1201295;DB00901;35330;30392-40-6;NA;FZGVEKPRDOIXJY-UHFFFAOYSA-N;CC1=CC=C(C=C1)C(=O)OC2=C(C=C(C=C2)C(CNC(C)(C)C)O)OC(=O)C3=CC=C(C=C3)C;4615;52;849;658;0;2;6;10;34;4;Approved;1984;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;30000241, 3895171, 3278878
93;nafarelin;S-nafarelin;CHEMBL1201309;DB00666;49800011;76932-56-4;1X0094V6JV;PPXLVGBVOZLEIW-ITQXDASVSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CC=CC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13225;8;475;2730;0;16;15;33;96;4;Approved;1990;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;5A60.3;Central precocious puberty;2;Unknown;1749914533;28430010, 2140979, 10900582
93;nafarelin;S-nafarelin;CHEMBL1201309;DB00666;49800011;76932-56-4;1X0094V6JV;PPXLVGBVOZLEIW-ITQXDASVSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CC=CC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13225;8;475;2730;0;16;15;33;96;4;Approved;1990;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA10.Z;Endometriosis of unspecified site;4;Approved;1838213761/unspecified;28430010, 2140979, 10900582
93;nafarelin;nafarelin;CHEMBL1201309;DB00666;25077405;76932-56-4;1X0094V6JV;RWHUEXWOYVBUCI-ITQXDASVSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CC3=CC=CC=C3C=C2)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13225;12;472;2720;0;17;15;34;96;4;Approved;1990;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;5A60.3;Central precocious puberty;2;Unknown;1749914533;28430010, 2140979, 10900582
93;nafarelin;nafarelin;CHEMBL1201309;DB00666;25077405;76932-56-4;1X0094V6JV;RWHUEXWOYVBUCI-ITQXDASVSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CC3=CC=CC=C3C=C2)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13225;12;472;2720;0;17;15;34;96;4;Approved;1990;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA10.Z;Endometriosis of unspecified site;4;Approved;1838213761/unspecified;28430010, 2140979, 10900582
94;metaraminol;metaraminol;CHEMBL1201319;DB00610;5906;54-49-9;818U2PZ2EH;WXFIGDLSSYIKKV-RCOVLWMOSA-N;CC(C(C1=CC(=CC=C1)O)O)N;1672;-4;665;141;0;3;3;2;12;4;Approved;1954;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;28232631, 34197654, 33663948
94;metaraminol;metaraminol;CHEMBL1201319;DB00610;5906;54-49-9;818U2PZ2EH;WXFIGDLSSYIKKV-RCOVLWMOSA-N;CC(C(C1=CC(=CC=C1)O)O)N;1672;-4;665;141;0;3;3;2;12;4;Approved;1954;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;28232631, 34197654, 33663948
94;metaraminol;metaraminol;CHEMBL1201319;DB00610;5906;54-49-9;818U2PZ2EH;WXFIGDLSSYIKKV-RCOVLWMOSA-N;CC(C(C1=CC(=CC=C1)O)O)N;1672;-4;665;141;0;3;3;2;12;4;Approved;1954;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;28232631, 34197654, 33663948
95;hexocyclium;hexocyclium;CHEMBL1201325;DB06787;24199;6004-98-4;LL3147PI1T;ZRYHPQCHHOKSMD-UHFFFAOYSA-N;C[N+]1(CCN(CC1)CC(C2CCCCC2)(C3=CC=CC=C3)O)C;3175;31;235;362;1;1;2;4;23;4;Approved;1982;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;8075869, 21951, 2372655
95;hexocyclium;hexocyclium;CHEMBL1201325;DB06787;24199;6004-98-4;LL3147PI1T;ZRYHPQCHHOKSMD-UHFFFAOYSA-N;C[N+]1(CCN(CC1)CC(C2CCCCC2)(C3=CC=CC=C3)O)C;3175;31;235;362;1;1;2;4;23;4;Approved;1982;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;ME05.1;Diarrhoea;4;Approved;116759077;8075869, 21951, 2372655
95;hexocyclium;hexocyclium;CHEMBL1201325;DB06787;24199;6004-98-4;LL3147PI1T;ZRYHPQCHHOKSMD-UHFFFAOYSA-N;C[N+]1(CCN(CC1)CC(C2CCCCC2)(C3=CC=CC=C3)O)C;3175;31;235;362;1;1;2;4;23;4;Approved;1982;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;8075869, 21951, 2372655
95;hexocyclium;hexocyclium;CHEMBL1201325;DB06787;24199;6004-98-4;LL3147PI1T;ZRYHPQCHHOKSMD-UHFFFAOYSA-N;C[N+]1(CCN(CC1)CC(C2CCCCC2)(C3=CC=CC=C3)O)C;3175;31;235;362;1;1;2;4;23;4;Approved;1982;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;ME05.1;Diarrhoea;4;Approved;116759077;8075869, 21951, 2372655
96;triptorelin;triptorelin;CHEMBL1201334;DB06825;25074470;57773-63-4;9081Y98W2V;VXKHXGOKWPXYNA-PGBVPBMZSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13114;1;488;2700;0;18;15;34;95;4;Approved;2000;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;1C62.Z;Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified;2;Unknown;1508081745/unspecified;31644065, 31294133, 24832495
96;triptorelin;triptorelin;CHEMBL1201334;DB06825;25074470;57773-63-4;9081Y98W2V;VXKHXGOKWPXYNA-PGBVPBMZSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13114;1;488;2700;0;18;15;34;95;4;Approved;2000;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2B68.2;Other specified malignant neoplasms of submandibular or sublingual glands;2;Active;921330276;31644065, 31294133, 24832495
96;triptorelin;triptorelin;CHEMBL1201334;DB06825;25074470;57773-63-4;9081Y98W2V;VXKHXGOKWPXYNA-PGBVPBMZSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13114;1;488;2700;0;18;15;34;95;4;Approved;2000;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;4;Approved;1047754165/unspecified;31644065, 31294133, 24832495
96;triptorelin;triptorelin;CHEMBL1201334;DB06825;25074470;57773-63-4;9081Y98W2V;VXKHXGOKWPXYNA-PGBVPBMZSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13114;1;488;2700;0;18;15;34;95;4;Approved;2000;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.0;Adenocarcinoma of prostate;4;Approved;1510677183;31644065, 31294133, 24832495
96;triptorelin;triptorelin;CHEMBL1201334;DB06825;25074470;57773-63-4;9081Y98W2V;VXKHXGOKWPXYNA-PGBVPBMZSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13114;1;488;2700;0;18;15;34;95;4;Approved;2000;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.Y;Other specified malignant neoplasms of prostate;4;Approved;1552457716/other;31644065, 31294133, 24832495
96;triptorelin;triptorelin;CHEMBL1201334;DB06825;25074470;57773-63-4;9081Y98W2V;VXKHXGOKWPXYNA-PGBVPBMZSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13114;1;488;2700;0;18;15;34;95;4;Approved;2000;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;4;Approved;1552457716/unspecified;31644065, 31294133, 24832495
96;triptorelin;triptorelin;CHEMBL1201334;DB06825;25074470;57773-63-4;9081Y98W2V;VXKHXGOKWPXYNA-PGBVPBMZSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13114;1;488;2700;0;18;15;34;95;4;Approved;2000;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;5A60.3;Central precocious puberty;4;Approved;1749914533;31644065, 31294133, 24832495
96;triptorelin;triptorelin;CHEMBL1201334;DB06825;25074470;57773-63-4;9081Y98W2V;VXKHXGOKWPXYNA-PGBVPBMZSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13114;1;488;2700;0;18;15;34;95;4;Approved;2000;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;5A92;Peripheral precocious puberty;4;Approved;1495024153;31644065, 31294133, 24832495
96;triptorelin;triptorelin;CHEMBL1201334;DB06825;25074470;57773-63-4;9081Y98W2V;VXKHXGOKWPXYNA-PGBVPBMZSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13114;1;488;2700;0;18;15;34;95;4;Approved;2000;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA10.Z;Endometriosis of unspecified site;3;Inactive;1838213761/unspecified;31644065, 31294133, 24832495
96;triptorelin;triptorelin;CHEMBL1201334;DB06825;25074470;57773-63-4;9081Y98W2V;VXKHXGOKWPXYNA-PGBVPBMZSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13114;1;488;2700;0;18;15;34;95;4;Approved;2000;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA11;Adenomyosis;1;Active;171294592;31644065, 31294133, 24832495
96;triptorelin;triptorelin;CHEMBL1201334;DB06825;25074470;57773-63-4;9081Y98W2V;VXKHXGOKWPXYNA-PGBVPBMZSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13114;1;488;2700;0;18;15;34;95;4;Approved;2000;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA30.6;Premature ovarian failure;3;Unknown;756899519;31644065, 31294133, 24832495
96;triptorelin;triptorelin;CHEMBL1201334;DB06825;25074470;57773-63-4;9081Y98W2V;VXKHXGOKWPXYNA-PGBVPBMZSA-N;CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8;13114;1;488;2700;0;18;15;34;95;4;Approved;2000;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GC8Y;Other specified diseases of the genitourinary system;4;Approved;30659757/other;31644065, 31294133, 24832495
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8D2Z;Cerebral palsy, unspecified;4;Approved;76906748/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BC9Z;Cardiac arrhythmia, unspecified;4;Approved;1457291912/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;3;Active;1656445230;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;4;Approved;1739126837;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;4;Approved;1416949107/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;RA01;COVID-19;2;Active;1730556128;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8D2Z;Cerebral palsy, unspecified;4;Approved;76906748/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BC9Z;Cardiac arrhythmia, unspecified;4;Approved;1457291912/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;3;Active;1656445230;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;4;Approved;1739126837;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;4;Approved;1416949107/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;RA01;COVID-19;2;Active;1730556128;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8D2Z;Cerebral palsy, unspecified;4;Approved;76906748/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BC9Z;Cardiac arrhythmia, unspecified;4;Approved;1457291912/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;3;Active;1656445230;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;4;Approved;1739126837;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;4;Approved;1416949107/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;RA01;COVID-19;2;Active;1730556128;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8D2Z;Cerebral palsy, unspecified;4;Approved;76906748/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BC9Z;Cardiac arrhythmia, unspecified;4;Approved;1457291912/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;3;Active;1656445230;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;4;Approved;1739126837;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;4;Approved;1416949107/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;RA01;COVID-19;2;Active;1730556128;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8D2Z;Cerebral palsy, unspecified;4;Approved;76906748/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BC9Z;Cardiac arrhythmia, unspecified;4;Approved;1457291912/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;3;Active;1656445230;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;4;Approved;1739126837;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;4;Approved;1416949107/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;RA01;COVID-19;2;Active;1730556128;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8D2Z;Cerebral palsy, unspecified;4;Approved;76906748/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BC9Z;Cardiac arrhythmia, unspecified;4;Approved;1457291912/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;3;Active;1656445230;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;4;Approved;1739126837;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;4;Approved;1416949107/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;RA01;COVID-19;2;Active;1730556128;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8D2Z;Cerebral palsy, unspecified;4;Approved;76906748/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BC9Z;Cardiac arrhythmia, unspecified;4;Approved;1457291912/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;3;Active;1656445230;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;4;Approved;1739126837;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;4;Approved;1416949107/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium;CHEMBL1201335;DB00986;9933193;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-HKUYNNGSSA-N;C[N+]1(CC[C@@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;RA01;COVID-19;2;Active;1730556128;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8D2Z;Cerebral palsy, unspecified;4;Approved;76906748/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BC9Z;Cardiac arrhythmia, unspecified;4;Approved;1457291912/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;3;Active;1656445230;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;4;Approved;1739126837;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;4;Approved;1416949107/unspecified;34342835, 27181606, 31468315
97;glycopyrronium;glycopyrronium bromide;CHEMBL1201335;DB00986;3494;740028-90-4;A14FB57V1D;ANGKOCUUWGHLCE-UHFFFAOYSA-N;C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3184;31;465;424;1;1;3;5;23;4;Approved;1961;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;RA01;COVID-19;2;Active;1730556128;34342835, 27181606, 31468315
98;cyclopentolate;cyclopentolate;CHEMBL1201338;DB00979;2905;512-15-2;I76F4SHP7J;SKYSRIRYMSLOIN-UHFFFAOYSA-N;CN(C)CCOC(=O)C(C1=CC=CC=C1)C2(CCCC2)O;2914;27;498;331;0;1;4;7;21;4;Approved;1974;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;30000724, 38087795, 36411874
98;cyclopentolate;cyclopentolate;CHEMBL1201338;DB00979;2905;512-15-2;I76F4SHP7J;SKYSRIRYMSLOIN-UHFFFAOYSA-N;CN(C)CCOC(=O)C(C1=CC=CC=C1)C2(CCCC2)O;2914;27;498;331;0;1;4;7;21;4;Approved;1974;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;30000724, 38087795, 36411874
99;diphemanil;diphemanil;CHEMBL1201340;DB13720;6127;15394-62-4;NA;LCTZPQRFOZKZNK-UHFFFAOYSA-N;C[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C;2784;44;0;335;1;0;0;2;21;4;Approved;1982;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;13710268, 6450282, 8239894
99;diphemanil;diphemanil;CHEMBL1201340;DB13720;6127;15394-62-4;NA;LCTZPQRFOZKZNK-UHFFFAOYSA-N;C[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C;2784;44;0;335;1;0;0;2;21;4;Approved;1982;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;4;Approved;1416949107/unspecified;13710268, 6450282, 8239894
99;diphemanil;diphemanil;CHEMBL1201340;DB13720;6127;15394-62-4;NA;LCTZPQRFOZKZNK-UHFFFAOYSA-N;C[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C;2784;44;0;335;1;0;0;2;21;4;Approved;1982;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;13710268, 6450282, 8239894
99;diphemanil;diphemanil;CHEMBL1201340;DB13720;6127;15394-62-4;NA;LCTZPQRFOZKZNK-UHFFFAOYSA-N;C[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C;2784;44;0;335;1;0;0;2;21;4;Approved;1982;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;4;Approved;1416949107/unspecified;13710268, 6450282, 8239894
100;methixene;methixene;CHEMBL1201342;DB00340;4167;4969-02-2;32VY6L26ZW;MJFJKKXQDNNUJF-UHFFFAOYSA-N;CN1CCCC(C1)CC2C3=CC=CC=C3SC4=CC=CC=C24;3095;49;285;349;0;0;2;2;22;4;Approved;1982;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;5238717, 4382078, 12608172
100;methixene;methixene;CHEMBL1201342;DB00340;4167;4969-02-2;32VY6L26ZW;MJFJKKXQDNNUJF-UHFFFAOYSA-N;CN1CCCC(C1)CC2C3=CC=CC=C3SC4=CC=CC=C24;3095;49;285;349;0;0;2;2;22;4;Approved;1982;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;5238717, 4382078, 12608172
100;methixene;methixene;CHEMBL1201342;DB00340;4167;4969-02-2;32VY6L26ZW;MJFJKKXQDNNUJF-UHFFFAOYSA-N;CN1CCCC(C1)CC2C3=CC=CC=C3SC4=CC=CC=C24;3095;49;285;349;0;0;2;2;22;4;Approved;1982;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;5238717, 4382078, 12608172
100;methixene;methixene;CHEMBL1201342;DB00340;4167;4969-02-2;32VY6L26ZW;MJFJKKXQDNNUJF-UHFFFAOYSA-N;CN1CCCC(C1)CC2C3=CC=CC=C3SC4=CC=CC=C24;3095;49;285;349;0;0;2;2;22;4;Approved;1982;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;5238717, 4382078, 12608172
100;methixene;methixene;CHEMBL1201342;DB00340;4167;4969-02-2;32VY6L26ZW;MJFJKKXQDNNUJF-UHFFFAOYSA-N;CN1CCCC(C1)CC2C3=CC=CC=C3SC4=CC=CC=C24;3095;49;285;349;0;0;2;2;22;4;Approved;1982;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;5238717, 4382078, 12608172
100;methixene;methixene;CHEMBL1201342;DB00340;4167;4969-02-2;32VY6L26ZW;MJFJKKXQDNNUJF-UHFFFAOYSA-N;CN1CCCC(C1)CC2C3=CC=CC=C3SC4=CC=CC=C24;3095;49;285;349;0;0;2;2;22;4;Approved;1982;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;5238717, 4382078, 12608172
101;tridihexethyl;tridihexethyl;CHEMBL1201354;DB00505;20299;60-49-1;NA;NPRHVSBSZMAEIN-UHFFFAOYSA-N;CC[N+](CC)(CC)CCC(C1CCCCC1)(C2=CC=CC=C2)O;3185;48;202;319;1;1;1;8;23;4;Approved;1954;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;1944902, 14482588, 6469893
101;tridihexethyl;tridihexethyl;CHEMBL1201354;DB00505;20299;60-49-1;NA;NPRHVSBSZMAEIN-UHFFFAOYSA-N;CC[N+](CC)(CC)CCC(C1CCCCC1)(C2=CC=CC=C2)O;3185;48;202;319;1;1;1;8;23;4;Approved;1954;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;1944902, 14482588, 6469893
102;methylergonovine;methylergonovine;CHEMBL1201356;DB00353;8226;113-42-8;W53L6FE61V;UNBRKDKAWYKMIV-QWQRMKEZSA-N;CCC(CO)NC(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3394;23;684;549;0;3;3;4;25;4;Approved;1946;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;4;Approved;940081636;28526143, 30000401, 23850529
102;methylergonovine;methylergonovine;CHEMBL1201356;DB00353;8226;113-42-8;W53L6FE61V;UNBRKDKAWYKMIV-QWQRMKEZSA-N;CCC(CO)NC(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3394;23;684;549;0;3;3;4;25;4;Approved;1946;Small molecule;Partial agonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;4;Approved;940081636;28526143, 30000401, 23850529
103;lutropin alfa;lutropin alfa;CHEMBL1201419;DB00044;;152923-57-4;3JGY52XJNA;NA;NA;;;;;;;;;;4;Approved;2004;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;5A61.Y;Other specified hypofunction or disorders of pituitary gland;4;Approved;292840069/other;18627209, 30341677, 19450267
103;lutropin alfa;lutropin alfa;CHEMBL1201419;DB00044;;152923-57-4;3JGY52XJNA;NA;NA;;;;;;;;;;4;Approved;2004;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GA31.Z;Female infertility without specification whether primary or secondary;4;Approved;1237004558/unspecified;18627209, 30341677, 19450267
103;lutropin alfa;lutropin alfa;CHEMBL1201419;DB00044;;152923-57-4;3JGY52XJNA;NA;NA;;;;;;;;;;4;Approved;2004;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GC8Y;Other specified diseases of the genitourinary system;4;Approved;30659757/other;18627209, 30341677, 19450267
104;choriogonadotropin alfa;choriogonadotropin alfa;CHEMBL1201464;DB00097;;177073-44-8;6413W06WR3;NA;NA;;;;;;;;;;4;Approved;2000;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;5A61.Y;Other specified hypofunction or disorders of pituitary gland;4;Approved;292840069/other;38299472, 37962964, 16949587
104;choriogonadotropin alfa;choriogonadotropin alfa;CHEMBL1201464;DB00097;;177073-44-8;6413W06WR3;NA;NA;;;;;;;;;;4;Approved;2000;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GA32.0;Ovarian hyperstimulation syndrome;3;Unknown;1216664013;38299472, 37962964, 16949587
104;choriogonadotropin alfa;choriogonadotropin alfa;CHEMBL1201464;DB00097;;177073-44-8;6413W06WR3;NA;NA;;;;;;;;;;4;Approved;2000;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GC8Y;Other specified diseases of the genitourinary system;4;Approved;30659757/other;38299472, 37962964, 16949587
104;choriogonadotropin alfa;choriogonadotropin alfa;CHEMBL1201464;DB00097;;177073-44-8;6413W06WR3;NA;NA;;;;;;;;;;4;Approved;2000;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;5A61.Y;Other specified hypofunction or disorders of pituitary gland;4;Approved;292840069/other;38299472, 37962964, 16949587
104;choriogonadotropin alfa;choriogonadotropin alfa;CHEMBL1201464;DB00097;;177073-44-8;6413W06WR3;NA;NA;;;;;;;;;;4;Approved;2000;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GA32.0;Ovarian hyperstimulation syndrome;3;Unknown;1216664013;38299472, 37962964, 16949587
104;choriogonadotropin alfa;choriogonadotropin alfa;CHEMBL1201464;DB00097;;177073-44-8;6413W06WR3;NA;NA;;;;;;;;;;4;Approved;2000;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GC8Y;Other specified diseases of the genitourinary system;4;Approved;30659757/other;38299472, 37962964, 16949587
106;gonadotropin, chorionic;gonadotropin, chorionic;CHEMBL1201509;DB09126;;9002-61-3;20ED16GHEB;NA;NA;;;;;;;;;;4;Approved;1973;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C6Z;Malignant neoplasms of breast, unspecified;3;Unknown;1047754165/unspecified;401030, 13560144
106;gonadotropin, chorionic;gonadotropin, chorionic;CHEMBL1201509;DB09126;;9002-61-3;20ED16GHEB;NA;NA;;;;;;;;;;4;Approved;1973;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;4B24.0;Acute graft-versus-host disease;2;Active;83784921;401030, 13560144
106;gonadotropin, chorionic;gonadotropin, chorionic;CHEMBL1201509;DB09126;;9002-61-3;20ED16GHEB;NA;NA;;;;;;;;;;4;Approved;1973;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;5A61.2;Gonadotropin deficiency;4;Approved;1409526590;401030, 13560144
106;gonadotropin, chorionic;gonadotropin, chorionic;CHEMBL1201509;DB09126;;9002-61-3;20ED16GHEB;NA;NA;;;;;;;;;;4;Approved;1973;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;5A80.1;Polycystic ovary syndrome;4;Approved;1213633323;401030, 13560144
106;gonadotropin, chorionic;gonadotropin, chorionic;CHEMBL1201509;DB09126;;9002-61-3;20ED16GHEB;NA;NA;;;;;;;;;;4;Approved;1973;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;5A8Z;Disorders of the gonadal hormone system, unspecified;2;Inactive;1465641389/unspecified;401030, 13560144
106;gonadotropin, chorionic;gonadotropin, chorionic;CHEMBL1201509;DB09126;;9002-61-3;20ED16GHEB;NA;NA;;;;;;;;;;4;Approved;1973;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GC8Y;Other specified diseases of the genitourinary system;4;Approved;30659757/other;401030, 13560144
106;gonadotropin, chorionic;gonadotropin, chorionic;CHEMBL1201509;DB09126;;9002-61-3;20ED16GHEB;NA;NA;;;;;;;;;;4;Approved;1973;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;JB2Z;Delivery, unspecified;4;Approved;973282267/unspecified;401030, 13560144
107;follitropin;follitropin;"CHEMBL1201520;CHEMBL1201692";"DB00066;DB00094";62819;"146479-72-3;97048-13-0";2M2GGL7HUP,W9BB98U6HP;ZDRRIRUAESZNIH-UHFFFAOYSA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O;9802;-15;427;1790;0;12;15;15;67;4;Approved;1986;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;5A50.Z;Hypoparathyroidism, unspecified;4;Approved;1708733050/unspecified;27342604, 27382014, 16895623
107;follitropin;follitropin;"CHEMBL1201520;CHEMBL1201692";"DB00066;DB00094";62819;"146479-72-3;97048-13-0";2M2GGL7HUP,W9BB98U6HP;ZDRRIRUAESZNIH-UHFFFAOYSA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O;9802;-15;427;1790;0;12;15;15;67;4;Approved;1986;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;5A61.Y;Other specified hypofunction or disorders of pituitary gland;4;Approved;292840069/other;27342604, 27382014, 16895623
107;follitropin;follitropin;"CHEMBL1201520;CHEMBL1201692";"DB00066;DB00094";62819;"146479-72-3;97048-13-0";2M2GGL7HUP,W9BB98U6HP;ZDRRIRUAESZNIH-UHFFFAOYSA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O;9802;-15;427;1790;0;12;15;15;67;4;Approved;1986;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GA30.6;Premature ovarian failure;4;Approved;756899519;27342604, 27382014, 16895623
107;follitropin;follitropin;"CHEMBL1201520;CHEMBL1201692";"DB00066;DB00094";62819;"146479-72-3;97048-13-0";2M2GGL7HUP,W9BB98U6HP;ZDRRIRUAESZNIH-UHFFFAOYSA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O;9802;-15;427;1790;0;12;15;15;67;4;Approved;1986;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GB04.Z;Male infertility, unspecified;3;Inactive;753457327/unspecified;27342604, 27382014, 16895623
107;follitropin;follitropin;"CHEMBL1201520;CHEMBL1201692";"DB00066;DB00094";62819;"146479-72-3;97048-13-0";2M2GGL7HUP,W9BB98U6HP;ZDRRIRUAESZNIH-UHFFFAOYSA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O;9802;-15;427;1790;0;12;15;15;67;4;Approved;1986;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GC8Y;Other specified diseases of the genitourinary system;4;Approved;30659757/other;27342604, 27382014, 16895623
109;thyrotropin alfa;thyrotropin alfa;CHEMBL1201533;DB00024;32281;194100-83-9;AVX3D5A4LM;XNSAINXGIQZQOO-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C(CC2=CN=CN2)NC(=O)C3CCC(=O)N3)C(=O)N;36238;-25;150;597;0;4;5;6;26;4;Approved;1998;Protein;Agonist;P16473;tshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2D10.Y;Other specified malignant neoplasms of thyroid gland;4;Approved;447433352/other;37396298, 36848475, 34386895
109;thyrotropin alfa;thyrotropin alfa;CHEMBL1201533;DB00024;32281;194100-83-9;AVX3D5A4LM;XNSAINXGIQZQOO-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C(CC2=CN=CN2)NC(=O)C3CCC(=O)N3)C(=O)N;36238;-25;150;597;0;4;5;6;26;4;Approved;1998;Protein;Agonist;P16473;tshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2D10.Z;Malignant neoplasms of thyroid gland, unspecified;4;Approved;447433352/unspecified;37396298, 36848475, 34386895
109;thyrotropin alfa;thyrotropin alfa;CHEMBL1201533;DB00024;32281;194100-83-9;AVX3D5A4LM;XNSAINXGIQZQOO-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C(CC2=CN=CN2)NC(=O)C3CCC(=O)N3)C(=O)N;36238;-25;150;597;0;4;5;6;26;4;Approved;1998;Protein;Agonist;P16473;tshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2F9A;Neoplasms of unknown behaviour of endocrine glands;4;Approved;1442164144;37396298, 36848475, 34386895
109;thyrotropin alfa;thyrotropin alfa;CHEMBL1201533;DB00024;32281;194100-83-9;AVX3D5A4LM;XNSAINXGIQZQOO-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C(CC2=CN=CN2)NC(=O)C3CCC(=O)N3)C(=O)N;36238;-25;150;597;0;4;5;6;26;4;Approved;1998;Protein;Agonist;P16473;tshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;5A02.0;Thyrotoxicosis with diffuse goitre;2;Inactive;713028385;37396298, 36848475, 34386895
110;teriparatide acetate;teriparatide acetate hydrate;CHEMBL1201549;NA;16129682;NA;NA;OGBMKVWORPGQRR-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;5A50.Z;Hypoparathyroidism, unspecified;3;Inactive;1708733050/unspecified;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide acetate hydrate;CHEMBL1201549;NA;16129682;NA;NA;OGBMKVWORPGQRR-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;5B5K.1Z;Calcium deficiency, unspecified;2;Inactive;393562786/unspecified;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide acetate hydrate;CHEMBL1201549;NA;16129682;NA;NA;OGBMKVWORPGQRR-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;EA90.0;Plaque psoriasis;2;Inactive;1088800108;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide acetate hydrate;CHEMBL1201549;NA;16129682;NA;NA;OGBMKVWORPGQRR-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;FA0Z;Osteoarthritis, unspecified;2;Active;558562409/unspecified;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide acetate hydrate;CHEMBL1201549;NA;16129682;NA;NA;OGBMKVWORPGQRR-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;FA5Z;Arthropathies, unspecified;2;Inactive;1525792972/unspecified;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide acetate hydrate;CHEMBL1201549;NA;16129682;NA;NA;OGBMKVWORPGQRR-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;FB83.11;Postmenopausal osteoporosis;4;Approved;123797893;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide acetate hydrate;CHEMBL1201549;NA;16129682;NA;NA;OGBMKVWORPGQRR-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;FB83.1Z;Osteoporosis, unspecified;4;Approved;2113001430/unspecified;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide acetate hydrate;CHEMBL1201549;NA;16129682;NA;NA;OGBMKVWORPGQRR-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;LD24.K0;Osteogenesis imperfecta;2;Inactive;1219932551;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide acetate hydrate;CHEMBL1201549;NA;16129682;NA;NA;OGBMKVWORPGQRR-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;NC32.Y;Fracture of other specified parts of forearm;2;Inactive;999379672/other;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide acetate hydrate;CHEMBL1201549;NA;16129682;NA;NA;OGBMKVWORPGQRR-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;NC72.2Z;Fracture of neck of femur, unspecified;3;Unknown;398412176/unspecified;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide acetate hydrate;CHEMBL1201549;NA;16129682;NA;NA;OGBMKVWORPGQRR-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;ND56.2;Fracture of unspecified body region;3;Active;1504538171;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide;CHEMBL525610;DB06285;16133850;52232-67-4;10T9CSU89I;OGBMKVWORPGQRR-UMXFMPSGSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;5A50.Z;Hypoparathyroidism, unspecified;3;Inactive;1708733050/unspecified;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide;CHEMBL525610;DB06285;16133850;52232-67-4;10T9CSU89I;OGBMKVWORPGQRR-UMXFMPSGSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;5B5K.1Z;Calcium deficiency, unspecified;2;Inactive;393562786/unspecified;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide;CHEMBL525610;DB06285;16133850;52232-67-4;10T9CSU89I;OGBMKVWORPGQRR-UMXFMPSGSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;EA90.0;Plaque psoriasis;2;Inactive;1088800108;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide;CHEMBL525610;DB06285;16133850;52232-67-4;10T9CSU89I;OGBMKVWORPGQRR-UMXFMPSGSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;FA0Z;Osteoarthritis, unspecified;2;Active;558562409/unspecified;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide;CHEMBL525610;DB06285;16133850;52232-67-4;10T9CSU89I;OGBMKVWORPGQRR-UMXFMPSGSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;FA5Z;Arthropathies, unspecified;2;Inactive;1525792972/unspecified;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide;CHEMBL525610;DB06285;16133850;52232-67-4;10T9CSU89I;OGBMKVWORPGQRR-UMXFMPSGSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;FB83.11;Postmenopausal osteoporosis;4;Approved;123797893;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide;CHEMBL525610;DB06285;16133850;52232-67-4;10T9CSU89I;OGBMKVWORPGQRR-UMXFMPSGSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;FB83.1Z;Osteoporosis, unspecified;4;Approved;2113001430/unspecified;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide;CHEMBL525610;DB06285;16133850;52232-67-4;10T9CSU89I;OGBMKVWORPGQRR-UMXFMPSGSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;LD24.K0;Osteogenesis imperfecta;2;Inactive;1219932551;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide;CHEMBL525610;DB06285;16133850;52232-67-4;10T9CSU89I;OGBMKVWORPGQRR-UMXFMPSGSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;NC32.Y;Fracture of other specified parts of forearm;2;Inactive;999379672/other;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide;CHEMBL525610;DB06285;16133850;52232-67-4;10T9CSU89I;OGBMKVWORPGQRR-UMXFMPSGSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;NC72.2Z;Fracture of neck of femur, unspecified;3;Unknown;398412176/unspecified;30890377, 35442604, 32644674
110;teriparatide acetate;teriparatide;CHEMBL525610;DB06285;16133850;52232-67-4;10T9CSU89I;OGBMKVWORPGQRR-UMXFMPSGSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N;4118;-187;1800;9740;0;60;62;146;289;4;Approved;1987;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;ND56.2;Fracture of unspecified body region;3;Active;1504538171;30890377, 35442604, 32644674
111;corticorelin ovine triflutate;corticorelin ovine triflutate;CHEMBL1201591;DB09067;16132344;121249-14-7;56X54T817Q;QEEJLLNYQOBRRM-KSHGRFHLSA-N;CCC(C)C(C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC2=CN=CN2)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCSC)C(=O)NC(C(C)O)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(C)C(=O)NC(CC3=CN=CN3)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)N)NC(=O)C4CCCN4C(=O)C5CCCN5C(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(CO)N;4670;-186;2010;11500;0;66;71;161;328;4;Approved;1996;Protein;Agonist;P34998;crfr1_human;Class B1 (Secretin);Corticotropin-releasing factor receptors;Peptide receptors;5A70.0;Pituitary-dependent Cushing disease;4;Approved;380861892;8299324
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;4A40.Z;Lupus erythematosus, unspecified;4;Approved;1443317238/unspecified;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;4A41.0Z;Dermatomyositis, unspecified;2;Inactive;739030149/unspecified;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;4A41.1Z;Polymyositis, unspecified;4;Approved;1157134196/unspecified;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;4B20.Z;Sarcoidosis, unspecified;4;Approved;330792642/unspecified;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;8A40.1;Primary progressive multiple sclerosis;2;Active;1020720762;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;8A40.2;Secondary progressive multiple sclerosis;2;Active;1045965709;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;8A40.Z;Multiple sclerosis, unspecified;4;Approved;1298865187/unspecified;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;8A62.0;Infantile spasms;4;Approved;1023597213;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;8A80.Z;Migraine, unspecified;2;Inactive;669367341/unspecified;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;8B60.0;Amyotrophic lateral sclerosis;3;Inactive;1982355687;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;9A96.Z;Anterior uveitis, unspecified;2;Unknown;908233081/unspecified;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;9B51;Scleritis;2;Active;2097802831;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;9B78.2;Other proliferative retinopathy;1;Active;1289434438;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;9C40.1Z;Optic neuritis, unspecified;1;Inactive;210935787/unspecified;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;EB13.0;Stevens-Johnson syndrome;4;Approved;450167795;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;FA20.Z;Rheumatoid arthritis, serology unspecified;4;Approved;576319925/unspecified;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;FA21.Z;Psoriatic arthritis, unspecified;4;Approved;868183264/unspecified;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;FA92.0Z;Axial spondyloarthritis, unspecified;4;Approved;1505896560/unspecified;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;GB40;Nephritic syndrome;1;Inactive;1783829886;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;GB41;Nephrotic syndrome;3;Inactive;1184209951;29999767, 32723550, 24145148
112;corticotropin;corticotropin;CHEMBL1201610;DB01285;16132265;12427-33-7;K0U68Q2TXA;IDLFZVILOHSSID-OVLDLUHVSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N;4541;-197;1860;11200;0;63;68;148;322;4;Approved;1950;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;MF96.Z;Proteinuria, unspecified;2;Unknown;930895737/unspecified;29999767, 32723550, 24145148
114;glucagon hydrochloride;glucagon hydrochloride;CHEMBL1201618;NA;16186213;NA;NA;RKGLLHCSSVJTAN-YYICOITRSA-N;CC(C)CC(C(=O)NC(CCSC)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CN=CN7)N.Cl;35192;;1560;8160;0;56;55;115;247;4;Approved;1960;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A41;Hypoglycaemia without associated diabetes;4;Approved;1004695600;10397121, 22683196
117;alcaftadine;alcaftadine;CHEMBL1201747;DB06766;19371515;147084-10-4;7Z8O94ECSX;MWTBKTRZPHJQLH-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3CCN4C2=NC=C4C=O)CC1;3074;17;381;479;0;0;3;1;23;4;Approved;2010;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;22811343, 22348913, 32501774
117;alcaftadine;alcaftadine;CHEMBL1201747;DB06766;19371515;147084-10-4;7Z8O94ECSX;MWTBKTRZPHJQLH-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3CCN4C2=NC=C4C=O)CC1;3074;17;381;479;0;0;3;1;23;4;Approved;2010;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;22811343, 22348913, 32501774
118;bepotastine;bepotastine;CHEMBL1201758;DB04890;164522;125602-71-3;HYD2U48IAS;YWGDOWXRIALTES-NRFANRHFSA-N;C1CN(CCC1O[C@@H](C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O;3889;1;627;449;0;1;5;8;27;4;Approved;2009;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000754, 24191914, 20687621
118;bepotastine;bepotastine;CHEMBL1201758;DB04890;164522;125602-71-3;HYD2U48IAS;YWGDOWXRIALTES-NRFANRHFSA-N;C1CN(CCC1O[C@@H](C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O;3889;1;627;449;0;1;5;8;27;4;Approved;2009;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;2;Inactive;1565925107;30000754, 24191914, 20687621
118;bepotastine;bepotastine;CHEMBL1201758;DB04890;164522;125602-71-3;HYD2U48IAS;YWGDOWXRIALTES-NRFANRHFSA-N;C1CN(CCC1O[C@@H](C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O;3889;1;627;449;0;1;5;8;27;4;Approved;2009;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.03;Other allergic rhinitis;3;Inactive;941478759;30000754, 24191914, 20687621
118;bepotastine;bepotastine;CHEMBL1201758;DB04890;164522;125602-71-3;HYD2U48IAS;YWGDOWXRIALTES-NRFANRHFSA-N;C1CN(CCC1O[C@@H](C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O;3889;1;627;449;0;1;5;8;27;4;Approved;2009;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;30000754, 24191914, 20687621
118;bepotastine;bepotastine free base;CHEMBL1201758;DB04890;2350;125602-71-3;HYD2U48IAS;YWGDOWXRIALTES-UHFFFAOYSA-N;C1CN(CCC1OC(C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O;3889;1;627;449;0;1;5;8;27;4;Approved;2009;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000754, 24191914, 20687621
118;bepotastine;bepotastine free base;CHEMBL1201758;DB04890;2350;125602-71-3;HYD2U48IAS;YWGDOWXRIALTES-UHFFFAOYSA-N;C1CN(CCC1OC(C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O;3889;1;627;449;0;1;5;8;27;4;Approved;2009;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;2;Inactive;1565925107;30000754, 24191914, 20687621
118;bepotastine;bepotastine free base;CHEMBL1201758;DB04890;2350;125602-71-3;HYD2U48IAS;YWGDOWXRIALTES-UHFFFAOYSA-N;C1CN(CCC1OC(C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O;3889;1;627;449;0;1;5;8;27;4;Approved;2009;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.03;Other allergic rhinitis;3;Inactive;941478759;30000754, 24191914, 20687621
118;bepotastine;bepotastine free base;CHEMBL1201758;DB04890;2350;125602-71-3;HYD2U48IAS;YWGDOWXRIALTES-UHFFFAOYSA-N;C1CN(CCC1OC(C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O;3889;1;627;449;0;1;5;8;27;4;Approved;2009;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;30000754, 24191914, 20687621
119;fesoterodine;fesoterodine;CHEMBL1201764;DB06702;6918558;286930-02-7;621G617227;DCCSDBARQIPTGU-HSZRJFAPSA-N;CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;4116;55;498;491;0;1;4;11;30;4;Approved;2008;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8D8C;Autonomic dysreflexia;2;Inactive;1401282234;31644117, 29999896, 29803689
119;fesoterodine;fesoterodine;CHEMBL1201764;DB06702;6918558;286930-02-7;621G617227;DCCSDBARQIPTGU-HSZRJFAPSA-N;CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;4116;55;498;491;0;1;4;11;30;4;Approved;2008;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC01.4;Neuromuscular dysfunction of bladder, not elsewhere classified;4;Approved;590198069;31644117, 29999896, 29803689
119;fesoterodine;fesoterodine;CHEMBL1201764;DB06702;6918558;286930-02-7;621G617227;DCCSDBARQIPTGU-HSZRJFAPSA-N;CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;4116;55;498;491;0;1;4;11;30;4;Approved;2008;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;31644117, 29999896, 29803689
119;fesoterodine;fesoterodine;CHEMBL1201764;DB06702;6918558;286930-02-7;621G617227;DCCSDBARQIPTGU-HSZRJFAPSA-N;CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;4116;55;498;491;0;1;4;11;30;4;Approved;2008;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;31644117, 29999896, 29803689
119;fesoterodine;fesoterodine;CHEMBL1201764;DB06702;6918558;286930-02-7;621G617227;DCCSDBARQIPTGU-HSZRJFAPSA-N;CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;4116;55;498;491;0;1;4;11;30;4;Approved;2008;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF55;Polyuria;4;Approved;2137636828;31644117, 29999896, 29803689
119;fesoterodine;fesoterodine;CHEMBL1201764;DB06702;6918558;286930-02-7;621G617227;DCCSDBARQIPTGU-HSZRJFAPSA-N;CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;4116;55;498;491;0;1;4;11;30;4;Approved;2008;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8D8C;Autonomic dysreflexia;2;Inactive;1401282234;31644117, 29999896, 29803689
119;fesoterodine;fesoterodine;CHEMBL1201764;DB06702;6918558;286930-02-7;621G617227;DCCSDBARQIPTGU-HSZRJFAPSA-N;CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;4116;55;498;491;0;1;4;11;30;4;Approved;2008;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC01.4;Neuromuscular dysfunction of bladder, not elsewhere classified;4;Approved;590198069;31644117, 29999896, 29803689
119;fesoterodine;fesoterodine;CHEMBL1201764;DB06702;6918558;286930-02-7;621G617227;DCCSDBARQIPTGU-HSZRJFAPSA-N;CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;4116;55;498;491;0;1;4;11;30;4;Approved;2008;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;31644117, 29999896, 29803689
119;fesoterodine;fesoterodine;CHEMBL1201764;DB06702;6918558;286930-02-7;621G617227;DCCSDBARQIPTGU-HSZRJFAPSA-N;CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;4116;55;498;491;0;1;4;11;30;4;Approved;2008;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;31644117, 29999896, 29803689
119;fesoterodine;fesoterodine;CHEMBL1201764;DB06702;6918558;286930-02-7;621G617227;DCCSDBARQIPTGU-HSZRJFAPSA-N;CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;4116;55;498;491;0;1;4;11;30;4;Approved;2008;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF55;Polyuria;4;Approved;2137636828;31644117, 29999896, 29803689
120;prasugrel;prasugrel;CHEMBL1201772;DB06209;6918456;150322-43-3;34K66TBT99;DTGLZDAWLRGWQN-UHFFFAOYSA-N;CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4;3734;36;748;555;0;0;6;6;26;4;Approved;2009;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;1E32;Influenza, virus not identified;3;Active;1235618695;31475799, 17982182, 32491359
120;prasugrel;prasugrel;CHEMBL1201772;DB06209;6918456;150322-43-3;34K66TBT99;DTGLZDAWLRGWQN-UHFFFAOYSA-N;CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4;3734;36;748;555;0;0;6;6;26;4;Approved;2009;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;3A51.1;Sickle cell disease without crisis;3;Inactive;1711513381;31475799, 17982182, 32491359
120;prasugrel;prasugrel;CHEMBL1201772;DB06209;6918456;150322-43-3;34K66TBT99;DTGLZDAWLRGWQN-UHFFFAOYSA-N;CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4;3734;36;748;555;0;0;6;6;26;4;Approved;2009;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA41.0;Acute ST elevation myocardial infarction;4;Approved;391388807;31475799, 17982182, 32491359
120;prasugrel;prasugrel;CHEMBL1201772;DB06209;6918456;150322-43-3;34K66TBT99;DTGLZDAWLRGWQN-UHFFFAOYSA-N;CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4;3734;36;748;555;0;0;6;6;26;4;Approved;2009;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA41.1;Acute non-ST elevation myocardial infarction;4;Approved;680129526;31475799, 17982182, 32491359
120;prasugrel;prasugrel;CHEMBL1201772;DB06209;6918456;150322-43-3;34K66TBT99;DTGLZDAWLRGWQN-UHFFFAOYSA-N;CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4;3734;36;748;555;0;0;6;6;26;4;Approved;2009;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;31475799, 17982182, 32491359
120;prasugrel;prasugrel;CHEMBL1201772;DB06209;6918456;150322-43-3;34K66TBT99;DTGLZDAWLRGWQN-UHFFFAOYSA-N;CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4;3734;36;748;555;0;0;6;6;26;4;Approved;2009;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA4Z;Acute ischaemic heart disease, unspecified;4;Approved;1829545371/unspecified;31475799, 17982182, 32491359
120;prasugrel;prasugrel;CHEMBL1201772;DB06209;6918456;150322-43-3;34K66TBT99;DTGLZDAWLRGWQN-UHFFFAOYSA-N;CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4;3734;36;748;555;0;0;6;6;26;4;Approved;2009;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA8Z;Diseases of coronary artery, unspecified;4;Approved;1059873720/unspecified;31475799, 17982182, 32491359
120;prasugrel;prasugrel;CHEMBL1201772;DB06209;6918456;150322-43-3;34K66TBT99;DTGLZDAWLRGWQN-UHFFFAOYSA-N;CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4;3734;36;748;555;0;0;6;6;26;4;Approved;2009;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BC4Z;Diseases of the myocardium or cardiac chambers, unspecified;2;Inactive;2135151223/unspecified;31475799, 17982182, 32491359
120;prasugrel;prasugrel;CHEMBL1201772;DB06209;6918456;150322-43-3;34K66TBT99;DTGLZDAWLRGWQN-UHFFFAOYSA-N;CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4;3734;36;748;555;0;0;6;6;26;4;Approved;2009;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;CA23.20;Aspirin-induced asthma;2;Unknown;1030818265;31475799, 17982182, 32491359
120;prasugrel;prasugrel;CHEMBL1201772;DB06209;6918456;150322-43-3;34K66TBT99;DTGLZDAWLRGWQN-UHFFFAOYSA-N;CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4;3734;36;748;555;0;0;6;6;26;4;Approved;2009;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;CA40.Z;Pneumonia, organism unspecified;3;Active;142052508/unspecified;31475799, 17982182, 32491359
120;prasugrel;prasugrel;CHEMBL1201772;DB06209;6918456;150322-43-3;34K66TBT99;DTGLZDAWLRGWQN-UHFFFAOYSA-N;CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4;3734;36;748;555;0;0;6;6;26;4;Approved;2009;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;GB61.Z;Chronic kidney disease, stage unspecified;3;Inactive;412389819/unspecified;31475799, 17982182, 32491359
121;tapentadol;tapentadol;CHEMBL1201776;DB06204;9838022;175591-23-8;H8A007M585;KWTWDQCKEHXFFR-SMDDNHRTSA-N;CCC(C1=CC(=CC=C1)O)C(C)CN(C)C;22134;35;235;193;0;1;2;5;16;4;Approved;2008;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8C03.0;Diabetic polyneuropathy;3;Inactive;1837670870;30835408, 34196947, 30079795
121;tapentadol;tapentadol;CHEMBL1201776;DB06204;9838022;175591-23-8;H8A007M585;KWTWDQCKEHXFFR-SMDDNHRTSA-N;CCC(C1=CC(=CC=C1)O)C(C)CN(C)C;22134;35;235;193;0;1;2;5;16;4;Approved;2008;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8E43.0Z;Neuropathic pain, unspecified;4;Approved;1339785363/unspecified;30835408, 34196947, 30079795
121;tapentadol;tapentadol;CHEMBL1201776;DB06204;9838022;175591-23-8;H8A007M585;KWTWDQCKEHXFFR-SMDDNHRTSA-N;CCC(C1=CC(=CC=C1)O)C(C)CN(C)C;22134;35;235;193;0;1;2;5;16;4;Approved;2008;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;3;Inactive;1815305992/unspecified;30835408, 34196947, 30079795
121;tapentadol;tapentadol;CHEMBL1201776;DB06204;9838022;175591-23-8;H8A007M585;KWTWDQCKEHXFFR-SMDDNHRTSA-N;CCC(C1=CC(=CC=C1)O)C(C)CN(C)C;22134;35;235;193;0;1;2;5;16;4;Approved;2008;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;4;Approved;1581976053/unspecified;30835408, 34196947, 30079795
121;tapentadol;tapentadol;CHEMBL1201776;DB06204;9838022;175591-23-8;H8A007M585;KWTWDQCKEHXFFR-SMDDNHRTSA-N;CCC(C1=CC(=CC=C1)O)C(C)CN(C)C;22134;35;235;193;0;1;2;5;16;4;Approved;2008;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30835408, 34196947, 30079795
122;ethopropazine;ethopropazine;CHEMBL1206;DB00392;3290;522-00-9;7WI4P02YN1;CDOZDBSBBXSXLB-UHFFFAOYSA-N;CCN(CC)C(C)CN1C2=CC=CC=C2SC3=CC=CC=C31;3125;48;318;322;0;0;3;5;22;4;Approved;1982;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;33969, 21740955, 13278201
123;beraprost;beraprost;CHEMBL1207745;DB05229;6917951;88430-50-6;35E3NJJ4O6;CTPOHARTNNSRSR-APJZLKAGSA-N;CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)O)O)O;3985;32;87;659;0;3;5;8;29;4;Approved;1992;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BA00.Z;Essential hypertension, unspecified;1;Unknown;761947693/unspecified;33993186, 36318524, 11790158
123;beraprost;beraprost;CHEMBL1207745;DB05229;6917951;88430-50-6;35E3NJJ4O6;CTPOHARTNNSRSR-APJZLKAGSA-N;CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)O)O)O;3985;32;87;659;0;3;5;8;29;4;Approved;1992;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;33993186, 36318524, 11790158
123;beraprost;beraprost;CHEMBL1207745;DB05229;6917951;88430-50-6;35E3NJJ4O6;CTPOHARTNNSRSR-APJZLKAGSA-N;CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)O)O)O;3985;32;87;659;0;3;5;8;29;4;Approved;1992;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD5Z;Diseases of arteries or arterioles, unspecified;4;Approved;1164983645/unspecified;33993186, 36318524, 11790158
123;beraprost;beraprost;CHEMBL1207745;DB05229;6917951;88430-50-6;35E3NJJ4O6;CTPOHARTNNSRSR-APJZLKAGSA-N;CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)O)O)O;3985;32;87;659;0;3;5;8;29;4;Approved;1992;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;GB6Z;Kidney failure, unspecified;2;Unknown;761526554/unspecified;33993186, 36318524, 11790158
123;beraprost;beraprost sodium;CHEMBL1207745;DB05229;23663404;88430-50-6;35E3NJJ4O6;YTCZZXIRLARSET-VJRSQJMHSA-M;CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)[O-])O)O.[Na+];4205;;898;653;0;2;5;7;30;4;Approved;1992;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BA00.Z;Essential hypertension, unspecified;1;Unknown;761947693/unspecified;33993186, 36318524, 11790158
123;beraprost;beraprost sodium;CHEMBL1207745;DB05229;23663404;88430-50-6;35E3NJJ4O6;YTCZZXIRLARSET-VJRSQJMHSA-M;CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)[O-])O)O.[Na+];4205;;898;653;0;2;5;7;30;4;Approved;1992;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;33993186, 36318524, 11790158
123;beraprost;beraprost sodium;CHEMBL1207745;DB05229;23663404;88430-50-6;35E3NJJ4O6;YTCZZXIRLARSET-VJRSQJMHSA-M;CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)[O-])O)O.[Na+];4205;;898;653;0;2;5;7;30;4;Approved;1992;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD5Z;Diseases of arteries or arterioles, unspecified;4;Approved;1164983645/unspecified;33993186, 36318524, 11790158
123;beraprost;beraprost sodium;CHEMBL1207745;DB05229;23663404;88430-50-6;35E3NJJ4O6;YTCZZXIRLARSET-VJRSQJMHSA-M;CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)[O-])O)O.[Na+];4205;;898;653;0;2;5;7;30;4;Approved;1992;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;GB6Z;Kidney failure, unspecified;2;Unknown;761526554/unspecified;33993186, 36318524, 11790158
124;elagolix;elagolix;CHEMBL1208155;DB11979;11250647;834153-87-6;5B2546MB5Z;HEAUOKZIVMZVQL-VWLOTQADSA-N;CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)O)C4=C(C(=CC=C4)OC)F;6316;26;992;1080;0;2;11;12;45;4;Approved;2018;Small molecule;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;5A80.1;Polycystic ovary syndrome;2;Inactive;1213633323;28525302, 30222288, 31643392
124;elagolix;elagolix;CHEMBL1208155;DB11979;11250647;834153-87-6;5B2546MB5Z;HEAUOKZIVMZVQL-VWLOTQADSA-N;CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)O)C4=C(C(=CC=C4)OC)F;6316;26;992;1080;0;2;11;12;45;4;Approved;2018;Small molecule;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;28525302, 30222288, 31643392
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1E32;Influenza, virus not identified;4;Approved;1235618695;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;4;Approved;1683090852;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;3;Active;1614716959/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;3;Unknown;1442995018;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA07.0;Acute upper respiratory infection, site unspecified;3;Inactive;819139656;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.3;Vasomotor rhinitis;3;Inactive;1286636442;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA41.Z;Acute bronchiolitis, unspecified;2;Inactive;1310075986/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA01.Z;Disorder of oral mucosa, unspecified;1;Inactive;569611257/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DB60.Z;Haemorrhoids, unspecified;4;Approved;1352501137/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME07.Z;Faecal incontinence, unspecified;3;Unknown;790417430/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NB32.3Z;Injury of lung, unspecified;2;Inactive;359051131/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1E32;Influenza, virus not identified;4;Approved;1235618695;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;4;Approved;1683090852;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;3;Active;1614716959/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;3;Unknown;1442995018;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA07.0;Acute upper respiratory infection, site unspecified;3;Inactive;819139656;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.3;Vasomotor rhinitis;3;Inactive;1286636442;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA41.Z;Acute bronchiolitis, unspecified;2;Inactive;1310075986/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA01.Z;Disorder of oral mucosa, unspecified;1;Inactive;569611257/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DB60.Z;Haemorrhoids, unspecified;4;Approved;1352501137/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME07.Z;Faecal incontinence, unspecified;3;Unknown;790417430/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NB32.3Z;Injury of lung, unspecified;2;Inactive;359051131/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1E32;Influenza, virus not identified;4;Approved;1235618695;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;4;Approved;1683090852;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;3;Active;1614716959/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;3;Unknown;1442995018;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA07.0;Acute upper respiratory infection, site unspecified;3;Inactive;819139656;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.3;Vasomotor rhinitis;3;Inactive;1286636442;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA41.Z;Acute bronchiolitis, unspecified;2;Inactive;1310075986/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA01.Z;Disorder of oral mucosa, unspecified;1;Inactive;569611257/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DB60.Z;Haemorrhoids, unspecified;4;Approved;1352501137/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME07.Z;Faecal incontinence, unspecified;3;Unknown;790417430/unspecified;30000498, 30521222, 35952179
125;phenylephrine;phenylephrine;CHEMBL1215;DB00388;6041;59-42-7;1WS297W6MV;SONNWYBIRXJNDC-VIFPVBQESA-N;CNCC(C1=CC(=CC=C1)O)O;1672;-3;525;130;0;3;3;3;12;4;Approved;1952;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NB32.3Z;Injury of lung, unspecified;2;Inactive;359051131/unspecified;30000498, 30521222, 35952179
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Inactive;1456478153/unspecified;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;6A7Z;Depressive disorders, unspecified;3;Inactive;1563440232/unspecified;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;7A41;Obstructive sleep apnoea;2;Inactive;1919233290;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;7B2Z;Sleep-wake disorders, unspecified;3;Inactive;274880002/unspecified;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;8A80.0;Migraine without aura;2;Inactive;2048783472;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;8A80.1Z;Migraine with aura, unspecified;2;Inactive;525744634/unspecified;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;2;Inactive;133207228/unspecified;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;RA01;COVID-19;2;Unknown;1730556128;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Inactive;1456478153/unspecified;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;6A7Z;Depressive disorders, unspecified;3;Inactive;1563440232/unspecified;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;7A41;Obstructive sleep apnoea;2;Inactive;1919233290;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;7B2Z;Sleep-wake disorders, unspecified;3;Inactive;274880002/unspecified;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;8A80.0;Migraine without aura;2;Inactive;2048783472;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;8A80.1Z;Migraine with aura, unspecified;2;Inactive;525744634/unspecified;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;2;Inactive;133207228/unspecified;29999812, 31643756, 31851436
126;ramelteon;ramelteon;CHEMBL1218;DB00980;208902;196597-26-9;901AS54I69;YLXDSYKOBKBWJQ-LBPRGKRZSA-N;CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3;25934;27;383;331;0;1;2;4;19;4;Approved;2005;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;RA01;COVID-19;2;Unknown;1730556128;29999812, 31643756, 31851436
127;acrivastine;acrivastine;CHEMBL1224;DB09488;5284514;87848-99-5;A20F9XAI7W;PWACSDKDOHSSQD-IUTFFREVSA-N;CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC(=N3)C=CC(=O)O;3484;16;534;514;0;1;4;6;26;4;Approved;1994;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000328, 31643918, 1715267
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GA30.4;Menopausal hot flush;2;Active;222407548;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6C00.Z;Enuresis, unspecified;3;Inactive;1157749237/unspecified;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;7A41;Obstructive sleep apnoea;2;Inactive;1919233290;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8C03.0;Diabetic polyneuropathy;3;Unknown;1837670870;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;2;Inactive;1565925107;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;3;Inactive;1416949107/unspecified;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC01.4;Neuromuscular dysfunction of bladder, not elsewhere classified;3;Inactive;590198069;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;LB31.2;Fetal lower urinary tract obstruction;2;Unknown;1661120971;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF55;Polyuria;4;Approved;2137636828;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GA30.4;Menopausal hot flush;2;Active;222407548;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6C00.Z;Enuresis, unspecified;3;Inactive;1157749237/unspecified;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;7A41;Obstructive sleep apnoea;2;Inactive;1919233290;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8C03.0;Diabetic polyneuropathy;3;Unknown;1837670870;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;2;Inactive;1565925107;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;3;Inactive;1416949107/unspecified;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC01.4;Neuromuscular dysfunction of bladder, not elsewhere classified;3;Inactive;590198069;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;LB31.2;Fetal lower urinary tract obstruction;2;Unknown;1661120971;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF55;Polyuria;4;Approved;2137636828;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GA30.4;Menopausal hot flush;2;Active;222407548;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6C00.Z;Enuresis, unspecified;3;Inactive;1157749237/unspecified;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;7A41;Obstructive sleep apnoea;2;Inactive;1919233290;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8C03.0;Diabetic polyneuropathy;3;Unknown;1837670870;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;2;Inactive;1565925107;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;3;Inactive;1416949107/unspecified;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC01.4;Neuromuscular dysfunction of bladder, not elsewhere classified;3;Inactive;590198069;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;LB31.2;Fetal lower urinary tract obstruction;2;Unknown;1661120971;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;29763161, 31643963, 19275276
128;oxybutynin;oxybutynin;CHEMBL1231;DB01062;4634;5633-20-5;K9P6MC7092;XIQVNETUBQGFHX-UHFFFAOYSA-N;CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O;3575;42;498;490;0;1;4;8;26;4;Approved;1975;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF55;Polyuria;4;Approved;2137636828;29763161, 31643963, 19275276
129;lurasidone;lurasidone;CHEMBL1237021;DB08815;213046;367514-87-2;22IC88528T;PQXKDMSYBGKCJA-CVTJIBDQSA-N;C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O;4927;54;85;804;0;0;6;5;35;4;Approved;2010;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;3;Inactive;437815624/unspecified;30000787, 31082101, 31643626
129;lurasidone;lurasidone;CHEMBL1237021;DB08815;213046;367514-87-2;22IC88528T;PQXKDMSYBGKCJA-CVTJIBDQSA-N;C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O;4927;54;85;804;0;0;6;5;35;4;Approved;2010;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000787, 31082101, 31643626
129;lurasidone;lurasidone;CHEMBL1237021;DB08815;213046;367514-87-2;22IC88528T;PQXKDMSYBGKCJA-CVTJIBDQSA-N;C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O;4927;54;85;804;0;0;6;5;35;4;Approved;2010;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;30000787, 31082101, 31643626
129;lurasidone;lurasidone;CHEMBL1237021;DB08815;213046;367514-87-2;22IC88528T;PQXKDMSYBGKCJA-CVTJIBDQSA-N;C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O;4927;54;85;804;0;0;6;5;35;4;Approved;2010;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000787, 31082101, 31643626
129;lurasidone;lurasidone;CHEMBL1237021;DB08815;213046;367514-87-2;22IC88528T;PQXKDMSYBGKCJA-CVTJIBDQSA-N;C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O;4927;54;85;804;0;0;6;5;35;4;Approved;2010;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;30000787, 31082101, 31643626
129;lurasidone;lurasidone;CHEMBL1237021;DB08815;213046;367514-87-2;22IC88528T;PQXKDMSYBGKCJA-CVTJIBDQSA-N;C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O;4927;54;85;804;0;0;6;5;35;4;Approved;2010;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;3;Inactive;437815624/unspecified;30000787, 31082101, 31643626
129;lurasidone;lurasidone;CHEMBL1237021;DB08815;213046;367514-87-2;22IC88528T;PQXKDMSYBGKCJA-CVTJIBDQSA-N;C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O;4927;54;85;804;0;0;6;5;35;4;Approved;2010;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000787, 31082101, 31643626
129;lurasidone;lurasidone;CHEMBL1237021;DB08815;213046;367514-87-2;22IC88528T;PQXKDMSYBGKCJA-CVTJIBDQSA-N;C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O;4927;54;85;804;0;0;6;5;35;4;Approved;2010;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;30000787, 31082101, 31643626
129;lurasidone;lurasidone;CHEMBL1237021;DB08815;213046;367514-87-2;22IC88528T;PQXKDMSYBGKCJA-CVTJIBDQSA-N;C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O;4927;54;85;804;0;0;6;5;35;4;Approved;2010;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000787, 31082101, 31643626
129;lurasidone;lurasidone;CHEMBL1237021;DB08815;213046;367514-87-2;22IC88528T;PQXKDMSYBGKCJA-CVTJIBDQSA-N;C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O;4927;54;85;804;0;0;6;5;35;4;Approved;2010;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;30000787, 31082101, 31643626
130;tesamorelin;S-tesamorelin;CHEMBL1237026;DB08869;56928011;218949-48-5;MQG94M5EEO;LAJJBLZKAIOLRM-YHAVXTEWSA-N;CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N;5006;-232;2300;12400;0;81;72;182;352;4;Approved;2010;Protein;Agonist;Q02643;ghrhr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;2;Inactive;119724091;31644039, 21283099, 32701508
130;tesamorelin;S-tesamorelin;CHEMBL1237026;DB08869;56928011;218949-48-5;MQG94M5EEO;LAJJBLZKAIOLRM-YHAVXTEWSA-N;CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N;5006;-232;2300;12400;0;81;72;182;352;4;Approved;2010;Protein;Agonist;Q02643;ghrhr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;2;Inactive;133207228/unspecified;31644039, 21283099, 32701508
130;tesamorelin;S-tesamorelin;CHEMBL1237026;DB08869;56928011;218949-48-5;MQG94M5EEO;LAJJBLZKAIOLRM-YHAVXTEWSA-N;CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N;5006;-232;2300;12400;0;81;72;182;352;4;Approved;2010;Protein;Agonist;Q02643;ghrhr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;EL3Y;Other specified cutaneous markers of internal disorders;4;Approved;141396655/other;31644039, 21283099, 32701508
130;tesamorelin;S-tesamorelin;CHEMBL1237026;DB08869;56928011;218949-48-5;MQG94M5EEO;LAJJBLZKAIOLRM-YHAVXTEWSA-N;CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N;5006;-232;2300;12400;0;81;72;182;352;4;Approved;2010;Protein;Agonist;Q02643;ghrhr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;2;Active;1282135070/unspecified;31644039, 21283099, 32701508
130;tesamorelin;tesamorelin;CHEMBL1237026;DB08869;16137828;218949-48-5;MQG94M5EEO;QBEPNUQJQWDYKU-BMGKTWPMSA-N;CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N;5136;-233;2360;12800;0;83;76;187;361;4;Approved;2010;Protein;Agonist;Q02643;ghrhr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;2;Inactive;119724091;31644039, 21283099, 32701508
130;tesamorelin;tesamorelin;CHEMBL1237026;DB08869;16137828;218949-48-5;MQG94M5EEO;QBEPNUQJQWDYKU-BMGKTWPMSA-N;CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N;5136;-233;2360;12800;0;83;76;187;361;4;Approved;2010;Protein;Agonist;Q02643;ghrhr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;2;Inactive;133207228/unspecified;31644039, 21283099, 32701508
130;tesamorelin;tesamorelin;CHEMBL1237026;DB08869;16137828;218949-48-5;MQG94M5EEO;QBEPNUQJQWDYKU-BMGKTWPMSA-N;CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N;5136;-233;2360;12800;0;83;76;187;361;4;Approved;2010;Protein;Agonist;Q02643;ghrhr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;EL3Y;Other specified cutaneous markers of internal disorders;4;Approved;141396655/other;31644039, 21283099, 32701508
130;tesamorelin;tesamorelin;CHEMBL1237026;DB08869;16137828;218949-48-5;MQG94M5EEO;QBEPNUQJQWDYKU-BMGKTWPMSA-N;CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N;5136;-233;2360;12800;0;83;76;187;361;4;Approved;2010;Protein;Agonist;Q02643;ghrhr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;2;Active;1282135070/unspecified;31644039, 21283099, 32701508
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;3;Inactive;1120716949/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;3;Inactive;219731531/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;3;Active;1339785363/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA0A.Y;Other specified disorders of teeth and supporting structures;3;Unknown;1767358557/other;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD81.4;Other and unspecified abdominal pain;3;Inactive;166022696;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME84.2Z;Low back pain, unspecified;3;Active;1815305992/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;3;Inactive;849253504;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.Z;Chronic pain, unspecified;4;Approved;1581976053/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;3;Inactive;1120716949/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;3;Inactive;219731531/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;3;Active;1339785363/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA0A.Y;Other specified disorders of teeth and supporting structures;3;Unknown;1767358557/other;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD81.4;Other and unspecified abdominal pain;3;Inactive;166022696;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME84.2Z;Low back pain, unspecified;3;Active;1815305992/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;3;Inactive;849253504;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.Z;Chronic pain, unspecified;4;Approved;1581976053/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;3;Inactive;1120716949/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;3;Inactive;219731531/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;3;Active;1339785363/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA0A.Y;Other specified disorders of teeth and supporting structures;3;Unknown;1767358557/other;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD81.4;Other and unspecified abdominal pain;3;Inactive;166022696;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME84.2Z;Low back pain, unspecified;3;Active;1815305992/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;3;Inactive;849253504;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.Z;Chronic pain, unspecified;4;Approved;1581976053/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;3;Inactive;1120716949/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;3;Inactive;219731531/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;3;Active;1339785363/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA0A.Y;Other specified disorders of teeth and supporting structures;3;Unknown;1767358557/other;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD81.4;Other and unspecified abdominal pain;3;Inactive;166022696;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME84.2Z;Low back pain, unspecified;3;Active;1815305992/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;3;Inactive;849253504;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.Z;Chronic pain, unspecified;4;Approved;1581976053/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;3;Inactive;1120716949/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;3;Inactive;219731531/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;3;Active;1339785363/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA0A.Y;Other specified disorders of teeth and supporting structures;3;Unknown;1767358557/other;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD81.4;Other and unspecified abdominal pain;3;Inactive;166022696;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME84.2Z;Low back pain, unspecified;3;Active;1815305992/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;3;Inactive;849253504;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.Z;Chronic pain, unspecified;4;Approved;1581976053/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;3;Inactive;1120716949/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;3;Inactive;219731531/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;3;Active;1339785363/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA0A.Y;Other specified disorders of teeth and supporting structures;3;Unknown;1767358557/other;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD81.4;Other and unspecified abdominal pain;3;Inactive;166022696;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME84.2Z;Low back pain, unspecified;3;Active;1815305992/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;3;Inactive;849253504;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.Z;Chronic pain, unspecified;4;Approved;1581976053/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6C43.2Z;Opioid dependence, unspecified;3;Inactive;1120716949/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;3;Inactive;219731531/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8E43.0Z;Neuropathic pain, unspecified;3;Active;1339785363/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DA0A.Y;Other specified disorders of teeth and supporting structures;3;Unknown;1767358557/other;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MD81.4;Other and unspecified abdominal pain;3;Inactive;166022696;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ME84.2Z;Low back pain, unspecified;3;Active;1815305992/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MG30.01;Chronic widespread pain;3;Inactive;849253504;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MG30.Z;Chronic pain, unspecified;4;Approved;1581976053/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6C43.2Z;Opioid dependence, unspecified;3;Inactive;1120716949/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;3;Inactive;219731531/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8E43.0Z;Neuropathic pain, unspecified;3;Active;1339785363/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DA0A.Y;Other specified disorders of teeth and supporting structures;3;Unknown;1767358557/other;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MD81.4;Other and unspecified abdominal pain;3;Inactive;166022696;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ME84.2Z;Low back pain, unspecified;3;Active;1815305992/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MG30.01;Chronic widespread pain;3;Inactive;849253504;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MG30.Z;Chronic pain, unspecified;4;Approved;1581976053/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;3;Inactive;1120716949/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;3;Inactive;219731531/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8E43.0Z;Neuropathic pain, unspecified;3;Active;1339785363/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DA0A.Y;Other specified disorders of teeth and supporting structures;3;Unknown;1767358557/other;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD81.4;Other and unspecified abdominal pain;3;Inactive;166022696;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;3;Active;1815305992/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.01;Chronic widespread pain;3;Inactive;849253504;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;4;Approved;1581976053/unspecified;15509185, 27861439, 30725745
131;tramadol;Ultram;CHEMBL1237044;DB00193;5523;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-UHFFFAOYSA-N;CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;3;Inactive;1120716949/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;3;Inactive;219731531/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8E43.0Z;Neuropathic pain, unspecified;3;Active;1339785363/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DA0A.Y;Other specified disorders of teeth and supporting structures;3;Unknown;1767358557/other;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD81.4;Other and unspecified abdominal pain;3;Inactive;166022696;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;3;Active;1815305992/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.01;Chronic widespread pain;3;Inactive;849253504;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;4;Approved;1581976053/unspecified;15509185, 27861439, 30725745
131;tramadol;tramadol;CHEMBL1237044;DB00193;33741;27203-92-5;39J1LGJ30J;TVYLLZQTGLZFBW-ZBFHGGJFSA-N;CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O;26337;26;327;282;0;1;3;4;19;4;Approved;1995;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;15509185, 27861439, 30725745
132;carboprost;carboprost;CHEMBL1237122;DB00429;5281075;35700-23-3;U4526F86FJ;DLJKPYFALUEJCK-IIELGFQLSA-N;CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O;3685;29;98;473;0;4;5;12;26;4;Approved;1979;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA43.Z;Postpartum haemorrhage, unspecified;4;Approved;820245648/unspecified;28526143, 35419799, 26622459
132;carboprost;carboprost tromethamine;CHEMBL1237105;DB00429;5281074;58551-69-2;U4526F86FJ;DLJKPYFALUEJCK-STIQMIDKSA-N;CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O;3685;29;98;473;0;4;5;12;26;4;Approved;1979;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA43.Z;Postpartum haemorrhage, unspecified;4;Approved;820245648/unspecified;28526143, 35419799, 26622459
132;carboprost;carboprost;CHEMBL1237122;DB00429;5281075;35700-23-3;U4526F86FJ;DLJKPYFALUEJCK-IIELGFQLSA-N;CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O;3685;29;98;473;0;4;5;12;26;4;Approved;1979;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA43.Z;Postpartum haemorrhage, unspecified;4;Approved;820245648/unspecified;28526143, 35419799, 26622459
132;carboprost;carboprost tromethamine;CHEMBL1237105;DB00429;5281074;58551-69-2;U4526F86FJ;DLJKPYFALUEJCK-STIQMIDKSA-N;CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O;3685;29;98;473;0;4;5;12;26;4;Approved;1979;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA43.Z;Postpartum haemorrhage, unspecified;4;Approved;820245648/unspecified;28526143, 35419799, 26622459
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;4A42.Z;Systemic sclerosis, unspecified;2;Inactive;1084365812/unspecified;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;5A10;Type 1 diabetes mellitus;1;Inactive;1651053999;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BB01.Z;Pulmonary hypertension, unspecified;4;Approved;1496633964/unspecified;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD40.Y;Other specified atherosclerotic chronic arterial occlusive disease;2;Inactive;109367356/other;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD42.0;Primary Raynaud disease;1;Inactive;1592720372;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD4Z;Chronic arterial occlusive disease, unspecified;3;Inactive;1821859817/unspecified;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD54;Diabetic foot ulcer;2;Active;74527684;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;2;Inactive;133207228/unspecified;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CB00;Acute respiratory distress syndrome;2;Inactive;1189702844;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CB03.4;Idiopathic pulmonary fibrosis;3;Active;1074069640;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;KB42;Persistent pulmonary hypertension of the newborn;2;Active;346808536;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;LA8Z;Structural developmental anomaly of heart or great vessels, unspecified;2;Inactive;2004408087/unspecified;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;NE84;Failure or rejection of transplanted organs or tissues;1;Active;129221830;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;4A42.Z;Systemic sclerosis, unspecified;2;Inactive;1084365812/unspecified;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;5A10;Type 1 diabetes mellitus;1;Inactive;1651053999;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BB01.Z;Pulmonary hypertension, unspecified;4;Approved;1496633964/unspecified;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD40.Y;Other specified atherosclerotic chronic arterial occlusive disease;2;Inactive;109367356/other;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD42.0;Primary Raynaud disease;1;Inactive;1592720372;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD4Z;Chronic arterial occlusive disease, unspecified;3;Inactive;1821859817/unspecified;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD54;Diabetic foot ulcer;2;Active;74527684;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;2;Inactive;133207228/unspecified;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CB00;Acute respiratory distress syndrome;2;Inactive;1189702844;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CB03.4;Idiopathic pulmonary fibrosis;3;Active;1074069640;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;KB42;Persistent pulmonary hypertension of the newborn;2;Active;346808536;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;LA8Z;Structural developmental anomaly of heart or great vessels, unspecified;2;Inactive;2004408087/unspecified;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;NE84;Failure or rejection of transplanted organs or tissues;1;Active;129221830;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;Q13258;pd2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;4A42.Z;Systemic sclerosis, unspecified;2;Inactive;1084365812/unspecified;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;Q13258;pd2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;5A10;Type 1 diabetes mellitus;1;Inactive;1651053999;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;Q13258;pd2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;Q13258;pd2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BB01.Z;Pulmonary hypertension, unspecified;4;Approved;1496633964/unspecified;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;Q13258;pd2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD40.Y;Other specified atherosclerotic chronic arterial occlusive disease;2;Inactive;109367356/other;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;Q13258;pd2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD42.0;Primary Raynaud disease;1;Inactive;1592720372;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;Q13258;pd2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD4Z;Chronic arterial occlusive disease, unspecified;3;Inactive;1821859817/unspecified;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;Q13258;pd2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD54;Diabetic foot ulcer;2;Active;74527684;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;Q13258;pd2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;2;Inactive;133207228/unspecified;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;Q13258;pd2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CB00;Acute respiratory distress syndrome;2;Inactive;1189702844;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;Q13258;pd2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CB03.4;Idiopathic pulmonary fibrosis;3;Active;1074069640;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;Q13258;pd2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;KB42;Persistent pulmonary hypertension of the newborn;2;Active;346808536;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;Q13258;pd2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;LA8Z;Structural developmental anomaly of heart or great vessels, unspecified;2;Inactive;2004408087/unspecified;33440084, 30000980, 31424736
133;treprostinil;treprostinil;CHEMBL1237119;DB00374;6918140;81846-19-7;RUM6K67ESG;PAJMKGZZBBTTOY-ZFORQUDYSA-N;CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O;3905;45;87;495;0;3;5;10;28;4;Approved;2002;Small molecule;Agonist;Q13258;pd2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;NE84;Failure or rejection of transplanted organs or tissues;1;Active;129221830;33440084, 30000980, 31424736
134;tripelennamine;tripelennamine;CHEMBL1241;DB00792;5587;91-81-6;3C5ORO99TY;UFLGIAIHIAPJJC-UHFFFAOYSA-N;CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2;25536;33;194;236;0;0;3;6;19;4;Approved;1948;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000187, 3709032, 6294681
134;tripelennamine;tripelennamine;CHEMBL1241;DB00792;5587;91-81-6;3C5ORO99TY;UFLGIAIHIAPJJC-UHFFFAOYSA-N;CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2;25536;33;194;236;0;0;3;6;19;4;Approved;1948;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;30000187, 3709032, 6294681
134;tripelennamine;tripelennamine;CHEMBL1241;DB00792;5587;91-81-6;3C5ORO99TY;UFLGIAIHIAPJJC-UHFFFAOYSA-N;CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2;25536;33;194;236;0;0;3;6;19;4;Approved;1948;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;30000187, 3709032, 6294681
135;ganirelix acetate;ganirelix acetate;CHEMBL1251;DB06785;16130957;124904-93-4;IX503L9WN0;GJNXBNATEDXMAK-PFLSVRRQSA-N;CCNC(=NCCCCC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN=C(NCC)NCC)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C)NCC;15703;54;452;3030;0;16;16;48;112;4;Approved;1999;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GC8Y;Other specified diseases of the genitourinary system;4;Approved;30659757/other;10582819, 11163814, 34913294
136;abarelix;abarelix;CHEMBL1252;DB00106;16131215;183552-38-7;NA;AIWRTTMUVOZGPW-HSPKUQOVSA-N;CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)N(C)C(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C;14161;37;425;2770;0;13;16;38;101;4;Approved;2003;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;4;Approved;1552457716/unspecified;12757402, 15637961, 17155895
137;formoterol;(S,S)-formoterol;CHEMBL1433762;DB00983;3034756;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-ORAYPTAESA-N;C[C@@H](CC1=CC=C(C=C1)OC)NC[C@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A20;Alzheimer disease;2;Unknown;1611724421;34342835, 29768149, 31112386
137;formoterol;(S,S)-formoterol;CHEMBL1433762;DB00983;3034756;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-ORAYPTAESA-N;C[C@@H](CC1=CC=C(C=C1)OC)NC[C@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;34342835, 29768149, 31112386
137;formoterol;(S,S)-formoterol;CHEMBL1433762;DB00983;3034756;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-ORAYPTAESA-N;C[C@@H](CC1=CC=C(C=C1)OC)NC[C@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;34342835, 29768149, 31112386
137;formoterol;(S,S)-formoterol;CHEMBL1433762;DB00983;3034756;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-ORAYPTAESA-N;C[C@@H](CC1=CC=C(C=C1)OC)NC[C@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;34342835, 29768149, 31112386
137;formoterol;(S,S)-formoterol;CHEMBL1433762;DB00983;3034756;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-ORAYPTAESA-N;C[C@@H](CC1=CC=C(C=C1)OC)NC[C@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;34342835, 29768149, 31112386
137;formoterol;(S,S)-formoterol;CHEMBL1433762;DB00983;3034756;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-ORAYPTAESA-N;C[C@@H](CC1=CC=C(C=C1)OC)NC[C@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA24;Bronchiectasis;3;Active;1935524933;34342835, 29768149, 31112386
137;formoterol;(S,S)-formoterol;CHEMBL1433762;DB00983;3034756;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-ORAYPTAESA-N;C[C@@H](CC1=CC=C(C=C1)OC)NC[C@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA26.Y;Other specified chronic bronchiolitis;2;Inactive;1067593741/other;34342835, 29768149, 31112386
137;formoterol;(S,S)-formoterol;CHEMBL1433762;DB00983;3034756;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-ORAYPTAESA-N;C[C@@H](CC1=CC=C(C=C1)OC)NC[C@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB00;Acute respiratory distress syndrome;2;Inactive;1189702844;34342835, 29768149, 31112386
137;formoterol;(S,S)-formoterol;CHEMBL1433762;DB00983;3034756;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-ORAYPTAESA-N;C[C@@H](CC1=CC=C(C=C1)OC)NC[C@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;34342835, 29768149, 31112386
137;formoterol;(S,S)-formoterol;CHEMBL1433762;DB00983;3034756;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-ORAYPTAESA-N;C[C@@H](CC1=CC=C(C=C1)OC)NC[C@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;3;Active;1730556128;34342835, 29768149, 31112386
137;formoterol;formoterol;CHEMBL1256786;DB00983;3410;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-UHFFFAOYSA-N;CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A20;Alzheimer disease;2;Unknown;1611724421;34342835, 29768149, 31112386
137;formoterol;formoterol;CHEMBL1256786;DB00983;3410;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-UHFFFAOYSA-N;CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;34342835, 29768149, 31112386
137;formoterol;formoterol;CHEMBL1256786;DB00983;3410;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-UHFFFAOYSA-N;CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;34342835, 29768149, 31112386
137;formoterol;formoterol;CHEMBL1256786;DB00983;3410;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-UHFFFAOYSA-N;CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;34342835, 29768149, 31112386
137;formoterol;formoterol;CHEMBL1256786;DB00983;3410;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-UHFFFAOYSA-N;CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;34342835, 29768149, 31112386
137;formoterol;formoterol;CHEMBL1256786;DB00983;3410;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-UHFFFAOYSA-N;CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA24;Bronchiectasis;3;Active;1935524933;34342835, 29768149, 31112386
137;formoterol;formoterol;CHEMBL1256786;DB00983;3410;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-UHFFFAOYSA-N;CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA26.Y;Other specified chronic bronchiolitis;2;Inactive;1067593741/other;34342835, 29768149, 31112386
137;formoterol;formoterol;CHEMBL1256786;DB00983;3410;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-UHFFFAOYSA-N;CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB00;Acute respiratory distress syndrome;2;Inactive;1189702844;34342835, 29768149, 31112386
137;formoterol;formoterol;CHEMBL1256786;DB00983;3410;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-UHFFFAOYSA-N;CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;34342835, 29768149, 31112386
137;formoterol;formoterol;CHEMBL1256786;DB00983;3410;73573-87-2;5ZZ84GCW8B,F91H02EBWT;BPZSYCZIITTYBL-UHFFFAOYSA-N;CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;3;Active;1730556128;34342835, 29768149, 31112386
137;formoterol;(R,R)-formoterol;CHEMBL1363;"DB00983;DB01274";3083544;67346-49-0;F91H02EBWT;BPZSYCZIITTYBL-YJYMSZOUSA-N;C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A20;Alzheimer disease;2;Unknown;1611724421;34342835, 29768149, 31112386
137;formoterol;(R,R)-formoterol;CHEMBL1363;"DB00983;DB01274";3083544;67346-49-0;F91H02EBWT;BPZSYCZIITTYBL-YJYMSZOUSA-N;C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;34342835, 29768149, 31112386
137;formoterol;(R,R)-formoterol;CHEMBL1363;"DB00983;DB01274";3083544;67346-49-0;F91H02EBWT;BPZSYCZIITTYBL-YJYMSZOUSA-N;C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;34342835, 29768149, 31112386
137;formoterol;(R,R)-formoterol;CHEMBL1363;"DB00983;DB01274";3083544;67346-49-0;F91H02EBWT;BPZSYCZIITTYBL-YJYMSZOUSA-N;C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;34342835, 29768149, 31112386
137;formoterol;(R,R)-formoterol;CHEMBL1363;"DB00983;DB01274";3083544;67346-49-0;F91H02EBWT;BPZSYCZIITTYBL-YJYMSZOUSA-N;C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;34342835, 29768149, 31112386
137;formoterol;(R,R)-formoterol;CHEMBL1363;"DB00983;DB01274";3083544;67346-49-0;F91H02EBWT;BPZSYCZIITTYBL-YJYMSZOUSA-N;C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA24;Bronchiectasis;3;Active;1935524933;34342835, 29768149, 31112386
137;formoterol;(R,R)-formoterol;CHEMBL1363;"DB00983;DB01274";3083544;67346-49-0;F91H02EBWT;BPZSYCZIITTYBL-YJYMSZOUSA-N;C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA26.Y;Other specified chronic bronchiolitis;2;Inactive;1067593741/other;34342835, 29768149, 31112386
137;formoterol;(R,R)-formoterol;CHEMBL1363;"DB00983;DB01274";3083544;67346-49-0;F91H02EBWT;BPZSYCZIITTYBL-YJYMSZOUSA-N;C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB00;Acute respiratory distress syndrome;2;Inactive;1189702844;34342835, 29768149, 31112386
137;formoterol;(R,R)-formoterol;CHEMBL1363;"DB00983;DB01274";3083544;67346-49-0;F91H02EBWT;BPZSYCZIITTYBL-YJYMSZOUSA-N;C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;34342835, 29768149, 31112386
137;formoterol;(R,R)-formoterol;CHEMBL1363;"DB00983;DB01274";3083544;67346-49-0;F91H02EBWT;BPZSYCZIITTYBL-YJYMSZOUSA-N;C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O;3444;18;908;388;0;4;5;8;25;4;Approved;2001;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;3;Active;1730556128;34342835, 29768149, 31112386
138;picotamide;picotamide;CHEMBL1257015;DB13327;4814;"1085306-93-9;32828-81-2";NA;KYWCWBXGRWWINE-UHFFFAOYSA-N;COC1=C(C=C(C=C1)C(=O)NCC2=CN=CC=C2)C(=O)NCC3=CN=CC=C3;3764;13;932;516;0;2;5;7;28;4;Approved;2010;Small molecule;Inhibitor;P21731;ta2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD5Z;Diseases of arteries or arterioles, unspecified;4;Approved;1164983645/unspecified;33929093, 17583179, 9058495
139;salmeterol;salmeterol;CHEMBL1263;DB00938;5152;89365-50-4;2I4BC502BT;GIIZNNXWQWCKIB-UHFFFAOYSA-N;C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O;4156;39;82;403;0;4;5;16;30;4;Approved;1994;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;27181606, 30000157, 32491385
139;salmeterol;salmeterol;CHEMBL1263;DB00938;5152;89365-50-4;2I4BC502BT;GIIZNNXWQWCKIB-UHFFFAOYSA-N;C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O;4156;39;82;403;0;4;5;16;30;4;Approved;1994;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;27181606, 30000157, 32491385
139;salmeterol;salmeterol;CHEMBL1263;DB00938;5152;89365-50-4;2I4BC502BT;GIIZNNXWQWCKIB-UHFFFAOYSA-N;C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O;4156;39;82;403;0;4;5;16;30;4;Approved;1994;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;27181606, 30000157, 32491385
139;salmeterol;salmeterol;CHEMBL1263;DB00938;5152;89365-50-4;2I4BC502BT;GIIZNNXWQWCKIB-UHFFFAOYSA-N;C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O;4156;39;82;403;0;4;5;16;30;4;Approved;1994;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;27181606, 30000157, 32491385
139;salmeterol;salmeterol;CHEMBL1263;DB00938;5152;89365-50-4;2I4BC502BT;GIIZNNXWQWCKIB-UHFFFAOYSA-N;C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O;4156;39;82;403;0;4;5;16;30;4;Approved;1994;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA26.Y;Other specified chronic bronchiolitis;3;Active;1067593741/other;27181606, 30000157, 32491385
140;tetrahydrozoline;tetrahydrozoline;CHEMBL1266;DB06764;5419;84-22-0;S9U025Y077;BYJAVTDNIXVSPW-UHFFFAOYSA-N;C1CC(C2=CC=CC=C2C1)C3=NCCN3;20028;18;244;259;0;1;1;1;15;4;Approved;1979;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;22211761, 21972870, 24516990
140;tetrahydrozoline;tetrahydrozoline;CHEMBL1266;DB06764;5419;84-22-0;S9U025Y077;BYJAVTDNIXVSPW-UHFFFAOYSA-N;C1CC(C2=CC=CC=C2C1)C3=NCCN3;20028;18;244;259;0;1;1;1;15;4;Approved;1979;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;22211761, 21972870, 24516990
140;tetrahydrozoline;tetrahydrozoline;CHEMBL1266;DB06764;5419;84-22-0;S9U025Y077;BYJAVTDNIXVSPW-UHFFFAOYSA-N;C1CC(C2=CC=CC=C2C1)C3=NCCN3;20028;18;244;259;0;1;1;1;15;4;Approved;1979;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;22211761, 21972870, 24516990
140;tetrahydrozoline;tetrahydrozoline;CHEMBL1266;DB06764;5419;84-22-0;S9U025Y077;BYJAVTDNIXVSPW-UHFFFAOYSA-N;C1CC(C2=CC=CC=C2C1)C3=NCCN3;20028;18;244;259;0;1;1;1;15;4;Approved;1979;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;22211761, 21972870, 24516990
140;tetrahydrozoline;tetrahydrozoline;CHEMBL1266;DB06764;5419;84-22-0;S9U025Y077;BYJAVTDNIXVSPW-UHFFFAOYSA-N;C1CC(C2=CC=CC=C2C1)C3=NCCN3;20028;18;244;259;0;1;1;1;15;4;Approved;1979;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;22211761, 21972870, 24516990
140;tetrahydrozoline;tetrahydrozoline;CHEMBL1266;DB06764;5419;84-22-0;S9U025Y077;BYJAVTDNIXVSPW-UHFFFAOYSA-N;C1CC(C2=CC=CC=C2C1)C3=NCCN3;20028;18;244;259;0;1;1;1;15;4;Approved;1979;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;22211761, 21972870, 24516990
140;tetrahydrozoline;tetrahydrozoline;CHEMBL1266;DB06764;5419;84-22-0;S9U025Y077;BYJAVTDNIXVSPW-UHFFFAOYSA-N;C1CC(C2=CC=CC=C2C1)C3=NCCN3;20028;18;244;259;0;1;1;1;15;4;Approved;1979;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;22211761, 21972870, 24516990
140;tetrahydrozoline;tetrahydrozoline;CHEMBL1266;DB06764;5419;84-22-0;S9U025Y077;BYJAVTDNIXVSPW-UHFFFAOYSA-N;C1CC(C2=CC=CC=C2C1)C3=NCCN3;20028;18;244;259;0;1;1;1;15;4;Approved;1979;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;22211761, 21972870, 24516990
140;tetrahydrozoline;tetrahydrozoline;CHEMBL1266;DB06764;5419;84-22-0;S9U025Y077;BYJAVTDNIXVSPW-UHFFFAOYSA-N;C1CC(C2=CC=CC=C2C1)C3=NCCN3;20028;18;244;259;0;1;1;1;15;4;Approved;1979;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;22211761, 21972870, 24516990
140;tetrahydrozoline;tetrahydrozoline;CHEMBL1266;DB06764;5419;84-22-0;S9U025Y077;BYJAVTDNIXVSPW-UHFFFAOYSA-N;C1CC(C2=CC=CC=C2C1)C3=NCCN3;20028;18;244;259;0;1;1;1;15;4;Approved;1979;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;22211761, 21972870, 24516990
140;tetrahydrozoline;tetrahydrozoline;CHEMBL1266;DB06764;5419;84-22-0;S9U025Y077;BYJAVTDNIXVSPW-UHFFFAOYSA-N;C1CC(C2=CC=CC=C2C1)C3=NCCN3;20028;18;244;259;0;1;1;1;15;4;Approved;1979;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;22211761, 21972870, 24516990
140;tetrahydrozoline;tetrahydrozoline;CHEMBL1266;DB06764;5419;84-22-0;S9U025Y077;BYJAVTDNIXVSPW-UHFFFAOYSA-N;C1CC(C2=CC=CC=C2C1)C3=NCCN3;20028;18;244;259;0;1;1;1;15;4;Approved;1979;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;22211761, 21972870, 24516990
143;naratriptan;naratriptan;CHEMBL1278;DB00952;4440;121679-13-8;QX3KXL1ZA2;AMKVXSZCKVJAGH-UHFFFAOYSA-N;CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C;3355;2;736;483;0;2;4;5;23;4;Approved;1998;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30000520, 12463278, 16389295
143;naratriptan;naratriptan;CHEMBL1278;DB00952;4440;121679-13-8;QX3KXL1ZA2;AMKVXSZCKVJAGH-UHFFFAOYSA-N;CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C;3355;2;736;483;0;2;4;5;23;4;Approved;1998;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30000520, 12463278, 16389295
143;naratriptan;naratriptan;CHEMBL1278;DB00952;4440;121679-13-8;QX3KXL1ZA2;AMKVXSZCKVJAGH-UHFFFAOYSA-N;CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C;3355;2;736;483;0;2;4;5;23;4;Approved;1998;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000520, 12463278, 16389295
143;naratriptan;naratriptan;CHEMBL1278;DB00952;4440;121679-13-8;QX3KXL1ZA2;AMKVXSZCKVJAGH-UHFFFAOYSA-N;CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C;3355;2;736;483;0;2;4;5;23;4;Approved;1998;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30000520, 12463278, 16389295
143;naratriptan;naratriptan;CHEMBL1278;DB00952;4440;121679-13-8;QX3KXL1ZA2;AMKVXSZCKVJAGH-UHFFFAOYSA-N;CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C;3355;2;736;483;0;2;4;5;23;4;Approved;1998;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30000520, 12463278, 16389295
143;naratriptan;naratriptan;CHEMBL1278;DB00952;4440;121679-13-8;QX3KXL1ZA2;AMKVXSZCKVJAGH-UHFFFAOYSA-N;CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C;3355;2;736;483;0;2;4;5;23;4;Approved;1998;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000520, 12463278, 16389295
143;naratriptan;naratriptan;CHEMBL1278;DB00952;4440;121679-13-8;QX3KXL1ZA2;AMKVXSZCKVJAGH-UHFFFAOYSA-N;CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C;3355;2;736;483;0;2;4;5;23;4;Approved;1998;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30000520, 12463278, 16389295
143;naratriptan;naratriptan;CHEMBL1278;DB00952;4440;121679-13-8;QX3KXL1ZA2;AMKVXSZCKVJAGH-UHFFFAOYSA-N;CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C;3355;2;736;483;0;2;4;5;23;4;Approved;1998;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30000520, 12463278, 16389295
143;naratriptan;naratriptan;CHEMBL1278;DB00952;4440;121679-13-8;QX3KXL1ZA2;AMKVXSZCKVJAGH-UHFFFAOYSA-N;CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C;3355;2;736;483;0;2;4;5;23;4;Approved;1998;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000520, 12463278, 16389295
143;naratriptan;naratriptan;CHEMBL1278;DB00952;4440;121679-13-8;QX3KXL1ZA2;AMKVXSZCKVJAGH-UHFFFAOYSA-N;CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C;3355;2;736;483;0;2;4;5;23;4;Approved;1998;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30000520, 12463278, 16389295
143;naratriptan;naratriptan;CHEMBL1278;DB00952;4440;121679-13-8;QX3KXL1ZA2;AMKVXSZCKVJAGH-UHFFFAOYSA-N;CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C;3355;2;736;483;0;2;4;5;23;4;Approved;1998;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30000520, 12463278, 16389295
143;naratriptan;naratriptan;CHEMBL1278;DB00952;4440;121679-13-8;QX3KXL1ZA2;AMKVXSZCKVJAGH-UHFFFAOYSA-N;CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C;3355;2;736;483;0;2;4;5;23;4;Approved;1998;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000520, 12463278, 16389295
144;frovatriptan;frovatriptan;CHEMBL1279;DB00998;77992;158747-02-5;H82Q2D5WA7;XPSQPHWEGNHMSK-SECBINFHSA-N;CNC1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N;2433;12;709;333;0;3;2;2;18;4;Approved;2001;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30000521, 11735616, 18001261
144;frovatriptan;frovatriptan;CHEMBL1279;DB00998;77992;158747-02-5;H82Q2D5WA7;XPSQPHWEGNHMSK-SECBINFHSA-N;CNC1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N;2433;12;709;333;0;3;2;2;18;4;Approved;2001;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30000521, 11735616, 18001261
144;frovatriptan;frovatriptan;CHEMBL1279;DB00998;77992;158747-02-5;H82Q2D5WA7;XPSQPHWEGNHMSK-SECBINFHSA-N;CNC1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N;2433;12;709;333;0;3;2;2;18;4;Approved;2001;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000521, 11735616, 18001261
144;frovatriptan;frovatriptan;CHEMBL1279;DB00998;77992;158747-02-5;H82Q2D5WA7;XPSQPHWEGNHMSK-SECBINFHSA-N;CNC1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N;2433;12;709;333;0;3;2;2;18;4;Approved;2001;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30000521, 11735616, 18001261
144;frovatriptan;frovatriptan;CHEMBL1279;DB00998;77992;158747-02-5;H82Q2D5WA7;XPSQPHWEGNHMSK-SECBINFHSA-N;CNC1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N;2433;12;709;333;0;3;2;2;18;4;Approved;2001;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30000521, 11735616, 18001261
144;frovatriptan;frovatriptan;CHEMBL1279;DB00998;77992;158747-02-5;H82Q2D5WA7;XPSQPHWEGNHMSK-SECBINFHSA-N;CNC1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N;2433;12;709;333;0;3;2;2;18;4;Approved;2001;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000521, 11735616, 18001261
145;sumatriptan;sumatriptan;CHEMBL128;DB00669;5358;103628-46-2;8R78F6L9VO;KQKPFRSPSRPDEB-UHFFFAOYSA-N;CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C;2954;9;736;405;0;2;4;6;20;4;Approved;1992;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30000314, 29262214, 35952241
145;sumatriptan;sumatriptan;CHEMBL128;DB00669;5358;103628-46-2;8R78F6L9VO;KQKPFRSPSRPDEB-UHFFFAOYSA-N;CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C;2954;9;736;405;0;2;4;6;20;4;Approved;1992;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30000314, 29262214, 35952241
145;sumatriptan;sumatriptan;CHEMBL128;DB00669;5358;103628-46-2;8R78F6L9VO;KQKPFRSPSRPDEB-UHFFFAOYSA-N;CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C;2954;9;736;405;0;2;4;6;20;4;Approved;1992;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000314, 29262214, 35952241
145;sumatriptan;sumatriptan;CHEMBL128;DB00669;5358;103628-46-2;8R78F6L9VO;KQKPFRSPSRPDEB-UHFFFAOYSA-N;CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C;2954;9;736;405;0;2;4;6;20;4;Approved;1992;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30000314, 29262214, 35952241
145;sumatriptan;sumatriptan;CHEMBL128;DB00669;5358;103628-46-2;8R78F6L9VO;KQKPFRSPSRPDEB-UHFFFAOYSA-N;CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C;2954;9;736;405;0;2;4;6;20;4;Approved;1992;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30000314, 29262214, 35952241
145;sumatriptan;sumatriptan;CHEMBL128;DB00669;5358;103628-46-2;8R78F6L9VO;KQKPFRSPSRPDEB-UHFFFAOYSA-N;CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C;2954;9;736;405;0;2;4;6;20;4;Approved;1992;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000314, 29262214, 35952241
145;sumatriptan;sumatriptan;CHEMBL128;DB00669;5358;103628-46-2;8R78F6L9VO;KQKPFRSPSRPDEB-UHFFFAOYSA-N;CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C;2954;9;736;405;0;2;4;6;20;4;Approved;1992;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30000314, 29262214, 35952241
145;sumatriptan;sumatriptan;CHEMBL128;DB00669;5358;103628-46-2;8R78F6L9VO;KQKPFRSPSRPDEB-UHFFFAOYSA-N;CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C;2954;9;736;405;0;2;4;6;20;4;Approved;1992;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30000314, 29262214, 35952241
145;sumatriptan;sumatriptan;CHEMBL128;DB00669;5358;103628-46-2;8R78F6L9VO;KQKPFRSPSRPDEB-UHFFFAOYSA-N;CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C;2954;9;736;405;0;2;4;6;20;4;Approved;1992;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000314, 29262214, 35952241
145;sumatriptan;sumatriptan;CHEMBL128;DB00669;5358;103628-46-2;8R78F6L9VO;KQKPFRSPSRPDEB-UHFFFAOYSA-N;CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C;2954;9;736;405;0;2;4;6;20;4;Approved;1992;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30000314, 29262214, 35952241
145;sumatriptan;sumatriptan;CHEMBL128;DB00669;5358;103628-46-2;8R78F6L9VO;KQKPFRSPSRPDEB-UHFFFAOYSA-N;CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C;2954;9;736;405;0;2;4;6;20;4;Approved;1992;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30000314, 29262214, 35952241
145;sumatriptan;sumatriptan;CHEMBL128;DB00669;5358;103628-46-2;8R78F6L9VO;KQKPFRSPSRPDEB-UHFFFAOYSA-N;CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C;2954;9;736;405;0;2;4;6;20;4;Approved;1992;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000314, 29262214, 35952241
146;tianeptine;tianeptine;CHEMBL1289110;DB09289;68870;72797-41-2;0T493YFU8O;JICJBGPOMZQUBB-UHFFFAOYSA-N;CN1C2=CC=CC=C2C(C3=C(S1(=O)=O)C=C(C=C3)Cl)NCCCCCCC(=O)O;437;12;951;654;0;2;6;8;29;4;Approved;1969;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Unknown;1456478153/unspecified;30612921, 38373171, 37453966
146;tianeptine;tianeptine;CHEMBL1289110;DB09289;68870;72797-41-2;0T493YFU8O;JICJBGPOMZQUBB-UHFFFAOYSA-N;CN1C2=CC=CC=C2C(C3=C(S1(=O)=O)C=C(C=C3)Cl)NCCCCCCC(=O)O;437;12;951;654;0;2;6;8;29;4;Approved;1969;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;30612921, 38373171, 37453966
146;tianeptine;tianeptine;CHEMBL1289110;DB09289;68870;72797-41-2;0T493YFU8O;JICJBGPOMZQUBB-UHFFFAOYSA-N;CN1C2=CC=CC=C2C(C3=C(S1(=O)=O)C=C(C=C3)Cl)NCCCCCCC(=O)O;437;12;951;654;0;2;6;8;29;4;Approved;1969;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30612921, 38373171, 37453966
147;penbutolol;penbutolol;CHEMBL1290;DB01359;37464;38363-40-5;78W62V43DY;KQXKVJAGOJTNJS-HNNXBMFYSA-N;CC(C)(C)NCC(COC1=CC=CC=C1C2CCCC2)O;2914;42;415;294;0;2;3;7;21;4;Approved;1987;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000218, 31643813, 3762014
147;penbutolol;penbutolol;CHEMBL1290;DB01359;37464;38363-40-5;78W62V43DY;KQXKVJAGOJTNJS-HNNXBMFYSA-N;CC(C)(C)NCC(COC1=CC=CC=C1C2CCCC2)O;2914;42;415;294;0;2;3;7;21;4;Approved;1987;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000218, 31643813, 3762014
147;penbutolol;penbutolol;CHEMBL1290;DB01359;37464;38363-40-5;78W62V43DY;KQXKVJAGOJTNJS-HNNXBMFYSA-N;CC(C)(C)NCC(COC1=CC=CC=C1C2CCCC2)O;2914;42;415;294;0;2;3;7;21;4;Approved;1987;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000218, 31643813, 3762014
148;metipranolol;metipranolol;CHEMBL1291;DB01214;31477;22664-55-7;X39AL81KEB;BQIPXWYNLPYNHW-UHFFFAOYSA-N;CC1=CC(=C(C(=C1OC(=O)C)C)C)OCC(CNC(C)C)O;3094;27;678;348;0;2;5;8;22;4;Approved;1989;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000214, 7977597, 30315650
148;metipranolol;metipranolol;CHEMBL1291;DB01214;31477;22664-55-7;X39AL81KEB;BQIPXWYNLPYNHW-UHFFFAOYSA-N;CC1=CC(=C(C(=C1OC(=O)C)C)C)OCC(CNC(C)C)O;3094;27;678;348;0;2;5;8;22;4;Approved;1989;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000214, 7977597, 30315650
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;3A50.2;Beta thalassaemia;3;Inactive;2063292324;30422518, 30000215, 35952115
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A11;Type 2 diabetes mellitus;2;Inactive;119724091;30422518, 30000215, 35952115
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;30422518, 30000215, 35952115
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8C70.1;Duchenne muscular dystrophy;3;Active;1479561744;30422518, 30000215, 35952115
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30422518, 30000215, 35952115
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA40.Z;Angina pectoris, unspecified;4;Approved;718946808/unspecified;30422518, 30000215, 35952115
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;30422518, 30000215, 35952115
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BB61.Z;Mitral valve insufficiency, unspecified;3;Inactive;637470326/unspecified;30422518, 30000215, 35952115
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC43.1Z;Hypertrophic cardiomyopathy, unspecified;2;Inactive;1830681485/unspecified;30422518, 30000215, 35952115
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC71.0Z;Ventricular tachycardia, unspecified;2;Inactive;1171837620/unspecified;30422518, 30000215, 35952115
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC71.1;Ventricular fibrillation;2;Inactive;1662472992;30422518, 30000215, 35952115
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;3;Inactive;171698302/unspecified;30422518, 30000215, 35952115
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;4;Approved;2136808878;30422518, 30000215, 35952115
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;30422518, 30000215, 35952115
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;3;Inactive;133207228/unspecified;30422518, 30000215, 35952115
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LD90.3;Prader-Willi syndrome;2;Inactive;393773440;30422518, 30000215, 35952115
149;metoprolol;metoprolol;CHEMBL13;DB00264;4171;51384-51-1;GEB06NHM23;IUBSYMUCCVWXPE-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOC)O;26736;19;507;215;0;2;4;9;19;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MC82.Z;Cardiac arrest, unspecified;2;Inactive;395422191/unspecified;30422518, 30000215, 35952115
150;rotigotine;rotigotine;CHEMBL1303;DB05271;59227;99755-59-6;87T4T8BO2E;KFQYTPMOWPVWEJ-INIZCTEOSA-N;CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O;3155;49;517;337;0;1;3;6;22;4;Approved;2007;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;4;Approved;1254916765;30000856, 31643273, 36695083
150;rotigotine;rotigotine;CHEMBL1303;DB05271;59227;99755-59-6;87T4T8BO2E;KFQYTPMOWPVWEJ-INIZCTEOSA-N;CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O;3155;49;517;337;0;1;3;6;22;4;Approved;2007;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30000856, 31643273, 36695083
150;rotigotine;rotigotine;CHEMBL1303;DB05271;59227;99755-59-6;87T4T8BO2E;KFQYTPMOWPVWEJ-INIZCTEOSA-N;CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O;3155;49;517;337;0;1;3;6;22;4;Approved;2007;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A20;Alzheimer disease;2;Inactive;1611724421;30000856, 31643273, 36695083
150;rotigotine;rotigotine;CHEMBL1303;DB05271;59227;99755-59-6;87T4T8BO2E;KFQYTPMOWPVWEJ-INIZCTEOSA-N;CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O;3155;49;517;337;0;1;3;6;22;4;Approved;2007;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;30000856, 31643273, 36695083
150;rotigotine;rotigotine;CHEMBL1303;DB05271;59227;99755-59-6;87T4T8BO2E;KFQYTPMOWPVWEJ-INIZCTEOSA-N;CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O;3155;49;517;337;0;1;3;6;22;4;Approved;2007;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;4;Approved;1254916765;30000856, 31643273, 36695083
150;rotigotine;rotigotine;CHEMBL1303;DB05271;59227;99755-59-6;87T4T8BO2E;KFQYTPMOWPVWEJ-INIZCTEOSA-N;CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O;3155;49;517;337;0;1;3;6;22;4;Approved;2007;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30000856, 31643273, 36695083
150;rotigotine;rotigotine;CHEMBL1303;DB05271;59227;99755-59-6;87T4T8BO2E;KFQYTPMOWPVWEJ-INIZCTEOSA-N;CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O;3155;49;517;337;0;1;3;6;22;4;Approved;2007;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A20;Alzheimer disease;2;Inactive;1611724421;30000856, 31643273, 36695083
150;rotigotine;rotigotine;CHEMBL1303;DB05271;59227;99755-59-6;87T4T8BO2E;KFQYTPMOWPVWEJ-INIZCTEOSA-N;CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O;3155;49;517;337;0;1;3;6;22;4;Approved;2007;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;30000856, 31643273, 36695083
150;rotigotine;rotigotine;CHEMBL1303;DB05271;59227;99755-59-6;87T4T8BO2E;KFQYTPMOWPVWEJ-INIZCTEOSA-N;CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O;3155;49;517;337;0;1;3;6;22;4;Approved;2007;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;4;Approved;1254916765;30000856, 31643273, 36695083
150;rotigotine;rotigotine;CHEMBL1303;DB05271;59227;99755-59-6;87T4T8BO2E;KFQYTPMOWPVWEJ-INIZCTEOSA-N;CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O;3155;49;517;337;0;1;3;6;22;4;Approved;2007;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30000856, 31643273, 36695083
150;rotigotine;rotigotine;CHEMBL1303;DB05271;59227;99755-59-6;87T4T8BO2E;KFQYTPMOWPVWEJ-INIZCTEOSA-N;CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O;3155;49;517;337;0;1;3;6;22;4;Approved;2007;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A20;Alzheimer disease;2;Inactive;1611724421;30000856, 31643273, 36695083
150;rotigotine;rotigotine;CHEMBL1303;DB05271;59227;99755-59-6;87T4T8BO2E;KFQYTPMOWPVWEJ-INIZCTEOSA-N;CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O;3155;49;517;337;0;1;3;6;22;4;Approved;2007;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;30000856, 31643273, 36695083
151;antazoline;antazoline;CHEMBL1305;DB08799;2200;91-75-8;DHA8014SS1;REYFJDPCWQRWAA-UHFFFAOYSA-N;C1CN=C(N1)CN(CC2=CC=CC=C2)C3=CC=CC=C3;26535;26;276;314;0;1;2;5;20;4;Approved;1994;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;35766936, 29377987, 30920001
151;antazoline;antazoline;CHEMBL1305;DB08799;2200;91-75-8;DHA8014SS1;REYFJDPCWQRWAA-UHFFFAOYSA-N;C1CN=C(N1)CN(CC2=CC=CC=C2)C3=CC=CC=C3;26535;26;276;314;0;1;2;5;20;4;Approved;1994;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;35766936, 29377987, 30920001
152;hyoscyamine;hyoscyamine;CHEMBL1331216;DB00424;154417;101-31-5;PX44XO846X;RKUNBYITZUJHSG-VFSICIBPSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1938;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;31644177, 36501358, 13203600
152;hyoscyamine;hyoscyamine;CHEMBL1331216;DB00424;154417;101-31-5;PX44XO846X;RKUNBYITZUJHSG-VFSICIBPSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1938;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;31644177, 36501358, 13203600
152;hyoscyamine;hyoscyamine;CHEMBL1331216;DB00424;154417;101-31-5;PX44XO846X;RKUNBYITZUJHSG-VFSICIBPSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1938;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC08.Z;Urinary tract infection, site and agent not specified;4;Approved;1848472780/unspecified;31644177, 36501358, 13203600
152;hyoscyamine;hyoscyamine;CHEMBL1331216;DB00424;154417;101-31-5;PX44XO846X;RKUNBYITZUJHSG-VFSICIBPSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1938;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;31644177, 36501358, 13203600
152;hyoscyamine;hyoscyamine;CHEMBL1331216;DB00424;154417;101-31-5;PX44XO846X;RKUNBYITZUJHSG-VFSICIBPSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1938;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;31644177, 36501358, 13203600
152;hyoscyamine;hyoscyamine;CHEMBL1331216;DB00424;154417;101-31-5;PX44XO846X;RKUNBYITZUJHSG-VFSICIBPSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1938;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC08.Z;Urinary tract infection, site and agent not specified;4;Approved;1848472780/unspecified;31644177, 36501358, 13203600
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C8Z;Malignant neoplasms of male genital organs, unspecified;3;Inactive;1894406676/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;4;Approved;821852937/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C41.2Z;Cannabis dependence, unspecified;3;Inactive;1129015467/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;2;Inactive;1120716949/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;1;Inactive;1691013484/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Active;897917531/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B1Z;Cerebral ischaemia, unspecified;1;Unknown;1427441570/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8C03.0;Diabetic polyneuropathy;2;Inactive;1837670870;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;4;Approved;1339785363/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA01.11;Oral mucositis;2;Active;1634507618;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;1;Active;215767047/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA60.0;Mild hyperemesis gravidarum;3;Inactive;1878037467;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Active;80293156;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.3;Anxiety;2;Unknown;2027043655;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME07.Z;Faecal incontinence, unspecified;3;Active;790417430/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME84.2Z;Low back pain, unspecified;2;Inactive;1815305992/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;1;Active;940081636;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Inactive;277610609/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NE8Z;Injury or harm arising from surgical or medical care, not elsewhere classified, unspecified;3;Unknown;383104340/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C8Z;Malignant neoplasms of male genital organs, unspecified;3;Inactive;1894406676/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;4;Approved;821852937/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C41.2Z;Cannabis dependence, unspecified;3;Inactive;1129015467/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;2;Inactive;1120716949/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;1;Inactive;1691013484/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Active;897917531/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B1Z;Cerebral ischaemia, unspecified;1;Unknown;1427441570/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8C03.0;Diabetic polyneuropathy;2;Inactive;1837670870;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;4;Approved;1339785363/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA01.11;Oral mucositis;2;Active;1634507618;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;1;Active;215767047/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA60.0;Mild hyperemesis gravidarum;3;Inactive;1878037467;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Active;80293156;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.3;Anxiety;2;Unknown;2027043655;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME07.Z;Faecal incontinence, unspecified;3;Active;790417430/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME84.2Z;Low back pain, unspecified;2;Inactive;1815305992/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;1;Active;940081636;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Inactive;277610609/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NE8Z;Injury or harm arising from surgical or medical care, not elsewhere classified, unspecified;3;Unknown;383104340/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C8Z;Malignant neoplasms of male genital organs, unspecified;3;Inactive;1894406676/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;4;Approved;821852937/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C41.2Z;Cannabis dependence, unspecified;3;Inactive;1129015467/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;2;Inactive;1120716949/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;1;Inactive;1691013484/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Active;897917531/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B1Z;Cerebral ischaemia, unspecified;1;Unknown;1427441570/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8C03.0;Diabetic polyneuropathy;2;Inactive;1837670870;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;4;Approved;1339785363/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA01.11;Oral mucositis;2;Active;1634507618;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;1;Active;215767047/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA60.0;Mild hyperemesis gravidarum;3;Inactive;1878037467;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Active;80293156;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.3;Anxiety;2;Unknown;2027043655;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME07.Z;Faecal incontinence, unspecified;3;Active;790417430/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME84.2Z;Low back pain, unspecified;2;Inactive;1815305992/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;1;Active;940081636;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Inactive;277610609/unspecified;29083638, 30000689, 35951908
153;clonidine;clonidine;CHEMBL134;DB00575;2803;4205-90-7;MN3L5RMN02;GJSURZIOUXUGAL-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl;23009;16;364;222;0;2;1;2;14;4;Approved;1974;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NE8Z;Injury or harm arising from surgical or medical care, not elsewhere classified, unspecified;3;Unknown;383104340/unspecified;29083638, 30000689, 35951908
154;darifenacin;darifenacin;CHEMBL1346;DB00496;444031;133099-04-4;APG9819VLM;HXGBXQDTNZMWGS-RUZDIDTESA-N;C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5;4265;46;556;607;0;1;3;7;32;4;Approved;2004;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Unknown;1982355687;31644105, 21583148, 16193097
154;darifenacin;darifenacin;CHEMBL1346;DB00496;444031;133099-04-4;APG9819VLM;HXGBXQDTNZMWGS-RUZDIDTESA-N;C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5;4265;46;556;607;0;1;3;7;32;4;Approved;2004;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;31644105, 21583148, 16193097
154;darifenacin;darifenacin;CHEMBL1346;DB00496;444031;133099-04-4;APG9819VLM;HXGBXQDTNZMWGS-RUZDIDTESA-N;C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5;4265;46;556;607;0;1;3;7;32;4;Approved;2004;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;31644105, 21583148, 16193097
154;darifenacin;darifenacin;CHEMBL1346;DB00496;444031;133099-04-4;APG9819VLM;HXGBXQDTNZMWGS-RUZDIDTESA-N;C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5;4265;46;556;607;0;1;3;7;32;4;Approved;2004;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF55;Polyuria;4;Approved;2137636828;31644105, 21583148, 16193097
154;darifenacin;R-darifenacin;CHEMBL1346;DB00496;72054;133099-04-4;APG9819VLM;HXGBXQDTNZMWGS-UHFFFAOYSA-N;C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5;4265;46;556;607;0;1;3;7;32;4;Approved;2004;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Unknown;1982355687;31644105, 21583148, 16193097
154;darifenacin;R-darifenacin;CHEMBL1346;DB00496;72054;133099-04-4;APG9819VLM;HXGBXQDTNZMWGS-UHFFFAOYSA-N;C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5;4265;46;556;607;0;1;3;7;32;4;Approved;2004;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;31644105, 21583148, 16193097
154;darifenacin;R-darifenacin;CHEMBL1346;DB00496;72054;133099-04-4;APG9819VLM;HXGBXQDTNZMWGS-UHFFFAOYSA-N;C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5;4265;46;556;607;0;1;3;7;32;4;Approved;2004;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;31644105, 21583148, 16193097
154;darifenacin;R-darifenacin;CHEMBL1346;DB00496;72054;133099-04-4;APG9819VLM;HXGBXQDTNZMWGS-UHFFFAOYSA-N;C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5;4265;46;556;607;0;1;3;7;32;4;Approved;2004;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF55;Polyuria;4;Approved;2137636828;31644105, 21583148, 16193097
154;darifenacin;darifenacin;CHEMBL1346;DB00496;444031;133099-04-4;APG9819VLM;HXGBXQDTNZMWGS-RUZDIDTESA-N;C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5;4265;46;556;607;0;1;3;7;32;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Unknown;1982355687;31644105, 21583148, 16193097
154;darifenacin;darifenacin;CHEMBL1346;DB00496;444031;133099-04-4;APG9819VLM;HXGBXQDTNZMWGS-RUZDIDTESA-N;C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5;4265;46;556;607;0;1;3;7;32;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;31644105, 21583148, 16193097
154;darifenacin;darifenacin;CHEMBL1346;DB00496;444031;133099-04-4;APG9819VLM;HXGBXQDTNZMWGS-RUZDIDTESA-N;C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5;4265;46;556;607;0;1;3;7;32;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;31644105, 21583148, 16193097
154;darifenacin;darifenacin;CHEMBL1346;DB00496;444031;133099-04-4;APG9819VLM;HXGBXQDTNZMWGS-RUZDIDTESA-N;C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5;4265;46;556;607;0;1;3;7;32;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF55;Polyuria;4;Approved;2137636828;31644105, 21583148, 16193097
154;darifenacin;R-darifenacin;CHEMBL1346;DB00496;72054;133099-04-4;APG9819VLM;HXGBXQDTNZMWGS-UHFFFAOYSA-N;C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5;4265;46;556;607;0;1;3;7;32;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Unknown;1982355687;31644105, 21583148, 16193097
154;darifenacin;R-darifenacin;CHEMBL1346;DB00496;72054;133099-04-4;APG9819VLM;HXGBXQDTNZMWGS-UHFFFAOYSA-N;C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5;4265;46;556;607;0;1;3;7;32;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;31644105, 21583148, 16193097
154;darifenacin;R-darifenacin;CHEMBL1346;DB00496;72054;133099-04-4;APG9819VLM;HXGBXQDTNZMWGS-UHFFFAOYSA-N;C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5;4265;46;556;607;0;1;3;7;32;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;31644105, 21583148, 16193097
154;darifenacin;R-darifenacin;CHEMBL1346;DB00496;72054;133099-04-4;APG9819VLM;HXGBXQDTNZMWGS-UHFFFAOYSA-N;C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5;4265;46;556;607;0;1;3;7;32;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF55;Polyuria;4;Approved;2137636828;31644105, 21583148, 16193097
155;piribedil;piribedil;CHEMBL1371770;DB12478;4850;3605-01-4;DO22K1PRDJ;OQDPVLVUJFGPGQ-UHFFFAOYSA-N;C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4;29834;18;507;356;0;0;6;3;22;4;Approved;1969;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;27344665, 21586915, 28745677
155;piribedil;piribedil;CHEMBL1371770;DB12478;4850;3605-01-4;DO22K1PRDJ;OQDPVLVUJFGPGQ-UHFFFAOYSA-N;C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4;29834;18;507;356;0;0;6;3;22;4;Approved;1969;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;27344665, 21586915, 28745677
155;piribedil;piribedil;CHEMBL1371770;DB12478;4850;3605-01-4;DO22K1PRDJ;OQDPVLVUJFGPGQ-UHFFFAOYSA-N;C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4;29834;18;507;356;0;0;6;3;22;4;Approved;1969;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;27344665, 21586915, 28745677
155;piribedil;piribedil;CHEMBL1371770;DB12478;4850;3605-01-4;DO22K1PRDJ;OQDPVLVUJFGPGQ-UHFFFAOYSA-N;C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4;29834;18;507;356;0;0;6;3;22;4;Approved;1969;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;27344665, 21586915, 28745677
155;piribedil;piribedil;CHEMBL1371770;DB12478;4850;3605-01-4;DO22K1PRDJ;OQDPVLVUJFGPGQ-UHFFFAOYSA-N;C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4;29834;18;507;356;0;0;6;3;22;4;Approved;1969;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;27344665, 21586915, 28745677
155;piribedil;piribedil;CHEMBL1371770;DB12478;4850;3605-01-4;DO22K1PRDJ;OQDPVLVUJFGPGQ-UHFFFAOYSA-N;C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4;29834;18;507;356;0;0;6;3;22;4;Approved;1969;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;27344665, 21586915, 28745677
156;nicergoline;nicergoline;CHEMBL1372950;DB00699;34040;27848-84-6;JCV8365FWN;YSEXMKHXIOCEJA-FVFQAYNVSA-N;CN1CC(CC2(C1CC3=CN(C4=CC=CC2=C34)C)OC)COC(=O)C5=CC(=CN=C5)Br;4844;32;566;681;0;0;5;5;31;4;Approved;2000;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;4;Approved;546689346/unspecified;18666801, 25712664, 25243157
156;nicergoline;nicergoline;CHEMBL1372950;DB00699;34040;27848-84-6;JCV8365FWN;YSEXMKHXIOCEJA-FVFQAYNVSA-N;CN1CC(CC2(C1CC3=CN(C4=CC=CC2=C34)C)OC)COC(=O)C5=CC(=CN=C5)Br;4844;32;566;681;0;0;5;5;31;4;Approved;2000;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD42.0;Primary Raynaud disease;3;Unknown;1592720372;18666801, 25712664, 25243157
156;nicergoline;nicergoline;CHEMBL1372950;DB00699;34040;27848-84-6;JCV8365FWN;YSEXMKHXIOCEJA-FVFQAYNVSA-N;CN1CC(CC2(C1CC3=CN(C4=CC=CC2=C34)C)OC)COC(=O)C5=CC(=CN=C5)Br;4844;32;566;681;0;0;5;5;31;4;Approved;2000;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD55;Asymptomatic stenosis of intracranial or extracranial artery;4;Approved;860460764;18666801, 25712664, 25243157
157;thiethylperazine;thiethylperazine;CHEMBL1378;DB00372;5440;"1179-69-7;1420-55-9";NA;XCTYLCDETUVOIP-UHFFFAOYSA-N;CCSC1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)C;3996;54;603;455;0;0;5;6;27;4;Approved;1961;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A20;Alzheimer disease;2;Inactive;1611724421;30000169, 12742335, 6507047
157;thiethylperazine;thiethylperazine;CHEMBL1378;DB00372;5440;"1179-69-7;1420-55-9";NA;XCTYLCDETUVOIP-UHFFFAOYSA-N;CCSC1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)C;3996;54;603;455;0;0;5;6;27;4;Approved;1961;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000169, 12742335, 6507047
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;2;Inactive;1339785363/unspecified;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF55;Polyuria;4;Approved;2137636828;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;2;Inactive;1339785363/unspecified;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF55;Polyuria;4;Approved;2137636828;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;2;Inactive;1339785363/unspecified;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF55;Polyuria;4;Approved;2137636828;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;2;Inactive;1339785363/unspecified;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF55;Polyuria;4;Approved;2137636828;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;2;Inactive;1339785363/unspecified;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;32491781, 31643834, 30000730
158;tolterodine;tolterodine;CHEMBL1382;DB01036;443879;124937-51-5;WHE7A56U7K;OOGJQPCLVADCPB-HXUWFJFHSA-N;CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2;3255;56;235;340;0;1;2;7;24;4;Approved;1998;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF55;Polyuria;4;Approved;2137636828;32491781, 31643834, 30000730
159;oxatomide;oxatomide;CHEMBL13828;DB12877;4615;60607-34-3;NA;BAINIUMDFURPJM-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3NC2=O)C(C4=CC=CC=C4)C5=CC=CC=C5;4266;41;388;575;0;1;3;7;32;4;Approved;1981;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;8C70.1;Duchenne muscular dystrophy;2;Unknown;1479561744;6200290, 12804426, 6861643
159;oxatomide;oxatomide;CHEMBL13828;DB12877;4615;60607-34-3;NA;BAINIUMDFURPJM-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3NC2=O)C(C4=CC=CC=C4)C5=CC=CC=C5;4266;41;388;575;0;1;3;7;32;4;Approved;1981;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;6200290, 12804426, 6861643
159;oxatomide;oxatomide;CHEMBL13828;DB12877;4615;60607-34-3;NA;BAINIUMDFURPJM-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3NC2=O)C(C4=CC=CC=C4)C5=CC=CC=C5;4266;41;388;575;0;1;3;7;32;4;Approved;1981;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;6200290, 12804426, 6861643
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Unknown;1982355687;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Unknown;1982355687;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Unknown;1982355687;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Unknown;1982355687;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Unknown;1982355687;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;30000125, 31644153, 33461384
160;pimozide;pimozide;CHEMBL1423;DB01100;16362;2062-78-4;1HIZ4DL86F;YVUQSNJEYSNKRX-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4615;63;356;632;0;1;4;7;34;4;Approved;1984;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Unknown;1982355687;30000125, 31644153, 33461384
161;naftopidil;naftopidil;CHEMBL142635;DB12092;4418;57149-07-2;NA;HRRBJVNMSRJFHQ-UHFFFAOYSA-N;COC1=CC=CC=C1N2CCN(CC2)CC(COC3=CC=CC4=CC=CC=C43)O;3925;41;452;483;0;1;5;7;29;4;Approved;1996;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA90;Hyperplasia of prostate;4;Approved;978159279;24188134, 28394500, 28306333
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;1B91;Leptospirosis;3;Inactive;751399056;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;1;Unknown;1552457716/unspecified;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;3B12;Von Willebrand disease;4;Approved;2112021600;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5A61.5;Central diabetes insipidus;4;Approved;1009553897;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6C00.Z;Enuresis, unspecified;4;Approved;1157749237/unspecified;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Inactive;873092535/unspecified;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GC50.0;Overactive bladder;2;Inactive;1118102209;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MF56;Renal colic;3;Unknown;821552851;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;ND56.0;Superficial injury of unspecified body region;2;Inactive;1212937040;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;1B91;Leptospirosis;3;Inactive;751399056;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;1;Unknown;1552457716/unspecified;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;3B12;Von Willebrand disease;4;Approved;2112021600;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5A61.5;Central diabetes insipidus;4;Approved;1009553897;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6C00.Z;Enuresis, unspecified;4;Approved;1157749237/unspecified;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Inactive;873092535/unspecified;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GC50.0;Overactive bladder;2;Inactive;1118102209;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MF56;Renal colic;3;Unknown;821552851;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;ND56.0;Superficial injury of unspecified body region;2;Inactive;1212937040;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;1B91;Leptospirosis;3;Inactive;751399056;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;1;Unknown;1552457716/unspecified;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;3B12;Von Willebrand disease;4;Approved;2112021600;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5A61.5;Central diabetes insipidus;4;Approved;1009553897;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6C00.Z;Enuresis, unspecified;4;Approved;1157749237/unspecified;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Inactive;873092535/unspecified;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GC50.0;Overactive bladder;2;Inactive;1118102209;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MF56;Renal colic;3;Unknown;821552851;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;ND56.0;Superficial injury of unspecified body region;2;Inactive;1212937040;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;1B91;Leptospirosis;3;Inactive;751399056;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;1;Unknown;1552457716/unspecified;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;3B12;Von Willebrand disease;4;Approved;2112021600;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5A61.5;Central diabetes insipidus;4;Approved;1009553897;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6C00.Z;Enuresis, unspecified;4;Approved;1157749237/unspecified;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Inactive;873092535/unspecified;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GC50.0;Overactive bladder;2;Inactive;1118102209;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MF56;Renal colic;3;Unknown;821552851;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;ND56.0;Superficial injury of unspecified body region;2;Inactive;1212937040;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;1B91;Leptospirosis;3;Inactive;751399056;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;1;Unknown;1552457716/unspecified;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;3B12;Von Willebrand disease;4;Approved;2112021600;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5A61.5;Central diabetes insipidus;4;Approved;1009553897;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6C00.Z;Enuresis, unspecified;4;Approved;1157749237/unspecified;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Inactive;873092535/unspecified;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GC50.0;Overactive bladder;2;Inactive;1118102209;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MF56;Renal colic;3;Unknown;821552851;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;ND56.0;Superficial injury of unspecified body region;2;Inactive;1212937040;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;1B91;Leptospirosis;3;Inactive;751399056;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;1;Unknown;1552457716/unspecified;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;3B12;Von Willebrand disease;4;Approved;2112021600;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5A61.5;Central diabetes insipidus;4;Approved;1009553897;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6C00.Z;Enuresis, unspecified;4;Approved;1157749237/unspecified;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Inactive;873092535/unspecified;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GC50.0;Overactive bladder;2;Inactive;1118102209;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MF56;Renal colic;3;Unknown;821552851;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;ND56.0;Superficial injury of unspecified body region;2;Inactive;1212937040;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;1B91;Leptospirosis;3;Inactive;751399056;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;1;Unknown;1552457716/unspecified;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;3B12;Von Willebrand disease;4;Approved;2112021600;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5A61.5;Central diabetes insipidus;4;Approved;1009553897;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6C00.Z;Enuresis, unspecified;4;Approved;1157749237/unspecified;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Inactive;873092535/unspecified;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GC50.0;Overactive bladder;2;Inactive;1118102209;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MF56;Renal colic;3;Unknown;821552851;30000372, 32119469, 36103267
162;desmopressin;S-desmopressin;CHEMBL376685;DB00035;16051933;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-NXBWRCJVSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;ND56.0;Superficial injury of unspecified body region;2;Inactive;1212937040;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;1B91;Leptospirosis;3;Inactive;751399056;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;1;Unknown;1552457716/unspecified;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;3B12;Von Willebrand disease;4;Approved;2112021600;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5A61.5;Central diabetes insipidus;4;Approved;1009553897;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6C00.Z;Enuresis, unspecified;4;Approved;1157749237/unspecified;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Inactive;873092535/unspecified;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GC50.0;Overactive bladder;2;Inactive;1118102209;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MF56;Renal colic;3;Unknown;821552851;30000372, 32119469, 36103267
162;desmopressin;R-desmopressin;CHEMBL1429;DB00035;5311065;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-PNIOQBSNSA-N;C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;ND56.0;Superficial injury of unspecified body region;2;Inactive;1212937040;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;1B91;Leptospirosis;3;Inactive;751399056;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;1;Unknown;1552457716/unspecified;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;3B12;Von Willebrand disease;4;Approved;2112021600;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5A61.5;Central diabetes insipidus;4;Approved;1009553897;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6C00.Z;Enuresis, unspecified;4;Approved;1157749237/unspecified;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Inactive;873092535/unspecified;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GC50.0;Overactive bladder;2;Inactive;1118102209;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MF56;Renal colic;3;Unknown;821552851;30000372, 32119469, 36103267
162;desmopressin;desmopressin;CHEMBL264448;DB00035;27991;16679-58-6;ENR1LLB0FP;NFLWUMRGJYTJIN-UHFFFAOYSA-N;C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10692;-4;489;2040;0;13;15;19;74;4;Approved;1978;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;ND56.0;Superficial injury of unspecified body region;2;Inactive;1212937040;30000372, 32119469, 36103267
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1C81;Acute poliomyelitis;4;Approved;588527933;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G40;Sepsis without septic shock;4;Approved;622600769;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;2;Inactive;56009591;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Y;Other specified hypotension;4;Approved;1663360295/other;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EJ7Z;Dermatoses due to ionizing radiation, unspecified;1;Inactive;2121277663/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;3;Inactive;1164022950/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X1;Anesthesia;3;Unknown;NA;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1C81;Acute poliomyelitis;4;Approved;588527933;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G40;Sepsis without septic shock;4;Approved;622600769;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;2;Inactive;56009591;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Y;Other specified hypotension;4;Approved;1663360295/other;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EJ7Z;Dermatoses due to ionizing radiation, unspecified;1;Inactive;2121277663/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;3;Inactive;1164022950/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X1;Anesthesia;3;Unknown;NA;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1C81;Acute poliomyelitis;4;Approved;588527933;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G40;Sepsis without septic shock;4;Approved;622600769;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;2;Inactive;56009591;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Y;Other specified hypotension;4;Approved;1663360295/other;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EJ7Z;Dermatoses due to ionizing radiation, unspecified;1;Inactive;2121277663/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;3;Inactive;1164022950/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X1;Anesthesia;3;Unknown;NA;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1C81;Acute poliomyelitis;4;Approved;588527933;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G40;Sepsis without septic shock;4;Approved;622600769;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;2;Inactive;56009591;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Y;Other specified hypotension;4;Approved;1663360295/other;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EJ7Z;Dermatoses due to ionizing radiation, unspecified;1;Inactive;2121277663/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;3;Inactive;1164022950/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X1;Anesthesia;3;Unknown;NA;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1C81;Acute poliomyelitis;4;Approved;588527933;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G40;Sepsis without septic shock;4;Approved;622600769;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;2;Inactive;56009591;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Y;Other specified hypotension;4;Approved;1663360295/other;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EJ7Z;Dermatoses due to ionizing radiation, unspecified;1;Inactive;2121277663/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;3;Inactive;1164022950/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X1;Anesthesia;3;Unknown;NA;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1C81;Acute poliomyelitis;4;Approved;588527933;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G40;Sepsis without septic shock;4;Approved;622600769;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;2;Inactive;56009591;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Y;Other specified hypotension;4;Approved;1663360295/other;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EJ7Z;Dermatoses due to ionizing radiation, unspecified;1;Inactive;2121277663/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;3;Inactive;1164022950/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X1;Anesthesia;3;Unknown;NA;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1C81;Acute poliomyelitis;4;Approved;588527933;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G40;Sepsis without septic shock;4;Approved;622600769;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;2;Inactive;56009591;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Y;Other specified hypotension;4;Approved;1663360295/other;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EJ7Z;Dermatoses due to ionizing radiation, unspecified;1;Inactive;2121277663/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;3;Inactive;1164022950/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X1;Anesthesia;3;Unknown;NA;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1C81;Acute poliomyelitis;4;Approved;588527933;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G40;Sepsis without septic shock;4;Approved;622600769;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;2;Inactive;56009591;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Y;Other specified hypotension;4;Approved;1663360295/other;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EJ7Z;Dermatoses due to ionizing radiation, unspecified;1;Inactive;2121277663/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;3;Inactive;1164022950/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X1;Anesthesia;3;Unknown;NA;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1C81;Acute poliomyelitis;4;Approved;588527933;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G40;Sepsis without septic shock;4;Approved;622600769;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;2;Inactive;56009591;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Y;Other specified hypotension;4;Approved;1663360295/other;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EJ7Z;Dermatoses due to ionizing radiation, unspecified;1;Inactive;2121277663/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;3;Inactive;1164022950/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;28509668, 36788938, 30000742
163;norepinephrine;norepinephrine;CHEMBL1437;DB00368;439260;51-41-2;X4W3ENH1CV;SFLSHLFXELFNJZ-QMMMGPOBSA-N;C1=CC(=C(C=C1C(CN)O)O)O;16918;-12;867;142;0;4;4;2;12;4;Approved;1950;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X1;Anesthesia;3;Unknown;NA;28509668, 36788938, 30000742
164;iloperidone;iloperidone;CHEMBL14376;DB04946;71360;133454-47-4;VPO7KJ050N;XMXHEBAFVSFQEX-UHFFFAOYSA-N;CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC;4265;41;648;586;0;0;7;8;31;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000759, 31643980, 19739696
164;iloperidone;iloperidone;CHEMBL14376;DB04946;71360;133454-47-4;VPO7KJ050N;XMXHEBAFVSFQEX-UHFFFAOYSA-N;CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC;4265;41;648;586;0;0;7;8;31;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Active;1456478153/unspecified;30000759, 31643980, 19739696
164;iloperidone;iloperidone;CHEMBL14376;DB04946;71360;133454-47-4;VPO7KJ050N;XMXHEBAFVSFQEX-UHFFFAOYSA-N;CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC;4265;41;648;586;0;0;7;8;31;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Inactive;2070699808;30000759, 31643980, 19739696
164;iloperidone;iloperidone;CHEMBL14376;DB04946;71360;133454-47-4;VPO7KJ050N;XMXHEBAFVSFQEX-UHFFFAOYSA-N;CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC;4265;41;648;586;0;0;7;8;31;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000759, 31643980, 19739696
164;iloperidone;iloperidone;CHEMBL14376;DB04946;71360;133454-47-4;VPO7KJ050N;XMXHEBAFVSFQEX-UHFFFAOYSA-N;CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC;4265;41;648;586;0;0;7;8;31;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Active;1456478153/unspecified;30000759, 31643980, 19739696
164;iloperidone;iloperidone;CHEMBL14376;DB04946;71360;133454-47-4;VPO7KJ050N;XMXHEBAFVSFQEX-UHFFFAOYSA-N;CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC;4265;41;648;586;0;0;7;8;31;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Inactive;2070699808;30000759, 31643980, 19739696
165;dibenzepin;dibenzepin;CHEMBL1442422;DB13225;9419;4498-32-2;NA;QPGGEKPRGVJKQB-UHFFFAOYSA-N;CN1C2=CC=CC=C2C(=O)N(C3=CC=CC=C31)CCN(C)C;2954;27;268;398;0;0;3;3;22;4;Approved;1965;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;20647, 5510629, 6143381
165;dibenzepin;dibenzepin;CHEMBL1442422;DB13225;9419;4498-32-2;NA;QPGGEKPRGVJKQB-UHFFFAOYSA-N;CN1C2=CC=CC=C2C(=O)N(C3=CC=CC=C31)CCN(C)C;2954;27;268;398;0;0;3;3;22;4;Approved;1965;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;20647, 5510629, 6143381
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD12;Cough;4;Approved;2027526159;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD90.0;Nausea;3;Inactive;596805318;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD90.1;Vomiting;3;Inactive;447658033;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;3;Inactive;1815305992/unspecified;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;3;Inactive;1581976053/unspecified;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD12;Cough;4;Approved;2027526159;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD90.0;Nausea;3;Inactive;596805318;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD90.1;Vomiting;3;Inactive;447658033;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;3;Inactive;1815305992/unspecified;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;3;Inactive;1581976053/unspecified;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD12;Cough;4;Approved;2027526159;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD90.0;Nausea;3;Inactive;596805318;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD90.1;Vomiting;3;Inactive;447658033;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;3;Inactive;1815305992/unspecified;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;3;Inactive;1581976053/unspecified;30725973, 30000284, 35952024
166;hydrocodone;hydrocodone;CHEMBL1457;DB00956;5284569;125-29-1;6YKS4Y3WQ7;LLPOLZWFYMWNKH-CMKMFDCUSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4;2994;22;388;509;0;0;4;1;22;4;Approved;1943;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30725973, 30000284, 35952024
167;aprepitant;aprepitant;CHEMBL1471;DB00673;;170729-80-3;1NF15YR6UY;ATALOFNDEOCMKK-OITMNORJSA-N;CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F;5344;42;752;810;0;2;11;6;37;4;Approved;2003;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;1C62.Z;Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified;1;Inactive;1508081745/unspecified;29057261, 31869069, 31644204
167;aprepitant;aprepitant;CHEMBL1471;DB00673;;170729-80-3;1NF15YR6UY;ATALOFNDEOCMKK-OITMNORJSA-N;CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F;5344;42;752;810;0;2;11;6;37;4;Approved;2003;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;2A00.00;Glioblastoma of brain;2;Inactive;650534447;29057261, 31869069, 31644204
167;aprepitant;aprepitant;CHEMBL1471;DB00673;;170729-80-3;1NF15YR6UY;ATALOFNDEOCMKK-OITMNORJSA-N;CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F;5344;42;752;810;0;2;11;6;37;4;Approved;2003;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;29057261, 31869069, 31644204
167;aprepitant;aprepitant;CHEMBL1471;DB00673;;170729-80-3;1NF15YR6UY;ATALOFNDEOCMKK-OITMNORJSA-N;CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F;5344;42;752;810;0;2;11;6;37;4;Approved;2003;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;2;Inactive;1580466198/unspecified;29057261, 31869069, 31644204
167;aprepitant;aprepitant;CHEMBL1471;DB00673;;170729-80-3;1NF15YR6UY;ATALOFNDEOCMKK-OITMNORJSA-N;CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F;5344;42;752;810;0;2;11;6;37;4;Approved;2003;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;29057261, 31869069, 31644204
167;aprepitant;aprepitant;CHEMBL1471;DB00673;;170729-80-3;1NF15YR6UY;ATALOFNDEOCMKK-OITMNORJSA-N;CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F;5344;42;752;810;0;2;11;6;37;4;Approved;2003;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;1;Inactive;1120716949/unspecified;29057261, 31869069, 31644204
167;aprepitant;aprepitant;CHEMBL1471;DB00673;;170729-80-3;1NF15YR6UY;ATALOFNDEOCMKK-OITMNORJSA-N;CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F;5344;42;752;810;0;2;11;6;37;4;Approved;2003;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;29057261, 31869069, 31644204
167;aprepitant;aprepitant;CHEMBL1471;DB00673;;170729-80-3;1NF15YR6UY;ATALOFNDEOCMKK-OITMNORJSA-N;CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F;5344;42;752;810;0;2;11;6;37;4;Approved;2003;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;EC90.Z;Pruritus, unspecified;2;Inactive;1729106757/unspecified;29057261, 31869069, 31644204
167;aprepitant;aprepitant;CHEMBL1471;DB00673;;170729-80-3;1NF15YR6UY;ATALOFNDEOCMKK-OITMNORJSA-N;CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F;5344;42;752;810;0;2;11;6;37;4;Approved;2003;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;MD90;Nausea or vomiting;4;Approved;677319549;29057261, 31869069, 31644204
167;aprepitant;aprepitant;CHEMBL1471;DB00673;;170729-80-3;1NF15YR6UY;ATALOFNDEOCMKK-OITMNORJSA-N;CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F;5344;42;752;810;0;2;11;6;37;4;Approved;2003;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;RA01;COVID-19;2;Inactive;1730556128;29057261, 31869069, 31644204
168;protirelin;protirelin;CHEMBL1472;DB09421;638678;24305-27-9;5Y5F15120W;XNSAINXGIQZQOO-SRVKXCTJSA-N;C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CCC(=O)N3)C(=O)N;36238;-25;150;597;0;4;5;6;26;4;Approved;1976;Protein;Agonist;P34981;trfr_human;Class A (Rhodopsin);Thyrotropin-releasing hormone receptors;Peptide receptors;5A0Z;Disorders of the thyroid gland or thyroid hormones system, unspecified;3;Unknown;1907280211/unspecified;2563937, 7944876, 6145398
168;protirelin;protirelin;CHEMBL1472;DB09421;638678;24305-27-9;5Y5F15120W;XNSAINXGIQZQOO-SRVKXCTJSA-N;C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CCC(=O)N3)C(=O)N;36238;-25;150;597;0;4;5;6;26;4;Approved;1976;Protein;Agonist;P34981;trfr_human;Class A (Rhodopsin);Thyrotropin-releasing hormone receptors;Peptide receptors;MG22;Fatigue;2;Unknown;1109546957;2563937, 7944876, 6145398
168;protirelin;protirelin;CHEMBL1472;DB09421;638678;24305-27-9;5Y5F15120W;XNSAINXGIQZQOO-SRVKXCTJSA-N;C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CCC(=O)N3)C(=O)N;36238;-25;150;597;0;4;5;6;26;4;Approved;1976;Protein;Agonist;P34981;trfr_human;Class A (Rhodopsin);Thyrotropin-releasing hormone receptors;Peptide receptors;X2;Diagnostis;4;Approved;NA;2563937, 7944876, 6145398
169;danazol;danazol;CHEMBL1479;DB01406;28417;17230-88-5;N29QWW3BUO;POZRVZJJTULAOH-LHZXLZLDSA-N;CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5;3375;38;463;677;0;1;3;1;25;4;Approved;1976;Small molecule;NAM;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2A3Z;Myelodysplastic syndromes, unspecified;3;Active;1147802348/unspecified;35396014, 33232014, 7041729
169;danazol;danazol;CHEMBL1479;DB01406;28417;17230-88-5;N29QWW3BUO;POZRVZJJTULAOH-LHZXLZLDSA-N;CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5;3375;38;463;677;0;1;3;1;25;4;Approved;1976;Small molecule;NAM;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C76.Z;Malignant neoplasms of corpus uteri, unspecified;2;Unknown;959493854/unspecified;35396014, 33232014, 7041729
169;danazol;danazol;CHEMBL1479;DB01406;28417;17230-88-5;N29QWW3BUO;POZRVZJJTULAOH-LHZXLZLDSA-N;CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5;3375;38;463;677;0;1;3;1;25;4;Approved;1976;Small molecule;NAM;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;3A70.0;Congenital aplastic anaemia;2;Inactive;350719523;35396014, 33232014, 7041729
169;danazol;danazol;CHEMBL1479;DB01406;28417;17230-88-5;N29QWW3BUO;POZRVZJJTULAOH-LHZXLZLDSA-N;CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5;3375;38;463;677;0;1;3;1;25;4;Approved;1976;Small molecule;NAM;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;3A70.Z;Aplastic anaemia, unspecified;2;Inactive;502834133/unspecified;35396014, 33232014, 7041729
169;danazol;danazol;CHEMBL1479;DB01406;28417;17230-88-5;N29QWW3BUO;POZRVZJJTULAOH-LHZXLZLDSA-N;CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5;3375;38;463;677;0;1;3;1;25;4;Approved;1976;Small molecule;NAM;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;3B64.10;Immune thrombocytopenic purpura;2;Active;364346400;35396014, 33232014, 7041729
169;danazol;danazol;CHEMBL1479;DB01406;28417;17230-88-5;N29QWW3BUO;POZRVZJJTULAOH-LHZXLZLDSA-N;CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5;3375;38;463;677;0;1;3;1;25;4;Approved;1976;Small molecule;NAM;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;3B64.14;Thrombotic thrombocytopenic purpura;2;Inactive;1708277768;35396014, 33232014, 7041729
169;danazol;danazol;CHEMBL1479;DB01406;28417;17230-88-5;N29QWW3BUO;POZRVZJJTULAOH-LHZXLZLDSA-N;CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5;3375;38;463;677;0;1;3;1;25;4;Approved;1976;Small molecule;NAM;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;EB04;Idiopathic angioedema;4;Approved;330898059;35396014, 33232014, 7041729
169;danazol;danazol;CHEMBL1479;DB01406;28417;17230-88-5;N29QWW3BUO;POZRVZJJTULAOH-LHZXLZLDSA-N;CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5;3375;38;463;677;0;1;3;1;25;4;Approved;1976;Small molecule;NAM;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA10.Z;Endometriosis of unspecified site;4;Approved;1838213761/unspecified;35396014, 33232014, 7041729
169;danazol;danazol;CHEMBL1479;DB01406;28417;17230-88-5;N29QWW3BUO;POZRVZJJTULAOH-LHZXLZLDSA-N;CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5;3375;38;463;677;0;1;3;1;25;4;Approved;1976;Small molecule;NAM;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GB20.0;Fibrocystic change of breast;4;Approved;840006864;35396014, 33232014, 7041729
169;danazol;danazol;CHEMBL1479;DB01406;28417;17230-88-5;N29QWW3BUO;POZRVZJJTULAOH-LHZXLZLDSA-N;CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5;3375;38;463;677;0;1;3;1;25;4;Approved;1976;Small molecule;NAM;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GB23.5;Mastodynia;2;Inactive;1793565521;35396014, 33232014, 7041729
169;danazol;danazol;CHEMBL1479;DB01406;28417;17230-88-5;N29QWW3BUO;POZRVZJJTULAOH-LHZXLZLDSA-N;CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5;3375;38;463;677;0;1;3;1;25;4;Approved;1976;Small molecule;NAM;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GC8Y;Other specified diseases of the genitourinary system;3;Inactive;30659757/other;35396014, 33232014, 7041729
170;bethanechol;bethanechol;CHEMBL1482;DB01019;2370;674-38-4;004F72P8F4;NZUPCNDJBJXXRF-UHFFFAOYSA-O;CC(C[N+](C)(C)C)OC(=O)N;16122;0;523;140;1;1;2;4;11;4;Approved;1948;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;2C10.Y;Other specified malignant neoplasms of pancreas;2;Active;542147910/other;32809422, 30000717, 30112787
170;bethanechol;bethanechol;CHEMBL1482;DB01019;2370;674-38-4;004F72P8F4;NZUPCNDJBJXXRF-UHFFFAOYSA-O;CC(C[N+](C)(C)C)OC(=O)N;16122;0;523;140;1;1;2;4;11;4;Approved;1948;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;5A11;Type 2 diabetes mellitus;1;Inactive;119724091;32809422, 30000717, 30112787
170;bethanechol;bethanechol;CHEMBL1482;DB01019;2370;674-38-4;004F72P8F4;NZUPCNDJBJXXRF-UHFFFAOYSA-O;CC(C[N+](C)(C)C)OC(=O)N;16122;0;523;140;1;1;2;4;11;4;Approved;1948;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA24.1;Eosinophilic oesophagitis;2;Inactive;21063503;32809422, 30000717, 30112787
170;bethanechol;bethanechol;CHEMBL1482;DB01019;2370;674-38-4;004F72P8F4;NZUPCNDJBJXXRF-UHFFFAOYSA-O;CC(C[N+](C)(C)C)OC(=O)N;16122;0;523;140;1;1;2;4;11;4;Approved;1948;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.3;Retention of urine;4;Approved;1775034842;32809422, 30000717, 30112787
170;bethanechol;bethanechol;CHEMBL1482;DB01019;2370;674-38-4;004F72P8F4;NZUPCNDJBJXXRF-UHFFFAOYSA-O;CC(C[N+](C)(C)C)OC(=O)N;16122;0;523;140;1;1;2;4;11;4;Approved;1948;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;2C10.Y;Other specified malignant neoplasms of pancreas;2;Active;542147910/other;32809422, 30000717, 30112787
170;bethanechol;bethanechol;CHEMBL1482;DB01019;2370;674-38-4;004F72P8F4;NZUPCNDJBJXXRF-UHFFFAOYSA-O;CC(C[N+](C)(C)C)OC(=O)N;16122;0;523;140;1;1;2;4;11;4;Approved;1948;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;5A11;Type 2 diabetes mellitus;1;Inactive;119724091;32809422, 30000717, 30112787
170;bethanechol;bethanechol;CHEMBL1482;DB01019;2370;674-38-4;004F72P8F4;NZUPCNDJBJXXRF-UHFFFAOYSA-O;CC(C[N+](C)(C)C)OC(=O)N;16122;0;523;140;1;1;2;4;11;4;Approved;1948;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA24.1;Eosinophilic oesophagitis;2;Inactive;21063503;32809422, 30000717, 30112787
170;bethanechol;bethanechol;CHEMBL1482;DB01019;2370;674-38-4;004F72P8F4;NZUPCNDJBJXXRF-UHFFFAOYSA-O;CC(C[N+](C)(C)C)OC(=O)N;16122;0;523;140;1;1;2;4;11;4;Approved;1948;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.3;Retention of urine;4;Approved;1775034842;32809422, 30000717, 30112787
171;trihexyphenidyl;trihexyphenidyl;CHEMBL1490;DB00376;5572;144-11-6;6RC5V8B7PO;HWHLPVGTWGOCJO-UHFFFAOYSA-N;C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O;3015;45;235;314;0;1;2;5;22;4;Approved;1949;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30000731, 30137772, 31643310
171;trihexyphenidyl;trihexyphenidyl;CHEMBL1490;DB00376;5572;144-11-6;6RC5V8B7PO;HWHLPVGTWGOCJO-UHFFFAOYSA-N;C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O;3015;45;235;314;0;1;2;5;22;4;Approved;1949;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A02.Z;Dystonic disorders, unspecified;2;Inactive;2145753518/unspecified;30000731, 30137772, 31643310
172;diphenylpyraline;diphenylpyraline;CHEMBL1492;DB01146;3103;147-20-6;33361OE3AV;OWQUZNMMYNAXSL-UHFFFAOYSA-N;CN1CCC(CC1)OC(C2=CC=CC=C2)C3=CC=CC=C3;2814;39;125;268;0;0;2;4;21;4;Approved;1982;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;36621026, 13475020, 13091417
173;dosulepin;dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5282426;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;trans-dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5284550;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dosulepin;"CHEMBL108947;CHEMBL1492500";DB09167;3155;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5282426;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;trans-dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5284550;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dosulepin;"CHEMBL108947;CHEMBL1492500";DB09167;3155;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5282426;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;trans-dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5284550;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dosulepin;"CHEMBL108947;CHEMBL1492500";DB09167;3155;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5282426;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;trans-dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5284550;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dosulepin;"CHEMBL108947;CHEMBL1492500";DB09167;3155;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5282426;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;trans-dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5284550;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dosulepin;"CHEMBL108947;CHEMBL1492500";DB09167;3155;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5282426;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;trans-dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5284550;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dosulepin;"CHEMBL108947;CHEMBL1492500";DB09167;3155;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5282426;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;trans-dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5284550;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dosulepin;"CHEMBL108947;CHEMBL1492500";DB09167;3155;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5282426;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;trans-dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5284550;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dosulepin;"CHEMBL108947;CHEMBL1492500";DB09167;3155;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5282426;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;trans-dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5284550;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dosulepin;"CHEMBL108947;CHEMBL1492500";DB09167;3155;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5282426;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;trans-dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5284550;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dosulepin;"CHEMBL108947;CHEMBL1492500";DB09167;3155;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5282426;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;trans-dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5284550;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dosulepin;"CHEMBL108947;CHEMBL1492500";DB09167;3155;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5282426;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;trans-dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5284550;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dosulepin;"CHEMBL108947;CHEMBL1492500";DB09167;3155;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5282426;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;trans-dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5284550;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dosulepin;"CHEMBL108947;CHEMBL1492500";DB09167;3155;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5282426;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;trans-dothiepin;"CHEMBL108947;CHEMBL1492500";DB09167;5284550;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
173;dosulepin;dosulepin;"CHEMBL108947;CHEMBL1492500";DB09167;3155;113-53-1;W13O82Z7HL;PHTUQLWOUWZIMZ-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31;2954;45;285;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;2444205, 30378237, 26936206
174;flavoxate;flavoxate;CHEMBL1493;DB01148;3354;15301-69-6;3E74Y80MEY;SPIUTQOUKAMGCX-UHFFFAOYSA-N;CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4;3915;43;558;631;0;0;5;6;29;4;Approved;1970;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GA91.Z;Inflammatory and other diseases of prostate, unspecified;4;Approved;1594247995/unspecified;29999994, 31644218, 25807422
174;flavoxate;flavoxate;CHEMBL1493;DB01148;3354;15301-69-6;3E74Y80MEY;SPIUTQOUKAMGCX-UHFFFAOYSA-N;CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4;3915;43;558;631;0;0;5;6;29;4;Approved;1970;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC02.Y;Other specified urethritis and urethral syndrome;4;Approved;1092991948/other;29999994, 31644218, 25807422
174;flavoxate;flavoxate;CHEMBL1493;DB01148;3354;15301-69-6;3E74Y80MEY;SPIUTQOUKAMGCX-UHFFFAOYSA-N;CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4;3915;43;558;631;0;0;5;6;29;4;Approved;1970;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.7;Dysuria;4;Approved;781372207;29999994, 31644218, 25807422
174;flavoxate;flavoxate;CHEMBL1493;DB01148;3354;15301-69-6;3E74Y80MEY;SPIUTQOUKAMGCX-UHFFFAOYSA-N;CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4;3915;43;558;631;0;0;5;6;29;4;Approved;1970;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GA91.Z;Inflammatory and other diseases of prostate, unspecified;4;Approved;1594247995/unspecified;29999994, 31644218, 25807422
174;flavoxate;flavoxate;CHEMBL1493;DB01148;3354;15301-69-6;3E74Y80MEY;SPIUTQOUKAMGCX-UHFFFAOYSA-N;CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4;3915;43;558;631;0;0;5;6;29;4;Approved;1970;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC02.Y;Other specified urethritis and urethral syndrome;4;Approved;1092991948/other;29999994, 31644218, 25807422
174;flavoxate;flavoxate;CHEMBL1493;DB01148;3354;15301-69-6;3E74Y80MEY;SPIUTQOUKAMGCX-UHFFFAOYSA-N;CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4;3915;43;558;631;0;0;5;6;29;4;Approved;1970;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.7;Dysuria;4;Approved;781372207;29999994, 31644218, 25807422
175;oxyphencyclimine;oxyphencyclimine;CHEMBL1495;DB00383;4642;125-53-1;4V44H1O8XI;DUDKAZCAISNGQN-UHFFFAOYSA-N;CN1CCCN=C1COC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O;3444;29;621;481;0;1;4;6;25;4;Approved;1982;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;13642276, 3786107, 1426023
175;oxyphencyclimine;oxyphencyclimine;CHEMBL1495;DB00383;4642;125-53-1;4V44H1O8XI;DUDKAZCAISNGQN-UHFFFAOYSA-N;CN1CCCN=C1COC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O;3444;29;621;481;0;1;4;6;25;4;Approved;1982;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;13642276, 3786107, 1426023
175;oxyphencyclimine;oxyphencyclimine;CHEMBL1495;DB00383;4642;125-53-1;4V44H1O8XI;DUDKAZCAISNGQN-UHFFFAOYSA-N;CN1CCCN=C1COC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O;3444;29;621;481;0;1;4;6;25;4;Approved;1982;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;13642276, 3786107, 1426023
176;almotriptan;almotriptan;CHEMBL1505;DB00918;123606;154323-57-6;1O4XL5SN61;WKEMJKQOLOHJLZ-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3;3355;16;648;483;0;1;4;6;23;4;Approved;2001;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;31082136, 30000519, 30845850
176;almotriptan;almotriptan;CHEMBL1505;DB00918;123606;154323-57-6;1O4XL5SN61;WKEMJKQOLOHJLZ-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3;3355;16;648;483;0;1;4;6;23;4;Approved;2001;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;31082136, 30000519, 30845850
176;almotriptan;almotriptan;CHEMBL1505;DB00918;123606;154323-57-6;1O4XL5SN61;WKEMJKQOLOHJLZ-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3;3355;16;648;483;0;1;4;6;23;4;Approved;2001;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;31082136, 30000519, 30845850
176;almotriptan;almotriptan;CHEMBL1505;DB00918;123606;154323-57-6;1O4XL5SN61;WKEMJKQOLOHJLZ-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3;3355;16;648;483;0;1;4;6;23;4;Approved;2001;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;31082136, 30000519, 30845850
176;almotriptan;almotriptan;CHEMBL1505;DB00918;123606;154323-57-6;1O4XL5SN61;WKEMJKQOLOHJLZ-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3;3355;16;648;483;0;1;4;6;23;4;Approved;2001;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;31082136, 30000519, 30845850
176;almotriptan;almotriptan;CHEMBL1505;DB00918;123606;154323-57-6;1O4XL5SN61;WKEMJKQOLOHJLZ-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3;3355;16;648;483;0;1;4;6;23;4;Approved;2001;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;31082136, 30000519, 30845850
176;almotriptan;almotriptan;CHEMBL1505;DB00918;123606;154323-57-6;1O4XL5SN61;WKEMJKQOLOHJLZ-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3;3355;16;648;483;0;1;4;6;23;4;Approved;2001;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;31082136, 30000519, 30845850
176;almotriptan;almotriptan;CHEMBL1505;DB00918;123606;154323-57-6;1O4XL5SN61;WKEMJKQOLOHJLZ-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3;3355;16;648;483;0;1;4;6;23;4;Approved;2001;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;31082136, 30000519, 30845850
176;almotriptan;almotriptan;CHEMBL1505;DB00918;123606;154323-57-6;1O4XL5SN61;WKEMJKQOLOHJLZ-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3;3355;16;648;483;0;1;4;6;23;4;Approved;2001;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;31082136, 30000519, 30845850
177;eletriptan;eletriptan;CHEMBL1510;DB00216;77993;143322-58-1;22QOO9B8KI;PWVXXGRKLHYWKM-LJQANCHMSA-N;CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4;3825;41;616;582;0;1;3;6;27;4;Approved;2002;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30000275, 38261688, 11772292
177;eletriptan;eletriptan;CHEMBL1510;DB00216;77993;143322-58-1;22QOO9B8KI;PWVXXGRKLHYWKM-LJQANCHMSA-N;CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4;3825;41;616;582;0;1;3;6;27;4;Approved;2002;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30000275, 38261688, 11772292
177;eletriptan;eletriptan;CHEMBL1510;DB00216;77993;143322-58-1;22QOO9B8KI;PWVXXGRKLHYWKM-LJQANCHMSA-N;CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4;3825;41;616;582;0;1;3;6;27;4;Approved;2002;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000275, 38261688, 11772292
177;eletriptan;eletriptan;CHEMBL1510;DB00216;77993;143322-58-1;22QOO9B8KI;PWVXXGRKLHYWKM-LJQANCHMSA-N;CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4;3825;41;616;582;0;1;3;6;27;4;Approved;2002;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30000275, 38261688, 11772292
177;eletriptan;eletriptan;CHEMBL1510;DB00216;77993;143322-58-1;22QOO9B8KI;PWVXXGRKLHYWKM-LJQANCHMSA-N;CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4;3825;41;616;582;0;1;3;6;27;4;Approved;2002;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30000275, 38261688, 11772292
177;eletriptan;eletriptan;CHEMBL1510;DB00216;77993;143322-58-1;22QOO9B8KI;PWVXXGRKLHYWKM-LJQANCHMSA-N;CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4;3825;41;616;582;0;1;3;6;27;4;Approved;2002;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000275, 38261688, 11772292
177;eletriptan;eletriptan;CHEMBL1510;DB00216;77993;143322-58-1;22QOO9B8KI;PWVXXGRKLHYWKM-LJQANCHMSA-N;CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4;3825;41;616;582;0;1;3;6;27;4;Approved;2002;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;30000275, 38261688, 11772292
177;eletriptan;eletriptan;CHEMBL1510;DB00216;77993;143322-58-1;22QOO9B8KI;PWVXXGRKLHYWKM-LJQANCHMSA-N;CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4;3825;41;616;582;0;1;3;6;27;4;Approved;2002;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;30000275, 38261688, 11772292
177;eletriptan;eletriptan;CHEMBL1510;DB00216;77993;143322-58-1;22QOO9B8KI;PWVXXGRKLHYWKM-LJQANCHMSA-N;CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4;3825;41;616;582;0;1;3;6;27;4;Approved;2002;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000275, 38261688, 11772292
178;irbesartan;irbesartan;CHEMBL1513;DB01029;3749;138402-11-6;J0E2756Z7N;YOSHYTLCDANDAN-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5;4285;41;871;682;0;1;5;7;32;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;1D60.0Z;Ebola disease, virus unspecified;2;Unknown;1517015847/unspecified;30000687, 30002098, 37921461
178;irbesartan;irbesartan;CHEMBL1513;DB01029;3749;138402-11-6;J0E2756Z7N;YOSHYTLCDANDAN-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5;4285;41;871;682;0;1;5;7;32;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;1G40;Sepsis without septic shock;3;Unknown;622600769;30000687, 30002098, 37921461
178;irbesartan;irbesartan;CHEMBL1513;DB01029;3749;138402-11-6;J0E2756Z7N;YOSHYTLCDANDAN-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5;4285;41;871;682;0;1;5;7;32;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000687, 30002098, 37921461
178;irbesartan;irbesartan;CHEMBL1513;DB01029;3749;138402-11-6;J0E2756Z7N;YOSHYTLCDANDAN-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5;4285;41;871;682;0;1;5;7;32;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA41.1;Acute non-ST elevation myocardial infarction;3;Unknown;680129526;30000687, 30002098, 37921461
178;irbesartan;irbesartan;CHEMBL1513;DB01029;3749;138402-11-6;J0E2756Z7N;YOSHYTLCDANDAN-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5;4285;41;871;682;0;1;5;7;32;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BC81.3Z;Atrial fibrillation, unspecified;3;Inactive;171698302/unspecified;30000687, 30002098, 37921461
178;irbesartan;irbesartan;CHEMBL1513;DB01029;3749;138402-11-6;J0E2756Z7N;YOSHYTLCDANDAN-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5;4285;41;871;682;0;1;5;7;32;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BD10;Congestive heart failure;3;Inactive;2136808878;30000687, 30002098, 37921461
178;irbesartan;irbesartan;CHEMBL1513;DB01029;3749;138402-11-6;J0E2756Z7N;YOSHYTLCDANDAN-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5;4285;41;871;682;0;1;5;7;32;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;DB93.0;Hepatic fibrosis;3;Unknown;1377614074;30000687, 30002098, 37921461
178;irbesartan;irbesartan;CHEMBL1513;DB01029;3749;138402-11-6;J0E2756Z7N;YOSHYTLCDANDAN-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5;4285;41;871;682;0;1;5;7;32;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;GB40;Nephritic syndrome;3;Active;1783829886;30000687, 30002098, 37921461
178;irbesartan;irbesartan;CHEMBL1513;DB01029;3749;138402-11-6;J0E2756Z7N;YOSHYTLCDANDAN-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5;4285;41;871;682;0;1;5;7;32;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;GB60.Z;Acute kidney failure, stage unspecified;3;Active;476391827/unspecified;30000687, 30002098, 37921461
178;irbesartan;irbesartan;CHEMBL1513;DB01029;3749;138402-11-6;J0E2756Z7N;YOSHYTLCDANDAN-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5;4285;41;871;682;0;1;5;7;32;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;GB61.Z;Chronic kidney disease, stage unspecified;4;Approved;412389819/unspecified;30000687, 30002098, 37921461
178;irbesartan;irbesartan;CHEMBL1513;DB01029;3749;138402-11-6;J0E2756Z7N;YOSHYTLCDANDAN-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5;4285;41;871;682;0;1;5;7;32;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;LD28.01;Marfan syndrome;2;Unknown;236564145;30000687, 30002098, 37921461
178;irbesartan;irbesartan;CHEMBL1513;DB01029;3749;138402-11-6;J0E2756Z7N;YOSHYTLCDANDAN-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5;4285;41;871;682;0;1;5;7;32;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;LD28.1Y;Other specified types of Ehlers-Danlos syndrome;3;Inactive;1122707206/other;30000687, 30002098, 37921461
178;irbesartan;irbesartan;CHEMBL1513;DB01029;3749;138402-11-6;J0E2756Z7N;YOSHYTLCDANDAN-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5;4285;41;871;682;0;1;5;7;32;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;MF8Y;Other specified clinical findings in specimens from the urinary system;3;Active;1039550850/other;30000687, 30002098, 37921461
179;levomethadyl acetate;levomethadyl acetate;CHEMBL1514;DB01227;15130;"1477-40-3;34433-66-4";NA;XBMIVRRWGCYBTQ-AVRDEDQJSA-N;CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C;3535;43;295;404;0;0;3;9;26;4;Approved;1993;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;4;Approved;1120716949/unspecified;11058673, 9707384, 11760927
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine hydrochloride;CHEMBL2146102;DB01364;65326;299-42-3;GN83C131XS;BALXUFOVQVENIU-GNAZCLTHSA-N;CC(C(C1=CC=CC=C1)O)NC.Cl;20169;;323;121;0;3;2;3;13;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine sulfate;CHEMBL1523964;DB01364;5359318;299-42-3;GN83C131XS;CAVQBDOACNULDN-KHFUBBAMSA-N;CC(C(C1=CC=CC=C1)O)NC.CC(C(C1=CC=CC=C1)O)NC.OS(=O)(=O)O;4285;;148;202;0;6;8;6;29;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;31613441, 29766529, 20781356
181;ephedrine;ephedrine;CHEMBL211456;DB01364;9294;299-42-3;GN83C131XS;KWGRBVOPPLSCSI-WPRPVWTQSA-N;C[C@@H]([C@@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;2016;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31613441, 29766529, 20781356
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A11;Type 2 diabetes mellitus;2;Inactive;119724091;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B04;Social anxiety disorder;3;Inactive;2062286624;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Inactive;2070699808;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;HA01.1Z;Male erectile dysfunction, unspecified;4;Approved;97556145/unspecified;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A11;Type 2 diabetes mellitus;2;Inactive;119724091;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B04;Social anxiety disorder;3;Inactive;2062286624;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Inactive;2070699808;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;HA01.1Z;Male erectile dysfunction, unspecified;4;Approved;97556145/unspecified;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A11;Type 2 diabetes mellitus;2;Inactive;119724091;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B04;Social anxiety disorder;3;Inactive;2062286624;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Inactive;2070699808;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;36263866, 31644013, 10698146
182;yohimbine;yohimbine;CHEMBL15245;DB01392;8969;146-48-5;2Y49VWD90Q;BLGXFZZNTVWLAY-SCYLSFHTSA-N;COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O;3544;29;656;555;0;2;4;2;26;4;Approved;1995;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;HA01.1Z;Male erectile dysfunction, unspecified;4;Approved;97556145/unspecified;36263866, 31644013, 10698146
183;doxofylline;doxofylline;CHEMBL1527608;DB09273;50942;69975-86-6;MPM23GMO7Z;HWXIGFIVGWUZAO-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3;26625;-9;769;398;0;0;5;2;19;4;Approved;2014;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;29255355, 29705620, 32094104
183;doxofylline;doxofylline;CHEMBL1527608;DB09273;50942;69975-86-6;MPM23GMO7Z;HWXIGFIVGWUZAO-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3;26625;-9;769;398;0;0;5;2;19;4;Approved;2014;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;29255355, 29705620, 32094104
183;doxofylline;doxofylline;CHEMBL1527608;DB09273;50942;69975-86-6;MPM23GMO7Z;HWXIGFIVGWUZAO-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3;26625;-9;769;398;0;0;5;2;19;4;Approved;2014;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;29255355, 29705620, 32094104
184;befunolol;befunolol;CHEMBL153984;DB09013;2309;39552-01-7;418546MT3A;ZPQPDBIHYCBNIG-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=C1OC(=C2)C(=O)C)O;29134;2;717;347;0;2;5;7;21;4;Approved;1983;Small molecule;Partial agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;1363082, 2698771, 2186874
184;befunolol;befunolol;CHEMBL153984;DB09013;2309;39552-01-7;418546MT3A;ZPQPDBIHYCBNIG-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=C1OC(=C2)C(=O)C)O;29134;2;717;347;0;2;5;7;21;4;Approved;1983;Small molecule;Partial agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;1363082, 2698771, 2186874
185;lisuride;lisuride;CHEMBL157138;DB00589;28864;18016-80-3;E0QN3D755O;BKRGVLQUQGGVSM-KBXCAEBGSA-N;CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3384;27;514;544;0;2;2;3;25;4;Approved;1975;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;3;Unknown;1254916765;29999863, 7212665, 3887215
185;lisuride;lisuride;CHEMBL157138;DB00589;28864;18016-80-3;E0QN3D755O;BKRGVLQUQGGVSM-KBXCAEBGSA-N;CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3384;27;514;544;0;2;2;3;25;4;Approved;1975;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;29999863, 7212665, 3887215
185;lisuride;lisuride;CHEMBL157138;DB00589;28864;18016-80-3;E0QN3D755O;BKRGVLQUQGGVSM-KBXCAEBGSA-N;CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3384;27;514;544;0;2;2;3;25;4;Approved;1975;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;29999863, 7212665, 3887215
185;lisuride;lisuride;CHEMBL157138;DB00589;28864;18016-80-3;E0QN3D755O;BKRGVLQUQGGVSM-KBXCAEBGSA-N;CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3384;27;514;544;0;2;2;3;25;4;Approved;1975;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;3;Unknown;1254916765;29999863, 7212665, 3887215
185;lisuride;lisuride;CHEMBL157138;DB00589;28864;18016-80-3;E0QN3D755O;BKRGVLQUQGGVSM-KBXCAEBGSA-N;CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3384;27;514;544;0;2;2;3;25;4;Approved;1975;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;29999863, 7212665, 3887215
185;lisuride;lisuride;CHEMBL157138;DB00589;28864;18016-80-3;E0QN3D755O;BKRGVLQUQGGVSM-KBXCAEBGSA-N;CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3384;27;514;544;0;2;2;3;25;4;Approved;1975;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;29999863, 7212665, 3887215
185;lisuride;lisuride;CHEMBL157138;DB00589;28864;18016-80-3;E0QN3D755O;BKRGVLQUQGGVSM-KBXCAEBGSA-N;CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3384;27;514;544;0;2;2;3;25;4;Approved;1975;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7A80;Restless legs syndrome;3;Unknown;1254916765;29999863, 7212665, 3887215
185;lisuride;lisuride;CHEMBL157138;DB00589;28864;18016-80-3;E0QN3D755O;BKRGVLQUQGGVSM-KBXCAEBGSA-N;CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3384;27;514;544;0;2;2;3;25;4;Approved;1975;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;29999863, 7212665, 3887215
185;lisuride;lisuride;CHEMBL157138;DB00589;28864;18016-80-3;E0QN3D755O;BKRGVLQUQGGVSM-KBXCAEBGSA-N;CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3384;27;514;544;0;2;2;3;25;4;Approved;1975;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;29999863, 7212665, 3887215
185;lisuride;lisuride;CHEMBL157138;DB00589;28864;18016-80-3;E0QN3D755O;BKRGVLQUQGGVSM-KBXCAEBGSA-N;CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3384;27;514;544;0;2;2;3;25;4;Approved;1975;Small molecule;Agonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7A80;Restless legs syndrome;3;Unknown;1254916765;29999863, 7212665, 3887215
185;lisuride;lisuride;CHEMBL157138;DB00589;28864;18016-80-3;E0QN3D755O;BKRGVLQUQGGVSM-KBXCAEBGSA-N;CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3384;27;514;544;0;2;2;3;25;4;Approved;1975;Small molecule;Agonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;29999863, 7212665, 3887215
185;lisuride;lisuride;CHEMBL157138;DB00589;28864;18016-80-3;E0QN3D755O;BKRGVLQUQGGVSM-KBXCAEBGSA-N;CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3384;27;514;544;0;2;2;3;25;4;Approved;1975;Small molecule;Agonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;29999863, 7212665, 3887215
185;lisuride;lisuride;CHEMBL157138;DB00589;28864;18016-80-3;E0QN3D755O;BKRGVLQUQGGVSM-KBXCAEBGSA-N;CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3384;27;514;544;0;2;2;3;25;4;Approved;1975;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;3;Unknown;1254916765;29999863, 7212665, 3887215
185;lisuride;lisuride;CHEMBL157138;DB00589;28864;18016-80-3;E0QN3D755O;BKRGVLQUQGGVSM-KBXCAEBGSA-N;CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3384;27;514;544;0;2;2;3;25;4;Approved;1975;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;29999863, 7212665, 3887215
185;lisuride;lisuride;CHEMBL157138;DB00589;28864;18016-80-3;E0QN3D755O;BKRGVLQUQGGVSM-KBXCAEBGSA-N;CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C;3384;27;514;544;0;2;2;3;25;4;Approved;1975;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;29999863, 7212665, 3887215
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C00.Z;Enuresis, unspecified;2;Inactive;1157749237/unspecified;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.03;Other allergic rhinitis;3;Unknown;941478759;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.3;Vasomotor rhinitis;3;Inactive;1286636442;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA09.0;Chronic rhinitis;3;Inactive;1346915097;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD12;Cough;4;Approved;2027526159;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C00.Z;Enuresis, unspecified;2;Inactive;1157749237/unspecified;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.03;Other allergic rhinitis;3;Unknown;941478759;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.3;Vasomotor rhinitis;3;Inactive;1286636442;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA09.0;Chronic rhinitis;3;Inactive;1346915097;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;34067981, 30000144, 35952197
186;pseudoephedrine;pseudoephedrine;CHEMBL1590;DB00852;7028;90-82-4;7CUC9DDI9F;KWGRBVOPPLSCSI-WCBMZHEXSA-N;C[C@@H]([C@H](C1=CC=CC=C1)O)NC;16523;9;323;121;0;2;2;3;12;4;Approved;1963;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD12;Cough;4;Approved;2027526159;34067981, 30000144, 35952197
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;4;Approved;873092535/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;4;Approved;1614716959/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;HA01.1Z;Male erectile dysfunction, unspecified;4;Approved;97556145/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;4;Approved;873092535/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;4;Approved;1614716959/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;HA01.1Z;Male erectile dysfunction, unspecified;4;Approved;97556145/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;4;Approved;873092535/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;4;Approved;1614716959/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;HA01.1Z;Male erectile dysfunction, unspecified;4;Approved;97556145/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;4;Approved;873092535/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;4;Approved;1614716959/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;HA01.1Z;Male erectile dysfunction, unspecified;4;Approved;97556145/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;4;Approved;873092535/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;4;Approved;1614716959/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;HA01.1Z;Male erectile dysfunction, unspecified;4;Approved;97556145/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;4;Approved;873092535/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;4;Approved;1614716959/unspecified;9711459, 9400450, 1350669
187;moxisylyte;moxisylyte;CHEMBL159226;DB09205;4260;54-32-0;PW8QYA7KI0;VRYMTAVOXVTQEF-UHFFFAOYSA-N;CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;27937;32;388;304;0;0;4;7;20;4;Approved;1987;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;HA01.1Z;Male erectile dysfunction, unspecified;4;Approved;97556145/unspecified;9711459, 9400450, 1350669
188;dihydrocodeine;dihydrocodeine;CHEMBL1595;DB01551;5284543;125-28-0;NA;RBOXVHNMENFORY-DNJOTXNNSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(CC4)O;3014;22;419;471;0;1;4;1;22;4;Approved;1983;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;29999751, 26479786, 36452126
189;procaterol;procaterol free base;CHEMBL1478530;DB01366;688561;"60443-17-6;72332-33-3";X7I3EMM5K0;FKNXQNWAXFXVNW-BLLLJJGKSA-N;CC[C@@H]([C@@H](C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C;29036;15;816;397;0;4;4;5;21;4;Approved;1980;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;31064913, 26538319, 30246320
189;procaterol;procaterol free base;CHEMBL1478530;DB01366;688561;"60443-17-6;72332-33-3";X7I3EMM5K0;FKNXQNWAXFXVNW-BLLLJJGKSA-N;CC[C@@H]([C@@H](C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C;29036;15;816;397;0;4;4;5;21;4;Approved;1980;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;31064913, 26538319, 30246320
189;procaterol;procaterol free base;CHEMBL1478530;DB01366;688561;"60443-17-6;72332-33-3";X7I3EMM5K0;FKNXQNWAXFXVNW-BLLLJJGKSA-N;CC[C@@H]([C@@H](C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C;29036;15;816;397;0;4;4;5;21;4;Approved;1980;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31064913, 26538319, 30246320
189;procaterol;procaterol;CHEMBL160519;DB01366;4916;"60443-17-6;72332-33-3";X7I3EMM5K0;FKNXQNWAXFXVNW-UHFFFAOYSA-N;CCC(C(C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C;29036;15;816;397;0;4;4;5;21;4;Approved;1980;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;31064913, 26538319, 30246320
189;procaterol;procaterol;CHEMBL160519;DB01366;4916;"60443-17-6;72332-33-3";X7I3EMM5K0;FKNXQNWAXFXVNW-UHFFFAOYSA-N;CCC(C(C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C;29036;15;816;397;0;4;4;5;21;4;Approved;1980;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;31064913, 26538319, 30246320
189;procaterol;procaterol;CHEMBL160519;DB01366;4916;"60443-17-6;72332-33-3";X7I3EMM5K0;FKNXQNWAXFXVNW-UHFFFAOYSA-N;CCC(C(C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C;29036;15;816;397;0;4;4;5;21;4;Approved;1980;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31064913, 26538319, 30246320
189;procaterol;(R,S)-procaterol;CHEMBL3249705;DB01366;688563;"60443-17-6;72332-33-3";X7I3EMM5K0;FKNXQNWAXFXVNW-WBMJQRKESA-N;CC[C@H]([C@H](C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C;29036;15;816;397;0;4;4;5;21;4;Approved;1980;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;31064913, 26538319, 30246320
189;procaterol;(R,S)-procaterol;CHEMBL3249705;DB01366;688563;"60443-17-6;72332-33-3";X7I3EMM5K0;FKNXQNWAXFXVNW-WBMJQRKESA-N;CC[C@H]([C@H](C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C;29036;15;816;397;0;4;4;5;21;4;Approved;1980;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;31064913, 26538319, 30246320
189;procaterol;(R,S)-procaterol;CHEMBL3249705;DB01366;688563;"60443-17-6;72332-33-3";X7I3EMM5K0;FKNXQNWAXFXVNW-WBMJQRKESA-N;CC[C@H]([C@H](C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C;29036;15;816;397;0;4;4;5;21;4;Approved;1980;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31064913, 26538319, 30246320
190;levocabastine;levocabastine;CHEMBL1615438;DB01106;54385;79516-68-0;H68BP06S81;ZCGOMHNNNFPNMX-YHYDXASRSA-N;CC1CN(CCC1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F;4205;25;643;681;0;1;5;4;31;4;Approved;1993;Small molecule;partial antagonist;O95665;ntr2_human;Class A (Rhodopsin);Neurotensin receptors;Peptide receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000060, 1680536, 1358140
190;levocabastine;levocabastine;CHEMBL1615438;DB01106;54385;79516-68-0;H68BP06S81;ZCGOMHNNNFPNMX-YHYDXASRSA-N;CC1CN(CCC1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F;4205;25;643;681;0;1;5;4;31;4;Approved;1993;Small molecule;partial antagonist;O95665;ntr2_human;Class A (Rhodopsin);Neurotensin receptors;Peptide receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;2;Inactive;1565925107;30000060, 1680536, 1358140
190;levocabastine;levocabastine;CHEMBL1615438;DB01106;54385;79516-68-0;H68BP06S81;ZCGOMHNNNFPNMX-YHYDXASRSA-N;CC1CN(CCC1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F;4205;25;643;681;0;1;5;4;31;4;Approved;1993;Small molecule;partial antagonist;O95665;ntr2_human;Class A (Rhodopsin);Neurotensin receptors;Peptide receptors;CA08.03;Other allergic rhinitis;3;Inactive;941478759;30000060, 1680536, 1358140
190;levocabastine;levocabastine;CHEMBL1615438;DB01106;54385;79516-68-0;H68BP06S81;ZCGOMHNNNFPNMX-YHYDXASRSA-N;CC1CN(CCC1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F;4205;25;643;681;0;1;5;4;31;4;Approved;1993;Small molecule;partial antagonist;O95665;ntr2_human;Class A (Rhodopsin);Neurotensin receptors;Peptide receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000060, 1680536, 1358140
190;levocabastine;levocabastine;CHEMBL1615438;DB01106;54385;79516-68-0;H68BP06S81;ZCGOMHNNNFPNMX-YHYDXASRSA-N;CC1CN(CCC1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F;4205;25;643;681;0;1;5;4;31;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000060, 1680536, 1358140
190;levocabastine;levocabastine;CHEMBL1615438;DB01106;54385;79516-68-0;H68BP06S81;ZCGOMHNNNFPNMX-YHYDXASRSA-N;CC1CN(CCC1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F;4205;25;643;681;0;1;5;4;31;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;2;Inactive;1565925107;30000060, 1680536, 1358140
190;levocabastine;levocabastine;CHEMBL1615438;DB01106;54385;79516-68-0;H68BP06S81;ZCGOMHNNNFPNMX-YHYDXASRSA-N;CC1CN(CCC1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F;4205;25;643;681;0;1;5;4;31;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.03;Other allergic rhinitis;3;Inactive;941478759;30000060, 1680536, 1358140
190;levocabastine;levocabastine;CHEMBL1615438;DB01106;54385;79516-68-0;H68BP06S81;ZCGOMHNNNFPNMX-YHYDXASRSA-N;CC1CN(CCC1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F;4205;25;643;681;0;1;5;4;31;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000060, 1680536, 1358140
191;phendimetrazine;phendimetrazine;CHEMBL1615439;DB01579;30487;634-03-7;AB2794W8KV;MFOCDFTXLCYLKU-CMPLNLGQSA-N;CC1C(OCCN1C)C2=CC=CC=C2;19127;19;125;177;0;0;2;1;14;4;Approved;1976;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;26866973, 26932737, 26933876
192;butylscopolamine;scopolamine butylbromide;CHEMBL1618102;DB09300;6852391;7182-53-8;2Z3E1OF81V;HOZOZZFCZRXYEK-HNHWXVNLSA-M;CCCC[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C.[Br-];4404;;591;500;0;1;5;8;27;4;Approved;1951;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;32270308, 30076627, 37340145
192;butylscopolamine;scopolamine butylbromide;CHEMBL1618102;DB09300;6852391;7182-53-8;2Z3E1OF81V;HOZOZZFCZRXYEK-HNHWXVNLSA-M;CCCC[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C.[Br-];4404;;591;500;0;1;5;8;27;4;Approved;1951;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;32270308, 30076627, 37340145
192;butylscopolamine;butylscopolamine;CHEMBL1618102;DB09300;160883;7182-53-8;2Z3E1OF81V;YBCNXCRZPWQOBR-MWGADRMYSA-N;CCCC[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C;3605;26;591;500;1;1;4;8;26;4;Approved;1951;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;32270308, 30076627, 37340145
192;butylscopolamine;butylscopolamine;CHEMBL1618102;DB09300;160883;7182-53-8;2Z3E1OF81V;YBCNXCRZPWQOBR-MWGADRMYSA-N;CCCC[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C;3605;26;591;500;1;1;4;8;26;4;Approved;1951;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;32270308, 30076627, 37340145
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;3;Inactive;437815624/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Inactive;1456478153/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Inactive;1582741816/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;3;Inactive;437815624/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Inactive;1456478153/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Inactive;1582741816/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;3;Inactive;437815624/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Inactive;1456478153/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Inactive;1582741816/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;3;Inactive;437815624/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Inactive;1456478153/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Inactive;1582741816/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;3;Inactive;437815624/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Inactive;1456478153/unspecified;25943458, 30000552, 31643825
193;paliperidone;paliperidone;CHEMBL1621;DB01267;115237;144598-75-4;838F01T721;PMXMIIMHBWHSKN-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4265;22;822;764;0;1;7;4;31;4;Approved;2006;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Inactive;1582741816/unspecified;25943458, 30000552, 31643825
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BB01.0;Pulmonary arterial hypertension;3;Unknown;1931148955;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;2;Unknown;1739126837;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BB01.0;Pulmonary arterial hypertension;3;Unknown;1931148955;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;2;Unknown;1739126837;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BB01.0;Pulmonary arterial hypertension;3;Unknown;1931148955;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;2;Unknown;1739126837;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BB01.0;Pulmonary arterial hypertension;3;Unknown;1931148955;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;2;Unknown;1739126837;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BB01.0;Pulmonary arterial hypertension;3;Unknown;1931148955;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;31334981, 30000543, 31643978
194;ipratropium;ipratropium bromide;CHEMBL1621597;DB00332;657308;60205-81-4;GR88G0I6UL;LHLMOSXCXGLMMN-CLTUNHJMSA-M;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-];4124;;465;430;0;1;4;6;25;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;2;Unknown;1739126837;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BB01.0;Pulmonary arterial hypertension;3;Unknown;1931148955;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;31334981, 30000543, 31643978
194;ipratropium;ipratropium;CHEMBL1621597;DB00332;657309;60205-81-4;GR88G0I6UL;OEXHQOGQTVQTAT-BZQJJPTISA-N;CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C;3325;26;465;430;1;1;3;6;24;4;Approved;1986;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;2;Unknown;1739126837;31334981, 30000543, 31643978
195;meclizine;meclizine;CHEMBL1623;DB00737;4034;569-65-3;3L5TQ84570;OCJYIGYOJCODJL-UHFFFAOYSA-N;CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl;3909;58;65;448;0;0;2;5;28;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;2C12.02;Hepatocellular carcinoma of liver;1;Active;1294035808;30000495, 32809480, 35952091
195;meclizine;meclizine;CHEMBL1623;DB00737;4034;569-65-3;3L5TQ84570;OCJYIGYOJCODJL-UHFFFAOYSA-N;CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl;3909;58;65;448;0;0;2;5;28;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;30000495, 32809480, 35952091
195;meclizine;meclizine;CHEMBL1623;DB00737;4034;569-65-3;3L5TQ84570;OCJYIGYOJCODJL-UHFFFAOYSA-N;CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl;3909;58;65;448;0;0;2;5;28;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MB48.0Z;Vertigo, unspecified;4;Approved;1398634694/unspecified;30000495, 32809480, 35952091
195;meclizine;meclizine;CHEMBL1623;DB00737;4034;569-65-3;3L5TQ84570;OCJYIGYOJCODJL-UHFFFAOYSA-N;CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl;3909;58;65;448;0;0;2;5;28;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000495, 32809480, 35952091
195;meclizine;meclizine;CHEMBL1623;DB00737;4034;569-65-3;3L5TQ84570;OCJYIGYOJCODJL-UHFFFAOYSA-N;CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl;3909;58;65;448;0;0;2;5;28;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000495, 32809480, 35952091
195;meclizine;meclizine;CHEMBL1623;DB00737;4034;569-65-3;3L5TQ84570;OCJYIGYOJCODJL-UHFFFAOYSA-N;CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl;3909;58;65;448;0;0;2;5;28;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90.1;Vomiting;4;Approved;447658033;30000495, 32809480, 35952091
195;meclizine;meclizine;CHEMBL1623;DB00737;4034;569-65-3;3L5TQ84570;OCJYIGYOJCODJL-UHFFFAOYSA-N;CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl;3909;58;65;448;0;0;2;5;28;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000495, 32809480, 35952091
196;thonzylamine;thonzylamine;CHEMBL1623738;DB11235;5457;91-85-0;R79646H5Z8;GULNIHOSWFYMRN-UHFFFAOYSA-N;CN(C)CCN(CC1=CC=C(C=C1)OC)C2=NC=CC=N2;28637;26;415;274;0;0;5;7;21;4;Approved;1948;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;14891823, 14889075, 10719908
196;thonzylamine;thonzylamine;CHEMBL1623738;DB11235;5457;91-85-0;R79646H5Z8;GULNIHOSWFYMRN-UHFFFAOYSA-N;CN(C)CCN(CC1=CC=C(C=C1)OC)C2=NC=CC=N2;28637;26;415;274;0;0;5;7;21;4;Approved;1948;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;14891823, 14889075, 10719908
196;thonzylamine;thonzylamine;CHEMBL1623738;DB11235;5457;91-85-0;R79646H5Z8;GULNIHOSWFYMRN-UHFFFAOYSA-N;CN(C)CCN(CC1=CC=C(C=C1)OC)C2=NC=CC=N2;28637;26;415;274;0;0;5;7;21;4;Approved;1948;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;14891823, 14889075, 10719908
196;thonzylamine;thonzylamine;CHEMBL1623738;DB11235;5457;91-85-0;R79646H5Z8;GULNIHOSWFYMRN-UHFFFAOYSA-N;CN(C)CCN(CC1=CC=C(C=C1)OC)C2=NC=CC=N2;28637;26;415;274;0;0;5;7;21;4;Approved;1948;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;14891823, 14889075, 10719908
197;clemastine;clemastine;CHEMBL1626;DB00283;26987;15686-51-8;95QN29S1ID;YNNUSGIPVFPVBX-NHCUHLMSSA-N;CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCC3CCCN3C;3439;5;125;376;0;0;2;6;24;4;Approved;1977;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000667, 29029896, 31644019
197;clemastine;clemastine;CHEMBL1626;DB00283;26987;15686-51-8;95QN29S1ID;YNNUSGIPVFPVBX-NHCUHLMSSA-N;CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCC3CCCN3C;3439;5;125;376;0;0;2;6;24;4;Approved;1977;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;8A40.0;Relapsing-remitting multiple sclerosis;2;Active;799053936;30000667, 29029896, 31644019
197;clemastine;clemastine;CHEMBL1626;DB00283;26987;15686-51-8;95QN29S1ID;YNNUSGIPVFPVBX-NHCUHLMSSA-N;CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCC3CCCN3C;3439;5;125;376;0;0;2;6;24;4;Approved;1977;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;8A40.Y;Other specified multiple sclerosis;2;Active;1298865187/other;30000667, 29029896, 31644019
197;clemastine;clemastine;CHEMBL1626;DB00283;26987;15686-51-8;95QN29S1ID;YNNUSGIPVFPVBX-NHCUHLMSSA-N;CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCC3CCCN3C;3439;5;125;376;0;0;2;6;24;4;Approved;1977;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;8A40.Z;Multiple sclerosis, unspecified;3;Active;1298865187/unspecified;30000667, 29029896, 31644019
197;clemastine;clemastine;CHEMBL1626;DB00283;26987;15686-51-8;95QN29S1ID;YNNUSGIPVFPVBX-NHCUHLMSSA-N;CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCC3CCCN3C;3439;5;125;376;0;0;2;6;24;4;Approved;1977;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9C40.1Z;Optic neuritis, unspecified;2;Active;210935787/unspecified;30000667, 29029896, 31644019
197;clemastine;clemastine;CHEMBL1626;DB00283;26987;15686-51-8;95QN29S1ID;YNNUSGIPVFPVBX-NHCUHLMSSA-N;CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCC3CCCN3C;3439;5;125;376;0;0;2;6;24;4;Approved;1977;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;30000667, 29029896, 31644019
197;clemastine;clemastine;CHEMBL1626;DB00283;26987;15686-51-8;95QN29S1ID;YNNUSGIPVFPVBX-NHCUHLMSSA-N;CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCC3CCCN3C;3439;5;125;376;0;0;2;6;24;4;Approved;1977;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000667, 29029896, 31644019
197;clemastine;clemastine;CHEMBL1626;DB00283;26987;15686-51-8;95QN29S1ID;YNNUSGIPVFPVBX-NHCUHLMSSA-N;CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCC3CCCN3C;3439;5;125;376;0;0;2;6;24;4;Approved;1977;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000667, 29029896, 31644019
197;clemastine;clemastine;CHEMBL1626;DB00283;26987;15686-51-8;95QN29S1ID;YNNUSGIPVFPVBX-NHCUHLMSSA-N;CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCC3CCCN3C;3439;5;125;376;0;0;2;6;24;4;Approved;1977;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB04;Idiopathic angioedema;4;Approved;330898059;30000667, 29029896, 31644019
197;clemastine;clemastine;CHEMBL1626;DB00283;26987;15686-51-8;95QN29S1ID;YNNUSGIPVFPVBX-NHCUHLMSSA-N;CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCC3CCCN3C;3439;5;125;376;0;0;2;6;24;4;Approved;1977;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;30000667, 29029896, 31644019
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7B2Z;Sleep-wake disorders, unspecified;2;Inactive;274880002/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA01.11;Oral mucositis;3;Inactive;1634507618;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;2;Unknown;1158238623/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;4;Approved;215767047/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA8Z;Dermatitis or eczema, unspecified;2;Unknown;1887882424/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;3;Active;993242399;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MB24.3;Anxiety;4;Approved;2027043655;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7B2Z;Sleep-wake disorders, unspecified;2;Inactive;274880002/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA01.11;Oral mucositis;3;Inactive;1634507618;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;2;Unknown;1158238623/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;4;Approved;215767047/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA8Z;Dermatitis or eczema, unspecified;2;Unknown;1887882424/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;3;Active;993242399;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MB24.3;Anxiety;4;Approved;2027043655;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7B2Z;Sleep-wake disorders, unspecified;2;Inactive;274880002/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA01.11;Oral mucositis;3;Inactive;1634507618;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;2;Unknown;1158238623/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;4;Approved;215767047/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA8Z;Dermatitis or eczema, unspecified;2;Unknown;1887882424/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;3;Active;993242399;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MB24.3;Anxiety;4;Approved;2027043655;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7B2Z;Sleep-wake disorders, unspecified;2;Inactive;274880002/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA01.11;Oral mucositis;3;Inactive;1634507618;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;2;Unknown;1158238623/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;4;Approved;215767047/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA8Z;Dermatitis or eczema, unspecified;2;Unknown;1887882424/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;3;Active;993242399;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;30000240, 35951942, 31194446
199;doxepin;cidoxepin;CHEMBL101740;DB01142;667468;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-BOPFTXTBSA-N;CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MB24.3;Anxiety;4;Approved;2027043655;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7B2Z;Sleep-wake disorders, unspecified;2;Inactive;274880002/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA01.11;Oral mucositis;3;Inactive;1634507618;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;2;Unknown;1158238623/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;4;Approved;215767047/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA8Z;Dermatitis or eczema, unspecified;2;Unknown;1887882424/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;3;Active;993242399;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;30000240, 35951942, 31194446
199;doxepin;doxepin;CHEMBL860;DB01142;667477;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-GZTJUZNOSA-N;CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MB24.3;Anxiety;4;Approved;2027043655;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7B2Z;Sleep-wake disorders, unspecified;2;Inactive;274880002/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA01.11;Oral mucositis;3;Inactive;1634507618;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;2;Unknown;1158238623/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;4;Approved;215767047/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA8Z;Dermatitis or eczema, unspecified;2;Unknown;1887882424/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;3;Active;993242399;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;30000240, 35951942, 31194446
199;doxepin;zonalon;CHEMBL1628227;DB01142;3158;1668-19-5;5ASJ6HUZ7D;ODQWQRRAPPTVAG-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31;2794;43;125;363;0;0;2;3;21;4;Approved;1969;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MB24.3;Anxiety;4;Approved;2027043655;30000240, 35951942, 31194446
200;zibotentan;zibotentan;CHEMBL1628688;DB06629;9910224;186497-07-4;NA;FJHHZXWJVIEFGJ-UHFFFAOYSA-N;CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4;4244;14;141;654;0;1;10;6;30;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2B91.Z;Malignant neoplasms of rectosigmoid junction, unspecified;2;Inactive;774170412/unspecified;37931629, 35650639, 25487941
200;zibotentan;zibotentan;CHEMBL1628688;DB06629;9910224;186497-07-4;NA;FJHHZXWJVIEFGJ-UHFFFAOYSA-N;CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4;4244;14;141;654;0;1;10;6;30;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2C25.Y;Other specified malignant neoplasms of bronchus or lung;2;Inactive;316539081/other;37931629, 35650639, 25487941
200;zibotentan;zibotentan;CHEMBL1628688;DB06629;9910224;186497-07-4;NA;FJHHZXWJVIEFGJ-UHFFFAOYSA-N;CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4;4244;14;141;654;0;1;10;6;30;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2C73.Z;Malignant neoplasms of ovary, unspecified;2;Inactive;685124533/unspecified;37931629, 35650639, 25487941
200;zibotentan;zibotentan;CHEMBL1628688;DB06629;9910224;186497-07-4;NA;FJHHZXWJVIEFGJ-UHFFFAOYSA-N;CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4;4244;14;141;654;0;1;10;6;30;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2C82.0;Adenocarcinoma of prostate;2;Inactive;1510677183;37931629, 35650639, 25487941
200;zibotentan;zibotentan;CHEMBL1628688;DB06629;9910224;186497-07-4;NA;FJHHZXWJVIEFGJ-UHFFFAOYSA-N;CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4;4244;14;141;654;0;1;10;6;30;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;3;Inactive;1552457716/unspecified;37931629, 35650639, 25487941
200;zibotentan;zibotentan;CHEMBL1628688;DB06629;9910224;186497-07-4;NA;FJHHZXWJVIEFGJ-UHFFFAOYSA-N;CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4;4244;14;141;654;0;1;10;6;30;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BD40.0;Lower limb atherosclerosis;2;Inactive;897545836;37931629, 35650639, 25487941
200;zibotentan;zibotentan;CHEMBL1628688;DB06629;9910224;186497-07-4;NA;FJHHZXWJVIEFGJ-UHFFFAOYSA-N;CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4;4244;14;141;654;0;1;10;6;30;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BD5Z;Diseases of arteries or arterioles, unspecified;2;Inactive;1164983645/unspecified;37931629, 35650639, 25487941
200;zibotentan;zibotentan;CHEMBL1628688;DB06629;9910224;186497-07-4;NA;FJHHZXWJVIEFGJ-UHFFFAOYSA-N;CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4;4244;14;141;654;0;1;10;6;30;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;GB61.Z;Chronic kidney disease, stage unspecified;2;Active;412389819/unspecified;37931629, 35650639, 25487941
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A01.0Z;Meningiomas, unspecified;2;Active;672106711/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2B33.5;Malignant lymphoma, not elsewhere classified;2;Inactive;474972159;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.02;Hepatocellular carcinoma of liver;3;Inactive;1294035808;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.0Z;Malignant neoplasm of liver, unspecified;2;Inactive;1605020868/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C27.Y;Other specified malignant neoplasms of thymus;2;Unknown;1718833206/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Inactive;1552457716/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;3;Active;1594217552/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2E92.9;Benign neoplasm of endocrine pancreas;2;Inactive;170957983;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F91.Y;Neoplasms of unknown behaviour of other specified respiratory organ, intrathoracic organ or middle ear;2;Unknown;1795904876/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A4Y;Other specified disorders of glucose regulation or pancreatic internal secretion;2;Inactive;1283179793/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5B81.Z;Obesity, unspecified;2;Inactive;149403041/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;8A80.Z;Migraine, unspecified;2;Unknown;669367341/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;9B71.0Z;Diabetic retinopathy, unspecified;3;Inactive;1006882070/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;CB03.4;Idiopathic pulmonary fibrosis;2;Inactive;1074069640;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DB30.Y;Other specified obstruction of large intestine;2;Inactive;320939116/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;1;Unknown;1158238623/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;GB6Z;Kidney failure, unspecified;2;Active;761526554/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;GB81;Autosomal dominant polycystic kidney disease;3;Inactive;91220434;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.0;Constipation;2;Inactive;502284069;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.1;Diarrhoea;4;Approved;116759077;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;1;Inactive;2044414353/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A01.0Z;Meningiomas, unspecified;2;Active;672106711/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2B33.5;Malignant lymphoma, not elsewhere classified;2;Inactive;474972159;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.02;Hepatocellular carcinoma of liver;3;Inactive;1294035808;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.0Z;Malignant neoplasm of liver, unspecified;2;Inactive;1605020868/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C27.Y;Other specified malignant neoplasms of thymus;2;Unknown;1718833206/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Inactive;1552457716/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;3;Active;1594217552/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2E92.9;Benign neoplasm of endocrine pancreas;2;Inactive;170957983;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F91.Y;Neoplasms of unknown behaviour of other specified respiratory organ, intrathoracic organ or middle ear;2;Unknown;1795904876/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A4Y;Other specified disorders of glucose regulation or pancreatic internal secretion;2;Inactive;1283179793/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5B81.Z;Obesity, unspecified;2;Inactive;149403041/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;8A80.Z;Migraine, unspecified;2;Unknown;669367341/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;9B71.0Z;Diabetic retinopathy, unspecified;3;Inactive;1006882070/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;CB03.4;Idiopathic pulmonary fibrosis;2;Inactive;1074069640;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DB30.Y;Other specified obstruction of large intestine;2;Inactive;320939116/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;1;Unknown;1158238623/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;GB6Z;Kidney failure, unspecified;2;Active;761526554/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;GB81;Autosomal dominant polycystic kidney disease;3;Inactive;91220434;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.0;Constipation;2;Inactive;502284069;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.1;Diarrhoea;4;Approved;116759077;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;1;Inactive;2044414353/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A01.0Z;Meningiomas, unspecified;2;Active;672106711/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2B33.5;Malignant lymphoma, not elsewhere classified;2;Inactive;474972159;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.02;Hepatocellular carcinoma of liver;3;Inactive;1294035808;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.0Z;Malignant neoplasm of liver, unspecified;2;Inactive;1605020868/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C27.Y;Other specified malignant neoplasms of thymus;2;Unknown;1718833206/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Inactive;1552457716/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;3;Active;1594217552/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2E92.9;Benign neoplasm of endocrine pancreas;2;Inactive;170957983;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F91.Y;Neoplasms of unknown behaviour of other specified respiratory organ, intrathoracic organ or middle ear;2;Unknown;1795904876/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A4Y;Other specified disorders of glucose regulation or pancreatic internal secretion;2;Inactive;1283179793/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5B81.Z;Obesity, unspecified;2;Inactive;149403041/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;8A80.Z;Migraine, unspecified;2;Unknown;669367341/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;9B71.0Z;Diabetic retinopathy, unspecified;3;Inactive;1006882070/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;CB03.4;Idiopathic pulmonary fibrosis;2;Inactive;1074069640;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DB30.Y;Other specified obstruction of large intestine;2;Inactive;320939116/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;1;Unknown;1158238623/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;GB6Z;Kidney failure, unspecified;2;Active;761526554/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;GB81;Autosomal dominant polycystic kidney disease;3;Inactive;91220434;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.0;Constipation;2;Inactive;502284069;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.1;Diarrhoea;4;Approved;116759077;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;1;Inactive;2044414353/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A01.0Z;Meningiomas, unspecified;2;Active;672106711/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2B33.5;Malignant lymphoma, not elsewhere classified;2;Inactive;474972159;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.02;Hepatocellular carcinoma of liver;3;Inactive;1294035808;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.0Z;Malignant neoplasm of liver, unspecified;2;Inactive;1605020868/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C27.Y;Other specified malignant neoplasms of thymus;2;Unknown;1718833206/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Inactive;1552457716/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;3;Active;1594217552/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2E92.9;Benign neoplasm of endocrine pancreas;2;Inactive;170957983;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F91.Y;Neoplasms of unknown behaviour of other specified respiratory organ, intrathoracic organ or middle ear;2;Unknown;1795904876/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A4Y;Other specified disorders of glucose regulation or pancreatic internal secretion;2;Inactive;1283179793/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5B81.Z;Obesity, unspecified;2;Inactive;149403041/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;8A80.Z;Migraine, unspecified;2;Unknown;669367341/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;9B71.0Z;Diabetic retinopathy, unspecified;3;Inactive;1006882070/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;CB03.4;Idiopathic pulmonary fibrosis;2;Inactive;1074069640;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DB30.Y;Other specified obstruction of large intestine;2;Inactive;320939116/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;1;Unknown;1158238623/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;GB6Z;Kidney failure, unspecified;2;Active;761526554/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;GB81;Autosomal dominant polycystic kidney disease;3;Inactive;91220434;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.0;Constipation;2;Inactive;502284069;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.1;Diarrhoea;4;Approved;116759077;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;1;Inactive;2044414353/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A01.0Z;Meningiomas, unspecified;2;Active;672106711/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2B33.5;Malignant lymphoma, not elsewhere classified;2;Inactive;474972159;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.02;Hepatocellular carcinoma of liver;3;Inactive;1294035808;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.0Z;Malignant neoplasm of liver, unspecified;2;Inactive;1605020868/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C27.Y;Other specified malignant neoplasms of thymus;2;Unknown;1718833206/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Inactive;1552457716/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;3;Active;1594217552/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2E92.9;Benign neoplasm of endocrine pancreas;2;Inactive;170957983;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F91.Y;Neoplasms of unknown behaviour of other specified respiratory organ, intrathoracic organ or middle ear;2;Unknown;1795904876/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A4Y;Other specified disorders of glucose regulation or pancreatic internal secretion;2;Inactive;1283179793/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5B81.Z;Obesity, unspecified;2;Inactive;149403041/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;8A80.Z;Migraine, unspecified;2;Unknown;669367341/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;9B71.0Z;Diabetic retinopathy, unspecified;3;Inactive;1006882070/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;CB03.4;Idiopathic pulmonary fibrosis;2;Inactive;1074069640;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DB30.Y;Other specified obstruction of large intestine;2;Inactive;320939116/other;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;1;Unknown;1158238623/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;GB6Z;Kidney failure, unspecified;2;Active;761526554/unspecified;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;GB81;Autosomal dominant polycystic kidney disease;3;Inactive;91220434;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.0;Constipation;2;Inactive;502284069;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.1;Diarrhoea;4;Approved;116759077;30000784, 31335053, 32644756
201;octreotide;octreotide;CHEMBL1680;DB00104;448601;"79517-01-4;83150-76-9;83150-76-9 (free base)";NA;DEQANNDTNATYII-OULOTJBUSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O;10192;1;383;1740;0;13;14;17;71;4;Approved;1988;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;1;Inactive;2044414353/unspecified;30000784, 31335053, 32644756
202;dezocine;dezocine;CHEMBL1685;DB01209;3033053;53648-55-8;VHX8K5SV4X;VTMVHDZWSFQSQP-VBNZEHGJSA-N;CC12CCCCCC(C1N)CC3=C2C=C(C=C3)O;24536;37;462;306;0;2;2;0;18;4;Approved;1989;Small molecule;Partial agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;34737418, 31094808, 28615968
202;dezocine;dezocine;CHEMBL1685;DB01209;3033053;53648-55-8;VHX8K5SV4X;VTMVHDZWSFQSQP-VBNZEHGJSA-N;CC12CCCCCC(C1N)CC3=C2C=C(C=C3)O;24536;37;462;306;0;2;2;0;18;4;Approved;1989;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;34737418, 31094808, 28615968
203;cevimeline;R-cevimeline;CHEMBL1201267;DB00185;83898;107233-08-9;K9V0CDQ56E;WUTYZMFRCNBCHQ-PSASIEDQSA-N;C[C@@H]1O[C@]2(CN3CCC2CC3)CS1;19932;15;378;215;0;0;3;0;13;4;Approved;2000;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA02.1;Xerostomia;4;Approved;1810717437;31644140, 18681491, 34445613
203;cevimeline;cevimeline;CHEMBL168815;DB00185;2684;107233-08-9;K9V0CDQ56E;WUTYZMFRCNBCHQ-UHFFFAOYSA-N;CC1OC2(CN3CCC2CC3)CS1;19932;15;378;215;0;0;3;0;13;4;Approved;2000;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA02.1;Xerostomia;4;Approved;1810717437;31644140, 18681491, 34445613
203;cevimeline;R-cevimeline;CHEMBL1201267;DB00185;83898;107233-08-9;K9V0CDQ56E;WUTYZMFRCNBCHQ-PSASIEDQSA-N;C[C@@H]1O[C@]2(CN3CCC2CC3)CS1;19932;15;378;215;0;0;3;0;13;4;Approved;2000;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA02.1;Xerostomia;4;Approved;1810717437;31644140, 18681491, 34445613
203;cevimeline;cevimeline;CHEMBL168815;DB00185;2684;107233-08-9;K9V0CDQ56E;WUTYZMFRCNBCHQ-UHFFFAOYSA-N;CC1OC2(CN3CCC2CC3)CS1;19932;15;378;215;0;0;3;0;13;4;Approved;2000;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA02.1;Xerostomia;4;Approved;1810717437;31644140, 18681491, 34445613
204;isometheptene;isometheptene;CHEMBL1697841;DB06706;22297;503-01-5;Y7L24THH6T;XVQUOJBERHHONY-UHFFFAOYSA-N;CC(CCC=C(C)C)NC;14125;25;12;101;0;1;1;4;10;4;Approved;1948;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;31053059, 28474252, 11318886
204;isometheptene;isometheptene;CHEMBL1697841;DB06706;22297;503-01-5;Y7L24THH6T;XVQUOJBERHHONY-UHFFFAOYSA-N;CC(CCC=C(C)C)NC;14125;25;12;101;0;1;1;4;10;4;Approved;1948;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A81.Z;Tension-type headache, unspecified;4;Approved;1410019257/unspecified;31053059, 28474252, 11318886
205;ethylmorphine;ethylmorphine;CHEMBL1712170;DB01466;5359271;76-58-4;RWO67D87EU;OGDVEMNWJVYAJL-LEPYJNQMSA-N;CCOC1=C2C3=C(CC4C5C3(CCN4C)C(O2)C(C=C5)O)C=C1;3134;15;419;523;0;1;4;2;23;4;Approved;1953;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD12;Cough;4;Approved;2027526159;7654478, 34652878, 10460420
206;dihydroergotamine;dihydroergotamine;CHEMBL1732;DB00320;10531;511-12-6;436O5HM03C;LUZRJRNZXALNLM-JGRZULCMSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C;5837;24;118;1160;0;3;6;4;43;4;Approved;1946;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;34554670, 3389610, 24024602
206;dihydroergotamine;dihydroergotamine;CHEMBL1732;DB00320;10531;511-12-6;436O5HM03C;LUZRJRNZXALNLM-JGRZULCMSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C;5837;24;118;1160;0;3;6;4;43;4;Approved;1946;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;34554670, 3389610, 24024602
206;dihydroergotamine;dihydroergotamine;CHEMBL1732;DB00320;10531;511-12-6;436O5HM03C;LUZRJRNZXALNLM-JGRZULCMSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C;5837;24;118;1160;0;3;6;4;43;4;Approved;1946;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;34554670, 3389610, 24024602
206;dihydroergotamine;dihydroergotamine;CHEMBL1732;DB00320;10531;511-12-6;436O5HM03C;LUZRJRNZXALNLM-JGRZULCMSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C;5837;24;118;1160;0;3;6;4;43;4;Approved;1946;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;34554670, 3389610, 24024602
206;dihydroergotamine;dihydroergotamine;CHEMBL1732;DB00320;10531;511-12-6;436O5HM03C;LUZRJRNZXALNLM-JGRZULCMSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C;5837;24;118;1160;0;3;6;4;43;4;Approved;1946;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;34554670, 3389610, 24024602
206;dihydroergotamine;dihydroergotamine;CHEMBL1732;DB00320;10531;511-12-6;436O5HM03C;LUZRJRNZXALNLM-JGRZULCMSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C;5837;24;118;1160;0;3;6;4;43;4;Approved;1946;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;34554670, 3389610, 24024602
206;dihydroergotamine;dihydroergotamine;CHEMBL1732;DB00320;10531;511-12-6;436O5HM03C;LUZRJRNZXALNLM-JGRZULCMSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C;5837;24;118;1160;0;3;6;4;43;4;Approved;1946;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;34554670, 3389610, 24024602
206;dihydroergotamine;dihydroergotamine;CHEMBL1732;DB00320;10531;511-12-6;436O5HM03C;LUZRJRNZXALNLM-JGRZULCMSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C;5837;24;118;1160;0;3;6;4;43;4;Approved;1946;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;34554670, 3389610, 24024602
206;dihydroergotamine;dihydroergotamine;CHEMBL1732;DB00320;10531;511-12-6;436O5HM03C;LUZRJRNZXALNLM-JGRZULCMSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C;5837;24;118;1160;0;3;6;4;43;4;Approved;1946;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;34554670, 3389610, 24024602
207;solifenacin;solifenacin;CHEMBL1734;DB01591;154059;242478-37-1;A8910SQJ1U;FBOUYBDGKBSUES-VXKWHMMOSA-N;C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5;3625;4;328;525;0;0;3;3;27;4;Approved;2004;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;30000729, 31644025, 29866467
207;solifenacin;solifenacin;CHEMBL1734;DB01591;154059;242478-37-1;A8910SQJ1U;FBOUYBDGKBSUES-VXKWHMMOSA-N;C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5;3625;4;328;525;0;0;3;3;27;4;Approved;2004;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;30000729, 31644025, 29866467
207;solifenacin;solifenacin;CHEMBL1734;DB01591;154059;242478-37-1;A8910SQJ1U;FBOUYBDGKBSUES-VXKWHMMOSA-N;C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5;3625;4;328;525;0;0;3;3;27;4;Approved;2004;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF55;Polyuria;4;Approved;2137636828;30000729, 31644025, 29866467
207;solifenacin;solifenacin;CHEMBL1734;DB01591;154059;242478-37-1;A8910SQJ1U;FBOUYBDGKBSUES-VXKWHMMOSA-N;C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5;3625;4;328;525;0;0;3;3;27;4;Approved;2004;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF59;Urinary symptom or complaint;3;Unknown;873135456;30000729, 31644025, 29866467
207;solifenacin;solifenacin;CHEMBL1734;DB01591;154059;242478-37-1;A8910SQJ1U;FBOUYBDGKBSUES-VXKWHMMOSA-N;C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5;3625;4;328;525;0;0;3;3;27;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;30000729, 31644025, 29866467
207;solifenacin;solifenacin;CHEMBL1734;DB01591;154059;242478-37-1;A8910SQJ1U;FBOUYBDGKBSUES-VXKWHMMOSA-N;C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5;3625;4;328;525;0;0;3;3;27;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;30000729, 31644025, 29866467
207;solifenacin;solifenacin;CHEMBL1734;DB01591;154059;242478-37-1;A8910SQJ1U;FBOUYBDGKBSUES-VXKWHMMOSA-N;C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5;3625;4;328;525;0;0;3;3;27;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF55;Polyuria;4;Approved;2137636828;30000729, 31644025, 29866467
207;solifenacin;solifenacin;CHEMBL1734;DB01591;154059;242478-37-1;A8910SQJ1U;FBOUYBDGKBSUES-VXKWHMMOSA-N;C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5;3625;4;328;525;0;0;3;3;27;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF59;Urinary symptom or complaint;3;Unknown;873135456;30000729, 31644025, 29866467
208;racepinephrine;racepinephrine;CHEMBL1740;DB11124;838;329-65-7;NA;UCTWMZQNUQWSLP-UHFFFAOYSA-N;CNCC(C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;2000;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;8800972
208;racepinephrine;racepinephrine;CHEMBL1740;DB11124;838;329-65-7;NA;UCTWMZQNUQWSLP-UHFFFAOYSA-N;CNCC(C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;2000;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;8800972
208;racepinephrine;racepinephrine;CHEMBL1740;DB11124;838;329-65-7;NA;UCTWMZQNUQWSLP-UHFFFAOYSA-N;CNCC(C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;2000;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;8800972
208;racepinephrine;racepinephrine;CHEMBL1740;DB11124;838;329-65-7;NA;UCTWMZQNUQWSLP-UHFFFAOYSA-N;CNCC(C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;2000;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;8800972
208;racepinephrine;racepinephrine;CHEMBL1740;DB11124;838;329-65-7;NA;UCTWMZQNUQWSLP-UHFFFAOYSA-N;CNCC(C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;2000;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;8800972
208;racepinephrine;racepinephrine;CHEMBL1740;DB11124;838;329-65-7;NA;UCTWMZQNUQWSLP-UHFFFAOYSA-N;CNCC(C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;2000;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;8800972
208;racepinephrine;racepinephrine;CHEMBL1740;DB11124;838;329-65-7;NA;UCTWMZQNUQWSLP-UHFFFAOYSA-N;CNCC(C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;2000;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;8800972
208;racepinephrine;racepinephrine;CHEMBL1740;DB11124;838;329-65-7;NA;UCTWMZQNUQWSLP-UHFFFAOYSA-N;CNCC(C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;2000;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;8800972
208;racepinephrine;racepinephrine;CHEMBL1740;DB11124;838;329-65-7;NA;UCTWMZQNUQWSLP-UHFFFAOYSA-N;CNCC(C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;2000;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;8800972
209;lafutidine;lafutidine;CHEMBL1742461;DB12770;5282136;"118288-08-7;118288-08-7 (free base);206449-93-6";NA;KMZQAVXSMUKBPD-DJWKRKHSSA-N;C1CCN(CC1)CC2=CC(=NC=C2)OCC=CCNC(=O)CS(=O)CC3=CC=CO3;4316;14;104;569;0;1;7;11;30;4;Approved;2000;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;34848484, 28456772, 25298578
209;lafutidine;lafutidine;CHEMBL1742461;DB12770;5282136;"118288-08-7;118288-08-7 (free base);206449-93-6";NA;KMZQAVXSMUKBPD-DJWKRKHSSA-N;C1CCN(CC1)CC2=CC(=NC=C2)OCC=CCNC(=O)CS(=O)CC3=CC=CO3;4316;14;104;569;0;1;7;11;30;4;Approved;2000;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA42.Z;Gastritis, unspecified;4;Approved;1871672644/unspecified;34848484, 28456772, 25298578
209;lafutidine;lafutidine;CHEMBL1742461;DB12770;5282136;"118288-08-7;118288-08-7 (free base);206449-93-6";NA;KMZQAVXSMUKBPD-DJWKRKHSSA-N;C1CCN(CC1)CC2=CC(=NC=C2)OCC=CCNC(=O)CS(=O)CC3=CC=CO3;4316;14;104;569;0;1;7;11;30;4;Approved;2000;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA60.Z;Gastric ulcer, unspecified;4;Approved;1437411258/unspecified;34848484, 28456772, 25298578
209;lafutidine;lafutidine;CHEMBL1742461;DB12770;5282136;"118288-08-7;118288-08-7 (free base);206449-93-6";NA;KMZQAVXSMUKBPD-DJWKRKHSSA-N;C1CCN(CC1)CC2=CC(=NC=C2)OCC=CCNC(=O)CS(=O)CC3=CC=CO3;4316;14;104;569;0;1;7;11;30;4;Approved;2000;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;34848484, 28456772, 25298578
209;lafutidine;lafutidine;CHEMBL1742461;DB12770;5282136;"118288-08-7;118288-08-7 (free base);206449-93-6";NA;KMZQAVXSMUKBPD-DJWKRKHSSA-N;C1CCN(CC1)CC2=CC(=NC=C2)OCC=CCNC(=O)CS(=O)CC3=CC=CO3;4316;14;104;569;0;1;7;11;30;4;Approved;2000;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA63.Z;Duodenal ulcer, unspecified;4;Approved;553678663/unspecified;34848484, 28456772, 25298578
210;landiolol;landiolol;CHEMBL1742466;DB12212;114905;133242-30-5;NA;WMDSZGFJQKSLLH-RBBKRZOGSA-N;CC1(OCC(O1)COC(=O)CCC2=CC=C(C=C2)OCC(CNCCNC(=O)N3CCOCC3)O)C;5096;1;128;666;0;3;9;14;36;4;Approved;2022;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Unknown;1683090852;37877587, 29470800, 32243865
210;landiolol;landiolol;CHEMBL1742466;DB12212;114905;133242-30-5;NA;WMDSZGFJQKSLLH-RBBKRZOGSA-N;CC1(OCC(O1)COC(=O)CCC2=CC=C(C=C2)OCC(CNCCNC(=O)N3CCOCC3)O)C;5096;1;128;666;0;3;9;14;36;4;Approved;2022;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC71.1;Ventricular fibrillation;4;Approved;1662472992;37877587, 29470800, 32243865
210;landiolol;landiolol;CHEMBL1742466;DB12212;114905;133242-30-5;NA;WMDSZGFJQKSLLH-RBBKRZOGSA-N;CC1(OCC(O1)COC(=O)CCC2=CC=C(C=C2)OCC(CNCCNC(=O)N3CCOCC3)O)C;5096;1;128;666;0;3;9;14;36;4;Approved;2022;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;4;Approved;171698302/unspecified;37877587, 29470800, 32243865
210;landiolol;landiolol;CHEMBL1742466;DB12212;114905;133242-30-5;NA;WMDSZGFJQKSLLH-RBBKRZOGSA-N;CC1(OCC(O1)COC(=O)CCC2=CC=C(C=C2)OCC(CNCCNC(=O)N3CCOCC3)O)C;5096;1;128;666;0;3;9;14;36;4;Approved;2022;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.Z;Supraventricular tachyarrhythmia, unspecified;4;Approved;113146812/unspecified;37877587, 29470800, 32243865
210;landiolol;landiolol;CHEMBL1742466;DB12212;114905;133242-30-5;NA;WMDSZGFJQKSLLH-RBBKRZOGSA-N;CC1(OCC(O1)COC(=O)CCC2=CC=C(C=C2)OCC(CNCCNC(=O)N3CCOCC3)O)C;5096;1;128;666;0;3;9;14;36;4;Approved;2022;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC9Z;Cardiac arrhythmia, unspecified;3;Unknown;1457291912/unspecified;37877587, 29470800, 32243865
212;mogamulizumab;mogamulizumab;CHEMBL1743041;DB12498;;1159266-37-1;YI437801BE;NA;NA;;;;;;;;;;4;Approved;2018;Antibody;Inhibitor;P51679;ccr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2A90.5;Adult T-cell lymphoma or leukaemia, human T-cell lymphotropic virus type 1-associated;2;Inactive;1638811270;30100375, 30272896, 31643268
212;mogamulizumab;mogamulizumab;CHEMBL1743041;DB12498;;1159266-37-1;YI437801BE;NA;NA;;;;;;;;;;4;Approved;2018;Antibody;Inhibitor;P51679;ccr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2A90.C;Peripheral T-cell lymphoma, not otherwise specified;2;Inactive;855224800;30100375, 30272896, 31643268
212;mogamulizumab;mogamulizumab;CHEMBL1743041;DB12498;;1159266-37-1;YI437801BE;NA;NA;;;;;;;;;;4;Approved;2018;Antibody;Inhibitor;P51679;ccr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2B01;Mycosis fungoides;4;Approved;901411509;30100375, 30272896, 31643268
212;mogamulizumab;mogamulizumab;CHEMBL1743041;DB12498;;1159266-37-1;YI437801BE;NA;NA;;;;;;;;;;4;Approved;2018;Antibody;Inhibitor;P51679;ccr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2B02;Sézary syndrome;4;Approved;1358020385;30100375, 30272896, 31643268
212;mogamulizumab;mogamulizumab;CHEMBL1743041;DB12498;;1159266-37-1;YI437801BE;NA;NA;;;;;;;;;;4;Approved;2018;Antibody;Inhibitor;P51679;ccr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2B0Z;Primary cutaneous T-cell lymphoma of undetermined or unspecified type;3;Active;1998421548/unspecified;30100375, 30272896, 31643268
212;mogamulizumab;mogamulizumab;CHEMBL1743041;DB12498;;1159266-37-1;YI437801BE;NA;NA;;;;;;;;;;4;Approved;2018;Antibody;Inhibitor;P51679;ccr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2C25.Y;Other specified malignant neoplasms of bronchus or lung;1;Inactive;316539081/other;30100375, 30272896, 31643268
212;mogamulizumab;mogamulizumab;CHEMBL1743041;DB12498;;1159266-37-1;YI437801BE;NA;NA;;;;;;;;;;4;Approved;2018;Antibody;Inhibitor;P51679;ccr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;8A45.00;Human T-cell lymphotropic virus-associated myelopathy;3;Inactive;1043229589;30100375, 30272896, 31643268
213;dihydro-alpha-ergocryptine;dihydro-alpha-ergocryptine;CHEMBL1743263;DB11274;114948;25447-66-9;202229IR8Y;PBUNVLRHZGSROC-VTIMJTGVSA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O;5777;31;118;1130;0;3;6;5;42;4;Approved;1951;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;4;Approved;546689346/unspecified;10423622, 8028778
213;dihydro-alpha-ergocryptine;dihydro-alpha-ergocryptine;CHEMBL1743263;DB11274;114948;25447-66-9;202229IR8Y;PBUNVLRHZGSROC-VTIMJTGVSA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O;5777;31;118;1130;0;3;6;5;42;4;Approved;1951;Small molecule;Partial agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;4;Approved;546689346/unspecified;10423622, 8028778
213;dihydro-alpha-ergocryptine;dihydro-alpha-ergocryptine;CHEMBL1743263;DB11274;114948;25447-66-9;202229IR8Y;PBUNVLRHZGSROC-VTIMJTGVSA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O;5777;31;118;1130;0;3;6;5;42;4;Approved;1951;Small molecule;Partial agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;4;Approved;546689346/unspecified;10423622, 8028778
213;dihydro-alpha-ergocryptine;dihydro-alpha-ergocryptine;CHEMBL1743263;DB11274;114948;25447-66-9;202229IR8Y;PBUNVLRHZGSROC-VTIMJTGVSA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O;5777;31;118;1130;0;3;6;5;42;4;Approved;1951;Small molecule;Partial agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;4;Approved;546689346/unspecified;10423622, 8028778
214;dyphylline;dyphylline;CHEMBL1752;DB00651;3182;479-18-5;263T0E9RR9;KSCFJBIXMNOVSH-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O;25424;-18;989;364;0;2;5;3;18;4;Approved;1951;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA20.Z;Bronchitis, unspecified;4;Approved;11753425/unspecified;30000536, 35387498, 20313615
214;dyphylline;dyphylline;CHEMBL1752;DB00651;3182;479-18-5;263T0E9RR9;KSCFJBIXMNOVSH-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O;25424;-18;989;364;0;2;5;3;18;4;Approved;1951;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;30000536, 35387498, 20313615
214;dyphylline;dyphylline;CHEMBL1752;DB00651;3182;479-18-5;263T0E9RR9;KSCFJBIXMNOVSH-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O;25424;-18;989;364;0;2;5;3;18;4;Approved;1951;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA23;Asthma;4;Approved;1656445230;30000536, 35387498, 20313615
214;dyphylline;dyphylline;CHEMBL1752;DB00651;3182;479-18-5;263T0E9RR9;KSCFJBIXMNOVSH-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O;25424;-18;989;364;0;2;5;3;18;4;Approved;1951;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA20.Z;Bronchitis, unspecified;4;Approved;11753425/unspecified;30000536, 35387498, 20313615
214;dyphylline;dyphylline;CHEMBL1752;DB00651;3182;479-18-5;263T0E9RR9;KSCFJBIXMNOVSH-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O;25424;-18;989;364;0;2;5;3;18;4;Approved;1951;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;30000536, 35387498, 20313615
214;dyphylline;dyphylline;CHEMBL1752;DB00651;3182;479-18-5;263T0E9RR9;KSCFJBIXMNOVSH-UHFFFAOYSA-N;CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O;25424;-18;989;364;0;2;5;3;18;4;Approved;1951;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA23;Asthma;4;Approved;1656445230;30000536, 35387498, 20313615
215;conivaptan;conivaptan;CHEMBL1755;DB00872;151171;210101-16-9;0NJ98Y462X;IKENVDNFQMCRTR-UHFFFAOYSA-N;CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6;4986;57;781;820;0;2;3;4;38;4;Approved;2005;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5C72;Hypo-osmolality or hyponatraemia;4;Approved;761639036;24259735, 12054079, 18828645
215;conivaptan;conivaptan;CHEMBL1755;DB00872;151171;210101-16-9;0NJ98Y462X;IKENVDNFQMCRTR-UHFFFAOYSA-N;CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6;4986;57;781;820;0;2;3;4;38;4;Approved;2005;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;DB93.1;Hepatic cirrhosis;2;Inactive;1781315693;24259735, 12054079, 18828645
215;conivaptan;conivaptan;CHEMBL1755;DB00872;151171;210101-16-9;0NJ98Y462X;IKENVDNFQMCRTR-UHFFFAOYSA-N;CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6;4986;57;781;820;0;2;3;4;38;4;Approved;2005;Small molecule;Antagonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5C72;Hypo-osmolality or hyponatraemia;4;Approved;761639036;24259735, 12054079, 18828645
215;conivaptan;conivaptan;CHEMBL1755;DB00872;151171;210101-16-9;0NJ98Y462X;IKENVDNFQMCRTR-UHFFFAOYSA-N;CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6;4986;57;781;820;0;2;3;4;38;4;Approved;2005;Small molecule;Antagonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;DB93.1;Hepatic cirrhosis;2;Inactive;1781315693;24259735, 12054079, 18828645
216;terbutaline;terbutaline;CHEMBL1760;DB00871;5403;23031-25-6;N8ONU3L3PG;XWTYSIMOBUGWOL-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O;22528;9;727;205;0;4;4;4;16;4;Approved;1974;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;3B64.10;Immune thrombocytopenic purpura;2;Active;364346400;30000166, 10368508, 36227333
216;terbutaline;terbutaline;CHEMBL1760;DB00871;5403;23031-25-6;N8ONU3L3PG;XWTYSIMOBUGWOL-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O;22528;9;727;205;0;4;4;4;16;4;Approved;1974;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;2;Inactive;1339785363/unspecified;30000166, 10368508, 36227333
216;terbutaline;terbutaline;CHEMBL1760;DB00871;5403;23031-25-6;N8ONU3L3PG;XWTYSIMOBUGWOL-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O;22528;9;727;205;0;4;4;4;16;4;Approved;1974;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA20.Z;Bronchitis, unspecified;4;Approved;11753425/unspecified;30000166, 10368508, 36227333
216;terbutaline;terbutaline;CHEMBL1760;DB00871;5403;23031-25-6;N8ONU3L3PG;XWTYSIMOBUGWOL-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O;22528;9;727;205;0;4;4;4;16;4;Approved;1974;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;30000166, 10368508, 36227333
216;terbutaline;terbutaline;CHEMBL1760;DB00871;5403;23031-25-6;N8ONU3L3PG;XWTYSIMOBUGWOL-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O;22528;9;727;205;0;4;4;4;16;4;Approved;1974;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;3;Inactive;133207228/unspecified;30000166, 10368508, 36227333
216;terbutaline;terbutaline;CHEMBL1760;DB00871;5403;23031-25-6;N8ONU3L3PG;XWTYSIMOBUGWOL-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O;22528;9;727;205;0;4;4;4;16;4;Approved;1974;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;30000166, 10368508, 36227333
216;terbutaline;terbutaline;CHEMBL1760;DB00871;5403;23031-25-6;N8ONU3L3PG;XWTYSIMOBUGWOL-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O;22528;9;727;205;0;4;4;4;16;4;Approved;1974;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;30000166, 10368508, 36227333
217;levomepromazine;levomepromazine;CHEMBL1764;DB01403;72287;60-99-1;9G0LAW7ATQ;VRQVVMDWGGWHTJ-CQSZACIVSA-N;CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C;3285;47;41;378;0;0;4;5;23;4;Approved;1982;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;20927765, 22114097, 26524693
217;levomepromazine;levomepromazine;CHEMBL1764;DB01403;72287;60-99-1;9G0LAW7ATQ;VRQVVMDWGGWHTJ-CQSZACIVSA-N;CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C;3285;47;41;378;0;0;4;5;23;4;Approved;1982;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;20927765, 22114097, 26524693
217;levomepromazine;levomepromazine;CHEMBL1764;DB01403;72287;60-99-1;9G0LAW7ATQ;VRQVVMDWGGWHTJ-CQSZACIVSA-N;CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C;3285;47;41;378;0;0;4;5;23;4;Approved;1982;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;20927765, 22114097, 26524693
217;levomepromazine;levomepromazine;CHEMBL1764;DB01403;72287;60-99-1;9G0LAW7ATQ;VRQVVMDWGGWHTJ-CQSZACIVSA-N;CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C;3285;47;41;378;0;0;4;5;23;4;Approved;1982;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;20927765, 22114097, 26524693
217;levomepromazine;levomepromazine;CHEMBL1764;DB01403;72287;60-99-1;9G0LAW7ATQ;VRQVVMDWGGWHTJ-CQSZACIVSA-N;CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C;3285;47;41;378;0;0;4;5;23;4;Approved;1982;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;20927765, 22114097, 26524693
217;levomepromazine;levomepromazine;CHEMBL1764;DB01403;72287;60-99-1;9G0LAW7ATQ;VRQVVMDWGGWHTJ-CQSZACIVSA-N;CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C;3285;47;41;378;0;0;4;5;23;4;Approved;1982;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;20927765, 22114097, 26524693
217;levomepromazine;levomepromazine;CHEMBL1764;DB01403;72287;60-99-1;9G0LAW7ATQ;VRQVVMDWGGWHTJ-CQSZACIVSA-N;CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C;3285;47;41;378;0;0;4;5;23;4;Approved;1982;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;20927765, 22114097, 26524693
217;levomepromazine;levomepromazine;CHEMBL1764;DB01403;72287;60-99-1;9G0LAW7ATQ;VRQVVMDWGGWHTJ-CQSZACIVSA-N;CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C;3285;47;41;378;0;0;4;5;23;4;Approved;1982;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;20927765, 22114097, 26524693
217;levomepromazine;levomepromazine;CHEMBL1764;DB01403;72287;60-99-1;9G0LAW7ATQ;VRQVVMDWGGWHTJ-CQSZACIVSA-N;CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C;3285;47;41;378;0;0;4;5;23;4;Approved;1982;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;20927765, 22114097, 26524693
217;levomepromazine;levomepromazine;CHEMBL1764;DB01403;72287;60-99-1;9G0LAW7ATQ;VRQVVMDWGGWHTJ-CQSZACIVSA-N;CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C;3285;47;41;378;0;0;4;5;23;4;Approved;1982;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;20927765, 22114097, 26524693
217;levomepromazine;levomepromazine;CHEMBL1764;DB01403;72287;60-99-1;9G0LAW7ATQ;VRQVVMDWGGWHTJ-CQSZACIVSA-N;CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C;3285;47;41;378;0;0;4;5;23;4;Approved;1982;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;20927765, 22114097, 26524693
217;levomepromazine;levomepromazine;CHEMBL1764;DB01403;72287;60-99-1;9G0LAW7ATQ;VRQVVMDWGGWHTJ-CQSZACIVSA-N;CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C;3285;47;41;378;0;0;4;5;23;4;Approved;1982;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;20927765, 22114097, 26524693
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;2A20.4;Polycythaemia vera;2;Unknown;818364947;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;2D42;Malignant neoplasms of ill-defined sites;1;Active;2023965817;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;2F95;Neoplasms of unknown behaviour of breast;2;Inactive;1623614569;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;3B61.Z;Thrombophilia, unspecified;4;Approved;1733531851/unspecified;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;4A40.0Z;Systemic lupus erythematosus, unspecified;2;Inactive;749596428/unspecified;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;4A42.Z;Systemic sclerosis, unspecified;3;Active;1084365812/unspecified;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;8B10.Z;Transient ischaemic attack, unspecified;3;Inactive;826335789/unspecified;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;3;Active;1614716959/unspecified;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA40.Z;Angina pectoris, unspecified;3;Inactive;718946808/unspecified;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA41.0;Acute ST elevation myocardial infarction;4;Approved;391388807;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA41.1;Acute non-ST elevation myocardial infarction;4;Approved;680129526;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA4Z;Acute ischaemic heart disease, unspecified;4;Approved;1829545371/unspecified;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BB01.0;Pulmonary arterial hypertension;2;Inactive;1931148955;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BC81.3Z;Atrial fibrillation, unspecified;3;Inactive;171698302/unspecified;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BD1Z;Heart failure, unspecified;3;Inactive;1458683894/unspecified;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BD40.Z;Atherosclerotic chronic arterial occlusive disease, unspecified;3;Inactive;109367356/unspecified;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BD4Z;Chronic arterial occlusive disease, unspecified;3;Inactive;1821859817/unspecified;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BD55;Asymptomatic stenosis of intracranial or extracranial artery;3;Active;860460764;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BD5Z;Diseases of arteries or arterioles, unspecified;4;Approved;1164983645/unspecified;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BE2Z;Diseases of the circulatory system, unspecified;3;Inactive;426429380/unspecified;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;CA23;Asthma;2;Inactive;1656445230;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;LA8A.3;Congenital supravalvar aortic stenosis;3;Inactive;1066595728;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;3;Inactive;2044414353/unspecified;30998396, 32284734, 30601618
218;clopidogrel;clopidogrel;CHEMBL1771;DB00758;60606;113665-84-2;A74586SNO7;GKTWGGQPFAXNFI-HNNXBMFYSA-N;COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3;3218;38;578;381;0;0;4;4;21;4;Approved;1997;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;RA01;COVID-19;3;Active;1730556128;30998396, 32284734, 30601618
219;lofexidine;lofexidine;CHEMBL17860;DB04948;30668;31036-80-3;UI82K0T627;KSMAGQUYOIHWFS-UHFFFAOYSA-N;CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl;25913;26;336;263;0;1;2;3;16;4;Approved;2018;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;30000984, 31791720, 30724094
219;lofexidine;lofexidine;CHEMBL17860;DB04948;30668;31036-80-3;UI82K0T627;KSMAGQUYOIHWFS-UHFFFAOYSA-N;CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl;25913;26;336;263;0;1;2;3;16;4;Approved;2018;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;4;Approved;1120716949/unspecified;30000984, 31791720, 30724094
219;lofexidine;lofexidine;CHEMBL17860;DB04948;30668;31036-80-3;UI82K0T627;KSMAGQUYOIHWFS-UHFFFAOYSA-N;CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl;25913;26;336;263;0;1;2;3;16;4;Approved;2018;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.Z;Disorders due to use of opioids, unspecified;4;Approved;111507461/unspecified;30000984, 31791720, 30724094
219;lofexidine;lofexidine;CHEMBL17860;DB04948;30668;31036-80-3;UI82K0T627;KSMAGQUYOIHWFS-UHFFFAOYSA-N;CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl;25913;26;336;263;0;1;2;3;16;4;Approved;2018;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;4;Approved;2143971168/unspecified;30000984, 31791720, 30724094
219;lofexidine;lofexidine;CHEMBL17860;DB04948;30668;31036-80-3;UI82K0T627;KSMAGQUYOIHWFS-UHFFFAOYSA-N;CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl;25913;26;336;263;0;1;2;3;16;4;Approved;2018;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;4;Approved;219731531/unspecified;30000984, 31791720, 30724094
219;lofexidine;lofexidine;CHEMBL17860;DB04948;30668;31036-80-3;UI82K0T627;KSMAGQUYOIHWFS-UHFFFAOYSA-N;CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl;25913;26;336;263;0;1;2;3;16;4;Approved;2018;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;30000984, 31791720, 30724094
219;lofexidine;lofexidine;CHEMBL17860;DB04948;30668;31036-80-3;UI82K0T627;KSMAGQUYOIHWFS-UHFFFAOYSA-N;CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl;25913;26;336;263;0;1;2;3;16;4;Approved;2018;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;4;Approved;1120716949/unspecified;30000984, 31791720, 30724094
219;lofexidine;lofexidine;CHEMBL17860;DB04948;30668;31036-80-3;UI82K0T627;KSMAGQUYOIHWFS-UHFFFAOYSA-N;CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl;25913;26;336;263;0;1;2;3;16;4;Approved;2018;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.Z;Disorders due to use of opioids, unspecified;4;Approved;111507461/unspecified;30000984, 31791720, 30724094
219;lofexidine;lofexidine;CHEMBL17860;DB04948;30668;31036-80-3;UI82K0T627;KSMAGQUYOIHWFS-UHFFFAOYSA-N;CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl;25913;26;336;263;0;1;2;3;16;4;Approved;2018;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;4;Approved;2143971168/unspecified;30000984, 31791720, 30724094
219;lofexidine;lofexidine;CHEMBL17860;DB04948;30668;31036-80-3;UI82K0T627;KSMAGQUYOIHWFS-UHFFFAOYSA-N;CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl;25913;26;336;263;0;1;2;3;16;4;Approved;2018;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;4;Approved;219731531/unspecified;30000984, 31791720, 30724094
219;lofexidine;lofexidine;CHEMBL17860;DB04948;30668;31036-80-3;UI82K0T627;KSMAGQUYOIHWFS-UHFFFAOYSA-N;CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl;25913;26;336;263;0;1;2;3;16;4;Approved;2018;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;30000984, 31791720, 30724094
219;lofexidine;lofexidine;CHEMBL17860;DB04948;30668;31036-80-3;UI82K0T627;KSMAGQUYOIHWFS-UHFFFAOYSA-N;CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl;25913;26;336;263;0;1;2;3;16;4;Approved;2018;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;4;Approved;1120716949/unspecified;30000984, 31791720, 30724094
219;lofexidine;lofexidine;CHEMBL17860;DB04948;30668;31036-80-3;UI82K0T627;KSMAGQUYOIHWFS-UHFFFAOYSA-N;CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl;25913;26;336;263;0;1;2;3;16;4;Approved;2018;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.Z;Disorders due to use of opioids, unspecified;4;Approved;111507461/unspecified;30000984, 31791720, 30724094
219;lofexidine;lofexidine;CHEMBL17860;DB04948;30668;31036-80-3;UI82K0T627;KSMAGQUYOIHWFS-UHFFFAOYSA-N;CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl;25913;26;336;263;0;1;2;3;16;4;Approved;2018;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;4;Approved;2143971168/unspecified;30000984, 31791720, 30724094
219;lofexidine;lofexidine;CHEMBL17860;DB04948;30668;31036-80-3;UI82K0T627;KSMAGQUYOIHWFS-UHFFFAOYSA-N;CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl;25913;26;336;263;0;1;2;3;16;4;Approved;2018;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;4;Approved;219731531/unspecified;30000984, 31791720, 30724094
220;blonanserin;blonanserin;CHEMBL178803;DB09223;125564;132810-10-7;AQ316B4F8C;XVGOZDAJGBALKS-UHFFFAOYSA-N;CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(C=C4)F;3675;55;194;443;0;0;4;3;27;4;Approved;2008;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;34493318, 37189270, 23131856
220;blonanserin;blonanserin;CHEMBL178803;DB09223;125564;132810-10-7;AQ316B4F8C;XVGOZDAJGBALKS-UHFFFAOYSA-N;CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(C=C4)F;3675;55;194;443;0;0;4;3;27;4;Approved;2008;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;34493318, 37189270, 23131856
220;blonanserin;blonanserin;CHEMBL178803;DB09223;125564;132810-10-7;AQ316B4F8C;XVGOZDAJGBALKS-UHFFFAOYSA-N;CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(C=C4)F;3675;55;194;443;0;0;4;3;27;4;Approved;2008;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;34493318, 37189270, 23131856
221;ranitidine;ranitidine;CHEMBL1790041;DB00863;5039;NA;NA;VMXUWOKSQNHOCA-UHFFFAOYSA-N;CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C;31441;3;112;347;0;2;7;9;21;4;Approved;1983;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A01.34;Hyperimmunoglobulin E syndromes;2;Inactive;223461798;30000311, 30422583, 31644174
221;ranitidine;ranitidine;CHEMBL1790041;DB00863;5039;NA;NA;VMXUWOKSQNHOCA-UHFFFAOYSA-N;CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C;31441;3;112;347;0;2;7;9;21;4;Approved;1983;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;30000311, 30422583, 31644174
221;ranitidine;ranitidine;CHEMBL1790041;DB00863;5039;NA;NA;VMXUWOKSQNHOCA-UHFFFAOYSA-N;CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C;31441;3;112;347;0;2;7;9;21;4;Approved;1983;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA60;Gastric ulcer;4;Approved;1437411258;30000311, 30422583, 31644174
221;ranitidine;ranitidine;CHEMBL1790041;DB00863;5039;NA;NA;VMXUWOKSQNHOCA-UHFFFAOYSA-N;CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C;31441;3;112;347;0;2;7;9;21;4;Approved;1983;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA60.Z;Gastric ulcer, unspecified;4;Approved;1437411258/unspecified;30000311, 30422583, 31644174
221;ranitidine;ranitidine;CHEMBL1790041;DB00863;5039;NA;NA;VMXUWOKSQNHOCA-UHFFFAOYSA-N;CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C;31441;3;112;347;0;2;7;9;21;4;Approved;1983;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;30000311, 30422583, 31644174
221;ranitidine;ranitidine;CHEMBL1790041;DB00863;5039;NA;NA;VMXUWOKSQNHOCA-UHFFFAOYSA-N;CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C;31441;3;112;347;0;2;7;9;21;4;Approved;1983;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA63.Z;Duodenal ulcer, unspecified;4;Approved;553678663/unspecified;30000311, 30422583, 31644174
222;relugolix;relugolix;CHEMBL1800159;DB11853;10348973;737789-87-6;P76B05O5V6;AOMXMOCNKJTRQP-UHFFFAOYSA-N;CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC;6236;32;158;1010;0;2;11;9;44;4;Approved;2020;Small molecule;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.0;Adenocarcinoma of prostate;4;Approved;1510677183;33596357, 32469183, 36331779
222;relugolix;relugolix;CHEMBL1800159;DB11853;10348973;737789-87-6;P76B05O5V6;AOMXMOCNKJTRQP-UHFFFAOYSA-N;CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC;6236;32;158;1010;0;2;11;9;44;4;Approved;2020;Small molecule;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;4;Approved;1552457716/unspecified;33596357, 32469183, 36331779
222;relugolix;relugolix;CHEMBL1800159;DB11853;10348973;737789-87-6;P76B05O5V6;AOMXMOCNKJTRQP-UHFFFAOYSA-N;CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC;6236;32;158;1010;0;2;11;9;44;4;Approved;2020;Small molecule;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2E86.0;Leiomyoma of uterus;3;Inactive;455734276;33596357, 32469183, 36331779
222;relugolix;relugolix;CHEMBL1800159;DB11853;10348973;737789-87-6;P76B05O5V6;AOMXMOCNKJTRQP-UHFFFAOYSA-N;CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC;6236;32;158;1010;0;2;11;9;44;4;Approved;2020;Small molecule;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA10.Z;Endometriosis of unspecified site;3;Active;1838213761/unspecified;33596357, 32469183, 36331779
222;relugolix;relugolix;CHEMBL1800159;DB11853;10348973;737789-87-6;P76B05O5V6;AOMXMOCNKJTRQP-UHFFFAOYSA-N;CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC;6236;32;158;1010;0;2;11;9;44;4;Approved;2020;Small molecule;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;33596357, 32469183, 36331779
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.2Z;Macro reentrant atrial tachycardia, unspecified;4;Approved;337572245/unspecified;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;4;Approved;171698302/unspecified;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;3;Inactive;2136808878;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.2Z;Macro reentrant atrial tachycardia, unspecified;4;Approved;337572245/unspecified;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;4;Approved;171698302/unspecified;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;3;Inactive;2136808878;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.2Z;Macro reentrant atrial tachycardia, unspecified;4;Approved;337572245/unspecified;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;4;Approved;171698302/unspecified;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;3;Inactive;2136808878;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.2Z;Macro reentrant atrial tachycardia, unspecified;4;Approved;337572245/unspecified;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;4;Approved;171698302/unspecified;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;3;Inactive;2136808878;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.2Z;Macro reentrant atrial tachycardia, unspecified;4;Approved;337572245/unspecified;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;4;Approved;171698302/unspecified;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;3;Inactive;2136808878;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.2Z;Macro reentrant atrial tachycardia, unspecified;4;Approved;337572245/unspecified;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;4;Approved;171698302/unspecified;31643533, 21431100, 19678715
224;dronedarone;dronedarone;CHEMBL184412;DB04855;208898;141626-36-0;JQZ1L091Y2;ZQTNQVWKHCQYLQ-UHFFFAOYSA-N;CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC;5568;72;972;800;0;1;7;18;39;4;Approved;2009;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;3;Inactive;2136808878;31643533, 21431100, 19678715
225;plerixafor;plerixafor;CHEMBL18442;DB06809;65015;110078-46-1;S915P5499N;YIQPUIGJQJDJOS-UHFFFAOYSA-N;C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3;5028;0;787;456;0;6;8;4;36;4;Approved;2008;Small molecule;Partial agonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2A00.00;Glioblastoma of brain;2;Active;650534447;31643772, 25031928, 19180104
225;plerixafor;plerixafor;CHEMBL18442;DB06809;65015;110078-46-1;S915P5499N;YIQPUIGJQJDJOS-UHFFFAOYSA-N;C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3;5028;0;787;456;0;6;8;4;36;4;Approved;2008;Small molecule;Partial agonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2A3Z;Myelodysplastic syndromes, unspecified;2;Inactive;1147802348/unspecified;31643772, 25031928, 19180104
225;plerixafor;plerixafor;CHEMBL18442;DB06809;65015;110078-46-1;S915P5499N;YIQPUIGJQJDJOS-UHFFFAOYSA-N;C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3;5028;0;787;456;0;6;8;4;36;4;Approved;2008;Small molecule;Partial agonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2A60.3Z;Acute myeloid leukaemia, unspecified;2;Inactive;1611980611/unspecified;31643772, 25031928, 19180104
225;plerixafor;plerixafor;CHEMBL18442;DB06809;65015;110078-46-1;S915P5499N;YIQPUIGJQJDJOS-UHFFFAOYSA-N;C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3;5028;0;787;456;0;6;8;4;36;4;Approved;2008;Small molecule;Partial agonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2A61;Acute leukaemias of ambiguous lineage;1;Inactive;1062906118;31643772, 25031928, 19180104
225;plerixafor;plerixafor;CHEMBL18442;DB06809;65015;110078-46-1;S915P5499N;YIQPUIGJQJDJOS-UHFFFAOYSA-N;C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3;5028;0;787;456;0;6;8;4;36;4;Approved;2008;Small molecule;Partial agonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2A82.00;Chronic lymphocytic leukaemia of B-cell type;1;Inactive;1726842351;31643772, 25031928, 19180104
225;plerixafor;plerixafor;CHEMBL18442;DB06809;65015;110078-46-1;S915P5499N;YIQPUIGJQJDJOS-UHFFFAOYSA-N;C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3;5028;0;787;456;0;6;8;4;36;4;Approved;2008;Small molecule;Partial agonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2A83.1;Plasma cell myeloma;4;Approved;526287100;31643772, 25031928, 19180104
225;plerixafor;plerixafor;CHEMBL18442;DB06809;65015;110078-46-1;S915P5499N;YIQPUIGJQJDJOS-UHFFFAOYSA-N;C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3;5028;0;787;456;0;6;8;4;36;4;Approved;2008;Small molecule;Partial agonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2B30.Z;Hodgkin lymphoma, unspecified;2;Inactive;1528863768/unspecified;31643772, 25031928, 19180104
225;plerixafor;plerixafor;CHEMBL18442;DB06809;65015;110078-46-1;S915P5499N;YIQPUIGJQJDJOS-UHFFFAOYSA-N;C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3;5028;0;787;456;0;6;8;4;36;4;Approved;2008;Small molecule;Partial agonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2B33.3;Lymphoid leukaemia, not elsewhere classified;1;Inactive;216388623;31643772, 25031928, 19180104
225;plerixafor;plerixafor;CHEMBL18442;DB06809;65015;110078-46-1;S915P5499N;YIQPUIGJQJDJOS-UHFFFAOYSA-N;C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3;5028;0;787;456;0;6;8;4;36;4;Approved;2008;Small molecule;Partial agonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2B33.4;Leukaemia, unspecified;1;Inactive;1385484871;31643772, 25031928, 19180104
225;plerixafor;plerixafor;CHEMBL18442;DB06809;65015;110078-46-1;S915P5499N;YIQPUIGJQJDJOS-UHFFFAOYSA-N;C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3;5028;0;787;456;0;6;8;4;36;4;Approved;2008;Small molecule;Partial agonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2B33.5;Malignant lymphoma, not elsewhere classified;4;Approved;474972159;31643772, 25031928, 19180104
225;plerixafor;plerixafor;CHEMBL18442;DB06809;65015;110078-46-1;S915P5499N;YIQPUIGJQJDJOS-UHFFFAOYSA-N;C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3;5028;0;787;456;0;6;8;4;36;4;Approved;2008;Small molecule;Partial agonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2D42;Malignant neoplasms of ill-defined sites;2;Unknown;2023965817;31643772, 25031928, 19180104
225;plerixafor;plerixafor;CHEMBL18442;DB06809;65015;110078-46-1;S915P5499N;YIQPUIGJQJDJOS-UHFFFAOYSA-N;C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3;5028;0;787;456;0;6;8;4;36;4;Approved;2008;Small molecule;Partial agonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;3A50.Z;Thalassaemias, unspecified;2;Inactive;330259189/unspecified;31643772, 25031928, 19180104
225;plerixafor;plerixafor;CHEMBL18442;DB06809;65015;110078-46-1;S915P5499N;YIQPUIGJQJDJOS-UHFFFAOYSA-N;C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3;5028;0;787;456;0;6;8;4;36;4;Approved;2008;Small molecule;Partial agonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;3C0Z;Diseases of the blood or blood-forming organs, unspecified;2;Active;1766440644/unspecified;31643772, 25031928, 19180104
225;plerixafor;plerixafor;CHEMBL18442;DB06809;65015;110078-46-1;S915P5499N;YIQPUIGJQJDJOS-UHFFFAOYSA-N;C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3;5028;0;787;456;0;6;8;4;36;4;Approved;2008;Small molecule;Partial agonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;4B00.0Z;Neutropaenia, unspecified;1;Inactive;926492960/unspecified;31643772, 25031928, 19180104
225;plerixafor;plerixafor;CHEMBL18442;DB06809;65015;110078-46-1;S915P5499N;YIQPUIGJQJDJOS-UHFFFAOYSA-N;C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3;5028;0;787;456;0;6;8;4;36;4;Approved;2008;Small molecule;Partial agonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;5A10;Type 1 diabetes mellitus;2;Active;1651053999;31643772, 25031928, 19180104
225;plerixafor;plerixafor;CHEMBL18442;DB06809;65015;110078-46-1;S915P5499N;YIQPUIGJQJDJOS-UHFFFAOYSA-N;C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3;5028;0;787;456;0;6;8;4;36;4;Approved;2008;Small molecule;Partial agonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;BD54;Diabetic foot ulcer;1;Unknown;74527684;31643772, 25031928, 19180104
226;trospium;trospium;CHEMBL1888176;DB00209;5284632;47608-32-2;T4Y8ORK057;OYYDSUSKLWTMMQ-AIZNXBIQSA-N;C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O;3925;44;465;553;1;1;3;5;29;4;Approved;2004;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;3;Active;1683919430/unspecified;31644086, 36414626, 35552528
226;trospium;trospium;CHEMBL1888176;DB00209;5284632;47608-32-2;T4Y8ORK057;OYYDSUSKLWTMMQ-AIZNXBIQSA-N;C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O;3925;44;465;553;1;1;3;5;29;4;Approved;2004;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;2;Inactive;133207228/unspecified;31644086, 36414626, 35552528
226;trospium;trospium;CHEMBL1888176;DB00209;5284632;47608-32-2;T4Y8ORK057;OYYDSUSKLWTMMQ-AIZNXBIQSA-N;C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O;3925;44;465;553;1;1;3;5;29;4;Approved;2004;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;31644086, 36414626, 35552528
226;trospium;trospium;CHEMBL1888176;DB00209;5284632;47608-32-2;T4Y8ORK057;OYYDSUSKLWTMMQ-AIZNXBIQSA-N;C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O;3925;44;465;553;1;1;3;5;29;4;Approved;2004;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;31644086, 36414626, 35552528
226;trospium;trospium;CHEMBL1888176;DB00209;5284632;47608-32-2;T4Y8ORK057;OYYDSUSKLWTMMQ-AIZNXBIQSA-N;C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O;3925;44;465;553;1;1;3;5;29;4;Approved;2004;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;3;Active;1683919430/unspecified;31644086, 36414626, 35552528
226;trospium;trospium;CHEMBL1888176;DB00209;5284632;47608-32-2;T4Y8ORK057;OYYDSUSKLWTMMQ-AIZNXBIQSA-N;C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O;3925;44;465;553;1;1;3;5;29;4;Approved;2004;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;2;Inactive;133207228/unspecified;31644086, 36414626, 35552528
226;trospium;trospium;CHEMBL1888176;DB00209;5284632;47608-32-2;T4Y8ORK057;OYYDSUSKLWTMMQ-AIZNXBIQSA-N;C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O;3925;44;465;553;1;1;3;5;29;4;Approved;2004;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;31644086, 36414626, 35552528
226;trospium;trospium;CHEMBL1888176;DB00209;5284632;47608-32-2;T4Y8ORK057;OYYDSUSKLWTMMQ-AIZNXBIQSA-N;C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O;3925;44;465;553;1;1;3;5;29;4;Approved;2004;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;31644086, 36414626, 35552528
226;trospium;trospium;CHEMBL1888176;DB00209;5284632;47608-32-2;T4Y8ORK057;OYYDSUSKLWTMMQ-AIZNXBIQSA-N;C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O;3925;44;465;553;1;1;3;5;29;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;3;Active;1683919430/unspecified;31644086, 36414626, 35552528
226;trospium;trospium;CHEMBL1888176;DB00209;5284632;47608-32-2;T4Y8ORK057;OYYDSUSKLWTMMQ-AIZNXBIQSA-N;C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O;3925;44;465;553;1;1;3;5;29;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;2;Inactive;133207228/unspecified;31644086, 36414626, 35552528
226;trospium;trospium;CHEMBL1888176;DB00209;5284632;47608-32-2;T4Y8ORK057;OYYDSUSKLWTMMQ-AIZNXBIQSA-N;C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O;3925;44;465;553;1;1;3;5;29;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;31644086, 36414626, 35552528
226;trospium;trospium;CHEMBL1888176;DB00209;5284632;47608-32-2;T4Y8ORK057;OYYDSUSKLWTMMQ-AIZNXBIQSA-N;C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O;3925;44;465;553;1;1;3;5;29;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;31644086, 36414626, 35552528
227;ladarixin;ladarixin;CHEMBL189475;NA;11372270;"849776-05-2;849776-05-2 (free)";NA;DDLPYOCJHQSVSZ-SSDOTTSWSA-N;CC(C1=CC=C(C=C1)OS(=O)(=O)C(F)(F)F)C(=O)NS(=O)(=O)C;3753;2;123;624;0;1;9;5;23;3;Active;NA;Small molecule;PAM;P25024;cxcr1_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;5A10;Type 1 diabetes mellitus;3;Active;1651053999;36385556, 33123138, 35589610
227;ladarixin;ladarixin;CHEMBL189475;NA;11372270;"849776-05-2;849776-05-2 (free)";NA;DDLPYOCJHQSVSZ-SSDOTTSWSA-N;CC(C1=CC=C(C=C1)OS(=O)(=O)C(F)(F)F)C(=O)NS(=O)(=O)C;3753;2;123;624;0;1;9;5;23;3;Active;NA;Small molecule;PAM;P25024;cxcr1_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;EB41.0;Bullous pemphigoid;2;Inactive;233308710;36385556, 33123138, 35589610
227;ladarixin;ladarixin;CHEMBL189475;NA;11372270;"849776-05-2;849776-05-2 (free)";NA;DDLPYOCJHQSVSZ-SSDOTTSWSA-N;CC(C1=CC=C(C=C1)OS(=O)(=O)C(F)(F)F)C(=O)NS(=O)(=O)C;3753;2;123;624;0;1;9;5;23;3;Active;NA;Small molecule;PAM;P25025;cxcr2_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;5A10;Type 1 diabetes mellitus;3;Active;1651053999;36385556, 33123138, 35589610
227;ladarixin;ladarixin;CHEMBL189475;NA;11372270;"849776-05-2;849776-05-2 (free)";NA;DDLPYOCJHQSVSZ-SSDOTTSWSA-N;CC(C1=CC=C(C=C1)OS(=O)(=O)C(F)(F)F)C(=O)NS(=O)(=O)C;3753;2;123;624;0;1;9;5;23;3;Active;NA;Small molecule;PAM;P25025;cxcr2_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;EB41.0;Bullous pemphigoid;2;Inactive;233308710;36385556, 33123138, 35589610
228;trimebutine;trimebutine;CHEMBL190044;DB09089;5573;39133-31-8;QZ1OJ92E5R;LORDFXWUHHSAQU-UHFFFAOYSA-N;CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;3875;4;572;466;0;0;6;10;28;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;31617696, 34517011, 29977208
228;trimebutine;trimebutine;CHEMBL190044;DB09089;5573;39133-31-8;QZ1OJ92E5R;LORDFXWUHHSAQU-UHFFFAOYSA-N;CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;3875;4;572;466;0;0;6;10;28;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;ME05.0;Constipation;4;Approved;502284069;31617696, 34517011, 29977208
228;trimebutine;trimebutine;CHEMBL190044;DB09089;5573;39133-31-8;QZ1OJ92E5R;LORDFXWUHHSAQU-UHFFFAOYSA-N;CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;3875;4;572;466;0;0;6;10;28;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;ME05.1;Diarrhoea;4;Approved;116759077;31617696, 34517011, 29977208
228;trimebutine;trimebutine;CHEMBL190044;DB09089;5573;39133-31-8;QZ1OJ92E5R;LORDFXWUHHSAQU-UHFFFAOYSA-N;CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;3875;4;572;466;0;0;6;10;28;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;31617696, 34517011, 29977208
228;trimebutine;trimebutine;CHEMBL190044;DB09089;5573;39133-31-8;QZ1OJ92E5R;LORDFXWUHHSAQU-UHFFFAOYSA-N;CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;3875;4;572;466;0;0;6;10;28;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;ME05.0;Constipation;4;Approved;502284069;31617696, 34517011, 29977208
228;trimebutine;trimebutine;CHEMBL190044;DB09089;5573;39133-31-8;QZ1OJ92E5R;LORDFXWUHHSAQU-UHFFFAOYSA-N;CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;3875;4;572;466;0;0;6;10;28;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;ME05.1;Diarrhoea;4;Approved;116759077;31617696, 34517011, 29977208
228;trimebutine;trimebutine;CHEMBL190044;DB09089;5573;39133-31-8;QZ1OJ92E5R;LORDFXWUHHSAQU-UHFFFAOYSA-N;CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;3875;4;572;466;0;0;6;10;28;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;31617696, 34517011, 29977208
228;trimebutine;trimebutine;CHEMBL190044;DB09089;5573;39133-31-8;QZ1OJ92E5R;LORDFXWUHHSAQU-UHFFFAOYSA-N;CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;3875;4;572;466;0;0;6;10;28;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;ME05.0;Constipation;4;Approved;502284069;31617696, 34517011, 29977208
228;trimebutine;trimebutine;CHEMBL190044;DB09089;5573;39133-31-8;QZ1OJ92E5R;LORDFXWUHHSAQU-UHFFFAOYSA-N;CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;3875;4;572;466;0;0;6;10;28;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;ME05.1;Diarrhoea;4;Approved;116759077;31617696, 34517011, 29977208
228;trimebutine;trimebutine;CHEMBL190044;DB09089;5573;39133-31-8;QZ1OJ92E5R;LORDFXWUHHSAQU-UHFFFAOYSA-N;CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;3875;4;572;466;0;0;6;10;28;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;31617696, 34517011, 29977208
228;trimebutine;trimebutine;CHEMBL190044;DB09089;5573;39133-31-8;QZ1OJ92E5R;LORDFXWUHHSAQU-UHFFFAOYSA-N;CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;3875;4;572;466;0;0;6;10;28;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;ME05.0;Constipation;4;Approved;502284069;31617696, 34517011, 29977208
228;trimebutine;trimebutine;CHEMBL190044;DB09089;5573;39133-31-8;QZ1OJ92E5R;LORDFXWUHHSAQU-UHFFFAOYSA-N;CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;3875;4;572;466;0;0;6;10;28;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;ME05.1;Diarrhoea;4;Approved;116759077;31617696, 34517011, 29977208
228;trimebutine;trimebutine;CHEMBL190044;DB09089;5573;39133-31-8;QZ1OJ92E5R;LORDFXWUHHSAQU-UHFFFAOYSA-N;CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;3875;4;572;466;0;0;6;10;28;4;Approved;1979;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;31617696, 34517011, 29977208
228;trimebutine;trimebutine;CHEMBL190044;DB09089;5573;39133-31-8;QZ1OJ92E5R;LORDFXWUHHSAQU-UHFFFAOYSA-N;CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;3875;4;572;466;0;0;6;10;28;4;Approved;1979;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME05.0;Constipation;4;Approved;502284069;31617696, 34517011, 29977208
228;trimebutine;trimebutine;CHEMBL190044;DB09089;5573;39133-31-8;QZ1OJ92E5R;LORDFXWUHHSAQU-UHFFFAOYSA-N;CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;3875;4;572;466;0;0;6;10;28;4;Approved;1979;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME05.1;Diarrhoea;4;Approved;116759077;31617696, 34517011, 29977208
229;tiotropium;tiotropium;CHEMBL1900528;DB01409;5487427;186691-13-4;0EB439235F;LERNTVKEWCAPOY-FPISHFTHSA-N;C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C;3925;23;116;564;1;1;6;5;26;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;31082171, 30000544, 28877027
229;tiotropium;tiotropium;CHEMBL1900528;DB01409;5487427;186691-13-4;0EB439235F;LERNTVKEWCAPOY-FPISHFTHSA-N;C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C;3925;23;116;564;1;1;6;5;26;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;31082171, 30000544, 28877027
229;tiotropium;tiotropium;CHEMBL1900528;DB01409;5487427;186691-13-4;0EB439235F;LERNTVKEWCAPOY-FPISHFTHSA-N;C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C;3925;23;116;564;1;1;6;5;26;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;31082171, 30000544, 28877027
229;tiotropium;tiotropium;CHEMBL1900528;DB01409;5487427;186691-13-4;0EB439235F;LERNTVKEWCAPOY-FPISHFTHSA-N;C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C;3925;23;116;564;1;1;6;5;26;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA23;Asthma;4;Approved;1656445230;31082171, 30000544, 28877027
229;tiotropium;tiotropium;CHEMBL1900528;DB01409;5487427;186691-13-4;0EB439235F;LERNTVKEWCAPOY-FPISHFTHSA-N;C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C;3925;23;116;564;1;1;6;5;26;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA25.Z;Cystic fibrosis, unspecified;2;Unknown;514403112/unspecified;31082171, 30000544, 28877027
229;tiotropium;tiotropium;CHEMBL1900528;DB01409;5487427;186691-13-4;0EB439235F;LERNTVKEWCAPOY-FPISHFTHSA-N;C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C;3925;23;116;564;1;1;6;5;26;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;31082171, 30000544, 28877027
229;tiotropium;tiotropium;CHEMBL1900528;DB01409;5487427;186691-13-4;0EB439235F;LERNTVKEWCAPOY-FPISHFTHSA-N;C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C;3925;23;116;564;1;1;6;5;26;4;Approved;2004;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;ND51.2;Injury of spinal cord, level unspecified;2;Inactive;2131180445;31082171, 30000544, 28877027
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;5B81.Z;Obesity, unspecified;3;Active;149403041/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Unknown;437815624/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A7Z;Depressive disorders, unspecified;3;Active;1563440232/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6B8Z;Feeding or eating disorders, unspecified;3;Active;1412387537/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C40.1Z;Harmful pattern of use of alcohol, unspecified;4;Approved;714690795/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;4;Approved;1120716949/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;4;Approved;111507461/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Active;2016549355/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4A.2Z;Nicotine dependence, unspecified;3;Inactive;1699574100/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C50.Z;Gambling disorder, unspecified;3;Active;1041487064/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6D10.Z;Personality disorder, severity unspecified;3;Inactive;941859884/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8A80.Z;Migraine, unspecified;3;Inactive;669367341/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8C03.0;Diabetic polyneuropathy;2;Active;1837670870;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8C21.Z;Hereditary sensory or autonomic neuropathy, unspecified;3;Active;1091217288/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;9A1Y;Other specified disorders of lacrimal apparatus;2;Inactive;1628710366/other;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DD70.Z;Crohn disease, unspecified site;2;Inactive;1267652425/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;EA90.Z;Psoriasis of unspecified type;1;Inactive;63698555/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MB29.1;Binge eating;3;Active;1535148777;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;2;Inactive;1815305992/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG22;Fatigue;2;Active;1109546957;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.01;Chronic widespread pain;3;Active;849253504;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;3;Inactive;1581976053/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;5B81.Z;Obesity, unspecified;3;Active;149403041/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Unknown;437815624/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A7Z;Depressive disorders, unspecified;3;Active;1563440232/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6B8Z;Feeding or eating disorders, unspecified;3;Active;1412387537/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C40.1Z;Harmful pattern of use of alcohol, unspecified;4;Approved;714690795/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;4;Approved;1120716949/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;4;Approved;111507461/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Active;2016549355/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4A.2Z;Nicotine dependence, unspecified;3;Inactive;1699574100/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C50.Z;Gambling disorder, unspecified;3;Active;1041487064/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6D10.Z;Personality disorder, severity unspecified;3;Inactive;941859884/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8A80.Z;Migraine, unspecified;3;Inactive;669367341/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8C03.0;Diabetic polyneuropathy;2;Active;1837670870;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8C21.Z;Hereditary sensory or autonomic neuropathy, unspecified;3;Active;1091217288/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;9A1Y;Other specified disorders of lacrimal apparatus;2;Inactive;1628710366/other;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DD70.Z;Crohn disease, unspecified site;2;Inactive;1267652425/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;EA90.Z;Psoriasis of unspecified type;1;Inactive;63698555/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MB29.1;Binge eating;3;Active;1535148777;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;2;Inactive;1815305992/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG22;Fatigue;2;Active;1109546957;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.01;Chronic widespread pain;3;Active;849253504;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;3;Inactive;1581976053/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;5B81.Z;Obesity, unspecified;3;Active;149403041/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Unknown;437815624/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A7Z;Depressive disorders, unspecified;3;Active;1563440232/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6B8Z;Feeding or eating disorders, unspecified;3;Active;1412387537/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C40.1Z;Harmful pattern of use of alcohol, unspecified;4;Approved;714690795/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;4;Approved;1120716949/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;4;Approved;111507461/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Active;2016549355/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4A.2Z;Nicotine dependence, unspecified;3;Inactive;1699574100/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C50.Z;Gambling disorder, unspecified;3;Active;1041487064/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6D10.Z;Personality disorder, severity unspecified;3;Inactive;941859884/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8A80.Z;Migraine, unspecified;3;Inactive;669367341/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8C03.0;Diabetic polyneuropathy;2;Active;1837670870;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8C21.Z;Hereditary sensory or autonomic neuropathy, unspecified;3;Active;1091217288/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;9A1Y;Other specified disorders of lacrimal apparatus;2;Inactive;1628710366/other;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DD70.Z;Crohn disease, unspecified site;2;Inactive;1267652425/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;EA90.Z;Psoriasis of unspecified type;1;Inactive;63698555/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MB29.1;Binge eating;3;Active;1535148777;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;2;Inactive;1815305992/unspecified;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG22;Fatigue;2;Active;1109546957;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.01;Chronic widespread pain;3;Active;849253504;29117992, 33497547, 28325149
230;naltrexone;naltrexone;CHEMBL19019;DB00704;5360515;16590-41-3;5S6W795CQM;DQCKKXVULJGBQN-XFWGSAIBSA-N;C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O;3414;19;70;621;0;2;5;2;25;4;Approved;1984;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;3;Inactive;1581976053/unspecified;29117992, 33497547, 28325149
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;4B24.0;Acute graft-versus-host disease;2;Unknown;83784921;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;4B24.Z;Graft-versus-host disease, unspecified;2;Unknown;437372167/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Active;437815624/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6A20.Z;Schizophrenia, episode unspecified;2;Active;1683919430/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Active;1582741816/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6B40;Post traumatic stress disorder;2;Active;2070699808;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6B80.Z;Anorexia Nervosa, unspecified;1;Active;263852475/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C41.2Z;Cannabis dependence, unspecified;2;Active;1129015467/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C43.2Z;Opioid dependence, unspecified;2;Active;1120716949/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C43.Z;Disorders due to use of opioids, unspecified;2;Active;111507461/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C4A.2Z;Nicotine dependence, unspecified;1;Active;1699574100/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;1;Active;2143971168/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;7A0Z;Insomnia disorders, unspecified;2;Active;1038292737/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;7B2Z;Sleep-wake disorders, unspecified;2;Active;274880002/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A00.0Z;Parkinson disease, unspecified;2;Active;296066191/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A01.10;Huntington disease;2;Inactive;2132180242;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A04.1;Essential tremor or related tremors;2;Inactive;1036027657;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A05.00;Tourette syndrome;2;Active;119340957;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A61.11;Dravet syndrome;4;Approved;1255654700;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A62.0;Infantile spasms;3;Inactive;1023597213;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A62.1;Lennox-Gastaut syndrome;4;Approved;651135242;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A66.Z;Status epilepticus, unspecified;4;Approved;906174792/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A80.Z;Migraine, unspecified;2;Active;669367341/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8B60.0;Amyotrophic lateral sclerosis;3;Active;1982355687;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8C0Z;Polyneuropathy, unspecified;2;Unknown;58868923/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8E43.0Z;Neuropathic pain, unspecified;2;Active;1339785363/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;BA00.Z;Essential hypertension, unspecified;1;Active;761947693/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;BC42.Z;Myocarditis, unspecified;2;Active;1018829714/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;BD1Z;Heart failure, unspecified;1;Unknown;1458683894/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;DA0A.Y;Other specified disorders of teeth and supporting structures;2;Active;1767358557/other;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;DB92.Y;Other specified non-alcoholic fatty liver disease;2;Unknown;1912806631/other;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;DB96.0;Autoimmune hepatitis;2;Inactive;1235727122;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;DD70.Z;Crohn disease, unspecified site;2;Inactive;1267652425/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;DD71.Z;Ulcerative colitis, unspecified;2;Inactive;784669405/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;FB83.0Z;Osteopenia, unspecified;1;Active;611604654/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;GC00.3;Interstitial cystitis;1;Unknown;1650709285;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;LD23;Syndromes with vascular anomalies as a major feature;2;Active;1648590821;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;LD2D.2;Tuberous sclerosis;4;Approved;1903085809;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;LD55;Fragile X chromosome;3;Active;1524287677;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;LD90.4;Rett syndrome;3;Inactive;201200685;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MB24.3;Anxiety;2;Active;2027043655;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MG30.01;Chronic widespread pain;3;Active;849253504;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MG30.Z;Chronic pain, unspecified;3;Active;1581976053/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;32096470, 33221931, 31161980
231;cannabidiol;cannabidiol;CHEMBL190461;DB09061;644019;13956-29-1;19GBJ60SN5;QHMBSVQNZZTUGM-ZWKOTPCHSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O;3145;65;405;414;0;2;2;6;23;4;Approved;2018;Small molecule;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;RA01;COVID-19;2;Unknown;1730556128;32096470, 33221931, 31161980
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;1C62.Z;Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified;2;Inactive;1508081745/unspecified;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;1D65;Severe acute respiratory syndrome;3;Active;652944603;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;2A00.00;Glioblastoma of brain;3;Inactive;650534447;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;2B51.Z;Osteosarcoma of bone or articular cartilage of unspecified sites;1;Active;1210287093/unspecified;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;2C10.0;Adenocarcinoma of pancreas;2;Unknown;1663659989;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;2C10.Y;Other specified malignant neoplasms of pancreas;2;Active;542147910/other;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Active;1047754165/unspecified;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;3A51.1;Sickle cell disease without crisis;2;Inactive;1711513381;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BB01.Z;Pulmonary hypertension, unspecified;3;Inactive;1496633964/unspecified;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BC43.1Z;Hypertrophic cardiomyopathy, unspecified;2;Inactive;1830681485/unspecified;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BD1Z;Heart failure, unspecified;3;Inactive;1458683894/unspecified;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BD5Z;Diseases of arteries or arterioles, unspecified;1;Inactive;1164983645/unspecified;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;CA25.Z;Cystic fibrosis, unspecified;2;Active;514403112/unspecified;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;CB00;Acute respiratory distress syndrome;2;Inactive;1189702844;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;DA24.1;Eosinophilic oesophagitis;2;Inactive;21063503;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;FA01.Z;Osteoarthritis of knee, unspecified;2;Active;1685726407/unspecified;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;FB32.Y;Other specified disorders of muscles;2;Inactive;2052707382/other;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;GB40;Nephritic syndrome;3;Inactive;1783829886;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;GB61.Z;Chronic kidney disease, stage unspecified;4;Approved;412389819/unspecified;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;JA24.Z;Pre-eclampsia, unspecified;1;Active;229121159/unspecified;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;LD28.01;Marfan syndrome;3;Inactive;236564145;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;MF96.Z;Proteinuria, unspecified;4;Approved;930895737/unspecified;26051686, 16029066, 30252321
232;losartan;losartan;CHEMBL191;DB00678;3961;114798-26-4;JMS50MPO89;PSIFNNKUMBGKDQ-UHFFFAOYSA-N;CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl;4229;43;925;520;0;2;5;8;30;4;Approved;1995;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;RA01;COVID-19;3;Active;1730556128;26051686, 16029066, 30252321
233;reparixin;reparixin;CHEMBL191413;DB12614;9838712;"266359-83-5;266359-83-5 (free base)";NA;KQDRVXQXKZXMHP-LLVKDONJSA-N;CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C;28339;29;716;389;0;1;3;5;19;3;Active;NA;Small molecule;NAM;P25024;cxcr1_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;CA40.1Z;Viral pneumonia, unspecified;3;Inactive;1024154490/unspecified;37161521, 35599941, 28415590
233;reparixin;reparixin;CHEMBL191413;DB12614;9838712;"266359-83-5;266359-83-5 (free base)";NA;KQDRVXQXKZXMHP-LLVKDONJSA-N;CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C;28339;29;716;389;0;1;3;5;19;3;Active;NA;Small molecule;NAM;P25024;cxcr1_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;CA40.Z;Pneumonia, organism unspecified;2;Inactive;142052508/unspecified;37161521, 35599941, 28415590
233;reparixin;reparixin;CHEMBL191413;DB12614;9838712;"266359-83-5;266359-83-5 (free base)";NA;KQDRVXQXKZXMHP-LLVKDONJSA-N;CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C;28339;29;716;389;0;1;3;5;19;3;Active;NA;Small molecule;NAM;P25024;cxcr1_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;CB00;Acute respiratory distress syndrome;2;Active;1189702844;37161521, 35599941, 28415590
233;reparixin;reparixin;CHEMBL191413;DB12614;9838712;"266359-83-5;266359-83-5 (free base)";NA;KQDRVXQXKZXMHP-LLVKDONJSA-N;CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C;28339;29;716;389;0;1;3;5;19;3;Active;NA;Small molecule;NAM;P25024;cxcr1_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;NE84;Failure or rejection of transplanted organs or tissues;2;Inactive;129221830;37161521, 35599941, 28415590
233;reparixin;reparixin;CHEMBL191413;DB12614;9838712;"266359-83-5;266359-83-5 (free base)";NA;KQDRVXQXKZXMHP-LLVKDONJSA-N;CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C;28339;29;716;389;0;1;3;5;19;3;Active;NA;Small molecule;NAM;P25024;cxcr1_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;RA01;COVID-19;3;Active;1730556128;37161521, 35599941, 28415590
233;reparixin;reparixin;CHEMBL191413;DB12614;9838712;"266359-83-5;266359-83-5 (free base)";NA;KQDRVXQXKZXMHP-LLVKDONJSA-N;CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C;28339;29;716;389;0;1;3;5;19;3;Active;NA;Small molecule;NAM;P25025;cxcr2_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;CA40.1Z;Viral pneumonia, unspecified;3;Inactive;1024154490/unspecified;37161521, 35599941, 28415590
233;reparixin;reparixin;CHEMBL191413;DB12614;9838712;"266359-83-5;266359-83-5 (free base)";NA;KQDRVXQXKZXMHP-LLVKDONJSA-N;CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C;28339;29;716;389;0;1;3;5;19;3;Active;NA;Small molecule;NAM;P25025;cxcr2_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;CA40.Z;Pneumonia, organism unspecified;2;Inactive;142052508/unspecified;37161521, 35599941, 28415590
233;reparixin;reparixin;CHEMBL191413;DB12614;9838712;"266359-83-5;266359-83-5 (free base)";NA;KQDRVXQXKZXMHP-LLVKDONJSA-N;CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C;28339;29;716;389;0;1;3;5;19;3;Active;NA;Small molecule;NAM;P25025;cxcr2_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;CB00;Acute respiratory distress syndrome;2;Active;1189702844;37161521, 35599941, 28415590
233;reparixin;reparixin;CHEMBL191413;DB12614;9838712;"266359-83-5;266359-83-5 (free base)";NA;KQDRVXQXKZXMHP-LLVKDONJSA-N;CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C;28339;29;716;389;0;1;3;5;19;3;Active;NA;Small molecule;NAM;P25025;cxcr2_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;NE84;Failure or rejection of transplanted organs or tissues;2;Inactive;129221830;37161521, 35599941, 28415590
233;reparixin;reparixin;CHEMBL191413;DB12614;9838712;"266359-83-5;266359-83-5 (free base)";NA;KQDRVXQXKZXMHP-LLVKDONJSA-N;CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C;28339;29;716;389;0;1;3;5;19;3;Active;NA;Small molecule;NAM;P25025;cxcr2_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;RA01;COVID-19;3;Active;1730556128;37161521, 35599941, 28415590
234;aticaprant;aticaprant;CHEMBL1921847;DB12341;44129648;1174130-61-0;NA;ZHPMYDSXGRRERG-DEOSSOPVSA-N;CC1=CC(=CC(=C1)C2CCCN2CC3=CC=C(C=C3)OC4=C(C=C(C=C4)C(=O)N)F)C;4185;5;556;584;0;1;4;6;31;3;Active;NA;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Active;1669279433;35832748, 32894343
234;aticaprant;aticaprant;CHEMBL1921847;DB12341;44129648;1174130-61-0;NA;ZHPMYDSXGRRERG-DEOSSOPVSA-N;CC1=CC(=CC(=C1)C2CCCN2CC3=CC=C(C=C3)OC4=C(C=C(C=C4)C(=O)N)F)C;4185;5;556;584;0;1;4;6;31;3;Active;NA;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A7Y;Other specified depressive disorders;2;Inactive;1563440232/other;35832748, 32894343
234;aticaprant;aticaprant;CHEMBL1921847;DB12341;44129648;1174130-61-0;NA;ZHPMYDSXGRRERG-DEOSSOPVSA-N;CC1=CC(=CC(=C1)C2CCCN2CC3=CC=C(C=C3)OC4=C(C=C(C=C4)C(=O)N)F)C;4185;5;556;584;0;1;4;6;31;3;Active;NA;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;35832748, 32894343
235;moxonidine;moxonidine;CHEMBL19236;DB09242;4810;75438-57-2;CC6X0L40GW;WPNJAUFVNXKLIM-UHFFFAOYSA-N;CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC;24168;6;714;275;0;2;4;3;16;4;Approved;1974;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;11336590, 9282418, 9400904
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;1C1G.Z;Lyme borreliosis, unspecified;1;Active;1600014919/unspecified;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Active;1669279433;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Y;Other specified depressive disorders;2;Active;1563440232/other;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;3;Active;1563440232/unspecified;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;1;Active;1582741816/unspecified;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Active;2070699808;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;2;Active;263852475/unspecified;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C43.Z;Disorders due to use of opioids, unspecified;2;Active;111507461/unspecified;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Active;1691013484/unspecified;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Active;2016549355/unspecified;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Active;1699574100/unspecified;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;1;Active;669367341/unspecified;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.3;Anxiety;1;Inactive;2027043655;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;1;Active;1405405864;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;ME84.2Z;Low back pain, unspecified;2;Active;1815305992/unspecified;36815350, 37161273, 13608992
236;psilocybin;psilocybin;CHEMBL194378;DB11664;10624;520-52-5;NA;QVDSEJDULKLHCG-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O;28425;-16;858;347;0;3;5;5;19;3;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG30.01;Chronic widespread pain;1;Active;849253504;36815350, 37161273, 13608992
237;fimasartan;fimasartan;CHEMBL1951143;DB09279;9870652;247257-48-3;P58222188P;AMEROGPZOLAFBN-UHFFFAOYSA-N;CCCCC1=NC(=C(C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CC(=S)N(C)C)C;5016;35;123;849;0;1;6;9;36;4;Approved;2010;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;27272555, 21740078, 29676941
238;tafluprost;tafluprost;CHEMBL1963683;DB08819;9868491;209860-87-7;1O6WQ6T7G3;WSNODXPBBALQOF-VEJSHDCNSA-N;CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC=C2)(F)F)O)O;4525;45;76;614;0;2;7;13;32;4;Approved;2012;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C61.01;Ocular hypertension;4;Approved;535283437;30000970, 36109465, 21916788
238;tafluprost;tafluprost;CHEMBL1963683;DB08819;9868491;209860-87-7;1O6WQ6T7G3;WSNODXPBBALQOF-VEJSHDCNSA-N;CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC=C2)(F)F)O)O;4525;45;76;614;0;2;7;13;32;4;Approved;2012;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000970, 36109465, 21916788
239;aviptadil;aviptadil;CHEMBL1981592;NA;16132300;NA;NA;VBUWHHLIZKOSMS-RIWXPGAOSA-N;CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)C(CO)NC(=O)C(CC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)O)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CN=CN4)N;33268;-159;1470;7580;0;51;51;115;234;3;Active;NA;Protein;Agonist;P32241;vipr1_human;Class B1 (Secretin);VIP and PACAP receptors;Peptide receptors;CB00;Acute respiratory distress syndrome;2;Active;1189702844;11566015, 34846667, 37348524
239;aviptadil;aviptadil;CHEMBL1981592;NA;16132300;NA;NA;VBUWHHLIZKOSMS-RIWXPGAOSA-N;CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)C(CO)NC(=O)C(CC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)O)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CN=CN4)N;33268;-159;1470;7580;0;51;51;115;234;3;Active;NA;Protein;Agonist;P32241;vipr1_human;Class B1 (Secretin);VIP and PACAP receptors;Peptide receptors;NB32.3Z;Injury of lung, unspecified;3;Inactive;359051131/unspecified;11566015, 34846667, 37348524
239;aviptadil;aviptadil;CHEMBL1981592;NA;16132300;NA;NA;VBUWHHLIZKOSMS-RIWXPGAOSA-N;CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)C(CO)NC(=O)C(CC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)O)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CN=CN4)N;33268;-159;1470;7580;0;51;51;115;234;3;Active;NA;Protein;Agonist;P32241;vipr1_human;Class B1 (Secretin);VIP and PACAP receptors;Peptide receptors;RA01;COVID-19;3;Active;1730556128;11566015, 34846667, 37348524
239;aviptadil;aviptadil;CHEMBL1981592;NA;16132300;NA;NA;VBUWHHLIZKOSMS-RIWXPGAOSA-N;CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)C(CO)NC(=O)C(CC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)O)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CN=CN4)N;33268;-159;1470;7580;0;51;51;115;234;3;Active;NA;Protein;Agonist;P41587;vipr2_human;Class B1 (Secretin);VIP and PACAP receptors;Peptide receptors;CB00;Acute respiratory distress syndrome;2;Active;1189702844;11566015, 34846667, 37348524
239;aviptadil;aviptadil;CHEMBL1981592;NA;16132300;NA;NA;VBUWHHLIZKOSMS-RIWXPGAOSA-N;CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)C(CO)NC(=O)C(CC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)O)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CN=CN4)N;33268;-159;1470;7580;0;51;51;115;234;3;Active;NA;Protein;Agonist;P41587;vipr2_human;Class B1 (Secretin);VIP and PACAP receptors;Peptide receptors;NB32.3Z;Injury of lung, unspecified;3;Inactive;359051131/unspecified;11566015, 34846667, 37348524
239;aviptadil;aviptadil;CHEMBL1981592;NA;16132300;NA;NA;VBUWHHLIZKOSMS-RIWXPGAOSA-N;CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)C(CO)NC(=O)C(CC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)O)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CN=CN4)N;33268;-159;1470;7580;0;51;51;115;234;3;Active;NA;Protein;Agonist;P41587;vipr2_human;Class B1 (Secretin);VIP and PACAP receptors;Peptide receptors;RA01;COVID-19;3;Active;1730556128;11566015, 34846667, 37348524
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.4Z;Alcohol withdrawal, unspecified;2;Active;998231424/unspecified;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Inactive;2016549355/unspecified;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC01.4;Neuromuscular dysfunction of bladder, not elsewhere classified;2;Unknown;590198069;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.3;Anxiety;1;Unknown;2027043655;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;2;Active;1730556128;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.4Z;Alcohol withdrawal, unspecified;2;Active;998231424/unspecified;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Inactive;2016549355/unspecified;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC01.4;Neuromuscular dysfunction of bladder, not elsewhere classified;2;Unknown;590198069;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.3;Anxiety;1;Unknown;2027043655;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;2;Active;1730556128;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.4Z;Alcohol withdrawal, unspecified;2;Active;998231424/unspecified;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Inactive;2016549355/unspecified;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC01.4;Neuromuscular dysfunction of bladder, not elsewhere classified;2;Unknown;590198069;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.3;Anxiety;1;Unknown;2027043655;30000705, 32310419, 31644009
240;prazosin;prazosin;CHEMBL2;DB00457;4893;19216-56-9;XM03YJ541D;IENZQIKPVFGBNW-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC;3834;2;107;544;0;1;8;4;28;4;Approved;1976;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;2;Active;1730556128;30000705, 32310419, 31644009
241;methoxyphenamine;methoxyphenamine;CHEMBL2010507;DB13624;4117;93-30-1;J3Z5SRI26Z;OEHAYUOVELTAPG-UHFFFAOYSA-N;CC(CC1=CC=CC=C1OC)NC;17926;26;213;138;0;1;2;4;13;4;Approved;1949;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD12;Cough;4;Approved;2027526159;30267460, 33068108, 925116
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;3;Active;437815624/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;2;Unknown;1712535455;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;3;Active;437815624/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;2;Unknown;1712535455;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;3;Active;437815624/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;2;Unknown;1712535455;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;3;Active;437815624/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Partial agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;2;Unknown;1712535455;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;3;Active;437815624/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;33012874, 34091867, 29999816
242;cariprazine;cariprazine;CHEMBL2028019;DB06016;11154555;839712-12-8;F6RJL8B278;KPWSJANDNDDRMB-UHFFFAOYSA-N;CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl;4274;43;388;491;0;1;3;5;28;4;Approved;2015;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;2;Unknown;1712535455;33012874, 34091867, 29999816
243;azilsartan medoxomil;azilsartan medoxomil;CHEMBL2028661;DB08822;135409642;863031-21-4;LL0G25K7I2;QJFSABGVXDWMIW-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)OCC6=C(OC(=O)O6)C;5685;49;140;1100;0;1;9;10;42;4;Approved;2011;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;32164965, 22877322, 21971539
244;icatibant;icatibant;CHEMBL2028850;DB06196;6918173;130308-48-4;7PG89G35Q7;QURWXBZNHXJZBE-SKXRKSCCSA-N;C1CCC2C(C1)CC(N2C(=O)C3CC4=CC=CC=C4CN3C(=O)C(CO)NC(=O)C(CC5=CC=CS5)NC(=O)CNC(=O)C6CC(CN6C(=O)C7CCCN7C(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)N)O)C(=O)NC(CCCN=C(N)N)C(=O)O;13045;-64;552;2720;0;15;18;30;92;4;Approved;2011;Protein;Antagonist;P30411;bkrb2_human;Class A (Rhodopsin);Bradykinin receptors;Peptide receptors;4A00.14;Hereditary angioedema;4;Approved;795969334;36940272, 20030426, 20573077
244;icatibant;icatibant;CHEMBL2028850;DB06196;6918173;130308-48-4;7PG89G35Q7;QURWXBZNHXJZBE-SKXRKSCCSA-N;C1CCC2C(C1)CC(N2C(=O)C3CC4=CC=CC=C4CN3C(=O)C(CO)NC(=O)C(CC5=CC=CS5)NC(=O)CNC(=O)C6CC(CN6C(=O)C7CCCN7C(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)N)O)C(=O)NC(CCCN=C(N)N)C(=O)O;13045;-64;552;2720;0;15;18;30;92;4;Approved;2011;Protein;Antagonist;P30411;bkrb2_human;Class A (Rhodopsin);Bradykinin receptors;Peptide receptors;MG3Z;Pain, unspecified;2;Unknown;661232217/unspecified;36940272, 20030426, 20573077
244;icatibant;icatibant;CHEMBL2028850;DB06196;6918173;130308-48-4;7PG89G35Q7;QURWXBZNHXJZBE-SKXRKSCCSA-N;C1CCC2C(C1)CC(N2C(=O)C3CC4=CC=CC=C4CN3C(=O)C(CO)NC(=O)C(CC5=CC=CS5)NC(=O)CNC(=O)C6CC(CN6C(=O)C7CCCN7C(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)N)O)C(=O)NC(CCCN=C(N)N)C(=O)O;13045;-64;552;2720;0;15;18;30;92;4;Approved;2011;Protein;Antagonist;P30411;bkrb2_human;Class A (Rhodopsin);Bradykinin receptors;Peptide receptors;RA01;COVID-19;2;Active;1730556128;36940272, 20030426, 20573077
245;vicagrel;vicagrel;CHEMBL2042273;DB16349;53378151;1314081-53-2;8A63K3TN0U;GNHHCBSBCDGWND-KRWDZBQOSA-N;CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3Cl)C(=O)OC;3799;38;841;506;0;0;6;6;25;3;Active;NA;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA8Z;Diseases of coronary artery, unspecified;3;Active;1059873720/unspecified;35438151, 36519186, 30358688
246;glasdegib;glasdegib;CHEMBL2043437;DB11978;25166913;1095173-27-5;K673DMO5H9;SFNSLLSYNZWZQG-VQIMIIECSA-N;CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N;3744;24;968;595;0;3;4;3;28;4;Approved;2018;Small molecule;Antagonist;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2A00.00;Glioblastoma of brain;2;Active;650534447;30601609, 31643486, 30666593
246;glasdegib;glasdegib;CHEMBL2043437;DB11978;25166913;1095173-27-5;K673DMO5H9;SFNSLLSYNZWZQG-VQIMIIECSA-N;CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N;3744;24;968;595;0;3;4;3;28;4;Approved;2018;Small molecule;Antagonist;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2A3Z;Myelodysplastic syndromes, unspecified;1;Active;1147802348/unspecified;30601609, 31643486, 30666593
246;glasdegib;glasdegib;CHEMBL2043437;DB11978;25166913;1095173-27-5;K673DMO5H9;SFNSLLSYNZWZQG-VQIMIIECSA-N;CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N;3744;24;968;595;0;3;4;3;28;4;Approved;2018;Small molecule;Antagonist;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2A60.3Z;Acute myeloid leukaemia, unspecified;4;Approved;1611980611/unspecified;30601609, 31643486, 30666593
247;netupitant;netupitant;CHEMBL206253;DB09048;6451149;290297-26-6;7732P08TIR;WAXQNWCZJDTGBU-UHFFFAOYSA-N;CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C;5786;68;397;865;0;0;10;5;41;4;Approved;2014;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;MD90;Nausea or vomiting;4;Approved;677319549;34292534, 26613606, 26448661
248;bremelanotide;bremelanotide;CHEMBL2070241;DB11653;9941379;189691-06-3;6Y24O4F92S;FFHBJDQSGDNCIV-MFVUMRCOSA-N;CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C;10252;7;379;1950;0;13;12;17;74;4;Approved;2019;Protein;Agonist;P32245;mc4r_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;HA0Z;Sexual dysfunctions, unspecified;4;Approved;160690465/unspecified;34436837, 31369224, 31429064
248;bremelanotide;bremelanotide;CHEMBL2070241;DB11653;9941379;189691-06-3;6Y24O4F92S;FFHBJDQSGDNCIV-MFVUMRCOSA-N;CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C;10252;7;379;1950;0;13;12;17;74;4;Approved;2019;Protein;Agonist;P32245;mc4r_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;MD90.0;Nausea;1;Inactive;596805318;34436837, 31369224, 31429064
248;bremelanotide;bremelanotide;CHEMBL2070241;DB11653;9941379;189691-06-3;6Y24O4F92S;FFHBJDQSGDNCIV-MFVUMRCOSA-N;CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C;10252;7;379;1950;0;13;12;17;74;4;Approved;2019;Protein;Agonist;P33032;mc5r_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;HA0Z;Sexual dysfunctions, unspecified;4;Approved;160690465/unspecified;34436837, 31369224, 31429064
248;bremelanotide;bremelanotide;CHEMBL2070241;DB11653;9941379;189691-06-3;6Y24O4F92S;FFHBJDQSGDNCIV-MFVUMRCOSA-N;CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C;10252;7;379;1950;0;13;12;17;74;4;Approved;2019;Protein;Agonist;P33032;mc5r_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;MD90.0;Nausea;1;Inactive;596805318;34436837, 31369224, 31429064
248;bremelanotide;bremelanotide;CHEMBL2070241;DB11653;9941379;189691-06-3;6Y24O4F92S;FFHBJDQSGDNCIV-MFVUMRCOSA-N;CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C;10252;7;379;1950;0;13;12;17;74;4;Approved;2019;Protein;Agonist;P41968;mc3r_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;HA0Z;Sexual dysfunctions, unspecified;4;Approved;160690465/unspecified;34436837, 31369224, 31429064
248;bremelanotide;bremelanotide;CHEMBL2070241;DB11653;9941379;189691-06-3;6Y24O4F92S;FFHBJDQSGDNCIV-MFVUMRCOSA-N;CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C;10252;7;379;1950;0;13;12;17;74;4;Approved;2019;Protein;Agonist;P41968;mc3r_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;MD90.0;Nausea;1;Inactive;596805318;34436837, 31369224, 31429064
248;bremelanotide;bremelanotide;CHEMBL2070241;DB11653;9941379;189691-06-3;6Y24O4F92S;FFHBJDQSGDNCIV-MFVUMRCOSA-N;CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C;10252;7;379;1950;0;13;12;17;74;4;Approved;2019;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;HA0Z;Sexual dysfunctions, unspecified;4;Approved;160690465/unspecified;34436837, 31369224, 31429064
248;bremelanotide;bremelanotide;CHEMBL2070241;DB11653;9941379;189691-06-3;6Y24O4F92S;FFHBJDQSGDNCIV-MFVUMRCOSA-N;CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C;10252;7;379;1950;0;13;12;17;74;4;Approved;2019;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;MD90.0;Nausea;1;Inactive;596805318;34436837, 31369224, 31429064
248;bremelanotide;bremelanotide;CHEMBL2070241;DB11653;9941379;189691-06-3;6Y24O4F92S;FFHBJDQSGDNCIV-MFVUMRCOSA-N;CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C;10252;7;379;1950;0;13;12;17;74;4;Approved;2019;Protein;Agonist;Q01726;mshr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;HA0Z;Sexual dysfunctions, unspecified;4;Approved;160690465/unspecified;34436837, 31369224, 31429064
248;bremelanotide;bremelanotide;CHEMBL2070241;DB11653;9941379;189691-06-3;6Y24O4F92S;FFHBJDQSGDNCIV-MFVUMRCOSA-N;CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C;10252;7;379;1950;0;13;12;17;74;4;Approved;2019;Protein;Agonist;Q01726;mshr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;MD90.0;Nausea;1;Inactive;596805318;34436837, 31369224, 31429064
252;mirabegron;mirabegron;CHEMBL2095212;DB08893;9865528;223673-61-8;MVR3JL3B2V;PBAPPPCECJKMCM-IBGZPJMESA-N;C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O;3965;21;129;467;0;4;6;9;28;4;Approved;2012;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A40.Z;Intermediate hyperglycaemia, unspecified;2;Active;1583355636/unspecified;32697458, 30860748, 31643223
252;mirabegron;mirabegron;CHEMBL2095212;DB08893;9865528;223673-61-8;MVR3JL3B2V;PBAPPPCECJKMCM-IBGZPJMESA-N;C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O;3965;21;129;467;0;4;6;9;28;4;Approved;2012;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Active;873092535/unspecified;32697458, 30860748, 31643223
252;mirabegron;mirabegron;CHEMBL2095212;DB08893;9865528;223673-61-8;MVR3JL3B2V;PBAPPPCECJKMCM-IBGZPJMESA-N;C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O;3965;21;129;467;0;4;6;9;28;4;Approved;2012;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;2;Inactive;1458683894/unspecified;32697458, 30860748, 31643223
252;mirabegron;mirabegron;CHEMBL2095212;DB08893;9865528;223673-61-8;MVR3JL3B2V;PBAPPPCECJKMCM-IBGZPJMESA-N;C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O;3965;21;129;467;0;4;6;9;28;4;Approved;2012;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA21.0;Achalasia;1;Inactive;636464846;32697458, 30860748, 31643223
252;mirabegron;mirabegron;CHEMBL2095212;DB08893;9865528;223673-61-8;MVR3JL3B2V;PBAPPPCECJKMCM-IBGZPJMESA-N;C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O;3965;21;129;467;0;4;6;9;28;4;Approved;2012;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.0Z;Calculus of kidney, unspecified;3;Unknown;389168514/unspecified;32697458, 30860748, 31643223
252;mirabegron;mirabegron;CHEMBL2095212;DB08893;9865528;223673-61-8;MVR3JL3B2V;PBAPPPCECJKMCM-IBGZPJMESA-N;C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O;3965;21;129;467;0;4;6;9;28;4;Approved;2012;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC00.3;Interstitial cystitis;3;Unknown;1650709285;32697458, 30860748, 31643223
252;mirabegron;mirabegron;CHEMBL2095212;DB08893;9865528;223673-61-8;MVR3JL3B2V;PBAPPPCECJKMCM-IBGZPJMESA-N;C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O;3965;21;129;467;0;4;6;9;28;4;Approved;2012;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC01.4;Neuromuscular dysfunction of bladder, not elsewhere classified;3;Inactive;590198069;32697458, 30860748, 31643223
252;mirabegron;mirabegron;CHEMBL2095212;DB08893;9865528;223673-61-8;MVR3JL3B2V;PBAPPPCECJKMCM-IBGZPJMESA-N;C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O;3965;21;129;467;0;4;6;9;28;4;Approved;2012;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;32697458, 30860748, 31643223
252;mirabegron;mirabegron;CHEMBL2095212;DB08893;9865528;223673-61-8;MVR3JL3B2V;PBAPPPCECJKMCM-IBGZPJMESA-N;C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O;3965;21;129;467;0;4;6;9;28;4;Approved;2012;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;32697458, 30860748, 31643223
253;pramlintide;pramlintide;CHEMBL2103758;DB01278;70691388;151126-32-8;D3FM8FA78T;TZIRZGBAFTZREM-MKAGXXMWSA-N;CCC(C)C(C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N)NC(=O)C4CCCN4C(=O)CNC(=O)C(CC5=CC=CC=C5)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC6=CNC=N6)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C8CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N8)C(C)O)C)C(C)O)CC(=O)N)NC(=O)C(CCCCN)N;3949;-157;1740;9660;0;56;59;110;277;4;Approved;2005;Protein;Agonist;P30988;calcr_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;5A10;Type 1 diabetes mellitus;4;Approved;1651053999;30000033, 31644254, 16278328
253;pramlintide;pramlintide;CHEMBL2103758;DB01278;70691388;151126-32-8;D3FM8FA78T;TZIRZGBAFTZREM-MKAGXXMWSA-N;CCC(C)C(C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N)NC(=O)C4CCCN4C(=O)CNC(=O)C(CC5=CC=CC=C5)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC6=CNC=N6)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C8CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N8)C(C)O)C)C(C)O)CC(=O)N)NC(=O)C(CCCCN)N;3949;-157;1740;9660;0;56;59;110;277;4;Approved;2005;Protein;Agonist;P30988;calcr_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;5A11;Type 2 diabetes mellitus;4;Approved;119724091;30000033, 31644254, 16278328
253;pramlintide;pramlintide;CHEMBL2103758;DB01278;70691388;151126-32-8;D3FM8FA78T;TZIRZGBAFTZREM-MKAGXXMWSA-N;CCC(C)C(C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N)NC(=O)C4CCCN4C(=O)CNC(=O)C(CC5=CC=CC=C5)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC6=CNC=N6)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C8CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N8)C(C)O)C)C(C)O)CC(=O)N)NC(=O)C(CCCCN)N;3949;-157;1740;9660;0;56;59;110;277;4;Approved;2005;Protein;Agonist;P30988;calcr_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;5B81.Z;Obesity, unspecified;2;Inactive;149403041/unspecified;30000033, 31644254, 16278328
254;cosyntropin;cosyntropin;CHEMBL2103784;DB01284;16133802;16960-16-0;72YY86EA29;ZOEFCCMDUURGSE-SQKVDDBVSA-N;CC(C)C(C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)N3CCCC3C(=O)O)NC(=O)C4CCCN4C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC8=CNC=N8)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC9=CC=C(C=C9)O)NC(=O)C(CO)N;29334;-79;1180;6500;0;42;41;96;208;4;Approved;1970;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;5A7Z;Disorders of the adrenal glands or adrenal hormone system, unspecified;4;Approved;237003158/unspecified;31176302, 32310400, 34620807
254;cosyntropin;cosyntropin;CHEMBL2103784;DB01284;16133802;16960-16-0;72YY86EA29;ZOEFCCMDUURGSE-SQKVDDBVSA-N;CC(C)C(C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)N3CCCC3C(=O)O)NC(=O)C4CCCN4C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC8=CNC=N8)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC9=CC=C(C=C9)O)NC(=O)C(CO)N;29334;-79;1180;6500;0;42;41;96;208;4;Approved;1970;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;8A62.Z;Epileptic encephalopathies, unspecified;3;Unknown;1786562875/unspecified;31176302, 32310400, 34620807
254;cosyntropin;cosyntropin;CHEMBL2103784;DB01284;16133802;16960-16-0;72YY86EA29;ZOEFCCMDUURGSE-SQKVDDBVSA-N;CC(C)C(C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)N3CCCC3C(=O)O)NC(=O)C4CCCN4C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC8=CNC=N8)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC9=CC=C(C=C9)O)NC(=O)C(CO)N;29334;-79;1180;6500;0;42;41;96;208;4;Approved;1970;Protein;Agonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;GB40;Nephritic syndrome;2;Inactive;1783829886;31176302, 32310400, 34620807
255;tasimelteon;tasimelteon;CHEMBL2103822;DB09071;10220503;609799-22-6;SHS4PU80D9;PTOIAAWZLUQTIO-GXFFZTMASA-N;CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2;24532;22;383;318;0;1;2;4;18;4;Approved;2014;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;31643948, 33355733, 21548834
255;tasimelteon;tasimelteon;CHEMBL2103822;DB09071;10220503;609799-22-6;SHS4PU80D9;PTOIAAWZLUQTIO-GXFFZTMASA-N;CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2;24532;22;383;318;0;1;2;4;18;4;Approved;2014;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;7A0Z;Insomnia disorders, unspecified;3;Inactive;1038292737/unspecified;31643948, 33355733, 21548834
255;tasimelteon;tasimelteon;CHEMBL2103822;DB09071;10220503;609799-22-6;SHS4PU80D9;PTOIAAWZLUQTIO-GXFFZTMASA-N;CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2;24532;22;383;318;0;1;2;4;18;4;Approved;2014;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;7A6Z;Circadian rhythm sleep-wake disorders, unspecified;2;Inactive;1359329403/unspecified;31643948, 33355733, 21548834
255;tasimelteon;tasimelteon;CHEMBL2103822;DB09071;10220503;609799-22-6;SHS4PU80D9;PTOIAAWZLUQTIO-GXFFZTMASA-N;CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2;24532;22;383;318;0;1;2;4;18;4;Approved;2014;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;7B2Z;Sleep-wake disorders, unspecified;4;Approved;274880002/unspecified;31643948, 33355733, 21548834
255;tasimelteon;tasimelteon;CHEMBL2103822;DB09071;10220503;609799-22-6;SHS4PU80D9;PTOIAAWZLUQTIO-GXFFZTMASA-N;CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2;24532;22;383;318;0;1;2;4;18;4;Approved;2014;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;LD44.H1;Deletions of the short arm of chromosome 17;4;Approved;527787991;31643948, 33355733, 21548834
255;tasimelteon;tasimelteon;CHEMBL2103822;DB09071;10220503;609799-22-6;SHS4PU80D9;PTOIAAWZLUQTIO-GXFFZTMASA-N;CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2;24532;22;383;318;0;1;2;4;18;4;Approved;2014;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;31643948, 33355733, 21548834
255;tasimelteon;tasimelteon;CHEMBL2103822;DB09071;10220503;609799-22-6;SHS4PU80D9;PTOIAAWZLUQTIO-GXFFZTMASA-N;CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2;24532;22;383;318;0;1;2;4;18;4;Approved;2014;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;7A0Z;Insomnia disorders, unspecified;3;Inactive;1038292737/unspecified;31643948, 33355733, 21548834
255;tasimelteon;tasimelteon;CHEMBL2103822;DB09071;10220503;609799-22-6;SHS4PU80D9;PTOIAAWZLUQTIO-GXFFZTMASA-N;CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2;24532;22;383;318;0;1;2;4;18;4;Approved;2014;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;7A6Z;Circadian rhythm sleep-wake disorders, unspecified;2;Inactive;1359329403/unspecified;31643948, 33355733, 21548834
255;tasimelteon;tasimelteon;CHEMBL2103822;DB09071;10220503;609799-22-6;SHS4PU80D9;PTOIAAWZLUQTIO-GXFFZTMASA-N;CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2;24532;22;383;318;0;1;2;4;18;4;Approved;2014;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;7B2Z;Sleep-wake disorders, unspecified;4;Approved;274880002/unspecified;31643948, 33355733, 21548834
255;tasimelteon;tasimelteon;CHEMBL2103822;DB09071;10220503;609799-22-6;SHS4PU80D9;PTOIAAWZLUQTIO-GXFFZTMASA-N;CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2;24532;22;383;318;0;1;2;4;18;4;Approved;2014;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;LD44.H1;Deletions of the short arm of chromosome 17;4;Approved;527787991;31643948, 33355733, 21548834
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8D87.0Z;Multiple system atrophy, unspecified;4;Approved;1890931931/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;4;Approved;56009591;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Inactive;1663360295/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8D87.0Z;Multiple system atrophy, unspecified;4;Approved;1890931931/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;4;Approved;56009591;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Inactive;1663360295/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8D87.0Z;Multiple system atrophy, unspecified;4;Approved;1890931931/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;4;Approved;56009591;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Inactive;1663360295/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8D87.0Z;Multiple system atrophy, unspecified;4;Approved;1890931931/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;4;Approved;56009591;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Inactive;1663360295/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8D87.0Z;Multiple system atrophy, unspecified;4;Approved;1890931931/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;4;Approved;56009591;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Inactive;1663360295/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8D87.0Z;Multiple system atrophy, unspecified;4;Approved;1890931931/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;4;Approved;56009591;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Inactive;1663360295/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8D87.0Z;Multiple system atrophy, unspecified;4;Approved;1890931931/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;4;Approved;56009591;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Inactive;1663360295/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8D87.0Z;Multiple system atrophy, unspecified;4;Approved;1890931931/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;4;Approved;56009591;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Inactive;1663360295/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8D87.0Z;Multiple system atrophy, unspecified;4;Approved;1890931931/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;4;Approved;56009591;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Inactive;1663360295/unspecified;31643765, 35787811, 27442791
256;droxidopa;droxidopa;CHEMBL2103827;DB06262;92974;23651-95-8;J7A92W69L7;QXWYKJLNLSIPIN-JGVFFNPUSA-N;C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O;21319;-32;124;235;0;5;6;3;15;4;Approved;2014;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;31643765, 35787811, 27442791
257;macitentan;macitentan;CHEMBL2103873;DB08932;16004692;441798-33-0;Z9K9Y9WMVL;JGCMEBMXRHSZKX-UHFFFAOYSA-N;CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br;5883;37;137;642;0;2;10;11;32;4;Approved;2010;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2A00.00;Glioblastoma of brain;1;Inactive;650534447;23984728, 31643393, 35265193
257;macitentan;macitentan;CHEMBL2103873;DB08932;16004692;441798-33-0;Z9K9Y9WMVL;JGCMEBMXRHSZKX-UHFFFAOYSA-N;CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br;5883;37;137;642;0;2;10;11;32;4;Approved;2010;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;23984728, 31643393, 35265193
257;macitentan;macitentan;CHEMBL2103873;DB08932;16004692;441798-33-0;Z9K9Y9WMVL;JGCMEBMXRHSZKX-UHFFFAOYSA-N;CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br;5883;37;137;642;0;2;10;11;32;4;Approved;2010;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;23984728, 31643393, 35265193
257;macitentan;macitentan;CHEMBL2103873;DB08932;16004692;441798-33-0;Z9K9Y9WMVL;JGCMEBMXRHSZKX-UHFFFAOYSA-N;CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br;5883;37;137;642;0;2;10;11;32;4;Approved;2010;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BB01.Z;Pulmonary hypertension, unspecified;4;Approved;1496633964/unspecified;23984728, 31643393, 35265193
257;macitentan;macitentan;CHEMBL2103873;DB08932;16004692;441798-33-0;Z9K9Y9WMVL;JGCMEBMXRHSZKX-UHFFFAOYSA-N;CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br;5883;37;137;642;0;2;10;11;32;4;Approved;2010;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BD1Z;Heart failure, unspecified;2;Inactive;1458683894/unspecified;23984728, 31643393, 35265193
257;macitentan;macitentan;CHEMBL2103873;DB08932;16004692;441798-33-0;Z9K9Y9WMVL;JGCMEBMXRHSZKX-UHFFFAOYSA-N;CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br;5883;37;137;642;0;2;10;11;32;4;Approved;2010;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;CB03.4;Idiopathic pulmonary fibrosis;2;Inactive;1074069640;23984728, 31643393, 35265193
257;macitentan;macitentan;CHEMBL2103873;DB08932;16004692;441798-33-0;Z9K9Y9WMVL;JGCMEBMXRHSZKX-UHFFFAOYSA-N;CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br;5883;37;137;642;0;2;10;11;32;4;Approved;2010;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;DA60;Gastric ulcer;3;Inactive;1437411258;23984728, 31643393, 35265193
257;macitentan;macitentan;CHEMBL2103873;DB08932;16004692;441798-33-0;Z9K9Y9WMVL;JGCMEBMXRHSZKX-UHFFFAOYSA-N;CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br;5883;37;137;642;0;2;10;11;32;4;Approved;2010;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;LA8Z;Structural developmental anomaly of heart or great vessels, unspecified;3;Active;2004408087/unspecified;23984728, 31643393, 35265193
257;macitentan;macitentan;CHEMBL2103873;DB08932;16004692;441798-33-0;Z9K9Y9WMVL;JGCMEBMXRHSZKX-UHFFFAOYSA-N;CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br;5883;37;137;642;0;2;10;11;32;4;Approved;2010;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2A00.00;Glioblastoma of brain;1;Inactive;650534447;23984728, 31643393, 35265193
257;macitentan;macitentan;CHEMBL2103873;DB08932;16004692;441798-33-0;Z9K9Y9WMVL;JGCMEBMXRHSZKX-UHFFFAOYSA-N;CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br;5883;37;137;642;0;2;10;11;32;4;Approved;2010;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;23984728, 31643393, 35265193
257;macitentan;macitentan;CHEMBL2103873;DB08932;16004692;441798-33-0;Z9K9Y9WMVL;JGCMEBMXRHSZKX-UHFFFAOYSA-N;CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br;5883;37;137;642;0;2;10;11;32;4;Approved;2010;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;23984728, 31643393, 35265193
257;macitentan;macitentan;CHEMBL2103873;DB08932;16004692;441798-33-0;Z9K9Y9WMVL;JGCMEBMXRHSZKX-UHFFFAOYSA-N;CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br;5883;37;137;642;0;2;10;11;32;4;Approved;2010;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BB01.Z;Pulmonary hypertension, unspecified;4;Approved;1496633964/unspecified;23984728, 31643393, 35265193
257;macitentan;macitentan;CHEMBL2103873;DB08932;16004692;441798-33-0;Z9K9Y9WMVL;JGCMEBMXRHSZKX-UHFFFAOYSA-N;CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br;5883;37;137;642;0;2;10;11;32;4;Approved;2010;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BD1Z;Heart failure, unspecified;2;Inactive;1458683894/unspecified;23984728, 31643393, 35265193
257;macitentan;macitentan;CHEMBL2103873;DB08932;16004692;441798-33-0;Z9K9Y9WMVL;JGCMEBMXRHSZKX-UHFFFAOYSA-N;CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br;5883;37;137;642;0;2;10;11;32;4;Approved;2010;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;CB03.4;Idiopathic pulmonary fibrosis;2;Inactive;1074069640;23984728, 31643393, 35265193
257;macitentan;macitentan;CHEMBL2103873;DB08932;16004692;441798-33-0;Z9K9Y9WMVL;JGCMEBMXRHSZKX-UHFFFAOYSA-N;CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br;5883;37;137;642;0;2;10;11;32;4;Approved;2010;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;DA60;Gastric ulcer;3;Inactive;1437411258;23984728, 31643393, 35265193
257;macitentan;macitentan;CHEMBL2103873;DB08932;16004692;441798-33-0;Z9K9Y9WMVL;JGCMEBMXRHSZKX-UHFFFAOYSA-N;CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br;5883;37;137;642;0;2;10;11;32;4;Approved;2010;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;LA8Z;Structural developmental anomaly of heart or great vessels, unspecified;3;Active;2004408087/unspecified;23984728, 31643393, 35265193
258;teverelix;teverelix;CHEMBL2103945;DB05624;16135076;151272-78-5;D19V7048JK;NOENHWMKHNSHGX-IAOPALDYSA-N;C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C;14591;45;446;2810;0;15;16;41;104;2;Active;NA;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2F34;Benign neoplasm of male genital organs;2;Active;317567417;34448368, 37109639, 12878396
258;teverelix;teverelix;CHEMBL2103945;DB05624;16135076;151272-78-5;D19V7048JK;NOENHWMKHNSHGX-IAOPALDYSA-N;C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C;14591;45;446;2810;0;15;16;41;104;2;Active;NA;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;MF50.3;Retention of urine;2;Active;1775034842;34448368, 37109639, 12878396
258;teverelix;Antarelix;CHEMBL2103945;DB05624;20055560;151272-78-5;D19V7048JK;NOENHWMKHNSHGX-UHFFFAOYSA-N;CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCCNC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C;14591;45;446;2810;0;15;16;41;104;2;Active;NA;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2F34;Benign neoplasm of male genital organs;2;Active;317567417;34448368, 37109639, 12878396
258;teverelix;Antarelix;CHEMBL2103945;DB05624;20055560;151272-78-5;D19V7048JK;NOENHWMKHNSHGX-UHFFFAOYSA-N;CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCCNC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C;14591;45;446;2810;0;15;16;41;104;2;Active;NA;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;MF50.3;Retention of urine;2;Active;1775034842;34448368, 37109639, 12878396
259;vapreotide;vapreotide;CHEMBL2103975;NA;70689318;NA;NA;SWXOGPJRIDTIRL-KTJGOPLGSA-N;CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CC6=CNC7=CC=CC=C76)C(=O)N;11314;36;401;2080;0;13;13;18;80;4;Approved;2004;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;36378411, 19708854, 16047258
259;vapreotide;vapreotide;CHEMBL2103975;NA;70689318;NA;NA;SWXOGPJRIDTIRL-KTJGOPLGSA-N;CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CC6=CNC7=CC=CC=C76)C(=O)N;11314;36;401;2080;0;13;13;18;80;4;Approved;2004;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DA26.0Z;Oesophageal varices, unspecified;4;Approved;933570887/unspecified;36378411, 19708854, 16047258
259;vapreotide;vapreotide;CHEMBL2103975;NA;70689318;NA;NA;SWXOGPJRIDTIRL-KTJGOPLGSA-N;CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CC6=CNC7=CC=CC=C76)C(=O)N;11314;36;401;2080;0;13;13;18;80;4;Approved;2004;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.1;Diarrhoea;4;Approved;116759077;36378411, 19708854, 16047258
259;vapreotide;vapreotide;CHEMBL2103975;NA;70689318;NA;NA;SWXOGPJRIDTIRL-KTJGOPLGSA-N;CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CC6=CNC7=CC=CC=C76)C(=O)N;11314;36;401;2080;0;13;13;18;80;4;Approved;2004;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;36378411, 19708854, 16047258
259;vapreotide;vapreotide;CHEMBL2103975;NA;70689318;NA;NA;SWXOGPJRIDTIRL-KTJGOPLGSA-N;CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CC6=CNC7=CC=CC=C76)C(=O)N;11314;36;401;2080;0;13;13;18;80;4;Approved;2004;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DA26.0Z;Oesophageal varices, unspecified;4;Approved;933570887/unspecified;36378411, 19708854, 16047258
259;vapreotide;vapreotide;CHEMBL2103975;NA;70689318;NA;NA;SWXOGPJRIDTIRL-KTJGOPLGSA-N;CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CC6=CNC7=CC=CC=C76)C(=O)N;11314;36;401;2080;0;13;13;18;80;4;Approved;2004;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.1;Diarrhoea;4;Approved;116759077;36378411, 19708854, 16047258
259;vapreotide;vapreotide;CHEMBL2103975;NA;70689318;NA;NA;SWXOGPJRIDTIRL-KTJGOPLGSA-N;CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CC6=CNC7=CC=CC=C76)C(=O)N;11314;36;401;2080;0;13;13;18;80;4;Approved;2004;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;36378411, 19708854, 16047258
259;vapreotide;vapreotide;CHEMBL2103975;NA;70689318;NA;NA;SWXOGPJRIDTIRL-KTJGOPLGSA-N;CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CC6=CNC7=CC=CC=C76)C(=O)N;11314;36;401;2080;0;13;13;18;80;4;Approved;2004;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DA26.0Z;Oesophageal varices, unspecified;4;Approved;933570887/unspecified;36378411, 19708854, 16047258
259;vapreotide;vapreotide;CHEMBL2103975;NA;70689318;NA;NA;SWXOGPJRIDTIRL-KTJGOPLGSA-N;CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CC6=CNC7=CC=CC=C76)C(=O)N;11314;36;401;2080;0;13;13;18;80;4;Approved;2004;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ME05.1;Diarrhoea;4;Approved;116759077;36378411, 19708854, 16047258
260;cinitapride;cinitapride;CHEMBL2104523;DB08810;68867;66564-14-5;R8I97I2L24;ZDLBNXXKDMLZMF-UHFFFAOYSA-N;CCOC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3CCC=CC3)[N+](=O)[O-])N;4025;36;113;586;0;2;6;6;29;4;Approved;2008;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;20461977, 24440931, 36065758
260;cinitapride;cinitapride;CHEMBL2104523;DB08810;68867;66564-14-5;R8I97I2L24;ZDLBNXXKDMLZMF-UHFFFAOYSA-N;CCOC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3CCC=CC3)[N+](=O)[O-])N;4025;36;113;586;0;2;6;6;29;4;Approved;2008;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DA41.00;Gastroparesis;4;Approved;598423727;20461977, 24440931, 36065758
260;cinitapride;cinitapride;CHEMBL2104523;DB08810;68867;66564-14-5;R8I97I2L24;ZDLBNXXKDMLZMF-UHFFFAOYSA-N;CCOC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3CCC=CC3)[N+](=O)[O-])N;4025;36;113;586;0;2;6;6;29;4;Approved;2008;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD92;Dyspepsia;4;Approved;869622187;20461977, 24440931, 36065758
260;cinitapride;cinitapride;CHEMBL2104523;DB08810;68867;66564-14-5;R8I97I2L24;ZDLBNXXKDMLZMF-UHFFFAOYSA-N;CCOC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3CCC=CC3)[N+](=O)[O-])N;4025;36;113;586;0;2;6;6;29;4;Approved;2008;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;20461977, 24440931, 36065758
260;cinitapride;cinitapride;CHEMBL2104523;DB08810;68867;66564-14-5;R8I97I2L24;ZDLBNXXKDMLZMF-UHFFFAOYSA-N;CCOC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3CCC=CC3)[N+](=O)[O-])N;4025;36;113;586;0;2;6;6;29;4;Approved;2008;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DA41.00;Gastroparesis;4;Approved;598423727;20461977, 24440931, 36065758
260;cinitapride;cinitapride;CHEMBL2104523;DB08810;68867;66564-14-5;R8I97I2L24;ZDLBNXXKDMLZMF-UHFFFAOYSA-N;CCOC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3CCC=CC3)[N+](=O)[O-])N;4025;36;113;586;0;2;6;6;29;4;Approved;2008;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD92;Dyspepsia;4;Approved;869622187;20461977, 24440931, 36065758
261;teduglutide;teduglutide;CHEMBL2104987;DB08900;16139605;197922-42-2;7M19191IKG;CILIXQOJUNDIDU-ASQIGDHWSA-N;CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC5=CN=CN5)N;37521;-152;1650;9030;0;55;60;126;264;4;Approved;2012;Protein;Agonist;O95838;glp2r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;4B24.Z;Graft-versus-host disease, unspecified;1;Inactive;437372167/unspecified;33798402, 36701512, 31495952
261;teduglutide;teduglutide;CHEMBL2104987;DB08900;16139605;197922-42-2;7M19191IKG;CILIXQOJUNDIDU-ASQIGDHWSA-N;CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC5=CN=CN5)N;37521;-152;1650;9030;0;55;60;126;264;4;Approved;2012;Protein;Agonist;O95838;glp2r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B7Z;Unspecified undernutrition;2;Inactive;1517885800/unspecified;33798402, 36701512, 31495952
261;teduglutide;teduglutide;CHEMBL2104987;DB08900;16139605;197922-42-2;7M19191IKG;CILIXQOJUNDIDU-ASQIGDHWSA-N;CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC5=CN=CN5)N;37521;-152;1650;9030;0;55;60;126;264;4;Approved;2012;Protein;Agonist;O95838;glp2r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5C80.Z;Hyperlipoproteinaemia, unspecified;3;Inactive;2023062398/unspecified;33798402, 36701512, 31495952
261;teduglutide;teduglutide;CHEMBL2104987;DB08900;16139605;197922-42-2;7M19191IKG;CILIXQOJUNDIDU-ASQIGDHWSA-N;CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC5=CN=CN5)N;37521;-152;1650;9030;0;55;60;126;264;4;Approved;2012;Protein;Agonist;O95838;glp2r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DA96.04;Short bowel syndrome;4;Approved;780637678;33798402, 36701512, 31495952
261;teduglutide;teduglutide;CHEMBL2104987;DB08900;16139605;197922-42-2;7M19191IKG;CILIXQOJUNDIDU-ASQIGDHWSA-N;CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC5=CN=CN5)N;37521;-152;1650;9030;0;55;60;126;264;4;Approved;2012;Protein;Agonist;O95838;glp2r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DD70.Z;Crohn disease, unspecified site;2;Inactive;1267652425/unspecified;33798402, 36701512, 31495952
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Unknown;1456478153/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;3;Inactive;1712535455;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB29.1;Binge eating;2;Unknown;1535148777;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Unknown;1456478153/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;3;Inactive;1712535455;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB29.1;Binge eating;2;Unknown;1535148777;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Partial agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Partial agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Unknown;1456478153/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Partial agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Partial agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Partial agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;3;Inactive;1712535455;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Partial agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB29.1;Binge eating;2;Unknown;1535148777;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Partial agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Partial agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Unknown;1456478153/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Partial agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Partial agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Partial agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;3;Inactive;1712535455;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Partial agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB29.1;Binge eating;2;Unknown;1535148777;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Unknown;1456478153/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;3;Inactive;1712535455;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine;CHEMBL2104993;DB09068;9966051;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-N;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C;2984;42;406;316;0;1;3;3;21;4;Approved;2013;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB29.1;Binge eating;2;Unknown;1535148777;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Unknown;1456478153/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;3;Inactive;1712535455;29189941, 30457395, 29999894
262;vortioxetine;vortioxetine+;CHEMBL2104993;DB09068;71768094;508233-74-7;3O2K1S3WQV;YQNWZWMKLDQSAC-UHFFFAOYSA-O;CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CC[NH2+]CC3)C;2995;42;452;316;1;1;2;3;21;4;Approved;2013;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB29.1;Binge eating;2;Unknown;1535148777;29189941, 30457395, 29999894
263;pholcodine;pholcodine;CHEMBL2105224;DB09209;5311356;509-67-1;LPP64AWZ7L;GPFAJKDEDBRFOS-FKQDBXSBSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OCCN6CCOCC6)OC3C(C=C4)O;3985;8;544;653;0;1;6;4;29;4;Approved;1959;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;3283158, 36967281, 24251966
263;pholcodine;pholcodine;CHEMBL2105224;DB09209;5311356;509-67-1;LPP64AWZ7L;GPFAJKDEDBRFOS-FKQDBXSBSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OCCN6CCOCC6)OC3C(C=C4)O;3985;8;544;653;0;1;6;4;29;4;Approved;1959;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD12;Cough;4;Approved;2027526159;3283158, 36967281, 24251966
263;pholcodine;pholcodine;CHEMBL2105224;DB09209;5311356;509-67-1;LPP64AWZ7L;GPFAJKDEDBRFOS-FKQDBXSBSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OCCN6CCOCC6)OC3C(C=C4)O;3985;8;544;653;0;1;6;4;29;4;Approved;1959;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;3283158, 36967281, 24251966
263;pholcodine;pholcodine;CHEMBL2105224;DB09209;5311356;509-67-1;LPP64AWZ7L;GPFAJKDEDBRFOS-FKQDBXSBSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OCCN6CCOCC6)OC3C(C=C4)O;3985;8;544;653;0;1;6;4;29;4;Approved;1959;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD12;Cough;4;Approved;2027526159;3283158, 36967281, 24251966
264;orvepitant;orvepitant;CHEMBL2105667;DB12427;9852175;579475-18-6;NA;XWNBGDJPEXZSQM-VZOBGQTKSA-N;CC1=C(C=CC(=C1)F)C2CC(CCN2C(=O)N(C)C(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN5C(C4)CCC5=O;6286;54;471;1020;0;0;10;4;44;2;Active;NA;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;CB03.4;Idiopathic pulmonary fibrosis;2;Active;1074069640;32034016, 31421110, 23539641
264;orvepitant;orvepitant;CHEMBL2105667;DB12427;9852175;579475-18-6;NA;XWNBGDJPEXZSQM-VZOBGQTKSA-N;CC1=C(C=CC(=C1)F)C2CC(CCN2C(=O)N(C)C(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN5C(C4)CCC5=O;6286;54;471;1020;0;0;10;4;44;2;Active;NA;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;MD12;Cough;2;Active;2027526159;32034016, 31421110, 23539641
265;sonidegib;sonidegib;CHEMBL2105737;DB09143;24775005;956697-53-3;0RLU3VTK5M;VZZJRYRQSPEMTK-CALCHBBNSA-N;CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F;4855;58;637;691;0;1;8;5;35;4;Approved;2015;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2A00.10;Medulloblastoma of brain;2;Active;290815825;29999928, 31990414, 31644228
265;sonidegib;sonidegib;CHEMBL2105737;DB09143;24775005;956697-53-3;0RLU3VTK5M;VZZJRYRQSPEMTK-CALCHBBNSA-N;CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F;4855;58;637;691;0;1;8;5;35;4;Approved;2015;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2A83.1;Plasma cell myeloma;2;Inactive;526287100;29999928, 31990414, 31644228
265;sonidegib;sonidegib;CHEMBL2105737;DB09143;24775005;956697-53-3;0RLU3VTK5M;VZZJRYRQSPEMTK-CALCHBBNSA-N;CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F;4855;58;637;691;0;1;8;5;35;4;Approved;2015;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2B33.4;Leukaemia, unspecified;2;Inactive;1385484871;29999928, 31990414, 31644228
265;sonidegib;sonidegib;CHEMBL2105737;DB09143;24775005;956697-53-3;0RLU3VTK5M;VZZJRYRQSPEMTK-CALCHBBNSA-N;CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F;4855;58;637;691;0;1;8;5;35;4;Approved;2015;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2B70.Z;Malignant neoplasms of oesophagus, unspecified;1;Inactive;669033105/unspecified;29999928, 31990414, 31644228
265;sonidegib;sonidegib;CHEMBL2105737;DB09143;24775005;956697-53-3;0RLU3VTK5M;VZZJRYRQSPEMTK-CALCHBBNSA-N;CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F;4855;58;637;691;0;1;8;5;35;4;Approved;2015;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C10.Y;Other specified malignant neoplasms of pancreas;1;Inactive;542147910/other;29999928, 31990414, 31644228
265;sonidegib;sonidegib;CHEMBL2105737;DB09143;24775005;956697-53-3;0RLU3VTK5M;VZZJRYRQSPEMTK-CALCHBBNSA-N;CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F;4855;58;637;691;0;1;8;5;35;4;Approved;2015;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C32.Z;Basal cell carcinoma of skin, unspecified;4;Approved;1203447657/unspecified;29999928, 31990414, 31644228
265;sonidegib;sonidegib;CHEMBL2105737;DB09143;24775005;956697-53-3;0RLU3VTK5M;VZZJRYRQSPEMTK-CALCHBBNSA-N;CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F;4855;58;637;691;0;1;8;5;35;4;Approved;2015;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;29999928, 31990414, 31644228
265;sonidegib;sonidegib;CHEMBL2105737;DB09143;24775005;956697-53-3;0RLU3VTK5M;VZZJRYRQSPEMTK-CALCHBBNSA-N;CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F;4855;58;637;691;0;1;8;5;35;4;Approved;2015;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C73.Z;Malignant neoplasms of ovary, unspecified;1;Inactive;685124533/unspecified;29999928, 31990414, 31644228
265;sonidegib;sonidegib;CHEMBL2105737;DB09143;24775005;956697-53-3;0RLU3VTK5M;VZZJRYRQSPEMTK-CALCHBBNSA-N;CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F;4855;58;637;691;0;1;8;5;35;4;Approved;2015;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;1;Inactive;1552457716/unspecified;29999928, 31990414, 31644228
265;sonidegib;sonidegib;CHEMBL2105737;DB09143;24775005;956697-53-3;0RLU3VTK5M;VZZJRYRQSPEMTK-CALCHBBNSA-N;CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F;4855;58;637;691;0;1;8;5;35;4;Approved;2015;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2F95;Neoplasms of unknown behaviour of breast;2;Unknown;1623614569;29999928, 31990414, 31644228
265;sonidegib;sonidegib;CHEMBL2105737;DB09143;24775005;956697-53-3;0RLU3VTK5M;VZZJRYRQSPEMTK-CALCHBBNSA-N;CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F;4855;58;637;691;0;1;8;5;35;4;Approved;2015;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;4B24.Z;Graft-versus-host disease, unspecified;1;Inactive;437372167/unspecified;29999928, 31990414, 31644228
266;naldemedine;naldemedine;CHEMBL2105755;DB11691;54732242;916072-89-4;03KSI6WLXH;AXQACEQYCPKDMV-RZAWKFBISA-N;CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C(C4C56CCN(C(C5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O;5706;32;141;1140;0;4;9;6;42;4;Approved;2017;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DC31.Z;Acute pancreatitis, unspecified;3;Active;698285441/unspecified;31643694, 30652502, 35750467
266;naldemedine;naldemedine;CHEMBL2105755;DB11691;54732242;916072-89-4;03KSI6WLXH;AXQACEQYCPKDMV-RZAWKFBISA-N;CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C(C4C56CCN(C(C5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O;5706;32;141;1140;0;4;9;6;42;4;Approved;2017;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DD9Z;Functional gastrointestinal disorders, unspecified;4;Approved;132592466/unspecified;31643694, 30652502, 35750467
266;naldemedine;naldemedine;CHEMBL2105755;DB11691;54732242;916072-89-4;03KSI6WLXH;AXQACEQYCPKDMV-RZAWKFBISA-N;CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C(C4C56CCN(C(C5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O;5706;32;141;1140;0;4;9;6;42;4;Approved;2017;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME05.0;Constipation;4;Approved;502284069;31643694, 30652502, 35750467
266;naldemedine;naldemedine;CHEMBL2105755;DB11691;54732242;916072-89-4;03KSI6WLXH;AXQACEQYCPKDMV-RZAWKFBISA-N;CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C(C4C56CCN(C(C5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O;5706;32;141;1140;0;4;9;6;42;4;Approved;2017;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DC31.Z;Acute pancreatitis, unspecified;3;Active;698285441/unspecified;31643694, 30652502, 35750467
266;naldemedine;naldemedine;CHEMBL2105755;DB11691;54732242;916072-89-4;03KSI6WLXH;AXQACEQYCPKDMV-RZAWKFBISA-N;CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C(C4C56CCN(C(C5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O;5706;32;141;1140;0;4;9;6;42;4;Approved;2017;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DD9Z;Functional gastrointestinal disorders, unspecified;4;Approved;132592466/unspecified;31643694, 30652502, 35750467
266;naldemedine;naldemedine;CHEMBL2105755;DB11691;54732242;916072-89-4;03KSI6WLXH;AXQACEQYCPKDMV-RZAWKFBISA-N;CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C(C4C56CCN(C(C5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O;5706;32;141;1140;0;4;9;6;42;4;Approved;2017;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME05.0;Constipation;4;Approved;502284069;31643694, 30652502, 35750467
266;naldemedine;naldemedine;CHEMBL2105755;DB11691;54732242;916072-89-4;03KSI6WLXH;AXQACEQYCPKDMV-RZAWKFBISA-N;CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C(C4C56CCN(C(C5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O;5706;32;141;1140;0;4;9;6;42;4;Approved;2017;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DC31.Z;Acute pancreatitis, unspecified;3;Active;698285441/unspecified;31643694, 30652502, 35750467
266;naldemedine;naldemedine;CHEMBL2105755;DB11691;54732242;916072-89-4;03KSI6WLXH;AXQACEQYCPKDMV-RZAWKFBISA-N;CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C(C4C56CCN(C(C5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O;5706;32;141;1140;0;4;9;6;42;4;Approved;2017;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DD9Z;Functional gastrointestinal disorders, unspecified;4;Approved;132592466/unspecified;31643694, 30652502, 35750467
266;naldemedine;naldemedine;CHEMBL2105755;DB11691;54732242;916072-89-4;03KSI6WLXH;AXQACEQYCPKDMV-RZAWKFBISA-N;CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C(C4C56CCN(C(C5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O;5706;32;141;1140;0;4;9;6;42;4;Approved;2017;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME05.0;Constipation;4;Approved;502284069;31643694, 30652502, 35750467
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Active;1456478153/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;2;Inactive;941859884/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7B2Z;Sleep-wake disorders, unspecified;3;Inactive;274880002/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Active;1456478153/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;2;Inactive;941859884/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7B2Z;Sleep-wake disorders, unspecified;3;Inactive;274880002/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Partial agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Active;1456478153/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;2;Inactive;941859884/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7B2Z;Sleep-wake disorders, unspecified;3;Inactive;274880002/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Active;1456478153/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;2;Inactive;941859884/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7B2Z;Sleep-wake disorders, unspecified;3;Inactive;274880002/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Active;1456478153/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;2;Inactive;941859884/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7B2Z;Sleep-wake disorders, unspecified;3;Inactive;274880002/unspecified;31708380, 29999808, 28228056
267;brexpiprazole;brexpiprazole;CHEMBL2105760;DB09128;11978813;913611-97-9;2J3YBM1K8C;ZKIAIYBUSXZPLP-UHFFFAOYSA-N;C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4;4336;47;73;636;0;1;5;7;31;4;Approved;2015;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;31708380, 29999808, 28228056
268;calcium citrate;calcium citrate;CHEMBL2106123;DB11093;13136;813-94-5;86117BWO7P;FNAQSUUGMSOBHW-UHFFFAOYSA-H;C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Ca+2].[Ca+2].[Ca+2];4984;;281;211;0;2;14;4;29;4;Approved;1973;Small molecule;Agonist;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;5A50.Z;Hypoparathyroidism, unspecified;4;Approved;1708733050/unspecified;34343801, 31643038, 35466449
268;calcium citrate;calcium citrate;CHEMBL2106123;DB11093;13136;813-94-5;86117BWO7P;FNAQSUUGMSOBHW-UHFFFAOYSA-H;C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Ca+2].[Ca+2].[Ca+2];4984;;281;211;0;2;14;4;29;4;Approved;1973;Small molecule;Agonist;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;FB83.1Z;Osteoporosis, unspecified;4;Approved;2113001430/unspecified;34343801, 31643038, 35466449
268;calcium citrate;calcium citrate;CHEMBL2106123;DB11093;13136;813-94-5;86117BWO7P;FNAQSUUGMSOBHW-UHFFFAOYSA-H;C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Ca+2].[Ca+2].[Ca+2];4984;;281;211;0;2;14;4;29;4;Approved;1973;Small molecule;Agonist;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;FB83.2Z;Adult osteomalacia, unspecified;4;Approved;414849600/unspecified;34343801, 31643038, 35466449
268;calcium citrate;calcium citrate;CHEMBL2106123;DB11093;13136;813-94-5;86117BWO7P;FNAQSUUGMSOBHW-UHFFFAOYSA-H;C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Ca+2].[Ca+2].[Ca+2];4984;;281;211;0;2;14;4;29;4;Approved;1973;Small molecule;Agonist;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;MB47.D;Tetany;4;Approved;1468891747;34343801, 31643038, 35466449
268;calcium citrate;citric acid;CHEMBL1261;DB11093;311;813-94-5;86117BWO7P;KRKNYBCHXYNGOX-UHFFFAOYSA-N;C(C(=O)O)C(CC(=O)O)(C(=O)O)O;19212;-17;132;227;0;4;7;5;13;4;Approved;1973;Small molecule;Agonist;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;5A50.Z;Hypoparathyroidism, unspecified;4;Approved;1708733050/unspecified;34343801, 31643038, 35466449
268;calcium citrate;citric acid;CHEMBL1261;DB11093;311;813-94-5;86117BWO7P;KRKNYBCHXYNGOX-UHFFFAOYSA-N;C(C(=O)O)C(CC(=O)O)(C(=O)O)O;19212;-17;132;227;0;4;7;5;13;4;Approved;1973;Small molecule;Agonist;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;FB83.1Z;Osteoporosis, unspecified;4;Approved;2113001430/unspecified;34343801, 31643038, 35466449
268;calcium citrate;citric acid;CHEMBL1261;DB11093;311;813-94-5;86117BWO7P;KRKNYBCHXYNGOX-UHFFFAOYSA-N;C(C(=O)O)C(CC(=O)O)(C(=O)O)O;19212;-17;132;227;0;4;7;5;13;4;Approved;1973;Small molecule;Agonist;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;FB83.2Z;Adult osteomalacia, unspecified;4;Approved;414849600/unspecified;34343801, 31643038, 35466449
268;calcium citrate;citric acid;CHEMBL1261;DB11093;311;813-94-5;86117BWO7P;KRKNYBCHXYNGOX-UHFFFAOYSA-N;C(C(=O)O)C(CC(=O)O)(C(=O)O)O;19212;-17;132;227;0;4;7;5;13;4;Approved;1973;Small molecule;Agonist;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;MB47.D;Tetany;4;Approved;1468891747;34343801, 31643038, 35466449
269;paliperidone palmitate;paliperidone palmitate;CHEMBL2107360;NA;9852746;199739-10-1;NA;VOMKSBFLAZZBOW-UHFFFAOYSA-N;CCCCCCCCCCCCCCCC(=O)OC1CCCN2C1=NC(=C(C2=O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F)C;6649;101;882;1090;0;0;8;20;48;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;34791283, 20155997, 29359582
269;paliperidone palmitate;paliperidone palmitate;CHEMBL2107360;NA;9852746;199739-10-1;NA;VOMKSBFLAZZBOW-UHFFFAOYSA-N;CCCCCCCCCCCCCCCC(=O)OC1CCCN2C1=NC(=C(C2=O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F)C;6649;101;882;1090;0;0;8;20;48;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;34791283, 20155997, 29359582
269;paliperidone palmitate;paliperidone palmitate;CHEMBL2107360;NA;9852746;199739-10-1;NA;VOMKSBFLAZZBOW-UHFFFAOYSA-N;CCCCCCCCCCCCCCCC(=O)OC1CCCN2C1=NC(=C(C2=O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F)C;6649;101;882;1090;0;0;8;20;48;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;34791283, 20155997, 29359582
269;paliperidone palmitate;paliperidone palmitate;CHEMBL2107360;NA;9852746;199739-10-1;NA;VOMKSBFLAZZBOW-UHFFFAOYSA-N;CCCCCCCCCCCCCCCC(=O)OC1CCCN2C1=NC(=C(C2=O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F)C;6649;101;882;1090;0;0;8;20;48;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;34791283, 20155997, 29359582
270;limaprost;limaprost;CHEMBL2107456;DB09211;6438378;74397-12-9;L02U804092;OJZYRQPMEIEQFC-UAWLTFRCSA-N;CCCCC(C)CC(C=CC1C(CC(=O)C1CCCCC=CC(=O)O)O)O;3805;41;948;511;0;3;5;13;27;4;Approved;1988;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;8B42;Myelopathy;3;Active;740682437;17209669, 38171315, 29080243
270;limaprost;limaprost;CHEMBL2107456;DB09211;6438378;74397-12-9;L02U804092;OJZYRQPMEIEQFC-UAWLTFRCSA-N;CCCCC(C)CC(C=CC1C(CC(=O)C1CCCCC=CC(=O)O)O)O;3805;41;948;511;0;3;5;13;27;4;Approved;1988;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;FA82;Spinal stenosis;4;Approved;1847895828;17209669, 38171315, 29080243
271;itopride;itopride;CHEMBL2107457;DB04924;3792;"122898-67-3;122898-67-3 (free base)";NA;QQQIECGTIMUVDS-UHFFFAOYSA-N;CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC;3584;23;60;411;0;1;5;9;26;4;Approved;2015;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;35357058, 28217377, 23326147
271;itopride;itopride;CHEMBL2107457;DB04924;3792;"122898-67-3;122898-67-3 (free base)";NA;QQQIECGTIMUVDS-UHFFFAOYSA-N;CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC;3584;23;60;411;0;1;5;9;26;4;Approved;2015;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;DA41.00;Gastroparesis;4;Approved;598423727;35357058, 28217377, 23326147
271;itopride;itopride;CHEMBL2107457;DB04924;3792;"122898-67-3;122898-67-3 (free base)";NA;QQQIECGTIMUVDS-UHFFFAOYSA-N;CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC;3584;23;60;411;0;1;5;9;26;4;Approved;2015;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;DC50.Z;Peritonitis, unspecified;3;Active;775356003/unspecified;35357058, 28217377, 23326147
271;itopride;itopride;CHEMBL2107457;DB04924;3792;"122898-67-3;122898-67-3 (free base)";NA;QQQIECGTIMUVDS-UHFFFAOYSA-N;CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC;3584;23;60;411;0;1;5;9;26;4;Approved;2015;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;2;Inactive;1158238623/unspecified;35357058, 28217377, 23326147
271;itopride;itopride;CHEMBL2107457;DB04924;3792;"122898-67-3;122898-67-3 (free base)";NA;QQQIECGTIMUVDS-UHFFFAOYSA-N;CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC;3584;23;60;411;0;1;5;9;26;4;Approved;2015;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD92;Dyspepsia;4;Approved;869622187;35357058, 28217377, 23326147
271;itopride;itopride;CHEMBL2107457;DB04924;3792;"122898-67-3;122898-67-3 (free base)";NA;QQQIECGTIMUVDS-UHFFFAOYSA-N;CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC;3584;23;60;411;0;1;5;9;26;4;Approved;2015;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;ME05.0;Constipation;2;Inactive;502284069;35357058, 28217377, 23326147
272;vibegron;vibegron;CHEMBL2107826;DB14895;44472635;1190389-15-1;M5TSE03W5U;DJXRIQMCROIRCZ-XOEOCAAJSA-N;C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O;4445;18;94;782;0;3;5;6;33;4;Approved;2018;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;2;Inactive;1158238623/unspecified;37535798, 34537953, 33704365
272;vibegron;vibegron;CHEMBL2107826;DB14895;44472635;1190389-15-1;M5TSE03W5U;DJXRIQMCROIRCZ-XOEOCAAJSA-N;C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O;4445;18;94;782;0;3;5;6;33;4;Approved;2018;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;37535798, 34537953, 33704365
272;vibegron;vibegron;CHEMBL2107826;DB14895;44472635;1190389-15-1;M5TSE03W5U;DJXRIQMCROIRCZ-XOEOCAAJSA-N;C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O;4445;18;94;782;0;3;5;6;33;4;Approved;2018;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;4;Approved;766129123/unspecified;37535798, 34537953, 33704365
273;albiglutide;albiglutide;CHEMBL2107841;DB09043;145994868;782500-75-8;5E7U48495E;JYDZPPZAYQTOIV-OTSUTHPESA-N;CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC6=CN=CN6)N;32836;-146;1390;7620;0;49;50;109;233;4;Approved;2014;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A10;Type 1 diabetes mellitus;2;Inactive;1651053999;31643385, 30291013, 27904741
273;albiglutide;albiglutide;CHEMBL2107841;DB09043;145994868;782500-75-8;5E7U48495E;JYDZPPZAYQTOIV-OTSUTHPESA-N;CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC6=CN=CN6)N;32836;-146;1390;7620;0;49;50;109;233;4;Approved;2014;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;4;Approved;119724091;31643385, 30291013, 27904741
273;albiglutide;albiglutide;CHEMBL2107841;DB09043;145994868;782500-75-8;5E7U48495E;JYDZPPZAYQTOIV-OTSUTHPESA-N;CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC6=CN=CN6)N;32836;-146;1390;7620;0;49;50;109;233;4;Approved;2014;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A14;Diabetes mellitus, type unspecified;4;Approved;1697306310;31643385, 30291013, 27904741
273;albiglutide;albiglutide;CHEMBL2107841;DB09043;145994868;782500-75-8;5E7U48495E;JYDZPPZAYQTOIV-OTSUTHPESA-N;CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC6=CN=CN6)N;32836;-146;1390;7620;0;49;50;109;233;4;Approved;2014;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;BD10;Congestive heart failure;2;Inactive;2136808878;31643385, 30291013, 27904741
274;dulaglutide;dulaglutide;CHEMBL2108027;DB09045;;923950-08-7;WTT295HSY5;NA;NA;;;;;;;;;;4;Approved;2014;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A10;Type 1 diabetes mellitus;2;Inactive;1651053999;31189511, 29397376, 35658022
274;dulaglutide;dulaglutide;CHEMBL2108027;DB09045;;923950-08-7;WTT295HSY5;NA;NA;;;;;;;;;;4;Approved;2014;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;4;Approved;119724091;31189511, 29397376, 35658022
274;dulaglutide;dulaglutide;CHEMBL2108027;DB09045;;923950-08-7;WTT295HSY5;NA;NA;;;;;;;;;;4;Approved;2014;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A14;Diabetes mellitus, type unspecified;4;Approved;1697306310;31189511, 29397376, 35658022
274;dulaglutide;dulaglutide;CHEMBL2108027;DB09045;;923950-08-7;WTT295HSY5;NA;NA;;;;;;;;;;4;Approved;2014;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Active;1699574100/unspecified;31189511, 29397376, 35658022
274;dulaglutide;dulaglutide;CHEMBL2108027;DB09045;;923950-08-7;WTT295HSY5;NA;NA;;;;;;;;;;4;Approved;2014;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;GB61.Z;Chronic kidney disease, stage unspecified;2;Active;412389819/unspecified;31189511, 29397376, 35658022
274;dulaglutide;dulaglutide;CHEMBL2108027;DB09045;;923950-08-7;WTT295HSY5;NA;NA;;;;;;;;;;4;Approved;2014;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;MG43.0;Polydipsia;2;Inactive;439093618;31189511, 29397376, 35658022
275;parathyroid hormone;parathyroid hormone;CHEMBL2108078;DB05829;;9002-64-6;N19A0T0E5J;NA;NA;;;;;;;;;;4;Approved;2015;Protein;Agonist;P49190;pth2r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;5A50.Z;Hypoparathyroidism, unspecified;4;Approved;1708733050/unspecified;37748012, 33706890, 29763115
275;parathyroid hormone;parathyroid hormone;CHEMBL2108078;DB05829;;9002-64-6;N19A0T0E5J;NA;NA;;;;;;;;;;4;Approved;2015;Protein;Agonist;P49190;pth2r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;5B5K.1Z;Calcium deficiency, unspecified;4;Approved;393562786/unspecified;37748012, 33706890, 29763115
275;parathyroid hormone;parathyroid hormone;CHEMBL2108078;DB05829;;9002-64-6;N19A0T0E5J;NA;NA;;;;;;;;;;4;Approved;2015;Protein;Agonist;P49190;pth2r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;EA90.Z;Psoriasis of unspecified type;2;Inactive;63698555/unspecified;37748012, 33706890, 29763115
275;parathyroid hormone;parathyroid hormone;CHEMBL2108078;DB05829;;9002-64-6;N19A0T0E5J;NA;NA;;;;;;;;;;4;Approved;2015;Protein;Agonist;P49190;pth2r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;FB83.11;Postmenopausal osteoporosis;1;Inactive;123797893;37748012, 33706890, 29763115
275;parathyroid hormone;parathyroid hormone;CHEMBL2108078;DB05829;;9002-64-6;N19A0T0E5J;NA;NA;;;;;;;;;;4;Approved;2015;Protein;Agonist;P49190;pth2r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;FB83.1Z;Osteoporosis, unspecified;3;Inactive;2113001430/unspecified;37748012, 33706890, 29763115
275;parathyroid hormone;parathyroid hormone;CHEMBL2108078;DB05829;;9002-64-6;N19A0T0E5J;NA;NA;;;;;;;;;;4;Approved;2015;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;5A50.Z;Hypoparathyroidism, unspecified;4;Approved;1708733050/unspecified;37748012, 33706890, 29763115
275;parathyroid hormone;parathyroid hormone;CHEMBL2108078;DB05829;;9002-64-6;N19A0T0E5J;NA;NA;;;;;;;;;;4;Approved;2015;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;5B5K.1Z;Calcium deficiency, unspecified;4;Approved;393562786/unspecified;37748012, 33706890, 29763115
275;parathyroid hormone;parathyroid hormone;CHEMBL2108078;DB05829;;9002-64-6;N19A0T0E5J;NA;NA;;;;;;;;;;4;Approved;2015;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;EA90.Z;Psoriasis of unspecified type;2;Inactive;63698555/unspecified;37748012, 33706890, 29763115
275;parathyroid hormone;parathyroid hormone;CHEMBL2108078;DB05829;;9002-64-6;N19A0T0E5J;NA;NA;;;;;;;;;;4;Approved;2015;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;FB83.11;Postmenopausal osteoporosis;1;Inactive;123797893;37748012, 33706890, 29763115
275;parathyroid hormone;parathyroid hormone;CHEMBL2108078;DB05829;;9002-64-6;N19A0T0E5J;NA;NA;;;;;;;;;;4;Approved;2015;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;FB83.1Z;Osteoporosis, unspecified;3;Inactive;2113001430/unspecified;37748012, 33706890, 29763115
276;corifollitropin alfa;corifollitropin alfa;CHEMBL2108185;DB09066;;195962-23-3;T7K20Y2GWY;NA;NA;;;;;;;;;;4;Approved;2010;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;5A61.2;Gonadotropin deficiency;4;Approved;1409526590;22129170, 21815699, 19337959
276;corifollitropin alfa;corifollitropin alfa;CHEMBL2108185;DB09066;;195962-23-3;T7K20Y2GWY;NA;NA;;;;;;;;;;4;Approved;2010;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GC8Y;Other specified diseases of the genitourinary system;4;Approved;30659757/other;22129170, 21815699, 19337959
277;lixisenatide;S-lixisenatide;CHEMBL2108336;DB09265;90472060;320367-13-3;74O62BB01U;XVVOERDUTLJJHN-IAEQDCLQSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC8=CNC=N8)N;4858;-308;2090;11800;0;70;77;170;342;4;Approved;2016;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;4;Approved;119724091;31643608, 30000034, 26630143
277;lixisenatide;S-lixisenatide;CHEMBL2108336;DB09265;90472060;320367-13-3;74O62BB01U;XVVOERDUTLJJHN-IAEQDCLQSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC8=CNC=N8)N;4858;-308;2090;11800;0;70;77;170;342;4;Approved;2016;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A14;Diabetes mellitus, type unspecified;4;Approved;1697306310;31643608, 30000034, 26630143
277;lixisenatide;S-lixisenatide;CHEMBL2108336;DB09265;90472060;320367-13-3;74O62BB01U;XVVOERDUTLJJHN-IAEQDCLQSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC8=CNC=N8)N;4858;-308;2090;11800;0;70;77;170;342;4;Approved;2016;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;8A00.0Z;Parkinson disease, unspecified;2;Inactive;296066191/unspecified;31643608, 30000034, 26630143
277;lixisenatide;S-lixisenatide;CHEMBL2108336;DB09265;90472060;320367-13-3;74O62BB01U;XVVOERDUTLJJHN-IAEQDCLQSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC8=CNC=N8)N;4858;-308;2090;11800;0;70;77;170;342;4;Approved;2016;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;BA4Z;Acute ischaemic heart disease, unspecified;3;Inactive;1829545371/unspecified;31643608, 30000034, 26630143
277;lixisenatide;lixisenatide;CHEMBL2108336;DB09265;132427670;320367-13-3;74O62BB01U;XVVOERDUTLJJHN-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC8=CNC=N8)N;4858;-308;2090;11800;0;70;77;170;342;4;Approved;2016;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;4;Approved;119724091;31643608, 30000034, 26630143
277;lixisenatide;lixisenatide;CHEMBL2108336;DB09265;132427670;320367-13-3;74O62BB01U;XVVOERDUTLJJHN-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC8=CNC=N8)N;4858;-308;2090;11800;0;70;77;170;342;4;Approved;2016;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A14;Diabetes mellitus, type unspecified;4;Approved;1697306310;31643608, 30000034, 26630143
277;lixisenatide;lixisenatide;CHEMBL2108336;DB09265;132427670;320367-13-3;74O62BB01U;XVVOERDUTLJJHN-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC8=CNC=N8)N;4858;-308;2090;11800;0;70;77;170;342;4;Approved;2016;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;8A00.0Z;Parkinson disease, unspecified;2;Inactive;296066191/unspecified;31643608, 30000034, 26630143
277;lixisenatide;lixisenatide;CHEMBL2108336;DB09265;132427670;320367-13-3;74O62BB01U;XVVOERDUTLJJHN-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC8=CNC=N8)N;4858;-308;2090;11800;0;70;77;170;342;4;Approved;2016;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;BA4Z;Acute ischaemic heart disease, unspecified;3;Inactive;1829545371/unspecified;31643608, 30000034, 26630143
278;serelaxin;serelaxin;CHEMBL2108358;NA;71300755;NA;NA;DTLOVISJEFBXLX-REAFJZEQSA-N;CCC(C)C1C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)C)C(C)CC)CCC(=O)N)C)CCCNC(=N)N)C(C)C)CC(C)C)CCC(=O)O)CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CO)NC(=O)C(CC(=O)O)N)C(=O)NC(C(=O)NC(C(=O)NCC(=O)N2)C(C)C)CC5=CN=CN5)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CC(C)C)NC(=O)C7CCC(=O)N7)C(C)O)CCCCN)CCCNC(=N)N)CO)CC(C)C)C)CCCNC(=N)N)CC8=CC=CC=C8)C(=O)O)C(=O)NCC(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(CC9=CNC1=CC=CC=C19)C(=O)NC(CO)C(=O)O;5963;-193;2600;14800;0;87;91;194;412;4;Approved;2017;Protein;Agonist;Q8WXD0;rxfp2_human;Class A (Rhodopsin);Relaxin family peptide receptors;Peptide receptors;BA8Z;Diseases of coronary artery, unspecified;2;Inactive;1059873720/unspecified;32226528, 26603680, 31433919
278;serelaxin;serelaxin;CHEMBL2108358;NA;71300755;NA;NA;DTLOVISJEFBXLX-REAFJZEQSA-N;CCC(C)C1C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)C)C(C)CC)CCC(=O)N)C)CCCNC(=N)N)C(C)C)CC(C)C)CCC(=O)O)CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CO)NC(=O)C(CC(=O)O)N)C(=O)NC(C(=O)NC(C(=O)NCC(=O)N2)C(C)C)CC5=CN=CN5)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CC(C)C)NC(=O)C7CCC(=O)N7)C(C)O)CCCCN)CCCNC(=N)N)CO)CC(C)C)C)CCCNC(=N)N)CC8=CC=CC=C8)C(=O)O)C(=O)NCC(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(CC9=CNC1=CC=CC=C19)C(=O)NC(CO)C(=O)O;5963;-193;2600;14800;0;87;91;194;412;4;Approved;2017;Protein;Agonist;Q8WXD0;rxfp2_human;Class A (Rhodopsin);Relaxin family peptide receptors;Peptide receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;32226528, 26603680, 31433919
278;serelaxin;serelaxin;CHEMBL2108358;NA;71300755;NA;NA;DTLOVISJEFBXLX-REAFJZEQSA-N;CCC(C)C1C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)C)C(C)CC)CCC(=O)N)C)CCCNC(=N)N)C(C)C)CC(C)C)CCC(=O)O)CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CO)NC(=O)C(CC(=O)O)N)C(=O)NC(C(=O)NC(C(=O)NCC(=O)N2)C(C)C)CC5=CN=CN5)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CC(C)C)NC(=O)C7CCC(=O)N7)C(C)O)CCCCN)CCCNC(=N)N)CO)CC(C)C)C)CCCNC(=N)N)CC8=CC=CC=C8)C(=O)O)C(=O)NCC(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(CC9=CNC1=CC=CC=C19)C(=O)NC(CO)C(=O)O;5963;-193;2600;14800;0;87;91;194;412;4;Approved;2017;Protein;Agonist;Q9HBX9;rxfp1_human;Class A (Rhodopsin);Relaxin family peptide receptors;Peptide receptors;BA8Z;Diseases of coronary artery, unspecified;2;Inactive;1059873720/unspecified;32226528, 26603680, 31433919
278;serelaxin;serelaxin;CHEMBL2108358;NA;71300755;NA;NA;DTLOVISJEFBXLX-REAFJZEQSA-N;CCC(C)C1C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)C)C(C)CC)CCC(=O)N)C)CCCNC(=N)N)C(C)C)CC(C)C)CCC(=O)O)CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CO)NC(=O)C(CC(=O)O)N)C(=O)NC(C(=O)NC(C(=O)NCC(=O)N2)C(C)C)CC5=CN=CN5)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CC(C)C)NC(=O)C7CCC(=O)N7)C(C)O)CCCCN)CCCNC(=N)N)CO)CC(C)C)C)CCCNC(=N)N)CC8=CC=CC=C8)C(=O)O)C(=O)NCC(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(CC9=CNC1=CC=CC=C19)C(=O)NC(CO)C(=O)O;5963;-193;2600;14800;0;87;91;194;412;4;Approved;2017;Protein;Agonist;Q9HBX9;rxfp1_human;Class A (Rhodopsin);Relaxin family peptide receptors;Peptide receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;32226528, 26603680, 31433919
280;menotropins;menotropins;CHEMBL2108427;DB00032;21888462;9002-68-0;8FYM5179QJ;CBUWTGCATVNMJE-UHFFFAOYSA-N;CC(C)(C)CCCCC=O;14224;3;171;89;0;0;1;5;10;4;Approved;1975;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;5A61.2;Gonadotropin deficiency;2;Inactive;1409526590;1900476, 5694897, 3522280
280;menotropins;menotropins;CHEMBL2108427;DB00032;21888462;9002-68-0;8FYM5179QJ;CBUWTGCATVNMJE-UHFFFAOYSA-N;CC(C)(C)CCCCC=O;14224;3;171;89;0;0;1;5;10;4;Approved;1975;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;5A61.Y;Other specified hypofunction or disorders of pituitary gland;3;Inactive;292840069/other;1900476, 5694897, 3522280
280;menotropins;menotropins;CHEMBL2108427;DB00032;21888462;9002-68-0;8FYM5179QJ;CBUWTGCATVNMJE-UHFFFAOYSA-N;CC(C)(C)CCCCC=O;14224;3;171;89;0;0;1;5;10;4;Approved;1975;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;5A8Z;Disorders of the gonadal hormone system, unspecified;2;Inactive;1465641389/unspecified;1900476, 5694897, 3522280
280;menotropins;menotropins;CHEMBL2108427;DB00032;21888462;9002-68-0;8FYM5179QJ;CBUWTGCATVNMJE-UHFFFAOYSA-N;CC(C)(C)CCCCC=O;14224;3;171;89;0;0;1;5;10;4;Approved;1975;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GA31.Z;Female infertility without specification whether primary or secondary;4;Approved;1237004558/unspecified;1900476, 5694897, 3522280
280;menotropins;menotropins;CHEMBL2108427;DB00032;21888462;9002-68-0;8FYM5179QJ;CBUWTGCATVNMJE-UHFFFAOYSA-N;CC(C)(C)CCCCC=O;14224;3;171;89;0;0;1;5;10;4;Approved;1975;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GB04.0;Azoospermia;2;Unknown;532688254;1900476, 5694897, 3522280
280;menotropins;menotropins;CHEMBL2108427;DB00032;21888462;9002-68-0;8FYM5179QJ;CBUWTGCATVNMJE-UHFFFAOYSA-N;CC(C)(C)CCCCC=O;14224;3;171;89;0;0;1;5;10;4;Approved;1975;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GC8Y;Other specified diseases of the genitourinary system;4;Approved;30659757/other;1900476, 5694897, 3522280
280;menotropins;menotropins;CHEMBL2108427;DB00032;21888462;9002-68-0;8FYM5179QJ;CBUWTGCATVNMJE-UHFFFAOYSA-N;CC(C)(C)CCCCC=O;14224;3;171;89;0;0;1;5;10;4;Approved;1975;Protein;Agonist;P22888;lshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;JB2Z;Delivery, unspecified;4;Approved;973282267/unspecified;1900476, 5694897, 3522280
280;menotropins;menotropins;CHEMBL2108427;DB00032;21888462;9002-68-0;8FYM5179QJ;CBUWTGCATVNMJE-UHFFFAOYSA-N;CC(C)(C)CCCCC=O;14224;3;171;89;0;0;1;5;10;4;Approved;1975;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;5A61.2;Gonadotropin deficiency;2;Inactive;1409526590;1900476, 5694897, 3522280
280;menotropins;menotropins;CHEMBL2108427;DB00032;21888462;9002-68-0;8FYM5179QJ;CBUWTGCATVNMJE-UHFFFAOYSA-N;CC(C)(C)CCCCC=O;14224;3;171;89;0;0;1;5;10;4;Approved;1975;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;5A61.Y;Other specified hypofunction or disorders of pituitary gland;3;Inactive;292840069/other;1900476, 5694897, 3522280
280;menotropins;menotropins;CHEMBL2108427;DB00032;21888462;9002-68-0;8FYM5179QJ;CBUWTGCATVNMJE-UHFFFAOYSA-N;CC(C)(C)CCCCC=O;14224;3;171;89;0;0;1;5;10;4;Approved;1975;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;5A8Z;Disorders of the gonadal hormone system, unspecified;2;Inactive;1465641389/unspecified;1900476, 5694897, 3522280
280;menotropins;menotropins;CHEMBL2108427;DB00032;21888462;9002-68-0;8FYM5179QJ;CBUWTGCATVNMJE-UHFFFAOYSA-N;CC(C)(C)CCCCC=O;14224;3;171;89;0;0;1;5;10;4;Approved;1975;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GA31.Z;Female infertility without specification whether primary or secondary;4;Approved;1237004558/unspecified;1900476, 5694897, 3522280
280;menotropins;menotropins;CHEMBL2108427;DB00032;21888462;9002-68-0;8FYM5179QJ;CBUWTGCATVNMJE-UHFFFAOYSA-N;CC(C)(C)CCCCC=O;14224;3;171;89;0;0;1;5;10;4;Approved;1975;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GB04.0;Azoospermia;2;Unknown;532688254;1900476, 5694897, 3522280
280;menotropins;menotropins;CHEMBL2108427;DB00032;21888462;9002-68-0;8FYM5179QJ;CBUWTGCATVNMJE-UHFFFAOYSA-N;CC(C)(C)CCCCC=O;14224;3;171;89;0;0;1;5;10;4;Approved;1975;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GC8Y;Other specified diseases of the genitourinary system;4;Approved;30659757/other;1900476, 5694897, 3522280
280;menotropins;menotropins;CHEMBL2108427;DB00032;21888462;9002-68-0;8FYM5179QJ;CBUWTGCATVNMJE-UHFFFAOYSA-N;CC(C)(C)CCCCC=O;14224;3;171;89;0;0;1;5;10;4;Approved;1975;Protein;Agonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;JB2Z;Delivery, unspecified;4;Approved;973282267/unspecified;1900476, 5694897, 3522280
281;semaglutide;semaglutide;CHEMBL2108724;NA;56843331;NA;NA;DLSWIYLPEUIQAV-CCUURXOWSA-N;CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N;4114;-58;1650;9590;0;57;63;151;291;4;Approved;2017;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A10;Type 1 diabetes mellitus;3;Active;1651053999;33567185, 34305810, 36322838
281;semaglutide;semaglutide;CHEMBL2108724;NA;56843331;NA;NA;DLSWIYLPEUIQAV-CCUURXOWSA-N;CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N;4114;-58;1650;9590;0;57;63;151;291;4;Approved;2017;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;4;Approved;119724091;33567185, 34305810, 36322838
281;semaglutide;semaglutide;CHEMBL2108724;NA;56843331;NA;NA;DLSWIYLPEUIQAV-CCUURXOWSA-N;CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N;4114;-58;1650;9590;0;57;63;151;291;4;Approved;2017;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A14;Diabetes mellitus, type unspecified;4;Approved;1697306310;33567185, 34305810, 36322838
281;semaglutide;semaglutide;CHEMBL2108724;NA;56843331;NA;NA;DLSWIYLPEUIQAV-CCUURXOWSA-N;CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N;4114;-58;1650;9590;0;57;63;151;291;4;Approved;2017;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;33567185, 34305810, 36322838
281;semaglutide;semaglutide;CHEMBL2108724;NA;56843331;NA;NA;DLSWIYLPEUIQAV-CCUURXOWSA-N;CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N;4114;-58;1650;9590;0;57;63;151;291;4;Approved;2017;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;8A00.0Z;Parkinson disease, unspecified;2;Active;296066191/unspecified;33567185, 34305810, 36322838
281;semaglutide;semaglutide;CHEMBL2108724;NA;56843331;NA;NA;DLSWIYLPEUIQAV-CCUURXOWSA-N;CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N;4114;-58;1650;9590;0;57;63;151;291;4;Approved;2017;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;8A20;Alzheimer disease;3;Active;1611724421;33567185, 34305810, 36322838
281;semaglutide;semaglutide;CHEMBL2108724;NA;56843331;NA;NA;DLSWIYLPEUIQAV-CCUURXOWSA-N;CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N;4114;-58;1650;9590;0;57;63;151;291;4;Approved;2017;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;BA8Z;Diseases of coronary artery, unspecified;3;Active;1059873720/unspecified;33567185, 34305810, 36322838
281;semaglutide;semaglutide;CHEMBL2108724;NA;56843331;NA;NA;DLSWIYLPEUIQAV-CCUURXOWSA-N;CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N;4114;-58;1650;9590;0;57;63;151;291;4;Approved;2017;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;CA23;Asthma;2;Active;1656445230;33567185, 34305810, 36322838
281;semaglutide;semaglutide;CHEMBL2108724;NA;56843331;NA;NA;DLSWIYLPEUIQAV-CCUURXOWSA-N;CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N;4114;-58;1650;9590;0;57;63;151;291;4;Approved;2017;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;3;Active;1884917970;33567185, 34305810, 36322838
281;semaglutide;semaglutide;CHEMBL2108724;NA;56843331;NA;NA;DLSWIYLPEUIQAV-CCUURXOWSA-N;CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N;4114;-58;1650;9590;0;57;63;151;291;4;Approved;2017;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.Z;Non-alcoholic fatty liver disease, unspecified;3;Active;1912806631/unspecified;33567185, 34305810, 36322838
281;semaglutide;semaglutide;CHEMBL2108724;NA;56843331;NA;NA;DLSWIYLPEUIQAV-CCUURXOWSA-N;CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N;4114;-58;1650;9590;0;57;63;151;291;4;Approved;2017;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;FB83.0Z;Osteopenia, unspecified;2;Unknown;611604654/unspecified;33567185, 34305810, 36322838
281;semaglutide;semaglutide;CHEMBL2108724;NA;56843331;NA;NA;DLSWIYLPEUIQAV-CCUURXOWSA-N;CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N;4114;-58;1650;9590;0;57;63;151;291;4;Approved;2017;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;2;Unknown;1282135070/unspecified;33567185, 34305810, 36322838
282;leronlimab;leronlimab;CHEMBL2109343;DB05941;;674782-26-4;Y1J4NP8FF0;NA;NA;;;;;;;;;;3;Active;NA;Antibody;Antagonist;P51681;ccr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;1C62.Z;Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified;3;Active;1508081745/unspecified;33485378, 33079180, 33521616
282;leronlimab;leronlimab;CHEMBL2109343;DB05941;;674782-26-4;Y1J4NP8FF0;NA;NA;;;;;;;;;;3;Active;NA;Antibody;Antagonist;P51681;ccr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2F95;Neoplasms of unknown behaviour of breast;2;Unknown;1623614569;33485378, 33079180, 33521616
282;leronlimab;leronlimab;CHEMBL2109343;DB05941;;674782-26-4;Y1J4NP8FF0;NA;NA;;;;;;;;;;3;Active;NA;Antibody;Antagonist;P51681;ccr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;4B24.Z;Graft-versus-host disease, unspecified;2;Inactive;437372167/unspecified;33485378, 33079180, 33521616
282;leronlimab;leronlimab;CHEMBL2109343;DB05941;;674782-26-4;Y1J4NP8FF0;NA;NA;;;;;;;;;;3;Active;NA;Antibody;Antagonist;P51681;ccr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;DB92.1;Non-alcoholic steatohepatitis;2;Inactive;1884917970;33485378, 33079180, 33521616
282;leronlimab;leronlimab;CHEMBL2109343;DB05941;;674782-26-4;Y1J4NP8FF0;NA;NA;;;;;;;;;;3;Active;NA;Antibody;Antagonist;P51681;ccr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;RA01;COVID-19;3;Active;1730556128;33485378, 33079180, 33521616
283;anamorelin;anamorelin;CHEMBL2110579;DB06645;9828911;249921-19-5;NA;VQPFSIRUEPQQPP-MXBOTTGLSA-N;CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC(C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N;5467;28;115;904;0;3;5;9;40;4;Approved;2020;Small molecule;Agonist;Q92847;ghsr_human;Class A (Rhodopsin);Ghrelin receptors;Peptide receptors;2B72.Z;Malignant neoplasms of stomach, unspecified;4;Approved;1397617262/unspecified;35274629, 37389636, 29205286
283;anamorelin;anamorelin;CHEMBL2110579;DB06645;9828911;249921-19-5;NA;VQPFSIRUEPQQPP-MXBOTTGLSA-N;CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC(C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N;5467;28;115;904;0;3;5;9;40;4;Approved;2020;Small molecule;Agonist;Q92847;ghsr_human;Class A (Rhodopsin);Ghrelin receptors;Peptide receptors;2B91.Z;Malignant neoplasms of rectosigmoid junction, unspecified;4;Approved;774170412/unspecified;35274629, 37389636, 29205286
283;anamorelin;anamorelin;CHEMBL2110579;DB06645;9828911;249921-19-5;NA;VQPFSIRUEPQQPP-MXBOTTGLSA-N;CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC(C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N;5467;28;115;904;0;3;5;9;40;4;Approved;2020;Small molecule;Agonist;Q92847;ghsr_human;Class A (Rhodopsin);Ghrelin receptors;Peptide receptors;2C10.Y;Other specified malignant neoplasms of pancreas;4;Approved;542147910/other;35274629, 37389636, 29205286
283;anamorelin;anamorelin;CHEMBL2110579;DB06645;9828911;249921-19-5;NA;VQPFSIRUEPQQPP-MXBOTTGLSA-N;CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC(C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N;5467;28;115;904;0;3;5;9;40;4;Approved;2020;Small molecule;Agonist;Q92847;ghsr_human;Class A (Rhodopsin);Ghrelin receptors;Peptide receptors;2C25.Y;Other specified malignant neoplasms of bronchus or lung;4;Approved;316539081/other;35274629, 37389636, 29205286
283;anamorelin;anamorelin;CHEMBL2110579;DB06645;9828911;249921-19-5;NA;VQPFSIRUEPQQPP-MXBOTTGLSA-N;CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC(C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N;5467;28;115;904;0;3;5;9;40;4;Approved;2020;Small molecule;Agonist;Q92847;ghsr_human;Class A (Rhodopsin);Ghrelin receptors;Peptide receptors;MG20.Z;Cachexia, unspecified;4;Approved;914154382/unspecified;35274629, 37389636, 29205286
283;anamorelin;anamorelin;CHEMBL2110579;DB06645;9828911;249921-19-5;NA;VQPFSIRUEPQQPP-MXBOTTGLSA-N;CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC(C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N;5467;28;115;904;0;3;5;9;40;4;Approved;2020;Small molecule;Agonist;Q92847;ghsr_human;Class A (Rhodopsin);Ghrelin receptors;Peptide receptors;MG22;Fatigue;2;Active;1109546957;35274629, 37389636, 29205286
285;chlorphenoxamine;chlorphenoxamine;CHEMBL2110774;DB09007;6475;77-38-3;NA;KKHPNPMTPORSQE-UHFFFAOYSA-N;CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCN(C)C;3038;41;125;296;0;0;2;6;21;4;Approved;1959;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA8Z;Dermatitis or eczema, unspecified;4;Approved;1887882424/unspecified;13779077, 13819745, 14455272
285;chlorphenoxamine;chlorphenoxamine;CHEMBL2110774;DB09007;6475;77-38-3;NA;KKHPNPMTPORSQE-UHFFFAOYSA-N;CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCN(C)C;3038;41;125;296;0;0;2;6;21;4;Approved;1959;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;13779077, 13819745, 14455272
285;chlorphenoxamine;chlorphenoxamine;CHEMBL2110774;DB09007;6475;77-38-3;NA;KKHPNPMTPORSQE-UHFFFAOYSA-N;CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCN(C)C;3038;41;125;296;0;0;2;6;21;4;Approved;1959;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;13779077, 13819745, 14455272
286;buserelin;buserelin;CHEMBL2110824;DB06719;50225;57982-77-1;PXW8U3YXDV;CUWODFFVMXJOKD-UVLQAERKSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12394;-1;441;2450;0;15;15;33;89;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;4;Approved;1047754165/unspecified;8156885, 35410205, 2109679
286;buserelin;buserelin;CHEMBL2110824;DB06719;50225;57982-77-1;PXW8U3YXDV;CUWODFFVMXJOKD-UVLQAERKSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12394;-1;441;2450;0;15;15;33;89;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.0;Adenocarcinoma of prostate;4;Approved;1510677183;8156885, 35410205, 2109679
286;buserelin;buserelin;CHEMBL2110824;DB06719;50225;57982-77-1;PXW8U3YXDV;CUWODFFVMXJOKD-UVLQAERKSA-N;CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6;12394;-1;441;2450;0;15;15;33;89;4;Approved;1985;Protein;Agonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;4;Approved;1552457716/unspecified;8156885, 35410205, 2109679
287;dapoxetine;dapoxetine;CHEMBL2110900;DB04884;71353;119356-77-3;GB2433A4M3;USRHYDPUVLEVMC-FQEVSTJZSA-N;CN(C)C(CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3;3054;51;125;337;0;0;2;6;23;4;Approved;2009;Small molecule;Inhibitor;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;HA03.0Z;Male early ejaculation, unspecified;4;Approved;361151087/unspecified;37267615, 34773634, 16128601
287;dapoxetine;dapoxetine;CHEMBL2110900;DB04884;71353;119356-77-3;GB2433A4M3;USRHYDPUVLEVMC-FQEVSTJZSA-N;CN(C)C(CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3;3054;51;125;337;0;0;2;6;23;4;Approved;2009;Small molecule;Inhibitor;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;HA03.0Z;Male early ejaculation, unspecified;4;Approved;361151087/unspecified;37267615, 34773634, 16128601
287;dapoxetine;dapoxetine;CHEMBL2110900;DB04884;71353;119356-77-3;GB2433A4M3;USRHYDPUVLEVMC-FQEVSTJZSA-N;CN(C)C(CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3;3054;51;125;337;0;0;2;6;23;4;Approved;2009;Small molecule;Inhibitor;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;HA03.0Z;Male early ejaculation, unspecified;4;Approved;361151087/unspecified;37267615, 34773634, 16128601
289;pimavanserin;pimavanserin;CHEMBL2111101;DB05316;10071196;706779-91-1;JZ963P0DIK;RKEWSXXUOLRFBX-UHFFFAOYSA-N;CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C;4276;45;448;523;0;1;4;8;31;4;Approved;2016;Small molecule;Inverse agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;3;Active;1683919430/unspecified;34289275, 36153942, 32491644
289;pimavanserin;pimavanserin;CHEMBL2111101;DB05316;10071196;706779-91-1;JZ963P0DIK;RKEWSXXUOLRFBX-UHFFFAOYSA-N;CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C;4276;45;448;523;0;1;4;8;31;4;Approved;2016;Small molecule;Inverse agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;34289275, 36153942, 32491644
289;pimavanserin;pimavanserin;CHEMBL2111101;DB05316;10071196;706779-91-1;JZ963P0DIK;RKEWSXXUOLRFBX-UHFFFAOYSA-N;CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C;4276;45;448;523;0;1;4;8;31;4;Approved;2016;Small molecule;Inverse agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6E0Y;Other specified neurocognitive disorders;3;Active;213458094/other;34289275, 36153942, 32491644
289;pimavanserin;pimavanserin;CHEMBL2111101;DB05316;10071196;706779-91-1;JZ963P0DIK;RKEWSXXUOLRFBX-UHFFFAOYSA-N;CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C;4276;45;448;523;0;1;4;8;31;4;Approved;2016;Small molecule;Inverse agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;34289275, 36153942, 32491644
289;pimavanserin;pimavanserin;CHEMBL2111101;DB05316;10071196;706779-91-1;JZ963P0DIK;RKEWSXXUOLRFBX-UHFFFAOYSA-N;CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C;4276;45;448;523;0;1;4;8;31;4;Approved;2016;Small molecule;Inverse agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;1;Inactive;119340957;34289275, 36153942, 32491644
289;pimavanserin;pimavanserin;CHEMBL2111101;DB05316;10071196;706779-91-1;JZ963P0DIK;RKEWSXXUOLRFBX-UHFFFAOYSA-N;CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C;4276;45;448;523;0;1;4;8;31;4;Approved;2016;Small molecule;Inverse agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A20;Alzheimer disease;2;Inactive;1611724421;34289275, 36153942, 32491644
289;pimavanserin;pimavanserin;CHEMBL2111101;DB05316;10071196;706779-91-1;JZ963P0DIK;RKEWSXXUOLRFBX-UHFFFAOYSA-N;CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C;4276;45;448;523;0;1;4;8;31;4;Approved;2016;Small molecule;Inverse agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB27.2Z;Hallucinations, unspecified;4;Approved;665363966/unspecified;34289275, 36153942, 32491644
290;pranlukast;pranlukast;CHEMBL21333;DB01411;4887;103177-37-3;TB8Z891092;NBQKINXMPLXUET-UHFFFAOYSA-N;C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4=C3OC(=CC4=O)C5=NNN=N5;4815;42;119;778;0;2;7;9;36;4;Approved;1995;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;12699401, 35268621, 32494122
290;pranlukast;pranlukast;CHEMBL21333;DB01411;4887;103177-37-3;TB8Z891092;NBQKINXMPLXUET-UHFFFAOYSA-N;C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4=C3OC(=CC4=O)C5=NNN=N5;4815;42;119;778;0;2;7;9;36;4;Approved;1995;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CA23;Asthma;4;Approved;1656445230;12699401, 35268621, 32494122
291;terlipressin;terlipressin;CHEMBL2135460;DB02638;72081;14636-12-5;7Z5X49W53P;BENFXAYNYRLAIU-QSVFAHTRSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N;12274;-58;563;2380;0;16;19;25;85;4;Approved;1980;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;1G41;Sepsis with septic shock;2;Inactive;1683090852;33657294, 29668606, 25644760
291;terlipressin;terlipressin;CHEMBL2135460;DB02638;72081;14636-12-5;7Z5X49W53P;BENFXAYNYRLAIU-QSVFAHTRSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N;12274;-58;563;2380;0;16;19;25;85;4;Approved;1980;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;DB99.7;Hepatic failure without mention whether acute or chronic;2;Inactive;508643963;33657294, 29668606, 25644760
291;terlipressin;terlipressin;CHEMBL2135460;DB02638;72081;14636-12-5;7Z5X49W53P;BENFXAYNYRLAIU-QSVFAHTRSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N;12274;-58;563;2380;0;16;19;25;85;4;Approved;1980;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GB6Z;Kidney failure, unspecified;4;Approved;761526554/unspecified;33657294, 29668606, 25644760
291;terlipressin;terlipressin;CHEMBL2135460;DB02638;72081;14636-12-5;7Z5X49W53P;BENFXAYNYRLAIU-QSVFAHTRSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N;12274;-58;563;2380;0;16;19;25;85;4;Approved;1980;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MD22;Haemoptysis;3;Active;899998313;33657294, 29668606, 25644760
291;terlipressin;terlipressin;CHEMBL2135460;DB02638;72081;14636-12-5;7Z5X49W53P;BENFXAYNYRLAIU-QSVFAHTRSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N;12274;-58;563;2380;0;16;19;25;85;4;Approved;1980;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG27;Haemorrhage, not elsewhere classified;2;Inactive;940081636;33657294, 29668606, 25644760
291;terlipressin;terlipressin;CHEMBL2135460;DB02638;72081;14636-12-5;7Z5X49W53P;BENFXAYNYRLAIU-QSVFAHTRSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N;12274;-58;563;2380;0;16;19;25;85;4;Approved;1980;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;1G41;Sepsis with septic shock;2;Inactive;1683090852;33657294, 29668606, 25644760
291;terlipressin;terlipressin;CHEMBL2135460;DB02638;72081;14636-12-5;7Z5X49W53P;BENFXAYNYRLAIU-QSVFAHTRSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N;12274;-58;563;2380;0;16;19;25;85;4;Approved;1980;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;DB99.7;Hepatic failure without mention whether acute or chronic;2;Inactive;508643963;33657294, 29668606, 25644760
291;terlipressin;terlipressin;CHEMBL2135460;DB02638;72081;14636-12-5;7Z5X49W53P;BENFXAYNYRLAIU-QSVFAHTRSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N;12274;-58;563;2380;0;16;19;25;85;4;Approved;1980;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GB6Z;Kidney failure, unspecified;4;Approved;761526554/unspecified;33657294, 29668606, 25644760
291;terlipressin;terlipressin;CHEMBL2135460;DB02638;72081;14636-12-5;7Z5X49W53P;BENFXAYNYRLAIU-QSVFAHTRSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N;12274;-58;563;2380;0;16;19;25;85;4;Approved;1980;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MD22;Haemoptysis;3;Active;899998313;33657294, 29668606, 25644760
291;terlipressin;terlipressin;CHEMBL2135460;DB02638;72081;14636-12-5;7Z5X49W53P;BENFXAYNYRLAIU-QSVFAHTRSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N;12274;-58;563;2380;0;16;19;25;85;4;Approved;1980;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG27;Haemorrhage, not elsewhere classified;2;Inactive;940081636;33657294, 29668606, 25644760
291;terlipressin;terlipressin;CHEMBL2135460;DB02638;72081;14636-12-5;7Z5X49W53P;BENFXAYNYRLAIU-QSVFAHTRSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N;12274;-58;563;2380;0;16;19;25;85;4;Approved;1980;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;1G41;Sepsis with septic shock;2;Inactive;1683090852;33657294, 29668606, 25644760
291;terlipressin;terlipressin;CHEMBL2135460;DB02638;72081;14636-12-5;7Z5X49W53P;BENFXAYNYRLAIU-QSVFAHTRSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N;12274;-58;563;2380;0;16;19;25;85;4;Approved;1980;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;DB99.7;Hepatic failure without mention whether acute or chronic;2;Inactive;508643963;33657294, 29668606, 25644760
291;terlipressin;terlipressin;CHEMBL2135460;DB02638;72081;14636-12-5;7Z5X49W53P;BENFXAYNYRLAIU-QSVFAHTRSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N;12274;-58;563;2380;0;16;19;25;85;4;Approved;1980;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GB6Z;Kidney failure, unspecified;4;Approved;761526554/unspecified;33657294, 29668606, 25644760
291;terlipressin;terlipressin;CHEMBL2135460;DB02638;72081;14636-12-5;7Z5X49W53P;BENFXAYNYRLAIU-QSVFAHTRSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N;12274;-58;563;2380;0;16;19;25;85;4;Approved;1980;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MD22;Haemoptysis;3;Active;899998313;33657294, 29668606, 25644760
291;terlipressin;terlipressin;CHEMBL2135460;DB02638;72081;14636-12-5;7Z5X49W53P;BENFXAYNYRLAIU-QSVFAHTRSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N;12274;-58;563;2380;0;16;19;25;85;4;Approved;1980;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG27;Haemorrhage, not elsewhere classified;2;Inactive;940081636;33657294, 29668606, 25644760
292;taladegib;taladegib;CHEMBL2142592;DB12550;49848070;1258861-20-9;NA;SZBGQDXLNMELTB-UHFFFAOYSA-N;CN1C(=CC=N1)C2=NN=C(C3=CC=CC=C32)N4CCC(CC4)N(C)C(=O)C5=C(C=C(C=C5)F)C(F)(F)F;5125;43;672;794;0;0;9;4;37;2;Active;NA;Small molecule;Antagonist;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C25.1;Small cell carcinoma of bronchus or lung;2;Inactive;1800431439;29159582, 32509193, 29453627
292;taladegib;taladegib;CHEMBL2142592;DB12550;49848070;1258861-20-9;NA;SZBGQDXLNMELTB-UHFFFAOYSA-N;CN1C(=CC=N1)C2=NN=C(C3=CC=CC=C32)N4CCC(CC4)N(C)C(=O)C5=C(C=C(C=C5)F)C(F)(F)F;5125;43;672;794;0;0;9;4;37;2;Active;NA;Small molecule;Antagonist;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;CB03.4;Idiopathic pulmonary fibrosis;2;Active;1074069640;29159582, 32509193, 29453627
293;xanomeline;xanomeline;CHEMBL21536;DB15357;60809;"1018845-70-9;131986-45-3";NA;JOLJIIDDOBNFHW-UHFFFAOYSA-N;CCCCCCOC1=NSN=C1C2=CCCN(C2)C;28142;33;665;298;0;0;5;7;19;4;Approved;2024;Small molecule;Agonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;28141924, 37193547, 36414626
293;xanomeline;xanomeline;CHEMBL21536;DB15357;60809;"1018845-70-9;131986-45-3";NA;JOLJIIDDOBNFHW-UHFFFAOYSA-N;CCCCCCOC1=NSN=C1C2=CCCN(C2)C;28142;33;665;298;0;0;5;7;19;4;Approved;2024;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;28141924, 37193547, 36414626
294;eluxadoline;eluxadoline;CHEMBL2159122;DB09272;11250029;864821-90-9;45TPJ4MBQ1;QFNHIDANIVGXPE-FNZWTVRRSA-N;CC1=CC(=CC(=C1CC(C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)C(C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N;5696;9;165;917;0;4;7;11;42;4;Approved;2015;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;30694622, 31644175, 28493170
294;eluxadoline;eluxadoline;CHEMBL2159122;DB09272;11250029;864821-90-9;45TPJ4MBQ1;QFNHIDANIVGXPE-FNZWTVRRSA-N;CC1=CC(=CC(=C1CC(C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)C(C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N;5696;9;165;917;0;4;7;11;42;4;Approved;2015;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;30694622, 31644175, 28493170
294;eluxadoline;eluxadoline;CHEMBL2159122;DB09272;11250029;864821-90-9;45TPJ4MBQ1;QFNHIDANIVGXPE-FNZWTVRRSA-N;CC1=CC(=CC(=C1CC(C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)C(C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N;5696;9;165;917;0;4;7;11;42;4;Approved;2015;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;30694622, 31644175, 28493170
295;aprocitentan;aprocitentan;CHEMBL2165326;DB15059;25099191;1103522-45-7;NA;DKULOVKANLVDEA-UHFFFAOYSA-N;C1=CC(=CC=C1C2=C(N=CN=C2OCCOC3=NC=C(C=N3)Br)NS(=O)(=O)N)Br;5462;24;151;597;0;2;10;8;29;4;Approved;2024;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;36356632, 35686330, 36620614
295;aprocitentan;aprocitentan;CHEMBL2165326;DB15059;25099191;1103522-45-7;NA;DKULOVKANLVDEA-UHFFFAOYSA-N;C1=CC(=CC=C1C2=C(N=CN=C2OCCOC3=NC=C(C=N3)Br)NS(=O)(=O)N)Br;5462;24;151;597;0;2;10;8;29;4;Approved;2024;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;36356632, 35686330, 36620614
296;rimegepant;rimegepant;CHEMBL2178422;DB12457;51049968;1289023-67-1;997WVV895X;KRNAOFGYEFKHPB-ANJVHQHFSA-N;C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6;5346;23;114;891;0;2;8;4;39;4;Approved;2020;Small molecule;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;8A80.0;Migraine without aura;4;Approved;2048783472;33338437, 36739335, 31311674
296;rimegepant;rimegepant;CHEMBL2178422;DB12457;51049968;1289023-67-1;997WVV895X;KRNAOFGYEFKHPB-ANJVHQHFSA-N;C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6;5346;23;114;891;0;2;8;4;39;4;Approved;2020;Small molecule;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;33338437, 36739335, 31311674
296;rimegepant;rimegepant;CHEMBL2178422;DB12457;51049968;1289023-67-1;997WVV895X;KRNAOFGYEFKHPB-ANJVHQHFSA-N;C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6;5346;23;114;891;0;2;8;4;39;4;Approved;2020;Small molecule;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;33338437, 36739335, 31311674
296;rimegepant;rimegepant;CHEMBL2178422;DB12457;51049968;1289023-67-1;997WVV895X;KRNAOFGYEFKHPB-ANJVHQHFSA-N;C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6;5346;23;114;891;0;2;8;4;39;4;Approved;2020;Small molecule;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;33338437, 36739335, 31311674
296;rimegepant;rimegepant;CHEMBL2178422;DB12457;51049968;1289023-67-1;997WVV895X;KRNAOFGYEFKHPB-ANJVHQHFSA-N;C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6;5346;23;114;891;0;2;8;4;39;4;Approved;2020;Small molecule;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;DA0E.8;Temporomandibular joint disorders;3;Active;897101649;33338437, 36739335, 31311674
296;rimegepant;rimegepant;CHEMBL2178422;DB12457;51049968;1289023-67-1;997WVV895X;KRNAOFGYEFKHPB-ANJVHQHFSA-N;C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6;5346;23;114;891;0;2;8;4;39;4;Approved;2020;Small molecule;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;EA90.Z;Psoriasis of unspecified type;2;Active;63698555/unspecified;33338437, 36739335, 31311674
298;domperidone;domperidone;CHEMBL219916;DB01184;3151;57808-66-9;5587267Z69;FGXWKSZFVQUSTL-UHFFFAOYSA-N;C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O;4259;39;679;655;0;2;3;5;30;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A40.0;Relapsing-remitting multiple sclerosis;2;Inactive;799053936;17488253, 30000430, 37159421
298;domperidone;domperidone;CHEMBL219916;DB01184;3151;57808-66-9;5587267Z69;FGXWKSZFVQUSTL-UHFFFAOYSA-N;C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O;4259;39;679;655;0;2;3;5;30;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A40.Y;Other specified multiple sclerosis;2;Inactive;1298865187/other;17488253, 30000430, 37159421
298;domperidone;domperidone;CHEMBL219916;DB01184;3151;57808-66-9;5587267Z69;FGXWKSZFVQUSTL-UHFFFAOYSA-N;C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O;4259;39;679;655;0;2;3;5;30;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;DA41.00;Gastroparesis;4;Approved;598423727;17488253, 30000430, 37159421
298;domperidone;domperidone;CHEMBL219916;DB01184;3151;57808-66-9;5587267Z69;FGXWKSZFVQUSTL-UHFFFAOYSA-N;C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O;4259;39;679;655;0;2;3;5;30;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;17488253, 30000430, 37159421
298;domperidone;domperidone;CHEMBL219916;DB01184;3151;57808-66-9;5587267Z69;FGXWKSZFVQUSTL-UHFFFAOYSA-N;C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O;4259;39;679;655;0;2;3;5;30;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;17488253, 30000430, 37159421
298;domperidone;domperidone;CHEMBL219916;DB01184;3151;57808-66-9;5587267Z69;FGXWKSZFVQUSTL-UHFFFAOYSA-N;C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O;4259;39;679;655;0;2;3;5;30;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.1;Vomiting;4;Approved;447658033;17488253, 30000430, 37159421
298;domperidone;domperidone;CHEMBL219916;DB01184;3151;57808-66-9;5587267Z69;FGXWKSZFVQUSTL-UHFFFAOYSA-N;C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O;4259;39;679;655;0;2;3;5;30;4;Approved;1979;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A40.0;Relapsing-remitting multiple sclerosis;2;Inactive;799053936;17488253, 30000430, 37159421
298;domperidone;domperidone;CHEMBL219916;DB01184;3151;57808-66-9;5587267Z69;FGXWKSZFVQUSTL-UHFFFAOYSA-N;C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O;4259;39;679;655;0;2;3;5;30;4;Approved;1979;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A40.Y;Other specified multiple sclerosis;2;Inactive;1298865187/other;17488253, 30000430, 37159421
298;domperidone;domperidone;CHEMBL219916;DB01184;3151;57808-66-9;5587267Z69;FGXWKSZFVQUSTL-UHFFFAOYSA-N;C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O;4259;39;679;655;0;2;3;5;30;4;Approved;1979;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;DA41.00;Gastroparesis;4;Approved;598423727;17488253, 30000430, 37159421
298;domperidone;domperidone;CHEMBL219916;DB01184;3151;57808-66-9;5587267Z69;FGXWKSZFVQUSTL-UHFFFAOYSA-N;C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O;4259;39;679;655;0;2;3;5;30;4;Approved;1979;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;17488253, 30000430, 37159421
298;domperidone;domperidone;CHEMBL219916;DB01184;3151;57808-66-9;5587267Z69;FGXWKSZFVQUSTL-UHFFFAOYSA-N;C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O;4259;39;679;655;0;2;3;5;30;4;Approved;1979;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;17488253, 30000430, 37159421
298;domperidone;domperidone;CHEMBL219916;DB01184;3151;57808-66-9;5587267Z69;FGXWKSZFVQUSTL-UHFFFAOYSA-N;C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O;4259;39;679;655;0;2;3;5;30;4;Approved;1979;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.1;Vomiting;4;Approved;447658033;17488253, 30000430, 37159421
299;dimethindene;dimethindene;CHEMBL22108;DB08801;21855;5636-83-9;661FH77Z3P;MVMQESMQSYOVGV-UHFFFAOYSA-N;CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C;2924;27;161;399;0;0;2;5;22;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;36364422, 7726737, 12593665
299;dimethindene;dimethindene;CHEMBL22108;DB08801;21855;5636-83-9;661FH77Z3P;MVMQESMQSYOVGV-UHFFFAOYSA-N;CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C;2924;27;161;399;0;0;2;5;22;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NE2Z;Burns, unspecified;4;Approved;163532889/unspecified;36364422, 7726737, 12593665
299;dimethindene;dimethindene;CHEMBL22108;DB08801;21855;5636-83-9;661FH77Z3P;MVMQESMQSYOVGV-UHFFFAOYSA-N;CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C;2924;27;161;399;0;0;2;5;22;4;Approved;1960;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;36364422, 7726737, 12593665
299;dimethindene;dimethindene;CHEMBL22108;DB08801;21855;5636-83-9;661FH77Z3P;MVMQESMQSYOVGV-UHFFFAOYSA-N;CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C;2924;27;161;399;0;0;2;5;22;4;Approved;1960;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;NE2Z;Burns, unspecified;4;Approved;163532889/unspecified;36364422, 7726737, 12593665
300;diquafosol;diquafosol;CHEMBL221326;NA;148197;59985-21-6;NA;NMLMACJWHPHKGR-NCOIDOBVSA-N;C1=CN(C(=O)NC1=O)C2C(C(C(O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OCC3C(C(C(O3)N4C=CC(=O)NC4=O)O)O)O)O;7903;-91;394;1490;0;10;23;14;49;4;Approved;2010;Small molecule;Agonist;P41231;p2ry2_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;9A1Y;Other specified disorders of lacrimal apparatus;4;Approved;1628710366/other;28700254, 26028958, 25968930
300;diquafosol;diquafosol;CHEMBL221326;NA;148197;59985-21-6;NA;NMLMACJWHPHKGR-NCOIDOBVSA-N;C1=CN(C(=O)NC1=O)C2C(C(C(O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OCC3C(C(C(O3)N4C=CC(=O)NC4=O)O)O)O)O;7903;-91;394;1490;0;10;23;14;49;4;Approved;2010;Small molecule;Agonist;P47900;p2ry1_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;9A1Y;Other specified disorders of lacrimal apparatus;4;Approved;1628710366/other;28700254, 26028958, 25968930
300;diquafosol;diquafosol;CHEMBL221326;NA;148197;59985-21-6;NA;NMLMACJWHPHKGR-NCOIDOBVSA-N;C1=CN(C(=O)NC1=O)C2C(C(C(O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OCC3C(C(C(O3)N4C=CC(=O)NC4=O)O)O)O)O;7903;-91;394;1490;0;10;23;14;49;4;Approved;2010;Small molecule;Agonist;P51582;p2ry4_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;9A1Y;Other specified disorders of lacrimal apparatus;4;Approved;1628710366/other;28700254, 26028958, 25968930
300;diquafosol;diquafosol;CHEMBL221326;NA;148197;59985-21-6;NA;NMLMACJWHPHKGR-NCOIDOBVSA-N;C1=CN(C(=O)NC1=O)C2C(C(C(O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OCC3C(C(C(O3)N4C=CC(=O)NC4=O)O)O)O)O;7903;-91;394;1490;0;10;23;14;49;4;Approved;2010;Small molecule;Agonist;Q15077;p2ry6_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;9A1Y;Other specified disorders of lacrimal apparatus;4;Approved;1628710366/other;28700254, 26028958, 25968930
301;chlorcyclizine;chlorcyclizine;CHEMBL22150;DB08936;2710;82-93-9;M26C4IP44P;WFNAKBGANONZEQ-UHFFFAOYSA-N;CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3008;45;65;300;0;0;2;3;21;4;Approved;1949;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;32386595, 21058326, 15666293
302;quinagolide;quinagolide;CHEMBL2218861;NA;55645;130793-77-0;NA;GDFGTRDCCWFXTG-UHFFFAOYSA-N;CCCN1CC(CC2C1CC3=C(C2)C(=CC=C3)O)NS(=O)(=O)N(CC)CC;3956;31;813;576;0;2;6;7;27;4;Approved;1994;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A60.1;Hyperprolactinaemia;4;Approved;1417218455;35163699, 16452531, 31663762
303;nabilone;nabilone;CHEMBL2218896;NA;39860;56496-90-3;NA;GECBBEABIDMGGL-UHFFFAOYSA-N;CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O;3725;64;465;524;0;1;3;6;27;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;5B81.Z;Obesity, unspecified;2;Active;149403041/unspecified;31643201, 31182351, 26923810
303;nabilone;nabilone;CHEMBL2218896;NA;39860;56496-90-3;NA;GECBBEABIDMGGL-UHFFFAOYSA-N;CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O;3725;64;465;524;0;1;3;6;27;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Active;1582741816/unspecified;31643201, 31182351, 26923810
303;nabilone;nabilone;CHEMBL2218896;NA;39860;56496-90-3;NA;GECBBEABIDMGGL-UHFFFAOYSA-N;CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O;3725;64;465;524;0;1;3;6;27;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C41.2Z;Cannabis dependence, unspecified;3;Active;1129015467/unspecified;31643201, 31182351, 26923810
303;nabilone;nabilone;CHEMBL2218896;NA;39860;56496-90-3;NA;GECBBEABIDMGGL-UHFFFAOYSA-N;CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O;3725;64;465;524;0;1;3;6;27;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A00.0Z;Parkinson disease, unspecified;3;Inactive;296066191/unspecified;31643201, 31182351, 26923810
303;nabilone;nabilone;CHEMBL2218896;NA;39860;56496-90-3;NA;GECBBEABIDMGGL-UHFFFAOYSA-N;CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O;3725;64;465;524;0;1;3;6;27;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8E43.0Z;Neuropathic pain, unspecified;3;Inactive;1339785363/unspecified;31643201, 31182351, 26923810
303;nabilone;nabilone;CHEMBL2218896;NA;39860;56496-90-3;NA;GECBBEABIDMGGL-UHFFFAOYSA-N;CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O;3725;64;465;524;0;1;3;6;27;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MB26.A;Suicidal ideation;2;Unknown;778734771;31643201, 31182351, 26923810
303;nabilone;nabilone;CHEMBL2218896;NA;39860;56496-90-3;NA;GECBBEABIDMGGL-UHFFFAOYSA-N;CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O;3725;64;465;524;0;1;3;6;27;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MB47.3;Cramp or spasm;2;Inactive;157838476;31643201, 31182351, 26923810
303;nabilone;nabilone;CHEMBL2218896;NA;39860;56496-90-3;NA;GECBBEABIDMGGL-UHFFFAOYSA-N;CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O;3725;64;465;524;0;1;3;6;27;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MD90;Nausea or vomiting;4;Approved;677319549;31643201, 31182351, 26923810
303;nabilone;nabilone;CHEMBL2218896;NA;39860;56496-90-3;NA;GECBBEABIDMGGL-UHFFFAOYSA-N;CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O;3725;64;465;524;0;1;3;6;27;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MG3Z;Pain, unspecified;2;Unknown;661232217/unspecified;31643201, 31182351, 26923810
304;naloxegol;naloxegol;CHEMBL2219418;DB09049;56959087;854601-70-0;44T7335BKE;XNKCCCKFOQNXKV-ZRSCBOBOSA-N;COCCOCCOCCOCCOCCOCCOCCOC1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC=C)O;6518;-1;127;899;0;2;12;24;46;4;Approved;2014;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DA93.0;Paralytic ileus;3;Active;1868011045;31260226, 31643924, 27582887
304;naloxegol;naloxegol;CHEMBL2219418;DB09049;56959087;854601-70-0;44T7335BKE;XNKCCCKFOQNXKV-ZRSCBOBOSA-N;COCCOCCOCCOCCOCCOCCOCCOC1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC=C)O;6518;-1;127;899;0;2;12;24;46;4;Approved;2014;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DD9Z;Functional gastrointestinal disorders, unspecified;4;Approved;132592466/unspecified;31260226, 31643924, 27582887
304;naloxegol;naloxegol;CHEMBL2219418;DB09049;56959087;854601-70-0;44T7335BKE;XNKCCCKFOQNXKV-ZRSCBOBOSA-N;COCCOCCOCCOCCOCCOCCOCCOC1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC=C)O;6518;-1;127;899;0;2;12;24;46;4;Approved;2014;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME05.0;Constipation;4;Approved;502284069;31260226, 31643924, 27582887
304;naloxegol;naloxegol;CHEMBL2219418;DB09049;56959087;854601-70-0;44T7335BKE;XNKCCCKFOQNXKV-ZRSCBOBOSA-N;COCCOCCOCCOCCOCCOCCOCCOC1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC=C)O;6518;-1;127;899;0;2;12;24;46;4;Approved;2014;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;31260226, 31643924, 27582887
306;flibanserin;flibanserin;CHEMBL231068;DB04908;6918248;167933-07-5;37JK4STR6Z;PPRRDFIXUUSXRA-UHFFFAOYSA-N;C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F;3904;33;388;550;0;1;6;4;28;4;Approved;2015;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;HA0Z;Sexual dysfunctions, unspecified;4;Approved;160690465/unspecified;36943967, 26873507, 31643404
306;flibanserin;flibanserin;CHEMBL231068;DB04908;6918248;167933-07-5;37JK4STR6Z;PPRRDFIXUUSXRA-UHFFFAOYSA-N;C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F;3904;33;388;550;0;1;6;4;28;4;Approved;2015;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;HA0Z;Sexual dysfunctions, unspecified;4;Approved;160690465/unspecified;36943967, 26873507, 31643404
306;flibanserin;flibanserin;CHEMBL231068;DB04908;6918248;167933-07-5;37JK4STR6Z;PPRRDFIXUUSXRA-UHFFFAOYSA-N;C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F;3904;33;388;550;0;1;6;4;28;4;Approved;2015;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;HA0Z;Sexual dysfunctions, unspecified;4;Approved;160690465/unspecified;36943967, 26873507, 31643404
306;flibanserin;flibanserin;CHEMBL231068;DB04908;6918248;167933-07-5;37JK4STR6Z;PPRRDFIXUUSXRA-UHFFFAOYSA-N;C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F;3904;33;388;550;0;1;6;4;28;4;Approved;2015;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;HA0Z;Sexual dysfunctions, unspecified;4;Approved;160690465/unspecified;36943967, 26873507, 31643404
306;flibanserin;flibanserin;CHEMBL231068;DB04908;6918248;167933-07-5;37JK4STR6Z;PPRRDFIXUUSXRA-UHFFFAOYSA-N;C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F;3904;33;388;550;0;1;6;4;28;4;Approved;2015;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;HA0Z;Sexual dysfunctions, unspecified;4;Approved;160690465/unspecified;36943967, 26873507, 31643404
308;siponimod;siponimod;CHEMBL2336071;DB12371;44599207;1230487-00-9;RR6P8L282I;KIHYPELVXPAIDH-HNSNBQBZSA-N;CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O;5166;48;621;777;0;1;8;9;37;4;Approved;2019;Small molecule;Modulator;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;4A41.0Z;Dermatomyositis, unspecified;2;Inactive;739030149/unspecified;31260231, 29576505, 32011841
308;siponimod;siponimod;CHEMBL2336071;DB12371;44599207;1230487-00-9;RR6P8L282I;KIHYPELVXPAIDH-HNSNBQBZSA-N;CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O;5166;48;621;777;0;1;8;9;37;4;Approved;2019;Small molecule;Modulator;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;4A41.1Z;Polymyositis, unspecified;2;Inactive;1157134196/unspecified;31260231, 29576505, 32011841
308;siponimod;siponimod;CHEMBL2336071;DB12371;44599207;1230487-00-9;RR6P8L282I;KIHYPELVXPAIDH-HNSNBQBZSA-N;CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O;5166;48;621;777;0;1;8;9;37;4;Approved;2019;Small molecule;Modulator;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.0;Relapsing-remitting multiple sclerosis;4;Approved;799053936;31260231, 29576505, 32011841
308;siponimod;siponimod;CHEMBL2336071;DB12371;44599207;1230487-00-9;RR6P8L282I;KIHYPELVXPAIDH-HNSNBQBZSA-N;CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O;5166;48;621;777;0;1;8;9;37;4;Approved;2019;Small molecule;Modulator;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.2;Secondary progressive multiple sclerosis;4;Approved;1045965709;31260231, 29576505, 32011841
308;siponimod;siponimod;CHEMBL2336071;DB12371;44599207;1230487-00-9;RR6P8L282I;KIHYPELVXPAIDH-HNSNBQBZSA-N;CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O;5166;48;621;777;0;1;8;9;37;4;Approved;2019;Small molecule;Modulator;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.Y;Other specified multiple sclerosis;4;Approved;1298865187/other;31260231, 29576505, 32011841
308;siponimod;siponimod;CHEMBL2336071;DB12371;44599207;1230487-00-9;RR6P8L282I;KIHYPELVXPAIDH-HNSNBQBZSA-N;CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O;5166;48;621;777;0;1;8;9;37;4;Approved;2019;Small molecule;Modulator;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.Z;Multiple sclerosis, unspecified;4;Approved;1298865187/unspecified;31260231, 29576505, 32011841
308;siponimod;siponimod;CHEMBL2336071;DB12371;44599207;1230487-00-9;RR6P8L282I;KIHYPELVXPAIDH-HNSNBQBZSA-N;CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O;5166;48;621;777;0;1;8;9;37;4;Approved;2019;Small molecule;Modulator;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;4A41.0Z;Dermatomyositis, unspecified;2;Inactive;739030149/unspecified;31260231, 29576505, 32011841
308;siponimod;siponimod;CHEMBL2336071;DB12371;44599207;1230487-00-9;RR6P8L282I;KIHYPELVXPAIDH-HNSNBQBZSA-N;CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O;5166;48;621;777;0;1;8;9;37;4;Approved;2019;Small molecule;Modulator;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;4A41.1Z;Polymyositis, unspecified;2;Inactive;1157134196/unspecified;31260231, 29576505, 32011841
308;siponimod;siponimod;CHEMBL2336071;DB12371;44599207;1230487-00-9;RR6P8L282I;KIHYPELVXPAIDH-HNSNBQBZSA-N;CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O;5166;48;621;777;0;1;8;9;37;4;Approved;2019;Small molecule;Modulator;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.0;Relapsing-remitting multiple sclerosis;4;Approved;799053936;31260231, 29576505, 32011841
308;siponimod;siponimod;CHEMBL2336071;DB12371;44599207;1230487-00-9;RR6P8L282I;KIHYPELVXPAIDH-HNSNBQBZSA-N;CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O;5166;48;621;777;0;1;8;9;37;4;Approved;2019;Small molecule;Modulator;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.2;Secondary progressive multiple sclerosis;4;Approved;1045965709;31260231, 29576505, 32011841
308;siponimod;siponimod;CHEMBL2336071;DB12371;44599207;1230487-00-9;RR6P8L282I;KIHYPELVXPAIDH-HNSNBQBZSA-N;CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O;5166;48;621;777;0;1;8;9;37;4;Approved;2019;Small molecule;Modulator;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.Y;Other specified multiple sclerosis;4;Approved;1298865187/other;31260231, 29576505, 32011841
308;siponimod;siponimod;CHEMBL2336071;DB12371;44599207;1230487-00-9;RR6P8L282I;KIHYPELVXPAIDH-HNSNBQBZSA-N;CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O;5166;48;621;777;0;1;8;9;37;4;Approved;2019;Small molecule;Modulator;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.Z;Multiple sclerosis, unspecified;4;Approved;1298865187/unspecified;31260231, 29576505, 32011841
309;dipraglurant;dipraglurant;CHEMBL2346738;DB12733;44557636;872363-17-2;CV8JZR21A1;LZXMUJCJAWVHPZ-UHFFFAOYSA-N;C1=CC=NC(=C1)C#CCCC2=CN3C=C(C=CC3=N2)F;26528;35;302;386;0;0;3;3;20;2;Active;NA;Small molecule;NAM;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;8A00.0Z;Parkinson disease, unspecified;2;Active;296066191/unspecified;24865335, 27214664, 38310362
309;dipraglurant;dipraglurant;CHEMBL2346738;DB12733;44557636;872363-17-2;CV8JZR21A1;LZXMUJCJAWVHPZ-UHFFFAOYSA-N;C1=CC=NC(=C1)C#CCCC2=CN3C=C(C=CC3=N2)F;26528;35;302;386;0;0;3;3;20;2;Active;NA;Small molecule;NAM;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;8A02.00;Benign essential blepharospasm;2;Inactive;1127235959;24865335, 27214664, 38310362
310;cebranopadol;cebranopadol;"CHEMBL2364605;CHEMBL3545616;CHEMBL3962932";DB12830;11848225;"863513-91-1;863513-91-1 (free base);863513-93-3";NA;CSMVOZKEWSOFER-UHFFFAOYSA-N;CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5;3785;43;283;553;0;1;3;2;28;2;Active;NA;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;2;Active;661232217/unspecified;37556044, 35807228, 27778406
310;cebranopadol;cebranopadol;"CHEMBL2364605;CHEMBL3545616;CHEMBL3962932";DB12830;11848225;"863513-91-1;863513-91-1 (free base);863513-93-3";NA;CSMVOZKEWSOFER-UHFFFAOYSA-N;CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5;3785;43;283;553;0;1;3;2;28;2;Active;NA;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;2;Active;1815305992/unspecified;37556044, 35807228, 27778406
310;cebranopadol;cebranopadol;"CHEMBL2364605;CHEMBL3545616;CHEMBL3962932";DB12830;11848225;"863513-91-1;863513-91-1 (free base);863513-93-3";NA;CSMVOZKEWSOFER-UHFFFAOYSA-N;CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5;3785;43;283;553;0;1;3;2;28;2;Active;NA;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;2;Active;661232217/unspecified;37556044, 35807228, 27778406
310;cebranopadol;cebranopadol;"CHEMBL2364605;CHEMBL3545616;CHEMBL3962932";DB12830;11848225;"863513-91-1;863513-91-1 (free base);863513-93-3";NA;CSMVOZKEWSOFER-UHFFFAOYSA-N;CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5;3785;43;283;553;0;1;3;2;28;2;Active;NA;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;2;Active;1815305992/unspecified;37556044, 35807228, 27778406
310;cebranopadol;cebranopadol;"CHEMBL2364605;CHEMBL3545616;CHEMBL3962932";DB12830;11848225;"863513-91-1;863513-91-1 (free base);863513-93-3";NA;CSMVOZKEWSOFER-UHFFFAOYSA-N;CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5;3785;43;283;553;0;1;3;2;28;2;Active;NA;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;2;Active;661232217/unspecified;37556044, 35807228, 27778406
310;cebranopadol;cebranopadol;"CHEMBL2364605;CHEMBL3545616;CHEMBL3962932";DB12830;11848225;"863513-91-1;863513-91-1 (free base);863513-93-3";NA;CSMVOZKEWSOFER-UHFFFAOYSA-N;CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5;3785;43;283;553;0;1;3;2;28;2;Active;NA;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;2;Active;1815305992/unspecified;37556044, 35807228, 27778406
310;cebranopadol;cebranopadol;"CHEMBL2364605;CHEMBL3545616;CHEMBL3962932";DB12830;11848225;"863513-91-1;863513-91-1 (free base);863513-93-3";NA;CSMVOZKEWSOFER-UHFFFAOYSA-N;CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5;3785;43;283;553;0;1;3;2;28;2;Active;NA;Small molecule;Agonist;P41146;oprx_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;2;Active;661232217/unspecified;37556044, 35807228, 27778406
310;cebranopadol;cebranopadol;"CHEMBL2364605;CHEMBL3545616;CHEMBL3962932";DB12830;11848225;"863513-91-1;863513-91-1 (free base);863513-93-3";NA;CSMVOZKEWSOFER-UHFFFAOYSA-N;CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5;3785;43;283;553;0;1;3;2;28;2;Active;NA;Small molecule;Agonist;P41146;oprx_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;2;Active;1815305992/unspecified;37556044, 35807228, 27778406
311;latanoprostene bunod;latanoprostene bunod;CHEMBL2364612;DB11660;11156438;860005-21-6;I6393O0922;LOVMMUBRQUFEAH-UIEAZXIASA-N;C1C(C(C(C1O)CC=CCCCC(=O)OCCCCO[N+](=O)[O-])CCC(CCC2=CC=CC=C2)O)O;5076;44;142;646;0;3;8;18;36;4;Approved;2017;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C61.01;Ocular hypertension;4;Approved;535283437;30000019, 31695162, 29761382
311;latanoprostene bunod;latanoprostene bunod;CHEMBL2364612;DB11660;11156438;860005-21-6;I6393O0922;LOVMMUBRQUFEAH-UIEAZXIASA-N;C1C(C(C(C1O)CC=CCCCC(=O)OCCCCO[N+](=O)[O-])CCC(CCC2=CC=CC=C2)O)O;5076;44;142;646;0;3;8;18;36;4;Approved;2017;Small molecule;Agonist;P43088;pf2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000019, 31695162, 29761382
312;ubrogepant;ubrogepant;CHEMBL2364638;DB15328;68748835;1374248-77-7;AD0O8X2QJR;DDOOFTLHJSMHLN-ZQHRPCGSSA-N;CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6;5495;31;104;1000;0;2;8;4;40;4;Approved;2019;Small molecule;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;8A80.0;Migraine without aura;4;Approved;2048783472;31800988, 33104317, 34324284
312;ubrogepant;ubrogepant;CHEMBL2364638;DB15328;68748835;1374248-77-7;AD0O8X2QJR;DDOOFTLHJSMHLN-ZQHRPCGSSA-N;CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6;5495;31;104;1000;0;2;8;4;40;4;Approved;2019;Small molecule;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;31800988, 33104317, 34324284
312;ubrogepant;ubrogepant;CHEMBL2364638;DB15328;68748835;1374248-77-7;AD0O8X2QJR;DDOOFTLHJSMHLN-ZQHRPCGSSA-N;CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6;5495;31;104;1000;0;2;8;4;40;4;Approved;2019;Small molecule;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;31800988, 33104317, 34324284
313;selexipag;selexipag;CHEMBL238804;DB11362;9913767;475086-01-2;5EXC0E384L;QXWZQTURMXZVHJ-UHFFFAOYSA-N;CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3;4966;38;110;730;0;1;7;12;35;4;Approved;2015;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;26699168, 34824052, 34727317
314;zavegepant;zavegepant;CHEMBL2397415;DB15688;53472683;1337918-83-8;ODU3ZAZ94J;JJVAPHYEOZSKJZ-JGCGQSQUSA-N;CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O;6388;31;117;1160;0;3;6;6;47;4;Approved;2023;Small molecule;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;8A80.0;Migraine without aura;4;Approved;2048783472;36804093, 36239038, 37227596
314;zavegepant;zavegepant;CHEMBL2397415;DB15688;53472683;1337918-83-8;ODU3ZAZ94J;JJVAPHYEOZSKJZ-JGCGQSQUSA-N;CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O;6388;31;117;1160;0;3;6;6;47;4;Approved;2023;Small molecule;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;36804093, 36239038, 37227596
314;zavegepant;zavegepant;CHEMBL2397415;DB15688;53472683;1337918-83-8;ODU3ZAZ94J;JJVAPHYEOZSKJZ-JGCGQSQUSA-N;CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O;6388;31;117;1160;0;3;6;6;47;4;Approved;2023;Small molecule;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;36804093, 36239038, 37227596
315;atenolol;atenolol;CHEMBL24;DB00335;2249;29122-68-7;50VV3VW0TI;METKIMKYRPQLGS-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O;26634;2;846;263;0;3;4;8;19;4;Approved;1981;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2E81.0Z;Neoplastic haemangioma, unspecified site;3;Inactive;228855241/unspecified;30969666, 30000201, 35951848
315;atenolol;atenolol;CHEMBL24;DB00335;2249;29122-68-7;50VV3VW0TI;METKIMKYRPQLGS-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O;26634;2;846;263;0;3;4;8;19;4;Approved;1981;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;30969666, 30000201, 35951848
315;atenolol;atenolol;CHEMBL24;DB00335;2249;29122-68-7;50VV3VW0TI;METKIMKYRPQLGS-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O;26634;2;846;263;0;3;4;8;19;4;Approved;1981;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30969666, 30000201, 35951848
315;atenolol;atenolol;CHEMBL24;DB00335;2249;29122-68-7;50VV3VW0TI;METKIMKYRPQLGS-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O;26634;2;846;263;0;3;4;8;19;4;Approved;1981;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA40.Z;Angina pectoris, unspecified;4;Approved;718946808/unspecified;30969666, 30000201, 35951848
315;atenolol;atenolol;CHEMBL24;DB00335;2249;29122-68-7;50VV3VW0TI;METKIMKYRPQLGS-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O;26634;2;846;263;0;3;4;8;19;4;Approved;1981;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;30969666, 30000201, 35951848
315;atenolol;atenolol;CHEMBL24;DB00335;2249;29122-68-7;50VV3VW0TI;METKIMKYRPQLGS-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O;26634;2;846;263;0;3;4;8;19;4;Approved;1981;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA52.Z;Coronary atherosclerosis, unspecified site;4;Approved;1280712786/unspecified;30969666, 30000201, 35951848
315;atenolol;atenolol;CHEMBL24;DB00335;2249;29122-68-7;50VV3VW0TI;METKIMKYRPQLGS-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O;26634;2;846;263;0;3;4;8;19;4;Approved;1981;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LD28.01;Marfan syndrome;4;Approved;236564145;30969666, 30000201, 35951848
317;amisulpride;amisulpride;CHEMBL243712;DB06288;2159;71675-85-9;8110R61I4U;NTJOBXMMWNYJFB-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC;3695;15;110;549;0;2;6;7;25;4;Approved;2020;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000816, 33196816, 33656662
317;amisulpride;amisulpride;CHEMBL243712;DB06288;2159;71675-85-9;8110R61I4U;NTJOBXMMWNYJFB-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC;3695;15;110;549;0;2;6;7;25;4;Approved;2020;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Unknown;1456478153/unspecified;30000816, 33196816, 33656662
317;amisulpride;amisulpride;CHEMBL243712;DB06288;2159;71675-85-9;8110R61I4U;NTJOBXMMWNYJFB-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC;3695;15;110;549;0;2;6;7;25;4;Approved;2020;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000816, 33196816, 33656662
317;amisulpride;amisulpride;CHEMBL243712;DB06288;2159;71675-85-9;8110R61I4U;NTJOBXMMWNYJFB-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC;3695;15;110;549;0;2;6;7;25;4;Approved;2020;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000816, 33196816, 33656662
317;amisulpride;amisulpride;CHEMBL243712;DB06288;2159;71675-85-9;8110R61I4U;NTJOBXMMWNYJFB-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC;3695;15;110;549;0;2;6;7;25;4;Approved;2020;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Unknown;1456478153/unspecified;30000816, 33196816, 33656662
317;amisulpride;amisulpride;CHEMBL243712;DB06288;2159;71675-85-9;8110R61I4U;NTJOBXMMWNYJFB-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC;3695;15;110;549;0;2;6;7;25;4;Approved;2020;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000816, 33196816, 33656662
318;srx246;srx246;CHEMBL244243;NA;44428551;NA;NA;ZPKHVQNRKMCYGL-AFAPVMNMSA-N;CC(C1=CC(=CC=C1)C(F)(F)F)NC(=O)C(CC(=O)N2CCC(CC2)N3CCCCC3)N4C(C(C4=O)N5C(COC5=O)C6=CC=CC=C6)C=CC7=CC=CC=C7;7719;6;103;1400;0;1;9;11;56;2;Active;NA;Small molecule;Antagonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6B40;Post traumatic stress disorder;2;Active;2070699808;36294700, 33970290, 23471831
318;srx246;srx246;CHEMBL244243;NA;44428551;NA;NA;ZPKHVQNRKMCYGL-AFAPVMNMSA-N;CC(C1=CC(=CC=C1)C(F)(F)F)NC(=O)C(CC(=O)N2CCC(CC2)N3CCCCC3)N4C(C(C4=O)N5C(COC5=O)C6=CC=CC=C6)C=CC7=CC=CC=C7;7719;6;103;1400;0;1;9;11;56;2;Active;NA;Small molecule;Antagonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;8A01.10;Huntington disease;2;Active;2132180242;36294700, 33970290, 23471831
319;oliceridine;oliceridine;CHEMBL2443262;DB14881;66553195;1401028-24-7;MCN858TCP0;DMNOVGJWPASQDL-OAQYLSRUSA-N;COC1=C(SC=C1)CNCCC2(CCOC3(C2)CCCC3)C4=CC=CC=N4;3866;35;716;471;0;1;5;7;27;4;Approved;2020;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;33025536, 35261592, 34868743
320;betahistine;betahistine;CHEMBL24441;DB06698;2366;5638-76-6;X32KK4201D;UUQMNUMQCIQDMZ-UHFFFAOYSA-N;CNCCC1=CC=CC=N1;13619;4;249;83;0;1;2;3;10;4;Approved;1970;Small molecule;Agonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;1;Inactive;821852937/unspecified;27327415, 34233329, 30908589
320;betahistine;betahistine;CHEMBL24441;DB06698;2366;5638-76-6;X32KK4201D;UUQMNUMQCIQDMZ-UHFFFAOYSA-N;CNCCC1=CC=CC=N1;13619;4;249;83;0;1;2;3;10;4;Approved;1970;Small molecule;Agonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;27327415, 34233329, 30908589
320;betahistine;betahistine;CHEMBL24441;DB06698;2366;5638-76-6;X32KK4201D;UUQMNUMQCIQDMZ-UHFFFAOYSA-N;CNCCC1=CC=CC=N1;13619;4;249;83;0;1;2;3;10;4;Approved;1970;Small molecule;Agonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;AB31.0;Meniere disease;4;Approved;683932278;27327415, 34233329, 30908589
320;betahistine;betahistine;CHEMBL24441;DB06698;2366;5638-76-6;X32KK4201D;UUQMNUMQCIQDMZ-UHFFFAOYSA-N;CNCCC1=CC=CC=N1;13619;4;249;83;0;1;2;3;10;4;Approved;1970;Small molecule;Agonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MB48.0Z;Vertigo, unspecified;4;Approved;1398634694/unspecified;27327415, 34233329, 30908589
320;betahistine;betahistine;CHEMBL24441;DB06698;2366;5638-76-6;X32KK4201D;UUQMNUMQCIQDMZ-UHFFFAOYSA-N;CNCCC1=CC=CC=N1;13619;4;249;83;0;1;2;3;10;4;Approved;1970;Small molecule;Agonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MG43.6;Excessive weight gain;2;Inactive;493865499;27327415, 34233329, 30908589
320;betahistine;betahistine;CHEMBL24441;DB06698;2366;5638-76-6;X32KK4201D;UUQMNUMQCIQDMZ-UHFFFAOYSA-N;CNCCC1=CC=CC=N1;13619;4;249;83;0;1;2;3;10;4;Approved;1970;Small molecule;Antagonist;Q9Y5N1;hrh3_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;1;Inactive;821852937/unspecified;27327415, 34233329, 30908589
320;betahistine;betahistine;CHEMBL24441;DB06698;2366;5638-76-6;X32KK4201D;UUQMNUMQCIQDMZ-UHFFFAOYSA-N;CNCCC1=CC=CC=N1;13619;4;249;83;0;1;2;3;10;4;Approved;1970;Small molecule;Antagonist;Q9Y5N1;hrh3_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;27327415, 34233329, 30908589
320;betahistine;betahistine;CHEMBL24441;DB06698;2366;5638-76-6;X32KK4201D;UUQMNUMQCIQDMZ-UHFFFAOYSA-N;CNCCC1=CC=CC=N1;13619;4;249;83;0;1;2;3;10;4;Approved;1970;Small molecule;Antagonist;Q9Y5N1;hrh3_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;AB31.0;Meniere disease;4;Approved;683932278;27327415, 34233329, 30908589
320;betahistine;betahistine;CHEMBL24441;DB06698;2366;5638-76-6;X32KK4201D;UUQMNUMQCIQDMZ-UHFFFAOYSA-N;CNCCC1=CC=CC=N1;13619;4;249;83;0;1;2;3;10;4;Approved;1970;Small molecule;Antagonist;Q9Y5N1;hrh3_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MB48.0Z;Vertigo, unspecified;4;Approved;1398634694/unspecified;27327415, 34233329, 30908589
320;betahistine;betahistine;CHEMBL24441;DB06698;2366;5638-76-6;X32KK4201D;UUQMNUMQCIQDMZ-UHFFFAOYSA-N;CNCCC1=CC=CC=N1;13619;4;249;83;0;1;2;3;10;4;Approved;1970;Small molecule;Antagonist;Q9Y5N1;hrh3_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MG43.6;Excessive weight gain;2;Inactive;493865499;27327415, 34233329, 30908589
321;silodosin;silodosin;CHEMBL24778;DB06207;5312125;160970-54-7;CUZ39LUY82;PNCPYILNMDWPEY-QGZVFWFLSA-N;CC(CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F;4955;36;97;654;0;3;9;13;35;4;Approved;2008;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;3;Unknown;1552457716/unspecified;31643499, 35864693, 30523608
321;silodosin;silodosin;CHEMBL24778;DB06207;5312125;160970-54-7;CUZ39LUY82;PNCPYILNMDWPEY-QGZVFWFLSA-N;CC(CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F;4955;36;97;654;0;3;9;13;35;4;Approved;2008;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA90;Hyperplasia of prostate;4;Approved;978159279;31643499, 35864693, 30523608
321;silodosin;silodosin;CHEMBL24778;DB06207;5312125;160970-54-7;CUZ39LUY82;PNCPYILNMDWPEY-QGZVFWFLSA-N;CC(CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F;4955;36;97;654;0;3;9;13;35;4;Approved;2008;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA91.Z;Inflammatory and other diseases of prostate, unspecified;2;Inactive;1594247995/unspecified;31643499, 35864693, 30523608
321;silodosin;silodosin;CHEMBL24778;DB06207;5312125;160970-54-7;CUZ39LUY82;PNCPYILNMDWPEY-QGZVFWFLSA-N;CC(CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F;4955;36;97;654;0;3;9;13;35;4;Approved;2008;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;3;Unknown;1552457716/unspecified;31643499, 35864693, 30523608
321;silodosin;silodosin;CHEMBL24778;DB06207;5312125;160970-54-7;CUZ39LUY82;PNCPYILNMDWPEY-QGZVFWFLSA-N;CC(CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F;4955;36;97;654;0;3;9;13;35;4;Approved;2008;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA90;Hyperplasia of prostate;4;Approved;978159279;31643499, 35864693, 30523608
321;silodosin;silodosin;CHEMBL24778;DB06207;5312125;160970-54-7;CUZ39LUY82;PNCPYILNMDWPEY-QGZVFWFLSA-N;CC(CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F;4955;36;97;654;0;3;9;13;35;4;Approved;2008;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA91.Z;Inflammatory and other diseases of prostate, unspecified;2;Inactive;1594247995/unspecified;31643499, 35864693, 30523608
321;silodosin;silodosin;CHEMBL24778;DB06207;5312125;160970-54-7;CUZ39LUY82;PNCPYILNMDWPEY-QGZVFWFLSA-N;CC(CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F;4955;36;97;654;0;3;9;13;35;4;Approved;2008;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;3;Unknown;1552457716/unspecified;31643499, 35864693, 30523608
321;silodosin;silodosin;CHEMBL24778;DB06207;5312125;160970-54-7;CUZ39LUY82;PNCPYILNMDWPEY-QGZVFWFLSA-N;CC(CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F;4955;36;97;654;0;3;9;13;35;4;Approved;2008;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA90;Hyperplasia of prostate;4;Approved;978159279;31643499, 35864693, 30523608
321;silodosin;silodosin;CHEMBL24778;DB06207;5312125;160970-54-7;CUZ39LUY82;PNCPYILNMDWPEY-QGZVFWFLSA-N;CC(CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F;4955;36;97;654;0;3;9;13;35;4;Approved;2008;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA91.Z;Inflammatory and other diseases of prostate, unspecified;2;Inactive;1594247995/unspecified;31643499, 35864693, 30523608
322;periciazine;periciazine;CHEMBL251940;DB01608;4747;2622-26-6;3405M6FD73;LUALIOATIOESLM-UHFFFAOYSA-N;C1CN(CCC1O)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C#N;3655;35;758;513;0;1;5;4;26;4;Approved;1961;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;35442605, 35361275, 27062
322;periciazine;periciazine;CHEMBL251940;DB01608;4747;2622-26-6;3405M6FD73;LUALIOATIOESLM-UHFFFAOYSA-N;C1CN(CCC1O)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C#N;3655;35;758;513;0;1;5;4;26;4;Approved;1961;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.3;Anxiety;4;Approved;2027043655;35442605, 35361275, 27062
322;periciazine;periciazine;CHEMBL251940;DB01608;4747;2622-26-6;3405M6FD73;LUALIOATIOESLM-UHFFFAOYSA-N;C1CN(CCC1O)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C#N;3655;35;758;513;0;1;5;4;26;4;Approved;1961;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;35442605, 35361275, 27062
322;periciazine;periciazine;CHEMBL251940;DB01608;4747;2622-26-6;3405M6FD73;LUALIOATIOESLM-UHFFFAOYSA-N;C1CN(CCC1O)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C#N;3655;35;758;513;0;1;5;4;26;4;Approved;1961;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.3;Anxiety;4;Approved;2027043655;35442605, 35361275, 27062
323;alverine;alverine;CHEMBL253371;DB01616;3678;150-59-4;46TIR1560O;ZPFXAOWNKLFJDN-UHFFFAOYSA-N;CCN(CCCC1=CC=CC=C1)CCCC2=CC=CC=C2;2814;53;32;214;0;0;1;9;21;4;Approved;2014;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;32326535, 34847441, 33551820
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;3;Inactive;1563440232/unspecified;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;HA03.0Z;Male early ejaculation, unspecified;4;Approved;361151087/unspecified;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.3;Anxiety;4;Approved;2027043655;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB27.2Z;Hallucinations, unspecified;4;Approved;665363966/unspecified;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB48.0Z;Vertigo, unspecified;4;Approved;1398634694/unspecified;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;3;Inactive;1563440232/unspecified;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;HA03.0Z;Male early ejaculation, unspecified;4;Approved;361151087/unspecified;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.3;Anxiety;4;Approved;2027043655;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB27.2Z;Hallucinations, unspecified;4;Approved;665363966/unspecified;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB48.0Z;Vertigo, unspecified;4;Approved;1398634694/unspecified;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;3;Inactive;1563440232/unspecified;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;HA03.0Z;Male early ejaculation, unspecified;4;Approved;361151087/unspecified;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.3;Anxiety;4;Approved;2027043655;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB27.2Z;Hallucinations, unspecified;4;Approved;665363966/unspecified;30000510, 10796605, 20091661
325;sulpiride;levosulpiride;CHEMBL267044;NA;688272;23672-07-3;NA;BGRJTUBHPOOWDU-NSHDSACASA-N;CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB48.0Z;Vertigo, unspecified;4;Approved;1398634694/unspecified;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;3;Inactive;1563440232/unspecified;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;HA03.0Z;Male early ejaculation, unspecified;4;Approved;361151087/unspecified;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.3;Anxiety;4;Approved;2027043655;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB27.2Z;Hallucinations, unspecified;4;Approved;665363966/unspecified;30000510, 10796605, 20091661
325;sulpiride;sulpiride;CHEMBL26;DB00391;5355;15676-16-1;7MNE9M8287;BGRJTUBHPOOWDU-UHFFFAOYSA-N;CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;3414;6;110;505;0;2;6;6;23;4;Approved;1972;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB48.0Z;Vertigo, unspecified;4;Approved;1398634694/unspecified;30000510, 10796605, 20091661
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;1F51.Z;African trypanosomiasis, unspecified;4;Approved;875488052/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;1F54.Z;Leishmaniasis, unspecified;4;Approved;1082373067/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2A0Z;Other and unspecified neoplasms of brain or central nervous system;2;Inactive;879154182/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2A83.1;Plasma cell myeloma;2;Inactive;526287100;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2B91.Z;Malignant neoplasms of rectosigmoid junction, unspecified;1;Inactive;774170412/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C82.0;Adenocarcinoma of prostate;2;Inactive;1510677183;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;3;Inactive;1552457716/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C90.0;Renal cell carcinoma of kidney, except renal pelvis;2;Inactive;825917541;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2C94.Z;Malignant neoplasms of bladder, unspecified;1;Inactive;1244512758/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;2D11.Z;Malignant neoplasms of adrenal gland, unspecified;2;Inactive;1766185236/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Inactive;437815624/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P23945;fshr_human;Class A (Rhodopsin);Glycoprotein hormone receptors;Protein receptors;GB60.Z;Acute kidney failure, stage unspecified;2;Active;476391827/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P41231;p2ry2_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;1F51.Z;African trypanosomiasis, unspecified;4;Approved;875488052/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P41231;p2ry2_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;1F54.Z;Leishmaniasis, unspecified;4;Approved;1082373067/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P41231;p2ry2_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;2A0Z;Other and unspecified neoplasms of brain or central nervous system;2;Inactive;879154182/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P41231;p2ry2_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;2A83.1;Plasma cell myeloma;2;Inactive;526287100;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P41231;p2ry2_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;2B91.Z;Malignant neoplasms of rectosigmoid junction, unspecified;1;Inactive;774170412/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P41231;p2ry2_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P41231;p2ry2_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;2C82.0;Adenocarcinoma of prostate;2;Inactive;1510677183;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P41231;p2ry2_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;3;Inactive;1552457716/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P41231;p2ry2_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;2C90.0;Renal cell carcinoma of kidney, except renal pelvis;2;Inactive;825917541;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P41231;p2ry2_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;2C94.Z;Malignant neoplasms of bladder, unspecified;1;Inactive;1244512758/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P41231;p2ry2_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;2D11.Z;Malignant neoplasms of adrenal gland, unspecified;2;Inactive;1766185236/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P41231;p2ry2_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Inactive;437815624/unspecified;31844000, 8020006, 1588368
326;suramin;suramin;CHEMBL265502;DB04786;5361;145-63-1;6032D45BEM;FIAFUQMPZJWCLV-UHFFFAOYSA-N;CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C;12973;15;534;3020;0;12;23;16;86;4;Approved;1924;Small molecule;Antagonist;P41231;p2ry2_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;GB60.Z;Acute kidney failure, stage unspecified;2;Active;476391827/unspecified;31844000, 8020006, 1588368
327;glucagon;glucagon;CHEMBL266481;DB00040;16133817;16941-32-5;76LA80IG2G;MASNOZXLGMXCHN-ZLPAWPGGSA-N;CC(C)CC(C(=O)NC(CCSC)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CNC=N7)N;34827;-169;1560;8160;0;55;55;115;246;4;Approved;1998;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A14;Diabetes mellitus, type unspecified;4;Approved;1697306310;31284506, 36639733, 25905350
327;glucagon;glucagon;CHEMBL266481;DB00040;16133817;16941-32-5;76LA80IG2G;MASNOZXLGMXCHN-ZLPAWPGGSA-N;CC(C)CC(C(=O)NC(CCSC)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CNC=N7)N;34827;-169;1560;8160;0;55;55;115;246;4;Approved;1998;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A41;Hypoglycaemia without associated diabetes;4;Approved;1004695600;31284506, 36639733, 25905350
327;glucagon;glucagon;CHEMBL266481;DB00040;16133817;16941-32-5;76LA80IG2G;MASNOZXLGMXCHN-ZLPAWPGGSA-N;CC(C)CC(C(=O)NC(CCSC)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CNC=N7)N;34827;-169;1560;8160;0;55;55;115;246;4;Approved;1998;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A4Z;Disorders of glucose regulation or pancreatic internal secretion, unspecified;2;Inactive;1283179793/unspecified;31284506, 36639733, 25905350
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2B56.Z;Angiosarcoma, unspecified primary site;2;Active;423002561/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2B5Y;Other specified malignant mesenchymal neoplasms;2;Unknown;1965082709/other;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2B72.Z;Malignant neoplasms of stomach, unspecified;2;Unknown;1397617262/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2B91.Z;Malignant neoplasms of rectosigmoid junction, unspecified;3;Active;774170412/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C10.Z;Malignant neoplasm of pancreas, unspecified;2;Active;542147910/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C30.Z;Melanoma of skin, unspecified;2;Active;488336723/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C94.Z;Malignant neoplasms of bladder, unspecified;2;Active;1244512758/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2E81.0Z;Neoplastic haemangioma, unspecified site;4;Approved;228855241/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;3A51.1;Sickle cell disease without crisis;2;Inactive;1711513381;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;1;Inactive;437815624/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B01;Panic disorder;2;Unknown;56162827;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;3;Inactive;1699574100/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4E.2Z;Other specified psychoactive substance dependence, unspecified;2;Inactive;1934475925/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A41;Obstructive sleep apnoea;2;Active;1919233290;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B22.41;Cerebral cavernous malformation;1;Unknown;916773262;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9B71.3;Retinopathy of prematurity;3;Active;947283385;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9B75.0Z;Age-related macular degeneration, unspecified;3;Unknown;1514301548/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA40.Z;Angina pectoris, unspecified;4;Approved;718946808/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.4;Wolff-Parkinson-White syndrome;4;Approved;1091030330;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC9Z;Cardiac arrhythmia, unspecified;4;Approved;1457291912/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA26.0Z;Oesophageal varices, unspecified;3;Unknown;933570887/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JB02.4;Hypertonic, incoordinate, or prolonged uterine contractions;2;Active;693926988;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA88.2Z;Tetralogy of Fallot, unspecified;1;Active;90973426/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA90.00;Hereditary haemorrhagic telangiectasia;3;Active;714406192;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;1;Unknown;1282135070/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME04.Z;Ascites, unspecified;3;Inactive;1133729855/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME84.2Z;Low back pain, unspecified;2;Inactive;1815305992/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG45.Z;Syncope and collapse, unspecified;2;Inactive;1418136013/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;3;Active;277610609/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2B56.Z;Angiosarcoma, unspecified primary site;2;Active;423002561/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2B5Y;Other specified malignant mesenchymal neoplasms;2;Unknown;1965082709/other;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2B72.Z;Malignant neoplasms of stomach, unspecified;2;Unknown;1397617262/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2B91.Z;Malignant neoplasms of rectosigmoid junction, unspecified;3;Active;774170412/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C10.Z;Malignant neoplasm of pancreas, unspecified;2;Active;542147910/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C30.Z;Melanoma of skin, unspecified;2;Active;488336723/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C94.Z;Malignant neoplasms of bladder, unspecified;2;Active;1244512758/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2E81.0Z;Neoplastic haemangioma, unspecified site;4;Approved;228855241/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;3A51.1;Sickle cell disease without crisis;2;Inactive;1711513381;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;1;Inactive;437815624/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B01;Panic disorder;2;Unknown;56162827;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;3;Inactive;1699574100/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4E.2Z;Other specified psychoactive substance dependence, unspecified;2;Inactive;1934475925/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A41;Obstructive sleep apnoea;2;Active;1919233290;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.0;Migraine without aura;4;Approved;2048783472;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;4;Approved;525744634/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B22.41;Cerebral cavernous malformation;1;Unknown;916773262;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9B71.3;Retinopathy of prematurity;3;Active;947283385;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9B75.0Z;Age-related macular degeneration, unspecified;3;Unknown;1514301548/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA40.Z;Angina pectoris, unspecified;4;Approved;718946808/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.4;Wolff-Parkinson-White syndrome;4;Approved;1091030330;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC9Z;Cardiac arrhythmia, unspecified;4;Approved;1457291912/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA26.0Z;Oesophageal varices, unspecified;3;Unknown;933570887/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JB02.4;Hypertonic, incoordinate, or prolonged uterine contractions;2;Active;693926988;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA88.2Z;Tetralogy of Fallot, unspecified;1;Active;90973426/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA90.00;Hereditary haemorrhagic telangiectasia;3;Active;714406192;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;1;Unknown;1282135070/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME04.Z;Ascites, unspecified;3;Inactive;1133729855/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME84.2Z;Low back pain, unspecified;2;Inactive;1815305992/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG45.Z;Syncope and collapse, unspecified;2;Inactive;1418136013/unspecified;28431779, 30000221, 32491733
329;propranolol;propranolol;CHEMBL27;DB00571;4946;525-66-6;9Y8NXQ24VQ;AQHHHDLHHXJYJD-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O;25934;3;415;257;0;2;3;6;19;4;Approved;1967;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;3;Active;277610609/unspecified;28431779, 30000221, 32491733
330;alvimopan;alvimopan;CHEMBL270190;DB06274;5488548;156053-89-3;Q153V49P3Z;UPNUIXSCZBYVBB-JVFUWBCBSA-N;CC1CN(CCC1(C)C2=CC(=CC=C2)O)CC(CC3=CC=CC=C3)C(=O)NCC(=O)O;4245;17;899;606;0;3;5;8;31;4;Approved;2008;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DA93.0;Paralytic ileus;4;Approved;1868011045;18778122, 19574601, 28462518
330;alvimopan;alvimopan;CHEMBL270190;DB06274;5488548;156053-89-3;Q153V49P3Z;UPNUIXSCZBYVBB-JVFUWBCBSA-N;CC1CN(CCC1(C)C2=CC(=CC=C2)O)CC(CC3=CC=CC=C3)C(=O)NCC(=O)O;4245;17;899;606;0;3;5;8;31;4;Approved;2008;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DE2Z;Diseases of the digestive system, unspecified;4;Approved;1256772020/unspecified;18778122, 19574601, 28462518
331;celiprolol;celiprolol;CHEMBL27810;DB04846;2663;56980-93-9;DRB57K47QC;JOATXPAWOHTVSZ-UHFFFAOYSA-N;CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C;3795;19;909;474;0;3;5;10;27;4;Approved;1982;Small molecule;Partial agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;1348344, 1346201, 2903654
331;celiprolol;celiprolol;CHEMBL27810;DB04846;2663;56980-93-9;DRB57K47QC;JOATXPAWOHTVSZ-UHFFFAOYSA-N;CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C;3795;19;909;474;0;3;5;10;27;4;Approved;1982;Small molecule;Partial agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LD28.1;Ehlers-Danlos syndrome;3;Active;1122707206;1348344, 1346201, 2903654
331;celiprolol;celiprolol;CHEMBL27810;DB04846;2663;56980-93-9;DRB57K47QC;JOATXPAWOHTVSZ-UHFFFAOYSA-N;CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C;3795;19;909;474;0;3;5;10;27;4;Approved;1982;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;1348344, 1346201, 2903654
331;celiprolol;celiprolol;CHEMBL27810;DB04846;2663;56980-93-9;DRB57K47QC;JOATXPAWOHTVSZ-UHFFFAOYSA-N;CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C;3795;19;909;474;0;3;5;10;27;4;Approved;1982;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LD28.1;Ehlers-Danlos syndrome;3;Active;1122707206;1348344, 1346201, 2903654
331;celiprolol;celiprolol;CHEMBL27810;DB04846;2663;56980-93-9;DRB57K47QC;JOATXPAWOHTVSZ-UHFFFAOYSA-N;CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C;3795;19;909;474;0;3;5;10;27;4;Approved;1982;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;1348344, 1346201, 2903654
331;celiprolol;celiprolol;CHEMBL27810;DB04846;2663;56980-93-9;DRB57K47QC;JOATXPAWOHTVSZ-UHFFFAOYSA-N;CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C;3795;19;909;474;0;3;5;10;27;4;Approved;1982;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LD28.1;Ehlers-Danlos syndrome;3;Active;1122707206;1348344, 1346201, 2903654
331;celiprolol;celiprolol;CHEMBL27810;DB04846;2663;56980-93-9;DRB57K47QC;JOATXPAWOHTVSZ-UHFFFAOYSA-N;CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C;3795;19;909;474;0;3;5;10;27;4;Approved;1982;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;1348344, 1346201, 2903654
331;celiprolol;celiprolol;CHEMBL27810;DB04846;2663;56980-93-9;DRB57K47QC;JOATXPAWOHTVSZ-UHFFFAOYSA-N;CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C;3795;19;909;474;0;3;5;10;27;4;Approved;1982;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LD28.1;Ehlers-Danlos syndrome;3;Active;1122707206;1348344, 1346201, 2903654
331;celiprolol;celiprolol;CHEMBL27810;DB04846;2663;56980-93-9;DRB57K47QC;JOATXPAWOHTVSZ-UHFFFAOYSA-N;CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C;3795;19;909;474;0;3;5;10;27;4;Approved;1982;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;1348344, 1346201, 2903654
331;celiprolol;celiprolol;CHEMBL27810;DB04846;2663;56980-93-9;DRB57K47QC;JOATXPAWOHTVSZ-UHFFFAOYSA-N;CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C;3795;19;909;474;0;3;5;10;27;4;Approved;1982;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LD28.1;Ehlers-Danlos syndrome;3;Active;1122707206;1348344, 1346201, 2903654
332;phenindamine;phenindamine;CHEMBL278398;DB01619;11291;82-88-2;772BQ8KSST;ISFHAYSTHMVOJR-UHFFFAOYSA-N;CN1CCC2=C(C1)C(C3=CC=CC=C23)C4=CC=CC=C4;2614;31;32;391;0;0;1;1;20;4;Approved;1947;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;30000124, 1360991, 3816
332;phenindamine;phenindamine;CHEMBL278398;DB01619;11291;82-88-2;772BQ8KSST;ISFHAYSTHMVOJR-UHFFFAOYSA-N;CN1CCC2=C(C1)C(C3=CC=CC=C23)C4=CC=CC=C4;2614;31;32;391;0;0;1;1;20;4;Approved;1947;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000124, 1360991, 3816
333;macimorelin;macimorelin;CHEMBL278623;DB13074;9804938;381231-18-1;8680B21W73;UJVDJAPJQWZRFR-DHIUTWEWSA-N;CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC3=CNC4=CC=CC=C43)NC=O)N;4746;18;145;761;0;6;4;9;35;4;Approved;2017;Small molecule;Agonist;Q92847;ghsr_human;Class A (Rhodopsin);Ghrelin receptors;Peptide receptors;MG20.Z;Cachexia, unspecified;2;Inactive;914154382/unspecified;36694890, 29860473, 36860137
333;macimorelin;macimorelin;CHEMBL278623;DB13074;9804938;381231-18-1;8680B21W73;UJVDJAPJQWZRFR-DHIUTWEWSA-N;CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC3=CNC4=CC=CC=C43)NC=O)N;4746;18;145;761;0;6;4;9;35;4;Approved;2017;Small molecule;Agonist;Q92847;ghsr_human;Class A (Rhodopsin);Ghrelin receptors;Peptide receptors;X2;Diagnostis;4;Approved;NA;36694890, 29860473, 36860137
334;bromperidol;bromperidol;CHEMBL28218;DB12401;2448;10457-90-6;NA;RKLNONIVDFXQRX-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Br)O)CCCC(=O)C3=CC=C(C=C3)F;4203;33;405;451;0;1;4;6;26;4;Approved;1973;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;23152208, 21901678, 3048975
335;gepirone;gepirone;CHEMBL284092;DB12184;55191;83928-76-1;NA;QOIGKGMMAGJZNZ-UHFFFAOYSA-N;CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C;3595;18;696;476;0;0;6;6;26;4;Approved;2023;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;31347611, 37856644, 38079093
335;gepirone;gepirone;CHEMBL284092;DB12184;55191;83928-76-1;NA;QOIGKGMMAGJZNZ-UHFFFAOYSA-N;CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C;3595;18;696;476;0;0;6;6;26;4;Approved;2023;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;31347611, 37856644, 38079093
337;alizapride;alizapride;CHEMBL290194;DB01425;135413504;59338-93-1;P55703ZRZY;KSEYRUGYKHXGFW-UHFFFAOYSA-N;COC1=CC2=C(C=C1C(=O)NCC3CCCN3CC=C)NN=N2;31537;15;831;433;0;2;5;6;23;4;Approved;1981;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;3048762, 26086285, 32903143
339;crinecerfont;crinecerfont;"CHEMBL1628268;CHEMBL291657";NA;5282340;"752253-39-7;752253-39-7 (free base)";NA;IEAKXXNRGSLYTQ-DEOSSOPVSA-N;CC1=C(C=C(C=C1)C(CC2CC2)N(CC#C)C3=NC(=C(S3)C)C4=C(C=C(C(=C4)C)OC)Cl)F;483;8;536;699;0;0;5;8;33;3;Active;NA;Small molecule;Antagonist;P34998;crfr1_human;Class B1 (Secretin);Corticotropin-releasing factor receptors;Peptide receptors;5A71.01;Congenital adrenal hyperplasia;3;Active;172733763;34653252, 37650613, 37216921
339;crinecerfont;crinecerfont;"CHEMBL1628268;CHEMBL291657";NA;5282340;"752253-39-7;752253-39-7 (free base)";NA;IEAKXXNRGSLYTQ-DEOSSOPVSA-N;CC1=C(C=C(C=C1)C(CC2CC2)N(CC#C)C3=NC(=C(S3)C)C4=C(C=C(C(=C4)C)OC)Cl)F;483;8;536;699;0;0;5;8;33;3;Active;NA;Small molecule;Antagonist;P34998;crfr1_human;Class B1 (Secretin);Corticotropin-releasing factor receptors;Peptide receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;34653252, 37650613, 37216921
340;pizotifen;pizotifen;CHEMBL294951;DB06153;27400;15574-96-6;0BY8440V3N;FIADGNVRKBPQEU-UHFFFAOYSA-N;CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1;2954;38;315;406;0;0;2;0;21;4;Approved;1974;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;335788, 36841865, 35202750
340;pizotifen;pizotifen;CHEMBL294951;DB06153;27400;15574-96-6;0BY8440V3N;FIADGNVRKBPQEU-UHFFFAOYSA-N;CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1;2954;38;315;406;0;0;2;0;21;4;Approved;1974;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;335788, 36841865, 35202750
340;pizotifen;pizotifen;CHEMBL294951;DB06153;27400;15574-96-6;0BY8440V3N;FIADGNVRKBPQEU-UHFFFAOYSA-N;CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1;2954;38;315;406;0;0;2;0;21;4;Approved;1974;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;335788, 36841865, 35202750
340;pizotifen;pizotifen;CHEMBL294951;DB06153;27400;15574-96-6;0BY8440V3N;FIADGNVRKBPQEU-UHFFFAOYSA-N;CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1;2954;38;315;406;0;0;2;0;21;4;Approved;1974;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;335788, 36841865, 35202750
340;pizotifen;pizotifen;CHEMBL294951;DB06153;27400;15574-96-6;0BY8440V3N;FIADGNVRKBPQEU-UHFFFAOYSA-N;CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1;2954;38;315;406;0;0;2;0;21;4;Approved;1974;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;335788, 36841865, 35202750
340;pizotifen;pizotifen;CHEMBL294951;DB06153;27400;15574-96-6;0BY8440V3N;FIADGNVRKBPQEU-UHFFFAOYSA-N;CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1;2954;38;315;406;0;0;2;0;21;4;Approved;1974;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;335788, 36841865, 35202750
340;pizotifen;pizotifen;CHEMBL294951;DB06153;27400;15574-96-6;0BY8440V3N;FIADGNVRKBPQEU-UHFFFAOYSA-N;CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1;2954;38;315;406;0;0;2;0;21;4;Approved;1974;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;335788, 36841865, 35202750
340;pizotifen;pizotifen;CHEMBL294951;DB06153;27400;15574-96-6;0BY8440V3N;FIADGNVRKBPQEU-UHFFFAOYSA-N;CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1;2954;38;315;406;0;0;2;0;21;4;Approved;1974;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;335788, 36841865, 35202750
340;pizotifen;pizotifen;CHEMBL294951;DB06153;27400;15574-96-6;0BY8440V3N;FIADGNVRKBPQEU-UHFFFAOYSA-N;CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1;2954;38;315;406;0;0;2;0;21;4;Approved;1974;Small molecule;Antagonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;335788, 36841865, 35202750
340;pizotifen;pizotifen;CHEMBL294951;DB06153;27400;15574-96-6;0BY8440V3N;FIADGNVRKBPQEU-UHFFFAOYSA-N;CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1;2954;38;315;406;0;0;2;0;21;4;Approved;1974;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;335788, 36841865, 35202750
340;pizotifen;pizotifen;CHEMBL294951;DB06153;27400;15574-96-6;0BY8440V3N;FIADGNVRKBPQEU-UHFFFAOYSA-N;CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1;2954;38;315;406;0;0;2;0;21;4;Approved;1974;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;335788, 36841865, 35202750
340;pizotifen;pizotifen;CHEMBL294951;DB06153;27400;15574-96-6;0BY8440V3N;FIADGNVRKBPQEU-UHFFFAOYSA-N;CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1;2954;38;315;406;0;0;2;0;21;4;Approved;1974;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;335788, 36841865, 35202750
340;pizotifen;pizotifen;CHEMBL294951;DB06153;27400;15574-96-6;0BY8440V3N;FIADGNVRKBPQEU-UHFFFAOYSA-N;CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1;2954;38;315;406;0;0;2;0;21;4;Approved;1974;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;335788, 36841865, 35202750
340;pizotifen;pizotifen;CHEMBL294951;DB06153;27400;15574-96-6;0BY8440V3N;FIADGNVRKBPQEU-UHFFFAOYSA-N;CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1;2954;38;315;406;0;0;2;0;21;4;Approved;1974;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;335788, 36841865, 35202750
340;pizotifen;pizotifen;CHEMBL294951;DB06153;27400;15574-96-6;0BY8440V3N;FIADGNVRKBPQEU-UHFFFAOYSA-N;CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1;2954;38;315;406;0;0;2;0;21;4;Approved;1974;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;335788, 36841865, 35202750
341;benperidol;benperidol;CHEMBL297302;DB12867;16363;"2062-84-2;983-42-6";NA;FEBOTPHFXYHVPL-UHFFFAOYSA-N;C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F;3814;37;526;556;0;1;4;6;28;4;Approved;1966;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;15846648, 11869652, 28791627
342;ecopipam;ecopipam;CHEMBL298406;DB12273;107930;112108-01-7;NA;DMJWENQHWZZWDF-PKOBYXMFSA-N;CN1CCC2=CC(=C(C=C2C3C1CCC4=CC=CC=C34)O)Cl;3138;44;235;403;0;1;2;0;22;3;Active;NA;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5C55.01;Lesch-Nyhan syndrome;1;Inactive;1886495906;36628546, 31369655, 30192018
342;ecopipam;ecopipam;CHEMBL298406;DB12273;107930;112108-01-7;NA;DMJWENQHWZZWDF-PKOBYXMFSA-N;CN1CCC2=CC(=C(C=C2C3C1CCC4=CC=CC=C34)O)Cl;3138;44;235;403;0;1;2;0;22;3;Active;NA;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A01.22;Developmental language disorder with impairment of mainly pragmatic language;3;Unknown;854708918;36628546, 31369655, 30192018
342;ecopipam;ecopipam;CHEMBL298406;DB12273;107930;112108-01-7;NA;DMJWENQHWZZWDF-PKOBYXMFSA-N;CN1CCC2=CC(=C(C=C2C3C1CCC4=CC=CC=C34)O)Cl;3138;44;235;403;0;1;2;0;22;3;Active;NA;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C50.Z;Gambling disorder, unspecified;2;Inactive;1041487064/unspecified;36628546, 31369655, 30192018
342;ecopipam;ecopipam;CHEMBL298406;DB12273;107930;112108-01-7;NA;DMJWENQHWZZWDF-PKOBYXMFSA-N;CN1CCC2=CC(=C(C=C2C3C1CCC4=CC=CC=C34)O)Cl;3138;44;235;403;0;1;2;0;22;3;Active;NA;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;1;Active;1254916765;36628546, 31369655, 30192018
342;ecopipam;ecopipam;CHEMBL298406;DB12273;107930;112108-01-7;NA;DMJWENQHWZZWDF-PKOBYXMFSA-N;CN1CCC2=CC(=C(C=C2C3C1CCC4=CC=CC=C34)O)Cl;3138;44;235;403;0;1;2;0;22;3;Active;NA;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;3;Active;119340957;36628546, 31369655, 30192018
343;cimetidine;cimetidine;CHEMBL30;DB00501;2756;51481-61-9;80061L1WGD;AQIXAKUUQRKLND-UHFFFAOYSA-N;CC1=C(N=CN1)CSCCNC(=NC)NC#N;25234;4;114;296;0;3;4;7;17;4;Approved;1977;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;5C58.12;Erythropoietic porphyrias;2;Active;1074667008;31334975, 30000265, 31643460
343;cimetidine;cimetidine;CHEMBL30;DB00501;2756;51481-61-9;80061L1WGD;AQIXAKUUQRKLND-UHFFFAOYSA-N;CC1=C(N=CN1)CSCCNC(=NC)NC#N;25234;4;114;296;0;3;4;7;17;4;Approved;1977;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;31334975, 30000265, 31643460
343;cimetidine;cimetidine;CHEMBL30;DB00501;2756;51481-61-9;80061L1WGD;AQIXAKUUQRKLND-UHFFFAOYSA-N;CC1=C(N=CN1)CSCCNC(=NC)NC#N;25234;4;114;296;0;3;4;7;17;4;Approved;1977;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA60;Gastric ulcer;3;Inactive;1437411258;31334975, 30000265, 31643460
343;cimetidine;cimetidine;CHEMBL30;DB00501;2756;51481-61-9;80061L1WGD;AQIXAKUUQRKLND-UHFFFAOYSA-N;CC1=C(N=CN1)CSCCNC(=NC)NC#N;25234;4;114;296;0;3;4;7;17;4;Approved;1977;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;31334975, 30000265, 31643460
343;cimetidine;cimetidine;CHEMBL30;DB00501;2756;51481-61-9;80061L1WGD;AQIXAKUUQRKLND-UHFFFAOYSA-N;CC1=C(N=CN1)CSCCNC(=NC)NC#N;25234;4;114;296;0;3;4;7;17;4;Approved;1977;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA63.Z;Duodenal ulcer, unspecified;4;Approved;553678663/unspecified;31334975, 30000265, 31643460
343;cimetidine;cimetidine;CHEMBL30;DB00501;2756;51481-61-9;80061L1WGD;AQIXAKUUQRKLND-UHFFFAOYSA-N;CC1=C(N=CN1)CSCCNC(=NC)NC#N;25234;4;114;296;0;3;4;7;17;4;Approved;1977;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;3;Unknown;215767047/unspecified;31334975, 30000265, 31643460
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;3;Unknown;1683919430/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Unknown;106339515/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Inactive;1456478153/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Active;1582741816/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B8Z;Feeding or eating disorders, unspecified;3;Unknown;1412387537/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;1;Inactive;1691013484/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;4;Approved;1254916765;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A04.1;Essential tremor or related tremors;3;Unknown;1036027657;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;3;Unknown;119340957;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A20;Alzheimer disease;2;Inactive;1611724421;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Inactive;1982355687;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MF56;Renal colic;2;Active;821552851;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Unknown;849253504;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG30.Z;Chronic pain, unspecified;1;Inactive;1581976053/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;3;Unknown;1683919430/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Unknown;106339515/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Inactive;1456478153/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Active;1582741816/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B8Z;Feeding or eating disorders, unspecified;3;Unknown;1412387537/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;1;Inactive;1691013484/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;4;Approved;1254916765;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A04.1;Essential tremor or related tremors;3;Unknown;1036027657;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;3;Unknown;119340957;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A20;Alzheimer disease;2;Inactive;1611724421;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Inactive;1982355687;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MF56;Renal colic;2;Active;821552851;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Unknown;849253504;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG30.Z;Chronic pain, unspecified;1;Inactive;1581976053/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;3;Unknown;1683919430/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Unknown;106339515/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Inactive;1456478153/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Active;1582741816/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B8Z;Feeding or eating disorders, unspecified;3;Unknown;1412387537/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;1;Inactive;1691013484/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;4;Approved;1254916765;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A04.1;Essential tremor or related tremors;3;Unknown;1036027657;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;3;Unknown;119340957;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A20;Alzheimer disease;2;Inactive;1611724421;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Inactive;1982355687;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MF56;Renal colic;2;Active;821552851;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Unknown;849253504;30000589, 32491471, 31643301
344;pramipexole;pramipexole;CHEMBL301265;DB00413;119570;104632-26-0;83619PEU5T;FASDKYOPVNHBLU-ZETCQYMHSA-N;CCCNC1CCC2=C(C1)SC(=N2)N;21133;19;792;188;0;2;4;3;14;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG30.Z;Chronic pain, unspecified;1;Inactive;1581976053/unspecified;30000589, 32491471, 31643301
345;arbaclofen;arbaclofen;CHEMBL301742;DB08891;44602;69308-37-8;NYU6UTW25B;KPYSYYIEGFHWSV-QMMMGPOBSA-N;C1=CC(=CC=C1[C@@H](CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;3;Active;NA;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6A02.Z;Autism spectrum disorder, unspecified;3;Active;437815624/unspecified;36519155, 24872724, 28616094
345;arbaclofen;arbaclofen;CHEMBL301742;DB08891;44602;69308-37-8;NYU6UTW25B;KPYSYYIEGFHWSV-QMMMGPOBSA-N;C1=CC(=CC=C1[C@@H](CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;3;Active;NA;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;LD55;Fragile X chromosome;3;Inactive;1524287677;36519155, 24872724, 28616094
345;arbaclofen;arbaclofen;CHEMBL301742;DB08891;44602;69308-37-8;NYU6UTW25B;KPYSYYIEGFHWSV-QMMMGPOBSA-N;C1=CC(=CC=C1[C@@H](CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;3;Active;NA;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MB47.3;Cramp or spasm;3;Active;157838476;36519155, 24872724, 28616094
345;arbaclofen;arbaclofen;CHEMBL301742;DB08891;44602;69308-37-8;NYU6UTW25B;KPYSYYIEGFHWSV-QMMMGPOBSA-N;C1=CC(=CC=C1[C@@H](CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;3;Active;NA;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6A02.Z;Autism spectrum disorder, unspecified;3;Active;437815624/unspecified;36519155, 24872724, 28616094
345;arbaclofen;arbaclofen;CHEMBL301742;DB08891;44602;69308-37-8;NYU6UTW25B;KPYSYYIEGFHWSV-QMMMGPOBSA-N;C1=CC(=CC=C1[C@@H](CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;3;Active;NA;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;LD55;Fragile X chromosome;3;Inactive;1524287677;36519155, 24872724, 28616094
345;arbaclofen;arbaclofen;CHEMBL301742;DB08891;44602;69308-37-8;NYU6UTW25B;KPYSYYIEGFHWSV-QMMMGPOBSA-N;C1=CC(=CC=C1[C@@H](CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;3;Active;NA;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MB47.3;Cramp or spasm;3;Active;157838476;36519155, 24872724, 28616094
346;grapiprant;grapiprant;CHEMBL3039498;DB12836;11677589;415903-37-6;J9F5ZPH7NB;HZVLFTCYCLXTGV-UHFFFAOYSA-N;CCC1=NC2=C(N1C3=CC=C(C=C3)CCNC(=O)NS(=O)(=O)C4=CC=C(C=C4)C)C=C(N=C2C)C;4916;46;114;802;0;2;5;7;35;1;Active;NA;Small molecule;Antagonist;P35408;pe2r4_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;2B91.Z;Malignant neoplasms of rectosigmoid junction, unspecified;1;Active;774170412/unspecified;34057218, 35531962, 35524955
346;grapiprant;grapiprant;CHEMBL3039498;DB12836;11677589;415903-37-6;J9F5ZPH7NB;HZVLFTCYCLXTGV-UHFFFAOYSA-N;CCC1=NC2=C(N1C3=CC=C(C=C3)CCNC(=O)NS(=O)(=O)C4=CC=C(C=C4)C)C=C(N=C2C)C;4916;46;114;802;0;2;5;7;35;1;Active;NA;Small molecule;Antagonist;P35408;pe2r4_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;2C25.Y;Other specified malignant neoplasms of bronchus or lung;1;Inactive;316539081/other;34057218, 35531962, 35524955
346;grapiprant;grapiprant;CHEMBL3039498;DB12836;11677589;415903-37-6;J9F5ZPH7NB;HZVLFTCYCLXTGV-UHFFFAOYSA-N;CCC1=NC2=C(N1C3=CC=C(C=C3)CCNC(=O)NS(=O)(=O)C4=CC=C(C=C4)C)C=C(N=C2C)C;4916;46;114;802;0;2;5;7;35;1;Active;NA;Small molecule;Antagonist;P35408;pe2r4_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;2C6Y;Other specified malignant neoplasms of breast;1;Active;1047754165/other;34057218, 35531962, 35524955
346;grapiprant;grapiprant;CHEMBL3039498;DB12836;11677589;415903-37-6;J9F5ZPH7NB;HZVLFTCYCLXTGV-UHFFFAOYSA-N;CCC1=NC2=C(N1C3=CC=C(C=C3)CCNC(=O)NS(=O)(=O)C4=CC=C(C=C4)C)C=C(N=C2C)C;4916;46;114;802;0;2;5;7;35;1;Active;NA;Small molecule;Antagonist;P35408;pe2r4_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;FA0Z;Osteoarthritis, unspecified;1;Inactive;558562409/unspecified;34057218, 35531962, 35524955
347;lasmiditan;lasmiditan;CHEMBL3039520;DB11732;11610526;439239-90-4;760I9WM792;XEDHVZKDSYZQBF-UHFFFAOYSA-N;CN1CCC(CC1)C(=O)C2=NC(=CC=C2)NC(=O)C3=C(C=C(C=C3F)F)F;3774;28;623;530;0;1;7;4;27;4;Approved;2020;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;32522164, 34324283, 33104315
350;secretin;secretin;CHEMBL3039582;DB09532;16158474;108153-74-8;A0426J905J;OWMZNFCDEHGFEP-NFBCVYDUSA-N;CC(C)CC(C(=O)NC(C(C)C)C(=O)N)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC2=CN=CN2)N;30394;-131;1400;6940;0;51;46;109;214;4;Approved;2002;Protein;Agonist;P47872;sctr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;6A02.Z;Autism spectrum disorder, unspecified;3;Inactive;437815624/unspecified;30725801, 34158656, 12392059
350;secretin;secretin;CHEMBL3039582;DB09532;16158474;108153-74-8;A0426J905J;OWMZNFCDEHGFEP-NFBCVYDUSA-N;CC(C)CC(C(=O)NC(C(C)C)C(=O)N)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC2=CN=CN2)N;30394;-131;1400;6940;0;51;46;109;214;4;Approved;2002;Protein;Agonist;P47872;sctr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30725801, 34158656, 12392059
350;secretin;secretin;CHEMBL3039582;DB09532;16158474;108153-74-8;A0426J905J;OWMZNFCDEHGFEP-NFBCVYDUSA-N;CC(C)CC(C(=O)NC(C(C)C)C(=O)N)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC2=CN=CN2)N;30394;-131;1400;6940;0;51;46;109;214;4;Approved;2002;Protein;Agonist;P47872;sctr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DC31.Z;Acute pancreatitis, unspecified;4;Approved;698285441/unspecified;30725801, 34158656, 12392059
350;secretin;secretin;CHEMBL3039582;DB09532;16158474;108153-74-8;A0426J905J;OWMZNFCDEHGFEP-NFBCVYDUSA-N;CC(C)CC(C(=O)NC(C(C)C)C(=O)N)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC2=CN=CN2)N;30394;-131;1400;6940;0;51;46;109;214;4;Approved;2002;Protein;Agonist;P47872;sctr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DC32.Z;Chronic pancreatitis, unspecified;1;Inactive;1758007371/unspecified;30725801, 34158656, 12392059
350;secretin;secretin;CHEMBL3039582;DB09532;16158474;108153-74-8;A0426J905J;OWMZNFCDEHGFEP-NFBCVYDUSA-N;CC(C)CC(C(=O)NC(C(C)C)C(=O)N)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC2=CN=CN2)N;30394;-131;1400;6940;0;51;46;109;214;4;Approved;2002;Protein;Agonist;P47872;sctr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;MD92;Dyspepsia;1;Inactive;869622187;30725801, 34158656, 12392059
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A01.0Z;Meningiomas, unspecified;2;Inactive;672106711/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A83.1;Plasma cell myeloma;2;Unknown;526287100;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2B3Z;Neoplasms of haematopoietic or lymphoid tissues, unspecified;2;Inactive;944754984/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C10.Y;Other specified malignant neoplasms of pancreas;3;Inactive;542147910/other;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.02;Hepatocellular carcinoma of liver;2;Inactive;1294035808;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C25.1;Small cell carcinoma of bronchus or lung;2;Unknown;1800431439;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C25.5;Unspecified malignant epithelial neoplasm of bronchus or lung;2;Inactive;1826627197;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C27.Y;Other specified malignant neoplasms of thymus;2;Inactive;1718833206/other;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C34;Cutaneous neuroendocrine carcinoma;1;Inactive;680322043;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.0;Adenocarcinoma of prostate;1;Inactive;1510677183;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Inactive;1552457716/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D10.4;Medullary carcinoma of thyroid gland;2;Unknown;578519098;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D10.Z;Malignant neoplasms of thyroid gland, unspecified;2;Inactive;447433352/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;3;Active;1594217552/other;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Z;Unspecified malignant neoplasms of unspecified sites;2;Inactive;1594217552/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2E65.2;Ductal carcinoma in situ of breast;1;Inactive;722360431;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2E92.9;Benign neoplasm of endocrine pancreas;2;Inactive;170957983;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F37.Y;Other specified benign neoplasm of endocrine glands;2;Inactive;1290583069/other;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A70.0;Pituitary-dependent Cushing disease;3;Inactive;380861892;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A70.1;Ectopic ACTH syndrome;2;Unknown;1646144829;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A70.Z;Cushing syndrome, unspecified;2;Unknown;1654321425/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DE11;Dumping syndrome;2;Inactive;237191235;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A01.0Z;Meningiomas, unspecified;2;Inactive;672106711/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A83.1;Plasma cell myeloma;2;Unknown;526287100;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2B3Z;Neoplasms of haematopoietic or lymphoid tissues, unspecified;2;Inactive;944754984/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C10.Y;Other specified malignant neoplasms of pancreas;3;Inactive;542147910/other;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.02;Hepatocellular carcinoma of liver;2;Inactive;1294035808;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C25.1;Small cell carcinoma of bronchus or lung;2;Unknown;1800431439;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C25.5;Unspecified malignant epithelial neoplasm of bronchus or lung;2;Inactive;1826627197;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C27.Y;Other specified malignant neoplasms of thymus;2;Inactive;1718833206/other;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C34;Cutaneous neuroendocrine carcinoma;1;Inactive;680322043;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.0;Adenocarcinoma of prostate;1;Inactive;1510677183;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Inactive;1552457716/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D10.4;Medullary carcinoma of thyroid gland;2;Unknown;578519098;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D10.Z;Malignant neoplasms of thyroid gland, unspecified;2;Inactive;447433352/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;3;Active;1594217552/other;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Z;Unspecified malignant neoplasms of unspecified sites;2;Inactive;1594217552/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2E65.2;Ductal carcinoma in situ of breast;1;Inactive;722360431;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2E92.9;Benign neoplasm of endocrine pancreas;2;Inactive;170957983;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F37.Y;Other specified benign neoplasm of endocrine glands;2;Inactive;1290583069/other;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A70.0;Pituitary-dependent Cushing disease;3;Inactive;380861892;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A70.1;Ectopic ACTH syndrome;2;Unknown;1646144829;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A70.Z;Cushing syndrome, unspecified;2;Unknown;1654321425/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DE11;Dumping syndrome;2;Inactive;237191235;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A01.0Z;Meningiomas, unspecified;2;Inactive;672106711/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A83.1;Plasma cell myeloma;2;Unknown;526287100;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2B3Z;Neoplasms of haematopoietic or lymphoid tissues, unspecified;2;Inactive;944754984/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C10.Y;Other specified malignant neoplasms of pancreas;3;Inactive;542147910/other;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.02;Hepatocellular carcinoma of liver;2;Inactive;1294035808;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C25.1;Small cell carcinoma of bronchus or lung;2;Unknown;1800431439;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C25.5;Unspecified malignant epithelial neoplasm of bronchus or lung;2;Inactive;1826627197;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C27.Y;Other specified malignant neoplasms of thymus;2;Inactive;1718833206/other;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C34;Cutaneous neuroendocrine carcinoma;1;Inactive;680322043;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.0;Adenocarcinoma of prostate;1;Inactive;1510677183;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Inactive;1552457716/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D10.4;Medullary carcinoma of thyroid gland;2;Unknown;578519098;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D10.Z;Malignant neoplasms of thyroid gland, unspecified;2;Inactive;447433352/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;3;Active;1594217552/other;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Z;Unspecified malignant neoplasms of unspecified sites;2;Inactive;1594217552/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2E65.2;Ductal carcinoma in situ of breast;1;Inactive;722360431;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2E92.9;Benign neoplasm of endocrine pancreas;2;Inactive;170957983;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F37.Y;Other specified benign neoplasm of endocrine glands;2;Inactive;1290583069/other;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A70.0;Pituitary-dependent Cushing disease;3;Inactive;380861892;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A70.1;Ectopic ACTH syndrome;2;Unknown;1646144829;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A70.Z;Cushing syndrome, unspecified;2;Unknown;1654321425/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DE11;Dumping syndrome;2;Inactive;237191235;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A01.0Z;Meningiomas, unspecified;2;Inactive;672106711/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A83.1;Plasma cell myeloma;2;Unknown;526287100;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2B3Z;Neoplasms of haematopoietic or lymphoid tissues, unspecified;2;Inactive;944754984/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C10.Y;Other specified malignant neoplasms of pancreas;3;Inactive;542147910/other;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C12.02;Hepatocellular carcinoma of liver;2;Inactive;1294035808;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C25.1;Small cell carcinoma of bronchus or lung;2;Unknown;1800431439;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C25.5;Unspecified malignant epithelial neoplasm of bronchus or lung;2;Inactive;1826627197;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C27.Y;Other specified malignant neoplasms of thymus;2;Inactive;1718833206/other;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C34;Cutaneous neuroendocrine carcinoma;1;Inactive;680322043;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.0;Adenocarcinoma of prostate;1;Inactive;1510677183;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Inactive;1552457716/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D10.4;Medullary carcinoma of thyroid gland;2;Unknown;578519098;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D10.Z;Malignant neoplasms of thyroid gland, unspecified;2;Inactive;447433352/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;3;Active;1594217552/other;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Z;Unspecified malignant neoplasms of unspecified sites;2;Inactive;1594217552/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2E65.2;Ductal carcinoma in situ of breast;1;Inactive;722360431;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2E92.9;Benign neoplasm of endocrine pancreas;2;Inactive;170957983;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2F37.Y;Other specified benign neoplasm of endocrine glands;2;Inactive;1290583069/other;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A70.0;Pituitary-dependent Cushing disease;3;Inactive;380861892;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A70.1;Ectopic ACTH syndrome;2;Unknown;1646144829;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A70.Z;Cushing syndrome, unspecified;2;Unknown;1654321425/unspecified;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;DE11;Dumping syndrome;2;Inactive;237191235;31145573, 31644171, 24427831
351;pasireotide;pasireotide;CHEMBL3039583;NA;73348210;NA;NA;VMZMNAABQBOLAK-IXZCVAHUSA-N;C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN;10472;47;281;1940;0;9;11;18;77;4;Approved;2012;Protein;Agonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31145573, 31644171, 24427831
352;clothiapine;clothiapine;CHEMBL304902;DB13256;16351;2058-52-8;NA;KAAZGXDPUNNEFN-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3SC4=C2C=C(C=C4)Cl;3439;36;441;450;0;0;3;1;23;4;Approved;1970;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;33369916, 15324, 7911824
352;clothiapine;clothiapine;CHEMBL304902;DB13256;16351;2058-52-8;NA;KAAZGXDPUNNEFN-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3SC4=C2C=C(C=C4)Cl;3439;36;441;450;0;0;3;1;23;4;Approved;1970;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;33369916, 15324, 7911824
352;clothiapine;clothiapine;CHEMBL304902;DB13256;16351;2058-52-8;NA;KAAZGXDPUNNEFN-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3SC4=C2C=C(C=C4)Cl;3439;36;441;450;0;0;3;1;23;4;Approved;1970;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;33369916, 15324, 7911824
352;clothiapine;clothiapine;CHEMBL304902;DB13256;16351;2058-52-8;NA;KAAZGXDPUNNEFN-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3SC4=C2C=C(C=C4)Cl;3439;36;441;450;0;0;3;1;23;4;Approved;1970;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;33369916, 15324, 7911824
353;bupranolol;bupranolol;CHEMBL305380;DB08808;2475;14556-46-8;858YGI5PIT;HQIRNZOQPUAHHV-UHFFFAOYSA-N;CC1=CC(=C(C=C1)Cl)OCC(CNC(C)(C)C)O;27178;28;415;242;0;2;3;6;18;4;Approved;1986;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;26456674, 8276051, 6259541
353;bupranolol;bupranolol;CHEMBL305380;DB08808;2475;14556-46-8;858YGI5PIT;HQIRNZOQPUAHHV-UHFFFAOYSA-N;CC1=CC(=C(C=C1)Cl)OCC(CNC(C)(C)C)O;27178;28;415;242;0;2;3;6;18;4;Approved;1986;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;26456674, 8276051, 6259541
353;bupranolol;bupranolol;CHEMBL305380;DB08808;2475;14556-46-8;858YGI5PIT;HQIRNZOQPUAHHV-UHFFFAOYSA-N;CC1=CC(=C(C=C1)Cl)OCC(CNC(C)(C)C)O;27178;28;415;242;0;2;3;6;18;4;Approved;1986;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;26456674, 8276051, 6259541
354;ebastine;ebastine;CHEMBL305660;DB11742;3191;90729-43-4;NA;MJJALKDDGIKVBE-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4;4697;72;295;594;0;0;3;10;35;4;Approved;1990;Small molecule;Inverse agonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;32352696, 19032340, 10804044
354;ebastine;ebastine;CHEMBL305660;DB11742;3191;90729-43-4;NA;MJJALKDDGIKVBE-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4;4697;72;295;594;0;0;3;10;35;4;Approved;1990;Small molecule;Inverse agonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;32352696, 19032340, 10804044
354;ebastine;ebastine;CHEMBL305660;DB11742;3191;90729-43-4;NA;MJJALKDDGIKVBE-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4;4697;72;295;594;0;0;3;10;35;4;Approved;1990;Small molecule;Inverse agonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;32352696, 19032340, 10804044
355;mavoglurant;mavoglurant;CHEMBL3087515;DB13004;9926832;"1636881-61-2;543906-09-8";NA;ZFPZEYHRWGMJCV-ZHALLVOQSA-N;CC1=CC(=CC=C1)C#CC2(CCCC3C2CCN3C(=O)OC)O;3134;29;498;519;0;1;3;3;23;2;Active;NA;Small molecule;Antagonist;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Inactive;1582741816/unspecified;34014397, 24960254, 24007304
355;mavoglurant;mavoglurant;CHEMBL3087515;DB13004;9926832;"1636881-61-2;543906-09-8";NA;ZFPZEYHRWGMJCV-ZHALLVOQSA-N;CC1=CC(=CC=C1)C#CC2(CCCC3C2CCN3C(=O)OC)O;3134;29;498;519;0;1;3;3;23;2;Active;NA;Small molecule;Antagonist;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;34014397, 24960254, 24007304
355;mavoglurant;mavoglurant;CHEMBL3087515;DB13004;9926832;"1636881-61-2;543906-09-8";NA;ZFPZEYHRWGMJCV-ZHALLVOQSA-N;CC1=CC(=CC=C1)C#CC2(CCCC3C2CCN3C(=O)OC)O;3134;29;498;519;0;1;3;3;23;2;Active;NA;Small molecule;Antagonist;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;8A02.10;Drug-induced dystonia;2;Unknown;678203506;34014397, 24960254, 24007304
355;mavoglurant;mavoglurant;CHEMBL3087515;DB13004;9926832;"1636881-61-2;543906-09-8";NA;ZFPZEYHRWGMJCV-ZHALLVOQSA-N;CC1=CC(=CC=C1)C#CC2(CCCC3C2CCN3C(=O)OC)O;3134;29;498;519;0;1;3;3;23;2;Active;NA;Small molecule;Antagonist;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;8A0Y;Other specified movement disorders;2;Inactive;384289569/other;34014397, 24960254, 24007304
355;mavoglurant;mavoglurant;CHEMBL3087515;DB13004;9926832;"1636881-61-2;543906-09-8";NA;ZFPZEYHRWGMJCV-ZHALLVOQSA-N;CC1=CC(=CC=C1)C#CC2(CCCC3C2CCN3C(=O)OC)O;3134;29;498;519;0;1;3;3;23;2;Active;NA;Small molecule;Antagonist;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;LD55;Fragile X chromosome;2;Active;1524287677;34014397, 24960254, 24007304
355;mavoglurant;mavoglurant;CHEMBL3087515;DB13004;9926832;"1636881-61-2;543906-09-8";NA;ZFPZEYHRWGMJCV-ZHALLVOQSA-N;CC1=CC(=CC=C1)C#CC2(CCCC3C2CCN3C(=O)OC)O;3134;29;498;519;0;1;3;3;23;2;Active;NA;Small molecule;Antagonist;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;34014397, 24960254, 24007304
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;3;Inactive;2066255370;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;3;Inactive;2066255370;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;3;Inactive;2066255370;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;3;Inactive;2066255370;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;3;Inactive;2066255370;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;3;Inactive;2066255370;36171065, 20151787, 33518471
356;xylometazoline;xylometazoline;CHEMBL312448;DB06694;5709;526-36-3;WPY40FTH8K;HUCJFAOMUPXHDK-UHFFFAOYSA-N;CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C;24437;32;244;302;0;1;1;3;18;4;Approved;1959;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;36171065, 20151787, 33518471
357;benzhydrocodone;benzhydrocodone;CHEMBL3137321;DB15465;76314940;NA;NA;VPMRSLWWUXNYRY-NDOYXKHWSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=CC4)OC(=O)C6=CC=CC=C6;4035;41;48;731;0;0;5;4;30;4;Approved;2018;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;4;Approved;2143971168/unspecified;31381547, 30140595, 29092079
357;benzhydrocodone;benzhydrocodone;CHEMBL3137321;DB15465;76314940;NA;NA;VPMRSLWWUXNYRY-NDOYXKHWSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=CC4)OC(=O)C6=CC=CC=C6;4035;41;48;731;0;0;5;4;30;4;Approved;2018;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;31381547, 30140595, 29092079
357;benzhydrocodone;benzhydrocodone;CHEMBL3137321;DB15465;76314940;NA;NA;VPMRSLWWUXNYRY-NDOYXKHWSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=CC4)OC(=O)C6=CC=CC=C6;4035;41;48;731;0;0;5;4;30;4;Approved;2018;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;4;Approved;2143971168/unspecified;31381547, 30140595, 29092079
357;benzhydrocodone;benzhydrocodone;CHEMBL3137321;DB15465;76314940;NA;NA;VPMRSLWWUXNYRY-NDOYXKHWSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=CC4)OC(=O)C6=CC=CC=C6;4035;41;48;731;0;0;5;4;30;4;Approved;2018;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;31381547, 30140595, 29092079
357;benzhydrocodone;benzhydrocodone;CHEMBL3137321;DB15465;76314940;NA;NA;VPMRSLWWUXNYRY-NDOYXKHWSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=CC4)OC(=O)C6=CC=CC=C6;4035;41;48;731;0;0;5;4;30;4;Approved;2018;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;4;Approved;2143971168/unspecified;31381547, 30140595, 29092079
357;benzhydrocodone;benzhydrocodone;CHEMBL3137321;DB15465;76314940;NA;NA;VPMRSLWWUXNYRY-NDOYXKHWSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=CC4)OC(=O)C6=CC=CC=C6;4035;41;48;731;0;0;5;4;30;4;Approved;2018;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;31381547, 30140595, 29092079
358;meptazinol;meptazinol;CHEMBL314437;DB13478;41049;54340-58-8;NA;JLICHNCFTLFZJN-UHFFFAOYSA-N;CCC1(CCCCN(C1)C)C2=CC(=CC=C2)O;23335;34;235;243;0;1;2;2;17;4;Approved;1983;Small molecule;Partial agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;6135879, 6138571, 35410473
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95136;s1pr2_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;4B0Z;Immune system disorders involving white cell lineages, unspecified;1;Unknown;966435382/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95136;s1pr2_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;4B4Z;Diseases of the immune system, unspecified;4;Approved;1954798891/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95136;s1pr2_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95136;s1pr2_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.0;Relapsing-remitting multiple sclerosis;3;Active;799053936;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95136;s1pr2_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.1;Primary progressive multiple sclerosis;4;Approved;1020720762;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95136;s1pr2_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.Y;Other specified multiple sclerosis;4;Approved;1298865187/other;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95136;s1pr2_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.Z;Multiple sclerosis, unspecified;4;Approved;1298865187/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95136;s1pr2_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Inactive;1442995018;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95136;s1pr2_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8B60.0;Amyotrophic lateral sclerosis;2;Inactive;1982355687;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95136;s1pr2_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8C01.3;Chronic inflammatory demyelinating polyneuropathy;3;Inactive;224318510;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95136;s1pr2_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8C0Z;Polyneuropathy, unspecified;1;Unknown;58868923/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95136;s1pr2_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;9A96.Z;Anterior uveitis, unspecified;2;Unknown;908233081/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95136;s1pr2_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;9C40.1Z;Optic neuritis, unspecified;2;Inactive;210935787/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95136;s1pr2_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;CA23;Asthma;2;Unknown;1656445230;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95136;s1pr2_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;LD90.4;Rett syndrome;1;Inactive;201200685;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95977;s1pr4_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;4B0Z;Immune system disorders involving white cell lineages, unspecified;1;Unknown;966435382/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95977;s1pr4_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;4B4Z;Diseases of the immune system, unspecified;4;Approved;1954798891/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95977;s1pr4_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95977;s1pr4_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.0;Relapsing-remitting multiple sclerosis;3;Active;799053936;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95977;s1pr4_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.1;Primary progressive multiple sclerosis;4;Approved;1020720762;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95977;s1pr4_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.Y;Other specified multiple sclerosis;4;Approved;1298865187/other;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95977;s1pr4_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.Z;Multiple sclerosis, unspecified;4;Approved;1298865187/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95977;s1pr4_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Inactive;1442995018;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95977;s1pr4_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8B60.0;Amyotrophic lateral sclerosis;2;Inactive;1982355687;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95977;s1pr4_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8C01.3;Chronic inflammatory demyelinating polyneuropathy;3;Inactive;224318510;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95977;s1pr4_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8C0Z;Polyneuropathy, unspecified;1;Unknown;58868923/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95977;s1pr4_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;9A96.Z;Anterior uveitis, unspecified;2;Unknown;908233081/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95977;s1pr4_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;9C40.1Z;Optic neuritis, unspecified;2;Inactive;210935787/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95977;s1pr4_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;CA23;Asthma;2;Unknown;1656445230;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;O95977;s1pr4_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;LD90.4;Rett syndrome;1;Inactive;201200685;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;4B0Z;Immune system disorders involving white cell lineages, unspecified;1;Unknown;966435382/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;4B4Z;Diseases of the immune system, unspecified;4;Approved;1954798891/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.0;Relapsing-remitting multiple sclerosis;3;Active;799053936;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.1;Primary progressive multiple sclerosis;4;Approved;1020720762;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.Y;Other specified multiple sclerosis;4;Approved;1298865187/other;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.Z;Multiple sclerosis, unspecified;4;Approved;1298865187/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Inactive;1442995018;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8B60.0;Amyotrophic lateral sclerosis;2;Inactive;1982355687;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8C01.3;Chronic inflammatory demyelinating polyneuropathy;3;Inactive;224318510;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8C0Z;Polyneuropathy, unspecified;1;Unknown;58868923/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;9A96.Z;Anterior uveitis, unspecified;2;Unknown;908233081/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;9C40.1Z;Optic neuritis, unspecified;2;Inactive;210935787/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;CA23;Asthma;2;Unknown;1656445230;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;LD90.4;Rett syndrome;1;Inactive;201200685;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q99500;s1pr3_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;4B0Z;Immune system disorders involving white cell lineages, unspecified;1;Unknown;966435382/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q99500;s1pr3_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;4B4Z;Diseases of the immune system, unspecified;4;Approved;1954798891/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q99500;s1pr3_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q99500;s1pr3_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.0;Relapsing-remitting multiple sclerosis;3;Active;799053936;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q99500;s1pr3_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.1;Primary progressive multiple sclerosis;4;Approved;1020720762;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q99500;s1pr3_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.Y;Other specified multiple sclerosis;4;Approved;1298865187/other;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q99500;s1pr3_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.Z;Multiple sclerosis, unspecified;4;Approved;1298865187/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q99500;s1pr3_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Inactive;1442995018;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q99500;s1pr3_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8B60.0;Amyotrophic lateral sclerosis;2;Inactive;1982355687;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q99500;s1pr3_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8C01.3;Chronic inflammatory demyelinating polyneuropathy;3;Inactive;224318510;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q99500;s1pr3_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8C0Z;Polyneuropathy, unspecified;1;Unknown;58868923/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q99500;s1pr3_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;9A96.Z;Anterior uveitis, unspecified;2;Unknown;908233081/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q99500;s1pr3_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;9C40.1Z;Optic neuritis, unspecified;2;Inactive;210935787/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q99500;s1pr3_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;CA23;Asthma;2;Unknown;1656445230;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q99500;s1pr3_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;LD90.4;Rett syndrome;1;Inactive;201200685;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;4B0Z;Immune system disorders involving white cell lineages, unspecified;1;Unknown;966435382/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;4B4Z;Diseases of the immune system, unspecified;4;Approved;1954798891/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.0;Relapsing-remitting multiple sclerosis;3;Active;799053936;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.1;Primary progressive multiple sclerosis;4;Approved;1020720762;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.Y;Other specified multiple sclerosis;4;Approved;1298865187/other;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.Z;Multiple sclerosis, unspecified;4;Approved;1298865187/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Inactive;1442995018;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8B60.0;Amyotrophic lateral sclerosis;2;Inactive;1982355687;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8C01.3;Chronic inflammatory demyelinating polyneuropathy;3;Inactive;224318510;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8C0Z;Polyneuropathy, unspecified;1;Unknown;58868923/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;9A96.Z;Anterior uveitis, unspecified;2;Unknown;908233081/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;9C40.1Z;Optic neuritis, unspecified;2;Inactive;210935787/unspecified;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;CA23;Asthma;2;Unknown;1656445230;30000788, 31643705, 29443307
359;fingolimod;fingolimod;CHEMBL314854;DB08868;107970;162359-55-9;3QN8BYN5QF;KKGQTZUTZRNORY-UHFFFAOYSA-N;CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N;3075;42;665;258;0;3;3;12;22;4;Approved;2010;Small molecule;Agonist;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;LD90.4;Rett syndrome;1;Inactive;201200685;30000788, 31643705, 29443307
360;regadenoson;regadenoson;CHEMBL317052;DB06213;219024;313348-27-5;7AXV542LZ4;LZPZPHGJDAGEJZ-AKAIJSEGSA-N;CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N;39035;-15;187;587;0;5;10;4;28;4;Approved;2008;Small molecule;Agonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;X3;Diagnosis stress;4;Approved;NA;29999988, 20063904, 22718059
361;nizatidine;(E)-nizatidine;CHEMBL3183075;DB00585;3033637;76963-41-2;P41PML4GHR;SGXXNSQHWDMGGP-IZZDOVSWSA-N;CN/C(=C\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C;3315;16;140;349;0;2;8;9;21;4;Approved;1988;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;30000299, 31643707, 37576886
361;nizatidine;(E)-nizatidine;CHEMBL3183075;DB00585;3033637;76963-41-2;P41PML4GHR;SGXXNSQHWDMGGP-IZZDOVSWSA-N;CN/C(=C\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C;3315;16;140;349;0;2;8;9;21;4;Approved;1988;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA24.Z;Oesophagitis, unspecified;4;Approved;1540965840/unspecified;30000299, 31643707, 37576886
361;nizatidine;(E)-nizatidine;CHEMBL3183075;DB00585;3033637;76963-41-2;P41PML4GHR;SGXXNSQHWDMGGP-IZZDOVSWSA-N;CN/C(=C\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C;3315;16;140;349;0;2;8;9;21;4;Approved;1988;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA41.00;Gastroparesis;1;Inactive;598423727;30000299, 31643707, 37576886
361;nizatidine;(E)-nizatidine;CHEMBL3183075;DB00585;3033637;76963-41-2;P41PML4GHR;SGXXNSQHWDMGGP-IZZDOVSWSA-N;CN/C(=C\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C;3315;16;140;349;0;2;8;9;21;4;Approved;1988;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA42.Z;Gastritis, unspecified;1;Unknown;1871672644/unspecified;30000299, 31643707, 37576886
361;nizatidine;(E)-nizatidine;CHEMBL3183075;DB00585;3033637;76963-41-2;P41PML4GHR;SGXXNSQHWDMGGP-IZZDOVSWSA-N;CN/C(=C\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C;3315;16;140;349;0;2;8;9;21;4;Approved;1988;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;30000299, 31643707, 37576886
361;nizatidine;(E)-nizatidine;CHEMBL3183075;DB00585;3033637;76963-41-2;P41PML4GHR;SGXXNSQHWDMGGP-IZZDOVSWSA-N;CN/C(=C\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C;3315;16;140;349;0;2;8;9;21;4;Approved;1988;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA63.Z;Duodenal ulcer, unspecified;4;Approved;553678663/unspecified;30000299, 31643707, 37576886
361;nizatidine;nizatidine;CHEMBL3183075;DB00585;4513;76963-41-2;P41PML4GHR;SGXXNSQHWDMGGP-UHFFFAOYSA-N;CNC(=C[N+](=O)[O-])NCCSCC1=CSC(=N1)CN(C)C;3315;16;140;349;0;2;8;9;21;4;Approved;1988;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;30000299, 31643707, 37576886
361;nizatidine;nizatidine;CHEMBL3183075;DB00585;4513;76963-41-2;P41PML4GHR;SGXXNSQHWDMGGP-UHFFFAOYSA-N;CNC(=C[N+](=O)[O-])NCCSCC1=CSC(=N1)CN(C)C;3315;16;140;349;0;2;8;9;21;4;Approved;1988;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA24.Z;Oesophagitis, unspecified;4;Approved;1540965840/unspecified;30000299, 31643707, 37576886
361;nizatidine;nizatidine;CHEMBL3183075;DB00585;4513;76963-41-2;P41PML4GHR;SGXXNSQHWDMGGP-UHFFFAOYSA-N;CNC(=C[N+](=O)[O-])NCCSCC1=CSC(=N1)CN(C)C;3315;16;140;349;0;2;8;9;21;4;Approved;1988;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA41.00;Gastroparesis;1;Inactive;598423727;30000299, 31643707, 37576886
361;nizatidine;nizatidine;CHEMBL3183075;DB00585;4513;76963-41-2;P41PML4GHR;SGXXNSQHWDMGGP-UHFFFAOYSA-N;CNC(=C[N+](=O)[O-])NCCSCC1=CSC(=N1)CN(C)C;3315;16;140;349;0;2;8;9;21;4;Approved;1988;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA42.Z;Gastritis, unspecified;1;Unknown;1871672644/unspecified;30000299, 31643707, 37576886
361;nizatidine;nizatidine;CHEMBL3183075;DB00585;4513;76963-41-2;P41PML4GHR;SGXXNSQHWDMGGP-UHFFFAOYSA-N;CNC(=C[N+](=O)[O-])NCCSCC1=CSC(=N1)CN(C)C;3315;16;140;349;0;2;8;9;21;4;Approved;1988;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;30000299, 31643707, 37576886
361;nizatidine;nizatidine;CHEMBL3183075;DB00585;4513;76963-41-2;P41PML4GHR;SGXXNSQHWDMGGP-UHFFFAOYSA-N;CNC(=C[N+](=O)[O-])NCCSCC1=CSC(=N1)CN(C)C;3315;16;140;349;0;2;8;9;21;4;Approved;1988;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA63.Z;Duodenal ulcer, unspecified;4;Approved;553678663/unspecified;30000299, 31643707, 37576886
362;asenapine;(S,S)-asenapine;CHEMBL504548;DB06216;163091;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-GJZGRUSLSA-N;CN1C[C@H]2[C@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A01.1;Developmental speech fluency disorder;3;Unknown;654956298;30000744, 31643422, 19689168
362;asenapine;(S,S)-asenapine;CHEMBL504548;DB06216;163091;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-GJZGRUSLSA-N;CN1C[C@H]2[C@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000744, 31643422, 19689168
362;asenapine;(S,S)-asenapine;CHEMBL504548;DB06216;163091;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-GJZGRUSLSA-N;CN1C[C@H]2[C@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;30000744, 31643422, 19689168
362;asenapine;(S,S)-asenapine;CHEMBL504548;DB06216;163091;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-GJZGRUSLSA-N;CN1C[C@H]2[C@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000744, 31643422, 19689168
362;asenapine;(S,S)-asenapine;CHEMBL504548;DB06216;163091;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-GJZGRUSLSA-N;CN1C[C@H]2[C@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000744, 31643422, 19689168
362;asenapine;(R,R)-asenapine;"CHEMBL3187365;CHEMBL504548";DB06216;3036780;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-MLCCFXAWSA-N;CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A01.1;Developmental speech fluency disorder;3;Unknown;654956298;30000744, 31643422, 19689168
362;asenapine;(R,R)-asenapine;"CHEMBL3187365;CHEMBL504548";DB06216;3036780;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-MLCCFXAWSA-N;CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000744, 31643422, 19689168
362;asenapine;(R,R)-asenapine;"CHEMBL3187365;CHEMBL504548";DB06216;3036780;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-MLCCFXAWSA-N;CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;30000744, 31643422, 19689168
362;asenapine;(R,R)-asenapine;"CHEMBL3187365;CHEMBL504548";DB06216;3036780;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-MLCCFXAWSA-N;CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000744, 31643422, 19689168
362;asenapine;(R,R)-asenapine;"CHEMBL3187365;CHEMBL504548";DB06216;3036780;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-MLCCFXAWSA-N;CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000744, 31643422, 19689168
362;asenapine;asenapine;CHEMBL3187365;DB06216;9903970;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-UHFFFAOYSA-N;CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A01.1;Developmental speech fluency disorder;3;Unknown;654956298;30000744, 31643422, 19689168
362;asenapine;asenapine;CHEMBL3187365;DB06216;9903970;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-UHFFFAOYSA-N;CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000744, 31643422, 19689168
362;asenapine;asenapine;CHEMBL3187365;DB06216;9903970;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-UHFFFAOYSA-N;CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;30000744, 31643422, 19689168
362;asenapine;asenapine;CHEMBL3187365;DB06216;9903970;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-UHFFFAOYSA-N;CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000744, 31643422, 19689168
362;asenapine;asenapine;CHEMBL3187365;DB06216;9903970;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-UHFFFAOYSA-N;CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000744, 31643422, 19689168
362;asenapine;(S,S)-asenapine;CHEMBL504548;DB06216;163091;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-GJZGRUSLSA-N;CN1C[C@H]2[C@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A01.1;Developmental speech fluency disorder;3;Unknown;654956298;30000744, 31643422, 19689168
362;asenapine;(S,S)-asenapine;CHEMBL504548;DB06216;163091;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-GJZGRUSLSA-N;CN1C[C@H]2[C@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000744, 31643422, 19689168
362;asenapine;(S,S)-asenapine;CHEMBL504548;DB06216;163091;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-GJZGRUSLSA-N;CN1C[C@H]2[C@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;30000744, 31643422, 19689168
362;asenapine;(S,S)-asenapine;CHEMBL504548;DB06216;163091;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-GJZGRUSLSA-N;CN1C[C@H]2[C@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000744, 31643422, 19689168
362;asenapine;(S,S)-asenapine;CHEMBL504548;DB06216;163091;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-GJZGRUSLSA-N;CN1C[C@H]2[C@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000744, 31643422, 19689168
362;asenapine;(R,R)-asenapine;"CHEMBL3187365;CHEMBL504548";DB06216;3036780;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-MLCCFXAWSA-N;CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A01.1;Developmental speech fluency disorder;3;Unknown;654956298;30000744, 31643422, 19689168
362;asenapine;(R,R)-asenapine;"CHEMBL3187365;CHEMBL504548";DB06216;3036780;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-MLCCFXAWSA-N;CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000744, 31643422, 19689168
362;asenapine;(R,R)-asenapine;"CHEMBL3187365;CHEMBL504548";DB06216;3036780;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-MLCCFXAWSA-N;CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;30000744, 31643422, 19689168
362;asenapine;(R,R)-asenapine;"CHEMBL3187365;CHEMBL504548";DB06216;3036780;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-MLCCFXAWSA-N;CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000744, 31643422, 19689168
362;asenapine;(R,R)-asenapine;"CHEMBL3187365;CHEMBL504548";DB06216;3036780;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-MLCCFXAWSA-N;CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000744, 31643422, 19689168
362;asenapine;asenapine;CHEMBL3187365;DB06216;9903970;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-UHFFFAOYSA-N;CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A01.1;Developmental speech fluency disorder;3;Unknown;654956298;30000744, 31643422, 19689168
362;asenapine;asenapine;CHEMBL3187365;DB06216;9903970;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-UHFFFAOYSA-N;CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000744, 31643422, 19689168
362;asenapine;asenapine;CHEMBL3187365;DB06216;9903970;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-UHFFFAOYSA-N;CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;30000744, 31643422, 19689168
362;asenapine;asenapine;CHEMBL3187365;DB06216;9903970;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-UHFFFAOYSA-N;CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000744, 31643422, 19689168
362;asenapine;asenapine;CHEMBL3187365;DB06216;9903970;65576-45-6;JKZ19V908O;VSWBSWWIRNCQIJ-UHFFFAOYSA-N;CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24;2858;38;125;363;0;0;2;0;20;4;Approved;2009;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000744, 31643422, 19689168
363;irl-1620;irl-1620;CHEMBL3188091;DB06138;;142569-99-1;11X778QIZS;DXPHNGAMYPPTBJ-TZMIJSMNSA-N;CCC(C)C(C(=O)NC(C(C)CC)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC3=CN=CN3)NC(=O)C(C)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)CCC(=O)O;18209;21;696;3920;0;23;28;56;130;4;Approved;2023;Protein;Agonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;2;Unknown;1844086508/unspecified;33428177, 29947531, 34826534
363;irl-1620;irl-1620;CHEMBL3188091;DB06138;;142569-99-1;11X778QIZS;DXPHNGAMYPPTBJ-TZMIJSMNSA-N;CCC(C)C(C(=O)NC(C(C)CC)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC3=CN=CN3)NC(=O)C(C)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)CCC(=O)O;18209;21;696;3920;0;23;28;56;130;4;Approved;2023;Protein;Agonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;4;Approved;1614716959/unspecified;33428177, 29947531, 34826534
363;irl-1620;irl-1620;CHEMBL3188091;DB06138;;142569-99-1;11X778QIZS;DXPHNGAMYPPTBJ-TZMIJSMNSA-N;CCC(C)C(C(=O)NC(C(C)CC)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC3=CN=CN3)NC(=O)C(C)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)CCC(=O)O;18209;21;696;3920;0;23;28;56;130;4;Approved;2023;Protein;Agonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BE2Z;Diseases of the circulatory system, unspecified;2;Unknown;426429380/unspecified;33428177, 29947531, 34826534
363;irl-1620;irl-1620;CHEMBL3188091;DB06138;;142569-99-1;11X778QIZS;DXPHNGAMYPPTBJ-TZMIJSMNSA-N;CCC(C)C(C(=O)NC(C(C)CC)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC3=CN=CN3)NC(=O)C(C)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)CCC(=O)O;18209;21;696;3920;0;23;28;56;130;4;Approved;2023;Protein;Agonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;ND51.2;Injury of spinal cord, level unspecified;2;Active;2131180445;33428177, 29947531, 34826534
364;bucindolol;bucindolol;CHEMBL321582;DB12752;51045;71119-11-4;NA;FBMYKMYQHCBIGU-UHFFFAOYSA-N;CC(C)(CC1=CNC2=CC=CC=C21)NCC(COC3=CC=CC=C3C#N)O;3635;33;811;515;0;3;4;8;27;2;Active;NA;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;2;Inactive;171698302/unspecified;28975475, 25959096, 28162002
364;bucindolol;bucindolol;CHEMBL321582;DB12752;51045;71119-11-4;NA;FBMYKMYQHCBIGU-UHFFFAOYSA-N;CC(C)(CC1=CNC2=CC=CC=C21)NCC(COC3=CC=CC=C3C#N)O;3635;33;811;515;0;3;4;8;27;2;Active;NA;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;2;Inactive;171698302/unspecified;28975475, 25959096, 28162002
364;bucindolol;bucindolol;CHEMBL321582;DB12752;51045;71119-11-4;NA;FBMYKMYQHCBIGU-UHFFFAOYSA-N;CC(C)(CC1=CNC2=CC=CC=C21)NCC(COC3=CC=CC=C3C#N)O;3635;33;811;515;0;3;4;8;27;2;Active;NA;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;2;Inactive;171698302/unspecified;28975475, 25959096, 28162002
364;bucindolol;bucindolol;CHEMBL321582;DB12752;51045;71119-11-4;NA;FBMYKMYQHCBIGU-UHFFFAOYSA-N;CC(C)(CC1=CNC2=CC=CC=C21)NCC(COC3=CC=CC=C3C#N)O;3635;33;811;515;0;3;4;8;27;2;Active;NA;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;2;Inactive;171698302/unspecified;28975475, 25959096, 28162002
364;bucindolol;bucindolol;CHEMBL321582;DB12752;51045;71119-11-4;NA;FBMYKMYQHCBIGU-UHFFFAOYSA-N;CC(C)(CC1=CNC2=CC=CC=C21)NCC(COC3=CC=CC=C3C#N)O;3635;33;811;515;0;3;4;8;27;2;Active;NA;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;2;Inactive;171698302/unspecified;28975475, 25959096, 28162002
365;netazepide;netazepide;CHEMBL324547;DB12355;9870520;155488-25-8;NA;YDZYKNJZCVIKPP-VWLOTQADSA-N;CC(C)(C)C(=O)CN1C2=CC=CC=C2C(=NC(C1=O)NC(=O)NC3=CC=CC(=C3)NC)C4=CC=CC=N4;4986;38;116;869;0;3;6;7;37;2;Active;NA;Protein;Antagonist;P32239;gasr_human;Class A (Rhodopsin);Cholecystokinin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;2;Unknown;1594217552/other;32004755, 33782049, 27704617
365;netazepide;netazepide;CHEMBL324547;DB12355;9870520;155488-25-8;NA;YDZYKNJZCVIKPP-VWLOTQADSA-N;CC(C)(C)C(=O)CN1C2=CC=CC=C2C(=NC(C1=O)NC(=O)NC3=CC=CC(=C3)NC)C4=CC=CC=N4;4986;38;116;869;0;3;6;7;37;2;Active;NA;Protein;Antagonist;P32239;gasr_human;Class A (Rhodopsin);Cholecystokinin receptors;Peptide receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;2;Unknown;1844086508/unspecified;32004755, 33782049, 27704617
365;netazepide;netazepide;CHEMBL324547;DB12355;9870520;155488-25-8;NA;YDZYKNJZCVIKPP-VWLOTQADSA-N;CC(C)(C)C(=O)CN1C2=CC=CC=C2C(=NC(C1=O)NC(=O)NC3=CC=CC(=C3)NC)C4=CC=CC=N4;4986;38;116;869;0;3;6;7;37;2;Active;NA;Protein;Antagonist;P32239;gasr_human;Class A (Rhodopsin);Cholecystokinin receptors;Peptide receptors;DA22.1;Erosive gastro-oesophageal reflux disease;1;Inactive;417695496;32004755, 33782049, 27704617
365;netazepide;netazepide;CHEMBL324547;DB12355;9870520;155488-25-8;NA;YDZYKNJZCVIKPP-VWLOTQADSA-N;CC(C)(C)C(=O)CN1C2=CC=CC=C2C(=NC(C1=O)NC(=O)NC3=CC=CC(=C3)NC)C4=CC=CC=N4;4986;38;116;869;0;3;6;7;37;2;Active;NA;Protein;Antagonist;P32239;gasr_human;Class A (Rhodopsin);Cholecystokinin receptors;Peptide receptors;MD92;Dyspepsia;1;Inactive;869622187;32004755, 33782049, 27704617
366;clebopride;clebopride;CHEMBL325109;DB13511;2780;55905-53-8;NA;BVPWJMCABCPUQY-UHFFFAOYSA-N;COC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3=CC=CC=C3)Cl)N;3739;32;676;450;0;2;4;5;26;4;Approved;1978;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;DE2Z;Diseases of the digestive system, unspecified;4;Approved;1256772020/unspecified;37868913, 29333306, 3072237
366;clebopride;clebopride;CHEMBL325109;DB13511;2780;55905-53-8;NA;BVPWJMCABCPUQY-UHFFFAOYSA-N;COC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3=CC=CC=C3)Cl)N;3739;32;676;450;0;2;4;5;26;4;Approved;1978;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DE2Z;Diseases of the digestive system, unspecified;4;Approved;1256772020/unspecified;37868913, 29333306, 3072237
368;abaloparatide;abaloparatide;CHEMBL3301581;NA;145705876;NA;NA;BVISQZFBLRSESR-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C)(C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC1=CN=CN1)C(=O)NC(C(C)O)C(=O)NC(C)C(=O)N)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC2=CN=CN2)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)N)NC(=O)C(CC3=CN=CN3)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(C)N;3961;-209;1740;9310;0;61;60;145;279;4;Approved;2017;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;FB83.11;Postmenopausal osteoporosis;3;Inactive;123797893;27533157, 36512663, 27920805
368;abaloparatide;abaloparatide;CHEMBL3301581;NA;145705876;NA;NA;BVISQZFBLRSESR-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C)(C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC1=CN=CN1)C(=O)NC(C(C)O)C(=O)NC(C)C(=O)N)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC2=CN=CN2)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)N)NC(=O)C(CC3=CN=CN3)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(C)N;3961;-209;1740;9310;0;61;60;145;279;4;Approved;2017;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;FB83.1Z;Osteoporosis, unspecified;4;Approved;2113001430/unspecified;27533157, 36512663, 27920805
368;abaloparatide;abaloparatide;CHEMBL3301581;NA;145705876;NA;NA;BVISQZFBLRSESR-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C)(C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC1=CN=CN1)C(=O)NC(C(C)O)C(=O)NC(C)C(=O)N)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC2=CN=CN2)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)N)NC(=O)C(CC3=CN=CN3)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(C)N;3961;-209;1740;9310;0;61;60;145;279;4;Approved;2017;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;ND56.2;Fracture of unspecified body region;2;Active;1504538171;27533157, 36512663, 27920805
369;ralinepag;ralinepag;"CHEMBL3301604;CHEMBL3919269";DB12462;44219292;1187856-49-0;NA;NPDKXVKJRHPDQT-UHFFFAOYSA-N;C1CC(CCC1COCC(=O)O)COC(=O)N(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;4319;5;761;538;0;1;5;9;30;3;Active;NA;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BB01.0;Pulmonary arterial hypertension;3;Active;1931148955;31391223, 38198043, 32489643
371;setmelanotide;setmelanotide;CHEMBL3301624;DB11700;11993702;920014-72-8;N7T15V1FUY;HDHDTKMUACZDAA-PHNIDTBTSA-N;CC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)N1)NC(=O)C(CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5;11173;-25;500;2130;0;15;14;18;78;4;Approved;2020;Protein;Agonist;P32245;mc4r_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;5A61.0;Hypopituitarism;4;Approved;768216194;33638809, 36943959, 34518444
371;setmelanotide;setmelanotide;CHEMBL3301624;DB11700;11993702;920014-72-8;N7T15V1FUY;HDHDTKMUACZDAA-PHNIDTBTSA-N;CC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)N1)NC(=O)C(CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5;11173;-25;500;2130;0;15;14;18;78;4;Approved;2020;Protein;Agonist;P32245;mc4r_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;5B81.01;Obesity in adults;1;Inactive;2062927079;33638809, 36943959, 34518444
371;setmelanotide;setmelanotide;CHEMBL3301624;DB11700;11993702;920014-72-8;N7T15V1FUY;HDHDTKMUACZDAA-PHNIDTBTSA-N;CC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)N1)NC(=O)C(CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5;11173;-25;500;2130;0;15;14;18;78;4;Approved;2020;Protein;Agonist;P32245;mc4r_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;33638809, 36943959, 34518444
371;setmelanotide;setmelanotide;CHEMBL3301624;DB11700;11993702;920014-72-8;N7T15V1FUY;HDHDTKMUACZDAA-PHNIDTBTSA-N;CC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)N1)NC(=O)C(CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5;11173;-25;500;2130;0;15;14;18;78;4;Approved;2020;Protein;Agonist;P32245;mc4r_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;LD44.H1;Deletions of the short arm of chromosome 17;2;Active;527787991;33638809, 36943959, 34518444
372;basimglurant;basimglurant;CHEMBL3301626;DB11833;11438771;"1034442-21-1 (free base);802906-73-6";NA;UPZWINBEAHDTLA-UHFFFAOYSA-N;CC1=C(N=C(N1C2=CC=C(C=C2)F)C)C#CC3=CC(=NC=C3)Cl;3258;45;307;465;0;0;3;3;23;2;Active;NA;Small molecule;Modulator;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;26219727, 28816242, 27304433
372;basimglurant;basimglurant;CHEMBL3301626;DB11833;11438771;"1034442-21-1 (free base);802906-73-6";NA;UPZWINBEAHDTLA-UHFFFAOYSA-N;CC1=C(N=C(N1C2=CC=C(C=C2)F)C)C#CC3=CC(=NC=C3)Cl;3258;45;307;465;0;0;3;3;23;2;Active;NA;Small molecule;Modulator;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;26219727, 28816242, 27304433
372;basimglurant;basimglurant;CHEMBL3301626;DB11833;11438771;"1034442-21-1 (free base);802906-73-6";NA;UPZWINBEAHDTLA-UHFFFAOYSA-N;CC1=C(N=C(N1C2=CC=C(C=C2)F)C)C#CC3=CC(=NC=C3)Cl;3258;45;307;465;0;0;3;3;23;2;Active;NA;Small molecule;Modulator;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;8A68.Z;Type of seizure, unspecified;2;Unknown;539646260/unspecified;26219727, 28816242, 27304433
372;basimglurant;basimglurant;CHEMBL3301626;DB11833;11438771;"1034442-21-1 (free base);802906-73-6";NA;UPZWINBEAHDTLA-UHFFFAOYSA-N;CC1=C(N=C(N1C2=CC=C(C=C2)F)C)C#CC3=CC(=NC=C3)Cl;3258;45;307;465;0;0;3;3;23;2;Active;NA;Small molecule;Modulator;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;LD55;Fragile X chromosome;2;Inactive;1524287677;26219727, 28816242, 27304433
372;basimglurant;basimglurant;CHEMBL3301626;DB11833;11438771;"1034442-21-1 (free base);802906-73-6";NA;UPZWINBEAHDTLA-UHFFFAOYSA-N;CC1=C(N=C(N1C2=CC=C(C=C2)F)C)C#CC3=CC(=NC=C3)Cl;3258;45;307;465;0;0;3;3;23;2;Active;NA;Small molecule;Modulator;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;MG3Z;Pain, unspecified;2;Unknown;661232217/unspecified;26219727, 28816242, 27304433
373;carbetocin;S-carbetocin;CHEMBL3301668;DB01282;165708555;37025-55-1;88TWF8015Y;NSTRIRCPWQHTIA-CPWZVOFUSA-N;CC[C@H](C)[C@H]1C(=O)NC(C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;9882;-11;388;1850;0;10;13;18;69;4;Approved;1997;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;JA43.Z;Postpartum haemorrhage, unspecified;4;Approved;820245648/unspecified;35343585, 31764790, 31164260
373;carbetocin;S-carbetocin;CHEMBL3301668;DB01282;165708555;37025-55-1;88TWF8015Y;NSTRIRCPWQHTIA-CPWZVOFUSA-N;CC[C@H](C)[C@H]1C(=O)NC(C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;9882;-11;388;1850;0;10;13;18;69;4;Approved;1997;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;LD90.3;Prader-Willi syndrome;3;Active;393773440;35343585, 31764790, 31164260
373;carbetocin;carbetocin;CHEMBL3301668;DB01282;16681432;37025-55-1;88TWF8015Y;NSTRIRCPWQHTIA-DTRKZRJBSA-N;CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;9882;-11;388;1850;0;10;13;18;69;4;Approved;1997;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;JA43.Z;Postpartum haemorrhage, unspecified;4;Approved;820245648/unspecified;35343585, 31764790, 31164260
373;carbetocin;carbetocin;CHEMBL3301668;DB01282;16681432;37025-55-1;88TWF8015Y;NSTRIRCPWQHTIA-DTRKZRJBSA-N;CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;9882;-11;388;1850;0;10;13;18;69;4;Approved;1997;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;LD90.3;Prader-Willi syndrome;3;Active;393773440;35343585, 31764790, 31164260
374;lumateperone;lumateperone;CHEMBL3306803;DB06077;21302490;313368-91-1;70BSQ12069;HOIIHACBCFLJET-SFTDATJTSA-N;CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F;3935;38;268;593;0;0;5;5;29;4;Approved;2019;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;31913424, 32809679, 35877948
374;lumateperone;lumateperone;CHEMBL3306803;DB06077;21302490;313368-91-1;70BSQ12069;HOIIHACBCFLJET-SFTDATJTSA-N;CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F;3935;38;268;593;0;0;5;5;29;4;Approved;2019;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;31913424, 32809679, 35877948
374;lumateperone;lumateperone;CHEMBL3306803;DB06077;21302490;313368-91-1;70BSQ12069;HOIIHACBCFLJET-SFTDATJTSA-N;CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F;3935;38;268;593;0;0;5;5;29;4;Approved;2019;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;31913424, 32809679, 35877948
374;lumateperone;lumateperone;CHEMBL3306803;DB06077;21302490;313368-91-1;70BSQ12069;HOIIHACBCFLJET-SFTDATJTSA-N;CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F;3935;38;268;593;0;0;5;5;29;4;Approved;2019;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Active;1669279433;31913424, 32809679, 35877948
374;lumateperone;lumateperone;CHEMBL3306803;DB06077;21302490;313368-91-1;70BSQ12069;HOIIHACBCFLJET-SFTDATJTSA-N;CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F;3935;38;268;593;0;0;5;5;29;4;Approved;2019;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;2;Active;941859884/unspecified;31913424, 32809679, 35877948
374;lumateperone;lumateperone;CHEMBL3306803;DB06077;21302490;313368-91-1;70BSQ12069;HOIIHACBCFLJET-SFTDATJTSA-N;CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F;3935;38;268;593;0;0;5;5;29;4;Approved;2019;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;31913424, 32809679, 35877948
374;lumateperone;lumateperone;CHEMBL3306803;DB06077;21302490;313368-91-1;70BSQ12069;HOIIHACBCFLJET-SFTDATJTSA-N;CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F;3935;38;268;593;0;0;5;5;29;4;Approved;2019;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;31913424, 32809679, 35877948
374;lumateperone;lumateperone;CHEMBL3306803;DB06077;21302490;313368-91-1;70BSQ12069;HOIIHACBCFLJET-SFTDATJTSA-N;CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F;3935;38;268;593;0;0;5;5;29;4;Approved;2019;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;31913424, 32809679, 35877948
374;lumateperone;lumateperone;CHEMBL3306803;DB06077;21302490;313368-91-1;70BSQ12069;HOIIHACBCFLJET-SFTDATJTSA-N;CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F;3935;38;268;593;0;0;5;5;29;4;Approved;2019;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;31913424, 32809679, 35877948
374;lumateperone;lumateperone;CHEMBL3306803;DB06077;21302490;313368-91-1;70BSQ12069;HOIIHACBCFLJET-SFTDATJTSA-N;CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F;3935;38;268;593;0;0;5;5;29;4;Approved;2019;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Active;1669279433;31913424, 32809679, 35877948
374;lumateperone;lumateperone;CHEMBL3306803;DB06077;21302490;313368-91-1;70BSQ12069;HOIIHACBCFLJET-SFTDATJTSA-N;CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F;3935;38;268;593;0;0;5;5;29;4;Approved;2019;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;2;Active;941859884/unspecified;31913424, 32809679, 35877948
374;lumateperone;lumateperone;CHEMBL3306803;DB06077;21302490;313368-91-1;70BSQ12069;HOIIHACBCFLJET-SFTDATJTSA-N;CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F;3935;38;268;593;0;0;5;5;29;4;Approved;2019;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;31913424, 32809679, 35877948
376;cangrelor;cangrelor;CHEMBL334966;DB06441;9854012;163706-06-7;6AQ1Y404U7;PAEBIVWUMLRPSK-IDTAVKCVSA-N;CSCCNC1=C2C(=NC(=N1)SCCC(F)(F)F)N(C=N2)C3C(C(C(O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O;7764;-1;307;1140;0;7;21;15;44;4;Approved;2015;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;3;Unknown;1614716959/unspecified;37603660, 31643758, 27729681
376;cangrelor;cangrelor;CHEMBL334966;DB06441;9854012;163706-06-7;6AQ1Y404U7;PAEBIVWUMLRPSK-IDTAVKCVSA-N;CSCCNC1=C2C(=NC(=N1)SCCC(F)(F)F)N(C=N2)C3C(C(C(O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O;7764;-1;307;1140;0;7;21;15;44;4;Approved;2015;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA41.0;Acute ST elevation myocardial infarction;2;Active;391388807;37603660, 31643758, 27729681
376;cangrelor;cangrelor;CHEMBL334966;DB06441;9854012;163706-06-7;6AQ1Y404U7;PAEBIVWUMLRPSK-IDTAVKCVSA-N;CSCCNC1=C2C(=NC(=N1)SCCC(F)(F)F)N(C=N2)C3C(C(C(O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O;7764;-1;307;1140;0;7;21;15;44;4;Approved;2015;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;37603660, 31643758, 27729681
376;cangrelor;cangrelor;CHEMBL334966;DB06441;9854012;163706-06-7;6AQ1Y404U7;PAEBIVWUMLRPSK-IDTAVKCVSA-N;CSCCNC1=C2C(=NC(=N1)SCCC(F)(F)F)N(C=N2)C3C(C(C(O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O;7764;-1;307;1140;0;7;21;15;44;4;Approved;2015;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA4Z;Acute ischaemic heart disease, unspecified;2;Inactive;1829545371/unspecified;37603660, 31643758, 27729681
376;cangrelor;cangrelor;CHEMBL334966;DB06441;9854012;163706-06-7;6AQ1Y404U7;PAEBIVWUMLRPSK-IDTAVKCVSA-N;CSCCNC1=C2C(=NC(=N1)SCCC(F)(F)F)N(C=N2)C3C(C(C(O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O;7764;-1;307;1140;0;7;21;15;44;4;Approved;2015;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA8Z;Diseases of coronary artery, unspecified;2;Inactive;1059873720/unspecified;37603660, 31643758, 27729681
377;etrasimod;etrasimod;CHEMBL3358920;DB14766;44623998;"1206123-37-6;1206123-37-6 (free base)";NA;MVGWUTBTXDYMND-QGZVFWFLSA-N;C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CCC5CC(=O)O)C(F)(F)F;4575;64;623;695;0;2;6;6;33;4;Approved;2023;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;1B7Y;Other specified pyogenic bacterial infection of skin or subcutaneous tissue;2;Inactive;1412960686/other;36789612, 38051804, 36871574
377;etrasimod;etrasimod;CHEMBL3358920;DB14766;44623998;"1206123-37-6;1206123-37-6 (free base)";NA;MVGWUTBTXDYMND-QGZVFWFLSA-N;C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CCC5CC(=O)O)C(F)(F)F;4575;64;623;695;0;2;6;6;33;4;Approved;2023;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;DA24.1;Eosinophilic oesophagitis;2;Active;21063503;36789612, 38051804, 36871574
377;etrasimod;etrasimod;CHEMBL3358920;DB14766;44623998;"1206123-37-6;1206123-37-6 (free base)";NA;MVGWUTBTXDYMND-QGZVFWFLSA-N;C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CCC5CC(=O)O)C(F)(F)F;4575;64;623;695;0;2;6;6;33;4;Approved;2023;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;DB96.1Z;Primary biliary cholangitis, unspecified;2;Inactive;649193479/unspecified;36789612, 38051804, 36871574
377;etrasimod;etrasimod;CHEMBL3358920;DB14766;44623998;"1206123-37-6;1206123-37-6 (free base)";NA;MVGWUTBTXDYMND-QGZVFWFLSA-N;C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CCC5CC(=O)O)C(F)(F)F;4575;64;623;695;0;2;6;6;33;4;Approved;2023;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;DD70.Z;Crohn disease, unspecified site;3;Active;1267652425/unspecified;36789612, 38051804, 36871574
377;etrasimod;etrasimod;CHEMBL3358920;DB14766;44623998;"1206123-37-6;1206123-37-6 (free base)";NA;MVGWUTBTXDYMND-QGZVFWFLSA-N;C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CCC5CC(=O)O)C(F)(F)F;4575;64;623;695;0;2;6;6;33;4;Approved;2023;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;DD71.Z;Ulcerative colitis, unspecified;4;Approved;784669405/unspecified;36789612, 38051804, 36871574
377;etrasimod;etrasimod;CHEMBL3358920;DB14766;44623998;"1206123-37-6;1206123-37-6 (free base)";NA;MVGWUTBTXDYMND-QGZVFWFLSA-N;C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CCC5CC(=O)O)C(F)(F)F;4575;64;623;695;0;2;6;6;33;4;Approved;2023;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;DD7Z;Inflammatory bowel diseases, unspecified;2;Inactive;598093212/unspecified;36789612, 38051804, 36871574
377;etrasimod;etrasimod;CHEMBL3358920;DB14766;44623998;"1206123-37-6;1206123-37-6 (free base)";NA;MVGWUTBTXDYMND-QGZVFWFLSA-N;C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CCC5CC(=O)O)C(F)(F)F;4575;64;623;695;0;2;6;6;33;4;Approved;2023;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;EA80.Z;Atopic eczema, unspecified;2;Inactive;215767047/unspecified;36789612, 38051804, 36871574
377;etrasimod;etrasimod;CHEMBL3358920;DB14766;44623998;"1206123-37-6;1206123-37-6 (free base)";NA;MVGWUTBTXDYMND-QGZVFWFLSA-N;C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CCC5CC(=O)O)C(F)(F)F;4575;64;623;695;0;2;6;6;33;4;Approved;2023;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;ED70.2Z;Alopecia areata, unspecified;2;Active;65720611/unspecified;36789612, 38051804, 36871574
378;synephrine;synephrine;CHEMBL33720;DB09203;7172;94-07-5;PEG5DP7434;YRCWQPVGYLYSOX-UHFFFAOYSA-N;CNCC(C1=CC=C(C=C1)O)O;1672;-6;525;122;0;3;3;3;12;4;Approved;1931;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;33467423, 32101364, 28058460
378;synephrine;synephrine;CHEMBL33720;DB09203;7172;94-07-5;PEG5DP7434;YRCWQPVGYLYSOX-UHFFFAOYSA-N;CNCC(C1=CC=C(C=C1)O)O;1672;-6;525;122;0;3;3;3;12;4;Approved;1931;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;33467423, 32101364, 28058460
378;synephrine;synephrine;CHEMBL33720;DB09203;7172;94-07-5;PEG5DP7434;YRCWQPVGYLYSOX-UHFFFAOYSA-N;CNCC(C1=CC=C(C=C1)O)O;1672;-6;525;122;0;3;3;3;12;4;Approved;1931;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;33467423, 32101364, 28058460
379;butorphanol;S-butorphanol;CHEMBL33986;DB00611;6916249;42408-82-2;QV897JC36D;IFKLAQQSCNILHL-PWRODBHTSA-N;C1CC[C@]2([C@@H]3CC4=C([C@@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O;3275;38;437;492;0;2;3;2;24;4;Approved;1978;Small molecule;Partial agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000262, 31643238, 3888579
379;butorphanol;butorphanol;CHEMBL33986;DB00611;5361092;42408-82-2;QV897JC36D;IFKLAQQSCNILHL-QHAWAJNXSA-N;C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O;3275;38;437;492;0;2;3;2;24;4;Approved;1978;Small molecule;Partial agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000262, 31643238, 3888579
379;butorphanol;S-butorphanol;CHEMBL33986;DB00611;6916249;42408-82-2;QV897JC36D;IFKLAQQSCNILHL-PWRODBHTSA-N;C1CC[C@]2([C@@H]3CC4=C([C@@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O;3275;38;437;492;0;2;3;2;24;4;Approved;1978;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000262, 31643238, 3888579
379;butorphanol;butorphanol;CHEMBL33986;DB00611;5361092;42408-82-2;QV897JC36D;IFKLAQQSCNILHL-QHAWAJNXSA-N;C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O;3275;38;437;492;0;2;3;2;24;4;Approved;1978;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000262, 31643238, 3888579
379;butorphanol;S-butorphanol;CHEMBL33986;DB00611;6916249;42408-82-2;QV897JC36D;IFKLAQQSCNILHL-PWRODBHTSA-N;C1CC[C@]2([C@@H]3CC4=C([C@@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O;3275;38;437;492;0;2;3;2;24;4;Approved;1978;Small molecule;Partial agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000262, 31643238, 3888579
379;butorphanol;butorphanol;CHEMBL33986;DB00611;5361092;42408-82-2;QV897JC36D;IFKLAQQSCNILHL-QHAWAJNXSA-N;C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O;3275;38;437;492;0;2;3;2;24;4;Approved;1978;Small molecule;Partial agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000262, 31643238, 3888579
380;mevidalen;mevidalen;CHEMBL3421729;NA;86290953;1638667-79-4;NA;XHCSBQBBGNQINS-DOTOQJQBSA-N;CC1C2=CC=CC(=C2CC(N1C(=O)CC3=C(C=CC=C3Cl)Cl)CO)CCC(C)(C)O;4504;44;608;577;0;2;3;6;30;2;Active;NA;Small molecule;PAM;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D82;Dementia due to Lewy body disease;2;Inactive;1777436789;34859493, 34664427, 33029934
380;mevidalen;mevidalen;CHEMBL3421729;NA;86290953;1638667-79-4;NA;XHCSBQBBGNQINS-DOTOQJQBSA-N;CC1C2=CC=CC(=C2CC(N1C(=O)CC3=C(C=CC=C3Cl)Cl)CO)CCC(C)(C)O;4504;44;608;577;0;2;3;6;30;2;Active;NA;Small molecule;PAM;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;2;Inactive;296066191/unspecified;34859493, 34664427, 33029934
381;tolvaptan;tolvaptan;CHEMBL344159;DB06212;216237;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-UHFFFAOYSA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5A60.2Z;Syndrome of inappropriate secretion of antidiuretic hormone, unspecified;3;Inactive;550787432/unspecified;30228150, 23121377, 29105594
381;tolvaptan;tolvaptan;CHEMBL344159;DB06212;216237;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-UHFFFAOYSA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5C72;Hypo-osmolality or hyponatraemia;4;Approved;761639036;30228150, 23121377, 29105594
381;tolvaptan;tolvaptan;CHEMBL344159;DB06212;216237;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-UHFFFAOYSA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BD10;Congestive heart failure;4;Approved;2136808878;30228150, 23121377, 29105594
381;tolvaptan;tolvaptan;CHEMBL344159;DB06212;216237;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-UHFFFAOYSA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;30228150, 23121377, 29105594
381;tolvaptan;tolvaptan;CHEMBL344159;DB06212;216237;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-UHFFFAOYSA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30228150, 23121377, 29105594
381;tolvaptan;tolvaptan;CHEMBL344159;DB06212;216237;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-UHFFFAOYSA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GB61.Z;Chronic kidney disease, stage unspecified;3;Inactive;412389819/unspecified;30228150, 23121377, 29105594
381;tolvaptan;tolvaptan;CHEMBL344159;DB06212;216237;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-UHFFFAOYSA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GB70.0Z;Calculus of kidney, unspecified;1;Inactive;389168514/unspecified;30228150, 23121377, 29105594
381;tolvaptan;tolvaptan;CHEMBL344159;DB06212;216237;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-UHFFFAOYSA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GB81;Autosomal dominant polycystic kidney disease;3;Inactive;91220434;30228150, 23121377, 29105594
381;tolvaptan;tolvaptan;CHEMBL344159;DB06212;216237;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-UHFFFAOYSA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GB8Y;Other specified cystic or dysplastic kidney disease;4;Approved;854539401/other;30228150, 23121377, 29105594
381;tolvaptan;tolvaptan;CHEMBL344159;DB06212;216237;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-UHFFFAOYSA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GC2Z;Diseases of the urinary system, unspecified;3;Inactive;1932345217/unspecified;30228150, 23121377, 29105594
381;tolvaptan;tolvaptan;CHEMBL344159;DB06212;216237;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-UHFFFAOYSA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG29.Z;Oedema, unspecified;3;Unknown;826220775/unspecified;30228150, 23121377, 29105594
381;tolvaptan;R-tolvaptan;CHEMBL344159;DB06212;443894;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-XMMPIXPASA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCC[C@H](C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5A60.2Z;Syndrome of inappropriate secretion of antidiuretic hormone, unspecified;3;Inactive;550787432/unspecified;30228150, 23121377, 29105594
381;tolvaptan;R-tolvaptan;CHEMBL344159;DB06212;443894;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-XMMPIXPASA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCC[C@H](C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5C72;Hypo-osmolality or hyponatraemia;4;Approved;761639036;30228150, 23121377, 29105594
381;tolvaptan;R-tolvaptan;CHEMBL344159;DB06212;443894;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-XMMPIXPASA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCC[C@H](C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BD10;Congestive heart failure;4;Approved;2136808878;30228150, 23121377, 29105594
381;tolvaptan;R-tolvaptan;CHEMBL344159;DB06212;443894;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-XMMPIXPASA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCC[C@H](C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;30228150, 23121377, 29105594
381;tolvaptan;R-tolvaptan;CHEMBL344159;DB06212;443894;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-XMMPIXPASA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCC[C@H](C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30228150, 23121377, 29105594
381;tolvaptan;R-tolvaptan;CHEMBL344159;DB06212;443894;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-XMMPIXPASA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCC[C@H](C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GB61.Z;Chronic kidney disease, stage unspecified;3;Inactive;412389819/unspecified;30228150, 23121377, 29105594
381;tolvaptan;R-tolvaptan;CHEMBL344159;DB06212;443894;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-XMMPIXPASA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCC[C@H](C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GB70.0Z;Calculus of kidney, unspecified;1;Inactive;389168514/unspecified;30228150, 23121377, 29105594
381;tolvaptan;R-tolvaptan;CHEMBL344159;DB06212;443894;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-XMMPIXPASA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCC[C@H](C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GB81;Autosomal dominant polycystic kidney disease;3;Inactive;91220434;30228150, 23121377, 29105594
381;tolvaptan;R-tolvaptan;CHEMBL344159;DB06212;443894;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-XMMPIXPASA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCC[C@H](C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GB8Y;Other specified cystic or dysplastic kidney disease;4;Approved;854539401/other;30228150, 23121377, 29105594
381;tolvaptan;R-tolvaptan;CHEMBL344159;DB06212;443894;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-XMMPIXPASA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCC[C@H](C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GC2Z;Diseases of the urinary system, unspecified;3;Inactive;1932345217/unspecified;30228150, 23121377, 29105594
381;tolvaptan;R-tolvaptan;CHEMBL344159;DB06212;443894;150683-30-0;1E2497LPNY;GYHCTFXIZSNGJT-XMMPIXPASA-N;CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCC[C@H](C4=C3C=CC(=C4)Cl)O)C;4489;48;696;674;0;2;3;3;32;4;Approved;2009;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG29.Z;Oedema, unspecified;3;Unknown;826220775/unspecified;30228150, 23121377, 29105594
382;relenopride;relenopride;CHEMBL3544975;DB12798;45275554;1221416-43-8;NA;KGMMSPVVHZGPHL-NRFANRHFSA-N;COC1=CC(=C(C=C1C(=O)NCC2CCN(CC2)CCC(C3=CC=C(C=C3)F)OC(=O)N)Cl)N;493;32;120;659;0;3;7;10;34;2;Active;NA;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;ME05.0;Constipation;2;Inactive;502284069;NA
383;tradipitant;tradipitant;CHEMBL3544984;DB12580;9916461;622370-35-8;NA;CAVRKWRKTNINFF-UHFFFAOYSA-N;C1=CC=C(C(=C1)C(=O)C2=C(N=CC=C2)C3=C(N(N=N3)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=CC=NC=C5)Cl;5879;62;736;865;0;0;11;6;41;3;Active;NA;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;6B04;Social anxiety disorder;2;Inactive;2062286624;35804474, 35804471, 32693185
383;tradipitant;tradipitant;CHEMBL3544984;DB12580;9916461;622370-35-8;NA;CAVRKWRKTNINFF-UHFFFAOYSA-N;C1=CC=C(C(=C1)C(=O)C2=C(N=CC=C2)C3=C(N(N=N3)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=CC=NC=C5)Cl;5879;62;736;865;0;0;11;6;41;3;Active;NA;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;2;Inactive;1580466198/unspecified;35804474, 35804471, 32693185
383;tradipitant;tradipitant;CHEMBL3544984;DB12580;9916461;622370-35-8;NA;CAVRKWRKTNINFF-UHFFFAOYSA-N;C1=CC=C(C(=C1)C(=O)C2=C(N=CC=C2)C3=C(N(N=N3)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=CC=NC=C5)Cl;5879;62;736;865;0;0;11;6;41;3;Active;NA;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;DA41.00;Gastroparesis;3;Active;598423727;35804474, 35804471, 32693185
383;tradipitant;tradipitant;CHEMBL3544984;DB12580;9916461;622370-35-8;NA;CAVRKWRKTNINFF-UHFFFAOYSA-N;C1=CC=C(C(=C1)C(=O)C2=C(N=CC=C2)C3=C(N(N=N3)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=CC=NC=C5)Cl;5879;62;736;865;0;0;11;6;41;3;Active;NA;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;EA80.Z;Atopic eczema, unspecified;3;Inactive;215767047/unspecified;35804474, 35804471, 32693185
383;tradipitant;tradipitant;CHEMBL3544984;DB12580;9916461;622370-35-8;NA;CAVRKWRKTNINFF-UHFFFAOYSA-N;C1=CC=C(C(=C1)C(=O)C2=C(N=CC=C2)C3=C(N(N=N3)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=CC=NC=C5)Cl;5879;62;736;865;0;0;11;6;41;3;Active;NA;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;EC90.Z;Pruritus, unspecified;2;Inactive;1729106757/unspecified;35804474, 35804471, 32693185
383;tradipitant;tradipitant;CHEMBL3544984;DB12580;9916461;622370-35-8;NA;CAVRKWRKTNINFF-UHFFFAOYSA-N;C1=CC=C(C(=C1)C(=O)C2=C(N=CC=C2)C3=C(N(N=N3)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=CC=NC=C5)Cl;5879;62;736;865;0;0;11;6;41;3;Active;NA;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;NF08.3;Motion sickness;3;Inactive;1078108554;35804474, 35804471, 32693185
383;tradipitant;tradipitant;CHEMBL3544984;DB12580;9916461;622370-35-8;NA;CAVRKWRKTNINFF-UHFFFAOYSA-N;C1=CC=C(C(=C1)C(=O)C2=C(N=CC=C2)C3=C(N(N=N3)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=CC=NC=C5)Cl;5879;62;736;865;0;0;11;6;41;3;Active;NA;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;RA01;COVID-19;3;Unknown;1730556128;35804474, 35804471, 32693185
384;asapiprant;asapiprant;CHEMBL3545043;NA;59232326;932372-01-5;NA;ZMZNWNTZRWXTJU-UHFFFAOYSA-N;CC(C)OC1=CC=C(C=C1)S(=O)(=O)N2CCN(CC2)C3=CC(=C(C=C3)C4=NC=CO4)OCC(=O)O;5016;31;131;789;0;1;10;9;35;2;Active;NA;Small molecule;Antagonist;Q13258;pd2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;2;Inactive;1565925107;26277322
384;asapiprant;asapiprant;CHEMBL3545043;NA;59232326;932372-01-5;NA;ZMZNWNTZRWXTJU-UHFFFAOYSA-N;CC(C)OC1=CC=C(C=C1)S(=O)(=O)N2CCN(CC2)C3=CC(=C(C=C3)C4=NC=CO4)OCC(=O)O;5016;31;131;789;0;1;10;9;35;2;Active;NA;Small molecule;Antagonist;Q13258;pd2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;RA01;COVID-19;2;Active;1730556128;26277322
385;krp203;krp203;CHEMBL3545101;NA;11155874;NA;NA;IINUNQPYJGJCJI-UHFFFAOYSA-N;C1=CC=C(C=C1)COC2=CC(=CC=C2)SC3=CC(=C(C=C3)CCC(CO)(CO)N)Cl;444;43;101;487;0;3;5;10;30;3;Active;NA;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;2A60.3Z;Acute myeloid leukaemia, unspecified;3;Active;1611980611/unspecified;31685933, 37683456, 33313070
385;krp203;krp203;CHEMBL3545101;NA;11155874;NA;NA;IINUNQPYJGJCJI-UHFFFAOYSA-N;C1=CC=C(C=C1)COC2=CC(=CC=C2)SC3=CC(=C(C=C3)CCC(CO)(CO)N)Cl;444;43;101;487;0;3;5;10;30;3;Active;NA;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;DD71.Z;Ulcerative colitis, unspecified;2;Inactive;784669405/unspecified;31685933, 37683456, 33313070
385;krp203;krp203;CHEMBL3545101;NA;11155874;NA;NA;IINUNQPYJGJCJI-UHFFFAOYSA-N;C1=CC=C(C=C1)COC2=CC(=CC=C2)SC3=CC(=C(C=C3)CCC(CO)(CO)N)Cl;444;43;101;487;0;3;5;10;30;3;Active;NA;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;EB5Z;Cutaneous lupus erythematosus of unspecified type;2;Inactive;1401395930/unspecified;31685933, 37683456, 33313070
385;krp203;krp203;CHEMBL3545101;NA;11155874;NA;NA;IINUNQPYJGJCJI-UHFFFAOYSA-N;C1=CC=C(C=C1)COC2=CC(=CC=C2)SC3=CC(=C(C=C3)CCC(CO)(CO)N)Cl;444;43;101;487;0;3;5;10;30;3;Active;NA;Small molecule;Agonist;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;NE84;Failure or rejection of transplanted organs or tissues;1;Unknown;129221830;31685933, 37683456, 33313070
686;ABBV-932;ABBV-932;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Modulator;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;1;Active;1456478153/unspecified;NA
686;ABBV-932;ABBV-932;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Modulator;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;1;Active;1456478153/unspecified;NA
387;fe 202767;fe 202767;CHEMBL3545167;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;JB46.4;Hypogalactia;2;Unknown;640971691;NA
388;velcalcetide;velcalcetide;CHEMBL3545184;DB12865;71511839;1262780-97-1;60ME133FJB;ANIAZGVDEUQPRI-ZJQCGQFWSA-N;CC(C(=O)NC(CCCN=C(N)N)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(CSSCC(C(=O)O)N)NC(=O)C;10483;-107;618;1910;0;18;17;36;71;4;Approved;2017;Protein;Agonist;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;5A51.1;Secondary hyperparathyroidism;4;Approved;1442752937;24235081, 23903371, 23674604
390;burixafor;burixafor;CHEMBL3545224;NA;44479007;1191448-17-5;NA;QLVSJMZJSABWRX-UHFFFAOYSA-N;C1CCC(CC1)NCCCNCC2CCC(CC2)CNC3=NC(=CC(=N3)N4CCN(CC4)CCP(=O)(O)O)N;5667;-1;152;724;0;6;11;14;39;2;Active;NA;Small molecule;Antagonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;1;Inactive;1552457716/unspecified;37539772
390;burixafor;burixafor;CHEMBL3545224;NA;44479007;1191448-17-5;NA;QLVSJMZJSABWRX-UHFFFAOYSA-N;C1CCC(CC1)NCCCNCC2CCC(CC2)CNC3=NC(=CC(=N3)N4CCN(CC4)CCP(=O)(O)O)N;5667;-1;152;724;0;6;11;14;39;2;Active;NA;Small molecule;Antagonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;3C0Z;Diseases of the blood or blood-forming organs, unspecified;2;Inactive;1766440644/unspecified;37539772
391;pbf-999;pbf-999;CHEMBL3545271;NA;77107498;NA;NA;OQCWNHHZPYJHQR-UHFFFAOYSA-N;C#CCNC1=NC(=NC(=C1Br)N)N2C=NC=N2;29411;11;945;303;0;2;6;3;17;2;Active;NA;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2D4Z;Unspecified malignant neoplasms of unspecified sites;1;Active;1594217552/unspecified;NA
391;pbf-999;pbf-999;CHEMBL3545271;NA;77107498;NA;NA;OQCWNHHZPYJHQR-UHFFFAOYSA-N;C#CCNC1=NC(=NC(=C1Br)N)N2C=NC=N2;29411;11;945;303;0;2;6;3;17;2;Active;NA;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A01.10;Huntington disease;1;Inactive;2132180242;NA
391;pbf-999;pbf-999;CHEMBL3545271;NA;77107498;NA;NA;OQCWNHHZPYJHQR-UHFFFAOYSA-N;C#CCNC1=NC(=NC(=C1Br)N)N2C=NC=N2;29411;11;945;303;0;2;6;3;17;2;Active;NA;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;LD90.3;Prader-Willi syndrome;2;Active;393773440;NA
393;txa127;txa127;CHEMBL3545347;DB11720;123805;"39386-80-6;51833-78-4";NA;PVHLMTREZMEJCG-GDTLVBQBSA-N;CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N;899;-3;380;1660;0;12;14;25;64;2;Active;NA;Protein;Agonist;P04201;mas_human;Class A (Rhodopsin);Class A orphans;Orphan receptors;1C62.Z;Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified;1;Inactive;1508081745/unspecified;35902867
393;txa127;txa127;CHEMBL3545347;DB11720;123805;"39386-80-6;51833-78-4";NA;PVHLMTREZMEJCG-GDTLVBQBSA-N;CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N;899;-3;380;1660;0;12;14;25;64;2;Active;NA;Protein;Agonist;P04201;mas_human;Class A (Rhodopsin);Class A orphans;Orphan receptors;2A3Z;Myelodysplastic syndromes, unspecified;1;Inactive;1147802348/unspecified;35902867
393;txa127;txa127;CHEMBL3545347;DB11720;123805;"39386-80-6;51833-78-4";NA;PVHLMTREZMEJCG-GDTLVBQBSA-N;CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N;899;-3;380;1660;0;12;14;25;64;2;Active;NA;Protein;Agonist;P04201;mas_human;Class A (Rhodopsin);Class A orphans;Orphan receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;2;Inactive;1844086508/unspecified;35902867
393;txa127;txa127;CHEMBL3545347;DB11720;123805;"39386-80-6;51833-78-4";NA;PVHLMTREZMEJCG-GDTLVBQBSA-N;CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N;899;-3;380;1660;0;12;14;25;64;2;Active;NA;Protein;Agonist;P04201;mas_human;Class A (Rhodopsin);Class A orphans;Orphan receptors;BA00.Z;Essential hypertension, unspecified;1;Active;761947693/unspecified;35902867
393;txa127;txa127;CHEMBL3545347;DB11720;123805;"39386-80-6;51833-78-4";NA;PVHLMTREZMEJCG-GDTLVBQBSA-N;CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N;899;-3;380;1660;0;12;14;25;64;2;Active;NA;Protein;Agonist;P04201;mas_human;Class A (Rhodopsin);Class A orphans;Orphan receptors;BD1Z;Heart failure, unspecified;1;Active;1458683894/unspecified;35902867
393;txa127;txa127;CHEMBL3545347;DB11720;123805;"39386-80-6;51833-78-4";NA;PVHLMTREZMEJCG-GDTLVBQBSA-N;CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N;899;-3;380;1660;0;12;14;25;64;2;Active;NA;Protein;Agonist;P04201;mas_human;Class A (Rhodopsin);Class A orphans;Orphan receptors;BD5Z;Diseases of arteries or arterioles, unspecified;1;Active;1164983645/unspecified;35902867
393;txa127;txa127;CHEMBL3545347;DB11720;123805;"39386-80-6;51833-78-4";NA;PVHLMTREZMEJCG-GDTLVBQBSA-N;CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N;899;-3;380;1660;0;12;14;25;64;2;Active;NA;Protein;Agonist;P04201;mas_human;Class A (Rhodopsin);Class A orphans;Orphan receptors;MG2A;Ageing associated decline in intrinsic capacity;1;Unknown;835503193;35902867
393;txa127;txa127;CHEMBL3545347;DB11720;123805;"39386-80-6;51833-78-4";NA;PVHLMTREZMEJCG-GDTLVBQBSA-N;CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N;899;-3;380;1660;0;12;14;25;64;2;Active;NA;Protein;Agonist;P04201;mas_human;Class A (Rhodopsin);Class A orphans;Orphan receptors;RA01;COVID-19;2;Active;1730556128;35902867
394;lemborexant;lemborexant;CHEMBL3545367;DB11951;56944144;1369764-02-2;0K5743G68X;MUGXRYIUWFITCP-PGRDOPGGSA-N;CC1=NC(=NC=C1OCC2(CC2C(=O)NC3=NC=C(C=C3)F)C4=CC(=CC=C4)F)C;4104;32;77;612;0;1;7;6;30;4;Approved;2020;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;3;Active;1580466198/unspecified;33104322, 32644496, 31880796
394;lemborexant;lemborexant;CHEMBL3545367;DB11951;56944144;1369764-02-2;0K5743G68X;MUGXRYIUWFITCP-PGRDOPGGSA-N;CC1=NC(=NC=C1OCC2(CC2C(=O)NC3=NC=C(C=C3)F)C4=CC(=CC=C4)F)C;4104;32;77;612;0;1;7;6;30;4;Approved;2020;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;33104322, 32644496, 31880796
394;lemborexant;lemborexant;CHEMBL3545367;DB11951;56944144;1369764-02-2;0K5743G68X;MUGXRYIUWFITCP-PGRDOPGGSA-N;CC1=NC(=NC=C1OCC2(CC2C(=O)NC3=NC=C(C=C3)F)C4=CC(=CC=C4)F)C;4104;32;77;612;0;1;7;6;30;4;Approved;2020;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A6Z;Circadian rhythm sleep-wake disorders, unspecified;2;Inactive;1359329403/unspecified;33104322, 32644496, 31880796
394;lemborexant;lemborexant;CHEMBL3545367;DB11951;56944144;1369764-02-2;0K5743G68X;MUGXRYIUWFITCP-PGRDOPGGSA-N;CC1=NC(=NC=C1OCC2(CC2C(=O)NC3=NC=C(C=C3)F)C4=CC(=CC=C4)F)C;4104;32;77;612;0;1;7;6;30;4;Approved;2020;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;3;Active;1580466198/unspecified;33104322, 32644496, 31880796
394;lemborexant;lemborexant;CHEMBL3545367;DB11951;56944144;1369764-02-2;0K5743G68X;MUGXRYIUWFITCP-PGRDOPGGSA-N;CC1=NC(=NC=C1OCC2(CC2C(=O)NC3=NC=C(C=C3)F)C4=CC(=CC=C4)F)C;4104;32;77;612;0;1;7;6;30;4;Approved;2020;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;33104322, 32644496, 31880796
394;lemborexant;lemborexant;CHEMBL3545367;DB11951;56944144;1369764-02-2;0K5743G68X;MUGXRYIUWFITCP-PGRDOPGGSA-N;CC1=NC(=NC=C1OCC2(CC2C(=O)NC3=NC=C(C=C3)F)C4=CC(=CC=C4)F)C;4104;32;77;612;0;1;7;6;30;4;Approved;2020;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A6Z;Circadian rhythm sleep-wake disorders, unspecified;2;Inactive;1359329403/unspecified;33104322, 32644496, 31880796
396;benzphetamine;benzphetamine;CHEMBL3545985;DB00865;5311017;156-08-1;0M3S43XK27;YXKTVDFXDRQTKV-HNNXBMFYSA-N;CC(CC1=CC=CC=C1)N(C)CC2=CC=CC=C2;23935;41;32;214;0;0;1;5;18;4;Approved;1960;Protein;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;28373066, 3146764, 7593649
396;benzphetamine;benzphetamine;CHEMBL3545985;DB00865;5311017;156-08-1;0M3S43XK27;YXKTVDFXDRQTKV-HNNXBMFYSA-N;CC(CC1=CC=CC=C1)N(C)CC2=CC=CC=C2;23935;41;32;214;0;0;1;5;18;4;Approved;1960;Protein;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;28373066, 3146764, 7593649
662;ACT-1004-1239;ACT-1004-1239;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Antagonist;P25106;ackr3_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;8A40.Z;Multiple sclerosis, unspecified;1;Active;1298865187/unspecified;35431953, 33595155, 34794236
680;ACT-777991;ACT-777991;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Antagonist;P49682;cxcr3_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;5A10;Type 1 diabetes mellitus;1;Active;1651053999;36883854, 37458220, 37752659
667;AEF0117;AEF0117;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Inhibitor;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C41.2Z;Cannabis dependence, unspecified;2;Active;1129015467/unspecified;NA
665;ANPA-0073;ANPA-0073;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P35414;apj_human;Class A (Rhodopsin);Apelin receptors;Peptide receptors;5B81.Z;Obesity, unspecified;1;Active;149403041/unspecified;NA
691;ASP8062;ASP8062;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;PAM;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C40.2Z;Alcohol dependence, unspecified;1;Active;1580466198/unspecified;36925215, 34994232, 31926000
691;ASP8062;ASP8062;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;PAM;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C40.2Z;Alcohol dependence, unspecified;1;Active;1580466198/unspecified;36925215, 34994232, 31926000
726;Atumelnant;Atumelnant;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;Q01718;acthr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;2;Active;405565289/unspecified;NA
734;AZD4041;AZD4041;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;2;Active;1120716949/unspecified;NA
743;AZD5462;AZD5462;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;Q9HBX9;rxfp1_human;Class A (Rhodopsin);Relaxin family peptide receptors;Peptide receptors;BD1Z;Heart failure, unspecified;1;Active;1458683894/unspecified;38502782
706;AZD9550;AZD9550;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;1;Active;1884917970;NA
706;AZD9550;AZD9550;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;1;Active;1884917970;NA
715;BAY 3178275;BAY 3178275;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Antagonist;Q9NQS5;gpr84_human;Class A (Rhodopsin);Class A orphans;Orphan receptors;8E43.0Z;Neuropathic pain, unspecified;1;Active;1339785363/unspecified;NA
399;seltorexant;seltorexant;CHEMBL3597971;NA;67116280;1293281-49-8;NA;SQOCEMCKYDVLMM-UHFFFAOYSA-N;CC1=CC(=NC(=N1)N2CC3CN(CC3C2)C(=O)C4=C(C=CC=C4F)N5N=CC=N5)C;4074;28;80;609;0;0;7;3;30;3;Active;NA;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Active;1669279433;37110810, 34791262, 34324636
399;seltorexant;seltorexant;CHEMBL3597971;NA;67116280;1293281-49-8;NA;SQOCEMCKYDVLMM-UHFFFAOYSA-N;CC1=CC(=NC(=N1)N2CC3CN(CC3C2)C(=O)C4=C(C=CC=C4F)N5N=CC=N5)C;4074;28;80;609;0;0;7;3;30;3;Active;NA;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A0Z;Insomnia disorders, unspecified;2;Inactive;1038292737/unspecified;37110810, 34791262, 34324636
399;seltorexant;seltorexant;CHEMBL3597971;NA;67116280;1293281-49-8;NA;SQOCEMCKYDVLMM-UHFFFAOYSA-N;CC1=CC(=NC(=N1)N2CC3CN(CC3C2)C(=O)C4=C(C=CC=C4F)N5N=CC=N5)C;4074;28;80;609;0;0;7;3;30;3;Active;NA;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A41;Obstructive sleep apnoea;1;Inactive;1919233290;37110810, 34791262, 34324636
399;seltorexant;seltorexant;CHEMBL3597971;NA;67116280;1293281-49-8;NA;SQOCEMCKYDVLMM-UHFFFAOYSA-N;CC1=CC(=NC(=N1)N2CC3CN(CC3C2)C(=O)C4=C(C=CC=C4F)N5N=CC=N5)C;4074;28;80;609;0;0;7;3;30;3;Active;NA;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;8A20;Alzheimer disease;2;Active;1611724421;37110810, 34791262, 34324636
400;fezolinetant;fezolinetant;CHEMBL3608680;DB15669;117604931;1629229-37-3;NA;PPSNFPASKFYPMN-SECBINFHSA-N;CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NS4)C;3584;16;105;505;0;0;7;2;25;4;Approved;2023;Small molecule;Antagonist;P29371;nk3r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;GA30.4;Menopausal hot flush;4;Approved;222407548;36734148, 36924778, 33724119
401;ramatroban;ramatroban;CHEMBL361812;DB13036;123879;116649-85-5;P1ALI72U6C;LDXDSHIEDAPSSA-OAHLLOKOSA-N;C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O;4165;29;968;689;0;2;6;6;29;4;Approved;2000;Small molecule;Antagonist;P21731;ta2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;35068281, 32952595, 11778458
401;ramatroban;ramatroban;CHEMBL361812;DB13036;123879;116649-85-5;P1ALI72U6C;LDXDSHIEDAPSSA-OAHLLOKOSA-N;C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O;4165;29;968;689;0;2;6;6;29;4;Approved;2000;Small molecule;Antagonist;P21731;ta2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;RA01;COVID-19;3;Active;1730556128;35068281, 32952595, 11778458
401;ramatroban;ramatroban;CHEMBL361812;DB13036;123879;116649-85-5;P1ALI72U6C;LDXDSHIEDAPSSA-OAHLLOKOSA-N;C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O;4165;29;968;689;0;2;6;6;29;4;Approved;2000;Small molecule;Antagonist;Q9Y5Y4;pd2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;35068281, 32952595, 11778458
401;ramatroban;ramatroban;CHEMBL361812;DB13036;123879;116649-85-5;P1ALI72U6C;LDXDSHIEDAPSSA-OAHLLOKOSA-N;C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O;4165;29;968;689;0;2;6;6;29;4;Approved;2000;Small molecule;Antagonist;Q9Y5Y4;pd2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;RA01;COVID-19;3;Active;1730556128;35068281, 32952595, 11778458
402;linzagolix;linzagolix;CHEMBL3668014;DB17083;16656889;935283-04-8;7CDW97HUEX;BMAAMIIYNNPHAB-UHFFFAOYSA-N;COC1=C(C(=C(C=C1)F)F)COC2=C(C=C(C(=C2)N3C(=O)C4=C(SC=C4NC3=O)C(=O)O)F)OC;5084;34;143;826;0;2;11;7;35;4;Approved;2022;Small molecule;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2E86.0;Leiomyoma of uterus;4;Approved;455734276;35997940, 36116480, 32505383
402;linzagolix;linzagolix;CHEMBL3668014;DB17083;16656889;935283-04-8;7CDW97HUEX;BMAAMIIYNNPHAB-UHFFFAOYSA-N;COC1=C(C(=C(C=C1)F)F)COC2=C(C=C(C(=C2)N3C(=O)C4=C(SC=C4NC3=O)C(=O)O)F)OC;5084;34;143;826;0;2;11;7;35;4;Approved;2022;Small molecule;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA10.Z;Endometriosis of unspecified site;3;Active;1838213761/unspecified;35997940, 36116480, 32505383
403;pbf-509;pbf-509;CHEMBL3694769;NA;53466958;1337962-47-6;NA;ATFXVNUWQOXRRU-UHFFFAOYSA-N;C1=CN(N=C1)C2=NC(=NC(=C2Br)N)N3C=CC=N3;30612;12;874;291;0;1;5;2;18;2;Active;NA;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2C25.Y;Other specified malignant neoplasms of bronchus or lung;2;Active;316539081/other;NA
403;pbf-509;pbf-509;CHEMBL3694769;NA;53466958;1337962-47-6;NA;ATFXVNUWQOXRRU-UHFFFAOYSA-N;C1=CN(N=C1)C2=NC(=NC(=C2Br)N)N3C=CC=N3;30612;12;874;291;0;1;5;2;18;2;Active;NA;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A00.0Z;Parkinson disease, unspecified;1;Inactive;296066191/unspecified;NA
404;tavapadon;tavapadon;CHEMBL3697617;DB14899;86764100;"1643462-64-9;1643489-24-0";NA;AKQXQLUNFKDZBN-UHFFFAOYSA-N;CC1=C(C=CC(=C1)OC2=C(C=CC=N2)C(F)(F)F)C3=C(C(=O)NC(=O)N3C)C;3913;33;715;665;0;1;7;3;28;3;Active;NA;Small molecule;Partial agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;3;Active;296066191/unspecified;36999711
404;tavapadon;tavapadon;CHEMBL3697617;DB14899;86764100;"1643462-64-9;1643489-24-0";NA;AKQXQLUNFKDZBN-UHFFFAOYSA-N;CC1=C(C=CC(=C1)OC2=C(C=CC=N2)C(F)(F)F)C3=C(C(=O)NC(=O)N3C)C;3913;33;715;665;0;1;7;3;28;3;Active;NA;Small molecule;Partial agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;3;Active;296066191/unspecified;36999711
405;sofpironium;sofpironium;CHEMBL3707224;NA;86301317;1628251-49-9;NA;SEVCTUCCZYBJER-BSJAROSPSA-N;CCOC(=O)C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3905;33;728;555;1;1;5;9;28;4;Approved;2020;Small molecule;Inhibitor;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;4;Approved;1416949107/unspecified;33236266, 34890517, 35394087
405;sofpironium;sofpironium;CHEMBL3707224;NA;86301317;1628251-49-9;NA;SEVCTUCCZYBJER-BSJAROSPSA-N;CCOC(=O)C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3905;33;728;555;1;1;5;9;28;4;Approved;2020;Small molecule;Inhibitor;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;4;Approved;1416949107/unspecified;33236266, 34890517, 35394087
405;sofpironium;sofpironium;CHEMBL3707224;NA;86301317;1628251-49-9;NA;SEVCTUCCZYBJER-BSJAROSPSA-N;CCOC(=O)C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3905;33;728;555;1;1;5;9;28;4;Approved;2020;Small molecule;Inhibitor;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;4;Approved;1416949107/unspecified;33236266, 34890517, 35394087
405;sofpironium;sofpironium;CHEMBL3707224;NA;86301317;1628251-49-9;NA;SEVCTUCCZYBJER-BSJAROSPSA-N;CCOC(=O)C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3905;33;728;555;1;1;5;9;28;4;Approved;2020;Small molecule;Inhibitor;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;4;Approved;1416949107/unspecified;33236266, 34890517, 35394087
405;sofpironium;sofpironium;CHEMBL3707224;NA;86301317;1628251-49-9;NA;SEVCTUCCZYBJER-BSJAROSPSA-N;CCOC(=O)C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C;3905;33;728;555;1;1;5;9;28;4;Approved;2020;Small molecule;Inhibitor;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;EE00.Z;Hyperhidrosis, unspecified;4;Approved;1416949107/unspecified;33236266, 34890517, 35394087
407;ozanimod;ozanimod;CHEMBL3707247;DB12612;52938427;1306760-87-1;Z80293URPV;XRVDGNKRPOAQTN-FQEVSTJZSA-N;CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N;4045;31;104;609;0;2;7;7;30;4;Approved;2020;Small molecule;Modulator;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;4B4Z;Diseases of the immune system, unspecified;3;Unknown;1954798891/unspecified;34587385, 35994200, 27144850
407;ozanimod;ozanimod;CHEMBL3707247;DB12612;52938427;1306760-87-1;Z80293URPV;XRVDGNKRPOAQTN-FQEVSTJZSA-N;CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N;4045;31;104;609;0;2;7;7;30;4;Approved;2020;Small molecule;Modulator;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A40.Z;Multiple sclerosis, unspecified;4;Approved;1298865187/unspecified;34587385, 35994200, 27144850
407;ozanimod;ozanimod;CHEMBL3707247;DB12612;52938427;1306760-87-1;Z80293URPV;XRVDGNKRPOAQTN-FQEVSTJZSA-N;CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N;4045;31;104;609;0;2;7;7;30;4;Approved;2020;Small molecule;Modulator;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;DD70.Z;Crohn disease, unspecified site;3;Active;1267652425/unspecified;34587385, 35994200, 27144850
407;ozanimod;ozanimod;CHEMBL3707247;DB12612;52938427;1306760-87-1;Z80293URPV;XRVDGNKRPOAQTN-FQEVSTJZSA-N;CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N;4045;31;104;609;0;2;7;7;30;4;Approved;2020;Small molecule;Modulator;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;DD71.Z;Ulcerative colitis, unspecified;4;Approved;784669405/unspecified;34587385, 35994200, 27144850
407;ozanimod;ozanimod;CHEMBL3707247;DB12612;52938427;1306760-87-1;Z80293URPV;XRVDGNKRPOAQTN-FQEVSTJZSA-N;CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N;4045;31;104;609;0;2;7;7;30;4;Approved;2020;Small molecule;Modulator;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;RA01;COVID-19;2;Active;1730556128;34587385, 35994200, 27144850
409;rolapitant;rolapitant;CHEMBL3707331;DB09291;10311306;552292-08-7;NLE429IZUC;FIVSJYGQAIEMOC-ZGNKEGEESA-N;CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OCC2(CCC3(CCC(=O)N3)CN2)C4=CC=CC=C4;5005;44;504;731;0;2;9;5;35;4;Approved;2015;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;MD90;Nausea or vomiting;4;Approved;677319549;31643534, 26467681, 28929404
409;rolapitant;rolapitant;CHEMBL3707331;DB09291;10311306;552292-08-7;NLE429IZUC;FIVSJYGQAIEMOC-ZGNKEGEESA-N;CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OCC2(CCC3(CCC(=O)N3)CN2)C4=CC=CC=C4;5005;44;504;731;0;2;9;5;35;4;Approved;2015;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;MD90.0;Nausea;4;Approved;596805318;31643534, 26467681, 28929404
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5A61.5;Central diabetes insipidus;4;Approved;1009553897;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Active;437815624/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BB01.Z;Pulmonary hypertension, unspecified;2;Inactive;1496633964/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BC4Z;Diseases of the myocardium or cardiac chambers, unspecified;3;Active;2135151223/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BE2Z;Diseases of the circulatory system, unspecified;2;Unknown;426429380/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MC82.Z;Cardiac arrest, unspecified;3;Active;395422191/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG27;Haemorrhage, not elsewhere classified;3;Unknown;940081636;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG40.Z;Shock, unspecified;4;Approved;1164022950/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;NB32.3Z;Injury of lung, unspecified;2;Inactive;359051131/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5A61.5;Central diabetes insipidus;4;Approved;1009553897;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Active;437815624/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BB01.Z;Pulmonary hypertension, unspecified;2;Inactive;1496633964/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BC4Z;Diseases of the myocardium or cardiac chambers, unspecified;3;Active;2135151223/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BE2Z;Diseases of the circulatory system, unspecified;2;Unknown;426429380/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MC82.Z;Cardiac arrest, unspecified;3;Active;395422191/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG27;Haemorrhage, not elsewhere classified;3;Unknown;940081636;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG40.Z;Shock, unspecified;4;Approved;1164022950/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;NB32.3Z;Injury of lung, unspecified;2;Inactive;359051131/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5A61.5;Central diabetes insipidus;4;Approved;1009553897;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Active;437815624/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BB01.Z;Pulmonary hypertension, unspecified;2;Inactive;1496633964/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BC4Z;Diseases of the myocardium or cardiac chambers, unspecified;3;Active;2135151223/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BE2Z;Diseases of the circulatory system, unspecified;2;Unknown;426429380/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MC82.Z;Cardiac arrest, unspecified;3;Active;395422191/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG27;Haemorrhage, not elsewhere classified;3;Unknown;940081636;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG40.Z;Shock, unspecified;4;Approved;1164022950/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;NB32.3Z;Injury of lung, unspecified;2;Inactive;359051131/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5A61.5;Central diabetes insipidus;4;Approved;1009553897;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Active;437815624/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BA2Z;Hypotension, unspecified;4;Approved;1663360295/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BB01.Z;Pulmonary hypertension, unspecified;2;Inactive;1496633964/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BC4Z;Diseases of the myocardium or cardiac chambers, unspecified;3;Active;2135151223/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BE2Z;Diseases of the circulatory system, unspecified;2;Unknown;426429380/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MC82.Z;Cardiac arrest, unspecified;3;Active;395422191/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG27;Haemorrhage, not elsewhere classified;3;Unknown;940081636;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG40.Z;Shock, unspecified;4;Approved;1164022950/unspecified;30252325, 29999710, 33477721
410;vasopressin;vasopressin;CHEMBL373742;DB00067;644077;11000-17-2;Y87Y826H08;KBZOIRJILGZLEJ-LGYYRGKSSA-N;C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N;10842;-48;515;2070;0;14;16;19;75;4;Approved;2014;Protein;Agonist;P47901;v1br_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;NB32.3Z;Injury of lung, unspecified;2;Inactive;359051131/unspecified;30252325, 29999710, 33477721
411;atosiban;S-atosiban;CHEMBL378642;DB09059;68613;90779-69-4;081D12SI0Z;VWXRQYYUEIYXCZ-AVTFEHRISA-N;CC[C@H](C)[C@H]1C(=O)NC(C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O;9942;-19;416;1770;0;11;15;18;68;4;Approved;2000;Protein;Antagonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GA10.Z;Endometriosis of unspecified site;2;Active;1838213761/unspecified;8616970, 37033236, 35840927
411;atosiban;S-atosiban;CHEMBL378642;DB09059;68613;90779-69-4;081D12SI0Z;VWXRQYYUEIYXCZ-AVTFEHRISA-N;CC[C@H](C)[C@H]1C(=O)NC(C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O;9942;-19;416;1770;0;11;15;18;68;4;Approved;2000;Protein;Antagonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;KA21.4Z;Preterm newborn, unspecified;4;Approved;1726201225/unspecified;8616970, 37033236, 35840927
411;atosiban;atosiban;CHEMBL382301;DB09059;5311010;90779-69-4;081D12SI0Z;VWXRQYYUEIYXCZ-OBIMUBPZSA-N;CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O;9942;-19;416;1770;0;11;15;18;68;4;Approved;2000;Protein;Antagonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GA10.Z;Endometriosis of unspecified site;2;Active;1838213761/unspecified;8616970, 37033236, 35840927
411;atosiban;atosiban;CHEMBL382301;DB09059;5311010;90779-69-4;081D12SI0Z;VWXRQYYUEIYXCZ-OBIMUBPZSA-N;CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O;9942;-19;416;1770;0;11;15;18;68;4;Approved;2000;Protein;Antagonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;KA21.4Z;Preterm newborn, unspecified;4;Approved;1726201225/unspecified;8616970, 37033236, 35840927
412;revefenacin;revefenacin;CHEMBL3833319;DB11855;11753673;864750-70-9;G2AE2VE07O;FYDWDCIFZSGNBU-UHFFFAOYSA-N;CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N;5977;41;108;918;0;2;6;11;44;4;Approved;2018;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30601616, 31644224, 30560478
412;revefenacin;revefenacin;CHEMBL3833319;DB11855;11753673;864750-70-9;G2AE2VE07O;FYDWDCIFZSGNBU-UHFFFAOYSA-N;CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N;5977;41;108;918;0;2;6;11;44;4;Approved;2018;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;30601616, 31644224, 30560478
412;revefenacin;revefenacin;CHEMBL3833319;DB11855;11753673;864750-70-9;G2AE2VE07O;FYDWDCIFZSGNBU-UHFFFAOYSA-N;CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N;5977;41;108;918;0;2;6;11;44;4;Approved;2018;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30601616, 31644224, 30560478
412;revefenacin;revefenacin;CHEMBL3833319;DB11855;11753673;864750-70-9;G2AE2VE07O;FYDWDCIFZSGNBU-UHFFFAOYSA-N;CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N;5977;41;108;918;0;2;6;11;44;4;Approved;2018;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;30601616, 31644224, 30560478
412;revefenacin;revefenacin;CHEMBL3833319;DB11855;11753673;864750-70-9;G2AE2VE07O;FYDWDCIFZSGNBU-UHFFFAOYSA-N;CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N;5977;41;108;918;0;2;6;11;44;4;Approved;2018;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30601616, 31644224, 30560478
412;revefenacin;revefenacin;CHEMBL3833319;DB11855;11753673;864750-70-9;G2AE2VE07O;FYDWDCIFZSGNBU-UHFFFAOYSA-N;CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N;5977;41;108;918;0;2;6;11;44;4;Approved;2018;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;30601616, 31644224, 30560478
412;revefenacin;revefenacin;CHEMBL3833319;DB11855;11753673;864750-70-9;G2AE2VE07O;FYDWDCIFZSGNBU-UHFFFAOYSA-N;CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N;5977;41;108;918;0;2;6;11;44;4;Approved;2018;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30601616, 31644224, 30560478
412;revefenacin;revefenacin;CHEMBL3833319;DB11855;11753673;864750-70-9;G2AE2VE07O;FYDWDCIFZSGNBU-UHFFFAOYSA-N;CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N;5977;41;108;918;0;2;6;11;44;4;Approved;2018;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;30601616, 31644224, 30560478
412;revefenacin;revefenacin;CHEMBL3833319;DB11855;11753673;864750-70-9;G2AE2VE07O;FYDWDCIFZSGNBU-UHFFFAOYSA-N;CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N;5977;41;108;918;0;2;6;11;44;4;Approved;2018;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;30601616, 31644224, 30560478
412;revefenacin;revefenacin;CHEMBL3833319;DB11855;11753673;864750-70-9;G2AE2VE07O;FYDWDCIFZSGNBU-UHFFFAOYSA-N;CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N;5977;41;108;918;0;2;6;11;44;4;Approved;2018;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;30601616, 31644224, 30560478
413;erenumab;erenumab;CHEMBL3833329;DB14039;;1582205-90-0;I5I8VB78VT;NA;NA;;;;;;;;;;4;Approved;2018;Antibody;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;34743579, 30000991, 29171821
413;erenumab;erenumab;CHEMBL3833329;DB14039;;1582205-90-0;I5I8VB78VT;NA;NA;;;;;;;;;;4;Approved;2018;Antibody;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;8B82.0;Trigeminal neuralgia;2;Unknown;1803581281;34743579, 30000991, 29171821
413;erenumab;erenumab;CHEMBL3833329;DB14039;;1582205-90-0;I5I8VB78VT;NA;NA;;;;;;;;;;4;Approved;2018;Antibody;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;8C0Z;Polyneuropathy, unspecified;2;Active;58868923/unspecified;34743579, 30000991, 29171821
413;erenumab;erenumab;CHEMBL3833329;DB14039;;1582205-90-0;I5I8VB78VT;NA;NA;;;;;;;;;;4;Approved;2018;Antibody;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;BA40.Z;Angina pectoris, unspecified;2;Inactive;718946808/unspecified;34743579, 30000991, 29171821
413;erenumab;erenumab;CHEMBL3833329;DB14039;;1582205-90-0;I5I8VB78VT;NA;NA;;;;;;;;;;4;Approved;2018;Antibody;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;DA0E.8;Temporomandibular joint disorders;2;Active;897101649;34743579, 30000991, 29171821
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Inactive;437815624/unspecified;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6B40;Post traumatic stress disorder;2;Unknown;2070699808;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A05.00;Tourette syndrome;3;Inactive;119340957;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A40.Z;Multiple sclerosis, unspecified;3;Active;1298865187/unspecified;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8D2Z;Cerebral palsy, unspecified;3;Inactive;76906748/unspecified;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8D43.2Y;Other specified neuropathy due to toxicity;2;Unknown;1851919630/other;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8E43.0Z;Neuropathic pain, unspecified;4;Approved;1339785363/unspecified;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MB47.3;Cramp or spasm;4;Approved;157838476;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Inactive;437815624/unspecified;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6B40;Post traumatic stress disorder;2;Unknown;2070699808;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A05.00;Tourette syndrome;3;Inactive;119340957;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A40.Z;Multiple sclerosis, unspecified;3;Active;1298865187/unspecified;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8D2Z;Cerebral palsy, unspecified;3;Inactive;76906748/unspecified;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8D43.2Y;Other specified neuropathy due to toxicity;2;Unknown;1851919630/other;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8E43.0Z;Neuropathic pain, unspecified;4;Approved;1339785363/unspecified;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MB47.3;Cramp or spasm;4;Approved;157838476;28923526, 30670894, 33561282
414;nabiximols;nabiximols;CHEMBL3833333;DB14011;9852188;56575-23-6;K4H93P747O;SSNHGLKFJISNTR-DYSNNVSPSA-N;CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;6289;;699;853;0;3;4;10;46;4;Approved;2010;Small molecule;Partial agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;28923526, 30670894, 33561282
415;dextromoramide;dextromoramide;CHEMBL3833389;NA;127021145;NA;NA;XHKXWINHANRSNT-NRFANRHFSA-N;CC(CC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N3CCCC3)N4CCOCC4;3925;38;328;495;0;0;3;6;29;4;Approved;1974;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;6017168, 6066616, 768800
415;dextromoramide;dextromoramide;CHEMBL3833389;NA;127021145;NA;NA;XHKXWINHANRSNT-NRFANRHFSA-N;CC(CC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N3CCCC3)N4CCOCC4;3925;38;328;495;0;0;3;6;29;4;Approved;1974;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;6017168, 6066616, 768800
415;dextromoramide;dextromoramide;CHEMBL3833389;NA;127021145;NA;NA;XHKXWINHANRSNT-NRFANRHFSA-N;CC(CC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N3CCCC3)N4CCOCC4;3925;38;328;495;0;0;3;6;29;4;Approved;1974;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;6017168, 6066616, 768800
416;cr-6086;cr-6086;CHEMBL3920982;NA;71186236;1417742-86-9;NA;CADWTPLFEZSAHM-UHFFFAOYSA-N;C1CC12CCN(C(C2)C(=O)NC3(CC3)C4=CC=C(C=C4)C(=O)O)CC5=CC=C(C=C5)C(F)(F)F;4725;26;696;777;0;2;7;6;34;2;Active;NA;Small molecule;Antagonist;P35408;pe2r4_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;FA20.Z;Rheumatoid arthritis, serology unspecified;2;Active;576319925/unspecified;NA
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;1;Inactive;642618805/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;5B81.Z;Obesity, unspecified;2;Active;149403041/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6A02.Z;Autism spectrum disorder, unspecified;3;Inactive;437815624/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;1;Inactive;821852937/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6A20.Z;Schizophrenia, episode unspecified;3;Active;1683919430/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6A21.Z;Schizoaffective disorder, unspecified;1;Inactive;106339515/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6A8Z;Mood disorders, unspecified;2;Active;76398729/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6B04;Social anxiety disorder;2;Inactive;2062286624;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Inactive;1582741816/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6B40;Post traumatic stress disorder;2;Active;2070699808;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6B80.Z;Anorexia Nervosa, unspecified;1;Inactive;263852475/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;3;Active;1580466198/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6C40.4Z;Alcohol withdrawal, unspecified;2;Inactive;998231424/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;1;Inactive;1120716949/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;1;Active;111507461/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6C4Z;Disorders due to substance use, unspecified;1;Inactive;590211325/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6D83;Frontotemporal dementia;2;Active;831337417;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;1;Active;334423054/other;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;6E8Z;Mental, behavioural or neurodevelopmental disorders, unspecified;2;Active;334423054/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;7A41;Obstructive sleep apnoea;2;Active;1919233290;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;8E43.0Z;Neuropathic pain, unspecified;2;Active;1339785363/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BA41.Z;Acute myocardial infarction, unspecified;2;Unknown;1334938734/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BC9Z;Cardiac arrhythmia, unspecified;1;Inactive;1457291912/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;DA41.00;Gastroparesis;1;Inactive;598423727;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;FA01.Z;Osteoarthritis of knee, unspecified;2;Active;1685726407/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;FA0Z;Osteoarthritis, unspecified;2;Active;558562409/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;GA30.2;Postmenopausal atrophic vaginitis;2;Inactive;1876048433;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;HA0Z;Sexual dysfunctions, unspecified;2;Inactive;160690465/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;JA24.Z;Pre-eclampsia, unspecified;1;Inactive;229121159/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;JA43.Z;Postpartum haemorrhage, unspecified;4;Approved;820245648/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;JB02.2;Other uterine inertia;4;Approved;1073291850;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;JB02.4;Hypertonic, incoordinate, or prolonged uterine contractions;3;Inactive;693926988;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;LD55;Fragile X chromosome;2;Inactive;1524287677;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;LD90.3;Prader-Willi syndrome;3;Active;393773440;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG27;Haemorrhage, not elsewhere classified;4;Approved;940081636;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG2A;Ageing associated decline in intrinsic capacity;2;Unknown;835503193;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;2;Active;1581976053/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;MG3Z;Pain, unspecified;2;Active;661232217/unspecified;32912963, 28867943, 29939625
417;oxytocin;oxytocin;CHEMBL395429;DB00107;439302;50-56-6;1JQS135EYN;XNOPRXBHLZRZKH-DSZYJQQASA-N;CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;10072;-26;450;1870;0;12;15;17;69;4;Approved;1980;Protein;Agonist;P30559;oxyr_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;RA01;COVID-19;2;Unknown;1730556128;32912963, 28867943, 29939625
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;3A51.1;Sickle cell disease without crisis;3;Inactive;1711513381;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;3B61.Z;Thrombophilia, unspecified;4;Approved;1733531851/unspecified;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;8B22.5;Cerebral aneurysm, nonruptured;3;Inactive;289522729;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA41.0;Acute ST elevation myocardial infarction;3;Inactive;391388807;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA41.1;Acute non-ST elevation myocardial infarction;3;Inactive;680129526;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA4Z;Acute ischaemic heart disease, unspecified;4;Approved;1829545371/unspecified;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA8Z;Diseases of coronary artery, unspecified;4;Approved;1059873720/unspecified;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BD40.Y;Other specified atherosclerotic chronic arterial occlusive disease;1;Inactive;109367356/other;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BD50.4Z;Abdominal aortic aneurysm, unspecified;2;Inactive;1154633768/unspecified;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BD55;Asymptomatic stenosis of intracranial or extracranial artery;2;Active;860460764;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BD5Z;Diseases of arteries or arterioles, unspecified;3;Active;1164983645/unspecified;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;2;Inactive;133207228/unspecified;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;CA40.Z;Pneumonia, organism unspecified;3;Active;142052508/unspecified;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;GB61.Z;Chronic kidney disease, stage unspecified;3;Inactive;412389819/unspecified;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;LA8A.3;Congenital supravalvar aortic stenosis;3;Inactive;1066595728;19717846, 35396017, 31475799
418;ticagrelor;ticagrelor;CHEMBL398435;DB08816;9871419;274693-27-5;GLH0314RVC;OEKWJQXRCDYSHL-FNOIDJSQSA-N;CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F;5226;2;164;736;0;4;12;10;36;4;Approved;2011;Small molecule;NAM;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;RA01;COVID-19;3;Active;1730556128;19717846, 35396017, 31475799
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;3;Active;1120716949/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DA93.0;Paralytic ileus;3;Inactive;1868011045;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;3;Inactive;1815305992/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.Z;Spinal pain, unspecified;3;Active;2051065876/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;3;Active;1581976053/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ND56.Z;Unspecified injury to unspecified part of trunk, limb or body region;1;Active;1842783299/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Partial agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;3;Active;1120716949/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Partial agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DA93.0;Paralytic ileus;3;Inactive;1868011045;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Partial agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;3;Inactive;1815305992/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Partial agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.Z;Spinal pain, unspecified;3;Active;2051065876/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Partial agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;3;Active;1581976053/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Partial agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Partial agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ND56.Z;Unspecified injury to unspecified part of trunk, limb or body region;1;Active;1842783299/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;3;Active;1120716949/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DA93.0;Paralytic ileus;3;Inactive;1868011045;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;3;Inactive;1815305992/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.Z;Spinal pain, unspecified;3;Active;2051065876/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;3;Active;1581976053/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;29261877, 30000286, 31644083
419;hydromorphone;hydromorphone;CHEMBL398707;DB00327;5284570;466-99-9;Q812464R06;WVLOADHCBXTIJK-YNHQPCIGSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4;28534;18;498;494;0;1;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ND56.Z;Unspecified injury to unspecified part of trunk, limb or body region;1;Active;1842783299/unspecified;29261877, 30000286, 31644083
421;avacopan;avacopan;CHEMBL3989871;DB15011;49841217;1346623-17-3;O880NM097T;PUKBOVABABRILL-YZNIXAGQSA-N;CC1=C(C(=CC=C1)F)C(=O)N2CCCC(C2C3=CC=C(C=C3)NC4CCCC4)C(=O)NC5=CC(=C(C=C5)C)C(F)(F)F;5816;72;614;918;0;2;7;6;42;4;Approved;2021;Small molecule;Antagonist;P21730;c5ar1_human;Class A (Rhodopsin);Complement peptide receptors;Peptide receptors;3A10.Y;Other specified hereditary haemolytic anaemia;2;Inactive;1909380523/other;33596356, 38051796, 28400446
421;avacopan;avacopan;CHEMBL3989871;DB15011;49841217;1346623-17-3;O880NM097T;PUKBOVABABRILL-YZNIXAGQSA-N;CC1=C(C(=CC=C1)F)C(=O)N2CCCC(C2C3=CC=C(C=C3)NC4CCCC4)C(=O)NC5=CC(=C(C=C5)C)C(F)(F)F;5816;72;614;918;0;2;7;6;42;4;Approved;2021;Small molecule;Antagonist;P21730;c5ar1_human;Class A (Rhodopsin);Complement peptide receptors;Peptide receptors;4A44.A0;Microscopic polyangiitis;4;Approved;999231798;33596356, 38051796, 28400446
421;avacopan;avacopan;CHEMBL3989871;DB15011;49841217;1346623-17-3;O880NM097T;PUKBOVABABRILL-YZNIXAGQSA-N;CC1=C(C(=CC=C1)F)C(=O)N2CCCC(C2C3=CC=C(C=C3)NC4CCCC4)C(=O)NC5=CC(=C(C=C5)C)C(F)(F)F;5816;72;614;918;0;2;7;6;42;4;Approved;2021;Small molecule;Antagonist;P21730;c5ar1_human;Class A (Rhodopsin);Complement peptide receptors;Peptide receptors;4A44.A1;Granulomatosis with polyangiitis;4;Approved;1020056159;33596356, 38051796, 28400446
421;avacopan;avacopan;CHEMBL3989871;DB15011;49841217;1346623-17-3;O880NM097T;PUKBOVABABRILL-YZNIXAGQSA-N;CC1=C(C(=CC=C1)F)C(=O)N2CCCC(C2C3=CC=C(C=C3)NC4CCCC4)C(=O)NC5=CC(=C(C=C5)C)C(F)(F)F;5816;72;614;918;0;2;7;6;42;4;Approved;2021;Small molecule;Antagonist;P21730;c5ar1_human;Class A (Rhodopsin);Complement peptide receptors;Peptide receptors;4A44.AZ;Antineutrophil cytoplasmic antibody-associated vasculitis, unspecified;4;Approved;1404622826/unspecified;33596356, 38051796, 28400446
421;avacopan;avacopan;CHEMBL3989871;DB15011;49841217;1346623-17-3;O880NM097T;PUKBOVABABRILL-YZNIXAGQSA-N;CC1=C(C(=CC=C1)F)C(=O)N2CCCC(C2C3=CC=C(C=C3)NC4CCCC4)C(=O)NC5=CC(=C(C=C5)C)C(F)(F)F;5816;72;614;918;0;2;7;6;42;4;Approved;2021;Small molecule;Antagonist;P21730;c5ar1_human;Class A (Rhodopsin);Complement peptide receptors;Peptide receptors;ED92.0;Hidradenitis suppurativa;2;Inactive;1621794154;33596356, 38051796, 28400446
421;avacopan;avacopan;CHEMBL3989871;DB15011;49841217;1346623-17-3;O880NM097T;PUKBOVABABRILL-YZNIXAGQSA-N;CC1=C(C(=CC=C1)F)C(=O)N2CCCC(C2C3=CC=C(C=C3)NC4CCCC4)C(=O)NC5=CC(=C(C=C5)C)C(F)(F)F;5816;72;614;918;0;2;7;6;42;4;Approved;2021;Small molecule;Antagonist;P21730;c5ar1_human;Class A (Rhodopsin);Complement peptide receptors;Peptide receptors;GB40;Nephritic syndrome;2;Inactive;1783829886;33596356, 38051796, 28400446
422;piclidenoson;piclidenoson;CHEMBL3989873;NA;6610314;NA;NA;JTZRECOPNKCRTE-MOROJQBDSA-N;CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=CN=C32)NCC4=CC=C(C=C4)I)O)O;5103;9;134;581;0;4;8;5;29;3;Active;NA;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;9A1Y;Other specified disorders of lacrimal apparatus;3;Inactive;1628710366/other;29862305, 38279575
422;piclidenoson;piclidenoson;CHEMBL3989873;NA;6610314;NA;NA;JTZRECOPNKCRTE-MOROJQBDSA-N;CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=CN=C32)NCC4=CC=C(C=C4)I)O)O;5103;9;134;581;0;4;8;5;29;3;Active;NA;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;9C61.01;Ocular hypertension;2;Inactive;535283437;29862305, 38279575
422;piclidenoson;piclidenoson;CHEMBL3989873;NA;6610314;NA;NA;JTZRECOPNKCRTE-MOROJQBDSA-N;CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=CN=C32)NCC4=CC=C(C=C4)I)O)O;5103;9;134;581;0;4;8;5;29;3;Active;NA;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;9C61.Z;Glaucoma, unspecified;2;Inactive;499924848/unspecified;29862305, 38279575
422;piclidenoson;piclidenoson;CHEMBL3989873;NA;6610314;NA;NA;JTZRECOPNKCRTE-MOROJQBDSA-N;CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=CN=C32)NCC4=CC=C(C=C4)I)O)O;5103;9;134;581;0;4;8;5;29;3;Active;NA;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;EA90.Z;Psoriasis of unspecified type;3;Active;63698555/unspecified;29862305, 38279575
422;piclidenoson;piclidenoson;CHEMBL3989873;NA;6610314;NA;NA;JTZRECOPNKCRTE-MOROJQBDSA-N;CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=CN=C32)NCC4=CC=C(C=C4)I)O)O;5103;9;134;581;0;4;8;5;29;3;Active;NA;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;FA20.Z;Rheumatoid arthritis, serology unspecified;3;Inactive;576319925/unspecified;29862305, 38279575
422;piclidenoson;piclidenoson;CHEMBL3989873;NA;6610314;NA;NA;JTZRECOPNKCRTE-MOROJQBDSA-N;CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=CN=C32)NCC4=CC=C(C=C4)I)O)O;5103;9;134;581;0;4;8;5;29;3;Active;NA;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;RA01;COVID-19;2;Active;1730556128;29862305, 38279575
423;difelikefalin;difelikefalin;CHEMBL3989915;DB11938;24794466;1024828-77-0;NA1U919MRO;FWMNVWWHGCHHJJ-SKKKGAJSSA-N;CC(C)CC(C(=O)NC(CCCCN)C(=O)N1CCC(CC1)(C(=O)O)N)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC3=CC=CC=C3)N;6798;-6;223;1080;0;7;9;18;49;4;Approved;2021;Protein;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;31702883, 34662080, 34674115
423;difelikefalin;difelikefalin;CHEMBL3989915;DB11938;24794466;1024828-77-0;NA1U919MRO;FWMNVWWHGCHHJJ-SKKKGAJSSA-N;CC(C)CC(C(=O)NC(CCCCN)C(=O)N1CCC(CC1)(C(=O)O)N)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC3=CC=CC=C3)N;6798;-6;223;1080;0;7;9;18;49;4;Approved;2021;Protein;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;FA0Z;Osteoarthritis, unspecified;2;Inactive;558562409/unspecified;31702883, 34662080, 34674115
423;difelikefalin;difelikefalin;CHEMBL3989915;DB11938;24794466;1024828-77-0;NA1U919MRO;FWMNVWWHGCHHJJ-SKKKGAJSSA-N;CC(C)CC(C(=O)NC(CCCCN)C(=O)N1CCC(CC1)(C(=O)O)N)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC3=CC=CC=C3)N;6798;-6;223;1080;0;7;9;18;49;4;Approved;2021;Protein;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;GB61.Z;Chronic kidney disease, stage unspecified;4;Approved;412389819/unspecified;31702883, 34662080, 34674115
423;difelikefalin;difelikefalin;CHEMBL3989915;DB11938;24794466;1024828-77-0;NA1U919MRO;FWMNVWWHGCHHJJ-SKKKGAJSSA-N;CC(C)CC(C(=O)NC(CCCCN)C(=O)N1CCC(CC1)(C(=O)O)N)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC3=CC=CC=C3)N;6798;-6;223;1080;0;7;9;18;49;4;Approved;2021;Protein;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;31702883, 34662080, 34674115
424;fosnetupitant;fosnetupitant;CHEMBL3989917;DB14019;71544786;1703748-89-3;T672P80L2S;HZIYEEMJNBKMJH-UHFFFAOYSA-N;CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CC[N+](CC4)(C)COP(=O)(O)[O-];6886;5;106;1100;0;1;13;8;47;4;Approved;2018;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;MD90;Nausea or vomiting;4;Approved;677319549;34793245, 36884027, 37715851
424;fosnetupitant;fosnetupitant;CHEMBL3989917;DB14019;71544786;1703748-89-3;T672P80L2S;HZIYEEMJNBKMJH-UHFFFAOYSA-N;CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CC[N+](CC4)(C)COP(=O)(O)[O-];6886;5;106;1100;0;1;13;8;47;4;Approved;2018;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;MD90.1;Vomiting;4;Approved;447658033;34793245, 36884027, 37715851
424;fosnetupitant;pronetupitant;CHEMBL3989917;DB14019;71544787;1703748-89-3;T672P80L2S;HZIYEEMJNBKMJH-UHFFFAOYSA-O;CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CC[N+](CC4)(C)COP(=O)(O)O;6896;51;103;1110;1;2;13;8;47;4;Approved;2018;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;MD90;Nausea or vomiting;4;Approved;677319549;34793245, 36884027, 37715851
424;fosnetupitant;pronetupitant;CHEMBL3989917;DB14019;71544787;1703748-89-3;T672P80L2S;HZIYEEMJNBKMJH-UHFFFAOYSA-O;CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CC[N+](CC4)(C)COP(=O)(O)O;6896;51;103;1110;1;2;13;8;47;4;Approved;2018;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;MD90.1;Vomiting;4;Approved;447658033;34793245, 36884027, 37715851
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A01.0Z;Meningiomas, unspecified;2;Active;672106711/unspecified;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C10.1;Neuroendocrine neoplasms of pancreas;4;Approved;1421495979;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C6Y;Other specified malignant neoplasms of breast;2;Active;1047754165/other;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D11.2;Neuroblastoma of adrenal gland;2;Active;591280607;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;4;Approved;1594217552/other;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A01.0Z;Meningiomas, unspecified;2;Active;672106711/unspecified;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C10.1;Neuroendocrine neoplasms of pancreas;4;Approved;1421495979;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C6Y;Other specified malignant neoplasms of breast;2;Active;1047754165/other;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D11.2;Neuroblastoma of adrenal gland;2;Active;591280607;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;4;Approved;1594217552/other;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A01.0Z;Meningiomas, unspecified;2;Active;672106711/unspecified;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C10.1;Neuroendocrine neoplasms of pancreas;4;Approved;1421495979;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C6Y;Other specified malignant neoplasms of breast;2;Active;1047754165/other;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D11.2;Neuroblastoma of adrenal gland;2;Active;591280607;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;4;Approved;1594217552/other;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A01.0Z;Meningiomas, unspecified;2;Active;672106711/unspecified;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C10.1;Neuroendocrine neoplasms of pancreas;4;Approved;1421495979;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C6Y;Other specified malignant neoplasms of breast;2;Active;1047754165/other;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D11.2;Neuroblastoma of adrenal gland;2;Active;591280607;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;4;Approved;1594217552/other;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2A01.0Z;Meningiomas, unspecified;2;Active;672106711/unspecified;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C10.1;Neuroendocrine neoplasms of pancreas;4;Approved;1421495979;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2C6Y;Other specified malignant neoplasms of breast;2;Active;1047754165/other;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D11.2;Neuroblastoma of adrenal gland;2;Active;591280607;30237849, 33899756, 35359899
425;lutetium dotatate;lutetium dotatate;"CHEMBL3989924;CHEMBL3991432;CHEMBL4297339";"DB13985;DB15873";;"1426155-87-4;437608-50-9";AE221IM3BB,N3858377KC;QVFLVLMYXXNJDT-CSBVGUNJSA-N;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O;14356;-93;548;2700;0;17;26;26;100;4;Approved;2018;Protein;Binding agent;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;4;Approved;1594217552/other;30237849, 33899756, 35359899
427;atogepant;atogepant;CHEMBL3991065;DB16098;72163100;1374248-81-3;7CRV8RR151;QIVUCLWGARAQIO-OLIXTKCUSA-N;CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F;6035;34;104;1110;0;2;11;4;43;4;Approved;2021;Small molecule;Antagonist;Q16602;calrl_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;34407343, 34964810, 36153941
428;bromopride;bromopride;CHEMBL399510;DB09018;2446;4093-35-0;75473V2YZK;GIYAQDDTCWHPPL-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Br;34425;28;676;300;0;2;4;7;20;4;Approved;1976;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;31669384, 28778685, 24992919
428;bromopride;bromopride;CHEMBL399510;DB09018;2446;4093-35-0;75473V2YZK;GIYAQDDTCWHPPL-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Br;34425;28;676;300;0;2;4;7;20;4;Approved;1976;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD92;Dyspepsia;3;Inactive;869622187;31669384, 28778685, 24992919
429;amphetamine;amphetamine;CHEMBL405;DB00182;3007;300-62-9;CK833KGX7E;KWTSXDURSIMDCE-UHFFFAOYSA-N;CC(CC1=CC=CC=C1)N;13521;18;26;84;0;1;1;2;10;4;Approved;1955;Small molecule;Agonist;Q96RJ0;taar1_human;Class A (Rhodopsin);Trace amine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;4;Approved;821852937/unspecified;30000366, 29939585, 32310563
429;amphetamine;amphetamine;CHEMBL405;DB00182;3007;300-62-9;CK833KGX7E;KWTSXDURSIMDCE-UHFFFAOYSA-N;CC(CC1=CC=CC=C1)N;13521;18;26;84;0;1;1;2;10;4;Approved;1955;Small molecule;Agonist;Q96RJ0;taar1_human;Class A (Rhodopsin);Trace amine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;30000366, 29939585, 32310563
429;amphetamine;amphetamine;CHEMBL405;DB00182;3007;300-62-9;CK833KGX7E;KWTSXDURSIMDCE-UHFFFAOYSA-N;CC(CC1=CC=CC=C1)N;13521;18;26;84;0;1;1;2;10;4;Approved;1955;Small molecule;Agonist;Q96RJ0;taar1_human;Class A (Rhodopsin);Trace amine receptors;Aminergic receptors;7A20.0;Narcolepsy, Type 1;4;Approved;1851015159;30000366, 29939585, 32310563
430;angiotensin ii;angiotensin ii;CHEMBL408403;DB11842;172198;4474-91-3;M089EFU921;CZGUSIXMZVURDU-JZXHSEFVSA-N;CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N;10462;-17;409;1980;0;13;15;29;75;4;Approved;2017;Protein;Agonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;38189932, 29763087, 30038440
430;angiotensin ii;angiotensin ii;CHEMBL408403;DB11842;172198;4474-91-3;M089EFU921;CZGUSIXMZVURDU-JZXHSEFVSA-N;CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N;10462;-17;409;1980;0;13;15;29;75;4;Approved;2017;Protein;Agonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;38189932, 29763087, 30038440
430;angiotensin ii;angiotensin ii;CHEMBL408403;DB11842;172198;4474-91-3;M089EFU921;CZGUSIXMZVURDU-JZXHSEFVSA-N;CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N;10462;-17;409;1980;0;13;15;29;75;4;Approved;2017;Protein;Agonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;GB6Z;Kidney failure, unspecified;1;Inactive;761526554/unspecified;38189932, 29763087, 30038440
430;angiotensin ii;angiotensin ii;CHEMBL408403;DB11842;172198;4474-91-3;M089EFU921;CZGUSIXMZVURDU-JZXHSEFVSA-N;CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N;10462;-17;409;1980;0;13;15;29;75;4;Approved;2017;Protein;Agonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;MG40.Z;Shock, unspecified;4;Approved;1164022950/unspecified;38189932, 29763087, 30038440
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A10;Type 1 diabetes mellitus;3;Active;1651053999;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;4;Approved;119724091;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A14;Diabetes mellitus, type unspecified;4;Approved;1697306310;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A40.Z;Intermediate hyperglycaemia, unspecified;3;Inactive;1583355636/unspecified;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Inactive;1456478153/unspecified;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;6B8Z;Feeding or eating disorders, unspecified;3;Inactive;1412387537/unspecified;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;1;Active;1120716949/unspecified;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Active;1699574100/unspecified;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;7A41;Obstructive sleep apnoea;1;Inactive;1919233290;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;8A00.0Z;Parkinson disease, unspecified;2;Active;296066191/unspecified;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;8A20;Alzheimer disease;2;Unknown;1611724421;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;BD1Z;Heart failure, unspecified;2;Inactive;1458683894/unspecified;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DA96.04;Short bowel syndrome;2;Unknown;780637678;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Inactive;1884917970;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DE2Y;Other specified diseases of the digestive system;2;Active;1256772020/other;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;GB61.Z;Chronic kidney disease, stage unspecified;3;Inactive;412389819/unspecified;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;MA18.0Z;Elevated blood glucose level, unspecified;3;Unknown;307705857/unspecified;31031702, 27295427, 26132939
431;liraglutide;liraglutide;"CHEMBL4084119;CHEMBL4524066";DB06655;16134956;204656-20-2;839I73S42A;YSDQQAXHVYUZIW-QCIJIYAXSA-N;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O;3751;-34;1510;8760;0;54;55;132;266;4;Approved;2010;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;MG43.5;Excessive weight loss;4;Approved;2015627151;31031702, 27295427, 26132939
432;masupirdine;masupirdine;CHEMBL4117187;DB06140;10073773;701205-60-9;8XZ281AO3G;GWCYPEHWIZXYFZ-UHFFFAOYSA-N;CN1CCN(CC1)CC2=CN(C3=C2C=C(C=C3)OC)S(=O)(=O)C4=CC=CC=C4Br;4784;35;632;650;0;0;5;5;29;3;Active;NA;Small molecule;Antagonist;P50406;5ht6r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A20;Alzheimer disease;3;Active;1611724421;36168659, 35662833, 35908254
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A10;Type 1 diabetes mellitus;2;Inactive;1651053999;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;4;Approved;119724091;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A14;Diabetes mellitus, type unspecified;4;Approved;1697306310;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A4Z;Disorders of glucose regulation or pancreatic internal secretion, unspecified;1;Inactive;1283179793/unspecified;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A80.1;Polycystic ovary syndrome;2;Inactive;1213633323;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.01;Obesity in adults;2;Inactive;2062927079;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;3;Active;149403041/unspecified;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;2;Inactive;1580466198/unspecified;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;6C45.2Z;Cocaine dependence, unspecified;1;Inactive;1691013484/unspecified;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;6C4A.2Z;Nicotine dependence, unspecified;1;Inactive;1699574100/unspecified;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;8A00.0Z;Parkinson disease, unspecified;3;Active;296066191/unspecified;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;2;Active;1614716959/unspecified;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Inactive;1442995018;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;8B2Z;Cerebrovascular diseases, unspecified;2;Active;843843448/unspecified;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;8D87.0Z;Multiple system atrophy, unspecified;2;Unknown;1890931931/unspecified;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;BA41.Z;Acute myocardial infarction, unspecified;3;Inactive;1334938734/unspecified;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;BA8Z;Diseases of coronary artery, unspecified;3;Inactive;1059873720/unspecified;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.Z;Non-alcoholic fatty liver disease, unspecified;2;Inactive;1912806631/unspecified;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;MA18.0Z;Elevated blood glucose level, unspecified;2;Inactive;307705857/unspecified;30000037, 30085523, 31643976
433;exenatide;exenatide;CHEMBL414357;DB01276;45588096;141758-74-9;9P1872D4OL;HTQBXNHDCUEHJF-XWLPCZSASA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N;4187;-21;1780;10300;0;58;66;135;295;4;Approved;2005;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;MG43.5;Excessive weight loss;3;Inactive;2015627151;30000037, 30085523, 31643976
434;clomipramine;clomipramine;CHEMBL415;DB01242;2801;303-49-1;NUV44L116D;GDLIGKIOYRNHDA-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl;3149;52;65;346;0;0;2;4;22;4;Approved;1989;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;3;Inactive;1683919430/unspecified;30000234, 31082050, 31644185
434;clomipramine;clomipramine;CHEMBL415;DB01242;2801;303-49-1;NUV44L116D;GDLIGKIOYRNHDA-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl;3149;52;65;346;0;0;2;4;22;4;Approved;1989;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000234, 31082050, 31644185
434;clomipramine;clomipramine;CHEMBL415;DB01242;2801;303-49-1;NUV44L116D;GDLIGKIOYRNHDA-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl;3149;52;65;346;0;0;2;4;22;4;Approved;1989;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;4;Approved;1582741816/unspecified;30000234, 31082050, 31644185
434;clomipramine;clomipramine;CHEMBL415;DB01242;2801;303-49-1;NUV44L116D;GDLIGKIOYRNHDA-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl;3149;52;65;346;0;0;2;4;22;4;Approved;1989;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;3;Unknown;546689346/unspecified;30000234, 31082050, 31644185
434;clomipramine;clomipramine;CHEMBL415;DB01242;2801;303-49-1;NUV44L116D;GDLIGKIOYRNHDA-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl;3149;52;65;346;0;0;2;4;22;4;Approved;1989;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;30000234, 31082050, 31644185
434;clomipramine;clomipramine;CHEMBL415;DB01242;2801;303-49-1;NUV44L116D;GDLIGKIOYRNHDA-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl;3149;52;65;346;0;0;2;4;22;4;Approved;1989;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;3;Inactive;1683919430/unspecified;30000234, 31082050, 31644185
434;clomipramine;clomipramine;CHEMBL415;DB01242;2801;303-49-1;NUV44L116D;GDLIGKIOYRNHDA-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl;3149;52;65;346;0;0;2;4;22;4;Approved;1989;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000234, 31082050, 31644185
434;clomipramine;clomipramine;CHEMBL415;DB01242;2801;303-49-1;NUV44L116D;GDLIGKIOYRNHDA-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl;3149;52;65;346;0;0;2;4;22;4;Approved;1989;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;4;Approved;1582741816/unspecified;30000234, 31082050, 31644185
434;clomipramine;clomipramine;CHEMBL415;DB01242;2801;303-49-1;NUV44L116D;GDLIGKIOYRNHDA-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl;3149;52;65;346;0;0;2;4;22;4;Approved;1989;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;3;Unknown;546689346/unspecified;30000234, 31082050, 31644185
434;clomipramine;clomipramine;CHEMBL415;DB01242;2801;303-49-1;NUV44L116D;GDLIGKIOYRNHDA-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl;3149;52;65;346;0;0;2;4;22;4;Approved;1989;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;30000234, 31082050, 31644185
434;clomipramine;clomipramine;CHEMBL415;DB01242;2801;303-49-1;NUV44L116D;GDLIGKIOYRNHDA-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl;3149;52;65;346;0;0;2;4;22;4;Approved;1989;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;3;Inactive;1683919430/unspecified;30000234, 31082050, 31644185
434;clomipramine;clomipramine;CHEMBL415;DB01242;2801;303-49-1;NUV44L116D;GDLIGKIOYRNHDA-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl;3149;52;65;346;0;0;2;4;22;4;Approved;1989;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000234, 31082050, 31644185
434;clomipramine;clomipramine;CHEMBL415;DB01242;2801;303-49-1;NUV44L116D;GDLIGKIOYRNHDA-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl;3149;52;65;346;0;0;2;4;22;4;Approved;1989;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;4;Approved;1582741816/unspecified;30000234, 31082050, 31644185
434;clomipramine;clomipramine;CHEMBL415;DB01242;2801;303-49-1;NUV44L116D;GDLIGKIOYRNHDA-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl;3149;52;65;346;0;0;2;4;22;4;Approved;1989;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;3;Unknown;546689346/unspecified;30000234, 31082050, 31644185
434;clomipramine;clomipramine;CHEMBL415;DB01242;2801;303-49-1;NUV44L116D;GDLIGKIOYRNHDA-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl;3149;52;65;346;0;0;2;4;22;4;Approved;1989;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;30000234, 31082050, 31644185
435;degarelix;degarelix;CHEMBL415606;DB06699;16136245;214766-78-6;SX0XJI3A11;MEUCPCLKGZSHTA-XYAYPHGZSA-N;CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C;16323;35;513;3390;0;17;18;41;117;4;Approved;2008;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C6Y;Other specified malignant neoplasms of breast;2;Active;1047754165/other;31643893, 19747011, 19035858
435;degarelix;degarelix;CHEMBL415606;DB06699;16136245;214766-78-6;SX0XJI3A11;MEUCPCLKGZSHTA-XYAYPHGZSA-N;CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C;16323;35;513;3390;0;17;18;41;117;4;Approved;2008;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Inactive;1047754165/unspecified;31643893, 19747011, 19035858
435;degarelix;degarelix;CHEMBL415606;DB06699;16136245;214766-78-6;SX0XJI3A11;MEUCPCLKGZSHTA-XYAYPHGZSA-N;CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C;16323;35;513;3390;0;17;18;41;117;4;Approved;2008;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.0;Adenocarcinoma of prostate;4;Approved;1510677183;31643893, 19747011, 19035858
435;degarelix;degarelix;CHEMBL415606;DB06699;16136245;214766-78-6;SX0XJI3A11;MEUCPCLKGZSHTA-XYAYPHGZSA-N;CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C;16323;35;513;3390;0;17;18;41;117;4;Approved;2008;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.Y;Other specified malignant neoplasms of prostate;4;Approved;1552457716/other;31643893, 19747011, 19035858
435;degarelix;degarelix;CHEMBL415606;DB06699;16136245;214766-78-6;SX0XJI3A11;MEUCPCLKGZSHTA-XYAYPHGZSA-N;CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C;16323;35;513;3390;0;17;18;41;117;4;Approved;2008;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;4;Approved;1552457716/unspecified;31643893, 19747011, 19035858
435;degarelix;degarelix;CHEMBL415606;DB06699;16136245;214766-78-6;SX0XJI3A11;MEUCPCLKGZSHTA-XYAYPHGZSA-N;CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C;16323;35;513;3390;0;17;18;41;117;4;Approved;2008;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2D40;Adenocarcinoma of unspecified site;2;Active;1979211198;31643893, 19747011, 19035858
435;degarelix;degarelix;CHEMBL415606;DB06699;16136245;214766-78-6;SX0XJI3A11;MEUCPCLKGZSHTA-XYAYPHGZSA-N;CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C;16323;35;513;3390;0;17;18;41;117;4;Approved;2008;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2F97;Neoplasms of unknown behaviour of male genital organs;3;Unknown;1860378384;31643893, 19747011, 19035858
435;degarelix;degarelix;CHEMBL415606;DB06699;16136245;214766-78-6;SX0XJI3A11;MEUCPCLKGZSHTA-XYAYPHGZSA-N;CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C;16323;35;513;3390;0;17;18;41;117;4;Approved;2008;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;4;Approved;1844086508/unspecified;31643893, 19747011, 19035858
435;degarelix;degarelix;CHEMBL415606;DB06699;16136245;214766-78-6;SX0XJI3A11;MEUCPCLKGZSHTA-XYAYPHGZSA-N;CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C;16323;35;513;3390;0;17;18;41;117;4;Approved;2008;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA10.Z;Endometriosis of unspecified site;3;Inactive;1838213761/unspecified;31643893, 19747011, 19035858
435;degarelix;degarelix;CHEMBL415606;DB06699;16136245;214766-78-6;SX0XJI3A11;MEUCPCLKGZSHTA-XYAYPHGZSA-N;CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C;16323;35;513;3390;0;17;18;41;117;4;Approved;2008;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA90;Hyperplasia of prostate;2;Inactive;978159279;31643893, 19747011, 19035858
435;degarelix;degarelix;CHEMBL415606;DB06699;16136245;214766-78-6;SX0XJI3A11;MEUCPCLKGZSHTA-XYAYPHGZSA-N;CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C;16323;35;513;3390;0;17;18;41;117;4;Approved;2008;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GC8Y;Other specified diseases of the genitourinary system;2;Inactive;30659757/other;31643893, 19747011, 19035858
435;degarelix;degarelix;CHEMBL415606;DB06699;16136245;214766-78-6;SX0XJI3A11;MEUCPCLKGZSHTA-XYAYPHGZSA-N;CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C;16323;35;513;3390;0;17;18;41;117;4;Approved;2008;Protein;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;RA01;COVID-19;2;Inactive;1730556128;31643893, 19747011, 19035858
438;clozapine;clozapine;CHEMBL42;DB00363;135398737;5786-21-0;J60AR2IKIC;QZUDBNBUXVUHMW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42;3268;31;309;446;0;1;3;1;23;4;Approved;1989;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A00.Z;Disorders of intellectual development, unspecified;3;Inactive;605267007/unspecified;32815018, 30000711, 30571020
438;clozapine;clozapine;CHEMBL42;DB00363;135398737;5786-21-0;J60AR2IKIC;QZUDBNBUXVUHMW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42;3268;31;309;446;0;1;3;1;23;4;Approved;1989;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;32815018, 30000711, 30571020
438;clozapine;clozapine;CHEMBL42;DB00363;135398737;5786-21-0;J60AR2IKIC;QZUDBNBUXVUHMW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42;3268;31;309;446;0;1;3;1;23;4;Approved;1989;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;32815018, 30000711, 30571020
438;clozapine;clozapine;CHEMBL42;DB00363;135398737;5786-21-0;J60AR2IKIC;QZUDBNBUXVUHMW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42;3268;31;309;446;0;1;3;1;23;4;Approved;1989;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;32815018, 30000711, 30571020
438;clozapine;clozapine;CHEMBL42;DB00363;135398737;5786-21-0;J60AR2IKIC;QZUDBNBUXVUHMW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42;3268;31;309;446;0;1;3;1;23;4;Approved;1989;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Inactive;1456478153/unspecified;32815018, 30000711, 30571020
438;clozapine;clozapine;CHEMBL42;DB00363;135398737;5786-21-0;J60AR2IKIC;QZUDBNBUXVUHMW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42;3268;31;309;446;0;1;3;1;23;4;Approved;1989;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A00.Z;Disorders of intellectual development, unspecified;3;Inactive;605267007/unspecified;32815018, 30000711, 30571020
438;clozapine;clozapine;CHEMBL42;DB00363;135398737;5786-21-0;J60AR2IKIC;QZUDBNBUXVUHMW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42;3268;31;309;446;0;1;3;1;23;4;Approved;1989;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;32815018, 30000711, 30571020
438;clozapine;clozapine;CHEMBL42;DB00363;135398737;5786-21-0;J60AR2IKIC;QZUDBNBUXVUHMW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42;3268;31;309;446;0;1;3;1;23;4;Approved;1989;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;32815018, 30000711, 30571020
438;clozapine;clozapine;CHEMBL42;DB00363;135398737;5786-21-0;J60AR2IKIC;QZUDBNBUXVUHMW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42;3268;31;309;446;0;1;3;1;23;4;Approved;1989;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;32815018, 30000711, 30571020
438;clozapine;clozapine;CHEMBL42;DB00363;135398737;5786-21-0;J60AR2IKIC;QZUDBNBUXVUHMW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42;3268;31;309;446;0;1;3;1;23;4;Approved;1989;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Inactive;1456478153/unspecified;32815018, 30000711, 30571020
440;guanabenz;guanaben-acetate;CHEMBL1331786;DB00629;5353646;5051-62-7;GGD30112WC;WDZVGELJXXEGPV-PQMHYQBVSA-N;C1=CC(=C(C(=C1)Cl)/C=N\N=C(N)N)Cl;23108;17;768;228;0;2;2;2;14;4;Approved;1982;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000573, 3946989, 3994191
440;guanabenz;guanabenz;CHEMBL420;DB00629;5702063;5051-62-7;GGD30112WC;WDZVGELJXXEGPV-YIXHJXPBSA-N;C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl;23108;17;768;228;0;2;2;2;14;4;Approved;1982;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000573, 3946989, 3994191
440;guanabenz;guanaben-acetate;CHEMBL1331786;DB00629;5353646;5051-62-7;GGD30112WC;WDZVGELJXXEGPV-PQMHYQBVSA-N;C1=CC(=C(C(=C1)Cl)/C=N\N=C(N)N)Cl;23108;17;768;228;0;2;2;2;14;4;Approved;1982;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000573, 3946989, 3994191
440;guanabenz;guanabenz;CHEMBL420;DB00629;5702063;5051-62-7;GGD30112WC;WDZVGELJXXEGPV-YIXHJXPBSA-N;C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl;23108;17;768;228;0;2;2;2;14;4;Approved;1982;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000573, 3946989, 3994191
440;guanabenz;guanaben-acetate;CHEMBL1331786;DB00629;5353646;5051-62-7;GGD30112WC;WDZVGELJXXEGPV-PQMHYQBVSA-N;C1=CC(=C(C(=C1)Cl)/C=N\N=C(N)N)Cl;23108;17;768;228;0;2;2;2;14;4;Approved;1982;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000573, 3946989, 3994191
440;guanabenz;guanabenz;CHEMBL420;DB00629;5702063;5051-62-7;GGD30112WC;WDZVGELJXXEGPV-YIXHJXPBSA-N;C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl;23108;17;768;228;0;2;2;2;14;4;Approved;1982;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000573, 3946989, 3994191
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B0Y;Other specified anxiety or fear-related disorders;4;Approved;1336943699/other;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B0Y;Other specified anxiety or fear-related disorders;4;Approved;1336943699/other;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B0Y;Other specified anxiety or fear-related disorders;4;Approved;1336943699/other;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B0Y;Other specified anxiety or fear-related disorders;4;Approved;1336943699/other;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B0Y;Other specified anxiety or fear-related disorders;4;Approved;1336943699/other;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B0Y;Other specified anxiety or fear-related disorders;4;Approved;1336943699/other;30000185, 31644233, 25197603
441;trifluoperazine;trifluoperazine;CHEMBL422;DB00831;5566;117-89-5;214IZI85K3;ZEWQUBUPAILYHI-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F;4075;5;35;510;0;0;7;4;28;4;Approved;1959;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;30000185, 31644233, 25197603
442;betaxolol;betaxolol;CHEMBL423;DB00195;2369;63659-18-7;O0ZR1R6RZ2;NWIUTZDMDHAVTP-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O;3074;28;507;286;0;2;4;11;22;4;Approved;1985;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.01;Ocular hypertension;4;Approved;535283437;30000202, 32491793, 31643930
442;betaxolol;betaxolol;CHEMBL423;DB00195;2369;63659-18-7;O0ZR1R6RZ2;NWIUTZDMDHAVTP-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O;3074;28;507;286;0;2;4;11;22;4;Approved;1985;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000202, 32491793, 31643930
442;betaxolol;betaxolol;CHEMBL423;DB00195;2369;63659-18-7;O0ZR1R6RZ2;NWIUTZDMDHAVTP-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O;3074;28;507;286;0;2;4;11;22;4;Approved;1985;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000202, 32491793, 31643930
442;betaxolol;betaxolol;CHEMBL423;DB00195;2369;63659-18-7;O0ZR1R6RZ2;NWIUTZDMDHAVTP-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O;3074;28;507;286;0;2;4;11;22;4;Approved;1985;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000202, 32491793, 31643930
442;betaxolol;betaxolol;CHEMBL423;DB00195;2369;63659-18-7;O0ZR1R6RZ2;NWIUTZDMDHAVTP-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O;3074;28;507;286;0;2;4;11;22;4;Approved;1985;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30000202, 32491793, 31643930
443;samidorphan;samidorphan;CHEMBL426084;DB12543;11667832;852626-89-2;7W2581Z5L8;RYIDHLJADOKWFM-MAODMQOUSA-N;C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O;3704;11;104;665;0;3;5;3;27;4;Approved;2021;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;34304374, 32791894, 35040357
443;samidorphan;samidorphan;CHEMBL426084;DB12543;11667832;852626-89-2;7W2581Z5L8;RYIDHLJADOKWFM-MAODMQOUSA-N;C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O;3704;11;104;665;0;3;5;3;27;4;Approved;2021;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;34304374, 32791894, 35040357
443;samidorphan;samidorphan;CHEMBL426084;DB12543;11667832;852626-89-2;7W2581Z5L8;RYIDHLJADOKWFM-MAODMQOUSA-N;C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O;3704;11;104;665;0;3;5;3;27;4;Approved;2021;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6B8Z;Feeding or eating disorders, unspecified;2;Inactive;1412387537/unspecified;34304374, 32791894, 35040357
443;samidorphan;samidorphan;CHEMBL426084;DB12543;11667832;852626-89-2;7W2581Z5L8;RYIDHLJADOKWFM-MAODMQOUSA-N;C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O;3704;11;104;665;0;3;5;3;27;4;Approved;2021;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;2;Inactive;1580466198/unspecified;34304374, 32791894, 35040357
443;samidorphan;samidorphan;CHEMBL426084;DB12543;11667832;852626-89-2;7W2581Z5L8;RYIDHLJADOKWFM-MAODMQOUSA-N;C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O;3704;11;104;665;0;3;5;3;27;4;Approved;2021;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C45.2Z;Cocaine dependence, unspecified;1;Inactive;1691013484/unspecified;34304374, 32791894, 35040357
443;samidorphan;samidorphan;CHEMBL426084;DB12543;11667832;852626-89-2;7W2581Z5L8;RYIDHLJADOKWFM-MAODMQOUSA-N;C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O;3704;11;104;665;0;3;5;3;27;4;Approved;2021;Small molecule;Partial agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;34304374, 32791894, 35040357
443;samidorphan;samidorphan;CHEMBL426084;DB12543;11667832;852626-89-2;7W2581Z5L8;RYIDHLJADOKWFM-MAODMQOUSA-N;C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O;3704;11;104;665;0;3;5;3;27;4;Approved;2021;Small molecule;Partial agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;34304374, 32791894, 35040357
443;samidorphan;samidorphan;CHEMBL426084;DB12543;11667832;852626-89-2;7W2581Z5L8;RYIDHLJADOKWFM-MAODMQOUSA-N;C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O;3704;11;104;665;0;3;5;3;27;4;Approved;2021;Small molecule;Partial agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6B8Z;Feeding or eating disorders, unspecified;2;Inactive;1412387537/unspecified;34304374, 32791894, 35040357
443;samidorphan;samidorphan;CHEMBL426084;DB12543;11667832;852626-89-2;7W2581Z5L8;RYIDHLJADOKWFM-MAODMQOUSA-N;C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O;3704;11;104;665;0;3;5;3;27;4;Approved;2021;Small molecule;Partial agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;2;Inactive;1580466198/unspecified;34304374, 32791894, 35040357
443;samidorphan;samidorphan;CHEMBL426084;DB12543;11667832;852626-89-2;7W2581Z5L8;RYIDHLJADOKWFM-MAODMQOUSA-N;C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O;3704;11;104;665;0;3;5;3;27;4;Approved;2021;Small molecule;Partial agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C45.2Z;Cocaine dependence, unspecified;1;Inactive;1691013484/unspecified;34304374, 32791894, 35040357
443;samidorphan;samidorphan;CHEMBL426084;DB12543;11667832;852626-89-2;7W2581Z5L8;RYIDHLJADOKWFM-MAODMQOUSA-N;C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O;3704;11;104;665;0;3;5;3;27;4;Approved;2021;Small molecule;Partial agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;34304374, 32791894, 35040357
443;samidorphan;samidorphan;CHEMBL426084;DB12543;11667832;852626-89-2;7W2581Z5L8;RYIDHLJADOKWFM-MAODMQOUSA-N;C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O;3704;11;104;665;0;3;5;3;27;4;Approved;2021;Small molecule;Partial agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;34304374, 32791894, 35040357
443;samidorphan;samidorphan;CHEMBL426084;DB12543;11667832;852626-89-2;7W2581Z5L8;RYIDHLJADOKWFM-MAODMQOUSA-N;C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O;3704;11;104;665;0;3;5;3;27;4;Approved;2021;Small molecule;Partial agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6B8Z;Feeding or eating disorders, unspecified;2;Inactive;1412387537/unspecified;34304374, 32791894, 35040357
443;samidorphan;samidorphan;CHEMBL426084;DB12543;11667832;852626-89-2;7W2581Z5L8;RYIDHLJADOKWFM-MAODMQOUSA-N;C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O;3704;11;104;665;0;3;5;3;27;4;Approved;2021;Small molecule;Partial agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;2;Inactive;1580466198/unspecified;34304374, 32791894, 35040357
443;samidorphan;samidorphan;CHEMBL426084;DB12543;11667832;852626-89-2;7W2581Z5L8;RYIDHLJADOKWFM-MAODMQOUSA-N;C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O;3704;11;104;665;0;3;5;3;27;4;Approved;2021;Small molecule;Partial agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C45.2Z;Cocaine dependence, unspecified;1;Inactive;1691013484/unspecified;34304374, 32791894, 35040357
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Active;873092535/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Active;1442995018;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA24.Z;Pre-eclampsia, unspecified;3;Active;229121159/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;2;Unknown;940081636;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;1;Inactive;661232217/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Active;873092535/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Active;1442995018;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA24.Z;Pre-eclampsia, unspecified;3;Active;229121159/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;2;Unknown;940081636;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;1;Inactive;661232217/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Active;873092535/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Active;1442995018;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA24.Z;Pre-eclampsia, unspecified;3;Active;229121159/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;2;Unknown;940081636;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;1;Inactive;661232217/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Active;873092535/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Active;1442995018;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA24.Z;Pre-eclampsia, unspecified;3;Active;229121159/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;2;Unknown;940081636;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;1;Inactive;661232217/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Active;873092535/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Active;1442995018;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA24.Z;Pre-eclampsia, unspecified;3;Active;229121159/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;2;Unknown;940081636;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;1;Inactive;661232217/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Active;873092535/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Active;1442995018;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA24.Z;Pre-eclampsia, unspecified;3;Active;229121159/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;2;Unknown;940081636;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;1;Inactive;661232217/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Active;873092535/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Active;1442995018;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA24.Z;Pre-eclampsia, unspecified;3;Active;229121159/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;2;Unknown;940081636;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;1;Inactive;661232217/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Active;873092535/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Active;1442995018;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA24.Z;Pre-eclampsia, unspecified;3;Active;229121159/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;2;Unknown;940081636;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;1;Inactive;661232217/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B00.Z;Intracerebral haemorrhage, site unspecified;2;Active;873092535/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Active;1442995018;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA24.Z;Pre-eclampsia, unspecified;3;Active;229121159/unspecified;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;2;Unknown;940081636;30521208, 30000210, 35952052
444;labetalol;labetalol;CHEMBL429;DB00598;3869;36894-69-6;R5H8897N95;SGUAFYQXFOLMHL-UHFFFAOYSA-N;CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O;3284;31;956;385;0;4;4;8;24;4;Approved;1984;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;1;Inactive;661232217/unspecified;30521208, 30000210, 35952052
446;ciforadenant;ciforadenant;CHEMBL4297184;NA;44537963;1202402-40-1;NA;KURQKNMKCGYWRJ-HNNXBMFYSA-N;CC1=CC=C(O1)C2=C3C(=NC(=N2)N)N(N=N3)CC4=NC(=CC=C4)COC5CCOC5;4074;8;127;573;0;1;9;6;30;2;Active;NA;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2A83.1;Plasma cell myeloma;1;Active;526287100;NA
446;ciforadenant;ciforadenant;CHEMBL4297184;NA;44537963;1202402-40-1;NA;KURQKNMKCGYWRJ-HNNXBMFYSA-N;CC1=CC=C(O1)C2=C3C(=NC(=N2)N)N(N=N3)CC4=NC(=CC=C4)COC5CCOC5;4074;8;127;573;0;1;9;6;30;2;Active;NA;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2C25.Y;Other specified malignant neoplasms of bronchus or lung;1;Active;316539081/other;NA
446;ciforadenant;ciforadenant;CHEMBL4297184;NA;44537963;1202402-40-1;NA;KURQKNMKCGYWRJ-HNNXBMFYSA-N;CC1=CC=C(O1)C2=C3C(=NC(=N2)N)N(N=N3)CC4=NC(=CC=C4)COC5CCOC5;4074;8;127;573;0;1;9;6;30;2;Active;NA;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2C90.0;Renal cell carcinoma of kidney, except renal pelvis;2;Active;825917541;NA
446;ciforadenant;ciforadenant;CHEMBL4297184;NA;44537963;1202402-40-1;NA;KURQKNMKCGYWRJ-HNNXBMFYSA-N;CC1=CC=C(O1)C2=C3C(=NC(=N2)N)N(N=N3)CC4=NC(=CC=C4)COC5CCOC5;4074;8;127;573;0;1;9;6;30;2;Active;NA;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;1;Inactive;821852937/unspecified;NA
446;ciforadenant;ciforadenant;CHEMBL4297184;NA;44537963;1202402-40-1;NA;KURQKNMKCGYWRJ-HNNXBMFYSA-N;CC1=CC=C(O1)C2=C3C(=NC(=N2)N)N(N=N3)CC4=NC(=CC=C4)COC5CCOC5;4074;8;127;573;0;1;9;6;30;2;Active;NA;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A00.0Z;Parkinson disease, unspecified;1;Inactive;296066191/unspecified;NA
448;suvn-g3031;suvn-g3031;CHEMBL4297328;DB14835;60151477;1394808-82-2;NA;LNXDUSQEXVQFGP-UHFFFAOYSA-N;C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)NC(=O)CN4CCOCC4;3735;23;54;463;0;1;5;6;27;2;Active;NA;Small molecule;Inverse agonist;Q9Y5N1;hrh3_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7A20.Z;Narcolepsy, unspecified;2;Active;1201727099/unspecified;33550481, 32399853, 32351118
449;dotatate gallium ga-68;Edotreotide Gallium Ga-68;CHEMBL4297340;DB15494;71661158;"1027785-90-5;2101630-92-4";9L17Y0H71P,Y68179SY2L;PZBPHYLKIMOZPR-FIYGWYQWSA-K;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)NC(CO)C(C)O)O.[Ga+3];14865;;540;2600;0;14;25;23;100;4;Approved;2018;Protein;Binding agent;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;X4;Diagnosis radioactive;4;Approved;NA;29999885
449;dotatate gallium ga-68;dotatate gallium ga-68;CHEMBL4297340;DB13925;44400135;"1027785-90-5;2101630-92-4";9L17Y0H71P,Y68179SY2L;XBJPSVQFCQFGDC-UZOALHFESA-K;C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[Ga+3];15023;;557;2690;0;14;26;23;101;4;Approved;2018;Protein;Binding agent;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;X4;Diagnosis radioactive;4;Approved;NA;29999885
449;dotatate gallium ga-68;gatate;CHEMBL4297340;DB13925;131634491;"1027785-90-5;2101630-92-4";9L17Y0H71P,Y68179SY2L;XBJPSVQFCQFGDC-WSCOIBMGSA-K;C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[68Ga+3];15005;;557;2690;0;14;26;23;101;4;Approved;2018;Protein;Binding agent;P30872;ssr1_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;X4;Diagnosis radioactive;4;Approved;NA;29999885
449;dotatate gallium ga-68;Edotreotide Gallium Ga-68;CHEMBL4297340;DB15494;71661158;"1027785-90-5;2101630-92-4";9L17Y0H71P,Y68179SY2L;PZBPHYLKIMOZPR-FIYGWYQWSA-K;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)NC(CO)C(C)O)O.[Ga+3];14865;;540;2600;0;14;25;23;100;4;Approved;2018;Protein;Binding agent;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;X4;Diagnosis radioactive;4;Approved;NA;29999885
449;dotatate gallium ga-68;dotatate gallium ga-68;CHEMBL4297340;DB13925;44400135;"1027785-90-5;2101630-92-4";9L17Y0H71P,Y68179SY2L;XBJPSVQFCQFGDC-UZOALHFESA-K;C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[Ga+3];15023;;557;2690;0;14;26;23;101;4;Approved;2018;Protein;Binding agent;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;X4;Diagnosis radioactive;4;Approved;NA;29999885
449;dotatate gallium ga-68;gatate;CHEMBL4297340;DB13925;131634491;"1027785-90-5;2101630-92-4";9L17Y0H71P,Y68179SY2L;XBJPSVQFCQFGDC-WSCOIBMGSA-K;C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[68Ga+3];15005;;557;2690;0;14;26;23;101;4;Approved;2018;Protein;Binding agent;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;X4;Diagnosis radioactive;4;Approved;NA;29999885
449;dotatate gallium ga-68;Edotreotide Gallium Ga-68;CHEMBL4297340;DB15494;71661158;"1027785-90-5;2101630-92-4";9L17Y0H71P,Y68179SY2L;PZBPHYLKIMOZPR-FIYGWYQWSA-K;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)NC(CO)C(C)O)O.[Ga+3];14865;;540;2600;0;14;25;23;100;4;Approved;2018;Protein;Binding agent;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;X4;Diagnosis radioactive;4;Approved;NA;29999885
449;dotatate gallium ga-68;dotatate gallium ga-68;CHEMBL4297340;DB13925;44400135;"1027785-90-5;2101630-92-4";9L17Y0H71P,Y68179SY2L;XBJPSVQFCQFGDC-UZOALHFESA-K;C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[Ga+3];15023;;557;2690;0;14;26;23;101;4;Approved;2018;Protein;Binding agent;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;X4;Diagnosis radioactive;4;Approved;NA;29999885
449;dotatate gallium ga-68;gatate;CHEMBL4297340;DB13925;131634491;"1027785-90-5;2101630-92-4";9L17Y0H71P,Y68179SY2L;XBJPSVQFCQFGDC-WSCOIBMGSA-K;C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[68Ga+3];15005;;557;2690;0;14;26;23;101;4;Approved;2018;Protein;Binding agent;P32745;ssr3_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;X4;Diagnosis radioactive;4;Approved;NA;29999885
449;dotatate gallium ga-68;Edotreotide Gallium Ga-68;CHEMBL4297340;DB15494;71661158;"1027785-90-5;2101630-92-4";9L17Y0H71P,Y68179SY2L;PZBPHYLKIMOZPR-FIYGWYQWSA-K;CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)NC(CO)C(C)O)O.[Ga+3];14865;;540;2600;0;14;25;23;100;4;Approved;2018;Protein;Binding agent;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;X4;Diagnosis radioactive;4;Approved;NA;29999885
449;dotatate gallium ga-68;dotatate gallium ga-68;CHEMBL4297340;DB13925;44400135;"1027785-90-5;2101630-92-4";9L17Y0H71P,Y68179SY2L;XBJPSVQFCQFGDC-UZOALHFESA-K;C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[Ga+3];15023;;557;2690;0;14;26;23;101;4;Approved;2018;Protein;Binding agent;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;X4;Diagnosis radioactive;4;Approved;NA;29999885
449;dotatate gallium ga-68;gatate;CHEMBL4297340;DB13925;131634491;"1027785-90-5;2101630-92-4";9L17Y0H71P,Y68179SY2L;XBJPSVQFCQFGDC-WSCOIBMGSA-K;C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[68Ga+3];15005;;557;2690;0;14;26;23;101;4;Approved;2018;Protein;Binding agent;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;X4;Diagnosis radioactive;4;Approved;NA;29999885
452;sx-682;sx-682;CHEMBL4297480;NA;90467234;1648843-04-2;NA;SDUDZBCEHIZMFZ-UHFFFAOYSA-N;B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O;4672;;130;606;0;3;11;7;32;2;Active;NA;Small molecule;Inhibitor;P25024;cxcr1_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2A3Z;Myelodysplastic syndromes, unspecified;1;Active;1147802348/unspecified;31848188
452;sx-682;sx-682;CHEMBL4297480;NA;90467234;1648843-04-2;NA;SDUDZBCEHIZMFZ-UHFFFAOYSA-N;B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O;4672;;130;606;0;3;11;7;32;2;Active;NA;Small molecule;Inhibitor;P25024;cxcr1_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2B90.Y;Other specified malignant neoplasms of colon;2;Active;1265576634/other;31848188
452;sx-682;sx-682;CHEMBL4297480;NA;90467234;1648843-04-2;NA;SDUDZBCEHIZMFZ-UHFFFAOYSA-N;B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O;4672;;130;606;0;3;11;7;32;2;Active;NA;Small molecule;Inhibitor;P25024;cxcr1_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2B92.Z;Malignant neoplasms of rectum, unspecified;1;Active;1113099195/unspecified;31848188
452;sx-682;sx-682;CHEMBL4297480;NA;90467234;1648843-04-2;NA;SDUDZBCEHIZMFZ-UHFFFAOYSA-N;B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O;4672;;130;606;0;3;11;7;32;2;Active;NA;Small molecule;Inhibitor;P25024;cxcr1_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2C10.0;Adenocarcinoma of pancreas;2;Active;1663659989;31848188
452;sx-682;sx-682;CHEMBL4297480;NA;90467234;1648843-04-2;NA;SDUDZBCEHIZMFZ-UHFFFAOYSA-N;B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O;4672;;130;606;0;3;11;7;32;2;Active;NA;Small molecule;Inhibitor;P25024;cxcr1_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2C25.Y;Other specified malignant neoplasms of bronchus or lung;2;Active;316539081/other;31848188
452;sx-682;sx-682;CHEMBL4297480;NA;90467234;1648843-04-2;NA;SDUDZBCEHIZMFZ-UHFFFAOYSA-N;B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O;4672;;130;606;0;3;11;7;32;2;Active;NA;Small molecule;Inhibitor;P25024;cxcr1_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2C30.Z;Melanoma of skin, unspecified;1;Active;488336723/unspecified;31848188
452;sx-682;sx-682;CHEMBL4297480;NA;90467234;1648843-04-2;NA;SDUDZBCEHIZMFZ-UHFFFAOYSA-N;B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O;4672;;130;606;0;3;11;7;32;2;Active;NA;Small molecule;Inhibitor;P25025;cxcr2_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2A3Z;Myelodysplastic syndromes, unspecified;1;Active;1147802348/unspecified;31848188
452;sx-682;sx-682;CHEMBL4297480;NA;90467234;1648843-04-2;NA;SDUDZBCEHIZMFZ-UHFFFAOYSA-N;B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O;4672;;130;606;0;3;11;7;32;2;Active;NA;Small molecule;Inhibitor;P25025;cxcr2_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2B90.Y;Other specified malignant neoplasms of colon;2;Active;1265576634/other;31848188
452;sx-682;sx-682;CHEMBL4297480;NA;90467234;1648843-04-2;NA;SDUDZBCEHIZMFZ-UHFFFAOYSA-N;B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O;4672;;130;606;0;3;11;7;32;2;Active;NA;Small molecule;Inhibitor;P25025;cxcr2_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2B92.Z;Malignant neoplasms of rectum, unspecified;1;Active;1113099195/unspecified;31848188
452;sx-682;sx-682;CHEMBL4297480;NA;90467234;1648843-04-2;NA;SDUDZBCEHIZMFZ-UHFFFAOYSA-N;B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O;4672;;130;606;0;3;11;7;32;2;Active;NA;Small molecule;Inhibitor;P25025;cxcr2_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2C10.0;Adenocarcinoma of pancreas;2;Active;1663659989;31848188
452;sx-682;sx-682;CHEMBL4297480;NA;90467234;1648843-04-2;NA;SDUDZBCEHIZMFZ-UHFFFAOYSA-N;B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O;4672;;130;606;0;3;11;7;32;2;Active;NA;Small molecule;Inhibitor;P25025;cxcr2_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2C25.Y;Other specified malignant neoplasms of bronchus or lung;2;Active;316539081/other;31848188
452;sx-682;sx-682;CHEMBL4297480;NA;90467234;1648843-04-2;NA;SDUDZBCEHIZMFZ-UHFFFAOYSA-N;B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O;4672;;130;606;0;3;11;7;32;2;Active;NA;Small molecule;Inhibitor;P25025;cxcr2_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2C30.Z;Melanoma of skin, unspecified;1;Active;488336723/unspecified;31848188
453;cenerimod;cenerimod;CHEMBL4297505;DB12705;49871973;1262414-04-9;NA;KJKKMMMRWISKRF-FQEVSTJZSA-N;CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC(=C3)OC)C4CCCC4)C)OCC(CO)O;4535;42;111;592;0;2;8;9;33;3;Active;NA;Small molecule;Modulator;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;4A40.0Z;Systemic lupus erythematosus, unspecified;3;Active;749596428/unspecified;34839819, 30679645, 32917831
454;piromelatine;piromelatine;CHEMBL4297523;DB12288;24815904;946846-83-9;NA;PNTNBIHOAPJYDB-UHFFFAOYSA-N;COC1=CC2=C(C=C1)NC=C2CCNC(=O)C3=CC(=O)C=CO3;31232;17;804;529;0;2;4;5;23;2;Active;NA;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;7A0Z;Insomnia disorders, unspecified;2;Inactive;1038292737/unspecified;27007604, 29025979, 36142262
454;piromelatine;piromelatine;CHEMBL4297523;DB12288;24815904;946846-83-9;NA;PNTNBIHOAPJYDB-UHFFFAOYSA-N;COC1=CC2=C(C=C1)NC=C2CCNC(=O)C3=CC(=O)C=CO3;31232;17;804;529;0;2;4;5;23;2;Active;NA;Small molecule;Agonist;P48039;mtr1a_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;8A20;Alzheimer disease;2;Active;1611724421;27007604, 29025979, 36142262
454;piromelatine;piromelatine;CHEMBL4297523;DB12288;24815904;946846-83-9;NA;PNTNBIHOAPJYDB-UHFFFAOYSA-N;COC1=CC2=C(C=C1)NC=C2CCNC(=O)C3=CC(=O)C=CO3;31232;17;804;529;0;2;4;5;23;2;Active;NA;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;7A0Z;Insomnia disorders, unspecified;2;Inactive;1038292737/unspecified;27007604, 29025979, 36142262
454;piromelatine;piromelatine;CHEMBL4297523;DB12288;24815904;946846-83-9;NA;PNTNBIHOAPJYDB-UHFFFAOYSA-N;COC1=CC2=C(C=C1)NC=C2CCNC(=O)C3=CC(=O)C=CO3;31232;17;804;529;0;2;4;5;23;2;Active;NA;Small molecule;Agonist;P49286;mtr1b_human;Class A (Rhodopsin);Melatonin;Melatonin receptors;8A20;Alzheimer disease;2;Active;1611724421;27007604, 29025979, 36142262
455;efinopegdutide;efinopegdutide;CHEMBL4297576;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;1;Inactive;119724091;37355043
455;efinopegdutide;efinopegdutide;CHEMBL4297576;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;2;Inactive;149403041/unspecified;37355043
455;efinopegdutide;efinopegdutide;CHEMBL4297576;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Active;1884917970;37355043
455;efinopegdutide;efinopegdutide;CHEMBL4297576;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;1;Inactive;119724091;37355043
455;efinopegdutide;efinopegdutide;CHEMBL4297576;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;2;Inactive;149403041/unspecified;37355043
455;efinopegdutide;efinopegdutide;CHEMBL4297576;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Active;1884917970;37355043
456;selatogrel;S-selatogrel;CHEMBL4297589;DB15163;134817253;1159500-34-1;6DPK7O4PR7;FYXHWMQPCJOJCH-FYYLOGMGSA-N;CCCCOC(=O)N1CCN(CC1)C(=O)[C@@H](CP(=O)(O)O)NC(=O)C2=CC(=NC(=N2)C3=CC=CC=C3)N4CC[C@H](C4)OC;6186;6;175;986;0;3;11;12;43;3;Active;NA;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA41.Z;Acute myocardial infarction, unspecified;3;Active;1334938734/unspecified;34132688, 32396484, 32439009
456;selatogrel;S-selatogrel;CHEMBL4297589;DB15163;134817253;1159500-34-1;6DPK7O4PR7;FYXHWMQPCJOJCH-FYYLOGMGSA-N;CCCCOC(=O)N1CCN(CC1)C(=O)[C@@H](CP(=O)(O)O)NC(=O)C2=CC(=NC(=N2)C3=CC=CC=C3)N4CC[C@H](C4)OC;6186;6;175;986;0;3;11;12;43;3;Active;NA;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA8Z;Diseases of coronary artery, unspecified;2;Inactive;1059873720/unspecified;34132688, 32396484, 32439009
456;selatogrel;selatogrel;CHEMBL4297589;DB15163;59534142;1159500-34-1;6DPK7O4PR7;FYXHWMQPCJOJCH-GMAHTHKFSA-N;CCCCOC(=O)N1CCN(CC1)C(=O)[C@H](CP(=O)(O)O)NC(=O)C2=CC(=NC(=N2)C3=CC=CC=C3)N4CC[C@@H](C4)OC;6186;6;175;986;0;3;11;12;43;3;Active;NA;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA41.Z;Acute myocardial infarction, unspecified;3;Active;1334938734/unspecified;34132688, 32396484, 32439009
456;selatogrel;selatogrel;CHEMBL4297589;DB15163;59534142;1159500-34-1;6DPK7O4PR7;FYXHWMQPCJOJCH-GMAHTHKFSA-N;CCCCOC(=O)N1CCN(CC1)C(=O)[C@H](CP(=O)(O)O)NC(=O)C2=CC(=NC(=N2)C3=CC=CC=C3)N4CC[C@@H](C4)OC;6186;6;175;986;0;3;11;12;43;3;Active;NA;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BA8Z;Diseases of coronary artery, unspecified;2;Inactive;1059873720/unspecified;34132688, 32396484, 32439009
457;daridorexant;daridorexant;CHEMBL4297590;DB15031;91801202;1505484-82-1;LMQ24G57E9;NBGABHGMJVIVBW-QHCPKHFHSA-N;CC1=C(C=CC2=C1N=C(N2)C3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl;4509;41;889;693;0;1;5;4;32;4;Approved;2022;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;35298826, 36045942, 35065036
457;daridorexant;daridorexant;CHEMBL4297590;DB15031;91801202;1505484-82-1;LMQ24G57E9;NBGABHGMJVIVBW-QHCPKHFHSA-N;CC1=C(C=CC2=C1N=C(N2)C3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl;4509;41;889;693;0;1;5;4;32;4;Approved;2022;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;MD11.Y;Other specified abnormalities of breathing;1;Unknown;208980208/other;35298826, 36045942, 35065036
457;daridorexant;daridorexant;CHEMBL4297590;DB15031;91801202;1505484-82-1;LMQ24G57E9;NBGABHGMJVIVBW-QHCPKHFHSA-N;CC1=C(C=CC2=C1N=C(N2)C3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl;4509;41;889;693;0;1;5;4;32;4;Approved;2022;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;35298826, 36045942, 35065036
457;daridorexant;daridorexant;CHEMBL4297590;DB15031;91801202;1505484-82-1;LMQ24G57E9;NBGABHGMJVIVBW-QHCPKHFHSA-N;CC1=C(C=CC2=C1N=C(N2)C3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl;4509;41;889;693;0;1;5;4;32;4;Approved;2022;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;MD11.Y;Other specified abnormalities of breathing;1;Unknown;208980208/other;35298826, 36045942, 35065036
458;evocalcet;evocalcet;CHEMBL4297621;DB12388;71242808;870964-67-3;NA;RZNUIYPHQFXBAN-XLIONFOSSA-N;CC(C1=CC=CC2=CC=CC=C21)NC3CCN(C3)C4=CC=C(C=C4)CC(=O)O;3745;21;526;517;0;2;4;6;28;4;Approved;2018;Small molecule;PAM;P41180;casr_human;Class C (Glutamate);Calcium-sensing receptors;Ion receptors;5A51.1;Secondary hyperparathyroidism;4;Approved;1442752937;36512619, 32552012, 31486206
459;rovatirelin;rovatirelin;CHEMBL4297622;DB15338;9951059;204386-76-5;NA;WTXWDXWZGJGIHV-URBCHYCLSA-N;CC1CCCN1C(=O)C(CC2=CSC=N2)NC(=O)C3C(OC(=O)N3)C;3664;1;129;546;0;2;6;5;25;3;Active;NA;Small molecule;Agonist;P34981;trfr_human;Class A (Rhodopsin);Thyrotropin-releasing hormone receptors;Peptide receptors;8A03.16;Spinocerebellar ataxia;3;Inactive;600993818;32534077, 29300135, 31937586
460;omidenepag isopropyl;omidenepag isopropyl;CHEMBL4297666;DB15071;44230999;1187451-19-9;G0G0H52U6K;VIQCWEGEHRBLAC-UHFFFAOYSA-N;CC(C)OC(=O)CNC1=CC=CC(=N1)CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4;5206;3;128;814;0;1;9;12;37;4;Approved;2018;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C61.01;Ocular hypertension;4;Approved;535283437;36545781, 32533949, 30465134
460;omidenepag isopropyl;omidenepag isopropyl;CHEMBL4297666;DB15071;44230999;1187451-19-9;G0G0H52U6K;VIQCWEGEHRBLAC-UHFFFAOYSA-N;CC(C)OC(=O)CNC1=CC=CC(=N1)CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4;5206;3;128;814;0;1;9;12;37;4;Approved;2018;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;36545781, 32533949, 30465134
461;dasiglucagon;dasiglucagon;CHEMBL4297741;DB15226;126961379;1544300-84-6;AD4J2O47FQ;RZRMFQMNPDPAIX-AJTOSFMRSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)(C)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CNC=N7)N;33816;-159;1450;7900;0;52;55;110;240;4;Approved;2021;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A10;Type 1 diabetes mellitus;4;Approved;1651053999;33886176, 34047955, 33998648
461;dasiglucagon;dasiglucagon;CHEMBL4297741;DB15226;126961379;1544300-84-6;AD4J2O47FQ;RZRMFQMNPDPAIX-AJTOSFMRSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)(C)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CNC=N7)N;33816;-159;1450;7900;0;52;55;110;240;4;Approved;2021;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A41;Hypoglycaemia without associated diabetes;4;Approved;1004695600;33886176, 34047955, 33998648
461;dasiglucagon;dasiglucagon;CHEMBL4297741;DB15226;126961379;1544300-84-6;AD4J2O47FQ;RZRMFQMNPDPAIX-AJTOSFMRSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)(C)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CNC=N7)N;33816;-159;1450;7900;0;52;55;110;240;4;Approved;2021;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A4Y;Other specified disorders of glucose regulation or pancreatic internal secretion;3;Active;1283179793/other;33886176, 34047955, 33998648
461;dasiglucagon;dasiglucagon;CHEMBL4297741;DB15226;126961379;1544300-84-6;AD4J2O47FQ;RZRMFQMNPDPAIX-AJTOSFMRSA-N;CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)(C)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CNC=N7)N;33816;-159;1450;7900;0;52;55;110;240;4;Approved;2021;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A4Z;Disorders of glucose regulation or pancreatic internal secretion, unspecified;2;Inactive;1283179793/unspecified;33886176, 34047955, 33998648
463;tirzepatide;R-tirzepatide;CHEMBL4297839;DB15171;163285897;2023788-19-2;OYN3CCI6QE;BTSOGEDATSQOAF-SMAAHMJQSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N;4813;-68;1790;11700;0;58;70;163;341;4;Approved;2022;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;4;Approved;119724091;35658024, 34170647, 34186022
463;tirzepatide;R-tirzepatide;CHEMBL4297839;DB15171;163285897;2023788-19-2;OYN3CCI6QE;BTSOGEDATSQOAF-SMAAHMJQSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N;4813;-68;1790;11700;0;58;70;163;341;4;Approved;2022;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;35658024, 34170647, 34186022
463;tirzepatide;R-tirzepatide;CHEMBL4297839;DB15171;163285897;2023788-19-2;OYN3CCI6QE;BTSOGEDATSQOAF-SMAAHMJQSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N;4813;-68;1790;11700;0;58;70;163;341;4;Approved;2022;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Active;1884917970;35658024, 34170647, 34186022
463;tirzepatide;tirzepatide;CHEMBL4297839;DB15171;166639051;2023788-19-2;OYN3CCI6QE;BTSOGEDATSQOAF-YXJNEUIDSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N;4813;-68;1790;11700;0;58;70;163;341;4;Approved;2022;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;4;Approved;119724091;35658024, 34170647, 34186022
463;tirzepatide;tirzepatide;CHEMBL4297839;DB15171;166639051;2023788-19-2;OYN3CCI6QE;BTSOGEDATSQOAF-YXJNEUIDSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N;4813;-68;1790;11700;0;58;70;163;341;4;Approved;2022;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;35658024, 34170647, 34186022
463;tirzepatide;tirzepatide;CHEMBL4297839;DB15171;166639051;2023788-19-2;OYN3CCI6QE;BTSOGEDATSQOAF-YXJNEUIDSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N;4813;-68;1790;11700;0;58;70;163;341;4;Approved;2022;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Active;1884917970;35658024, 34170647, 34186022
463;tirzepatide;R-tirzepatide;CHEMBL4297839;DB15171;163285897;2023788-19-2;OYN3CCI6QE;BTSOGEDATSQOAF-SMAAHMJQSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N;4813;-68;1790;11700;0;58;70;163;341;4;Approved;2022;Protein;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;4;Approved;119724091;35658024, 34170647, 34186022
463;tirzepatide;R-tirzepatide;CHEMBL4297839;DB15171;163285897;2023788-19-2;OYN3CCI6QE;BTSOGEDATSQOAF-SMAAHMJQSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N;4813;-68;1790;11700;0;58;70;163;341;4;Approved;2022;Protein;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;35658024, 34170647, 34186022
463;tirzepatide;R-tirzepatide;CHEMBL4297839;DB15171;163285897;2023788-19-2;OYN3CCI6QE;BTSOGEDATSQOAF-SMAAHMJQSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N;4813;-68;1790;11700;0;58;70;163;341;4;Approved;2022;Protein;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Active;1884917970;35658024, 34170647, 34186022
463;tirzepatide;tirzepatide;CHEMBL4297839;DB15171;166639051;2023788-19-2;OYN3CCI6QE;BTSOGEDATSQOAF-YXJNEUIDSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N;4813;-68;1790;11700;0;58;70;163;341;4;Approved;2022;Protein;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;4;Approved;119724091;35658024, 34170647, 34186022
463;tirzepatide;tirzepatide;CHEMBL4297839;DB15171;166639051;2023788-19-2;OYN3CCI6QE;BTSOGEDATSQOAF-YXJNEUIDSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N;4813;-68;1790;11700;0;58;70;163;341;4;Approved;2022;Protein;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;4;Approved;149403041/unspecified;35658024, 34170647, 34186022
463;tirzepatide;tirzepatide;CHEMBL4297839;DB15171;166639051;2023788-19-2;OYN3CCI6QE;BTSOGEDATSQOAF-YXJNEUIDSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N;4813;-68;1790;11700;0;58;70;163;341;4;Approved;2022;Protein;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Active;1884917970;35658024, 34170647, 34186022
464;nomacopan;nomacopan;CHEMBL4297928;NA;;NA;NA;NA;NA;;;;;;;;;;3;Active;NA;Protein;Inhibitor;P21730;c5ar1_human;Class A (Rhodopsin);Complement peptide receptors;Peptide receptors;3B65;Thrombotic microangiopathy, not elsewhere classified;3;Active;757747508;35507334, 31840801
464;nomacopan;nomacopan;CHEMBL4297928;NA;;NA;NA;NA;NA;;;;;;;;;;3;Active;NA;Protein;Inhibitor;Q15722;lt4r1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;3B65;Thrombotic microangiopathy, not elsewhere classified;3;Active;757747508;35507334, 31840801
464;nomacopan;nomacopan;CHEMBL4297928;NA;;NA;NA;NA;NA;;;;;;;;;;3;Active;NA;Protein;Inhibitor;Q9NPC1;lt4r2_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;3B65;Thrombotic microangiopathy, not elsewhere classified;3;Active;757747508;35507334, 31840801
465;avexitide;S-avexitide;CHEMBL4297949;NA;16198321;NA;NA;WSEVKKHALHSUMB-MVNVRWBSSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)N;33698;-167;1420;8000;0;45;52;109;237;3;Active;NA;Protein;Antagonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;3;Active;119724091;33616643, 32250530
465;avexitide;S-avexitide;CHEMBL4297949;NA;16198321;NA;NA;WSEVKKHALHSUMB-MVNVRWBSSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)N;33698;-167;1420;8000;0;45;52;109;237;3;Active;NA;Protein;Antagonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A41;Hypoglycaemia without associated diabetes;2;Inactive;1004695600;33616643, 32250530
465;avexitide;S-avexitide;CHEMBL4297949;NA;16198321;NA;NA;WSEVKKHALHSUMB-MVNVRWBSSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)N;33698;-167;1420;8000;0;45;52;109;237;3;Active;NA;Protein;Antagonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A4Y;Other specified disorders of glucose regulation or pancreatic internal secretion;1;Inactive;1283179793/other;33616643, 32250530
465;avexitide;S-avexitide;CHEMBL4297949;NA;16198321;NA;NA;WSEVKKHALHSUMB-MVNVRWBSSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)N;33698;-167;1420;8000;0;45;52;109;237;3;Active;NA;Protein;Antagonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A4Z;Disorders of glucose regulation or pancreatic internal secretion, unspecified;2;Active;1283179793/unspecified;33616643, 32250530
465;avexitide;S-avexitide;CHEMBL4297949;NA;16198321;NA;NA;WSEVKKHALHSUMB-MVNVRWBSSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)N;33698;-167;1420;8000;0;45;52;109;237;3;Active;NA;Protein;Antagonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5C3Z;Nutritional disorders, unspecified;1;Inactive;1671987290/unspecified;33616643, 32250530
465;avexitide;exendin (9-39);CHEMBL4297949;NA;129012199;NA;NA;WSEVKKHALHSUMB-RYVRVIGHSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)N;33698;-167;1420;8000;0;45;52;109;237;3;Active;NA;Protein;Antagonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;3;Active;119724091;33616643, 32250530
465;avexitide;exendin (9-39);CHEMBL4297949;NA;129012199;NA;NA;WSEVKKHALHSUMB-RYVRVIGHSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)N;33698;-167;1420;8000;0;45;52;109;237;3;Active;NA;Protein;Antagonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A41;Hypoglycaemia without associated diabetes;2;Inactive;1004695600;33616643, 32250530
465;avexitide;exendin (9-39);CHEMBL4297949;NA;129012199;NA;NA;WSEVKKHALHSUMB-RYVRVIGHSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)N;33698;-167;1420;8000;0;45;52;109;237;3;Active;NA;Protein;Antagonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A4Y;Other specified disorders of glucose regulation or pancreatic internal secretion;1;Inactive;1283179793/other;33616643, 32250530
465;avexitide;exendin (9-39);CHEMBL4297949;NA;129012199;NA;NA;WSEVKKHALHSUMB-RYVRVIGHSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)N;33698;-167;1420;8000;0;45;52;109;237;3;Active;NA;Protein;Antagonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A4Z;Disorders of glucose regulation or pancreatic internal secretion, unspecified;2;Active;1283179793/unspecified;33616643, 32250530
465;avexitide;exendin (9-39);CHEMBL4297949;NA;129012199;NA;NA;WSEVKKHALHSUMB-RYVRVIGHSA-N;CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)N;33698;-167;1420;8000;0;45;52;109;237;3;Active;NA;Protein;Antagonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5C3Z;Nutritional disorders, unspecified;1;Inactive;1671987290/unspecified;33616643, 32250530
465;avexitide;avexitide;CHEMBL4297949;NA;91976991;NA;NA;WSEVKKHALHSUMB-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)N;33698;-167;1420;8000;0;45;52;109;237;3;Active;NA;Protein;Antagonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;3;Active;119724091;33616643, 32250530
465;avexitide;avexitide;CHEMBL4297949;NA;91976991;NA;NA;WSEVKKHALHSUMB-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)N;33698;-167;1420;8000;0;45;52;109;237;3;Active;NA;Protein;Antagonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A41;Hypoglycaemia without associated diabetes;2;Inactive;1004695600;33616643, 32250530
465;avexitide;avexitide;CHEMBL4297949;NA;91976991;NA;NA;WSEVKKHALHSUMB-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)N;33698;-167;1420;8000;0;45;52;109;237;3;Active;NA;Protein;Antagonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A4Y;Other specified disorders of glucose regulation or pancreatic internal secretion;1;Inactive;1283179793/other;33616643, 32250530
465;avexitide;avexitide;CHEMBL4297949;NA;91976991;NA;NA;WSEVKKHALHSUMB-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)N;33698;-167;1420;8000;0;45;52;109;237;3;Active;NA;Protein;Antagonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A4Z;Disorders of glucose regulation or pancreatic internal secretion, unspecified;2;Active;1283179793/unspecified;33616643, 32250530
465;avexitide;avexitide;CHEMBL4297949;NA;91976991;NA;NA;WSEVKKHALHSUMB-UHFFFAOYSA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)N;33698;-167;1420;8000;0;45;52;109;237;3;Active;NA;Protein;Antagonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5C3Z;Nutritional disorders, unspecified;1;Inactive;1671987290/unspecified;33616643, 32250530
466;nimacimab;nimacimab;CHEMBL4298095;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;DA41.00;Gastroparesis;2;Unknown;598423727;NA
466;nimacimab;nimacimab;CHEMBL4298095;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;DB92.1;Non-alcoholic steatohepatitis;1;Active;1884917970;NA
466;nimacimab;nimacimab;CHEMBL4298095;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;NAM;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;5B81.Z;Obesity, unspecified;2;Active;149403041/unspecified;NA
467;volagidemab;volagidemab;CHEMBL4298213;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Inhibitor;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A10;Type 1 diabetes mellitus;2;Active;1651053999;36192552, 36932248
467;volagidemab;volagidemab;CHEMBL4298213;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Inhibitor;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;1;Inactive;119724091;36192552, 36932248
467;volagidemab;volagidemab;CHEMBL4298213;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Inhibitor;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;MA18.0Z;Elevated blood glucose level, unspecified;1;Inactive;307705857/unspecified;36192552, 36932248
469;cinnarizine;cinnarizine;CHEMBL43064;DB00568;1547484;298-57-7;3DI2E1X18L;DERZBLKQOCDDDZ-JLHYYAGUSA-N;C1CN(CCN1CC=CC2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4;3685;58;65;429;0;0;2;6;28;4;Approved;1955;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30222287, 33911336, 26051684
470;namodenoson;namodenoson;CHEMBL431733;DB12885;3035850;163042-96-4;NA;IPSYPUKKXMNCNQ-PFHKOEEOSA-N;CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O;5447;19;134;623;0;4;8;5;30;3;Active;NA;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;1E51.1;Chronic hepatitis C;1;Inactive;1615937473;33430312, 38002266, 31638172
470;namodenoson;namodenoson;CHEMBL431733;DB12885;3035850;163042-96-4;NA;IPSYPUKKXMNCNQ-PFHKOEEOSA-N;CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O;5447;19;134;623;0;4;8;5;30;3;Active;NA;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2C12.02;Hepatocellular carcinoma of liver;3;Active;1294035808;33430312, 38002266, 31638172
470;namodenoson;namodenoson;CHEMBL431733;DB12885;3035850;163042-96-4;NA;IPSYPUKKXMNCNQ-PFHKOEEOSA-N;CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O;5447;19;134;623;0;4;8;5;30;3;Active;NA;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Active;1884917970;33430312, 38002266, 31638172
470;namodenoson;namodenoson;CHEMBL431733;DB12885;3035850;163042-96-4;NA;IPSYPUKKXMNCNQ-PFHKOEEOSA-N;CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O;5447;19;134;623;0;4;8;5;30;3;Active;NA;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DB92.Z;Non-alcoholic fatty liver disease, unspecified;2;Inactive;1912806631/unspecified;33430312, 38002266, 31638172
471;istradefylline;istradefylline;CHEMBL431770;DB11757;5311037;155270-99-8;2GZ0LIK7T4;IQVRBWUUXZMOPW-PKNBQFBNSA-N;CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)C=CC3=CC(=C(C=C3)OC)OC)C;3844;25;769;613;0;0;5;6;28;4;Approved;2013;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;34787989, 37029952, 25676023
471;istradefylline;istradefylline;CHEMBL431770;DB11757;5311037;155270-99-8;2GZ0LIK7T4;IQVRBWUUXZMOPW-PKNBQFBNSA-N;CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)C=CC3=CC(=C(C=C3)OC)OC)C;3844;25;769;613;0;0;5;6;28;4;Approved;2013;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;34787989, 37029952, 25676023
472;isoproterenol;isoproterenol;CHEMBL434;DB01064;3779;7683-59-2;L628TT009W;JWZZKOKVBUJMES-UHFFFAOYSA-N;CC(C)NCC(C1=CC(=C(C=C1)O)O)O;21126;-6;727;187;0;4;4;4;15;4;Approved;1956;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2E80.0Z;Lipoma, unspecified site;1;Inactive;1090000716/unspecified;30252298, 29665719, 33334451
472;isoproterenol;isoproterenol;CHEMBL434;DB01064;3779;7683-59-2;L628TT009W;JWZZKOKVBUJMES-UHFFFAOYSA-N;CC(C)NCC(C1=CC(=C(C=C1)O)O)O;21126;-6;727;187;0;4;4;4;15;4;Approved;1956;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;2;Inactive;171698302/unspecified;30252298, 29665719, 33334451
472;isoproterenol;isoproterenol;CHEMBL434;DB01064;3779;7683-59-2;L628TT009W;JWZZKOKVBUJMES-UHFFFAOYSA-N;CC(C)NCC(C1=CC(=C(C=C1)O)O)O;21126;-6;727;187;0;4;4;4;15;4;Approved;1956;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30252298, 29665719, 33334451
472;isoproterenol;isoproterenol;CHEMBL434;DB01064;3779;7683-59-2;L628TT009W;JWZZKOKVBUJMES-UHFFFAOYSA-N;CC(C)NCC(C1=CC(=C(C=C1)O)O)O;21126;-6;727;187;0;4;4;4;15;4;Approved;1956;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;30252298, 29665719, 33334451
472;isoproterenol;isoproterenol;CHEMBL434;DB01064;3779;7683-59-2;L628TT009W;JWZZKOKVBUJMES-UHFFFAOYSA-N;CC(C)NCC(C1=CC(=C(C=C1)O)O)O;21126;-6;727;187;0;4;4;4;15;4;Approved;1956;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.0Z;Calculus of kidney, unspecified;2;Unknown;389168514/unspecified;30252298, 29665719, 33334451
472;isoproterenol;isoproterenol;CHEMBL434;DB01064;3779;7683-59-2;L628TT009W;JWZZKOKVBUJMES-UHFFFAOYSA-N;CC(C)NCC(C1=CC(=C(C=C1)O)O)O;21126;-6;727;187;0;4;4;4;15;4;Approved;1956;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2E80.0Z;Lipoma, unspecified site;1;Inactive;1090000716/unspecified;30252298, 29665719, 33334451
472;isoproterenol;isoproterenol;CHEMBL434;DB01064;3779;7683-59-2;L628TT009W;JWZZKOKVBUJMES-UHFFFAOYSA-N;CC(C)NCC(C1=CC(=C(C=C1)O)O)O;21126;-6;727;187;0;4;4;4;15;4;Approved;1956;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;2;Inactive;171698302/unspecified;30252298, 29665719, 33334451
472;isoproterenol;isoproterenol;CHEMBL434;DB01064;3779;7683-59-2;L628TT009W;JWZZKOKVBUJMES-UHFFFAOYSA-N;CC(C)NCC(C1=CC(=C(C=C1)O)O)O;21126;-6;727;187;0;4;4;4;15;4;Approved;1956;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30252298, 29665719, 33334451
472;isoproterenol;isoproterenol;CHEMBL434;DB01064;3779;7683-59-2;L628TT009W;JWZZKOKVBUJMES-UHFFFAOYSA-N;CC(C)NCC(C1=CC(=C(C=C1)O)O)O;21126;-6;727;187;0;4;4;4;15;4;Approved;1956;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;30252298, 29665719, 33334451
472;isoproterenol;isoproterenol;CHEMBL434;DB01064;3779;7683-59-2;L628TT009W;JWZZKOKVBUJMES-UHFFFAOYSA-N;CC(C)NCC(C1=CC(=C(C=C1)O)O)O;21126;-6;727;187;0;4;4;4;15;4;Approved;1956;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.0Z;Calculus of kidney, unspecified;2;Unknown;389168514/unspecified;30252298, 29665719, 33334451
472;isoproterenol;isoproterenol;CHEMBL434;DB01064;3779;7683-59-2;L628TT009W;JWZZKOKVBUJMES-UHFFFAOYSA-N;CC(C)NCC(C1=CC(=C(C=C1)O)O)O;21126;-6;727;187;0;4;4;4;15;4;Approved;1956;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2E80.0Z;Lipoma, unspecified site;1;Inactive;1090000716/unspecified;30252298, 29665719, 33334451
472;isoproterenol;isoproterenol;CHEMBL434;DB01064;3779;7683-59-2;L628TT009W;JWZZKOKVBUJMES-UHFFFAOYSA-N;CC(C)NCC(C1=CC(=C(C=C1)O)O)O;21126;-6;727;187;0;4;4;4;15;4;Approved;1956;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;2;Inactive;171698302/unspecified;30252298, 29665719, 33334451
472;isoproterenol;isoproterenol;CHEMBL434;DB01064;3779;7683-59-2;L628TT009W;JWZZKOKVBUJMES-UHFFFAOYSA-N;CC(C)NCC(C1=CC(=C(C=C1)O)O)O;21126;-6;727;187;0;4;4;4;15;4;Approved;1956;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30252298, 29665719, 33334451
472;isoproterenol;isoproterenol;CHEMBL434;DB01064;3779;7683-59-2;L628TT009W;JWZZKOKVBUJMES-UHFFFAOYSA-N;CC(C)NCC(C1=CC(=C(C=C1)O)O)O;21126;-6;727;187;0;4;4;4;15;4;Approved;1956;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;30252298, 29665719, 33334451
472;isoproterenol;isoproterenol;CHEMBL434;DB01064;3779;7683-59-2;L628TT009W;JWZZKOKVBUJMES-UHFFFAOYSA-N;CC(C)NCC(C1=CC(=C(C=C1)O)O)O;21126;-6;727;187;0;4;4;4;15;4;Approved;1956;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.0Z;Calculus of kidney, unspecified;2;Unknown;389168514/unspecified;30252298, 29665719, 33334451
473;nebivolol;nebivolol;CHEMBL434394;DB04861;71301;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;31869063, 30000861, 31643706
473;nebivolol;nebivolol;CHEMBL434394;DB04861;71301;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31869063, 30000861, 31643706
473;nebivolol;nebivolol;CHEMBL434394;DB04861;71301;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;31869063, 30000861, 31643706
473;nebivolol;nebivolol;CHEMBL434394;DB04861;71301;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LD28.01;Marfan syndrome;3;Unknown;236564145;31869063, 30000861, 31643706
473;nebivolol;nebivolol;CHEMBL434394;DB04861;71301;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;3;Active;1730556128;31869063, 30000861, 31643706
473;nebivolol;dexnebivolol;CHEMBL3526436;DB04861;189562;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHBROIRLSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@@H](CNC[C@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;31869063, 30000861, 31643706
473;nebivolol;dexnebivolol;CHEMBL3526436;DB04861;189562;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHBROIRLSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@@H](CNC[C@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31869063, 30000861, 31643706
473;nebivolol;dexnebivolol;CHEMBL3526436;DB04861;189562;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHBROIRLSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@@H](CNC[C@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;31869063, 30000861, 31643706
473;nebivolol;dexnebivolol;CHEMBL3526436;DB04861;189562;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHBROIRLSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@@H](CNC[C@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LD28.01;Marfan syndrome;3;Unknown;236564145;31869063, 30000861, 31643706
473;nebivolol;dexnebivolol;CHEMBL3526436;DB04861;189562;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHBROIRLSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@@H](CNC[C@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;3;Active;1730556128;31869063, 30000861, 31643706
473;nebivolol;levonebivolol;CHEMBL2365658;DB04861;9844194;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHDSQAASSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@H](CNC[C@@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;31869063, 30000861, 31643706
473;nebivolol;levonebivolol;CHEMBL2365658;DB04861;9844194;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHDSQAASSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@H](CNC[C@@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31869063, 30000861, 31643706
473;nebivolol;levonebivolol;CHEMBL2365658;DB04861;9844194;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHDSQAASSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@H](CNC[C@@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;31869063, 30000861, 31643706
473;nebivolol;levonebivolol;CHEMBL2365658;DB04861;9844194;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHDSQAASSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@H](CNC[C@@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LD28.01;Marfan syndrome;3;Unknown;236564145;31869063, 30000861, 31643706
473;nebivolol;levonebivolol;CHEMBL2365658;DB04861;9844194;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHDSQAASSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@H](CNC[C@@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;3;Active;1730556128;31869063, 30000861, 31643706
473;nebivolol;nebivolol;CHEMBL434394;DB04861;71301;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;31869063, 30000861, 31643706
473;nebivolol;nebivolol;CHEMBL434394;DB04861;71301;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31869063, 30000861, 31643706
473;nebivolol;nebivolol;CHEMBL434394;DB04861;71301;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;31869063, 30000861, 31643706
473;nebivolol;nebivolol;CHEMBL434394;DB04861;71301;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LD28.01;Marfan syndrome;3;Unknown;236564145;31869063, 30000861, 31643706
473;nebivolol;nebivolol;CHEMBL434394;DB04861;71301;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-UHFFFAOYSA-N;C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;3;Active;1730556128;31869063, 30000861, 31643706
473;nebivolol;dexnebivolol;CHEMBL3526436;DB04861;189562;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHBROIRLSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@@H](CNC[C@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;31869063, 30000861, 31643706
473;nebivolol;dexnebivolol;CHEMBL3526436;DB04861;189562;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHBROIRLSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@@H](CNC[C@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31869063, 30000861, 31643706
473;nebivolol;dexnebivolol;CHEMBL3526436;DB04861;189562;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHBROIRLSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@@H](CNC[C@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;31869063, 30000861, 31643706
473;nebivolol;dexnebivolol;CHEMBL3526436;DB04861;189562;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHBROIRLSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@@H](CNC[C@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LD28.01;Marfan syndrome;3;Unknown;236564145;31869063, 30000861, 31643706
473;nebivolol;dexnebivolol;CHEMBL3526436;DB04861;189562;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHBROIRLSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@@H](CNC[C@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;3;Active;1730556128;31869063, 30000861, 31643706
473;nebivolol;levonebivolol;CHEMBL2365658;DB04861;9844194;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHDSQAASSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@H](CNC[C@@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;31869063, 30000861, 31643706
473;nebivolol;levonebivolol;CHEMBL2365658;DB04861;9844194;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHDSQAASSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@H](CNC[C@@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31869063, 30000861, 31643706
473;nebivolol;levonebivolol;CHEMBL2365658;DB04861;9844194;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHDSQAASSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@H](CNC[C@@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;31869063, 30000861, 31643706
473;nebivolol;levonebivolol;CHEMBL2365658;DB04861;9844194;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHDSQAASSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@H](CNC[C@@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LD28.01;Marfan syndrome;3;Unknown;236564145;31869063, 30000861, 31643706
473;nebivolol;levonebivolol;CHEMBL2365658;DB04861;9844194;118457-14-0;030Y90569U;KOHIRBRYDXPAMZ-YHDSQAASSA-N;C1CC2=C(C=CC(=C2)F)O[C@H]1[C@H](CNC[C@@H]([C@@H]3CCC4=C(O3)C=CC(=C4)F)O)O;4054;3;71;483;0;3;7;6;29;4;Approved;2007;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;3;Active;1730556128;31869063, 30000861, 31643706
474;vilazodone;vilazodone;CHEMBL439849;DB06684;6918314;163521-12-8;NA;SGEGOXDYSFKCPT-UHFFFAOYSA-N;C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N;4415;4;102;729;0;2;5;7;33;4;Approved;2011;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;30000853, 31643548, 27231672
474;vilazodone;vilazodone;CHEMBL439849;DB06684;6918314;163521-12-8;NA;SGEGOXDYSFKCPT-UHFFFAOYSA-N;C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N;4415;4;102;729;0;2;5;7;33;4;Approved;2011;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000853, 31643548, 27231672
474;vilazodone;vilazodone;CHEMBL439849;DB06684;6918314;163521-12-8;NA;SGEGOXDYSFKCPT-UHFFFAOYSA-N;C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N;4415;4;102;729;0;2;5;7;33;4;Approved;2011;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;3;Inactive;1712535455;30000853, 31643548, 27231672
474;vilazodone;vilazodone;CHEMBL439849;DB06684;6918314;163521-12-8;NA;SGEGOXDYSFKCPT-UHFFFAOYSA-N;C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N;4415;4;102;729;0;2;5;7;33;4;Approved;2011;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Active;2070699808;30000853, 31643548, 27231672
474;vilazodone;vilazodone;CHEMBL439849;DB06684;6918314;163521-12-8;NA;SGEGOXDYSFKCPT-UHFFFAOYSA-N;C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N;4415;4;102;729;0;2;5;7;33;4;Approved;2011;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;30000853, 31643548, 27231672
474;vilazodone;vilazodone;CHEMBL439849;DB06684;6918314;163521-12-8;NA;SGEGOXDYSFKCPT-UHFFFAOYSA-N;C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N;4415;4;102;729;0;2;5;7;33;4;Approved;2011;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;2;Inactive;1282135070/unspecified;30000853, 31643548, 27231672
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;3;Unknown;405565289/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;3;Unknown;405565289/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;3;Unknown;405565289/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;3;Unknown;405565289/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;3;Unknown;405565289/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;3;Unknown;405565289/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;3;Unknown;405565289/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;3;Unknown;405565289/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;3;Unknown;405565289/unspecified;32394297, 28750419, 29543144
475;pipamperone;pipamperone;CHEMBL440294;DB09286;4830;1893-33-0;5402501F0W;AXKPFOAXAHJUAG-UHFFFAOYSA-N;C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N;3755;2;666;506;0;1;5;7;27;4;Approved;1961;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;32394297, 28750419, 29543144
476;afamelanotide;afamelanotide;CHEMBL441738;DB04931;16197727;75921-69-6;QW68W3J66U;UAHFGYDRQSXQEB-LEBBXHLNSA-N;CCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CN=CN1)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)NC(CCCCN)C(=O)N5CCCC5C(=O)NC(C(C)C)C(=O)N)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CO)NC(=O)C;16468;-35;643;3360;0;23;22;51;118;4;Approved;2015;Protein;Agonist;Q01726;mshr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;5C58.12;Erythropoietic porphyrias;4;Approved;1074667008;33507118, 26979527, 33683075
476;afamelanotide;afamelanotide;CHEMBL441738;DB04931;16197727;75921-69-6;QW68W3J66U;UAHFGYDRQSXQEB-LEBBXHLNSA-N;CCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CN=CN1)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)NC(CCCCN)C(=O)N5CCCC5C(=O)NC(C(C)C)C(=O)N)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CO)NC(=O)C;16468;-35;643;3360;0;23;22;51;118;4;Approved;2015;Protein;Agonist;Q01726;mshr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;2;Active;1614716959/unspecified;33507118, 26979527, 33683075
476;afamelanotide;afamelanotide;CHEMBL441738;DB04931;16197727;75921-69-6;QW68W3J66U;UAHFGYDRQSXQEB-LEBBXHLNSA-N;CCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CN=CN1)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)NC(CCCCN)C(=O)N5CCCC5C(=O)NC(C(C)C)C(=O)N)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CO)NC(=O)C;16468;-35;643;3360;0;23;22;51;118;4;Approved;2015;Protein;Agonist;Q01726;mshr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;EB05;Urticaria of unspecified type;2;Inactive;993242399;33507118, 26979527, 33683075
476;afamelanotide;afamelanotide;CHEMBL441738;DB04931;16197727;75921-69-6;QW68W3J66U;UAHFGYDRQSXQEB-LEBBXHLNSA-N;CCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CN=CN1)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)NC(CCCCN)C(=O)N5CCCC5C(=O)NC(C(C)C)C(=O)N)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CO)NC(=O)C;16468;-35;643;3360;0;23;22;51;118;4;Approved;2015;Protein;Agonist;Q01726;mshr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;ED63.0;Vitiligo;2;Active;1894744640;33507118, 26979527, 33683075
476;afamelanotide;afamelanotide;CHEMBL441738;DB04931;16197727;75921-69-6;QW68W3J66U;UAHFGYDRQSXQEB-LEBBXHLNSA-N;CCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CN=CN1)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)NC(CCCCN)C(=O)N5CCCC5C(=O)NC(C(C)C)C(=O)N)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CO)NC(=O)C;16468;-35;643;3360;0;23;22;51;118;4;Approved;2015;Protein;Agonist;Q01726;mshr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;ED80.Z;Acne, unspecified;2;Inactive;1892393023/unspecified;33507118, 26979527, 33683075
476;afamelanotide;afamelanotide;CHEMBL441738;DB04931;16197727;75921-69-6;QW68W3J66U;UAHFGYDRQSXQEB-LEBBXHLNSA-N;CCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CN=CN1)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)NC(CCCCN)C(=O)N5CCCC5C(=O)NC(C(C)C)C(=O)N)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CO)NC(=O)C;16468;-35;643;3360;0;23;22;51;118;4;Approved;2015;Protein;Agonist;Q01726;mshr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;LD27.1;Xeroderma pigmentosum;2;Active;1243068849;33507118, 26979527, 33683075
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;R-ergotamine;CHEMBL1982133;DB00696;3251;113-15-5;PR834Q503T;XCGSFFUVFURLIX-UHFFFAOYSA-N;CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA21;Orthostatic hypotension;1;Inactive;56009591;30000392, 32310413, 34447915
477;ergotamine;ergotamine;CHEMBL442;DB00696;8223;113-15-5;PR834Q503T;XCGSFFUVFURLIX-VFGNJEKYSA-N;C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C;5817;2;118;1220;0;3;6;4;43;4;Approved;1948;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;4;Approved;1405405864;30000392, 32310413, 34447915
479;nortriptyline;nortriptyline;CHEMBL445;DB00540;4543;72-69-5;BL03SY4LXB;PHVGLTMQBUFIQQ-UHFFFAOYSA-N;CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2634;45;12;307;0;1;1;3;20;4;Approved;1964;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;2D4Y;Other specified malignant neoplasms of unspecified primary sites;1;Inactive;1594217552/other;30000235, 29489270, 31643844
479;nortriptyline;nortriptyline;CHEMBL445;DB00540;4543;72-69-5;BL03SY4LXB;PHVGLTMQBUFIQQ-UHFFFAOYSA-N;CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2634;45;12;307;0;1;1;3;20;4;Approved;1964;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;30000235, 29489270, 31643844
479;nortriptyline;nortriptyline;CHEMBL445;DB00540;4543;72-69-5;BL03SY4LXB;PHVGLTMQBUFIQQ-UHFFFAOYSA-N;CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2634;45;12;307;0;1;1;3;20;4;Approved;1964;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000235, 29489270, 31643844
479;nortriptyline;nortriptyline;CHEMBL445;DB00540;4543;72-69-5;BL03SY4LXB;PHVGLTMQBUFIQQ-UHFFFAOYSA-N;CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2634;45;12;307;0;1;1;3;20;4;Approved;1964;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;30000235, 29489270, 31643844
479;nortriptyline;nortriptyline;CHEMBL445;DB00540;4543;72-69-5;BL03SY4LXB;PHVGLTMQBUFIQQ-UHFFFAOYSA-N;CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2634;45;12;307;0;1;1;3;20;4;Approved;1964;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DA41.00;Gastroparesis;3;Inactive;598423727;30000235, 29489270, 31643844
479;nortriptyline;nortriptyline;CHEMBL445;DB00540;4543;72-69-5;BL03SY4LXB;PHVGLTMQBUFIQQ-UHFFFAOYSA-N;CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2634;45;12;307;0;1;1;3;20;4;Approved;1964;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;2;Unknown;1158238623/unspecified;30000235, 29489270, 31643844
479;nortriptyline;nortriptyline;CHEMBL445;DB00540;4543;72-69-5;BL03SY4LXB;PHVGLTMQBUFIQQ-UHFFFAOYSA-N;CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2634;45;12;307;0;1;1;3;20;4;Approved;1964;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Unknown;661232217/unspecified;30000235, 29489270, 31643844
480;danuglipron;danuglipron;CHEMBL4518483;NA;134611040;2230198-02-2;NA;HYBAKUMPISVZQP-DEOSSOPVSA-N;C1CN(CCC1C2=NC(=CC=C2)OCC3=C(C=C(C=C3)C#N)F)CC4=NC5=C(N4CC6CCO6)C=C(C=C5)C(=O)O;5556;14;114;941;0;1;9;9;41;1;Active;NA;Small molecule;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;1;Active;119724091;34127852, 37213102, 37311722
480;danuglipron;danuglipron;CHEMBL4518483;NA;134611040;2230198-02-2;NA;HYBAKUMPISVZQP-DEOSSOPVSA-N;C1CN(CCC1C2=NC(=CC=C2)OCC3=C(C=C(C=C3)C#N)F)CC4=NC5=C(N4CC6CCO6)C=C(C=C5)C(=O)O;5556;14;114;941;0;1;9;9;41;1;Active;NA;Small molecule;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;1;Active;149403041/unspecified;34127852, 37213102, 37311722
481;befiradol;befiradol;CHEMBL45305;NA;9865384;208110-64-9;NA;PKZXLMVXBZICTF-UHFFFAOYSA-N;CC1=CN=C(C=C1)CNCC2(CCN(CC2)C(=O)C3=CC(=C(C=C3)F)Cl)F;3939;32;452;502;0;1;5;5;27;2;Active;NA;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A02.10;Drug-induced dystonia;2;Unknown;678203506;25313880
482;fe 203799;fe 203799;CHEMBL4563522;NA;155559189;NA;NA;AVYLMJODKHVQHD-WFOXQDBGSA-N;CCCCC(C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)O)C(=O)NC(C(C)CC)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(=O)O)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)CC)C(=O)NC(CC(=O)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CCC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC6=CN=CN6)N;3765;-91;1540;8990;0;53;56;126;267;3;Active;NA;Protein;Agonist;O95838;glp2r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;4B24.Z;Graft-versus-host disease, unspecified;2;Active;437372167/unspecified;30614011
482;fe 203799;fe 203799;CHEMBL4563522;NA;155559189;NA;NA;AVYLMJODKHVQHD-WFOXQDBGSA-N;CCCCC(C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)O)C(=O)NC(C(C)CC)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(=O)O)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)CC)C(=O)NC(CC(=O)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CCC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC6=CN=CN6)N;3765;-91;1540;8990;0;53;56;126;267;3;Active;NA;Protein;Agonist;O95838;glp2r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DA96.04;Short bowel syndrome;3;Active;780637678;30614011
483;methyldopa;methyldopa;CHEMBL459;DB00968;38853;555-30-6;M4R0H12F6M;CJCSPKMFHVPWAR-JTQLQIEISA-N;CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N;21121;-19;104;246;0;4;5;3;15;4;Approved;1962;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A10;Type 1 diabetes mellitus;2;Unknown;1651053999;30000085, 31869135, 31643501
483;methyldopa;methyldopa;CHEMBL459;DB00968;38853;555-30-6;M4R0H12F6M;CJCSPKMFHVPWAR-JTQLQIEISA-N;CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N;21121;-19;104;246;0;4;5;3;15;4;Approved;1962;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000085, 31869135, 31643501
483;methyldopa;methyldopa;CHEMBL459;DB00968;38853;555-30-6;M4R0H12F6M;CJCSPKMFHVPWAR-JTQLQIEISA-N;CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N;21121;-19;104;246;0;4;5;3;15;4;Approved;1962;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA24.Z;Pre-eclampsia, unspecified;2;Inactive;229121159/unspecified;30000085, 31869135, 31643501
483;methyldopa;methyldopa;CHEMBL459;DB00968;38853;555-30-6;M4R0H12F6M;CJCSPKMFHVPWAR-JTQLQIEISA-N;CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N;21121;-19;104;246;0;4;5;3;15;4;Approved;1962;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A10;Type 1 diabetes mellitus;2;Unknown;1651053999;30000085, 31869135, 31643501
483;methyldopa;methyldopa;CHEMBL459;DB00968;38853;555-30-6;M4R0H12F6M;CJCSPKMFHVPWAR-JTQLQIEISA-N;CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N;21121;-19;104;246;0;4;5;3;15;4;Approved;1962;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000085, 31869135, 31643501
483;methyldopa;methyldopa;CHEMBL459;DB00968;38853;555-30-6;M4R0H12F6M;CJCSPKMFHVPWAR-JTQLQIEISA-N;CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N;21121;-19;104;246;0;4;5;3;15;4;Approved;1962;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA24.Z;Pre-eclampsia, unspecified;2;Inactive;229121159/unspecified;30000085, 31869135, 31643501
483;methyldopa;methyldopa;CHEMBL459;DB00968;38853;555-30-6;M4R0H12F6M;CJCSPKMFHVPWAR-JTQLQIEISA-N;CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N;21121;-19;104;246;0;4;5;3;15;4;Approved;1962;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A10;Type 1 diabetes mellitus;2;Unknown;1651053999;30000085, 31869135, 31643501
483;methyldopa;methyldopa;CHEMBL459;DB00968;38853;555-30-6;M4R0H12F6M;CJCSPKMFHVPWAR-JTQLQIEISA-N;CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N;21121;-19;104;246;0;4;5;3;15;4;Approved;1962;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000085, 31869135, 31643501
483;methyldopa;methyldopa;CHEMBL459;DB00968;38853;555-30-6;M4R0H12F6M;CJCSPKMFHVPWAR-JTQLQIEISA-N;CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N;21121;-19;104;246;0;4;5;3;15;4;Approved;1962;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA24.Z;Pre-eclampsia, unspecified;2;Inactive;229121159/unspecified;30000085, 31869135, 31643501
484;btrx-335140;btrx-335140;CHEMBL4592045;NA;137434175;2244614-14-8;NA;CQOJHAJWCDJEAT-UHFFFAOYSA-N;CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C;4536;47;763;630;0;1;8;5;33;3;Active;NA;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Active;1669279433;30707578
485;diacetylmorphine;diacetylmorphine;CHEMBL459324;DB01452;5462328;561-27-3;70D95007SX;GVGLGOZIDCSQPN-PVHGPHFFSA-N;CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C;3694;15;651;692;0;0;6;4;27;4;Approved;1964;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;4;Approved;1120716949/unspecified;34482044, 36382218, 27049826
486;calcitonin;calcitonin salmon;CHEMBL3989767;NA;16133812;NA;NA;BBBFJLBPOGFECG-VJVYQDLKSA-N;CC(C)CC1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CC(=O)N)CO)N)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC2=CNC=N2)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N4CCCC4C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)N)C(C)O)CO;34319;-166;1560;7970;0;52;55;99;239;4;Approved;1978;Protein;Agonist;P30988;calcr_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;5B91.0;Hypercalcaemia;4;Approved;885246206;7355664, 8156913, 5544230
486;calcitonin;calcitonin salmon;CHEMBL3989767;NA;16133812;NA;NA;BBBFJLBPOGFECG-VJVYQDLKSA-N;CC(C)CC1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CC(=O)N)CO)N)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC2=CNC=N2)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N4CCCC4C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)N)C(C)O)CO;34319;-166;1560;7970;0;52;55;99;239;4;Approved;1978;Protein;Agonist;P30988;calcr_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;FB83.11;Postmenopausal osteoporosis;4;Approved;123797893;7355664, 8156913, 5544230
486;calcitonin;calcitonin salmon;CHEMBL3989767;NA;16133812;NA;NA;BBBFJLBPOGFECG-VJVYQDLKSA-N;CC(C)CC1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CC(=O)N)CO)N)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC2=CNC=N2)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N4CCCC4C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)N)C(C)O)CO;34319;-166;1560;7970;0;52;55;99;239;4;Approved;1978;Protein;Agonist;P30988;calcr_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;FB85.Z;Paget disease of bone, unspecified;4;Approved;1653656681/unspecified;7355664, 8156913, 5544230
486;calcitonin;calcitonin human;CHEMBL4594248;NA;45055432;NA;NA;LDVRMNJZLWXJPL-JKQNMTHDSA-N;CCC(C)C(C(=O)NCC(=O)NC(C(C)C)C(=O)NCC(=O)NC(C)C(=O)N1CCCC1C(=O)N)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C(C)O)NC(=O)C(CC4=CNC=N4)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=C(C=C7)O)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(CCSC)NC(=O)C8CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N8)C(C)O)CO)CC(C)C)CC(=O)N)N;34179;-109;1440;8000;0;45;51;91;239;4;Approved;1978;Protein;Agonist;P30988;calcr_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;5B91.0;Hypercalcaemia;4;Approved;885246206;7355664, 8156913, 5544230
486;calcitonin;calcitonin human;CHEMBL4594248;NA;45055432;NA;NA;LDVRMNJZLWXJPL-JKQNMTHDSA-N;CCC(C)C(C(=O)NCC(=O)NC(C(C)C)C(=O)NCC(=O)NC(C)C(=O)N1CCCC1C(=O)N)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C(C)O)NC(=O)C(CC4=CNC=N4)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=C(C=C7)O)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(CCSC)NC(=O)C8CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N8)C(C)O)CO)CC(C)C)CC(=O)N)N;34179;-109;1440;8000;0;45;51;91;239;4;Approved;1978;Protein;Agonist;P30988;calcr_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;FB83.11;Postmenopausal osteoporosis;4;Approved;123797893;7355664, 8156913, 5544230
486;calcitonin;calcitonin human;CHEMBL4594248;NA;45055432;NA;NA;LDVRMNJZLWXJPL-JKQNMTHDSA-N;CCC(C)C(C(=O)NCC(=O)NC(C(C)C)C(=O)NCC(=O)NC(C)C(=O)N1CCCC1C(=O)N)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C(C)O)NC(=O)C(CC4=CNC=N4)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=C(C=C7)O)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(CCSC)NC(=O)C8CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N8)C(C)O)CO)CC(C)C)CC(=O)N)N;34179;-109;1440;8000;0;45;51;91;239;4;Approved;1978;Protein;Agonist;P30988;calcr_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;FB85.Z;Paget disease of bone, unspecified;4;Approved;1653656681/unspecified;7355664, 8156913, 5544230
488;paltusotine;paltusotine;CHEMBL4594359;NA;134168328;NA;NA;GHILNKWBALQPDP-UHFFFAOYSA-N;C1CN(CCC1N)C2=C3C=C(C=CC3=NC=C2C4=CC(=CC(=C4)F)F)C5=CC=CC(=C5O)C#N;4565;53;862;727;0;2;7;3;34;3;Active;NA;Small molecule;Agonist;P30874;ssr2_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;3;Active;825410563;36353760, 36582134, 36810324
492;mesdopetam;mesdopetam;CHEMBL4594447;NA;70980485;1403894-72-3;NA;OSBPYFBXSLJHCR-UHFFFAOYSA-N;CCCNCCOC1=CC(=CC(=C1)S(=O)(=O)C)F;27534;17;638;329;0;1;5;7;18;2;Active;NA;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A02.10;Drug-induced dystonia;2;Unknown;678203506;34018344, 38368170
493;avdoralimab;avdoralimab;CHEMBL4594463;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Inhibitor;P21730;c5ar1_human;Class A (Rhodopsin);Complement peptide receptors;Peptide receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;2;Inactive;1844086508/unspecified;36218354
493;avdoralimab;avdoralimab;CHEMBL4594463;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Inhibitor;P21730;c5ar1_human;Class A (Rhodopsin);Complement peptide receptors;Peptide receptors;EB41.0;Bullous pemphigoid;2;Active;233308710;36218354
494;talquetamab;talquetamab;CHEMBL4594503;NA;;NA;NA;NA;NA;;;;;;;;;;4;Approved;2023;Antibody;Antagonist;Q9NZD1;gpc5d_human;Class C (Glutamate);Class C Orphans;Orphan receptors;2A83.1;Plasma cell myeloma;4;Approved;526287100;36507686, 37792138, 33890981
495;molindone;molindone;CHEMBL460;DB01618;23897;7416-34-4;RT3Y3QMF8N;KLPWJLBORRMFGK-UHFFFAOYSA-N;CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C;27637;17;453;354;0;1;3;3;20;4;Approved;1974;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;3;Inactive;821852937/unspecified;30000095, 31643787, 2671060
495;molindone;molindone;CHEMBL460;DB01618;23897;7416-34-4;RT3Y3QMF8N;KLPWJLBORRMFGK-UHFFFAOYSA-N;CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C;27637;17;453;354;0;1;3;3;20;4;Approved;1974;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000095, 31643787, 2671060
495;molindone;molindone;CHEMBL460;DB01618;23897;7416-34-4;RT3Y3QMF8N;KLPWJLBORRMFGK-UHFFFAOYSA-N;CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C;27637;17;453;354;0;1;3;3;20;4;Approved;1974;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000095, 31643787, 2671060
495;molindone;molindone;CHEMBL460;DB01618;23897;7416-34-4;RT3Y3QMF8N;KLPWJLBORRMFGK-UHFFFAOYSA-N;CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C;27637;17;453;354;0;1;3;3;20;4;Approved;1974;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;3;Inactive;821852937/unspecified;30000095, 31643787, 2671060
495;molindone;molindone;CHEMBL460;DB01618;23897;7416-34-4;RT3Y3QMF8N;KLPWJLBORRMFGK-UHFFFAOYSA-N;CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C;27637;17;453;354;0;1;3;3;20;4;Approved;1974;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000095, 31643787, 2671060
495;molindone;molindone;CHEMBL460;DB01618;23897;7416-34-4;RT3Y3QMF8N;KLPWJLBORRMFGK-UHFFFAOYSA-N;CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C;27637;17;453;354;0;1;3;3;20;4;Approved;1974;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000095, 31643787, 2671060
496;pitolisant;pitolisant;CHEMBL462605;DB11642;9948102;362665-56-3;4BC83L4PIY;NNACHAUCXXVJSP-UHFFFAOYSA-N;C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl;2958;43;125;235;0;0;2;8;20;4;Approved;2016;Small molecule;Inverse agonist;Q9Y5N1;hrh3_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;2;Inactive;1683919430/unspecified;36701509, 34516055, 24107292
496;pitolisant;pitolisant;CHEMBL462605;DB11642;9948102;362665-56-3;4BC83L4PIY;NNACHAUCXXVJSP-UHFFFAOYSA-N;C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl;2958;43;125;235;0;0;2;8;20;4;Approved;2016;Small molecule;Inverse agonist;Q9Y5N1;hrh3_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Unknown;1580466198/unspecified;36701509, 34516055, 24107292
496;pitolisant;pitolisant;CHEMBL462605;DB11642;9948102;362665-56-3;4BC83L4PIY;NNACHAUCXXVJSP-UHFFFAOYSA-N;C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl;2958;43;125;235;0;0;2;8;20;4;Approved;2016;Small molecule;Inverse agonist;Q9Y5N1;hrh3_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7A20.0;Narcolepsy, Type 1;4;Approved;1851015159;36701509, 34516055, 24107292
496;pitolisant;pitolisant;CHEMBL462605;DB11642;9948102;362665-56-3;4BC83L4PIY;NNACHAUCXXVJSP-UHFFFAOYSA-N;C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl;2958;43;125;235;0;0;2;8;20;4;Approved;2016;Small molecule;Inverse agonist;Q9Y5N1;hrh3_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7A20.Z;Narcolepsy, unspecified;4;Approved;1201727099/unspecified;36701509, 34516055, 24107292
496;pitolisant;pitolisant;CHEMBL462605;DB11642;9948102;362665-56-3;4BC83L4PIY;NNACHAUCXXVJSP-UHFFFAOYSA-N;C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl;2958;43;125;235;0;0;2;8;20;4;Approved;2016;Small molecule;Inverse agonist;Q9Y5N1;hrh3_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7A21;Idiopathic hypersomnia;4;Approved;631826564;36701509, 34516055, 24107292
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;1C62.Z;Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified;2;Active;1508081745/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;3A51.1;Sickle cell disease without crisis;1;Inactive;1711513381;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;5A11;Type 2 diabetes mellitus;1;Active;119724091;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6A20.Z;Schizophrenia, episode unspecified;1;Inactive;1683919430/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6A60.Z;Bipolar type I disorder, unspecified;1;Active;1456478153/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6B25.0;Trichotillomania;2;Inactive;1253999657;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6B40;Post traumatic stress disorder;2;Inactive;2070699808;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6B80.Z;Anorexia Nervosa, unspecified;3;Inactive;263852475/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C40.2Z;Alcohol dependence, unspecified;2;Inactive;1580466198/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C41.2Z;Cannabis dependence, unspecified;2;Active;1129015467/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C43.2Z;Opioid dependence, unspecified;2;Inactive;1120716949/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;7A41;Obstructive sleep apnoea;2;Inactive;1919233290;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A04.1;Essential tremor or related tremors;1;Inactive;1036027657;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A05.00;Tourette syndrome;2;Active;119340957;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A80.0;Migraine without aura;2;Inactive;2048783472;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A80.1Z;Migraine with aura, unspecified;2;Inactive;525744634/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8B60.0;Amyotrophic lateral sclerosis;2;Inactive;1982355687;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8E43.0Z;Neuropathic pain, unspecified;2;Active;1339785363/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;2;Inactive;1158238623/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;FA0Z;Osteoarthritis, unspecified;3;Active;558562409/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;FA21.Z;Psoriatic arthritis, unspecified;2;Active;868183264/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;FA71;Torticollis;2;Unknown;872242568;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MB47.3;Cramp or spasm;1;Unknown;157838476;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MD90.0;Nausea;4;Approved;596805318;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MG30.Z;Chronic pain, unspecified;2;Active;1581976053/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MG3Z;Pain, unspecified;2;Active;661232217/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P21554;cnr1_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MG43.7;Anorexia;4;Approved;2137507044;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;1C62.Z;Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified;2;Active;1508081745/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;3A51.1;Sickle cell disease without crisis;1;Inactive;1711513381;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;5A11;Type 2 diabetes mellitus;1;Active;119724091;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6A20.Z;Schizophrenia, episode unspecified;1;Inactive;1683919430/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6A60.Z;Bipolar type I disorder, unspecified;1;Active;1456478153/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6B25.0;Trichotillomania;2;Inactive;1253999657;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6B40;Post traumatic stress disorder;2;Inactive;2070699808;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6B80.Z;Anorexia Nervosa, unspecified;3;Inactive;263852475/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C40.2Z;Alcohol dependence, unspecified;2;Inactive;1580466198/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C41.2Z;Cannabis dependence, unspecified;2;Active;1129015467/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;6C43.2Z;Opioid dependence, unspecified;2;Inactive;1120716949/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;7A41;Obstructive sleep apnoea;2;Inactive;1919233290;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A04.1;Essential tremor or related tremors;1;Inactive;1036027657;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A05.00;Tourette syndrome;2;Active;119340957;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A80.0;Migraine without aura;2;Inactive;2048783472;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8A80.1Z;Migraine with aura, unspecified;2;Inactive;525744634/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8B60.0;Amyotrophic lateral sclerosis;2;Inactive;1982355687;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8E43.0Z;Neuropathic pain, unspecified;2;Active;1339785363/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;2;Inactive;1158238623/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;FA0Z;Osteoarthritis, unspecified;3;Active;558562409/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;FA21.Z;Psoriatic arthritis, unspecified;2;Active;868183264/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;FA71;Torticollis;2;Unknown;872242568;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MB47.3;Cramp or spasm;1;Unknown;157838476;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MD90.0;Nausea;4;Approved;596805318;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MG30.Z;Chronic pain, unspecified;2;Active;1581976053/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MG3Z;Pain, unspecified;2;Active;661232217/unspecified;30000656, 32491463, 31644137
497;dronabinol;dronabinol;CHEMBL465;DB00470;16078;1972-08-3;7J8897W37S;CYQFCXCEBYINGO-IAGOWNOFSA-N;CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O;3145;7;295;439;0;1;2;4;23;4;Approved;1985;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;MG43.7;Anorexia;4;Approved;2137507044;30000656, 32491463, 31644137
499;ulotaront;ulotaront;CHEMBL4650337;DB15665;89532783;1310426-33-5;3K6270MG59;ABDDQTDRAHXHOC-QMMMGPOBSA-N;CNCC1C2=C(CCO1)C=CS2;18327;9;495;154;0;1;3;2;12;3;Active;NA;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;3;Active;1683919430/unspecified;36533396, 37165101, 35047111
499;ulotaront;ulotaront;CHEMBL4650337;DB15665;89532783;1310426-33-5;3K6270MG59;ABDDQTDRAHXHOC-QMMMGPOBSA-N;CNCC1C2=C(CCO1)C=CS2;18327;9;495;154;0;1;3;2;12;3;Active;NA;Small molecule;Agonist;Q96RJ0;taar1_human;Class A (Rhodopsin);Trace amine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;3;Active;1683919430/unspecified;36533396, 37165101, 35047111
501;nly-01;nly-01;CHEMBL4650495;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;2;Inactive;119724091;NA
501;nly-01;nly-01;CHEMBL4650495;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;8A00.0Z;Parkinson disease, unspecified;2;Active;296066191/unspecified;NA
502;orn-0829 hydrate;orn-0829 hydrate;CHEMBL4650522;NA;154572855;NA;NA;VFOCOQRYYZPTLV-RUCMDRKWSA-N;CC1=CC(=C(C=C1)N2N=CC=N2)C(=O)N3CCCOC3CN4C=CC(=N4)C5=NC=C(C=C5)F.CC1=CC(=C(C=C1)N2N=CC=N2)C(=O)N3CCCOC3CN4C=CC(=N4)C5=NC=C(C=C5)F.CC1=CC(=C(C=C1)N2N=CC=N2)C(=O)N3CCCOC3CN4C=CC(=N4)C5=NC=C(C=C5)F.CC1=CC(=C(C=C1)N2N=CC=N2)C(=O)N3CCCOC3CN4C=CC(=N4)C5=NC=C(C=C5)F.O;18079;;365;667;0;1;29;20;133;3;Active;NA;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A0Z;Insomnia disorders, unspecified;3;Active;1038292737/unspecified;30000364, 31643698, 19499092
502;orn-0829 hydrate;orn-0829 hydrate;CHEMBL4650522;NA;154572855;NA;NA;VFOCOQRYYZPTLV-RUCMDRKWSA-N;CC1=CC(=C(C=C1)N2N=CC=N2)C(=O)N3CCCOC3CN4C=CC(=N4)C5=NC=C(C=C5)F.CC1=CC(=C(C=C1)N2N=CC=N2)C(=O)N3CCCOC3CN4C=CC(=N4)C5=NC=C(C=C5)F.CC1=CC(=C(C=C1)N2N=CC=N2)C(=O)N3CCCOC3CN4C=CC(=N4)C5=NC=C(C=C5)F.CC1=CC(=C(C=C1)N2N=CC=N2)C(=O)N3CCCOC3CN4C=CC(=N4)C5=NC=C(C=C5)F.O;18079;;365;667;0;1;29;20;133;3;Active;NA;Small molecule;Antagonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A0Z;Insomnia disorders, unspecified;3;Active;1038292737/unspecified;30000364, 31643698, 19499092
503;fluspirilene;fluspirilene;CHEMBL46516;DB04842;3396;1841-19-6;C5QA4GLR9M;QOYHHIBFXOOADH-UHFFFAOYSA-N;C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4756;56;356;653;0;1;5;7;35;4;Approved;1970;Small molecule;Inhibitor;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;17253464, 10796446, 25377899
503;fluspirilene;fluspirilene;CHEMBL46516;DB04842;3396;1841-19-6;C5QA4GLR9M;QOYHHIBFXOOADH-UHFFFAOYSA-N;C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F;4756;56;356;653;0;1;5;7;35;4;Approved;1970;Small molecule;Inhibitor;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;17253464, 10796446, 25377899
504;ketobemidone;ketobemidone;CHEMBL47072;DB06738;10101;469-79-4;PQS1L514CF;ALFGKMXHOUSVAD-UHFFFAOYSA-N;CCC(=O)C1(CCN(CC1)C)C2=CC(=CC=C2)O;24733;1;405;295;0;1;3;3;18;4;Approved;1947;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;22834454, 27731593, 20098777
504;ketobemidone;ketobemidone;CHEMBL47072;DB06738;10101;469-79-4;PQS1L514CF;ALFGKMXHOUSVAD-UHFFFAOYSA-N;CCC(=O)C1(CCN(CC1)C)C2=CC(=CC=C2)O;24733;1;405;295;0;1;3;3;18;4;Approved;1947;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;22834454, 27731593, 20098777
504;ketobemidone;ketobemidone;CHEMBL47072;DB06738;10101;469-79-4;PQS1L514CF;ALFGKMXHOUSVAD-UHFFFAOYSA-N;CCC(=O)C1(CCN(CC1)C)C2=CC(=CC=C2)O;24733;1;405;295;0;1;3;3;18;4;Approved;1947;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;22834454, 27731593, 20098777
505;sotalol;sotalol;CHEMBL471;DB00489;5253;3930-20-9;A6D97U294I;ZBMZVLHSJCTVON-UHFFFAOYSA-N;CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O;27237;2;868;330;0;3;5;6;18;4;Approved;1992;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC7Y;Other specified ventricular rhythm disturbance;4;Approved;1694741164/other;30000224, 30521253, 27261833
505;sotalol;sotalol;CHEMBL471;DB00489;5253;3930-20-9;A6D97U294I;ZBMZVLHSJCTVON-UHFFFAOYSA-N;CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O;27237;2;868;330;0;3;5;6;18;4;Approved;1992;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30000224, 30521253, 27261833
505;sotalol;sotalol;CHEMBL471;DB00489;5253;3930-20-9;A6D97U294I;ZBMZVLHSJCTVON-UHFFFAOYSA-N;CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O;27237;2;868;330;0;3;5;6;18;4;Approved;1992;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC7Y;Other specified ventricular rhythm disturbance;4;Approved;1694741164/other;30000224, 30521253, 27261833
505;sotalol;sotalol;CHEMBL471;DB00489;5253;3930-20-9;A6D97U294I;ZBMZVLHSJCTVON-UHFFFAOYSA-N;CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O;27237;2;868;330;0;3;5;6;18;4;Approved;1992;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30000224, 30521253, 27261833
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2A00.00;Glioblastoma of brain;2;Active;650534447;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2A00.10;Medulloblastoma of brain;2;Active;290815825;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2A01.0Z;Meningiomas, unspecified;2;Active;672106711/unspecified;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2A0Z;Other and unspecified neoplasms of brain or central nervous system;2;Inactive;879154182/unspecified;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2A20.2;Primary myelofibrosis;1;Inactive;336704235;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2A60.3Z;Acute myeloid leukaemia, unspecified;2;Active;1611980611/unspecified;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2A83.1;Plasma cell myeloma;1;Inactive;526287100;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2B50.Z;Chondrosarcoma of bone or articular cartilage of unspecified sites;2;Active;1625755389/unspecified;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C10.0;Adenocarcinoma of pancreas;2;Unknown;1663659989;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C10.Y;Other specified malignant neoplasms of pancreas;2;Inactive;542147910/other;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C25.1;Small cell carcinoma of bronchus or lung;2;Inactive;1800431439;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C32.Z;Basal cell carcinoma of skin, unspecified;4;Approved;1203447657/unspecified;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C6Y;Other specified malignant neoplasms of breast;2;Inactive;1047754165/other;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Unknown;1047754165/unspecified;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C73.Z;Malignant neoplasms of ovary, unspecified;2;Inactive;685124533/unspecified;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C82.0;Adenocarcinoma of prostate;1;Inactive;1510677183;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;1;Inactive;1552457716/unspecified;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2D4Z;Unspecified malignant neoplasms of unspecified sites;4;Approved;1594217552/unspecified;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2F90.Y;Neoplasms of unknown behaviour of oral cavity or digestive organs, other specified site;2;Inactive;1103514372/other;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;4;Approved;1844086508/unspecified;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;CB03.4;Idiopathic pulmonary fibrosis;2;Inactive;1074069640;29999931, 30069764, 30020732
506;vismodegib;vismodegib;CHEMBL473417;DB08828;24776445;879085-55-9;25X868M3DS;BPQMGSKTAYIVFO-UHFFFAOYSA-N;CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;4213;38;845;625;0;1;4;4;27;4;Approved;2012;Small molecule;Inhibitor;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;LD2D.4;Gorlin syndrome;2;Inactive;1012745138;29999931, 30069764, 30020732
507;etrumadenant;etrumadenant;CHEMBL4740383;NA;135242184;2239273-34-6;NA;BUXIAWLTBSXYSW-UHFFFAOYSA-N;CC1=C(C=CC=C1C2=CC(=NC(=N2)N)C3=CN(N=N3)CC4=NC(=CC=C4)C(C)(C)O)C#N;4265;14;139;680;0;2;8;5;32;2;Active;NA;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B91.Z;Malignant neoplasms of rectosigmoid junction, unspecified;1;Active;774170412/unspecified;36266575, 37264098
507;etrumadenant;etrumadenant;CHEMBL4740383;NA;135242184;2239273-34-6;NA;BUXIAWLTBSXYSW-UHFFFAOYSA-N;CC1=C(C=CC=C1C2=CC(=NC(=N2)N)C3=CN(N=N3)CC4=NC(=CC=C4)C(C)(C)O)C#N;4265;14;139;680;0;2;8;5;32;2;Active;NA;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B92.Z;Malignant neoplasms of rectum, unspecified;2;Active;1113099195/unspecified;36266575, 37264098
507;etrumadenant;etrumadenant;CHEMBL4740383;NA;135242184;2239273-34-6;NA;BUXIAWLTBSXYSW-UHFFFAOYSA-N;CC1=C(C=CC=C1C2=CC(=NC(=N2)N)C3=CN(N=N3)CC4=NC(=CC=C4)C(C)(C)O)C#N;4265;14;139;680;0;2;8;5;32;2;Active;NA;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2C25.Y;Other specified malignant neoplasms of bronchus or lung;2;Active;316539081/other;36266575, 37264098
507;etrumadenant;etrumadenant;CHEMBL4740383;NA;135242184;2239273-34-6;NA;BUXIAWLTBSXYSW-UHFFFAOYSA-N;CC1=C(C=CC=C1C2=CC(=NC(=N2)N)C3=CN(N=N3)CC4=NC(=CC=C4)C(C)(C)O)C#N;4265;14;139;680;0;2;8;5;32;2;Active;NA;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2C82.0;Adenocarcinoma of prostate;2;Active;1510677183;36266575, 37264098
507;etrumadenant;etrumadenant;CHEMBL4740383;NA;135242184;2239273-34-6;NA;BUXIAWLTBSXYSW-UHFFFAOYSA-N;CC1=C(C=CC=C1C2=CC(=NC(=N2)N)C3=CN(N=N3)CC4=NC(=CC=C4)C(C)(C)O)C#N;4265;14;139;680;0;2;8;5;32;2;Active;NA;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Active;1552457716/unspecified;36266575, 37264098
507;etrumadenant;etrumadenant;CHEMBL4740383;NA;135242184;2239273-34-6;NA;BUXIAWLTBSXYSW-UHFFFAOYSA-N;CC1=C(C=CC=C1C2=CC(=NC(=N2)N)C3=CN(N=N3)CC4=NC(=CC=C4)C(C)(C)O)C#N;4265;14;139;680;0;2;8;5;32;2;Active;NA;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B91.Z;Malignant neoplasms of rectosigmoid junction, unspecified;1;Active;774170412/unspecified;36266575, 37264098
507;etrumadenant;etrumadenant;CHEMBL4740383;NA;135242184;2239273-34-6;NA;BUXIAWLTBSXYSW-UHFFFAOYSA-N;CC1=C(C=CC=C1C2=CC(=NC(=N2)N)C3=CN(N=N3)CC4=NC(=CC=C4)C(C)(C)O)C#N;4265;14;139;680;0;2;8;5;32;2;Active;NA;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B92.Z;Malignant neoplasms of rectum, unspecified;2;Active;1113099195/unspecified;36266575, 37264098
507;etrumadenant;etrumadenant;CHEMBL4740383;NA;135242184;2239273-34-6;NA;BUXIAWLTBSXYSW-UHFFFAOYSA-N;CC1=C(C=CC=C1C2=CC(=NC(=N2)N)C3=CN(N=N3)CC4=NC(=CC=C4)C(C)(C)O)C#N;4265;14;139;680;0;2;8;5;32;2;Active;NA;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2C25.Y;Other specified malignant neoplasms of bronchus or lung;2;Active;316539081/other;36266575, 37264098
507;etrumadenant;etrumadenant;CHEMBL4740383;NA;135242184;2239273-34-6;NA;BUXIAWLTBSXYSW-UHFFFAOYSA-N;CC1=C(C=CC=C1C2=CC(=NC(=N2)N)C3=CN(N=N3)CC4=NC(=CC=C4)C(C)(C)O)C#N;4265;14;139;680;0;2;8;5;32;2;Active;NA;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2C82.0;Adenocarcinoma of prostate;2;Active;1510677183;36266575, 37264098
507;etrumadenant;etrumadenant;CHEMBL4740383;NA;135242184;2239273-34-6;NA;BUXIAWLTBSXYSW-UHFFFAOYSA-N;CC1=C(C=CC=C1C2=CC(=NC(=N2)N)C3=CN(N=N3)CC4=NC(=CC=C4)C(C)(C)O)C#N;4265;14;139;680;0;2;8;5;32;2;Active;NA;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Active;1552457716/unspecified;36266575, 37264098
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2A82.00;Chronic lymphocytic leukaemia of B-cell type;1;Inactive;1726842351;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA40.Z;Angina pectoris, unspecified;3;Inactive;718946808/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA41.0;Acute ST elevation myocardial infarction;2;Inactive;391388807;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA41.Z;Acute myocardial infarction, unspecified;3;Inactive;1334938734/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA8Z;Diseases of coronary artery, unspecified;3;Inactive;1059873720/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BC43.5;Stress-induced cardiomyopathy;2;Active;478139552;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BC43.Z;Cardiomyopathy, unspecified;2;Unknown;282225286/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BC81.4;Wolff-Parkinson-White syndrome;4;Approved;1091030330;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BD40.Y;Other specified atherosclerotic chronic arterial occlusive disease;3;Inactive;109367356/other;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CB00;Acute respiratory distress syndrome;2;Active;1189702844;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MC81.3;Paroxysmal tachycardia;4;Approved;1926915195;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P0DMS8;aa3r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NE8Z;Injury or harm arising from surgical or medical care, not elsewhere classified, unspecified;3;Unknown;383104340/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2A82.00;Chronic lymphocytic leukaemia of B-cell type;1;Inactive;1726842351;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA40.Z;Angina pectoris, unspecified;3;Inactive;718946808/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA41.0;Acute ST elevation myocardial infarction;2;Inactive;391388807;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA41.Z;Acute myocardial infarction, unspecified;3;Inactive;1334938734/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA8Z;Diseases of coronary artery, unspecified;3;Inactive;1059873720/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BC43.5;Stress-induced cardiomyopathy;2;Active;478139552;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BC43.Z;Cardiomyopathy, unspecified;2;Unknown;282225286/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BC81.4;Wolff-Parkinson-White syndrome;4;Approved;1091030330;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BD40.Y;Other specified atherosclerotic chronic arterial occlusive disease;3;Inactive;109367356/other;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CB00;Acute respiratory distress syndrome;2;Active;1189702844;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MC81.3;Paroxysmal tachycardia;4;Approved;1926915195;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NE8Z;Injury or harm arising from surgical or medical care, not elsewhere classified, unspecified;3;Unknown;383104340/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2A82.00;Chronic lymphocytic leukaemia of B-cell type;1;Inactive;1726842351;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA40.Z;Angina pectoris, unspecified;3;Inactive;718946808/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA41.0;Acute ST elevation myocardial infarction;2;Inactive;391388807;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA41.Z;Acute myocardial infarction, unspecified;3;Inactive;1334938734/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA8Z;Diseases of coronary artery, unspecified;3;Inactive;1059873720/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BC43.5;Stress-induced cardiomyopathy;2;Active;478139552;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BC43.Z;Cardiomyopathy, unspecified;2;Unknown;282225286/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BC81.4;Wolff-Parkinson-White syndrome;4;Approved;1091030330;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BD40.Y;Other specified atherosclerotic chronic arterial occlusive disease;3;Inactive;109367356/other;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CB00;Acute respiratory distress syndrome;2;Active;1189702844;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MC81.3;Paroxysmal tachycardia;4;Approved;1926915195;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NE8Z;Injury or harm arising from surgical or medical care, not elsewhere classified, unspecified;3;Unknown;383104340/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2A82.00;Chronic lymphocytic leukaemia of B-cell type;1;Inactive;1726842351;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA40.Z;Angina pectoris, unspecified;3;Inactive;718946808/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA41.0;Acute ST elevation myocardial infarction;2;Inactive;391388807;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA41.Z;Acute myocardial infarction, unspecified;3;Inactive;1334938734/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA8Z;Diseases of coronary artery, unspecified;3;Inactive;1059873720/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BC43.5;Stress-induced cardiomyopathy;2;Active;478139552;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BC43.Z;Cardiomyopathy, unspecified;2;Unknown;282225286/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BC81.4;Wolff-Parkinson-White syndrome;4;Approved;1091030330;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BD40.Y;Other specified atherosclerotic chronic arterial occlusive disease;3;Inactive;109367356/other;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CB00;Acute respiratory distress syndrome;2;Active;1189702844;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MC81.3;Paroxysmal tachycardia;4;Approved;1926915195;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;28646346, 20164566, 30085591
508;adenosine;adenosine;CHEMBL477;DB00640;60961;58-61-7;K72T3FS567;OIRDTQYFTABQOQ-KQYNXXCUSA-N;C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N;26724;-11;140;335;0;4;8;2;19;4;Approved;1989;Small molecule;Agonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NE8Z;Injury or harm arising from surgical or medical care, not elsewhere classified, unspecified;3;Unknown;383104340/unspecified;28646346, 20164566, 30085591
510;balixafortide;balixafortide;CHEMBL4802129;NA;162677492;NA;NA;MKXOUIKTXREBLX-NDKBASPVSA-N;CC1C(=O)NC2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N3CCCC3C(=O)N4CCCC4C(=O)NC(C(=O)NC(C(=O)N1)CC5=CNC=N5)CC6=CC=C(C=C6)O)CCCCN)CCC(=O)N)CC7=CC=C(C=C7)O)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C8CCCN8C(=O)C(NC(=O)C(NC2=O)CO)C)CCN)CCCNC(=N)N)CC9=CC=C(C=C9)O;18641;-36;757;3970;0;24;27;23;131;3;Active;NA;Protein;Antagonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2C6Z;Malignant neoplasms of breast, unspecified;3;Active;1047754165/unspecified;37244751, 29706375, 28049490
510;balixafortide;balixafortide;CHEMBL4802129;NA;162677492;NA;NA;MKXOUIKTXREBLX-NDKBASPVSA-N;CC1C(=O)NC2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N3CCCC3C(=O)N4CCCC4C(=O)NC(C(=O)NC(C(=O)N1)CC5=CNC=N5)CC6=CC=C(C=C6)O)CCCCN)CCC(=O)N)CC7=CC=C(C=C7)O)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C8CCCN8C(=O)C(NC(=O)C(NC2=O)CO)C)CCN)CCCNC(=N)N)CC9=CC=C(C=C9)O;18641;-36;757;3970;0;24;27;23;131;3;Active;NA;Protein;Antagonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;3C0Z;Diseases of the blood or blood-forming organs, unspecified;2;Unknown;1766440644/unspecified;37244751, 29706375, 28049490
511;elinzanetant;elinzanetant;CHEMBL4802157;NA;16063568;929046-33-3;NA;DWRIJNIPBUFCQS-DQEYMECFSA-N;CC1=C(C=CC(=C1)F)C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CC5COCCN5CC4CO;6686;59;691;1060;0;1;13;6;47;3;Active;NA;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;1;Unknown;111507461/unspecified;36720081, 33624806, 38224099
511;elinzanetant;elinzanetant;CHEMBL4802157;NA;16063568;929046-33-3;NA;DWRIJNIPBUFCQS-DQEYMECFSA-N;CC1=C(C=CC(=C1)F)C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CC5COCCN5CC4CO;6686;59;691;1060;0;1;13;6;47;3;Active;NA;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;GA30.0Z;Menopause, unspecified;3;Active;1965418440/unspecified;36720081, 33624806, 38224099
511;elinzanetant;elinzanetant;CHEMBL4802157;NA;16063568;929046-33-3;NA;DWRIJNIPBUFCQS-DQEYMECFSA-N;CC1=C(C=CC(=C1)F)C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CC5COCCN5CC4CO;6686;59;691;1060;0;1;13;6;47;3;Active;NA;Small molecule;Antagonist;P25103;nk1r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;GA30.4;Menopausal hot flush;3;Active;222407548;36720081, 33624806, 38224099
511;elinzanetant;elinzanetant;CHEMBL4802157;NA;16063568;929046-33-3;NA;DWRIJNIPBUFCQS-DQEYMECFSA-N;CC1=C(C=CC(=C1)F)C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CC5COCCN5CC4CO;6686;59;691;1060;0;1;13;6;47;3;Active;NA;Small molecule;Antagonist;P29371;nk3r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;1;Unknown;111507461/unspecified;36720081, 33624806, 38224099
511;elinzanetant;elinzanetant;CHEMBL4802157;NA;16063568;929046-33-3;NA;DWRIJNIPBUFCQS-DQEYMECFSA-N;CC1=C(C=CC(=C1)F)C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CC5COCCN5CC4CO;6686;59;691;1060;0;1;13;6;47;3;Active;NA;Small molecule;Antagonist;P29371;nk3r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;GA30.0Z;Menopause, unspecified;3;Active;1965418440/unspecified;36720081, 33624806, 38224099
511;elinzanetant;elinzanetant;CHEMBL4802157;NA;16063568;929046-33-3;NA;DWRIJNIPBUFCQS-DQEYMECFSA-N;CC1=C(C=CC(=C1)F)C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CC5COCCN5CC4CO;6686;59;691;1060;0;1;13;6;47;3;Active;NA;Small molecule;Antagonist;P29371;nk3r_human;Class A (Rhodopsin);Tachykinin receptors;Peptide receptors;GA30.4;Menopausal hot flush;3;Active;222407548;36720081, 33624806, 38224099
512;dersimelagon;dersimelagon;CHEMBL4802160;NA;126736894;1835256-48-8;NA;MUNWOYRHJPWQNE-GMFUQMJFSA-N;COCC1CN(CC1C2=C(C=C(C=C2)C(F)(F)F)N3CCC(CC3)C(=O)O)C(=O)C4(CN(CC4C5=CC=C(C=C5)OC)C6CCCC6)F;6758;31;826;1110;0;1;11;9;48;3;Active;NA;Small molecule;Agonist;Q01726;mshr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;4A42.Z;Systemic sclerosis, unspecified;2;Active;1084365812/unspecified;37043653, 37379150, 37379149
512;dersimelagon;dersimelagon;CHEMBL4802160;NA;126736894;1835256-48-8;NA;MUNWOYRHJPWQNE-GMFUQMJFSA-N;COCC1CN(CC1C2=C(C=C(C=C2)C(F)(F)F)N3CCC(CC3)C(=O)O)C(=O)C4(CN(CC4C5=CC=C(C=C5)OC)C6CCCC6)F;6758;31;826;1110;0;1;11;9;48;3;Active;NA;Small molecule;Agonist;Q01726;mshr_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;5C58.12;Erythropoietic porphyrias;3;Active;1074667008;37043653, 37379150, 37379149
513;codeine;codeine;CHEMBL485;DB00318;5284371;76-57-3;UX6OWY2V7J;OROGSEYTTFOCAN-DNJOTXNNSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O;2994;11;419;509;0;1;4;1;22;4;Approved;1952;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000271, 30252285, 35951914
513;codeine;codeine;CHEMBL485;DB00318;5284371;76-57-3;UX6OWY2V7J;OROGSEYTTFOCAN-DNJOTXNNSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O;2994;11;419;509;0;1;4;1;22;4;Approved;1952;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MB47.3;Cramp or spasm;4;Approved;157838476;30000271, 30252285, 35951914
513;codeine;codeine;CHEMBL485;DB00318;5284371;76-57-3;UX6OWY2V7J;OROGSEYTTFOCAN-DNJOTXNNSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O;2994;11;419;509;0;1;4;1;22;4;Approved;1952;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD12;Cough;4;Approved;2027526159;30000271, 30252285, 35951914
513;codeine;codeine;CHEMBL485;DB00318;5284371;76-57-3;UX6OWY2V7J;OROGSEYTTFOCAN-DNJOTXNNSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O;2994;11;419;509;0;1;4;1;22;4;Approved;1952;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000271, 30252285, 35951914
513;codeine;codeine;CHEMBL485;DB00318;5284371;76-57-3;UX6OWY2V7J;OROGSEYTTFOCAN-DNJOTXNNSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O;2994;11;419;509;0;1;4;1;22;4;Approved;1952;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000271, 30252285, 35951914
513;codeine;codeine;CHEMBL485;DB00318;5284371;76-57-3;UX6OWY2V7J;OROGSEYTTFOCAN-DNJOTXNNSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O;2994;11;419;509;0;1;4;1;22;4;Approved;1952;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MB47.3;Cramp or spasm;4;Approved;157838476;30000271, 30252285, 35951914
513;codeine;codeine;CHEMBL485;DB00318;5284371;76-57-3;UX6OWY2V7J;OROGSEYTTFOCAN-DNJOTXNNSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O;2994;11;419;509;0;1;4;1;22;4;Approved;1952;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD12;Cough;4;Approved;2027526159;30000271, 30252285, 35951914
513;codeine;codeine;CHEMBL485;DB00318;5284371;76-57-3;UX6OWY2V7J;OROGSEYTTFOCAN-DNJOTXNNSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O;2994;11;419;509;0;1;4;1;22;4;Approved;1952;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000271, 30252285, 35951914
513;codeine;codeine;CHEMBL485;DB00318;5284371;76-57-3;UX6OWY2V7J;OROGSEYTTFOCAN-DNJOTXNNSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O;2994;11;419;509;0;1;4;1;22;4;Approved;1952;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000271, 30252285, 35951914
513;codeine;codeine;CHEMBL485;DB00318;5284371;76-57-3;UX6OWY2V7J;OROGSEYTTFOCAN-DNJOTXNNSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O;2994;11;419;509;0;1;4;1;22;4;Approved;1952;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MB47.3;Cramp or spasm;4;Approved;157838476;30000271, 30252285, 35951914
513;codeine;codeine;CHEMBL485;DB00318;5284371;76-57-3;UX6OWY2V7J;OROGSEYTTFOCAN-DNJOTXNNSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O;2994;11;419;509;0;1;4;1;22;4;Approved;1952;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD12;Cough;4;Approved;2027526159;30000271, 30252285, 35951914
513;codeine;codeine;CHEMBL485;DB00318;5284371;76-57-3;UX6OWY2V7J;OROGSEYTTFOCAN-DNJOTXNNSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O;2994;11;419;509;0;1;4;1;22;4;Approved;1952;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000271, 30252285, 35951914
514;methysergide;1-Methyllysergic acid butanolamide;CHEMBL485253;DB00247;6540428;361-37-5;XZA9HY6Z98;KPJZHOPZRAFDTN-NQUBZZJWSA-N;CCC(CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C;3535;23;575;578;0;2;3;4;26;4;Approved;1962;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;9793694, 6038987, 14171102
514;methysergide;methysergide;CHEMBL1065;DB00247;9681;361-37-5;XZA9HY6Z98;KPJZHOPZRAFDTN-ZRGWGRIASA-N;CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C;3535;23;575;578;0;2;3;4;26;4;Approved;1962;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;9793694, 6038987, 14171102
514;methysergide;1-Methyllysergic acid butanolamide;CHEMBL485253;DB00247;6540428;361-37-5;XZA9HY6Z98;KPJZHOPZRAFDTN-NQUBZZJWSA-N;CCC(CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C;3535;23;575;578;0;2;3;4;26;4;Approved;1962;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;9793694, 6038987, 14171102
514;methysergide;methysergide;CHEMBL1065;DB00247;9681;361-37-5;XZA9HY6Z98;KPJZHOPZRAFDTN-ZRGWGRIASA-N;CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C;3535;23;575;578;0;2;3;4;26;4;Approved;1962;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;9793694, 6038987, 14171102
514;methysergide;1-Methyllysergic acid butanolamide;CHEMBL485253;DB00247;6540428;361-37-5;XZA9HY6Z98;KPJZHOPZRAFDTN-NQUBZZJWSA-N;CCC(CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C;3535;23;575;578;0;2;3;4;26;4;Approved;1962;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;9793694, 6038987, 14171102
514;methysergide;methysergide;CHEMBL1065;DB00247;9681;361-37-5;XZA9HY6Z98;KPJZHOPZRAFDTN-ZRGWGRIASA-N;CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C;3535;23;575;578;0;2;3;4;26;4;Approved;1962;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;9793694, 6038987, 14171102
514;methysergide;1-Methyllysergic acid butanolamide;CHEMBL485253;DB00247;6540428;361-37-5;XZA9HY6Z98;KPJZHOPZRAFDTN-NQUBZZJWSA-N;CCC(CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C;3535;23;575;578;0;2;3;4;26;4;Approved;1962;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;9793694, 6038987, 14171102
514;methysergide;methysergide;CHEMBL1065;DB00247;9681;361-37-5;XZA9HY6Z98;KPJZHOPZRAFDTN-ZRGWGRIASA-N;CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C;3535;23;575;578;0;2;3;4;26;4;Approved;1962;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;9793694, 6038987, 14171102
514;methysergide;1-Methyllysergic acid butanolamide;CHEMBL485253;DB00247;6540428;361-37-5;XZA9HY6Z98;KPJZHOPZRAFDTN-NQUBZZJWSA-N;CCC(CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C;3535;23;575;578;0;2;3;4;26;4;Approved;1962;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;9793694, 6038987, 14171102
514;methysergide;methysergide;CHEMBL1065;DB00247;9681;361-37-5;XZA9HY6Z98;KPJZHOPZRAFDTN-ZRGWGRIASA-N;CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C;3535;23;575;578;0;2;3;4;26;4;Approved;1962;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;9793694, 6038987, 14171102
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;4A42.Z;Systemic sclerosis, unspecified;1;Inactive;1084365812/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Inactive;437815624/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;3;Inactive;1683919430/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;4;Approved;1712535455;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B0Y;Other specified anxiety or fear-related disorders;4;Approved;1336943699/other;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A02.10;Drug-induced dystonia;3;Unknown;678203506;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DA41.00;Gastroparesis;2;Active;598423727;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.3;Anxiety;4;Approved;2027043655;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD11.0;Apnoea;3;Inactive;992235907;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD90;Nausea or vomiting;2;Inactive;677319549;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;1;Unknown;661232217/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Partial agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;ND51.2;Injury of spinal cord, level unspecified;2;Active;2131180445;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;4A42.Z;Systemic sclerosis, unspecified;1;Inactive;1084365812/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Inactive;437815624/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;3;Inactive;1683919430/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;3;Inactive;106339515/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;4;Approved;1712535455;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B0Y;Other specified anxiety or fear-related disorders;4;Approved;1336943699/other;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A02.10;Drug-induced dystonia;3;Unknown;678203506;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;DA41.00;Gastroparesis;2;Active;598423727;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.3;Anxiety;4;Approved;2027043655;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD11.0;Apnoea;3;Inactive;992235907;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;2;Inactive;677319549;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;1;Unknown;661232217/unspecified;30285372, 30000509, 31643299
516;buspirone;buspirone;CHEMBL49;DB00490;2477;36505-84-7;TK65WKS8HL;QWCRAEMEVRGPNT-UHFFFAOYSA-N;C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4;3855;26;696;529;0;0;6;6;28;4;Approved;1986;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;ND51.2;Injury of spinal cord, level unspecified;2;Active;2131180445;30285372, 30000509, 31643299
517;clenbuterol;clenbuterol;CHEMBL49080;DB01407;2783;37148-27-9;XTZ6AXU7KN;STJMRWALKKWQGH-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O;27719;22;583;233;0;3;3;4;17;4;Approved;1977;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A11;Type 2 diabetes mellitus;2;Unknown;119724091;28431781, 32908823, 35013148
517;clenbuterol;clenbuterol;CHEMBL49080;DB01407;2783;37148-27-9;XTZ6AXU7KN;STJMRWALKKWQGH-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O;27719;22;583;233;0;3;3;4;17;4;Approved;1977;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Unknown;1982355687;28431781, 32908823, 35013148
517;clenbuterol;clenbuterol;CHEMBL49080;DB01407;2783;37148-27-9;XTZ6AXU7KN;STJMRWALKKWQGH-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O;27719;22;583;233;0;3;3;4;17;4;Approved;1977;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;28431781, 32908823, 35013148
517;clenbuterol;clenbuterol;CHEMBL49080;DB01407;2783;37148-27-9;XTZ6AXU7KN;STJMRWALKKWQGH-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O;27719;22;583;233;0;3;3;4;17;4;Approved;1977;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB44.Z;Abnormalities of gait and mobility, unspecified;2;Unknown;1543612222/unspecified;28431781, 32908823, 35013148
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;2F37.Y;Other specified benign neoplasm of endocrine glands;4;Approved;1290583069/other;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A10;Type 1 diabetes mellitus;2;Inactive;1651053999;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A11;Type 2 diabetes mellitus;4;Approved;119724091;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A60.1;Hyperprolactinaemia;4;Approved;1417218455;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A00.Z;Disorders of intellectual development, unspecified;2;Unknown;605267007/unspecified;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;GA11;Adenomyosis;1;Inactive;171294592;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;GA32.0;Ovarian hyperstimulation syndrome;2;Inactive;1216664013;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;2F37.Y;Other specified benign neoplasm of endocrine glands;4;Approved;1290583069/other;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A10;Type 1 diabetes mellitus;2;Inactive;1651053999;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A11;Type 2 diabetes mellitus;4;Approved;119724091;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A60.1;Hyperprolactinaemia;4;Approved;1417218455;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A00.Z;Disorders of intellectual development, unspecified;2;Unknown;605267007/unspecified;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;GA11;Adenomyosis;1;Inactive;171294592;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;GA32.0;Ovarian hyperstimulation syndrome;2;Inactive;1216664013;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;2F37.Y;Other specified benign neoplasm of endocrine glands;4;Approved;1290583069/other;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A10;Type 1 diabetes mellitus;2;Inactive;1651053999;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A11;Type 2 diabetes mellitus;4;Approved;119724091;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A60.0;Acromegaly or pituitary gigantism;4;Approved;825410563;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A60.1;Hyperprolactinaemia;4;Approved;1417218455;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A00.Z;Disorders of intellectual development, unspecified;2;Unknown;605267007/unspecified;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;GA11;Adenomyosis;1;Inactive;171294592;30000365, 32310408, 31643914
518;bromocriptine;bromocriptine;CHEMBL493;DB01200;31101;25614-03-3;NA;OZVBMTJYIDMWIL-AYFBDAFISA-N;CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O;6546;38;118;1230;0;3;6;5;43;4;Approved;1978;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;GA32.0;Ovarian hyperstimulation syndrome;2;Inactive;1216664013;30000365, 32310408, 31643914
519;vorapaxar;vorapaxar;CHEMBL493982;DB09030;10077130;618385-01-6;ZCE93644N2;ZBGXUVOIWDMMJE-QHNZEKIYSA-N;CCOC(=O)NC1CCC2C(C1)CC3C(C2C=CC4=NC=C(C=C4)C5=CC(=CC=C5)F)C(OC3=O)C;4926;53;775;821;0;1;6;6;36;4;Approved;2014;Small molecule;Antagonist;P25116;par1_human;Class A (Rhodopsin);Proteinase-activated receptors;Peptide receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;2;Inactive;1614716959/unspecified;31644210, 21090833, 37036206
519;vorapaxar;vorapaxar;CHEMBL493982;DB09030;10077130;618385-01-6;ZCE93644N2;ZBGXUVOIWDMMJE-QHNZEKIYSA-N;CCOC(=O)NC1CCC2C(C1)CC3C(C2C=CC4=NC=C(C=C4)C5=CC(=CC=C5)F)C(OC3=O)C;4926;53;775;821;0;1;6;6;36;4;Approved;2014;Small molecule;Antagonist;P25116;par1_human;Class A (Rhodopsin);Proteinase-activated receptors;Peptide receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;31644210, 21090833, 37036206
519;vorapaxar;vorapaxar;CHEMBL493982;DB09030;10077130;618385-01-6;ZCE93644N2;ZBGXUVOIWDMMJE-QHNZEKIYSA-N;CCOC(=O)NC1CCC2C(C1)CC3C(C2C=CC4=NC=C(C=C4)C5=CC(=CC=C5)F)C(OC3=O)C;4926;53;775;821;0;1;6;6;36;4;Approved;2014;Small molecule;Antagonist;P25116;par1_human;Class A (Rhodopsin);Proteinase-activated receptors;Peptide receptors;BD5Z;Diseases of arteries or arterioles, unspecified;4;Approved;1164983645/unspecified;31644210, 21090833, 37036206
519;vorapaxar;vorapaxar;CHEMBL493982;DB09030;10077130;618385-01-6;ZCE93644N2;ZBGXUVOIWDMMJE-QHNZEKIYSA-N;CCOC(=O)NC1CCC2C(C1)CC3C(C2C=CC4=NC=C(C=C4)C5=CC(=CC=C5)F)C(OC3=O)C;4926;53;775;821;0;1;6;6;36;4;Approved;2014;Small molecule;Antagonist;P25116;par1_human;Class A (Rhodopsin);Proteinase-activated receptors;Peptide receptors;BD7Y;Other specified diseases of veins;4;Approved;723430526/other;31644210, 21090833, 37036206
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;1G41;Sepsis with septic shock;3;Active;1683090852;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;2C25.5;Unspecified malignant epithelial neoplasm of bronchus or lung;2;Unknown;1826627197;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;2C25.Z;Malignant neoplasms of bronchus or lung, unspecified;2;Inactive;316539081/unspecified;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;4A42.Z;Systemic sclerosis, unspecified;2;Inactive;1084365812/unspecified;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BA41.Z;Acute myocardial infarction, unspecified;1;Inactive;1334938734/unspecified;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BB01.Z;Pulmonary hypertension, unspecified;4;Approved;1496633964/unspecified;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD42.0;Primary Raynaud disease;4;Approved;1592720372;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;2;Inactive;133207228/unspecified;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CA23;Asthma;1;Inactive;1656445230;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CB00;Acute respiratory distress syndrome;3;Inactive;1189702844;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;GB61.Z;Chronic kidney disease, stage unspecified;2;Inactive;412389819/unspecified;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;MC82.Z;Cardiac arrest, unspecified;2;Inactive;395422191/unspecified;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;MG4A;Multi organ failure;2;Inactive;243925837;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;ND56.2;Fracture of unspecified body region;1;Unknown;1504538171;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;1G41;Sepsis with septic shock;3;Active;1683090852;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;2C25.5;Unspecified malignant epithelial neoplasm of bronchus or lung;2;Unknown;1826627197;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;2C25.Z;Malignant neoplasms of bronchus or lung, unspecified;2;Inactive;316539081/unspecified;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;4A42.Z;Systemic sclerosis, unspecified;2;Inactive;1084365812/unspecified;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BA41.Z;Acute myocardial infarction, unspecified;1;Inactive;1334938734/unspecified;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BB01.Z;Pulmonary hypertension, unspecified;4;Approved;1496633964/unspecified;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD42.0;Primary Raynaud disease;4;Approved;1592720372;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;2;Inactive;133207228/unspecified;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CA23;Asthma;1;Inactive;1656445230;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CB00;Acute respiratory distress syndrome;3;Inactive;1189702844;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;GB61.Z;Chronic kidney disease, stage unspecified;2;Inactive;412389819/unspecified;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;MC82.Z;Cardiac arrest, unspecified;2;Inactive;395422191/unspecified;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;MG4A;Multi organ failure;2;Inactive;243925837;38163330, 9366801, 36966492
520;iloprost;iloprost;CHEMBL494;DB01088;5311181;78919-13-8;JED5K35YGL;HIFJCPQKFCZDDL-ACWOEMLNSA-N;CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O;3605;28;778;606;0;3;4;8;26;4;Approved;2004;Small molecule;Agonist;P43119;pi2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;ND56.2;Fracture of unspecified body region;1;Unknown;1504538171;38163330, 9366801, 36966492
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9B78.3Z;Degeneration of macula or posterior pole, unspecified;3;Inactive;697366740/unspecified;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C40.40;Anterior ischemic optic neuropathy;2;Unknown;632323575;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD1Z;Heart failure, unspecified;3;Active;1458683894/unspecified;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD40.Z;Atherosclerotic chronic arterial occlusive disease, unspecified;2;Unknown;109367356/unspecified;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD4Z;Chronic arterial occlusive disease, unspecified;2;Unknown;1821859817/unspecified;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD5Z;Diseases of arteries or arterioles, unspecified;2;Unknown;1164983645/unspecified;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CB00;Acute respiratory distress syndrome;2;Inactive;1189702844;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;GB60.Z;Acute kidney failure, stage unspecified;2;Active;476391827/unspecified;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;HA01.1Z;Male erectile dysfunction, unspecified;4;Approved;97556145/unspecified;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;LA8B.4;Patent arterial duct;4;Approved;1262462321;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9B78.3Z;Degeneration of macula or posterior pole, unspecified;3;Inactive;697366740/unspecified;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C40.40;Anterior ischemic optic neuropathy;2;Unknown;632323575;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD1Z;Heart failure, unspecified;3;Active;1458683894/unspecified;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD40.Z;Atherosclerotic chronic arterial occlusive disease, unspecified;2;Unknown;109367356/unspecified;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD4Z;Chronic arterial occlusive disease, unspecified;2;Unknown;1821859817/unspecified;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD5Z;Diseases of arteries or arterioles, unspecified;2;Unknown;1164983645/unspecified;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CB00;Acute respiratory distress syndrome;2;Inactive;1189702844;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;GB60.Z;Acute kidney failure, stage unspecified;2;Active;476391827/unspecified;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;HA01.1Z;Male erectile dysfunction, unspecified;4;Approved;97556145/unspecified;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;LA8B.4;Patent arterial duct;4;Approved;1262462321;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9B78.3Z;Degeneration of macula or posterior pole, unspecified;3;Inactive;697366740/unspecified;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C40.40;Anterior ischemic optic neuropathy;2;Unknown;632323575;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD1Z;Heart failure, unspecified;3;Active;1458683894/unspecified;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD40.Z;Atherosclerotic chronic arterial occlusive disease, unspecified;2;Unknown;109367356/unspecified;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD4Z;Chronic arterial occlusive disease, unspecified;2;Unknown;1821859817/unspecified;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD5Z;Diseases of arteries or arterioles, unspecified;2;Unknown;1164983645/unspecified;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CB00;Acute respiratory distress syndrome;2;Inactive;1189702844;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;GB60.Z;Acute kidney failure, stage unspecified;2;Active;476391827/unspecified;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;HA01.1Z;Male erectile dysfunction, unspecified;4;Approved;97556145/unspecified;31194374, 24369066, 31331187
521;alprostadil;S-alprostadil;CHEMBL495;DB00770;149351;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DODZYUBVSA-N;CCCCC[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;LA8B.4;Patent arterial duct;4;Approved;1262462321;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9B78.3Z;Degeneration of macula or posterior pole, unspecified;3;Inactive;697366740/unspecified;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;9C40.40;Anterior ischemic optic neuropathy;2;Unknown;632323575;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD1Z;Heart failure, unspecified;3;Active;1458683894/unspecified;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD40.Z;Atherosclerotic chronic arterial occlusive disease, unspecified;2;Unknown;109367356/unspecified;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD4Z;Chronic arterial occlusive disease, unspecified;2;Unknown;1821859817/unspecified;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BD5Z;Diseases of arteries or arterioles, unspecified;2;Unknown;1164983645/unspecified;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CB00;Acute respiratory distress syndrome;2;Inactive;1189702844;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;GB60.Z;Acute kidney failure, stage unspecified;2;Active;476391827/unspecified;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;HA01.1Z;Male erectile dysfunction, unspecified;4;Approved;97556145/unspecified;31194374, 24369066, 31331187
521;alprostadil;alprostadil;CHEMBL495;DB00770;5280723;745-65-3;F5TD010360;GMVPRGQOIOIIMI-DWKJAMRDSA-N;CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O;3545;32;948;432;0;3;5;13;25;4;Approved;1981;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;LA8B.4;Patent arterial duct;4;Approved;1262462321;31194374, 24369066, 31331187
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2E81.0Z;Neoplastic haemangioma, unspecified site;3;Active;228855241/unspecified;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;2;Inactive;669367341/unspecified;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C40.40;Anterior ischemic optic neuropathy;1;Unknown;632323575;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.01;Ocular hypertension;4;Approved;535283437;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD74.3Z;Venous leg ulcer, unspecified;2;Inactive;9691905/unspecified;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA26.0Z;Oesophageal varices, unspecified;3;Unknown;933570887/unspecified;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA90.00;Hereditary haemorrhagic telangiectasia;2;Inactive;714406192;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ND56.Z;Unspecified injury to unspecified part of trunk, limb or body region;2;Active;1842783299/unspecified;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2E81.0Z;Neoplastic haemangioma, unspecified site;3;Active;228855241/unspecified;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A80.Z;Migraine, unspecified;2;Inactive;669367341/unspecified;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C40.40;Anterior ischemic optic neuropathy;1;Unknown;632323575;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.01;Ocular hypertension;4;Approved;535283437;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD74.3Z;Venous leg ulcer, unspecified;2;Inactive;9691905/unspecified;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA26.0Z;Oesophageal varices, unspecified;3;Unknown;933570887/unspecified;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA90.00;Hereditary haemorrhagic telangiectasia;2;Inactive;714406192;30000225, 31424760, 31643578
522;timolol;timolol;CHEMBL499;DB00373;33624;26839-75-8;5JKY92S7BR;BLJRIMJGRPQVNF-JTQLQIEISA-N;CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O;31642;18;108;310;0;2;8;7;21;4;Approved;1978;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ND56.Z;Unspecified injury to unspecified part of trunk, limb or body region;2;Active;1842783299/unspecified;30000225, 31424760, 31643578
523;pindolol;pindolol;CHEMBL500;DB00960;4828;13523-86-9;BJ4HF6IU1D;JZQKKSLKJUAGIC-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=C1C=CN2)O;24832;18;573;248;0;3;3;6;18;4;Approved;1982;Small molecule;Partial agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;30000220, 31643808, 37130578
523;pindolol;pindolol;CHEMBL500;DB00960;4828;13523-86-9;BJ4HF6IU1D;JZQKKSLKJUAGIC-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=C1C=CN2)O;24832;18;573;248;0;3;3;6;18;4;Approved;1982;Small molecule;Partial agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000220, 31643808, 37130578
523;pindolol;pindolol;CHEMBL500;DB00960;4828;13523-86-9;BJ4HF6IU1D;JZQKKSLKJUAGIC-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=C1C=CN2)O;24832;18;573;248;0;3;3;6;18;4;Approved;1982;Small molecule;Partial agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30000220, 31643808, 37130578
523;pindolol;pindolol;CHEMBL500;DB00960;4828;13523-86-9;BJ4HF6IU1D;JZQKKSLKJUAGIC-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=C1C=CN2)O;24832;18;573;248;0;3;3;6;18;4;Approved;1982;Small molecule;Partial agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;30000220, 31643808, 37130578
523;pindolol;pindolol;CHEMBL500;DB00960;4828;13523-86-9;BJ4HF6IU1D;JZQKKSLKJUAGIC-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=C1C=CN2)O;24832;18;573;248;0;3;3;6;18;4;Approved;1982;Small molecule;Partial agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000220, 31643808, 37130578
523;pindolol;pindolol;CHEMBL500;DB00960;4828;13523-86-9;BJ4HF6IU1D;JZQKKSLKJUAGIC-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC2=C1C=CN2)O;24832;18;573;248;0;3;3;6;18;4;Approved;1982;Small molecule;Partial agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30000220, 31643808, 37130578
524;chlorpheniramine;chlorpheniramine;CHEMBL505;DB01114;2725;132-22-9;3U6IO1965U;SOYKEARSMXGVTM-UHFFFAOYSA-N;CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2;27479;34;161;249;0;0;2;5;19;4;Approved;1950;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000590, 35951896, 24276502
524;chlorpheniramine;chlorpheniramine;CHEMBL505;DB01114;2725;132-22-9;3U6IO1965U;SOYKEARSMXGVTM-UHFFFAOYSA-N;CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2;27479;34;161;249;0;0;2;5;19;4;Approved;1950;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000590, 35951896, 24276502
524;chlorpheniramine;chlorpheniramine;CHEMBL505;DB01114;2725;132-22-9;3U6IO1965U;SOYKEARSMXGVTM-UHFFFAOYSA-N;CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2;27479;34;161;249;0;0;2;5;19;4;Approved;1950;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000590, 35951896, 24276502
524;chlorpheniramine;chlorpheniramine;CHEMBL505;DB01114;2725;132-22-9;3U6IO1965U;SOYKEARSMXGVTM-UHFFFAOYSA-N;CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2;27479;34;161;249;0;0;2;5;19;4;Approved;1950;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;30000590, 35951896, 24276502
524;chlorpheniramine;chlorpheniramine;CHEMBL505;DB01114;2725;132-22-9;3U6IO1965U;SOYKEARSMXGVTM-UHFFFAOYSA-N;CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2;27479;34;161;249;0;0;2;5;19;4;Approved;1950;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD12;Cough;4;Approved;2027526159;30000590, 35951896, 24276502
525;motixafortide;motixafortide;CHEMBL5095030;NA;166625217;NA;NA;JJVZSYKFCOBILL-DPNRMINZSA-N;C1CC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)C(CC4=CC5=CC=CC=C5C=C4)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C6=CC=C(C=C6)F)C(=O)NC(CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC7=CC=C(C=C7)O;21595;-29;943;4500;0;34;28;53;152;4;Approved;2023;Protein;Antagonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;3C0Z;Diseases of the blood or blood-forming organs, unspecified;4;Approved;1766440644/unspecified;37996648, 37069359, 37862457
526;ketanserin;ketanserin;CHEMBL51;DB12465;3822;74050-98-9;97F9DE4CT4;FPCCSQOGAWCVBH-UHFFFAOYSA-N;C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O;3954;26;697;627;0;1;5;5;29;4;Approved;1985;Small molecule;Inverse agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;2036747, 2130934, 3071462
526;ketanserin;ketanserin;CHEMBL51;DB12465;3822;74050-98-9;97F9DE4CT4;FPCCSQOGAWCVBH-UHFFFAOYSA-N;C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O;3954;26;697;627;0;1;5;5;29;4;Approved;1985;Small molecule;Inverse agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;BD54;Diabetic foot ulcer;1;Inactive;74527684;2036747, 2130934, 3071462
526;ketanserin;ketanserin;CHEMBL51;DB12465;3822;74050-98-9;97F9DE4CT4;FPCCSQOGAWCVBH-UHFFFAOYSA-N;C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O;3954;26;697;627;0;1;5;5;29;4;Approved;1985;Small molecule;Inverse agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;GB60.Z;Acute kidney failure, stage unspecified;3;Inactive;476391827/unspecified;2036747, 2130934, 3071462
527;pyrilamine;pyrilamine;CHEMBL511;DB06691;4992;91-84-9;HPE317O9TL;YECBIJXISLIIDS-UHFFFAOYSA-N;CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2;2854;33;286;277;0;0;4;7;21;4;Approved;1973;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000145, 29878742, 24813183
527;pyrilamine;pyrilamine;CHEMBL511;DB06691;4992;91-84-9;HPE317O9TL;YECBIJXISLIIDS-UHFFFAOYSA-N;CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2;2854;33;286;277;0;0;4;7;21;4;Approved;1973;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000145, 29878742, 24813183
527;pyrilamine;pyrilamine;CHEMBL511;DB06691;4992;91-84-9;HPE317O9TL;YECBIJXISLIIDS-UHFFFAOYSA-N;CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2;2854;33;286;277;0;0;4;7;21;4;Approved;1973;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;30000145, 29878742, 24813183
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;4;Approved;1120716949/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;4;Approved;111507461/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Active;2016549355/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;4;Approved;2143971168/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;3;Inactive;219731531/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4Z;Disorders due to substance use, unspecified;4;Approved;590211325/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Inactive;80293156;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;4;Approved;1815305992/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.Z;Spinal pain, unspecified;4;Approved;2051065876/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;4;Approved;1581976053/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;4;Approved;1120716949/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;4;Approved;111507461/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Active;2016549355/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;4;Approved;2143971168/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;3;Inactive;219731531/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4Z;Disorders due to substance use, unspecified;4;Approved;590211325/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Inactive;80293156;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.2Z;Low back pain, unspecified;4;Approved;1815305992/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME84.Z;Spinal pain, unspecified;4;Approved;2051065876/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;4;Approved;1581976053/unspecified;35940992, 36585223, 29083570
528;buprenorphine;buprenorphine;CHEMBL511142;NA;9848990;NA;NA;RMRJXGBAOAMLHD-CTAPUXPBSA-N;CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;4676;5;622;869;0;2;5;5;34;4;Approved;1981;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;35940992, 36585223, 29083570
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;BB61.Z;Mitral valve insufficiency, unspecified;2;Active;637470326/unspecified;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD81.4;Other and unspecified abdominal pain;2;Inactive;166022696;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG43.5;Excessive weight loss;3;Unknown;2015627151;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;BB61.Z;Mitral valve insufficiency, unspecified;2;Active;637470326/unspecified;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD81.4;Other and unspecified abdominal pain;2;Inactive;166022696;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG43.5;Excessive weight loss;3;Unknown;2015627151;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;BB61.Z;Mitral valve insufficiency, unspecified;2;Active;637470326/unspecified;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD81.4;Other and unspecified abdominal pain;2;Inactive;166022696;30000753, 31643741, 33632345
529;cyproheptadine;cyproheptadine;CHEMBL516;DB00434;2913;129-03-3;2YHB6175DO;JJCFRYNCJDLXIK-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1;2874;47;32;423;0;0;1;0;22;4;Approved;1961;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MG43.5;Excessive weight loss;3;Unknown;2015627151;30000753, 31643741, 33632345
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.0;Myopia;3;Active;1666440799;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.4;Anisometropia;3;Inactive;386251928;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D46;Impairment of binocular functions;3;Inactive;296599996;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BA2Z;Hypotension, unspecified;2;Unknown;1663360295/unspecified;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MB4D;Headache, not elsewhere classified;3;Active;1405405864;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MC81.1;Bradycardia, unspecified;4;Approved;2079810536;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NE61;Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified;2;Active;1119330136;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NE6Z;Harmful effects of unspecified substance;4;Approved;1236563202/unspecified;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;PK81.0;Ventilation associated with injury or harm in therapeutic use;2;Inactive;833290117;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.0;Myopia;3;Active;1666440799;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.4;Anisometropia;3;Inactive;386251928;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D46;Impairment of binocular functions;3;Inactive;296599996;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BA2Z;Hypotension, unspecified;2;Unknown;1663360295/unspecified;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MB4D;Headache, not elsewhere classified;3;Active;1405405864;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MC81.1;Bradycardia, unspecified;4;Approved;2079810536;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NE61;Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified;2;Active;1119330136;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NE6Z;Harmful effects of unspecified substance;4;Approved;1236563202/unspecified;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;PK81.0;Ventilation associated with injury or harm in therapeutic use;2;Inactive;833290117;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.0;Myopia;3;Active;1666440799;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.4;Anisometropia;3;Inactive;386251928;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D46;Impairment of binocular functions;3;Inactive;296599996;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BA2Z;Hypotension, unspecified;2;Unknown;1663360295/unspecified;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MB4D;Headache, not elsewhere classified;3;Active;1405405864;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MC81.1;Bradycardia, unspecified;4;Approved;2079810536;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NE61;Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified;2;Active;1119330136;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NE6Z;Harmful effects of unspecified substance;4;Approved;1236563202/unspecified;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;PK81.0;Ventilation associated with injury or harm in therapeutic use;2;Inactive;833290117;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.0;Myopia;3;Active;1666440799;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.4;Anisometropia;3;Inactive;386251928;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D46;Impairment of binocular functions;3;Inactive;296599996;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BA2Z;Hypotension, unspecified;2;Unknown;1663360295/unspecified;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MB4D;Headache, not elsewhere classified;3;Active;1405405864;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MC81.1;Bradycardia, unspecified;4;Approved;2079810536;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NE61;Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified;2;Active;1119330136;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NE6Z;Harmful effects of unspecified substance;4;Approved;1236563202/unspecified;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;PK81.0;Ventilation associated with injury or harm in therapeutic use;2;Inactive;833290117;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.0;Myopia;3;Active;1666440799;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.4;Anisometropia;3;Inactive;386251928;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D46;Impairment of binocular functions;3;Inactive;296599996;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BA2Z;Hypotension, unspecified;2;Unknown;1663360295/unspecified;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MB4D;Headache, not elsewhere classified;3;Active;1405405864;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MC81.1;Bradycardia, unspecified;4;Approved;2079810536;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NE61;Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified;2;Active;1119330136;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NE6Z;Harmful effects of unspecified substance;4;Approved;1236563202/unspecified;29262018, 30000531, 31644221
530;atropine;atropine;CHEMBL517712;DB00572;174174;51-55-8;7C0697DR9I;RKUNBYITZUJHSG-PJPHBNEVSA-N;CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3;2894;18;498;353;0;1;4;5;21;4;Approved;1960;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;PK81.0;Ventilation associated with injury or harm in therapeutic use;2;Inactive;833290117;29262018, 30000531, 31644221
531;mavorixafor;mavorixafor;CHEMBL518924;DB05501;11256587;558447-26-0;0G9LGB5O2W;WVLHHLRVNDMIAR-IBGZPJMESA-N;C1CC(C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3;3495;24;708;431;0;2;4;7;26;4;Approved;2024;Small molecule;Antagonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;1C62.Z;Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified;1;Inactive;1508081745/unspecified;36923305, 33507454, 32870250
531;mavorixafor;mavorixafor;CHEMBL518924;DB05501;11256587;558447-26-0;0G9LGB5O2W;WVLHHLRVNDMIAR-IBGZPJMESA-N;C1CC(C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3;3495;24;708;431;0;2;4;7;26;4;Approved;2024;Small molecule;Antagonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2A85.4;Lymphoplasmacytic lymphoma;1;Active;2058944823;36923305, 33507454, 32870250
531;mavorixafor;mavorixafor;CHEMBL518924;DB05501;11256587;558447-26-0;0G9LGB5O2W;WVLHHLRVNDMIAR-IBGZPJMESA-N;C1CC(C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3;3495;24;708;431;0;2;4;7;26;4;Approved;2024;Small molecule;Antagonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2C30.Z;Melanoma of skin, unspecified;1;Inactive;488336723/unspecified;36923305, 33507454, 32870250
531;mavorixafor;mavorixafor;CHEMBL518924;DB05501;11256587;558447-26-0;0G9LGB5O2W;WVLHHLRVNDMIAR-IBGZPJMESA-N;C1CC(C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3;3495;24;708;431;0;2;4;7;26;4;Approved;2024;Small molecule;Antagonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2C6Z;Malignant neoplasms of breast, unspecified;1;Unknown;1047754165/unspecified;36923305, 33507454, 32870250
531;mavorixafor;mavorixafor;CHEMBL518924;DB05501;11256587;558447-26-0;0G9LGB5O2W;WVLHHLRVNDMIAR-IBGZPJMESA-N;C1CC(C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3;3495;24;708;431;0;2;4;7;26;4;Approved;2024;Small molecule;Antagonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2C90.0;Renal cell carcinoma of kidney, except renal pelvis;1;Active;825917541;36923305, 33507454, 32870250
531;mavorixafor;mavorixafor;CHEMBL518924;DB05501;11256587;558447-26-0;0G9LGB5O2W;WVLHHLRVNDMIAR-IBGZPJMESA-N;C1CC(C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3;3495;24;708;431;0;2;4;7;26;4;Approved;2024;Small molecule;Antagonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;4A00.Y;Other specified primary immunodeficiencies due to disorders of innate immunity;4;Approved;551037838/other;36923305, 33507454, 32870250
531;mavorixafor;mavorixafor;CHEMBL518924;DB05501;11256587;558447-26-0;0G9LGB5O2W;WVLHHLRVNDMIAR-IBGZPJMESA-N;C1CC(C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3;3495;24;708;431;0;2;4;7;26;4;Approved;2024;Small molecule;Antagonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;4B00.0Z;Neutropaenia, unspecified;2;Active;926492960/unspecified;36923305, 33507454, 32870250
532;bambuterol;bambuterol;CHEMBL521589;DB01408;54766;81732-65-2;Y1850G1OVC;ANZXOIAKUNOVQU-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O;3674;12;913;446;0;2;6;8;26;4;Approved;1990;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;8896942, 38202655, 26137575
533;methoxamine;methoxamine;CHEMBL524;DB00723;6082;390-28-3;HUQ1KC1YLI;WJAJPNHVVFWKKL-UHFFFAOYSA-N;CC(C(C1=C(C=CC(=C1)OC)OC)O)N;21126;5;647;189;0;2;4;4;15;4;Approved;1982;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;34234694, 32787783, 18558435
533;methoxamine;methoxamine;CHEMBL524;DB00723;6082;390-28-3;HUQ1KC1YLI;WJAJPNHVVFWKKL-UHFFFAOYSA-N;CC(C(C1=C(C=CC(=C1)OC)OC)O)N;21126;5;647;189;0;2;4;4;15;4;Approved;1982;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME07.Z;Faecal incontinence, unspecified;2;Inactive;790417430/unspecified;34234694, 32787783, 18558435
533;methoxamine;methoxamine;CHEMBL524;DB00723;6082;390-28-3;HUQ1KC1YLI;WJAJPNHVVFWKKL-UHFFFAOYSA-N;CC(C(C1=C(C=CC(=C1)OC)OC)O)N;21126;5;647;189;0;2;4;4;15;4;Approved;1982;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;1;Unknown;766129123/unspecified;34234694, 32787783, 18558435
533;methoxamine;methoxamine;CHEMBL524;DB00723;6082;390-28-3;HUQ1KC1YLI;WJAJPNHVVFWKKL-UHFFFAOYSA-N;CC(C(C1=C(C=CC(=C1)OC)OC)O)N;21126;5;647;189;0;2;4;4;15;4;Approved;1982;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;34234694, 32787783, 18558435
533;methoxamine;methoxamine;CHEMBL524;DB00723;6082;390-28-3;HUQ1KC1YLI;WJAJPNHVVFWKKL-UHFFFAOYSA-N;CC(C(C1=C(C=CC(=C1)OC)OC)O)N;21126;5;647;189;0;2;4;4;15;4;Approved;1982;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME07.Z;Faecal incontinence, unspecified;2;Inactive;790417430/unspecified;34234694, 32787783, 18558435
533;methoxamine;methoxamine;CHEMBL524;DB00723;6082;390-28-3;HUQ1KC1YLI;WJAJPNHVVFWKKL-UHFFFAOYSA-N;CC(C(C1=C(C=CC(=C1)OC)OC)O)N;21126;5;647;189;0;2;4;4;15;4;Approved;1982;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;1;Unknown;766129123/unspecified;34234694, 32787783, 18558435
533;methoxamine;methoxamine;CHEMBL524;DB00723;6082;390-28-3;HUQ1KC1YLI;WJAJPNHVVFWKKL-UHFFFAOYSA-N;CC(C(C1=C(C=CC(=C1)OC)OC)O)N;21126;5;647;189;0;2;4;4;15;4;Approved;1982;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;34234694, 32787783, 18558435
533;methoxamine;methoxamine;CHEMBL524;DB00723;6082;390-28-3;HUQ1KC1YLI;WJAJPNHVVFWKKL-UHFFFAOYSA-N;CC(C(C1=C(C=CC(=C1)OC)OC)O)N;21126;5;647;189;0;2;4;4;15;4;Approved;1982;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME07.Z;Faecal incontinence, unspecified;2;Inactive;790417430/unspecified;34234694, 32787783, 18558435
533;methoxamine;methoxamine;CHEMBL524;DB00723;6082;390-28-3;HUQ1KC1YLI;WJAJPNHVVFWKKL-UHFFFAOYSA-N;CC(C(C1=C(C=CC(=C1)OC)OC)O)N;21126;5;647;189;0;2;4;4;15;4;Approved;1982;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MF50.2Z;Urinary incontinence, unspecified;1;Unknown;766129123/unspecified;34234694, 32787783, 18558435
534;mepenzolate;mepenzolate;CHEMBL524004;DB04843;4057;25990-43-6;ONW3LB39P7;GKNPSSNBBWDAGH-UHFFFAOYSA-N;C[N+]1(CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C;3404;32;465;432;1;1;3;5;25;4;Approved;1956;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DE2Z;Diseases of the digestive system, unspecified;4;Approved;1256772020/unspecified;30000725, 31643587, 27398156
534;mepenzolate;mepenzolate;CHEMBL524004;DB04843;4057;25990-43-6;ONW3LB39P7;GKNPSSNBBWDAGH-UHFFFAOYSA-N;C[N+]1(CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C;3404;32;465;432;1;1;3;5;25;4;Approved;1956;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DE2Z;Diseases of the digestive system, unspecified;4;Approved;1256772020/unspecified;30000725, 31643587, 27398156
536;sarpogrelate;sarpogrelate;CHEMBL52939;DB12163;5160;125926-17-2;19P708E787;FFYNAVGJSYHHFO-UHFFFAOYSA-N;CN(C)CC(COC1=CC=CC=C1CCC2=CC(=CC=C2)OC)OC(=O)CCC(=O)O;4295;12;853;540;0;1;7;14;31;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;3;Inactive;1614716959/unspecified;36126755, 15212624, 27571053
536;sarpogrelate;sarpogrelate;CHEMBL52939;DB12163;5160;125926-17-2;19P708E787;FFYNAVGJSYHHFO-UHFFFAOYSA-N;CN(C)CC(COC1=CC=CC=C1CCC2=CC(=CC=C2)OC)OC(=O)CCC(=O)O;4295;12;853;540;0;1;7;14;31;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;BD5Z;Diseases of arteries or arterioles, unspecified;4;Approved;1164983645/unspecified;36126755, 15212624, 27571053
536;sarpogrelate;sarpogrelate;CHEMBL52939;DB12163;5160;125926-17-2;19P708E787;FFYNAVGJSYHHFO-UHFFFAOYSA-N;CN(C)CC(COC1=CC=CC=C1CCC2=CC(=CC=C2)OC)OC(=O)CCC(=O)O;4295;12;853;540;0;1;7;14;31;4;Approved;1993;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8B11.5Z;Cerebral ischaemic stroke, unspecified;3;Inactive;1614716959/unspecified;36126755, 15212624, 27571053
536;sarpogrelate;sarpogrelate;CHEMBL52939;DB12163;5160;125926-17-2;19P708E787;FFYNAVGJSYHHFO-UHFFFAOYSA-N;CN(C)CC(COC1=CC=CC=C1CCC2=CC(=CC=C2)OC)OC(=O)CCC(=O)O;4295;12;853;540;0;1;7;14;31;4;Approved;1993;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;BD5Z;Diseases of arteries or arterioles, unspecified;4;Approved;1164983645/unspecified;36126755, 15212624, 27571053
537;apomorphine;apomorphine;CHEMBL53;DB00714;6005;58-00-4;N21FAR7B4S;VMWNQDUVQKEIOC-CYBMUJFWSA-N;CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O;26732;23;437;374;0;2;3;0;20;4;Approved;2004;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30835406, 31643473, 30323122
537;apomorphine;apomorphine;CHEMBL53;DB00714;6005;58-00-4;N21FAR7B4S;VMWNQDUVQKEIOC-CYBMUJFWSA-N;CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O;26732;23;437;374;0;2;3;0;20;4;Approved;2004;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;FB83.1Z;Osteoporosis, unspecified;1;Inactive;2113001430/unspecified;30835406, 31643473, 30323122
537;apomorphine;apomorphine;CHEMBL53;DB00714;6005;58-00-4;N21FAR7B4S;VMWNQDUVQKEIOC-CYBMUJFWSA-N;CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O;26732;23;437;374;0;2;3;0;20;4;Approved;2004;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;HA01.1Z;Male erectile dysfunction, unspecified;4;Approved;97556145/unspecified;30835406, 31643473, 30323122
537;apomorphine;apomorphine;CHEMBL53;DB00714;6005;58-00-4;N21FAR7B4S;VMWNQDUVQKEIOC-CYBMUJFWSA-N;CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O;26732;23;437;374;0;2;3;0;20;4;Approved;2004;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB27.2Z;Hallucinations, unspecified;2;Unknown;665363966/unspecified;30835406, 31643473, 30323122
537;apomorphine;apomorphine;CHEMBL53;DB00714;6005;58-00-4;N21FAR7B4S;VMWNQDUVQKEIOC-CYBMUJFWSA-N;CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O;26732;23;437;374;0;2;3;0;20;4;Approved;2004;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;30835406, 31643473, 30323122
537;apomorphine;apomorphine;CHEMBL53;DB00714;6005;58-00-4;N21FAR7B4S;VMWNQDUVQKEIOC-CYBMUJFWSA-N;CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O;26732;23;437;374;0;2;3;0;20;4;Approved;2004;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30835406, 31643473, 30323122
537;apomorphine;apomorphine;CHEMBL53;DB00714;6005;58-00-4;N21FAR7B4S;VMWNQDUVQKEIOC-CYBMUJFWSA-N;CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O;26732;23;437;374;0;2;3;0;20;4;Approved;2004;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;FB83.1Z;Osteoporosis, unspecified;1;Inactive;2113001430/unspecified;30835406, 31643473, 30323122
537;apomorphine;apomorphine;CHEMBL53;DB00714;6005;58-00-4;N21FAR7B4S;VMWNQDUVQKEIOC-CYBMUJFWSA-N;CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O;26732;23;437;374;0;2;3;0;20;4;Approved;2004;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;HA01.1Z;Male erectile dysfunction, unspecified;4;Approved;97556145/unspecified;30835406, 31643473, 30323122
537;apomorphine;apomorphine;CHEMBL53;DB00714;6005;58-00-4;N21FAR7B4S;VMWNQDUVQKEIOC-CYBMUJFWSA-N;CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O;26732;23;437;374;0;2;3;0;20;4;Approved;2004;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB27.2Z;Hallucinations, unspecified;2;Unknown;665363966/unspecified;30835406, 31643473, 30323122
537;apomorphine;apomorphine;CHEMBL53;DB00714;6005;58-00-4;N21FAR7B4S;VMWNQDUVQKEIOC-CYBMUJFWSA-N;CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O;26732;23;437;374;0;2;3;0;20;4;Approved;2004;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;30835406, 31643473, 30323122
537;apomorphine;apomorphine;CHEMBL53;DB00714;6005;58-00-4;N21FAR7B4S;VMWNQDUVQKEIOC-CYBMUJFWSA-N;CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O;26732;23;437;374;0;2;3;0;20;4;Approved;2004;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;30835406, 31643473, 30323122
537;apomorphine;apomorphine;CHEMBL53;DB00714;6005;58-00-4;N21FAR7B4S;VMWNQDUVQKEIOC-CYBMUJFWSA-N;CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O;26732;23;437;374;0;2;3;0;20;4;Approved;2004;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;FB83.1Z;Osteoporosis, unspecified;1;Inactive;2113001430/unspecified;30835406, 31643473, 30323122
537;apomorphine;apomorphine;CHEMBL53;DB00714;6005;58-00-4;N21FAR7B4S;VMWNQDUVQKEIOC-CYBMUJFWSA-N;CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O;26732;23;437;374;0;2;3;0;20;4;Approved;2004;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;HA01.1Z;Male erectile dysfunction, unspecified;4;Approved;97556145/unspecified;30835406, 31643473, 30323122
537;apomorphine;apomorphine;CHEMBL53;DB00714;6005;58-00-4;N21FAR7B4S;VMWNQDUVQKEIOC-CYBMUJFWSA-N;CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O;26732;23;437;374;0;2;3;0;20;4;Approved;2004;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB27.2Z;Hallucinations, unspecified;2;Unknown;665363966/unspecified;30835406, 31643473, 30323122
537;apomorphine;apomorphine;CHEMBL53;DB00714;6005;58-00-4;N21FAR7B4S;VMWNQDUVQKEIOC-CYBMUJFWSA-N;CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O;26732;23;437;374;0;2;3;0;20;4;Approved;2004;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;30835406, 31643473, 30323122
538;imidafenacin;imidafenacin;CHEMBL53366;DB09262;6433090;170105-16-5;XJR8Y07LJO;SQKXYSGRELMAAU-UHFFFAOYSA-N;CC1=NC=CN1CCC(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N;3194;27;609;395;0;1;2;6;24;4;Approved;2007;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;25636812, 23641864, 32405660
538;imidafenacin;imidafenacin;CHEMBL53366;DB09262;6433090;170105-16-5;XJR8Y07LJO;SQKXYSGRELMAAU-UHFFFAOYSA-N;CC1=NC=CN1CCC(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N;3194;27;609;395;0;1;2;6;24;4;Approved;2007;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;25636812, 23641864, 32405660
538;imidafenacin;imidafenacin;CHEMBL53366;DB09262;6433090;170105-16-5;XJR8Y07LJO;SQKXYSGRELMAAU-UHFFFAOYSA-N;CC1=NC=CN1CCC(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N;3194;27;609;395;0;1;2;6;24;4;Approved;2007;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;GC50.0;Overactive bladder;4;Approved;1118102209;25636812, 23641864, 32405660
539;ketotifen;ketotifen;CHEMBL534;DB00920;3827;34580-13-7;X49220T18G;ZCVMWBYGMWKGHF-UHFFFAOYSA-N;CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1;3094;32;486;476;0;0;3;0;22;4;Approved;1999;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000587, 1601503, 34410005
539;ketotifen;ketotifen;CHEMBL534;DB00920;3827;34580-13-7;X49220T18G;ZCVMWBYGMWKGHF-UHFFFAOYSA-N;CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1;3094;32;486;476;0;0;3;0;22;4;Approved;1999;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000587, 1601503, 34410005
539;ketotifen;ketotifen;CHEMBL534;DB00920;3827;34580-13-7;X49220T18G;ZCVMWBYGMWKGHF-UHFFFAOYSA-N;CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1;3094;32;486;476;0;0;3;0;22;4;Approved;1999;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.03;Other allergic rhinitis;4;Approved;941478759;30000587, 1601503, 34410005
539;ketotifen;ketotifen;CHEMBL534;DB00920;3827;34580-13-7;X49220T18G;ZCVMWBYGMWKGHF-UHFFFAOYSA-N;CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1;3094;32;486;476;0;0;3;0;22;4;Approved;1999;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;4;Approved;215767047/unspecified;30000587, 1601503, 34410005
539;ketotifen;ketotifen;CHEMBL534;DB00920;3827;34580-13-7;X49220T18G;ZCVMWBYGMWKGHF-UHFFFAOYSA-N;CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1;3094;32;486;476;0;0;3;0;22;4;Approved;1999;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;FA31.2;Flexion deformity;2;Inactive;1235041530;30000587, 1601503, 34410005
539;ketotifen;ketotifen;CHEMBL534;DB00920;3827;34580-13-7;X49220T18G;ZCVMWBYGMWKGHF-UHFFFAOYSA-N;CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1;3094;32;486;476;0;0;3;0;22;4;Approved;1999;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD92;Dyspepsia;3;Active;869622187;30000587, 1601503, 34410005
539;ketotifen;ketotifen;CHEMBL534;DB00920;3827;34580-13-7;X49220T18G;ZCVMWBYGMWKGHF-UHFFFAOYSA-N;CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1;3094;32;486;476;0;0;3;0;22;4;Approved;1999;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MG30.01;Chronic widespread pain;3;Inactive;849253504;30000587, 1601503, 34410005
539;ketotifen;ketotifen;CHEMBL534;DB00920;3827;34580-13-7;X49220T18G;ZCVMWBYGMWKGHF-UHFFFAOYSA-N;CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1;3094;32;486;476;0;0;3;0;22;4;Approved;1999;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MG30.Z;Chronic pain, unspecified;3;Inactive;1581976053/unspecified;30000587, 1601503, 34410005
539;ketotifen;ketotifen;CHEMBL534;DB00920;3827;34580-13-7;X49220T18G;ZCVMWBYGMWKGHF-UHFFFAOYSA-N;CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1;3094;32;486;476;0;0;3;0;22;4;Approved;1999;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;ND56.2;Fracture of unspecified body region;3;Active;1504538171;30000587, 1601503, 34410005
539;ketotifen;ketotifen;CHEMBL534;DB00920;3827;34580-13-7;X49220T18G;ZCVMWBYGMWKGHF-UHFFFAOYSA-N;CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1;3094;32;486;476;0;0;3;0;22;4;Approved;1999;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;RA01;COVID-19;3;Active;1730556128;30000587, 1601503, 34410005
540;patidegib;patidegib;CHEMBL538867;DB12655;25027363;1037210-93-7;NA;HZLFFNCLTRVYJG-WWGOJCOQSA-N;CC1CC2C(C(C3(O2)CCC4C5CCC6CC(CCC6(C5CC4=C(C3)C)C)NS(=O)(=O)C)C)NC1;5048;46;758;988;0;2;5;2;35;3;Active;NA;Small molecule;Antagonist;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2B50.Z;Chondrosarcoma of bone or articular cartilage of unspecified sites;2;Inactive;1625755389/unspecified;34639065
540;patidegib;patidegib;CHEMBL538867;DB12655;25027363;1037210-93-7;NA;HZLFFNCLTRVYJG-WWGOJCOQSA-N;CC1CC2C(C(C3(O2)CCC4C5CCC6CC(CCC6(C5CC4=C(C3)C)C)NS(=O)(=O)C)C)NC1;5048;46;758;988;0;2;5;2;35;3;Active;NA;Small molecule;Antagonist;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C10.Y;Other specified malignant neoplasms of pancreas;1;Inactive;542147910/other;34639065
540;patidegib;patidegib;CHEMBL538867;DB12655;25027363;1037210-93-7;NA;HZLFFNCLTRVYJG-WWGOJCOQSA-N;CC1CC2C(C(C3(O2)CCC4C5CCC6CC(CCC6(C5CC4=C(C3)C)C)NS(=O)(=O)C)C)NC1;5048;46;758;988;0;2;5;2;35;3;Active;NA;Small molecule;Antagonist;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2C32.Z;Basal cell carcinoma of skin, unspecified;3;Inactive;1203447657/unspecified;34639065
540;patidegib;patidegib;CHEMBL538867;DB12655;25027363;1037210-93-7;NA;HZLFFNCLTRVYJG-WWGOJCOQSA-N;CC1CC2C(C(C3(O2)CCC4C5CCC6CC(CCC6(C5CC4=C(C3)C)C)NS(=O)(=O)C)C)NC1;5048;46;758;988;0;2;5;2;35;3;Active;NA;Small molecule;Antagonist;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;3;Inactive;1844086508/unspecified;34639065
540;patidegib;patidegib;CHEMBL538867;DB12655;25027363;1037210-93-7;NA;HZLFFNCLTRVYJG-WWGOJCOQSA-N;CC1CC2C(C(C3(O2)CCC4C5CCC6CC(CCC6(C5CC4=C(C3)C)C)NS(=O)(=O)C)C)NC1;5048;46;758;988;0;2;5;2;35;3;Active;NA;Small molecule;Antagonist;Q99835;smo_human;Class F (Frizzled);Frizzled;Protein receptors;LD2D.4;Gorlin syndrome;3;Inactive;1012745138;34639065
541;zuclopenthixol;zuclopenthixol;CHEMBL53904;DB01624;5311507;53772-83-1;47ISU063SG;WFPIAZLQTJBIFN-DVZOWYKESA-N;C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO;401;43;52;509;0;1;4;5;27;4;Approved;1978;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000827, 26624987, 29144549
541;zuclopenthixol;zuclopenthixol;CHEMBL53904;DB01624;5311507;53772-83-1;47ISU063SG;WFPIAZLQTJBIFN-DVZOWYKESA-N;C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO;401;43;52;509;0;1;4;5;27;4;Approved;1978;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000827, 26624987, 29144549
541;zuclopenthixol;zuclopenthixol;CHEMBL53904;DB01624;5311507;53772-83-1;47ISU063SG;WFPIAZLQTJBIFN-DVZOWYKESA-N;C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO;401;43;52;509;0;1;4;5;27;4;Approved;1978;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000827, 26624987, 29144549
541;zuclopenthixol;zuclopenthixol;CHEMBL53904;DB01624;5311507;53772-83-1;47ISU063SG;WFPIAZLQTJBIFN-DVZOWYKESA-N;C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO;401;43;52;509;0;1;4;5;27;4;Approved;1978;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000827, 26624987, 29144549
541;zuclopenthixol;zuclopenthixol;CHEMBL53904;DB01624;5311507;53772-83-1;47ISU063SG;WFPIAZLQTJBIFN-DVZOWYKESA-N;C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO;401;43;52;509;0;1;4;5;27;4;Approved;1978;Small molecule;Antagonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000827, 26624987, 29144549
541;zuclopenthixol;zuclopenthixol;CHEMBL53904;DB01624;5311507;53772-83-1;47ISU063SG;WFPIAZLQTJBIFN-DVZOWYKESA-N;C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO;401;43;52;509;0;1;4;5;27;4;Approved;1978;Small molecule;Antagonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000827, 26624987, 29144549
542;sparsentan;sparsentan;CHEMBL539423;DB12548;10257882;254740-64-2;NA;WRFHGDPIDHPWIQ-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC;5928;5;123;1060;0;1;8;12;42;4;Approved;2023;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;2;Inactive;761947693/unspecified;37015244, 37022667, 30361325
542;sparsentan;sparsentan;CHEMBL539423;DB12548;10257882;254740-64-2;NA;WRFHGDPIDHPWIQ-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC;5928;5;123;1060;0;1;8;12;42;4;Approved;2023;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;GB40;Nephritic syndrome;4;Approved;1783829886;37015244, 37022667, 30361325
542;sparsentan;sparsentan;CHEMBL539423;DB12548;10257882;254740-64-2;NA;WRFHGDPIDHPWIQ-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC;5928;5;123;1060;0;1;8;12;42;4;Approved;2023;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;MF8Y;Other specified clinical findings in specimens from the urinary system;3;Active;1039550850/other;37015244, 37022667, 30361325
542;sparsentan;sparsentan;CHEMBL539423;DB12548;10257882;254740-64-2;NA;WRFHGDPIDHPWIQ-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC;5928;5;123;1060;0;1;8;12;42;4;Approved;2023;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;2;Inactive;761947693/unspecified;37015244, 37022667, 30361325
542;sparsentan;sparsentan;CHEMBL539423;DB12548;10257882;254740-64-2;NA;WRFHGDPIDHPWIQ-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC;5928;5;123;1060;0;1;8;12;42;4;Approved;2023;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;GB40;Nephritic syndrome;4;Approved;1783829886;37015244, 37022667, 30361325
542;sparsentan;sparsentan;CHEMBL539423;DB12548;10257882;254740-64-2;NA;WRFHGDPIDHPWIQ-UHFFFAOYSA-N;CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC;5928;5;123;1060;0;1;8;12;42;4;Approved;2023;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;MF8Y;Other specified clinical findings in specimens from the urinary system;3;Active;1039550850/other;37015244, 37022667, 30361325
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Inactive;1456478153/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A8Z;Mood disorders, unspecified;2;Inactive;76398729/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;4;Approved;897917531/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB23.0;Aggressive behaviour;4;Approved;501393848;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;3;Inactive;496629459;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD90.0;Nausea;3;Inactive;596805318;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Inactive;1456478153/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A8Z;Mood disorders, unspecified;2;Inactive;76398729/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;4;Approved;897917531/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB23.0;Aggressive behaviour;4;Approved;501393848;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.F;Restlessness;3;Inactive;496629459;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.0;Nausea;3;Inactive;596805318;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Inactive;1456478153/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A8Z;Mood disorders, unspecified;2;Inactive;76398729/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;4;Approved;897917531/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB23.0;Aggressive behaviour;4;Approved;501393848;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.F;Restlessness;3;Inactive;496629459;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.0;Nausea;3;Inactive;596805318;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Inactive;1456478153/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A8Z;Mood disorders, unspecified;2;Inactive;76398729/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;4;Approved;897917531/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB23.0;Aggressive behaviour;4;Approved;501393848;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;3;Inactive;496629459;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD90.0;Nausea;3;Inactive;596805318;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;3;Inactive;1456478153/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A8Z;Mood disorders, unspecified;2;Inactive;76398729/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;4;Approved;897917531/unspecified;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;4;Approved;119340957;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB23.0;Aggressive behaviour;4;Approved;501393848;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.F;Restlessness;3;Inactive;496629459;29999969, 32809727, 31643712
543;haloperidol;haloperidol;CHEMBL54;DB00502;3559;52-86-8;J6292F8L3D;LNEPOXFFQSENCJ-UHFFFAOYSA-N;C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F;3759;32;405;451;0;1;4;6;26;4;Approved;1967;Small molecule;Inverse agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.0;Nausea;3;Inactive;596805318;29999969, 32809727, 31643712
544;oxprenolol;oxprenolol;CHEMBL546;DB01580;4631;6452-71-7;519MXN9YZR;CEMAWMOMDPGJMB-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC=C1OCC=C)O;26535;21;507;246;0;2;4;9;19;4;Approved;1983;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;6356864, 36346141, 4121565
544;oxprenolol;oxprenolol;CHEMBL546;DB01580;4631;6452-71-7;519MXN9YZR;CEMAWMOMDPGJMB-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=CC=C1OCC=C)O;26535;21;507;246;0;2;4;9;19;4;Approved;1983;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;6356864, 36346141, 4121565
545;dinoprostone;dinoprostone;CHEMBL548;DB00917;5280360;363-24-6;K7Q1JQR04M;XEYBRNLFEZDVAW-ARSRFYASSA-N;CCCCCC(C=CC1C(CC(=O)C1CC=CCCCC(=O)O)O)O;3525;28;948;469;0;3;5;12;25;4;Approved;1977;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA00.24;Unspecified abortion, incomplete, without complication;2;Active;1946052500;30000698, 31424863, 30317521
545;dinoprostone;dinoprostone;CHEMBL548;DB00917;5280360;363-24-6;K7Q1JQR04M;XEYBRNLFEZDVAW-ARSRFYASSA-N;CCCCCC(C=CC1C(CC(=O)C1CC=CCCCC(=O)O)O)O;3525;28;948;469;0;3;5;12;25;4;Approved;1977;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JB2Z;Delivery, unspecified;4;Approved;973282267/unspecified;30000698, 31424863, 30317521
545;dinoprostone;dinoprostone;CHEMBL548;DB00917;5280360;363-24-6;K7Q1JQR04M;XEYBRNLFEZDVAW-ARSRFYASSA-N;CCCCCC(C=CC1C(CC(=O)C1CC=CCCCC(=O)O)O)O;3525;28;948;469;0;3;5;12;25;4;Approved;1977;Small molecule;Agonist;P35408;pe2r4_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA00.24;Unspecified abortion, incomplete, without complication;2;Active;1946052500;30000698, 31424863, 30317521
545;dinoprostone;dinoprostone;CHEMBL548;DB00917;5280360;363-24-6;K7Q1JQR04M;XEYBRNLFEZDVAW-ARSRFYASSA-N;CCCCCC(C=CC1C(CC(=O)C1CC=CCCCC(=O)O)O)O;3525;28;948;469;0;3;5;12;25;4;Approved;1977;Small molecule;Agonist;P35408;pe2r4_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JB2Z;Delivery, unspecified;4;Approved;973282267/unspecified;30000698, 31424863, 30317521
545;dinoprostone;dinoprostone;CHEMBL548;DB00917;5280360;363-24-6;K7Q1JQR04M;XEYBRNLFEZDVAW-ARSRFYASSA-N;CCCCCC(C=CC1C(CC(=O)C1CC=CCCCC(=O)O)O)O;3525;28;948;469;0;3;5;12;25;4;Approved;1977;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA00.24;Unspecified abortion, incomplete, without complication;2;Active;1946052500;30000698, 31424863, 30317521
545;dinoprostone;dinoprostone;CHEMBL548;DB00917;5280360;363-24-6;K7Q1JQR04M;XEYBRNLFEZDVAW-ARSRFYASSA-N;CCCCCC(C=CC1C(CC(=O)C1CC=CCCCC(=O)O)O)O;3525;28;948;469;0;3;5;12;25;4;Approved;1977;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JB2Z;Delivery, unspecified;4;Approved;973282267/unspecified;30000698, 31424863, 30317521
545;dinoprostone;dinoprostone;CHEMBL548;DB00917;5280360;363-24-6;K7Q1JQR04M;XEYBRNLFEZDVAW-ARSRFYASSA-N;CCCCCC(C=CC1C(CC(=O)C1CC=CCCCC(=O)O)O)O;3525;28;948;469;0;3;5;12;25;4;Approved;1977;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA00.24;Unspecified abortion, incomplete, without complication;2;Active;1946052500;30000698, 31424863, 30317521
545;dinoprostone;dinoprostone;CHEMBL548;DB00917;5280360;363-24-6;K7Q1JQR04M;XEYBRNLFEZDVAW-ARSRFYASSA-N;CCCCCC(C=CC1C(CC(=O)C1CC=CCCCC(=O)O)O)O;3525;28;948;469;0;3;5;12;25;4;Approved;1977;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JB2Z;Delivery, unspecified;4;Approved;973282267/unspecified;30000698, 31424863, 30317521
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9A1Y;Other specified disorders of lacrimal apparatus;2;Active;1628710366/other;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C61.01;Ocular hypertension;4;Approved;535283437;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C61.12;Primary angle closure glaucoma;4;Approved;559190357;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.3;Presbyopia;3;Active;22794400;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA02.1;Xerostomia;4;Approved;1810717437;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9A1Y;Other specified disorders of lacrimal apparatus;2;Active;1628710366/other;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C61.01;Ocular hypertension;4;Approved;535283437;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C61.12;Primary angle closure glaucoma;4;Approved;559190357;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.3;Presbyopia;3;Active;22794400;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA02.1;Xerostomia;4;Approved;1810717437;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9A1Y;Other specified disorders of lacrimal apparatus;2;Active;1628710366/other;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C61.01;Ocular hypertension;4;Approved;535283437;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C61.12;Primary angle closure glaucoma;4;Approved;559190357;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.3;Presbyopia;3;Active;22794400;30000719, 32310588, 31644122
546;pilocarpine;pilocarpine;CHEMBL550;DB01085;5910;92-13-7;01MI4Q9DI3;QCHFTSOMWOSFHM-WPRPVWTQSA-N;CCC1C(COC1=O)CC2=CN=CN2C;20826;11;441;245;0;0;3;3;15;4;Approved;1974;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA02.1;Xerostomia;4;Approved;1810717437;30000719, 32310588, 31644122
550;perphenazine;perphenazine;CHEMBL567;DB00850;4748;58-39-9;FTA7XXY4EZ;RGCVKNLCSQQDEP-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO;404;42;552;463;0;1;5;6;27;4;Approved;1957;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000123, 31643687, 38349994
550;perphenazine;perphenazine;CHEMBL567;DB00850;4748;58-39-9;FTA7XXY4EZ;RGCVKNLCSQQDEP-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO;404;42;552;463;0;1;5;6;27;4;Approved;1957;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000123, 31643687, 38349994
550;perphenazine;perphenazine;CHEMBL567;DB00850;4748;58-39-9;FTA7XXY4EZ;RGCVKNLCSQQDEP-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO;404;42;552;463;0;1;5;6;27;4;Approved;1957;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.F;Restlessness;3;Inactive;496629459;30000123, 31643687, 38349994
550;perphenazine;perphenazine;CHEMBL567;DB00850;4748;58-39-9;FTA7XXY4EZ;RGCVKNLCSQQDEP-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO;404;42;552;463;0;1;5;6;27;4;Approved;1957;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000123, 31643687, 38349994
550;perphenazine;perphenazine;CHEMBL567;DB00850;4748;58-39-9;FTA7XXY4EZ;RGCVKNLCSQQDEP-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO;404;42;552;463;0;1;5;6;27;4;Approved;1957;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000123, 31643687, 38349994
550;perphenazine;perphenazine;CHEMBL567;DB00850;4748;58-39-9;FTA7XXY4EZ;RGCVKNLCSQQDEP-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO;404;42;552;463;0;1;5;6;27;4;Approved;1957;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000123, 31643687, 38349994
550;perphenazine;perphenazine;CHEMBL567;DB00850;4748;58-39-9;FTA7XXY4EZ;RGCVKNLCSQQDEP-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO;404;42;552;463;0;1;5;6;27;4;Approved;1957;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.F;Restlessness;3;Inactive;496629459;30000123, 31643687, 38349994
550;perphenazine;perphenazine;CHEMBL567;DB00850;4748;58-39-9;FTA7XXY4EZ;RGCVKNLCSQQDEP-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO;404;42;552;463;0;1;5;6;27;4;Approved;1957;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000123, 31643687, 38349994
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;S-scopolamine;CHEMBL1187846;DB00747;119680147;51-34-3;DL48G20X8X;STECJAGHUSJQJN-SFSMXDMGSA-N;CC1=NN(C(=C1)NC(=O)CCCNC)C.Cl;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;(-)-scopolamine;CHEMBL13030;DB00747;5184;51-34-3;DL48G20X8X;STECJAGHUSJQJN-UHFFFAOYSA-N;CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;hyoscine;CHEMBL569713;DB00747;3000322;51-34-3;DL48G20X8X;STECJAGHUSJQJN-USLFZFAMSA-N;CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;2;Active;1456478153/unspecified;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;1;Unknown;1669279433;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Inactive;1563440232/unspecified;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6B04;Social anxiety disorder;1;Inactive;2062286624;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;1;Inactive;1611724421;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA04.6;Disturbances of salivary secretion;1;Inactive;1739126837;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD81.4;Other and unspecified abdominal pain;4;Approved;166022696;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;30000542, 32119284, 16175141
551;scopolamine;atroscine;CHEMBL516223;DB00747;452977;51-34-3;DL48G20X8X;STECJAGHUSJQJN-YXPYLGEYSA-N;CN1[C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4;30335;9;623;418;0;1;5;5;22;4;Approved;1979;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000542, 32119284, 16175141
552;triflupromazine;triflupromazine;CHEMBL570;DB00508;5568;146-54-3;RO16TQF95Y;XSCGXQMFQXDFCW-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F;3524;52;318;416;0;0;6;4;24;4;Approved;1957;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;13587265, 13498196, 37300428
552;triflupromazine;triflupromazine;CHEMBL570;DB00508;5568;146-54-3;RO16TQF95Y;XSCGXQMFQXDFCW-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F;3524;52;318;416;0;0;6;4;24;4;Approved;1957;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;13587265, 13498196, 37300428
552;triflupromazine;triflupromazine;CHEMBL570;DB00508;5568;146-54-3;RO16TQF95Y;XSCGXQMFQXDFCW-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F;3524;52;318;416;0;0;6;4;24;4;Approved;1957;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;13587265, 13498196, 37300428
552;triflupromazine;triflupromazine;CHEMBL570;DB00508;5568;146-54-3;RO16TQF95Y;XSCGXQMFQXDFCW-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F;3524;52;318;416;0;0;6;4;24;4;Approved;1957;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;13587265, 13498196, 37300428
552;triflupromazine;triflupromazine;CHEMBL570;DB00508;5568;146-54-3;RO16TQF95Y;XSCGXQMFQXDFCW-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F;3524;52;318;416;0;0;6;4;24;4;Approved;1957;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;13587265, 13498196, 37300428
553;azilsartan;azilsartan;CHEMBL57242;NA;135415867;"147403-03-0;1794817-45-0";NA;KGSXMPPBFPAXLY-UHFFFAOYSA-N;CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O;4564;44;115;783;0;2;6;7;34;4;Approved;2011;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000828, 30860708, 31643367
554;fenoldopam;fenoldopam;CHEMBL588;DB00800;3341;67227-56-9;INU8H2KAWG;TVURRHSHRRELCG-UHFFFAOYSA-N;C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O;30575;24;727;348;0;4;4;1;21;4;Approved;1997;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30252314, 30000704, 1974439
554;fenoldopam;fenoldopam;CHEMBL588;DB00800;3341;67227-56-9;INU8H2KAWG;TVURRHSHRRELCG-UHFFFAOYSA-N;C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O;30575;24;727;348;0;4;4;1;21;4;Approved;1997;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30252314, 30000704, 1974439
554;fenoldopam;fenoldopam;CHEMBL588;DB00800;3341;67227-56-9;INU8H2KAWG;TVURRHSHRRELCG-UHFFFAOYSA-N;C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O;30575;24;727;348;0;4;4;1;21;4;Approved;1997;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;GB60.Y;Other specified acute kidney failure;3;Unknown;476391827/other;30252314, 30000704, 1974439
554;fenoldopam;fenoldopam;CHEMBL588;DB00800;3341;67227-56-9;INU8H2KAWG;TVURRHSHRRELCG-UHFFFAOYSA-N;C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O;30575;24;727;348;0;4;4;1;21;4;Approved;1997;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30252314, 30000704, 1974439
554;fenoldopam;fenoldopam;CHEMBL588;DB00800;3341;67227-56-9;INU8H2KAWG;TVURRHSHRRELCG-UHFFFAOYSA-N;C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O;30575;24;727;348;0;4;4;1;21;4;Approved;1997;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30252314, 30000704, 1974439
554;fenoldopam;fenoldopam;CHEMBL588;DB00800;3341;67227-56-9;INU8H2KAWG;TVURRHSHRRELCG-UHFFFAOYSA-N;C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O;30575;24;727;348;0;4;4;1;21;4;Approved;1997;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;GB60.Y;Other specified acute kidney failure;3;Unknown;476391827/other;30252314, 30000704, 1974439
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A60.1;Hyperprolactinaemia;1;Inactive;1417218455;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;4;Approved;1254916765;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A61.41;Progressive myoclonic epilepsy;2;Unknown;173613583;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Inactive;1442995018;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A60.1;Hyperprolactinaemia;1;Inactive;1417218455;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;4;Approved;1254916765;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A61.41;Progressive myoclonic epilepsy;2;Unknown;173613583;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Inactive;1442995018;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A60.1;Hyperprolactinaemia;1;Inactive;1417218455;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A80;Restless legs syndrome;4;Approved;1254916765;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A61.41;Progressive myoclonic epilepsy;2;Unknown;173613583;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Inactive;1442995018;32119419, 30000578, 31643503
555;ropinirole;ropinirole;CHEMBL589;DB00268;5095;91374-21-9;030PYR8953;UHSKFQJFRQCDBE-UHFFFAOYSA-N;CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1;26037;27;323;287;0;1;2;7;19;4;Approved;1997;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;32119419, 30000578, 31643503
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;3;Active;296066191/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;4;Approved;2136808878;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;2;Inactive;1458683894/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB6Z;Kidney failure, unspecified;4;Approved;761526554/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;KA21.4Z;Preterm newborn, unspecified;2;Unknown;1726201225/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;2;Unknown;1282135070/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;3;Inactive;1164022950/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X1;Anesthesia;3;Unknown;NA;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;3;Active;296066191/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BD10;Congestive heart failure;4;Approved;2136808878;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BD1Z;Heart failure, unspecified;2;Inactive;1458683894/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;GB6Z;Kidney failure, unspecified;4;Approved;761526554/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;KA21.4Z;Preterm newborn, unspecified;2;Unknown;1726201225/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;2;Unknown;1282135070/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG40.Z;Shock, unspecified;3;Inactive;1164022950/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;X1;Anesthesia;3;Unknown;NA;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;3;Active;296066191/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BD10;Congestive heart failure;4;Approved;2136808878;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BD1Z;Heart failure, unspecified;2;Inactive;1458683894/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;GB6Z;Kidney failure, unspecified;4;Approved;761526554/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;KA21.4Z;Preterm newborn, unspecified;2;Unknown;1726201225/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;2;Unknown;1282135070/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG40.Z;Shock, unspecified;3;Inactive;1164022950/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;X1;Anesthesia;3;Unknown;NA;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;3;Active;296066191/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BD10;Congestive heart failure;4;Approved;2136808878;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BD1Z;Heart failure, unspecified;2;Inactive;1458683894/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;GB6Z;Kidney failure, unspecified;4;Approved;761526554/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;KA21.4Z;Preterm newborn, unspecified;2;Unknown;1726201225/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;2;Unknown;1282135070/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG40.Z;Shock, unspecified;3;Inactive;1164022950/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;X1;Anesthesia;3;Unknown;NA;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;3;Active;296066191/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BD10;Congestive heart failure;4;Approved;2136808878;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BD1Z;Heart failure, unspecified;2;Inactive;1458683894/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;GB6Z;Kidney failure, unspecified;4;Approved;761526554/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;KA21.4Z;Preterm newborn, unspecified;2;Unknown;1726201225/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;2;Unknown;1282135070/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG40.Z;Shock, unspecified;3;Inactive;1164022950/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;X1;Anesthesia;3;Unknown;NA;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;3;Active;296066191/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BD10;Congestive heart failure;4;Approved;2136808878;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BD1Z;Heart failure, unspecified;2;Inactive;1458683894/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;GB6Z;Kidney failure, unspecified;4;Approved;761526554/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;KA21.4Z;Preterm newborn, unspecified;2;Unknown;1726201225/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB21.Z;Symptoms and signs involving cognition, unspecified;2;Unknown;1282135070/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG40.Z;Shock, unspecified;3;Inactive;1164022950/unspecified;29760524, 31905114, 34852810
556;dopamine;dopamine;CHEMBL59;DB00988;681;51-61-6;VTD58H1Z2X;VYFYYTLLBUKUHU-UHFFFAOYSA-N;C1=CC(=C(C=C1CCN)O)O;15318;-1;665;119;0;3;3;2;11;4;Approved;1974;Small molecule;Agonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;X1;Anesthesia;3;Unknown;NA;29760524, 31905114, 34852810
557;levorphanol;levorphanol;CHEMBL592;DB00854;5359272;77-07-6;27618J1N2X;JAQUASYNZVUNQP-USXIJHARSA-N;CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)O;25737;31;235;357;0;1;2;0;19;4;Approved;1991;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;31643300, 32156130, 26635068
558;emedastine;emedastine;CHEMBL594;DB01084;3219;87233-61-2;9J1H7Y9OJV;KBUZBQVCBVDWKX-UHFFFAOYSA-N;CCOCCN1C2=CC=CC=C2N=C1N3CCCN(CC3)C;3024;22;335;341;0;0;4;5;22;4;Approved;1997;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000584, 19558341, 29395965
559;fentanyl;fentanyl;CHEMBL596;DB00813;3345;437-38-7;UF599785JZ;PJMPHNIQZUBGLI-UHFFFAOYSA-N;CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3;3365;4;236;391;0;0;2;6;25;4;Approved;1968;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8A80.Z;Migraine, unspecified;3;Inactive;669367341/unspecified;15907648, 36459152, 34030211
559;fentanyl;fentanyl;CHEMBL596;DB00813;3345;437-38-7;UF599785JZ;PJMPHNIQZUBGLI-UHFFFAOYSA-N;CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3;3365;4;236;391;0;0;2;6;25;4;Approved;1968;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;CB0Z;Respiratory diseases principally affecting the lung interstitium, unspecified;3;Inactive;111658096/unspecified;15907648, 36459152, 34030211
559;fentanyl;fentanyl;CHEMBL596;DB00813;3345;437-38-7;UF599785JZ;PJMPHNIQZUBGLI-UHFFFAOYSA-N;CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3;3365;4;236;391;0;0;2;6;25;4;Approved;1968;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;CB41;Respiratory failure;3;Unknown;370028006;15907648, 36459152, 34030211
559;fentanyl;fentanyl;CHEMBL596;DB00813;3345;437-38-7;UF599785JZ;PJMPHNIQZUBGLI-UHFFFAOYSA-N;CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3;3365;4;236;391;0;0;2;6;25;4;Approved;1968;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD11.5;Dyspnoea;3;Active;960305085;15907648, 36459152, 34030211
559;fentanyl;fentanyl;CHEMBL596;DB00813;3345;437-38-7;UF599785JZ;PJMPHNIQZUBGLI-UHFFFAOYSA-N;CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3;3365;4;236;391;0;0;2;6;25;4;Approved;1968;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;15907648, 36459152, 34030211
559;fentanyl;fentanyl;CHEMBL596;DB00813;3345;437-38-7;UF599785JZ;PJMPHNIQZUBGLI-UHFFFAOYSA-N;CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3;3365;4;236;391;0;0;2;6;25;4;Approved;1968;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8A80.Z;Migraine, unspecified;3;Inactive;669367341/unspecified;15907648, 36459152, 34030211
559;fentanyl;fentanyl;CHEMBL596;DB00813;3345;437-38-7;UF599785JZ;PJMPHNIQZUBGLI-UHFFFAOYSA-N;CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3;3365;4;236;391;0;0;2;6;25;4;Approved;1968;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;CB0Z;Respiratory diseases principally affecting the lung interstitium, unspecified;3;Inactive;111658096/unspecified;15907648, 36459152, 34030211
559;fentanyl;fentanyl;CHEMBL596;DB00813;3345;437-38-7;UF599785JZ;PJMPHNIQZUBGLI-UHFFFAOYSA-N;CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3;3365;4;236;391;0;0;2;6;25;4;Approved;1968;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;CB41;Respiratory failure;3;Unknown;370028006;15907648, 36459152, 34030211
559;fentanyl;fentanyl;CHEMBL596;DB00813;3345;437-38-7;UF599785JZ;PJMPHNIQZUBGLI-UHFFFAOYSA-N;CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3;3365;4;236;391;0;0;2;6;25;4;Approved;1968;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD11.5;Dyspnoea;3;Active;960305085;15907648, 36459152, 34030211
559;fentanyl;fentanyl;CHEMBL596;DB00813;3345;437-38-7;UF599785JZ;PJMPHNIQZUBGLI-UHFFFAOYSA-N;CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3;3365;4;236;391;0;0;2;6;25;4;Approved;1968;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;15907648, 36459152, 34030211
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;1;Active;1004695600;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9D00.3;Presbyopia;2;Inactive;22794400;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;3;Active;538839606;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X5;Diagnosis of pheochromocytoma;4;Approved;NA;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;1;Active;1004695600;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9D00.3;Presbyopia;2;Inactive;22794400;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;3;Active;538839606;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X5;Diagnosis of pheochromocytoma;4;Approved;NA;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;1;Active;1004695600;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9D00.3;Presbyopia;2;Inactive;22794400;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;3;Active;538839606;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X5;Diagnosis of pheochromocytoma;4;Approved;NA;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;1;Active;1004695600;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9D00.3;Presbyopia;2;Inactive;22794400;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;3;Active;538839606;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X5;Diagnosis of pheochromocytoma;4;Approved;NA;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;1;Active;1004695600;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9D00.3;Presbyopia;2;Inactive;22794400;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;3;Active;538839606;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X5;Diagnosis of pheochromocytoma;4;Approved;NA;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;1;Active;1004695600;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9D00.3;Presbyopia;2;Inactive;22794400;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;3;Active;538839606;949032, 4158359, 5352027
561;phentolamine;phentolamine;CHEMBL597;DB00692;5775;50-60-2;Z468598HBV;MRBDMNSDAVCSSF-UHFFFAOYSA-N;CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O;28135;26;479;363;0;2;3;4;21;4;Approved;1952;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X5;Diagnosis of pheochromocytoma;4;Approved;NA;949032, 4158359, 5352027
564;zafirlukast;zafirlukast;CHEMBL603;DB00549;5717;107753-78-6;XZ629S5L50;YEEZWCHGZNKEEK-UHFFFAOYSA-N;CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC;5757;55;124;1010;0;2;6;9;41;4;Approved;1996;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;2C73.Z;Malignant neoplasms of ovary, unspecified;2;Active;685124533/unspecified;32491776, 30000549, 31643251
564;zafirlukast;zafirlukast;CHEMBL603;DB00549;5717;107753-78-6;XZ629S5L50;YEEZWCHGZNKEEK-UHFFFAOYSA-N;CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC;5757;55;124;1010;0;2;6;9;41;4;Approved;1996;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CA23;Asthma;4;Approved;1656445230;32491776, 30000549, 31643251
564;zafirlukast;zafirlukast;CHEMBL603;DB00549;5717;107753-78-6;XZ629S5L50;YEEZWCHGZNKEEK-UHFFFAOYSA-N;CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC;5757;55;124;1010;0;2;6;9;41;4;Approved;1996;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;32491776, 30000549, 31643251
565;olodaterol;olodaterol;CHEMBL605846;DB09080;11504295;868049-49-4;VD2YSN1AFD;COUYJEVMBVSIHV-SFHVURJKSA-N;CC(C)(CC1=CC=C(C=C1)OC)NCC(C2=C3C(=CC(=C2)O)NC(=O)CO3)O;3864;18;100;521;0;4;6;7;28;4;Approved;2014;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA20.1Z;Chronic bronchitis, unspecified;4;Approved;290835130/unspecified;29999839, 31119643, 26683033
565;olodaterol;olodaterol;CHEMBL605846;DB09080;11504295;868049-49-4;VD2YSN1AFD;COUYJEVMBVSIHV-SFHVURJKSA-N;CC(C)(CC1=CC=C(C=C1)OC)NCC(C2=C3C(=CC(=C2)O)NC(=O)CO3)O;3864;18;100;521;0;4;6;7;28;4;Approved;2014;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA21.Z;Emphysema, unspecified;4;Approved;1948124976/unspecified;29999839, 31119643, 26683033
565;olodaterol;olodaterol;CHEMBL605846;DB09080;11504295;868049-49-4;VD2YSN1AFD;COUYJEVMBVSIHV-SFHVURJKSA-N;CC(C)(CC1=CC=C(C=C1)OC)NCC(C2=C3C(=CC(=C2)O)NC(=O)CO3)O;3864;18;100;521;0;4;6;7;28;4;Approved;2014;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;29999839, 31119643, 26683033
565;olodaterol;olodaterol;CHEMBL605846;DB09080;11504295;868049-49-4;VD2YSN1AFD;COUYJEVMBVSIHV-SFHVURJKSA-N;CC(C)(CC1=CC=C(C=C1)OC)NCC(C2=C3C(=CC(=C2)O)NC(=O)CO3)O;3864;18;100;521;0;4;6;7;28;4;Approved;2014;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;2;Inactive;1656445230;29999839, 31119643, 26683033
565;olodaterol;olodaterol;CHEMBL605846;DB09080;11504295;868049-49-4;VD2YSN1AFD;COUYJEVMBVSIHV-SFHVURJKSA-N;CC(C)(CC1=CC=C(C=C1)OC)NCC(C2=C3C(=CC(=C2)O)NC(=O)CO3)O;3864;18;100;521;0;4;6;7;28;4;Approved;2014;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;29999839, 31119643, 26683033
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;1A04;Intestinal infections due to Clostridioides difficile;2;Inactive;250688797;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;DA60.Z;Gastric ulcer, unspecified;4;Approved;1437411258/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;DA63.Z;Duodenal ulcer, unspecified;4;Approved;553678663/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;FA0Z;Osteoarthritis, unspecified;4;Approved;558562409/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA00.0;Spontaneous abortion;3;Inactive;696502028;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA00.24;Unspecified abortion, incomplete, without complication;1;Inactive;1946052500;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA43.Z;Postpartum haemorrhage, unspecified;3;Active;820245648/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JB2Z;Delivery, unspecified;3;Unknown;973282267/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;MB47.3;Cramp or spasm;3;Unknown;157838476;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;MG27;Haemorrhage, not elsewhere classified;3;Inactive;940081636;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P34995;pe2r1_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;1A04;Intestinal infections due to Clostridioides difficile;2;Inactive;250688797;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;DA60.Z;Gastric ulcer, unspecified;4;Approved;1437411258/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;DA63.Z;Duodenal ulcer, unspecified;4;Approved;553678663/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;FA0Z;Osteoarthritis, unspecified;4;Approved;558562409/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA00.0;Spontaneous abortion;3;Inactive;696502028;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA00.24;Unspecified abortion, incomplete, without complication;1;Inactive;1946052500;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA43.Z;Postpartum haemorrhage, unspecified;3;Active;820245648/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JB2Z;Delivery, unspecified;3;Unknown;973282267/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;MB47.3;Cramp or spasm;3;Unknown;157838476;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;MG27;Haemorrhage, not elsewhere classified;3;Inactive;940081636;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43115;pe2r3_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;1A04;Intestinal infections due to Clostridioides difficile;2;Inactive;250688797;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;DA60.Z;Gastric ulcer, unspecified;4;Approved;1437411258/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;DA63.Z;Duodenal ulcer, unspecified;4;Approved;553678663/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;FA0Z;Osteoarthritis, unspecified;4;Approved;558562409/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA00.0;Spontaneous abortion;3;Inactive;696502028;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA00.24;Unspecified abortion, incomplete, without complication;1;Inactive;1946052500;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JA43.Z;Postpartum haemorrhage, unspecified;3;Active;820245648/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;JB2Z;Delivery, unspecified;3;Unknown;973282267/unspecified;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;MB47.3;Cramp or spasm;3;Unknown;157838476;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;MG27;Haemorrhage, not elsewhere classified;3;Inactive;940081636;28526143, 30000496, 30969695
566;misoprostol;misoprostol;CHEMBL606;DB00929;5282381;59122-46-2;0E43V0BB57;OJLOPKGSLYJEMD-URPKTTJQSA-N;CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O;3825;37;838;487;0;2;5;14;27;4;Approved;1988;Small molecule;Agonist;P43116;pe2r2_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;28526143, 30000496, 30969695
567;meperidine;meperidine;CHEMBL607;DB00454;4058;57-42-1;9E338QE28F;XADCESSVHJOZHK-UHFFFAOYSA-N;CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2;24733;25;295;276;0;0;3;4;18;4;Approved;1942;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;29261967, 30000291, 31644073
568;mosapride;mosapride;CHEMBL60889;DB11675;119584;112885-41-3;NA;YPELFRMCRYSPKZ-UHFFFAOYSA-N;CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N;4219;28;768;521;0;2;6;7;29;4;Approved;1998;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DA42.Z;Gastritis, unspecified;4;Approved;1871672644/unspecified;35531622, 18457463, 32304239
568;mosapride;mosapride;CHEMBL60889;DB11675;119584;112885-41-3;NA;YPELFRMCRYSPKZ-UHFFFAOYSA-N;CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N;4219;28;768;521;0;2;6;7;29;4;Approved;1998;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DA93.0;Paralytic ileus;3;Inactive;1868011045;35531622, 18457463, 32304239
568;mosapride;mosapride;CHEMBL60889;DB11675;119584;112885-41-3;NA;YPELFRMCRYSPKZ-UHFFFAOYSA-N;CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N;4219;28;768;521;0;2;6;7;29;4;Approved;1998;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;4;Approved;1158238623/unspecified;35531622, 18457463, 32304239
568;mosapride;mosapride;CHEMBL60889;DB11675;119584;112885-41-3;NA;YPELFRMCRYSPKZ-UHFFFAOYSA-N;CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N;4219;28;768;521;0;2;6;7;29;4;Approved;1998;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DE2Z;Diseases of the digestive system, unspecified;4;Approved;1256772020/unspecified;35531622, 18457463, 32304239
568;mosapride;mosapride;CHEMBL60889;DB11675;119584;112885-41-3;NA;YPELFRMCRYSPKZ-UHFFFAOYSA-N;CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N;4219;28;768;521;0;2;6;7;29;4;Approved;1998;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD92;Dyspepsia;3;Inactive;869622187;35531622, 18457463, 32304239
569;thioproperazine;thioproperazine;CHEMBL609109;DB01622;9429;316-81-4;YJ050AQ56X;VZYCZNZBPPHOFY-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4466;37;808;661;0;0;7;6;30;4;Approved;1961;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;14201648, 14194225, 14190465
569;thioproperazine;thioproperazine;CHEMBL609109;DB01622;9429;316-81-4;YJ050AQ56X;VZYCZNZBPPHOFY-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4466;37;808;661;0;0;7;6;30;4;Approved;1961;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;14201648, 14194225, 14190465
569;thioproperazine;thioproperazine;CHEMBL609109;DB01622;9429;316-81-4;YJ050AQ56X;VZYCZNZBPPHOFY-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4466;37;808;661;0;0;7;6;30;4;Approved;1961;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;14201648, 14194225, 14190465
569;thioproperazine;thioproperazine;CHEMBL609109;DB01622;9429;316-81-4;YJ050AQ56X;VZYCZNZBPPHOFY-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4466;37;808;661;0;0;7;6;30;4;Approved;1961;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;14201648, 14194225, 14190465
569;thioproperazine;thioproperazine;CHEMBL609109;DB01622;9429;316-81-4;YJ050AQ56X;VZYCZNZBPPHOFY-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4466;37;808;661;0;0;7;6;30;4;Approved;1961;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;X1;Anesthesia;4;Approved;NA;14201648, 14194225, 14190465
569;thioproperazine;thioproperazine;CHEMBL609109;DB01622;9429;316-81-4;YJ050AQ56X;VZYCZNZBPPHOFY-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4466;37;808;661;0;0;7;6;30;4;Approved;1961;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;14201648, 14194225, 14190465
569;thioproperazine;thioproperazine;CHEMBL609109;DB01622;9429;316-81-4;YJ050AQ56X;VZYCZNZBPPHOFY-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4466;37;808;661;0;0;7;6;30;4;Approved;1961;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;14201648, 14194225, 14190465
569;thioproperazine;thioproperazine;CHEMBL609109;DB01622;9429;316-81-4;YJ050AQ56X;VZYCZNZBPPHOFY-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4466;37;808;661;0;0;7;6;30;4;Approved;1961;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;14201648, 14194225, 14190465
569;thioproperazine;thioproperazine;CHEMBL609109;DB01622;9429;316-81-4;YJ050AQ56X;VZYCZNZBPPHOFY-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4466;37;808;661;0;0;7;6;30;4;Approved;1961;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;14201648, 14194225, 14190465
569;thioproperazine;thioproperazine;CHEMBL609109;DB01622;9429;316-81-4;YJ050AQ56X;VZYCZNZBPPHOFY-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4466;37;808;661;0;0;7;6;30;4;Approved;1961;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X1;Anesthesia;4;Approved;NA;14201648, 14194225, 14190465
569;thioproperazine;thioproperazine;CHEMBL609109;DB01622;9429;316-81-4;YJ050AQ56X;VZYCZNZBPPHOFY-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4466;37;808;661;0;0;7;6;30;4;Approved;1961;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;14201648, 14194225, 14190465
569;thioproperazine;thioproperazine;CHEMBL609109;DB01622;9429;316-81-4;YJ050AQ56X;VZYCZNZBPPHOFY-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4466;37;808;661;0;0;7;6;30;4;Approved;1961;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;14201648, 14194225, 14190465
569;thioproperazine;thioproperazine;CHEMBL609109;DB01622;9429;316-81-4;YJ050AQ56X;VZYCZNZBPPHOFY-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4466;37;808;661;0;0;7;6;30;4;Approved;1961;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;14201648, 14194225, 14190465
569;thioproperazine;thioproperazine;CHEMBL609109;DB01622;9429;316-81-4;YJ050AQ56X;VZYCZNZBPPHOFY-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4466;37;808;661;0;0;7;6;30;4;Approved;1961;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;14201648, 14194225, 14190465
569;thioproperazine;thioproperazine;CHEMBL609109;DB01622;9429;316-81-4;YJ050AQ56X;VZYCZNZBPPHOFY-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C;4466;37;808;661;0;0;7;6;30;4;Approved;1961;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X1;Anesthesia;4;Approved;NA;14201648, 14194225, 14190465
570;terazosin;terazosin;CHEMBL611;DB01162;5401;63590-64-7;8L5014XET7;VCKUSRYTPJJLNI-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC;3874;14;103;544;0;1;8;4;28;4;Approved;1987;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;1;Inactive;296066191/unspecified;31424792, 30000707, 31643426
570;terazosin;terazosin;CHEMBL611;DB01162;5401;63590-64-7;8L5014XET7;VCKUSRYTPJJLNI-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC;3874;14;103;544;0;1;8;4;28;4;Approved;1987;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31424792, 30000707, 31643426
570;terazosin;terazosin;CHEMBL611;DB01162;5401;63590-64-7;8L5014XET7;VCKUSRYTPJJLNI-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC;3874;14;103;544;0;1;8;4;28;4;Approved;1987;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;3;Unknown;426429380/unspecified;31424792, 30000707, 31643426
570;terazosin;terazosin;CHEMBL611;DB01162;5401;63590-64-7;8L5014XET7;VCKUSRYTPJJLNI-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC;3874;14;103;544;0;1;8;4;28;4;Approved;1987;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA90;Hyperplasia of prostate;4;Approved;978159279;31424792, 30000707, 31643426
570;terazosin;terazosin;CHEMBL611;DB01162;5401;63590-64-7;8L5014XET7;VCKUSRYTPJJLNI-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC;3874;14;103;544;0;1;8;4;28;4;Approved;1987;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;1;Inactive;296066191/unspecified;31424792, 30000707, 31643426
570;terazosin;terazosin;CHEMBL611;DB01162;5401;63590-64-7;8L5014XET7;VCKUSRYTPJJLNI-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC;3874;14;103;544;0;1;8;4;28;4;Approved;1987;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31424792, 30000707, 31643426
570;terazosin;terazosin;CHEMBL611;DB01162;5401;63590-64-7;8L5014XET7;VCKUSRYTPJJLNI-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC;3874;14;103;544;0;1;8;4;28;4;Approved;1987;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;3;Unknown;426429380/unspecified;31424792, 30000707, 31643426
570;terazosin;terazosin;CHEMBL611;DB01162;5401;63590-64-7;8L5014XET7;VCKUSRYTPJJLNI-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC;3874;14;103;544;0;1;8;4;28;4;Approved;1987;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA90;Hyperplasia of prostate;4;Approved;978159279;31424792, 30000707, 31643426
570;terazosin;terazosin;CHEMBL611;DB01162;5401;63590-64-7;8L5014XET7;VCKUSRYTPJJLNI-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC;3874;14;103;544;0;1;8;4;28;4;Approved;1987;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;1;Inactive;296066191/unspecified;31424792, 30000707, 31643426
570;terazosin;terazosin;CHEMBL611;DB01162;5401;63590-64-7;8L5014XET7;VCKUSRYTPJJLNI-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC;3874;14;103;544;0;1;8;4;28;4;Approved;1987;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31424792, 30000707, 31643426
570;terazosin;terazosin;CHEMBL611;DB01162;5401;63590-64-7;8L5014XET7;VCKUSRYTPJJLNI-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC;3874;14;103;544;0;1;8;4;28;4;Approved;1987;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;3;Unknown;426429380/unspecified;31424792, 30000707, 31643426
570;terazosin;terazosin;CHEMBL611;DB01162;5401;63590-64-7;8L5014XET7;VCKUSRYTPJJLNI-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC;3874;14;103;544;0;1;8;4;28;4;Approved;1987;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA90;Hyperplasia of prostate;4;Approved;978159279;31424792, 30000707, 31643426
571;clidinium;clidinium;CHEMBL620;DB00771;2784;7020-55-5;BO76JF850N;HOOSGZJRQIVJSZ-UHFFFAOYSA-N;C[N+]12CCC(CC1)C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O;3524;33;465;482;1;1;3;5;26;4;Approved;1982;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DE2Z;Diseases of the digestive system, unspecified;4;Approved;1256772020/unspecified;32235033, 19465630, 27386057
571;clidinium;clidinium;CHEMBL620;DB00771;2784;7020-55-5;BO76JF850N;HOOSGZJRQIVJSZ-UHFFFAOYSA-N;C[N+]12CCC(CC1)C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O;3524;33;465;482;1;1;3;5;26;4;Approved;1982;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DE2Z;Diseases of the digestive system, unspecified;4;Approved;1256772020/unspecified;32235033, 19465630, 27386057
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6E20;Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium, without psychotic symptoms;1;Active;1124422593;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;3;Active;1038292737/unspecified;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A41;Obstructive sleep apnoea;1;Active;1919233290;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7B2Z;Sleep-wake disorders, unspecified;4;Approved;274880002/unspecified;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8C03.0;Diabetic polyneuropathy;2;Inactive;1837670870;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.F;Restlessness;3;Unknown;496629459;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6E20;Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium, without psychotic symptoms;1;Active;1124422593;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;3;Active;1038292737/unspecified;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7A41;Obstructive sleep apnoea;1;Active;1919233290;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7B2Z;Sleep-wake disorders, unspecified;4;Approved;274880002/unspecified;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8C03.0;Diabetic polyneuropathy;2;Inactive;1837670870;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;3;Unknown;496629459;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6E20;Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium, without psychotic symptoms;1;Active;1124422593;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;3;Active;1038292737/unspecified;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7A41;Obstructive sleep apnoea;1;Active;1919233290;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7B2Z;Sleep-wake disorders, unspecified;4;Approved;274880002/unspecified;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;8C03.0;Diabetic polyneuropathy;2;Inactive;1837670870;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;29552421, 34994734, 11603256
572;trazodone;trazodone;CHEMBL621;DB00656;5533;19794-93-5;YBK48BXK30;PHLBKPHSAVXXEF-UHFFFAOYSA-N;C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl;3719;28;424;611;0;0;4;5;26;4;Approved;1981;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MB24.F;Restlessness;3;Unknown;496629459;29552421, 34994734, 11603256
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;1C62.Z;Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified;1;Inactive;1508081745/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;1F40.Z;Malaria due to Plasmodium falciparum, unspecified;2;Inactive;579583286/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;1F54.1;Cutaneous leishmaniasis;2;Inactive;124737785;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;1F54.Z;Leishmaniasis, unspecified;2;Active;1082373067/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2A0Z;Other and unspecified neoplasms of brain or central nervous system;1;Unknown;879154182/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B33.3;Lymphoid leukaemia, not elsewhere classified;2;Unknown;216388623;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;3A9Z;Anaemias or other erythrocyte disorders, unspecified;1;Unknown;224336967/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;4A62;Behçet disease;2;Active;1668927157;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;4B20.0;Sarcoidosis of lung;2;Inactive;820827059;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A20.Z;Schizophrenia, episode unspecified;1;Active;1683919430/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A60.Z;Bipolar type I disorder, unspecified;1;Inactive;1456478153/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Active;1669279433;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A7Z;Depressive disorders, unspecified;1;Active;1563440232/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8B91.Z;Brachial plexus disorders, unspecified;3;Inactive;1367254559/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8C70.1;Duchenne muscular dystrophy;1;Inactive;1479561744;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA4Z;Acute ischaemic heart disease, unspecified;2;Active;1829545371/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA8Z;Diseases of coronary artery, unspecified;2;Inactive;1059873720/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Inactive;1884917970;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DB92.Y;Other specified non-alcoholic fatty liver disease;2;Inactive;1912806631/other;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DB93.1;Hepatic cirrhosis;3;Inactive;1781315693;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DB94.1Z;Alcoholic hepatitis, unspecified;3;Inactive;229221394/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DB96.1Z;Primary biliary cholangitis, unspecified;2;Inactive;649193479/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DB99.4;Hepatopulmonary syndrome;1;Inactive;866605228;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DB99.7;Hepatic failure without mention whether acute or chronic;3;Inactive;508643963;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DC31.Z;Acute pancreatitis, unspecified;1;Inactive;698285441/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DD70.Z;Crohn disease, unspecified site;1;Inactive;1267652425/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;FB81.Z;Osteonecrosis, unspecified;3;Active;536467755/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GA10.Z;Endometriosis of unspecified site;3;Inactive;1838213761/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB40;Nephritic syndrome;3;Inactive;1783829886;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB41;Nephrotic syndrome;3;Inactive;1184209951;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB60.Z;Acute kidney failure, stage unspecified;2;Unknown;476391827/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB61.Z;Chronic kidney disease, stage unspecified;3;Active;412389819/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GC8Y;Other specified diseases of the genitourinary system;1;Active;30659757/other;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;KA60;Sepsis of fetus or newborn;3;Active;381388700;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;KB88.Z;Necrotising enterocolitis of newborn, unspecified;2;Unknown;141267925/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;LA8B.4;Patent arterial duct;2;Unknown;1262462321;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;LB20.21;Biliary atresia;2;Active;645741117;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ND56.Z;Unspecified injury to unspecified part of trunk, limb or body region;2;Unknown;1842783299/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NF00;Effects of radiation, not elsewhere classified;2;Unknown;1820454;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;PL11.Y;Other specified mode of injury or harm associated with a surgical or other medical procedure;2;Inactive;1162198017/other;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29274;aa2ar_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;RA01;COVID-19;1;Unknown;1730556128;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;1C62.Z;Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified;1;Inactive;1508081745/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;1F40.Z;Malaria due to Plasmodium falciparum, unspecified;2;Inactive;579583286/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;1F54.1;Cutaneous leishmaniasis;2;Inactive;124737785;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;1F54.Z;Leishmaniasis, unspecified;2;Active;1082373067/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2A0Z;Other and unspecified neoplasms of brain or central nervous system;1;Unknown;879154182/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2B33.3;Lymphoid leukaemia, not elsewhere classified;2;Unknown;216388623;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;3A9Z;Anaemias or other erythrocyte disorders, unspecified;1;Unknown;224336967/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;4A62;Behçet disease;2;Active;1668927157;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;4B20.0;Sarcoidosis of lung;2;Inactive;820827059;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A20.Z;Schizophrenia, episode unspecified;1;Active;1683919430/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A60.Z;Bipolar type I disorder, unspecified;1;Inactive;1456478153/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Active;1669279433;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;6A7Z;Depressive disorders, unspecified;1;Active;1563440232/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8B91.Z;Brachial plexus disorders, unspecified;3;Inactive;1367254559/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;8C70.1;Duchenne muscular dystrophy;1;Inactive;1479561744;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA4Z;Acute ischaemic heart disease, unspecified;2;Active;1829545371/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BA8Z;Diseases of coronary artery, unspecified;2;Inactive;1059873720/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Inactive;1884917970;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DB92.Y;Other specified non-alcoholic fatty liver disease;2;Inactive;1912806631/other;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DB93.1;Hepatic cirrhosis;3;Inactive;1781315693;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DB94.1Z;Alcoholic hepatitis, unspecified;3;Inactive;229221394/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DB96.1Z;Primary biliary cholangitis, unspecified;2;Inactive;649193479/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DB99.4;Hepatopulmonary syndrome;1;Inactive;866605228;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DB99.7;Hepatic failure without mention whether acute or chronic;3;Inactive;508643963;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DC31.Z;Acute pancreatitis, unspecified;1;Inactive;698285441/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;DD70.Z;Crohn disease, unspecified site;1;Inactive;1267652425/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;FB81.Z;Osteonecrosis, unspecified;3;Active;536467755/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GA10.Z;Endometriosis of unspecified site;3;Inactive;1838213761/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB40;Nephritic syndrome;3;Inactive;1783829886;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB41;Nephrotic syndrome;3;Inactive;1184209951;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB60.Z;Acute kidney failure, stage unspecified;2;Unknown;476391827/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GB61.Z;Chronic kidney disease, stage unspecified;3;Active;412389819/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;GC8Y;Other specified diseases of the genitourinary system;1;Active;30659757/other;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;KA60;Sepsis of fetus or newborn;3;Active;381388700;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;KB88.Z;Necrotising enterocolitis of newborn, unspecified;2;Unknown;141267925/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;LA8B.4;Patent arterial duct;2;Unknown;1262462321;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;LB20.21;Biliary atresia;2;Active;645741117;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;ND56.Z;Unspecified injury to unspecified part of trunk, limb or body region;2;Unknown;1842783299/unspecified;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;NF00;Effects of radiation, not elsewhere classified;2;Unknown;1820454;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;PL11.Y;Other specified mode of injury or harm associated with a surgical or other medical procedure;2;Inactive;1162198017/other;25901427, 30000441, 32644522
573;pentoxifylline;pentoxifylline;CHEMBL628;DB00806;4740;6493-05-6;SD6QCT3TSU;BYPFEZZEUUWMEJ-UHFFFAOYSA-N;CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C;27831;3;755;426;0;0;4;5;20;4;Approved;1984;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;RA01;COVID-19;1;Unknown;1730556128;25901427, 30000441, 32644522
574;amitriptyline;amitriptyline;CHEMBL629;DB00321;2160;50-48-6;1806D8D52K;KRMDCWKBEZIMAB-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2774;5;32;331;0;0;1;3;21;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;30725910, 30000233, 35951832
574;amitriptyline;amitriptyline;CHEMBL629;DB00321;2160;50-48-6;1806D8D52K;KRMDCWKBEZIMAB-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2774;5;32;331;0;0;1;3;21;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30725910, 30000233, 35951832
574;amitriptyline;amitriptyline;CHEMBL629;DB00321;2160;50-48-6;1806D8D52K;KRMDCWKBEZIMAB-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2774;5;32;331;0;0;1;3;21;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;3;Inactive;1038292737/unspecified;30725910, 30000233, 35951832
574;amitriptyline;amitriptyline;CHEMBL629;DB00321;2160;50-48-6;1806D8D52K;KRMDCWKBEZIMAB-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2774;5;32;331;0;0;1;3;21;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;3;Inactive;669367341/unspecified;30725910, 30000233, 35951832
574;amitriptyline;amitriptyline;CHEMBL629;DB00321;2160;50-48-6;1806D8D52K;KRMDCWKBEZIMAB-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2774;5;32;331;0;0;1;3;21;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;3;Inactive;1339785363/unspecified;30725910, 30000233, 35951832
574;amitriptyline;amitriptyline;CHEMBL629;DB00321;2160;50-48-6;1806D8D52K;KRMDCWKBEZIMAB-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2774;5;32;331;0;0;1;3;21;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;CA05.0;Acute laryngitis;2;Unknown;1180710837;30725910, 30000233, 35951832
574;amitriptyline;amitriptyline;CHEMBL629;DB00321;2160;50-48-6;1806D8D52K;KRMDCWKBEZIMAB-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2774;5;32;331;0;0;1;3;21;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;CB0Z;Respiratory diseases principally affecting the lung interstitium, unspecified;2;Active;111658096/unspecified;30725910, 30000233, 35951832
574;amitriptyline;amitriptyline;CHEMBL629;DB00321;2160;50-48-6;1806D8D52K;KRMDCWKBEZIMAB-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2774;5;32;331;0;0;1;3;21;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DC14.2;Dyskinesia of sphincter of Oddi;2;Unknown;1632503092;30725910, 30000233, 35951832
574;amitriptyline;amitriptyline;CHEMBL629;DB00321;2160;50-48-6;1806D8D52K;KRMDCWKBEZIMAB-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2774;5;32;331;0;0;1;3;21;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DE2Z;Diseases of the digestive system, unspecified;2;Inactive;1256772020/unspecified;30725910, 30000233, 35951832
574;amitriptyline;amitriptyline;CHEMBL629;DB00321;2160;50-48-6;1806D8D52K;KRMDCWKBEZIMAB-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2774;5;32;331;0;0;1;3;21;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;2;Inactive;1729106757/unspecified;30725910, 30000233, 35951832
574;amitriptyline;amitriptyline;CHEMBL629;DB00321;2160;50-48-6;1806D8D52K;KRMDCWKBEZIMAB-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2774;5;32;331;0;0;1;3;21;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;FB53.0;Adhesive capsulitis of shoulder;2;Inactive;855105308;30725910, 30000233, 35951832
574;amitriptyline;amitriptyline;CHEMBL629;DB00321;2160;50-48-6;1806D8D52K;KRMDCWKBEZIMAB-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2774;5;32;331;0;0;1;3;21;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;GC00.3;Interstitial cystitis;3;Inactive;1650709285;30725910, 30000233, 35951832
574;amitriptyline;amitriptyline;CHEMBL629;DB00321;2160;50-48-6;1806D8D52K;KRMDCWKBEZIMAB-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2774;5;32;331;0;0;1;3;21;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;30725910, 30000233, 35951832
574;amitriptyline;amitriptyline;CHEMBL629;DB00321;2160;50-48-6;1806D8D52K;KRMDCWKBEZIMAB-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2774;5;32;331;0;0;1;3;21;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30725910, 30000233, 35951832
574;amitriptyline;amitriptyline;CHEMBL629;DB00321;2160;50-48-6;1806D8D52K;KRMDCWKBEZIMAB-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2774;5;32;331;0;0;1;3;21;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG30.01;Chronic widespread pain;3;Inactive;849253504;30725910, 30000233, 35951832
574;amitriptyline;amitriptyline;CHEMBL629;DB00321;2160;50-48-6;1806D8D52K;KRMDCWKBEZIMAB-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31;2774;5;32;331;0;0;1;3;21;4;Approved;1961;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Inactive;661232217/unspecified;30725910, 30000233, 35951832
575;propafenone;propafenone;CHEMBL631;DB01182;4932;54063-53-5;NA;JWHAUXFOSRPERK-UHFFFAOYSA-N;CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O;3414;33;586;368;0;2;4;11;25;4;Approved;1989;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC71.1;Ventricular fibrillation;4;Approved;1662472992;30000141, 31643337, 37698594
575;propafenone;propafenone;CHEMBL631;DB01182;4932;54063-53-5;NA;JWHAUXFOSRPERK-UHFFFAOYSA-N;CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O;3414;33;586;368;0;2;4;11;25;4;Approved;1989;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC7Y;Other specified ventricular rhythm disturbance;4;Approved;1694741164/other;30000141, 31643337, 37698594
575;propafenone;propafenone;CHEMBL631;DB01182;4932;54063-53-5;NA;JWHAUXFOSRPERK-UHFFFAOYSA-N;CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O;3414;33;586;368;0;2;4;11;25;4;Approved;1989;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;4;Approved;171698302/unspecified;30000141, 31643337, 37698594
575;propafenone;propafenone;CHEMBL631;DB01182;4932;54063-53-5;NA;JWHAUXFOSRPERK-UHFFFAOYSA-N;CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O;3414;33;586;368;0;2;4;11;25;4;Approved;1989;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC9Z;Cardiac arrhythmia, unspecified;4;Approved;1457291912/unspecified;30000141, 31643337, 37698594
575;propafenone;propafenone;CHEMBL631;DB01182;4932;54063-53-5;NA;JWHAUXFOSRPERK-UHFFFAOYSA-N;CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O;3414;33;586;368;0;2;4;11;25;4;Approved;1989;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC71.1;Ventricular fibrillation;4;Approved;1662472992;30000141, 31643337, 37698594
575;propafenone;propafenone;CHEMBL631;DB01182;4932;54063-53-5;NA;JWHAUXFOSRPERK-UHFFFAOYSA-N;CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O;3414;33;586;368;0;2;4;11;25;4;Approved;1989;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC7Y;Other specified ventricular rhythm disturbance;4;Approved;1694741164/other;30000141, 31643337, 37698594
575;propafenone;propafenone;CHEMBL631;DB01182;4932;54063-53-5;NA;JWHAUXFOSRPERK-UHFFFAOYSA-N;CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O;3414;33;586;368;0;2;4;11;25;4;Approved;1989;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;4;Approved;171698302/unspecified;30000141, 31643337, 37698594
575;propafenone;propafenone;CHEMBL631;DB01182;4932;54063-53-5;NA;JWHAUXFOSRPERK-UHFFFAOYSA-N;CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O;3414;33;586;368;0;2;4;11;25;4;Approved;1989;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC9Z;Cardiac arrhythmia, unspecified;4;Approved;1457291912/unspecified;30000141, 31643337, 37698594
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1D60.0Z;Ebola disease, virus unspecified;2;Unknown;1517015847/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC42.1;Infectious myocarditis;3;Unknown;654702340;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC43.Z;Cardiomyopathy, unspecified;3;Inactive;282225286/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC71.0Z;Ventricular tachycardia, unspecified;4;Approved;1171837620/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC71.1;Ventricular fibrillation;4;Approved;1662472992;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC7Y;Other specified ventricular rhythm disturbance;4;Approved;1694741164/other;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;4;Approved;171698302/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.Z;Supraventricular tachyarrhythmia, unspecified;2;Unknown;113146812/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC9Z;Cardiac arrhythmia, unspecified;4;Approved;1457291912/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;3;Inactive;2136808878;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;2;Inactive;1730556128;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1D60.0Z;Ebola disease, virus unspecified;2;Unknown;1517015847/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC42.1;Infectious myocarditis;3;Unknown;654702340;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC43.Z;Cardiomyopathy, unspecified;3;Inactive;282225286/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC71.0Z;Ventricular tachycardia, unspecified;4;Approved;1171837620/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC71.1;Ventricular fibrillation;4;Approved;1662472992;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC7Y;Other specified ventricular rhythm disturbance;4;Approved;1694741164/other;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;4;Approved;171698302/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.Z;Supraventricular tachyarrhythmia, unspecified;2;Unknown;113146812/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC9Z;Cardiac arrhythmia, unspecified;4;Approved;1457291912/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;3;Inactive;2136808878;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;2;Inactive;1730556128;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1D60.0Z;Ebola disease, virus unspecified;2;Unknown;1517015847/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC42.1;Infectious myocarditis;3;Unknown;654702340;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC43.Z;Cardiomyopathy, unspecified;3;Inactive;282225286/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC71.0Z;Ventricular tachycardia, unspecified;4;Approved;1171837620/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC71.1;Ventricular fibrillation;4;Approved;1662472992;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC7Y;Other specified ventricular rhythm disturbance;4;Approved;1694741164/other;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;4;Approved;171698302/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.Z;Supraventricular tachyarrhythmia, unspecified;2;Unknown;113146812/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC9Z;Cardiac arrhythmia, unspecified;4;Approved;1457291912/unspecified;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;3;Inactive;2136808878;36818930, 29999620, 29489285
576;amiodarone;amiodarone;CHEMBL633;DB01118;2157;1951-25-3;N3RQ532IUT;IYIKLHRQXLHMJQ-UHFFFAOYSA-N;CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I;6453;76;427;547;0;0;4;11;31;4;Approved;1985;Small molecule;Inhibitor;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;2;Inactive;1730556128;36818930, 29999620, 29489285
577;azelastine;azelastine;CHEMBL639;DB00972;2267;58581-89-8;ZQI909440X;MBUVEWMHONZEQD-UHFFFAOYSA-N;CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl;3819;44;359;558;0;0;3;3;27;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000120, 35951856, 23119447
577;azelastine;azelastine;CHEMBL639;DB00972;2267;58581-89-8;ZQI909440X;MBUVEWMHONZEQD-UHFFFAOYSA-N;CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl;3819;44;359;558;0;0;3;3;27;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000120, 35951856, 23119447
577;azelastine;azelastine;CHEMBL639;DB00972;2267;58581-89-8;ZQI909440X;MBUVEWMHONZEQD-UHFFFAOYSA-N;CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl;3819;44;359;558;0;0;3;3;27;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000120, 35951856, 23119447
577;azelastine;azelastine;CHEMBL639;DB00972;2267;58581-89-8;ZQI909440X;MBUVEWMHONZEQD-UHFFFAOYSA-N;CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl;3819;44;359;558;0;0;3;3;27;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.03;Other allergic rhinitis;4;Approved;941478759;30000120, 35951856, 23119447
577;azelastine;azelastine;CHEMBL639;DB00972;2267;58581-89-8;ZQI909440X;MBUVEWMHONZEQD-UHFFFAOYSA-N;CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl;3819;44;359;558;0;0;3;3;27;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000120, 35951856, 23119447
577;azelastine;azelastine;CHEMBL639;DB00972;2267;58581-89-8;ZQI909440X;MBUVEWMHONZEQD-UHFFFAOYSA-N;CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl;3819;44;359;558;0;0;3;3;27;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.1Z;Non-allergic rhinitis, unspecified;4;Approved;1650452542/unspecified;30000120, 35951856, 23119447
577;azelastine;azelastine;CHEMBL639;DB00972;2267;58581-89-8;ZQI909440X;MBUVEWMHONZEQD-UHFFFAOYSA-N;CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl;3819;44;359;558;0;0;3;3;27;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.3;Vasomotor rhinitis;4;Approved;1286636442;30000120, 35951856, 23119447
577;azelastine;azelastine;CHEMBL639;DB00972;2267;58581-89-8;ZQI909440X;MBUVEWMHONZEQD-UHFFFAOYSA-N;CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl;3819;44;359;558;0;0;3;3;27;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000120, 35951856, 23119447
578;acebutolol;acebutolol;CHEMBL642;DB01193;1978;37517-30-9;67P356D8GH;GOEMGAFJFRBGGG-UHFFFAOYSA-N;CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C;3364;17;877;401;0;3;5;10;24;4;Approved;1984;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2E81.0Z;Neoplastic haemangioma, unspecified site;3;Inactive;228855241/unspecified;30000200, 31644160, 3892259
578;acebutolol;acebutolol;CHEMBL642;DB01193;1978;37517-30-9;67P356D8GH;GOEMGAFJFRBGGG-UHFFFAOYSA-N;CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C;3364;17;877;401;0;3;5;10;24;4;Approved;1984;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000200, 31644160, 3892259
578;acebutolol;acebutolol;CHEMBL642;DB01193;1978;37517-30-9;67P356D8GH;GOEMGAFJFRBGGG-UHFFFAOYSA-N;CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C;3364;17;877;401;0;3;5;10;24;4;Approved;1984;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC7Y;Other specified ventricular rhythm disturbance;4;Approved;1694741164/other;30000200, 31644160, 3892259
578;acebutolol;acebutolol;CHEMBL642;DB01193;1978;37517-30-9;67P356D8GH;GOEMGAFJFRBGGG-UHFFFAOYSA-N;CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C;3364;17;877;401;0;3;5;10;24;4;Approved;1984;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30000200, 31644160, 3892259
579;promethazine;promethazine;CHEMBL643;DB01069;4927;60-87-7;FF28EJQ494;PWWVAXIEGOYWEE-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C;2844;48;318;298;0;0;3;3;20;4;Approved;1951;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;31335081, 30000140, 35952189
579;promethazine;promethazine;CHEMBL643;DB01069;4927;60-87-7;FF28EJQ494;PWWVAXIEGOYWEE-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C;2844;48;318;298;0;0;3;3;20;4;Approved;1951;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;8A80.0;Migraine without aura;3;Inactive;2048783472;31335081, 30000140, 35952189
579;promethazine;promethazine;CHEMBL643;DB01069;4927;60-87-7;FF28EJQ494;PWWVAXIEGOYWEE-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C;2844;48;318;298;0;0;3;3;20;4;Approved;1951;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;3;Inactive;525744634/unspecified;31335081, 30000140, 35952189
579;promethazine;promethazine;CHEMBL643;DB01069;4927;60-87-7;FF28EJQ494;PWWVAXIEGOYWEE-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C;2844;48;318;298;0;0;3;3;20;4;Approved;1951;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;31335081, 30000140, 35952189
579;promethazine;promethazine;CHEMBL643;DB01069;4927;60-87-7;FF28EJQ494;PWWVAXIEGOYWEE-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C;2844;48;318;298;0;0;3;3;20;4;Approved;1951;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;AB34.1;Other peripheral vertigo;3;Inactive;1550756489;31335081, 30000140, 35952189
579;promethazine;promethazine;CHEMBL643;DB01069;4927;60-87-7;FF28EJQ494;PWWVAXIEGOYWEE-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C;2844;48;318;298;0;0;3;3;20;4;Approved;1951;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;31335081, 30000140, 35952189
579;promethazine;promethazine;CHEMBL643;DB01069;4927;60-87-7;FF28EJQ494;PWWVAXIEGOYWEE-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C;2844;48;318;298;0;0;3;3;20;4;Approved;1951;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DD70.Z;Crohn disease, unspecified site;2;Inactive;1267652425/unspecified;31335081, 30000140, 35952189
579;promethazine;promethazine;CHEMBL643;DB01069;4927;60-87-7;FF28EJQ494;PWWVAXIEGOYWEE-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C;2844;48;318;298;0;0;3;3;20;4;Approved;1951;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;4;Approved;215767047/unspecified;31335081, 30000140, 35952189
579;promethazine;promethazine;CHEMBL643;DB01069;4927;60-87-7;FF28EJQ494;PWWVAXIEGOYWEE-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C;2844;48;318;298;0;0;3;3;20;4;Approved;1951;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;31335081, 30000140, 35952189
579;promethazine;promethazine;CHEMBL643;DB01069;4927;60-87-7;FF28EJQ494;PWWVAXIEGOYWEE-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C;2844;48;318;298;0;0;3;3;20;4;Approved;1951;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;31335081, 30000140, 35952189
579;promethazine;promethazine;CHEMBL643;DB01069;4927;60-87-7;FF28EJQ494;PWWVAXIEGOYWEE-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C;2844;48;318;298;0;0;3;3;20;4;Approved;1951;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;31335081, 30000140, 35952189
579;promethazine;promethazine;CHEMBL643;DB01069;4927;60-87-7;FF28EJQ494;PWWVAXIEGOYWEE-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C;2844;48;318;298;0;0;3;3;20;4;Approved;1951;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;31335081, 30000140, 35952189
579;promethazine;promethazine;CHEMBL643;DB01069;4927;60-87-7;FF28EJQ494;PWWVAXIEGOYWEE-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C;2844;48;318;298;0;0;3;3;20;4;Approved;1951;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90.1;Vomiting;4;Approved;447658033;31335081, 30000140, 35952189
579;promethazine;promethazine;CHEMBL643;DB01069;4927;60-87-7;FF28EJQ494;PWWVAXIEGOYWEE-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C;2844;48;318;298;0;0;3;3;20;4;Approved;1951;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;31335081, 30000140, 35952189
579;promethazine;promethazine;CHEMBL643;DB01069;4927;60-87-7;FF28EJQ494;PWWVAXIEGOYWEE-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C;2844;48;318;298;0;0;3;3;20;4;Approved;1951;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;31335081, 30000140, 35952189
580;mianserin;mianserin;CHEMBL6437;DB06148;4184;24219-97-4;250PJI13LM;UEQUQVLFIPOEMF-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42;2644;34;65;342;0;0;2;0;20;4;Approved;1979;Small molecule;Inhibitor;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000823, 78239, 7048075
580;mianserin;mianserin;CHEMBL6437;DB06148;4184;24219-97-4;250PJI13LM;UEQUQVLFIPOEMF-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42;2644;34;65;342;0;0;2;0;20;4;Approved;1979;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000823, 78239, 7048075
580;mianserin;mianserin;CHEMBL6437;DB06148;4184;24219-97-4;250PJI13LM;UEQUQVLFIPOEMF-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42;2644;34;65;342;0;0;2;0;20;4;Approved;1979;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000823, 78239, 7048075
580;mianserin;mianserin;CHEMBL6437;DB06148;4184;24219-97-4;250PJI13LM;UEQUQVLFIPOEMF-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42;2644;34;65;342;0;0;2;0;20;4;Approved;1979;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000823, 78239, 7048075
580;mianserin;mianserin;CHEMBL6437;DB06148;4184;24219-97-4;250PJI13LM;UEQUQVLFIPOEMF-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42;2644;34;65;342;0;0;2;0;20;4;Approved;1979;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000823, 78239, 7048075
580;mianserin;mianserin;CHEMBL6437;DB06148;4184;24219-97-4;250PJI13LM;UEQUQVLFIPOEMF-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42;2644;34;65;342;0;0;2;0;20;4;Approved;1979;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000823, 78239, 7048075
580;mianserin;mianserin;CHEMBL6437;DB06148;4184;24219-97-4;250PJI13LM;UEQUQVLFIPOEMF-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42;2644;34;65;342;0;0;2;0;20;4;Approved;1979;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000823, 78239, 7048075
580;mianserin;mianserin;CHEMBL6437;DB06148;4184;24219-97-4;250PJI13LM;UEQUQVLFIPOEMF-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42;2644;34;65;342;0;0;2;0;20;4;Approved;1979;Small molecule;Antagonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000823, 78239, 7048075
580;mianserin;mianserin;CHEMBL6437;DB06148;4184;24219-97-4;250PJI13LM;UEQUQVLFIPOEMF-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42;2644;34;65;342;0;0;2;0;20;4;Approved;1979;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000823, 78239, 7048075
580;mianserin;mianserin;CHEMBL6437;DB06148;4184;24219-97-4;250PJI13LM;UEQUQVLFIPOEMF-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42;2644;34;65;342;0;0;2;0;20;4;Approved;1979;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000823, 78239, 7048075
580;mianserin;mianserin;CHEMBL6437;DB06148;4184;24219-97-4;250PJI13LM;UEQUQVLFIPOEMF-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42;2644;34;65;342;0;0;2;0;20;4;Approved;1979;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000823, 78239, 7048075
580;mianserin;mianserin;CHEMBL6437;DB06148;4184;24219-97-4;250PJI13LM;UEQUQVLFIPOEMF-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42;2644;34;65;342;0;0;2;0;20;4;Approved;1979;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000823, 78239, 7048075
580;mianserin;mianserin;CHEMBL6437;DB06148;4184;24219-97-4;250PJI13LM;UEQUQVLFIPOEMF-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42;2644;34;65;342;0;0;2;0;20;4;Approved;1979;Small molecule;Partial agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000823, 78239, 7048075
580;mianserin;mianserin;CHEMBL6437;DB06148;4184;24219-97-4;250PJI13LM;UEQUQVLFIPOEMF-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42;2644;34;65;342;0;0;2;0;20;4;Approved;1979;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000823, 78239, 7048075
580;mianserin;mianserin;CHEMBL6437;DB06148;4184;24219-97-4;250PJI13LM;UEQUQVLFIPOEMF-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42;2644;34;65;342;0;0;2;0;20;4;Approved;1979;Small molecule;Antagonist;P50406;5ht6r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000823, 78239, 7048075
581;trimipramine;trimipramine;CHEMBL644;DB00726;5584;"3564-66-7;3564-75-8;739-71-9";NA;ZSCDBOWYZJWBIY-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C;2944;58;65;317;0;0;2;4;22;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000228, 31643192, 6015638
581;trimipramine;trimipramine;CHEMBL644;DB00726;5584;"3564-66-7;3564-75-8;739-71-9";NA;ZSCDBOWYZJWBIY-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C;2944;58;65;317;0;0;2;4;22;4;Approved;1979;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000228, 31643192, 6015638
581;trimipramine;trimipramine;CHEMBL644;DB00726;5584;"3564-66-7;3564-75-8;739-71-9";NA;ZSCDBOWYZJWBIY-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C;2944;58;65;317;0;0;2;4;22;4;Approved;1979;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000228, 31643192, 6015638
581;trimipramine;trimipramine;CHEMBL644;DB00726;5584;"3564-66-7;3564-75-8;739-71-9";NA;ZSCDBOWYZJWBIY-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C;2944;58;65;317;0;0;2;4;22;4;Approved;1979;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000228, 31643192, 6015638
581;trimipramine;trimipramine;CHEMBL644;DB00726;5584;"3564-66-7;3564-75-8;739-71-9";NA;ZSCDBOWYZJWBIY-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C;2944;58;65;317;0;0;2;4;22;4;Approved;1979;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000228, 31643192, 6015638
581;trimipramine;trimipramine;CHEMBL644;DB00726;5584;"3564-66-7;3564-75-8;739-71-9";NA;ZSCDBOWYZJWBIY-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C;2944;58;65;317;0;0;2;4;22;4;Approved;1979;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000228, 31643192, 6015638
581;trimipramine;trimipramine;CHEMBL644;DB00726;5584;"3564-66-7;3564-75-8;739-71-9";NA;ZSCDBOWYZJWBIY-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C;2944;58;65;317;0;0;2;4;22;4;Approved;1979;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000228, 31643192, 6015638
582;bisoprolol;bisoprolol;CHEMBL645;DB00612;2405;66722-44-9;Y41JS2NL6U;VHYCDWMUTMEGQY-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O;3254;19;60;278;0;2;5;12;23;4;Approved;1992;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;35093388, 31869087, 10023943
582;bisoprolol;bisoprolol;CHEMBL645;DB00612;2405;66722-44-9;Y41JS2NL6U;VHYCDWMUTMEGQY-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O;3254;19;60;278;0;2;5;12;23;4;Approved;1992;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BB01.0;Pulmonary arterial hypertension;1;Unknown;1931148955;35093388, 31869087, 10023943
582;bisoprolol;bisoprolol;CHEMBL645;DB00612;2405;66722-44-9;Y41JS2NL6U;VHYCDWMUTMEGQY-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O;3254;19;60;278;0;2;5;12;23;4;Approved;1992;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;35093388, 31869087, 10023943
582;bisoprolol;bisoprolol;CHEMBL645;DB00612;2405;66722-44-9;Y41JS2NL6U;VHYCDWMUTMEGQY-UHFFFAOYSA-N;CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O;3254;19;60;278;0;2;5;12;23;4;Approved;1992;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;1;Inactive;940081636;35093388, 31869087, 10023943
583;apraclonidine;apraclonidine;CHEMBL647;DB00964;2216;66711-21-5;843CEN85DI;IEJXVRYNEISIKR-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl;24511;13;624;247;0;3;2;2;15;4;Approved;1987;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A03.0Z;Blepharoptosis, unspecified;2;Unknown;1361674069/unspecified;30000720, 28431598, 28017248
583;apraclonidine;apraclonidine;CHEMBL647;DB00964;2216;66711-21-5;843CEN85DI;IEJXVRYNEISIKR-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl;24511;13;624;247;0;3;2;2;15;4;Approved;1987;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000720, 28431598, 28017248
583;apraclonidine;apraclonidine;CHEMBL647;DB00964;2216;66711-21-5;843CEN85DI;IEJXVRYNEISIKR-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl;24511;13;624;247;0;3;2;2;15;4;Approved;1987;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A03.0Z;Blepharoptosis, unspecified;2;Unknown;1361674069/unspecified;30000720, 28431598, 28017248
583;apraclonidine;apraclonidine;CHEMBL647;DB00964;2216;66711-21-5;843CEN85DI;IEJXVRYNEISIKR-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl;24511;13;624;247;0;3;2;2;15;4;Approved;1987;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000720, 28431598, 28017248
583;apraclonidine;apraclonidine;CHEMBL647;DB00964;2216;66711-21-5;843CEN85DI;IEJXVRYNEISIKR-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl;24511;13;624;247;0;3;2;2;15;4;Approved;1987;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A03.0Z;Blepharoptosis, unspecified;2;Unknown;1361674069/unspecified;30000720, 28431598, 28017248
583;apraclonidine;apraclonidine;CHEMBL647;DB00964;2216;66711-21-5;843CEN85DI;IEJXVRYNEISIKR-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl;24511;13;624;247;0;3;2;2;15;4;Approved;1987;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000720, 28431598, 28017248
583;apraclonidine;apraclonidine;CHEMBL647;DB00964;2216;66711-21-5;843CEN85DI;IEJXVRYNEISIKR-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl;24511;13;624;247;0;3;2;2;15;4;Approved;1987;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A03.0Z;Blepharoptosis, unspecified;2;Unknown;1361674069/unspecified;30000720, 28431598, 28017248
583;apraclonidine;apraclonidine;CHEMBL647;DB00964;2216;66711-21-5;843CEN85DI;IEJXVRYNEISIKR-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl;24511;13;624;247;0;3;2;2;15;4;Approved;1987;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000720, 28431598, 28017248
584;cyclizine;cyclizine;CHEMBL648;DB01176;6726;82-92-8;QRW9FCR9P2;UVKZSORBKUEBAZ-UHFFFAOYSA-N;CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3;2664;36;65;253;0;0;2;3;20;4;Approved;1982;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000808, 31643514, 12748165
585;nadolol;S-nadolol;CHEMBL3246778;DB01203;11823027;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-JQXSQYPDSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@H]([C@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2E81.0Z;Neoplastic haemangioma, unspecified site;3;Inactive;228855241/unspecified;31424773, 30000216, 31644048
585;nadolol;S-nadolol;CHEMBL3246778;DB01203;11823027;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-JQXSQYPDSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@H]([C@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;31424773, 30000216, 31644048
585;nadolol;S-nadolol;CHEMBL3246778;DB01203;11823027;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-JQXSQYPDSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@H]([C@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;31424773, 30000216, 31644048
585;nadolol;S-nadolol;CHEMBL3246778;DB01203;11823027;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-JQXSQYPDSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@H]([C@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31424773, 30000216, 31644048
585;nadolol;S-nadolol;CHEMBL3246778;DB01203;11823027;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-JQXSQYPDSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@H]([C@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA40.Z;Angina pectoris, unspecified;4;Approved;718946808/unspecified;31424773, 30000216, 31644048
585;nadolol;S-nadolol;CHEMBL3246778;DB01203;11823027;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-JQXSQYPDSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@H]([C@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;31424773, 30000216, 31644048
585;nadolol;S-nadolol;CHEMBL3246778;DB01203;11823027;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-JQXSQYPDSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@H]([C@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;31424773, 30000216, 31644048
585;nadolol;S-nadolol;CHEMBL3246778;DB01203;11823027;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-JQXSQYPDSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@H]([C@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;2;Inactive;1656445230;31424773, 30000216, 31644048
585;nadolol;nadolol;CHEMBL649;DB01203;39147;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UCWKZMIHSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2E81.0Z;Neoplastic haemangioma, unspecified site;3;Inactive;228855241/unspecified;31424773, 30000216, 31644048
585;nadolol;nadolol;CHEMBL649;DB01203;39147;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UCWKZMIHSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;31424773, 30000216, 31644048
585;nadolol;nadolol;CHEMBL649;DB01203;39147;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UCWKZMIHSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;31424773, 30000216, 31644048
585;nadolol;nadolol;CHEMBL649;DB01203;39147;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UCWKZMIHSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31424773, 30000216, 31644048
585;nadolol;nadolol;CHEMBL649;DB01203;39147;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UCWKZMIHSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA40.Z;Angina pectoris, unspecified;4;Approved;718946808/unspecified;31424773, 30000216, 31644048
585;nadolol;nadolol;CHEMBL649;DB01203;39147;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UCWKZMIHSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;31424773, 30000216, 31644048
585;nadolol;nadolol;CHEMBL649;DB01203;39147;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UCWKZMIHSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;31424773, 30000216, 31644048
585;nadolol;nadolol;CHEMBL649;DB01203;39147;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UCWKZMIHSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;2;Inactive;1656445230;31424773, 30000216, 31644048
585;nadolol;solgol;CHEMBL521606;DB01203;4411;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2E81.0Z;Neoplastic haemangioma, unspecified site;3;Inactive;228855241/unspecified;31424773, 30000216, 31644048
585;nadolol;solgol;CHEMBL521606;DB01203;4411;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;31424773, 30000216, 31644048
585;nadolol;solgol;CHEMBL521606;DB01203;4411;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;31424773, 30000216, 31644048
585;nadolol;solgol;CHEMBL521606;DB01203;4411;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31424773, 30000216, 31644048
585;nadolol;solgol;CHEMBL521606;DB01203;4411;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA40.Z;Angina pectoris, unspecified;4;Approved;718946808/unspecified;31424773, 30000216, 31644048
585;nadolol;solgol;CHEMBL521606;DB01203;4411;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;31424773, 30000216, 31644048
585;nadolol;solgol;CHEMBL521606;DB01203;4411;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;31424773, 30000216, 31644048
585;nadolol;solgol;CHEMBL521606;DB01203;4411;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;2;Inactive;1656445230;31424773, 30000216, 31644048
585;nadolol;S-nadolol;CHEMBL3246778;DB01203;11823027;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-JQXSQYPDSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@H]([C@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2E81.0Z;Neoplastic haemangioma, unspecified site;3;Inactive;228855241/unspecified;31424773, 30000216, 31644048
585;nadolol;S-nadolol;CHEMBL3246778;DB01203;11823027;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-JQXSQYPDSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@H]([C@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;31424773, 30000216, 31644048
585;nadolol;S-nadolol;CHEMBL3246778;DB01203;11823027;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-JQXSQYPDSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@H]([C@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;31424773, 30000216, 31644048
585;nadolol;S-nadolol;CHEMBL3246778;DB01203;11823027;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-JQXSQYPDSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@H]([C@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31424773, 30000216, 31644048
585;nadolol;S-nadolol;CHEMBL3246778;DB01203;11823027;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-JQXSQYPDSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@H]([C@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA40.Z;Angina pectoris, unspecified;4;Approved;718946808/unspecified;31424773, 30000216, 31644048
585;nadolol;S-nadolol;CHEMBL3246778;DB01203;11823027;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-JQXSQYPDSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@H]([C@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;31424773, 30000216, 31644048
585;nadolol;S-nadolol;CHEMBL3246778;DB01203;11823027;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-JQXSQYPDSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@H]([C@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;31424773, 30000216, 31644048
585;nadolol;S-nadolol;CHEMBL3246778;DB01203;11823027;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-JQXSQYPDSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@H]([C@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;2;Inactive;1656445230;31424773, 30000216, 31644048
585;nadolol;nadolol;CHEMBL649;DB01203;39147;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UCWKZMIHSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2E81.0Z;Neoplastic haemangioma, unspecified site;3;Inactive;228855241/unspecified;31424773, 30000216, 31644048
585;nadolol;nadolol;CHEMBL649;DB01203;39147;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UCWKZMIHSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;31424773, 30000216, 31644048
585;nadolol;nadolol;CHEMBL649;DB01203;39147;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UCWKZMIHSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;31424773, 30000216, 31644048
585;nadolol;nadolol;CHEMBL649;DB01203;39147;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UCWKZMIHSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31424773, 30000216, 31644048
585;nadolol;nadolol;CHEMBL649;DB01203;39147;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UCWKZMIHSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA40.Z;Angina pectoris, unspecified;4;Approved;718946808/unspecified;31424773, 30000216, 31644048
585;nadolol;nadolol;CHEMBL649;DB01203;39147;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UCWKZMIHSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;31424773, 30000216, 31644048
585;nadolol;nadolol;CHEMBL649;DB01203;39147;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UCWKZMIHSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;31424773, 30000216, 31644048
585;nadolol;nadolol;CHEMBL649;DB01203;39147;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UCWKZMIHSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;2;Inactive;1656445230;31424773, 30000216, 31644048
585;nadolol;solgol;CHEMBL521606;DB01203;4411;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2E81.0Z;Neoplastic haemangioma, unspecified site;3;Inactive;228855241/unspecified;31424773, 30000216, 31644048
585;nadolol;solgol;CHEMBL521606;DB01203;4411;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;31424773, 30000216, 31644048
585;nadolol;solgol;CHEMBL521606;DB01203;4411;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;31424773, 30000216, 31644048
585;nadolol;solgol;CHEMBL521606;DB01203;4411;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;31424773, 30000216, 31644048
585;nadolol;solgol;CHEMBL521606;DB01203;4411;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA40.Z;Angina pectoris, unspecified;4;Approved;718946808/unspecified;31424773, 30000216, 31644048
585;nadolol;solgol;CHEMBL521606;DB01203;4411;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;31424773, 30000216, 31644048
585;nadolol;solgol;CHEMBL521606;DB01203;4411;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;31424773, 30000216, 31644048
585;nadolol;solgol;CHEMBL521606;DB01203;4411;42200-33-9;FEN504330V;VWPOSFSPZNDTMJ-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O;3094;7;82;344;0;4;5;6;22;4;Approved;1979;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;2;Inactive;1656445230;31424773, 30000216, 31644048
586;methadone;methadone;CHEMBL651;DB00333;4095;76-99-3;UC6VBE7V1Z;USSIQXCVUWKGNF-UHFFFAOYSA-N;CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2;3094;39;203;346;0;0;2;7;23;4;Approved;1947;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;4;Approved;1120716949/unspecified;32965887, 35952103, 31643414
586;methadone;methadone;CHEMBL651;DB00333;4095;76-99-3;UC6VBE7V1Z;USSIQXCVUWKGNF-UHFFFAOYSA-N;CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2;3094;39;203;346;0;0;2;7;23;4;Approved;1947;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;4;Approved;111507461/unspecified;32965887, 35952103, 31643414
586;methadone;methadone;CHEMBL651;DB00333;4095;76-99-3;UC6VBE7V1Z;USSIQXCVUWKGNF-UHFFFAOYSA-N;CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2;3094;39;203;346;0;0;2;7;23;4;Approved;1947;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;32965887, 35952103, 31643414
586;methadone;methadone;CHEMBL651;DB00333;4095;76-99-3;UC6VBE7V1Z;USSIQXCVUWKGNF-UHFFFAOYSA-N;CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2;3094;39;203;346;0;0;2;7;23;4;Approved;1947;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;4;Approved;2143971168/unspecified;32965887, 35952103, 31643414
586;methadone;methadone;CHEMBL651;DB00333;4095;76-99-3;UC6VBE7V1Z;USSIQXCVUWKGNF-UHFFFAOYSA-N;CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2;3094;39;203;346;0;0;2;7;23;4;Approved;1947;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;7A80;Restless legs syndrome;2;Active;1254916765;32965887, 35952103, 31643414
586;methadone;methadone;CHEMBL651;DB00333;4095;76-99-3;UC6VBE7V1Z;USSIQXCVUWKGNF-UHFFFAOYSA-N;CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2;3094;39;203;346;0;0;2;7;23;4;Approved;1947;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;2;Inactive;80293156;32965887, 35952103, 31643414
586;methadone;methadone;CHEMBL651;DB00333;4095;76-99-3;UC6VBE7V1Z;USSIQXCVUWKGNF-UHFFFAOYSA-N;CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2;3094;39;203;346;0;0;2;7;23;4;Approved;1947;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;3;Inactive;1581976053/unspecified;32965887, 35952103, 31643414
586;methadone;methadone;CHEMBL651;DB00333;4095;76-99-3;UC6VBE7V1Z;USSIQXCVUWKGNF-UHFFFAOYSA-N;CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2;3094;39;203;346;0;0;2;7;23;4;Approved;1947;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;32965887, 35952103, 31643414
586;methadone;methadone;CHEMBL651;DB00333;4095;76-99-3;UC6VBE7V1Z;USSIQXCVUWKGNF-UHFFFAOYSA-N;CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2;3094;39;203;346;0;0;2;7;23;4;Approved;1947;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;4;Approved;1120716949/unspecified;32965887, 35952103, 31643414
586;methadone;methadone;CHEMBL651;DB00333;4095;76-99-3;UC6VBE7V1Z;USSIQXCVUWKGNF-UHFFFAOYSA-N;CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2;3094;39;203;346;0;0;2;7;23;4;Approved;1947;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;4;Approved;111507461/unspecified;32965887, 35952103, 31643414
586;methadone;methadone;CHEMBL651;DB00333;4095;76-99-3;UC6VBE7V1Z;USSIQXCVUWKGNF-UHFFFAOYSA-N;CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2;3094;39;203;346;0;0;2;7;23;4;Approved;1947;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C45.2Z;Cocaine dependence, unspecified;3;Inactive;1691013484/unspecified;32965887, 35952103, 31643414
586;methadone;methadone;CHEMBL651;DB00333;4095;76-99-3;UC6VBE7V1Z;USSIQXCVUWKGNF-UHFFFAOYSA-N;CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2;3094;39;203;346;0;0;2;7;23;4;Approved;1947;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;4;Approved;2143971168/unspecified;32965887, 35952103, 31643414
586;methadone;methadone;CHEMBL651;DB00333;4095;76-99-3;UC6VBE7V1Z;USSIQXCVUWKGNF-UHFFFAOYSA-N;CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2;3094;39;203;346;0;0;2;7;23;4;Approved;1947;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;7A80;Restless legs syndrome;2;Active;1254916765;32965887, 35952103, 31643414
586;methadone;methadone;CHEMBL651;DB00333;4095;76-99-3;UC6VBE7V1Z;USSIQXCVUWKGNF-UHFFFAOYSA-N;CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2;3094;39;203;346;0;0;2;7;23;4;Approved;1947;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;2;Inactive;80293156;32965887, 35952103, 31643414
586;methadone;methadone;CHEMBL651;DB00333;4095;76-99-3;UC6VBE7V1Z;USSIQXCVUWKGNF-UHFFFAOYSA-N;CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2;3094;39;203;346;0;0;2;7;23;4;Approved;1947;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;3;Inactive;1581976053/unspecified;32965887, 35952103, 31643414
586;methadone;methadone;CHEMBL651;DB00333;4095;76-99-3;UC6VBE7V1Z;USSIQXCVUWKGNF-UHFFFAOYSA-N;CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2;3094;39;203;346;0;0;2;7;23;4;Approved;1947;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;32965887, 35952103, 31643414
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;2;Active;263852475/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Inactive;1580466198/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;3;Unknown;1120716949/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Inactive;2016549355/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;2;Inactive;2143971168/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4Z;Disorders due to substance use, unspecified;2;Inactive;590211325/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;1;Active;1038292737/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A41;Obstructive sleep apnoea;1;Inactive;1919233290;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD90;Nausea or vomiting;3;Active;677319549;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG20.Z;Cachexia, unspecified;3;Active;914154382/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG43.5;Excessive weight loss;2;Inactive;2015627151;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG43.7;Anorexia;3;Active;2137507044;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;2;Active;263852475/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Inactive;1580466198/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;3;Unknown;1120716949/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Inactive;2016549355/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;2;Inactive;2143971168/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4Z;Disorders due to substance use, unspecified;2;Inactive;590211325/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;1;Active;1038292737/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A41;Obstructive sleep apnoea;1;Inactive;1919233290;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD90;Nausea or vomiting;3;Active;677319549;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG20.Z;Cachexia, unspecified;3;Active;914154382/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG43.5;Excessive weight loss;2;Inactive;2015627151;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG43.7;Anorexia;3;Active;2137507044;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;2;Active;263852475/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Inactive;1580466198/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;3;Unknown;1120716949/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Inactive;2016549355/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;2;Inactive;2143971168/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4Z;Disorders due to substance use, unspecified;2;Inactive;590211325/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;1;Active;1038292737/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A41;Obstructive sleep apnoea;1;Inactive;1919233290;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD90;Nausea or vomiting;3;Active;677319549;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG20.Z;Cachexia, unspecified;3;Active;914154382/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG43.5;Excessive weight loss;2;Inactive;2015627151;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG43.7;Anorexia;3;Active;2137507044;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;2;Active;263852475/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Inactive;1580466198/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;3;Unknown;1120716949/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Inactive;2016549355/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;2;Inactive;2143971168/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C4Z;Disorders due to substance use, unspecified;2;Inactive;590211325/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;1;Active;1038292737/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7A41;Obstructive sleep apnoea;1;Inactive;1919233290;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD90;Nausea or vomiting;3;Active;677319549;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG20.Z;Cachexia, unspecified;3;Active;914154382/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG43.5;Excessive weight loss;2;Inactive;2015627151;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG43.7;Anorexia;3;Active;2137507044;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;2;Active;263852475/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Inactive;1580466198/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;3;Unknown;1120716949/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Inactive;2016549355/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;2;Inactive;2143971168/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C4Z;Disorders due to substance use, unspecified;2;Inactive;590211325/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;1;Active;1038292737/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7A41;Obstructive sleep apnoea;1;Inactive;1919233290;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD90;Nausea or vomiting;3;Active;677319549;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG20.Z;Cachexia, unspecified;3;Active;914154382/unspecified;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG30.01;Chronic widespread pain;2;Inactive;849253504;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG43.5;Excessive weight loss;2;Inactive;2015627151;30085601, 11607047, 29678261
587;mirtazapine;mirtazapine;CHEMBL654;DB00370;4205;85650-52-8;A051Q2099Q;RONZAEMNMFQXRA-UHFFFAOYSA-N;CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4;26535;33;194;345;0;0;3;0;20;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG43.7;Anorexia;3;Active;2137507044;30085601, 11607047, 29678261
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;2;Unknown;1038292737/unspecified;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA09.0;Chronic rhinitis;4;Approved;1346915097;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA01.10;Oral aphthae or aphtha-like ulceration;2;Inactive;365022111;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA01.11;Oral mucositis;4;Approved;1634507618;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;2;Unknown;215767047/unspecified;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EJ40.Z;Sunburn, unspecified;4;Approved;318744822/unspecified;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MB48.Z;Dizziness and giddiness, unspecified;4;Approved;1890374210/unspecified;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD12;Cough;4;Approved;2027526159;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90.0;Nausea;4;Approved;596805318;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90.1;Vomiting;4;Approved;447658033;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;NE2Z;Burns, unspecified;4;Approved;163532889/unspecified;30000938, 30252266, 35951938
588;diphenhydramine;diphenhydramine;CHEMBL657;DB01075;3100;58-73-1;8GTS82S83M;ZZVUWRFHKOJYTH-UHFFFAOYSA-N;CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2;25535;33;125;211;0;0;2;6;19;4;Approved;1946;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;NF08.3;Motion sickness;4;Approved;1078108554;30000938, 30252266, 35951938
589;sufentanil;sufentanil;CHEMBL658;DB00708;41693;56030-54-7;AFE2YW0IIZ;GGCSSNBKKAUURC-UHFFFAOYSA-N;CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC;3866;4;61;459;0;0;4;8;27;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000313, 8896944, 31320770
590;amantadine;amantadine;CHEMBL660;DB00915;2130;768-94-5;BF4C9Z1J53;DKNWSYNQZKUICI-UHFFFAOYSA-N;C1C2CC3CC1CC(C2)(C3)N;15125;24;26;144;0;1;1;0;11;4;Approved;1968;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;1E32;Influenza, virus not identified;4;Approved;1235618695;29763128, 30000367, 31643287
590;amantadine;amantadine;CHEMBL660;DB00915;2130;768-94-5;BF4C9Z1J53;DKNWSYNQZKUICI-UHFFFAOYSA-N;C1C2CC3CC1CC(C2)(C3)N;15125;24;26;144;0;1;1;0;11;4;Approved;1968;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;1E51.1;Chronic hepatitis C;3;Inactive;1615937473;29763128, 30000367, 31643287
590;amantadine;amantadine;CHEMBL660;DB00915;2130;768-94-5;BF4C9Z1J53;DKNWSYNQZKUICI-UHFFFAOYSA-N;C1C2CC3CC1CC(C2)(C3)N;15125;24;26;144;0;1;1;0;11;4;Approved;1968;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A11;Type 2 diabetes mellitus;2;Inactive;119724091;29763128, 30000367, 31643287
590;amantadine;amantadine;CHEMBL660;DB00915;2130;768-94-5;BF4C9Z1J53;DKNWSYNQZKUICI-UHFFFAOYSA-N;C1C2CC3CC1CC(C2)(C3)N;15125;24;26;144;0;1;1;0;11;4;Approved;1968;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Unknown;821852937/unspecified;29763128, 30000367, 31643287
590;amantadine;amantadine;CHEMBL660;DB00915;2130;768-94-5;BF4C9Z1J53;DKNWSYNQZKUICI-UHFFFAOYSA-N;C1C2CC3CC1CC(C2)(C3)N;15125;24;26;144;0;1;1;0;11;4;Approved;1968;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;3;Inactive;1683919430/unspecified;29763128, 30000367, 31643287
590;amantadine;amantadine;CHEMBL660;DB00915;2130;768-94-5;BF4C9Z1J53;DKNWSYNQZKUICI-UHFFFAOYSA-N;C1C2CC3CC1CC(C2)(C3)N;15125;24;26;144;0;1;1;0;11;4;Approved;1968;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;29763128, 30000367, 31643287
590;amantadine;amantadine;CHEMBL660;DB00915;2130;768-94-5;BF4C9Z1J53;DKNWSYNQZKUICI-UHFFFAOYSA-N;C1C2CC3CC1CC(C2)(C3)N;15125;24;26;144;0;1;1;0;11;4;Approved;1968;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;29763128, 30000367, 31643287
590;amantadine;amantadine;CHEMBL660;DB00915;2130;768-94-5;BF4C9Z1J53;DKNWSYNQZKUICI-UHFFFAOYSA-N;C1C2CC3CC1CC(C2)(C3)N;15125;24;26;144;0;1;1;0;11;4;Approved;1968;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.22;Infectious or postinfectious parkinsonism;4;Approved;1973955757;29763128, 30000367, 31643287
590;amantadine;amantadine;CHEMBL660;DB00915;2130;768-94-5;BF4C9Z1J53;DKNWSYNQZKUICI-UHFFFAOYSA-N;C1C2CC3CC1CC(C2)(C3)N;15125;24;26;144;0;1;1;0;11;4;Approved;1968;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.2Y;Other specified secondary parkinsonism;4;Approved;502110033/other;29763128, 30000367, 31643287
590;amantadine;amantadine;CHEMBL660;DB00915;2130;768-94-5;BF4C9Z1J53;DKNWSYNQZKUICI-UHFFFAOYSA-N;C1C2CC3CC1CC(C2)(C3)N;15125;24;26;144;0;1;1;0;11;4;Approved;1968;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.Z;Parkinsonism, unspecified;4;Approved;2024168133/unspecified;29763128, 30000367, 31643287
590;amantadine;amantadine;CHEMBL660;DB00915;2130;768-94-5;BF4C9Z1J53;DKNWSYNQZKUICI-UHFFFAOYSA-N;C1C2CC3CC1CC(C2)(C3)N;15125;24;26;144;0;1;1;0;11;4;Approved;1968;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A40.Z;Multiple sclerosis, unspecified;3;Inactive;1298865187/unspecified;29763128, 30000367, 31643287
590;amantadine;amantadine;CHEMBL660;DB00915;2130;768-94-5;BF4C9Z1J53;DKNWSYNQZKUICI-UHFFFAOYSA-N;C1C2CC3CC1CC(C2)(C3)N;15125;24;26;144;0;1;1;0;11;4;Approved;1968;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;2;Active;1442995018;29763128, 30000367, 31643287
590;amantadine;amantadine;CHEMBL660;DB00915;2130;768-94-5;BF4C9Z1J53;DKNWSYNQZKUICI-UHFFFAOYSA-N;C1C2CC3CC1CC(C2)(C3)N;15125;24;26;144;0;1;1;0;11;4;Approved;1968;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG43.6;Excessive weight gain;3;Unknown;493865499;29763128, 30000367, 31643287
590;amantadine;amantadine;CHEMBL660;DB00915;2130;768-94-5;BF4C9Z1J53;DKNWSYNQZKUICI-UHFFFAOYSA-N;C1C2CC3CC1CC(C2)(C3)N;15125;24;26;144;0;1;1;0;11;4;Approved;1968;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Inactive;277610609/unspecified;29763128, 30000367, 31643287
590;amantadine;amantadine;CHEMBL660;DB00915;2130;768-94-5;BF4C9Z1J53;DKNWSYNQZKUICI-UHFFFAOYSA-N;C1C2CC3CC1CC(C2)(C3)N;15125;24;26;144;0;1;1;0;11;4;Approved;1968;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;RA01;COVID-19;3;Active;1730556128;29763128, 30000367, 31643287
591;acetylcholine;acetylcholine;CHEMBL667;DB03128;187;51-84-3;N9YNS0M02X;OIPILFWXSMYKGL-UHFFFAOYSA-N;CC(=O)OCC[N+](C)(C)C;14621;2;263;115;1;0;2;4;10;4;Approved;1973;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9E1Z;Diseases of the visual system, unspecified;4;Approved;868865918/unspecified;32503306, 29878346, 30000718
591;acetylcholine;acetylcholine;CHEMBL667;DB03128;187;51-84-3;N9YNS0M02X;OIPILFWXSMYKGL-UHFFFAOYSA-N;CC(=O)OCC[N+](C)(C)C;14621;2;263;115;1;0;2;4;10;4;Approved;1973;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;2;Unknown;426429380/unspecified;32503306, 29878346, 30000718
591;acetylcholine;acetylcholine;CHEMBL667;DB03128;187;51-84-3;N9YNS0M02X;OIPILFWXSMYKGL-UHFFFAOYSA-N;CC(=O)OCC[N+](C)(C)C;14621;2;263;115;1;0;2;4;10;4;Approved;1973;Small molecule;Agonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9E1Z;Diseases of the visual system, unspecified;4;Approved;868865918/unspecified;32503306, 29878346, 30000718
591;acetylcholine;acetylcholine;CHEMBL667;DB03128;187;51-84-3;N9YNS0M02X;OIPILFWXSMYKGL-UHFFFAOYSA-N;CC(=O)OCC[N+](C)(C)C;14621;2;263;115;1;0;2;4;10;4;Approved;1973;Small molecule;Agonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;2;Unknown;426429380/unspecified;32503306, 29878346, 30000718
591;acetylcholine;acetylcholine;CHEMBL667;DB03128;187;51-84-3;N9YNS0M02X;OIPILFWXSMYKGL-UHFFFAOYSA-N;CC(=O)OCC[N+](C)(C)C;14621;2;263;115;1;0;2;4;10;4;Approved;1973;Small molecule;Agonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9E1Z;Diseases of the visual system, unspecified;4;Approved;868865918/unspecified;32503306, 29878346, 30000718
591;acetylcholine;acetylcholine;CHEMBL667;DB03128;187;51-84-3;N9YNS0M02X;OIPILFWXSMYKGL-UHFFFAOYSA-N;CC(=O)OCC[N+](C)(C)C;14621;2;263;115;1;0;2;4;10;4;Approved;1973;Small molecule;Agonist;P08912;acm5_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;2;Unknown;426429380/unspecified;32503306, 29878346, 30000718
591;acetylcholine;acetylcholine;CHEMBL667;DB03128;187;51-84-3;N9YNS0M02X;OIPILFWXSMYKGL-UHFFFAOYSA-N;CC(=O)OCC[N+](C)(C)C;14621;2;263;115;1;0;2;4;10;4;Approved;1973;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9E1Z;Diseases of the visual system, unspecified;4;Approved;868865918/unspecified;32503306, 29878346, 30000718
591;acetylcholine;acetylcholine;CHEMBL667;DB03128;187;51-84-3;N9YNS0M02X;OIPILFWXSMYKGL-UHFFFAOYSA-N;CC(=O)OCC[N+](C)(C)C;14621;2;263;115;1;0;2;4;10;4;Approved;1973;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;2;Unknown;426429380/unspecified;32503306, 29878346, 30000718
591;acetylcholine;acetylcholine;CHEMBL667;DB03128;187;51-84-3;N9YNS0M02X;OIPILFWXSMYKGL-UHFFFAOYSA-N;CC(=O)OCC[N+](C)(C)C;14621;2;263;115;1;0;2;4;10;4;Approved;1973;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9E1Z;Diseases of the visual system, unspecified;4;Approved;868865918/unspecified;32503306, 29878346, 30000718
591;acetylcholine;acetylcholine;CHEMBL667;DB03128;187;51-84-3;N9YNS0M02X;OIPILFWXSMYKGL-UHFFFAOYSA-N;CC(=O)OCC[N+](C)(C)C;14621;2;263;115;1;0;2;4;10;4;Approved;1973;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;2;Unknown;426429380/unspecified;32503306, 29878346, 30000718
592;cyclobenzaprine;cyclobenzaprine;CHEMBL669;DB00924;2895;303-53-7;69O5WQQ5TI;JURKNVYFZMSNLP-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31;2754;52;32;365;0;0;1;3;21;4;Approved;1977;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;30020734, 30000455, 31644201
592;cyclobenzaprine;cyclobenzaprine;CHEMBL669;DB00924;2895;303-53-7;69O5WQQ5TI;JURKNVYFZMSNLP-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31;2754;52;32;365;0;0;1;3;21;4;Approved;1977;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;3;Inactive;669367341/unspecified;30020734, 30000455, 31644201
592;cyclobenzaprine;cyclobenzaprine;CHEMBL669;DB00924;2895;303-53-7;69O5WQQ5TI;JURKNVYFZMSNLP-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31;2754;52;32;365;0;0;1;3;21;4;Approved;1977;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;FB56.2;Myalgia;4;Approved;415195404;30020734, 30000455, 31644201
592;cyclobenzaprine;cyclobenzaprine;CHEMBL669;DB00924;2895;303-53-7;69O5WQQ5TI;JURKNVYFZMSNLP-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31;2754;52;32;365;0;0;1;3;21;4;Approved;1977;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;30020734, 30000455, 31644201
592;cyclobenzaprine;cyclobenzaprine;CHEMBL669;DB00924;2895;303-53-7;69O5WQQ5TI;JURKNVYFZMSNLP-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31;2754;52;32;365;0;0;1;3;21;4;Approved;1977;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG30.01;Chronic widespread pain;3;Active;849253504;30020734, 30000455, 31644201
592;cyclobenzaprine;cyclobenzaprine;CHEMBL669;DB00924;2895;303-53-7;69O5WQQ5TI;JURKNVYFZMSNLP-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31;2754;52;32;365;0;0;1;3;21;4;Approved;1977;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;30020734, 30000455, 31644201
592;cyclobenzaprine;cyclobenzaprine;CHEMBL669;DB00924;2895;303-53-7;69O5WQQ5TI;JURKNVYFZMSNLP-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31;2754;52;32;365;0;0;1;3;21;4;Approved;1977;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;30020734, 30000455, 31644201
592;cyclobenzaprine;cyclobenzaprine;CHEMBL669;DB00924;2895;303-53-7;69O5WQQ5TI;JURKNVYFZMSNLP-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31;2754;52;32;365;0;0;1;3;21;4;Approved;1977;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;3;Inactive;669367341/unspecified;30020734, 30000455, 31644201
592;cyclobenzaprine;cyclobenzaprine;CHEMBL669;DB00924;2895;303-53-7;69O5WQQ5TI;JURKNVYFZMSNLP-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31;2754;52;32;365;0;0;1;3;21;4;Approved;1977;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;FB56.2;Myalgia;4;Approved;415195404;30020734, 30000455, 31644201
592;cyclobenzaprine;cyclobenzaprine;CHEMBL669;DB00924;2895;303-53-7;69O5WQQ5TI;JURKNVYFZMSNLP-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31;2754;52;32;365;0;0;1;3;21;4;Approved;1977;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;30020734, 30000455, 31644201
592;cyclobenzaprine;cyclobenzaprine;CHEMBL669;DB00924;2895;303-53-7;69O5WQQ5TI;JURKNVYFZMSNLP-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31;2754;52;32;365;0;0;1;3;21;4;Approved;1977;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG30.01;Chronic widespread pain;3;Active;849253504;30020734, 30000455, 31644201
592;cyclobenzaprine;cyclobenzaprine;CHEMBL669;DB00924;2895;303-53-7;69O5WQQ5TI;JURKNVYFZMSNLP-UHFFFAOYSA-N;CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31;2754;52;32;365;0;0;1;3;21;4;Approved;1977;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;30020734, 30000455, 31644201
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;4;Approved;1683090852;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Y;Allergic or hypersensitivity conditions of other specified type;4;Approved;642618805/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;1;Unknown;1004695600;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Active;1663360295/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;3;Inactive;1458683894/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.03;Other allergic rhinitis;4;Approved;941478759;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA41.Z;Acute bronchiolitis, unspecified;3;Active;1310075986/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB04;Idiopathic angioedema;4;Approved;330898059;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MC82.Z;Cardiac arrest, unspecified;4;Approved;395422191/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;3;Inactive;2044414353/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;4;Approved;940081636;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;4;Approved;1164022950/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ND56.Z;Unspecified injury to unspecified part of trunk, limb or body region;2;Inactive;1842783299/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;4;Approved;1683090852;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Y;Allergic or hypersensitivity conditions of other specified type;4;Approved;642618805/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;1;Unknown;1004695600;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Active;1663360295/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;3;Inactive;1458683894/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.03;Other allergic rhinitis;4;Approved;941478759;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA41.Z;Acute bronchiolitis, unspecified;3;Active;1310075986/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB04;Idiopathic angioedema;4;Approved;330898059;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MC82.Z;Cardiac arrest, unspecified;4;Approved;395422191/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;3;Inactive;2044414353/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;4;Approved;940081636;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;4;Approved;1164022950/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ND56.Z;Unspecified injury to unspecified part of trunk, limb or body region;2;Inactive;1842783299/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;4;Approved;1683090852;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Y;Allergic or hypersensitivity conditions of other specified type;4;Approved;642618805/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;1;Unknown;1004695600;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Active;1663360295/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;3;Inactive;1458683894/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.03;Other allergic rhinitis;4;Approved;941478759;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA41.Z;Acute bronchiolitis, unspecified;3;Active;1310075986/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB04;Idiopathic angioedema;4;Approved;330898059;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MC82.Z;Cardiac arrest, unspecified;4;Approved;395422191/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;3;Inactive;2044414353/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;4;Approved;940081636;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;4;Approved;1164022950/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ND56.Z;Unspecified injury to unspecified part of trunk, limb or body region;2;Inactive;1842783299/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;4;Approved;1683090852;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Y;Allergic or hypersensitivity conditions of other specified type;4;Approved;642618805/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;1;Unknown;1004695600;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Active;1663360295/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;3;Inactive;1458683894/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.03;Other allergic rhinitis;4;Approved;941478759;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA41.Z;Acute bronchiolitis, unspecified;3;Active;1310075986/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB04;Idiopathic angioedema;4;Approved;330898059;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MC82.Z;Cardiac arrest, unspecified;4;Approved;395422191/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;3;Inactive;2044414353/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;4;Approved;940081636;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;4;Approved;1164022950/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ND56.Z;Unspecified injury to unspecified part of trunk, limb or body region;2;Inactive;1842783299/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;4;Approved;1683090852;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Y;Allergic or hypersensitivity conditions of other specified type;4;Approved;642618805/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;1;Unknown;1004695600;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Active;1663360295/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;3;Inactive;1458683894/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.03;Other allergic rhinitis;4;Approved;941478759;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA41.Z;Acute bronchiolitis, unspecified;3;Active;1310075986/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB04;Idiopathic angioedema;4;Approved;330898059;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MC82.Z;Cardiac arrest, unspecified;4;Approved;395422191/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;3;Inactive;2044414353/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;4;Approved;940081636;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;4;Approved;1164022950/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ND56.Z;Unspecified injury to unspecified part of trunk, limb or body region;2;Inactive;1842783299/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;4;Approved;1683090852;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Y;Allergic or hypersensitivity conditions of other specified type;4;Approved;642618805/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;1;Unknown;1004695600;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Active;1663360295/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;3;Inactive;1458683894/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.03;Other allergic rhinitis;4;Approved;941478759;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA41.Z;Acute bronchiolitis, unspecified;3;Active;1310075986/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB04;Idiopathic angioedema;4;Approved;330898059;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MC82.Z;Cardiac arrest, unspecified;4;Approved;395422191/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;3;Inactive;2044414353/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;4;Approved;940081636;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;4;Approved;1164022950/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ND56.Z;Unspecified injury to unspecified part of trunk, limb or body region;2;Inactive;1842783299/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;4;Approved;1683090852;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Y;Allergic or hypersensitivity conditions of other specified type;4;Approved;642618805/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;1;Unknown;1004695600;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Active;1663360295/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;3;Inactive;1458683894/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.03;Other allergic rhinitis;4;Approved;941478759;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA41.Z;Acute bronchiolitis, unspecified;3;Active;1310075986/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB04;Idiopathic angioedema;4;Approved;330898059;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MC82.Z;Cardiac arrest, unspecified;4;Approved;395422191/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;3;Inactive;2044414353/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;4;Approved;940081636;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;4;Approved;1164022950/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ND56.Z;Unspecified injury to unspecified part of trunk, limb or body region;2;Inactive;1842783299/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;4;Approved;1683090852;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Y;Allergic or hypersensitivity conditions of other specified type;4;Approved;642618805/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;1;Unknown;1004695600;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Active;1663360295/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;3;Inactive;1458683894/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.03;Other allergic rhinitis;4;Approved;941478759;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA41.Z;Acute bronchiolitis, unspecified;3;Active;1310075986/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB04;Idiopathic angioedema;4;Approved;330898059;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MC82.Z;Cardiac arrest, unspecified;4;Approved;395422191/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;3;Inactive;2044414353/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;4;Approved;940081636;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;4;Approved;1164022950/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ND56.Z;Unspecified injury to unspecified part of trunk, limb or body region;2;Inactive;1842783299/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;4;Approved;1683090852;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Y;Allergic or hypersensitivity conditions of other specified type;4;Approved;642618805/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;1;Unknown;1004695600;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA2Z;Hypotension, unspecified;2;Active;1663360295/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;3;Inactive;1458683894/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.03;Other allergic rhinitis;4;Approved;941478759;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA41.Z;Acute bronchiolitis, unspecified;3;Active;1310075986/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB04;Idiopathic angioedema;4;Approved;330898059;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;LA11.62;Anomalies of pupillary function;4;Approved;538839606;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB47.3;Cramp or spasm;4;Approved;157838476;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MC82.Z;Cardiac arrest, unspecified;4;Approved;395422191/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;3;Inactive;2044414353/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG27;Haemorrhage, not elsewhere classified;4;Approved;940081636;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;4;Approved;1164022950/unspecified;16861845, 30000703, 29489283
593;epinephrine;epinephrine;CHEMBL679;DB00668;5816;51-43-4;YKH834O4BH;UCTWMZQNUQWSLP-VIFPVBQESA-N;CNC[C@@H](C1=CC(=C(C=C1)O)O)O;1832;-14;727;154;0;4;4;3;13;4;Approved;1965;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ND56.Z;Unspecified injury to unspecified part of trunk, limb or body region;2;Inactive;1842783299/unspecified;16861845, 30000703, 29489283
594;etomidate;etomidate;CHEMBL681;DB00292;667484;33125-97-2;Z22628B598;NPUKDXXFDDZOKR-LLVKDONJSA-N;CCOC(=O)C1=CN=CN1C(C)C2=CC=CC=C2;24429;3;441;277;0;0;3;5;18;4;Approved;1982;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B20;Stroke not known if ischaemic or haemorrhagic;3;Inactive;1442995018;34060021, 30000359, 30570985
594;etomidate;etomidate;CHEMBL681;DB00292;667484;33125-97-2;Z22628B598;NPUKDXXFDDZOKR-LLVKDONJSA-N;CCOC(=O)C1=CN=CN1C(C)C2=CC=CC=C2;24429;3;441;277;0;0;3;5;18;4;Approved;1982;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X7;Sedation;4;Approved;NA;34060021, 30000359, 30570985
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;3;Inactive;1120716949/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;3;Inactive;111507461/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;7A41;Obstructive sleep apnoea;3;Inactive;1919233290;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;BA41.Z;Acute myocardial infarction, unspecified;3;Inactive;1334938734/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;BB01.0;Pulmonary arterial hypertension;2;Unknown;1931148955;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;3;Active;133207228/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;CB03.4;Idiopathic pulmonary fibrosis;3;Active;1074069640;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DA01.Z;Disorder of oral mucosa, unspecified;2;Inactive;569611257/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Active;80293156;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MC82.Z;Cardiac arrest, unspecified;1;Active;395422191/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD11.5;Dyspnoea;3;Active;960305085;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;4;Approved;1581976053/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;3;Inactive;1120716949/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;3;Inactive;111507461/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;7A41;Obstructive sleep apnoea;3;Inactive;1919233290;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;BA41.Z;Acute myocardial infarction, unspecified;3;Inactive;1334938734/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;BB01.0;Pulmonary arterial hypertension;2;Unknown;1931148955;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;3;Active;133207228/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;CB03.4;Idiopathic pulmonary fibrosis;3;Active;1074069640;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DA01.Z;Disorder of oral mucosa, unspecified;2;Inactive;569611257/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Active;80293156;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MC82.Z;Cardiac arrest, unspecified;1;Active;395422191/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD11.5;Dyspnoea;3;Active;960305085;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;4;Approved;1581976053/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;3;Inactive;1120716949/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;3;Inactive;111507461/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;7A41;Obstructive sleep apnoea;3;Inactive;1919233290;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;BA41.Z;Acute myocardial infarction, unspecified;3;Inactive;1334938734/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;BB01.0;Pulmonary arterial hypertension;2;Unknown;1931148955;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;3;Active;133207228/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;CB03.4;Idiopathic pulmonary fibrosis;3;Active;1074069640;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DA01.Z;Disorder of oral mucosa, unspecified;2;Inactive;569611257/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Active;80293156;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MC82.Z;Cardiac arrest, unspecified;1;Active;395422191/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD11.5;Dyspnoea;3;Active;960305085;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;4;Approved;1581976053/unspecified;33847389, 9061094, 14635822
595;morphine;morphine;CHEMBL70;DB00295;5288826;57-27-2;76I7G6D29C;BQJCRHHNABKAKU-KBQPJGBKSA-N;CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O;28534;8;529;494;0;2;4;0;21;4;Approved;1984;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;33847389, 9061094, 14635822
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;2C12.02;Hepatocellular carcinoma of liver;2;Unknown;1294035808;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;4A01.31;DNA repair defects other than combined T-cell or B-cell immunodeficiencies;1;Inactive;1362501774;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6A02.Z;Autism spectrum disorder, unspecified;1;Inactive;437815624/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C40.4Z;Alcohol withdrawal, unspecified;3;Inactive;998231424/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C45.2Z;Cocaine dependence, unspecified;2;Unknown;1691013484/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;1;Unknown;2143971168/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;8A40.Z;Multiple sclerosis, unspecified;4;Approved;1298865187/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;8C21.Z;Hereditary sensory or autonomic neuropathy, unspecified;3;Active;1091217288/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;8D2Z;Cerebral palsy, unspecified;4;Approved;76906748/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;3;Inactive;1391387859/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;LA07.Y;Other specified structural developmental anomalies of the neurenteric canal, spinal cord or vertebral column;4;Approved;725439990/other;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MB47.3;Cramp or spasm;4;Approved;157838476;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MG3Z;Pain, unspecified;2;Active;661232217/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;O75899;gabr2_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;ND51.2;Injury of spinal cord, level unspecified;4;Approved;2131180445;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;2C12.02;Hepatocellular carcinoma of liver;2;Unknown;1294035808;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;4A01.31;DNA repair defects other than combined T-cell or B-cell immunodeficiencies;1;Inactive;1362501774;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6A02.Z;Autism spectrum disorder, unspecified;1;Inactive;437815624/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C40.4Z;Alcohol withdrawal, unspecified;3;Inactive;998231424/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C45.2Z;Cocaine dependence, unspecified;2;Unknown;1691013484/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;1;Unknown;2143971168/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;8A40.Z;Multiple sclerosis, unspecified;4;Approved;1298865187/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;8C21.Z;Hereditary sensory or autonomic neuropathy, unspecified;3;Active;1091217288/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;8D2Z;Cerebral palsy, unspecified;4;Approved;76906748/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;3;Inactive;1391387859/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;LA07.Y;Other specified structural developmental anomalies of the neurenteric canal, spinal cord or vertebral column;4;Approved;725439990/other;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MB47.3;Cramp or spasm;4;Approved;157838476;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;MG3Z;Pain, unspecified;2;Active;661232217/unspecified;30000260, 27434299, 30252293
596;baclofen;baclofen;CHEMBL701;DB00181;2284;1134-47-0;H789N3FKE8;KPYSYYIEGFHWSV-UHFFFAOYSA-N;C1=CC(=CC=C1C(CC(=O)O)CN)Cl;21366;-1;633;191;0;2;3;4;14;4;Approved;1977;Small molecule;Agonist;Q9UBS5;gabr1_human;Class C (Glutamate);GABA<sub>B</sub> receptors;Amino acid receptors;ND51.2;Injury of spinal cord, level unspecified;4;Approved;2131180445;30000260, 27434299, 30252293
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Active;2070699808;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;1;Inactive;2143971168/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA6Z;Ischaemic heart diseases, unspecified;3;Inactive;1964269418/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;3;Inactive;1458683894/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;3;Unknown;426429380/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA90;Hyperplasia of prostate;4;Approved;978159279;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.0Z;Calculus of kidney, unspecified;3;Unknown;389168514/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Active;2070699808;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;1;Inactive;2143971168/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA6Z;Ischaemic heart diseases, unspecified;3;Inactive;1964269418/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;3;Inactive;1458683894/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;3;Unknown;426429380/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA90;Hyperplasia of prostate;4;Approved;978159279;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.0Z;Calculus of kidney, unspecified;3;Unknown;389168514/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Active;2070699808;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;1;Inactive;2143971168/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA6Z;Ischaemic heart diseases, unspecified;3;Inactive;1964269418/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;3;Inactive;1458683894/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;3;Unknown;426429380/unspecified;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA90;Hyperplasia of prostate;4;Approved;978159279;32491391, 30000706, 31644027
597;doxazosin;doxazosin;CHEMBL707;DB00590;3157;74191-85-8;NW1291F1W8;RUZYUOTYCVRMRZ-UHFFFAOYSA-N;COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC;4515;25;112;678;0;1;9;4;33;4;Approved;1990;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.0Z;Calculus of kidney, unspecified;3;Unknown;389168514/unspecified;32491391, 30000706, 31644027
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Inactive;437815624/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;3;Inactive;1563440232/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B04;Social anxiety disorder;2;Inactive;2062286624;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;1;Active;1120716949/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;1;Inactive;2143971168/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;2;Inactive;941859884/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Inactive;437815624/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;3;Inactive;1563440232/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B04;Social anxiety disorder;2;Inactive;2062286624;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;1;Active;1120716949/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;1;Inactive;2143971168/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;2;Inactive;941859884/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Inactive;437815624/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;3;Inactive;1563440232/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B04;Social anxiety disorder;2;Inactive;2062286624;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;1;Active;1120716949/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;1;Inactive;2143971168/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;2;Inactive;941859884/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Inactive;437815624/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;3;Inactive;1563440232/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B04;Social anxiety disorder;2;Inactive;2062286624;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;1;Active;1120716949/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;1;Inactive;2143971168/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;2;Inactive;941859884/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Inactive;437815624/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;3;Inactive;1563440232/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B04;Social anxiety disorder;2;Inactive;2062286624;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C43.2Z;Opioid dependence, unspecified;1;Active;1120716949/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;1;Inactive;2143971168/unspecified;30000199, 30346242, 28846230
598;ziprasidone;ziprasidone;CHEMBL708;DB00246;60854;146939-27-7;6UKA5VEJ6X;MVWVFYHBGMAFLY-UHFFFAOYSA-N;C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54;4129;4;767;573;0;1;5;4;28;4;Approved;2001;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;2;Inactive;941859884/unspecified;30000199, 30346242, 28846230
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA90;Hyperplasia of prostate;4;Approved;978159279;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA91.Z;Inflammatory and other diseases of prostate, unspecified;3;Inactive;1594247995/unspecified;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.0Z;Calculus of kidney, unspecified;3;Inactive;389168514/unspecified;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.1;Calculus of ureter;3;Inactive;1920593940;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC01.4;Neuromuscular dysfunction of bladder, not elsewhere classified;3;Inactive;590198069;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME05.0;Constipation;2;Inactive;502284069;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MF50.3;Retention of urine;3;Unknown;1775034842;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA90;Hyperplasia of prostate;4;Approved;978159279;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA91.Z;Inflammatory and other diseases of prostate, unspecified;3;Inactive;1594247995/unspecified;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.0Z;Calculus of kidney, unspecified;3;Inactive;389168514/unspecified;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.1;Calculus of ureter;3;Inactive;1920593940;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC01.4;Neuromuscular dysfunction of bladder, not elsewhere classified;3;Inactive;590198069;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME05.0;Constipation;2;Inactive;502284069;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MF50.3;Retention of urine;3;Unknown;1775034842;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA90;Hyperplasia of prostate;4;Approved;978159279;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA91.Z;Inflammatory and other diseases of prostate, unspecified;3;Inactive;1594247995/unspecified;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.0Z;Calculus of kidney, unspecified;3;Inactive;389168514/unspecified;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.1;Calculus of ureter;3;Inactive;1920593940;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC01.4;Neuromuscular dysfunction of bladder, not elsewhere classified;3;Inactive;590198069;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME05.0;Constipation;2;Inactive;502284069;31644057, 27127315, 32009306
599;alfuzosin;alfuzosin;CHEMBL709;DB00346;2092;81403-80-7;90347YTW5F;WNMJYKCGWZFFKR-UHFFFAOYSA-N;CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC;3894;17;112;511;0;2;8;8;28;4;Approved;2003;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MF50.3;Retention of urine;3;Unknown;1775034842;31644057, 27127315, 32009306
600;seratrodast;seratrodast;CHEMBL70972;DB06739;2449;112665-43-7;4U58JM421N;ZBVKEHDGYSLCCC-UHFFFAOYSA-N;CC1=C(C(=O)C(=C(C1=O)C)C(CCCCCC(=O)O)C2=CC=CC=C2)C;3544;44;714;633;0;1;4;8;26;4;Approved;1997;Small molecule;Antagonist;P21731;ta2r_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;36075466, 10375998, 12807169
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;2A00.00;Glioblastoma of brain;2;Active;650534447;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;2B90.Z;Malignant neoplasms of colon, unspecified;1;Unknown;1265576634/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;5C58.1Z;Porphyrias, unspecified;4;Approved;98434199/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Inactive;80293156;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;RA01;COVID-19;3;Unknown;1730556128;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;2A00.00;Glioblastoma of brain;2;Active;650534447;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;2B90.Z;Malignant neoplasms of colon, unspecified;1;Unknown;1265576634/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5C58.1Z;Porphyrias, unspecified;4;Approved;98434199/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Inactive;80293156;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;RA01;COVID-19;3;Unknown;1730556128;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;2A00.00;Glioblastoma of brain;2;Active;650534447;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;2B90.Z;Malignant neoplasms of colon, unspecified;1;Unknown;1265576634/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5C58.1Z;Porphyrias, unspecified;4;Approved;98434199/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Inactive;80293156;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;RA01;COVID-19;3;Unknown;1730556128;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;2A00.00;Glioblastoma of brain;2;Active;650534447;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;2B90.Z;Malignant neoplasms of colon, unspecified;1;Unknown;1265576634/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5C58.1Z;Porphyrias, unspecified;4;Approved;98434199/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Inactive;80293156;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;RA01;COVID-19;3;Unknown;1730556128;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;2A00.00;Glioblastoma of brain;2;Active;650534447;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;2B90.Z;Malignant neoplasms of colon, unspecified;1;Unknown;1265576634/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;5C58.1Z;Porphyrias, unspecified;4;Approved;98434199/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Inactive;80293156;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;RA01;COVID-19;3;Unknown;1730556128;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2A00.00;Glioblastoma of brain;2;Active;650534447;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2B90.Z;Malignant neoplasms of colon, unspecified;1;Unknown;1265576634/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5C58.1Z;Porphyrias, unspecified;4;Approved;98434199/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Inactive;80293156;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;3;Unknown;1730556128;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;2A00.00;Glioblastoma of brain;2;Active;650534447;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;2B90.Z;Malignant neoplasms of colon, unspecified;1;Unknown;1265576634/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;5C58.1Z;Porphyrias, unspecified;4;Approved;98434199/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Inactive;80293156;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;RA01;COVID-19;3;Unknown;1730556128;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2A00.00;Glioblastoma of brain;2;Active;650534447;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2B90.Z;Malignant neoplasms of colon, unspecified;1;Unknown;1265576634/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5C58.1Z;Porphyrias, unspecified;4;Approved;98434199/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Inactive;80293156;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;RA01;COVID-19;3;Unknown;1730556128;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;2A00.00;Glioblastoma of brain;2;Active;650534447;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;2B90.Z;Malignant neoplasms of colon, unspecified;1;Unknown;1265576634/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5C58.1Z;Porphyrias, unspecified;4;Approved;98434199/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;4;Approved;719572464/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6E8Y;Other specified mental, behavioural or neurodevelopmental disorders;4;Approved;334423054/other;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;KD35;Neonatal withdrawal syndrome from maternal use of drugs of addiction;3;Inactive;80293156;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000600, 31971720, 31644100
601;chlorpromazine;chlorpromazine;CHEMBL71;DB00477;2726;50-53-3;U42B7VYA4P;ZPEIMTDSQAKGNT-UHFFFAOYSA-N;CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3189;52;318;339;0;0;3;4;21;4;Approved;1957;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;RA01;COVID-19;3;Unknown;1730556128;30000600, 31971720, 31644100
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5C51.3;Glycogen storage disease;1;Inactive;1187107383;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8C21.1;Hereditary sensory and autonomic neuropathy type III;3;Inactive;831377479;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8C61;Congenital myasthenic syndromes;1;Inactive;1515367530;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BB01.0;Pulmonary arterial hypertension;3;Unknown;1931148955;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BB01.Z;Pulmonary hypertension, unspecified;3;Inactive;1496633964/unspecified;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;3;Inactive;2136808878;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;3;Inactive;1565925107;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;4;Approved;133207228/unspecified;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23.31;Unspecified asthma with status asthmaticus;2;Active;1480952049;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA41.Z;Acute bronchiolitis, unspecified;2;Inactive;1310075986/unspecified;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB00;Acute respiratory distress syndrome;2;Inactive;1189702844;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB03.4;Idiopathic pulmonary fibrosis;1;Inactive;1074069640;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB07.Z;Lymphangioleiomyomatosis, unspecified;1;Active;902628446/unspecified;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.Y;Other specified abnormalities of breathing;1;Inactive;208980208/other;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD12;Cough;2;Inactive;2027526159;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ND51.2;Injury of spinal cord, level unspecified;2;Inactive;2131180445;35569035, 29489143, 30000546
602;albuterol;albuterol;CHEMBL714;DB01001;2083;18559-94-9;QF8SVZ843E;NDAUXUAQIAJITI-UHFFFAOYSA-N;CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O;23931;3;727;227;0;4;4;5;17;4;Approved;1981;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NE61;Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified;3;Inactive;1119330136;35569035, 29489143, 30000546
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5C81.0;Hypoalphalipoproteinaemia;1;Inactive;1731667610;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A00.Z;Disorders of intellectual development, unspecified;3;Inactive;605267007/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Inactive;437815624/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Y;Other specified depressive disorders;3;Inactive;1563440232/other;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A8Z;Mood disorders, unspecified;1;Inactive;76398729/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;3;Active;263852475/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C43.Z;Disorders due to use of opioids, unspecified;2;Unknown;111507461/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C50.Z;Gambling disorder, unspecified;3;Inactive;1041487064/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;3;Inactive;941859884/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A01.10;Huntington disease;3;Inactive;2132180242;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;3;Active;677319549;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.0;Nausea;3;Active;596805318;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.1;Vomiting;2;Active;447658033;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG43.5;Excessive weight loss;2;Inactive;2015627151;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG43.7;Anorexia;3;Active;2137507044;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5C81.0;Hypoalphalipoproteinaemia;1;Inactive;1731667610;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A00.Z;Disorders of intellectual development, unspecified;3;Inactive;605267007/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Inactive;437815624/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Y;Other specified depressive disorders;3;Inactive;1563440232/other;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A8Z;Mood disorders, unspecified;1;Inactive;76398729/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;3;Active;263852475/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C43.Z;Disorders due to use of opioids, unspecified;2;Unknown;111507461/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C50.Z;Gambling disorder, unspecified;3;Inactive;1041487064/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;3;Inactive;941859884/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A01.10;Huntington disease;3;Inactive;2132180242;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;3;Active;677319549;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.0;Nausea;3;Active;596805318;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.1;Vomiting;2;Active;447658033;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG43.5;Excessive weight loss;2;Inactive;2015627151;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG43.7;Anorexia;3;Active;2137507044;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;5C81.0;Hypoalphalipoproteinaemia;1;Inactive;1731667610;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A00.Z;Disorders of intellectual development, unspecified;3;Inactive;605267007/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Inactive;437815624/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Y;Other specified depressive disorders;3;Inactive;1563440232/other;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A8Z;Mood disorders, unspecified;1;Inactive;76398729/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;3;Active;263852475/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C43.Z;Disorders due to use of opioids, unspecified;2;Unknown;111507461/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C50.Z;Gambling disorder, unspecified;3;Inactive;1041487064/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;3;Inactive;941859884/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A01.10;Huntington disease;3;Inactive;2132180242;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD90;Nausea or vomiting;3;Active;677319549;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD90.0;Nausea;3;Active;596805318;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD90.1;Vomiting;2;Active;447658033;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG43.5;Excessive weight loss;2;Inactive;2015627151;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG43.7;Anorexia;3;Active;2137507044;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;5C81.0;Hypoalphalipoproteinaemia;1;Inactive;1731667610;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A00.Z;Disorders of intellectual development, unspecified;3;Inactive;605267007/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Inactive;437815624/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Y;Other specified depressive disorders;3;Inactive;1563440232/other;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A8Z;Mood disorders, unspecified;1;Inactive;76398729/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;3;Active;263852475/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C43.Z;Disorders due to use of opioids, unspecified;2;Unknown;111507461/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C50.Z;Gambling disorder, unspecified;3;Inactive;1041487064/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;3;Inactive;941859884/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A01.10;Huntington disease;3;Inactive;2132180242;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD90;Nausea or vomiting;3;Active;677319549;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD90.0;Nausea;3;Active;596805318;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD90.1;Vomiting;2;Active;447658033;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG43.5;Excessive weight loss;2;Inactive;2015627151;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG43.7;Anorexia;3;Active;2137507044;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5C81.0;Hypoalphalipoproteinaemia;1;Inactive;1731667610;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A00.Z;Disorders of intellectual development, unspecified;3;Inactive;605267007/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;2;Inactive;437815624/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Y;Other specified depressive disorders;3;Inactive;1563440232/other;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A8Z;Mood disorders, unspecified;1;Inactive;76398729/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;3;Active;263852475/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C43.Z;Disorders due to use of opioids, unspecified;2;Unknown;111507461/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C50.Z;Gambling disorder, unspecified;3;Inactive;1041487064/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;3;Inactive;941859884/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;2;Active;897917531/unspecified;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A01.10;Huntington disease;3;Inactive;2132180242;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;3;Active;677319549;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.0;Nausea;3;Active;596805318;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.1;Vomiting;2;Active;447658033;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG43.5;Excessive weight loss;2;Inactive;2015627151;34528455, 10511917, 30000115
603;olanzapine;olanzapine;CHEMBL715;DB00334;135398745;132539-06-1;N7U69T4SZR;KVWDHTXUZHCGIO-UHFFFAOYSA-N;CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C;3124;29;591;432;0;1;4;1;22;4;Approved;1996;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MG43.7;Anorexia;3;Active;2137507044;34528455, 10511917, 30000115
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A61.Z;Bipolar type II disorder, unspecified;4;Approved;199053300/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Y;Other specified depressive disorders;3;Inactive;1563440232/other;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A8Z;Mood disorders, unspecified;3;Inactive;76398729/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;3;Inactive;1712535455;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B04;Social anxiety disorder;3;Inactive;2062286624;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;3;Inactive;1582741816/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;2;Inactive;263852475/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C40.1Z;Harmful pattern of use of alcohol, unspecified;3;Inactive;714690795/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;1;Inactive;2016549355/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;3;Inactive;941859884/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Inactive;897917531/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;3;Unknown;546689346/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6E20;Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium, without psychotic symptoms;2;Active;1124422593;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;2;Inactive;1038292737/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;7A41;Obstructive sleep apnoea;2;Active;1919233290;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;2;Inactive;296066191/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A02.10;Drug-induced dystonia;1;Inactive;678203506;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A40.Z;Multiple sclerosis, unspecified;1;Inactive;1298865187/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.F;Restlessness;3;Inactive;496629459;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A61.Z;Bipolar type II disorder, unspecified;4;Approved;199053300/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Y;Other specified depressive disorders;3;Inactive;1563440232/other;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A8Z;Mood disorders, unspecified;3;Inactive;76398729/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;3;Inactive;1712535455;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B04;Social anxiety disorder;3;Inactive;2062286624;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;3;Inactive;1582741816/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;2;Inactive;263852475/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.1Z;Harmful pattern of use of alcohol, unspecified;3;Inactive;714690795/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;1;Inactive;2016549355/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;3;Inactive;941859884/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Inactive;897917531/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;3;Unknown;546689346/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6E20;Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium, without psychotic symptoms;2;Active;1124422593;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;2;Inactive;1038292737/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7A41;Obstructive sleep apnoea;2;Active;1919233290;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;2;Inactive;296066191/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A02.10;Drug-induced dystonia;1;Inactive;678203506;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A40.Z;Multiple sclerosis, unspecified;1;Inactive;1298865187/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;3;Inactive;496629459;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;2;Inactive;821852937/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A61.Z;Bipolar type II disorder, unspecified;4;Approved;199053300/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;4;Approved;1669279433;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Y;Other specified depressive disorders;3;Inactive;1563440232/other;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A8Z;Mood disorders, unspecified;3;Inactive;76398729/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B00;Generalised anxiety disorder;3;Inactive;1712535455;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B04;Social anxiety disorder;3;Inactive;2062286624;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;3;Inactive;1582741816/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;3;Active;2070699808;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B80.Z;Anorexia Nervosa, unspecified;2;Inactive;263852475/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.1Z;Harmful pattern of use of alcohol, unspecified;3;Inactive;714690795/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C41.2Z;Cannabis dependence, unspecified;2;Inactive;1129015467/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;1;Inactive;2016549355/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;3;Inactive;941859884/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Inactive;897917531/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;3;Unknown;546689346/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6E20;Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium, without psychotic symptoms;2;Active;1124422593;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;2;Inactive;1038292737/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7A41;Obstructive sleep apnoea;2;Active;1919233290;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;2;Inactive;296066191/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A02.10;Drug-induced dystonia;1;Inactive;678203506;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A40.Z;Multiple sclerosis, unspecified;1;Inactive;1298865187/unspecified;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;33941603, 31556541, 30000146
604;quetiapine;quetiapine;CHEMBL716;DB01224;5002;111974-69-7;BGL0JSY5SI;URKOMYMAXPYINW-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42;3835;21;736;496;0;1;5;6;27;4;Approved;1997;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;3;Inactive;496629459;33941603, 31556541, 30000146
605;desipramine;desipramine;CHEMBL72;DB01151;2995;50-47-5;TG537D343B;HCYAFALTSJYZDH-UHFFFAOYSA-N;CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31;2664;49;153;267;0;1;2;4;20;4;Approved;1964;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;2C25.1;Small cell carcinoma of bronchus or lung;2;Inactive;1800431439;30000238, 29262158, 35951928
605;desipramine;desipramine;CHEMBL72;DB01151;2995;50-47-5;TG537D343B;HCYAFALTSJYZDH-UHFFFAOYSA-N;CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31;2664;49;153;267;0;1;2;4;20;4;Approved;1964;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;2;Inactive;1669279433;30000238, 29262158, 35951928
605;desipramine;desipramine;CHEMBL72;DB01151;2995;50-47-5;TG537D343B;HCYAFALTSJYZDH-UHFFFAOYSA-N;CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31;2664;49;153;267;0;1;2;4;20;4;Approved;1964;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;4;Approved;1563440232/unspecified;30000238, 29262158, 35951928
605;desipramine;desipramine;CHEMBL72;DB01151;2995;50-47-5;TG537D343B;HCYAFALTSJYZDH-UHFFFAOYSA-N;CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31;2664;49;153;267;0;1;2;4;20;4;Approved;1964;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;3;Inactive;1580466198/unspecified;30000238, 29262158, 35951928
605;desipramine;desipramine;CHEMBL72;DB01151;2995;50-47-5;TG537D343B;HCYAFALTSJYZDH-UHFFFAOYSA-N;CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31;2664;49;153;267;0;1;2;4;20;4;Approved;1964;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;30000238, 29262158, 35951928
605;desipramine;desipramine;CHEMBL72;DB01151;2995;50-47-5;TG537D343B;HCYAFALTSJYZDH-UHFFFAOYSA-N;CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31;2664;49;153;267;0;1;2;4;20;4;Approved;1964;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;7A41;Obstructive sleep apnoea;2;Inactive;1919233290;30000238, 29262158, 35951928
605;desipramine;desipramine;CHEMBL72;DB01151;2995;50-47-5;TG537D343B;HCYAFALTSJYZDH-UHFFFAOYSA-N;CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31;2664;49;153;267;0;1;2;4;20;4;Approved;1964;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;3;Inactive;1391387859/unspecified;30000238, 29262158, 35951928
605;desipramine;desipramine;CHEMBL72;DB01151;2995;50-47-5;TG537D343B;HCYAFALTSJYZDH-UHFFFAOYSA-N;CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31;2664;49;153;267;0;1;2;4;20;4;Approved;1964;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;LD90.4;Rett syndrome;2;Inactive;201200685;30000238, 29262158, 35951928
605;desipramine;desipramine;CHEMBL72;DB01151;2995;50-47-5;TG537D343B;HCYAFALTSJYZDH-UHFFFAOYSA-N;CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31;2664;49;153;267;0;1;2;4;20;4;Approved;1964;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Unknown;661232217/unspecified;30000238, 29262158, 35951928
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2A00.00;Glioblastoma of brain;1;Inactive;650534447;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Unknown;1552457716/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;2;Inactive;1004695600;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Unknown;2070699808;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A6Z;Epilepsy or seizures, unspecified;2;Inactive;1397288146/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA40.Z;Angina pectoris, unspecified;1;Inactive;718946808/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BB01.0;Pulmonary arterial hypertension;2;Inactive;1931148955;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BB01.Z;Pulmonary hypertension, unspecified;2;Inactive;1496633964/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC45;Cardiomegaly;3;Inactive;273368763;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;3;Inactive;171698302/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;4;Approved;2136808878;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA26.0Z;Oesophageal varices, unspecified;2;Active;933570887/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC2Z;Diseases of the urinary system, unspecified;2;Inactive;1932345217/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2A00.00;Glioblastoma of brain;1;Inactive;650534447;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Unknown;1552457716/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;2;Inactive;1004695600;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Unknown;2070699808;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A6Z;Epilepsy or seizures, unspecified;2;Inactive;1397288146/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA40.Z;Angina pectoris, unspecified;1;Inactive;718946808/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BB01.0;Pulmonary arterial hypertension;2;Inactive;1931148955;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BB01.Z;Pulmonary hypertension, unspecified;2;Inactive;1496633964/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC45;Cardiomegaly;3;Inactive;273368763;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;3;Inactive;171698302/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;4;Approved;2136808878;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA26.0Z;Oesophageal varices, unspecified;2;Active;933570887/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC2Z;Diseases of the urinary system, unspecified;2;Inactive;1932345217/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2A00.00;Glioblastoma of brain;1;Inactive;650534447;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Unknown;1552457716/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;2;Inactive;1004695600;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Unknown;2070699808;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A6Z;Epilepsy or seizures, unspecified;2;Inactive;1397288146/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA40.Z;Angina pectoris, unspecified;1;Inactive;718946808/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BB01.0;Pulmonary arterial hypertension;2;Inactive;1931148955;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BB01.Z;Pulmonary hypertension, unspecified;2;Inactive;1496633964/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC45;Cardiomegaly;3;Inactive;273368763;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;3;Inactive;171698302/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;4;Approved;2136808878;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA26.0Z;Oesophageal varices, unspecified;2;Active;933570887/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC2Z;Diseases of the urinary system, unspecified;2;Inactive;1932345217/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2A00.00;Glioblastoma of brain;1;Inactive;650534447;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Unknown;1552457716/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;2;Inactive;1004695600;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Unknown;2070699808;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A6Z;Epilepsy or seizures, unspecified;2;Inactive;1397288146/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA40.Z;Angina pectoris, unspecified;1;Inactive;718946808/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BB01.0;Pulmonary arterial hypertension;2;Inactive;1931148955;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BB01.Z;Pulmonary hypertension, unspecified;2;Inactive;1496633964/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC45;Cardiomegaly;3;Inactive;273368763;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;3;Inactive;171698302/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;4;Approved;2136808878;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA26.0Z;Oesophageal varices, unspecified;2;Active;933570887/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC2Z;Diseases of the urinary system, unspecified;2;Inactive;1932345217/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2A00.00;Glioblastoma of brain;1;Inactive;650534447;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Unknown;1552457716/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;2;Inactive;1004695600;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Unknown;2070699808;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A6Z;Epilepsy or seizures, unspecified;2;Inactive;1397288146/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA40.Z;Angina pectoris, unspecified;1;Inactive;718946808/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BB01.0;Pulmonary arterial hypertension;2;Inactive;1931148955;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BB01.Z;Pulmonary hypertension, unspecified;2;Inactive;1496633964/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC45;Cardiomegaly;3;Inactive;273368763;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;3;Inactive;171698302/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;4;Approved;2136808878;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA26.0Z;Oesophageal varices, unspecified;2;Active;933570887/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC2Z;Diseases of the urinary system, unspecified;2;Inactive;1932345217/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2A00.00;Glioblastoma of brain;1;Inactive;650534447;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Unknown;1552457716/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;2;Inactive;1004695600;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Unknown;2070699808;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A6Z;Epilepsy or seizures, unspecified;2;Inactive;1397288146/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA40.Z;Angina pectoris, unspecified;1;Inactive;718946808/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA41.Z;Acute myocardial infarction, unspecified;4;Approved;1334938734/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BB01.0;Pulmonary arterial hypertension;2;Inactive;1931148955;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BB01.Z;Pulmonary hypertension, unspecified;2;Inactive;1496633964/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC45;Cardiomegaly;3;Inactive;273368763;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;3;Inactive;171698302/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD10;Congestive heart failure;4;Approved;2136808878;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;DA26.0Z;Oesophageal varices, unspecified;2;Active;933570887/unspecified;36402762, 30521289, 30000204
606;carvedilol;carvedilol;CHEMBL723;DB01136;2585;72956-09-3;0K47UL67F2;OGHNVEJMJSYVRP-UHFFFAOYSA-N;COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O;4065;42;757;508;0;3;5;10;30;4;Approved;1995;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC2Z;Diseases of the urinary system, unspecified;2;Inactive;1932345217/unspecified;36402762, 30521289, 30000204
607;fluphenazine;fluphenazine;CHEMBL726;DB00623;3372;69-23-8;S79426A41Z;PLDUPXSUYLZYBN-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO;4375;44;552;544;0;1;8;6;30;4;Approved;1959;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;2A83.1;Plasma cell myeloma;1;Unknown;526287100;29083807, 29999791, 31643922
607;fluphenazine;fluphenazine;CHEMBL726;DB00623;3372;69-23-8;S79426A41Z;PLDUPXSUYLZYBN-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO;4375;44;552;544;0;1;8;6;30;4;Approved;1959;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;29083807, 29999791, 31643922
607;fluphenazine;fluphenazine;CHEMBL726;DB00623;3372;69-23-8;S79426A41Z;PLDUPXSUYLZYBN-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO;4375;44;552;544;0;1;8;6;30;4;Approved;1959;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;29083807, 29999791, 31643922
607;fluphenazine;fluphenazine;CHEMBL726;DB00623;3372;69-23-8;S79426A41Z;PLDUPXSUYLZYBN-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO;4375;44;552;544;0;1;8;6;30;4;Approved;1959;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;2A83.1;Plasma cell myeloma;1;Unknown;526287100;29083807, 29999791, 31643922
607;fluphenazine;fluphenazine;CHEMBL726;DB00623;3372;69-23-8;S79426A41Z;PLDUPXSUYLZYBN-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO;4375;44;552;544;0;1;8;6;30;4;Approved;1959;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;29083807, 29999791, 31643922
607;fluphenazine;fluphenazine;CHEMBL726;DB00623;3372;69-23-8;S79426A41Z;PLDUPXSUYLZYBN-UHFFFAOYSA-N;C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO;4375;44;552;544;0;1;8;6;30;4;Approved;1959;Small molecule;Antagonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;29083807, 29999791, 31643922
608;prochlorperazine;prochlorperazine;CHEMBL728;DB00433;4917;58-38-8;YHP6YLT61T;WIKYUJGCLQQFNW-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl;3739;49;35;429;0;0;4;4;25;4;Approved;1956;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30725768, 31643452, 30000139
608;prochlorperazine;prochlorperazine;CHEMBL728;DB00433;4917;58-38-8;YHP6YLT61T;WIKYUJGCLQQFNW-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl;3739;49;35;429;0;0;4;4;25;4;Approved;1956;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30725768, 31643452, 30000139
608;prochlorperazine;prochlorperazine;CHEMBL728;DB00433;4917;58-38-8;YHP6YLT61T;WIKYUJGCLQQFNW-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl;3739;49;35;429;0;0;4;4;25;4;Approved;1956;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B0Y;Other specified anxiety or fear-related disorders;4;Approved;1336943699/other;30725768, 31643452, 30000139
608;prochlorperazine;prochlorperazine;CHEMBL728;DB00433;4917;58-38-8;YHP6YLT61T;WIKYUJGCLQQFNW-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl;3739;49;35;429;0;0;4;4;25;4;Approved;1956;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;3;Inactive;669367341/unspecified;30725768, 31643452, 30000139
608;prochlorperazine;prochlorperazine;CHEMBL728;DB00433;4917;58-38-8;YHP6YLT61T;WIKYUJGCLQQFNW-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl;3739;49;35;429;0;0;4;4;25;4;Approved;1956;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30725768, 31643452, 30000139
608;prochlorperazine;prochlorperazine;CHEMBL728;DB00433;4917;58-38-8;YHP6YLT61T;WIKYUJGCLQQFNW-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl;3739;49;35;429;0;0;4;4;25;4;Approved;1956;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30725768, 31643452, 30000139
608;prochlorperazine;prochlorperazine;CHEMBL728;DB00433;4917;58-38-8;YHP6YLT61T;WIKYUJGCLQQFNW-UHFFFAOYSA-N;CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl;3739;49;35;429;0;0;4;4;25;4;Approved;1956;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.0;Nausea;3;Active;596805318;30725768, 31643452, 30000139
609;mequitazine;mequitazine;CHEMBL73451;DB01071;4066;29216-28-2;Y463242LY2;HOKDBMAJZXIPGC-UHFFFAOYSA-N;C1CN2CCC1C(C2)CN3C4=CC=CC=C4SC5=CC=CC=C53;3225;46;318;398;0;0;3;2;23;4;Approved;1976;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;18697448, 27488192, 21657243
610;nedocromil;nedocromil;CHEMBL746;DB00716;50294;69049-73-6;0B535E0BN0;RQTOOFIXOKYGAN-UHFFFAOYSA-N;CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)O)C(=O)C=C(N2CC)C(=O)O;3713;22;121;753;0;2;8;5;27;4;Approved;1992;Small molecule;Antagonist;Q9NS75;cltr2_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000551, 8394165, 11869595
610;nedocromil;nedocromil;CHEMBL746;DB00716;50294;69049-73-6;0B535E0BN0;RQTOOFIXOKYGAN-UHFFFAOYSA-N;CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)O)C(=O)C=C(N2CC)C(=O)O;3713;22;121;753;0;2;8;5;27;4;Approved;1992;Small molecule;Antagonist;Q9NS75;cltr2_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CA23;Asthma;4;Approved;1656445230;30000551, 8394165, 11869595
610;nedocromil;nedocromil;CHEMBL746;DB00716;50294;69049-73-6;0B535E0BN0;RQTOOFIXOKYGAN-UHFFFAOYSA-N;CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)O)C(=O)C=C(N2CC)C(=O)O;3713;22;121;753;0;2;8;5;27;4;Approved;1992;Small molecule;Antagonist;Q9NS75;cltr2_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;30000551, 8394165, 11869595
610;nedocromil;nedocromil;CHEMBL746;DB00716;50294;69049-73-6;0B535E0BN0;RQTOOFIXOKYGAN-UHFFFAOYSA-N;CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)O)C(=O)C=C(N2CC)C(=O)O;3713;22;121;753;0;2;8;5;27;4;Approved;1992;Small molecule;Antagonist;Q9NS75;cltr2_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000551, 8394165, 11869595
610;nedocromil;nedocromil;CHEMBL746;DB00716;50294;69049-73-6;0B535E0BN0;RQTOOFIXOKYGAN-UHFFFAOYSA-N;CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)O)C(=O)C=C(N2CC)C(=O)O;3713;22;121;753;0;2;8;5;27;4;Approved;1992;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000551, 8394165, 11869595
610;nedocromil;nedocromil;CHEMBL746;DB00716;50294;69049-73-6;0B535E0BN0;RQTOOFIXOKYGAN-UHFFFAOYSA-N;CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)O)C(=O)C=C(N2CC)C(=O)O;3713;22;121;753;0;2;8;5;27;4;Approved;1992;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CA23;Asthma;4;Approved;1656445230;30000551, 8394165, 11869595
610;nedocromil;nedocromil;CHEMBL746;DB00716;50294;69049-73-6;0B535E0BN0;RQTOOFIXOKYGAN-UHFFFAOYSA-N;CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)O)C(=O)C=C(N2CC)C(=O)O;3713;22;121;753;0;2;8;5;27;4;Approved;1992;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;30000551, 8394165, 11869595
610;nedocromil;nedocromil;CHEMBL746;DB00716;50294;69049-73-6;0B535E0BN0;RQTOOFIXOKYGAN-UHFFFAOYSA-N;CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)O)C(=O)C=C(N2CC)C(=O)O;3713;22;121;753;0;2;8;5;27;4;Approved;1992;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000551, 8394165, 11869595
611;phenoxybenzamine;phenoxybenzamine;CHEMBL753;DB00925;4768;59-96-1;0TTZ664R7Z;QZVCTJOXCFMACW-UHFFFAOYSA-N;CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2;3038;44;125;262;0;0;2;8;21;4;Approved;1953;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;32809502, 21863081, 875171
611;phenoxybenzamine;phenoxybenzamine;CHEMBL753;DB00925;4768;59-96-1;0TTZ664R7Z;QZVCTJOXCFMACW-UHFFFAOYSA-N;CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2;3038;44;125;262;0;0;2;8;21;4;Approved;1953;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;32809502, 21863081, 875171
611;phenoxybenzamine;phenoxybenzamine;CHEMBL753;DB00925;4768;59-96-1;0TTZ664R7Z;QZVCTJOXCFMACW-UHFFFAOYSA-N;CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2;3038;44;125;262;0;0;2;8;21;4;Approved;1953;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;32809502, 21863081, 875171
611;phenoxybenzamine;phenoxybenzamine;CHEMBL753;DB00925;4768;59-96-1;0TTZ664R7Z;QZVCTJOXCFMACW-UHFFFAOYSA-N;CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2;3038;44;125;262;0;0;2;8;21;4;Approved;1953;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;32809502, 21863081, 875171
611;phenoxybenzamine;phenoxybenzamine;CHEMBL753;DB00925;4768;59-96-1;0TTZ664R7Z;QZVCTJOXCFMACW-UHFFFAOYSA-N;CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2;3038;44;125;262;0;0;2;8;21;4;Approved;1953;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;32809502, 21863081, 875171
611;phenoxybenzamine;phenoxybenzamine;CHEMBL753;DB00925;4768;59-96-1;0TTZ664R7Z;QZVCTJOXCFMACW-UHFFFAOYSA-N;CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2;3038;44;125;262;0;0;2;8;21;4;Approved;1953;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;32809502, 21863081, 875171
611;phenoxybenzamine;phenoxybenzamine;CHEMBL753;DB00925;4768;59-96-1;0TTZ664R7Z;QZVCTJOXCFMACW-UHFFFAOYSA-N;CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2;3038;44;125;262;0;0;2;8;21;4;Approved;1953;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;32809502, 21863081, 875171
611;phenoxybenzamine;phenoxybenzamine;CHEMBL753;DB00925;4768;59-96-1;0TTZ664R7Z;QZVCTJOXCFMACW-UHFFFAOYSA-N;CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2;3038;44;125;262;0;0;2;8;21;4;Approved;1953;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;32809502, 21863081, 875171
611;phenoxybenzamine;phenoxybenzamine;CHEMBL753;DB00925;4768;59-96-1;0TTZ664R7Z;QZVCTJOXCFMACW-UHFFFAOYSA-N;CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2;3038;44;125;262;0;0;2;8;21;4;Approved;1953;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;32809502, 21863081, 875171
611;phenoxybenzamine;phenoxybenzamine;CHEMBL753;DB00925;4768;59-96-1;0TTZ664R7Z;QZVCTJOXCFMACW-UHFFFAOYSA-N;CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2;3038;44;125;262;0;0;2;8;21;4;Approved;1953;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;32809502, 21863081, 875171
611;phenoxybenzamine;phenoxybenzamine;CHEMBL753;DB00925;4768;59-96-1;0TTZ664R7Z;QZVCTJOXCFMACW-UHFFFAOYSA-N;CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2;3038;44;125;262;0;0;2;8;21;4;Approved;1953;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;32809502, 21863081, 875171
611;phenoxybenzamine;phenoxybenzamine;CHEMBL753;DB00925;4768;59-96-1;0TTZ664R7Z;QZVCTJOXCFMACW-UHFFFAOYSA-N;CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2;3038;44;125;262;0;0;2;8;21;4;Approved;1953;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;32809502, 21863081, 875171
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9E1Y;Other specified diseases of the visual system;1;Active;868865918/other;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9E1Y;Other specified diseases of the visual system;1;Active;868865918/other;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9E1Y;Other specified diseases of the visual system;1;Active;868865918/other;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9E1Y;Other specified diseases of the visual system;1;Active;868865918/other;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9E1Y;Other specified diseases of the visual system;1;Active;868865918/other;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9E1Y;Other specified diseases of the visual system;1;Active;868865918/other;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;7246278, 38155033, 36394965
613;naphazoline;naphazoline;CHEMBL761;DB06711;4436;835-31-4;H231GF11BV;CNIIGCLFLJGOGP-UHFFFAOYSA-N;C1CN=C(N1)CC2=CC=CC3=CC=CC=C32;21027;21;244;272;0;1;1;2;16;4;Approved;1971;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;7246278, 38155033, 36394965
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A03.0Z;Blepharoptosis, unspecified;4;Approved;1361674069/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9D00.3;Presbyopia;2;Inactive;22794400;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ED90.0Z;Rosacea, unspecified;4;Approved;134161404/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME07.Z;Faecal incontinence, unspecified;1;Active;790417430/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME64.0;Erythema;3;Inactive;800313204;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A03.0Z;Blepharoptosis, unspecified;4;Approved;1361674069/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9D00.3;Presbyopia;2;Inactive;22794400;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ED90.0Z;Rosacea, unspecified;4;Approved;134161404/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME07.Z;Faecal incontinence, unspecified;1;Active;790417430/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME64.0;Erythema;3;Inactive;800313204;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A03.0Z;Blepharoptosis, unspecified;4;Approved;1361674069/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9D00.3;Presbyopia;2;Inactive;22794400;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ED90.0Z;Rosacea, unspecified;4;Approved;134161404/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME07.Z;Faecal incontinence, unspecified;1;Active;790417430/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME64.0;Erythema;3;Inactive;800313204;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A03.0Z;Blepharoptosis, unspecified;4;Approved;1361674069/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9D00.3;Presbyopia;2;Inactive;22794400;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ED90.0Z;Rosacea, unspecified;4;Approved;134161404/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME07.Z;Faecal incontinence, unspecified;1;Active;790417430/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME64.0;Erythema;3;Inactive;800313204;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A03.0Z;Blepharoptosis, unspecified;4;Approved;1361674069/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9D00.3;Presbyopia;2;Inactive;22794400;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ED90.0Z;Rosacea, unspecified;4;Approved;134161404/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME07.Z;Faecal incontinence, unspecified;1;Active;790417430/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME64.0;Erythema;3;Inactive;800313204;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A03.0Z;Blepharoptosis, unspecified;4;Approved;1361674069/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9D00.3;Presbyopia;2;Inactive;22794400;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA0A.Z;Chronic rhinosinusitis, unspecified;4;Approved;1836987572/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ED90.0Z;Rosacea, unspecified;4;Approved;134161404/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME07.Z;Faecal incontinence, unspecified;1;Active;790417430/unspecified;30000423, 35952165, 28901959
614;oxymetazoline;oxymetazoline;CHEMBL762;DB00935;4636;1491-59-4;8VLN5B44ZY;WYWIFABBXFUGLM-UHFFFAOYSA-N;CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C;26037;29;446;345;0;2;2;3;19;4;Approved;1986;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME64.0;Erythema;3;Inactive;800313204;30000423, 35952165, 28901959
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;3;Inactive;642618805/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Active;897917531/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;3;Inactive;1038292737/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A41;Obstructive sleep apnoea;3;Inactive;1919233290;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A04.Y;Other specified disorders associated with tremor;3;Inactive;645263329/other;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B1Z;Cerebral ischaemia, unspecified;1;Inactive;1427441570/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;1;Active;1339785363/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;2;Inactive;761947693/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;1;Active;171698302/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;2;Unknown;426429380/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA24.Z;Pre-eclampsia, unspecified;2;Active;229121159/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.Y;Other specified abnormalities of breathing;3;Active;208980208/other;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD12;Cough;1;Unknown;2027526159;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD90;Nausea or vomiting;3;Unknown;677319549;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;3;Active;277610609/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NE8Z;Injury or harm arising from surgical or medical care, not elsewhere classified, unspecified;2;Unknown;383104340/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X1;Anesthesia;4;Approved;NA;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;3;Inactive;642618805/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Active;897917531/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;3;Inactive;1038292737/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A41;Obstructive sleep apnoea;3;Inactive;1919233290;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A04.Y;Other specified disorders associated with tremor;3;Inactive;645263329/other;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B1Z;Cerebral ischaemia, unspecified;1;Inactive;1427441570/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;1;Active;1339785363/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;2;Inactive;761947693/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;1;Active;171698302/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;2;Unknown;426429380/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA24.Z;Pre-eclampsia, unspecified;2;Active;229121159/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.Y;Other specified abnormalities of breathing;3;Active;208980208/other;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD12;Cough;1;Unknown;2027526159;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD90;Nausea or vomiting;3;Unknown;677319549;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;3;Active;277610609/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NE8Z;Injury or harm arising from surgical or medical care, not elsewhere classified, unspecified;2;Unknown;383104340/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X1;Anesthesia;4;Approved;NA;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;3;Inactive;1683090852;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;3;Inactive;642618805/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Active;897917531/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;3;Inactive;1038292737/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A41;Obstructive sleep apnoea;3;Inactive;1919233290;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A04.Y;Other specified disorders associated with tremor;3;Inactive;645263329/other;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B1Z;Cerebral ischaemia, unspecified;1;Inactive;1427441570/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8B60.0;Amyotrophic lateral sclerosis;2;Active;1982355687;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;1;Active;1339785363/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;2;Inactive;761947693/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BC81.3Z;Atrial fibrillation, unspecified;1;Active;171698302/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;2;Unknown;426429380/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;JA24.Z;Pre-eclampsia, unspecified;2;Active;229121159/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD11.Y;Other specified abnormalities of breathing;3;Active;208980208/other;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD12;Cough;1;Unknown;2027526159;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MD90;Nausea or vomiting;3;Unknown;677319549;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;3;Active;277610609/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NE8Z;Injury or harm arising from surgical or medical care, not elsewhere classified, unspecified;2;Unknown;383104340/unspecified;28105598, 34030806, 31220910
616;dexmedetomidine;dexmedetomidine;CHEMBL778;DB00633;5311068;113775-47-6;67VB76HONO;CUHVIMMYOGQXCV-NSHDSACASA-N;CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C;20028;31;287;205;0;1;1;2;15;4;Approved;1999;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;X1;Anesthesia;4;Approved;NA;28105598, 34030806, 31220910
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;1D2Z;Dengue fever, unspecified;2;Active;1959883044/unspecified;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;1D65;Severe acute respiratory syndrome;3;Active;652944603;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;3A51.1;Sickle cell disease without crisis;2;Inactive;1711513381;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;2;Unknown;642618805/unspecified;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;7A41;Obstructive sleep apnoea;3;Inactive;1919233290;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;8A20;Alzheimer disease;2;Active;1611724421;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CA08.03;Other allergic rhinitis;4;Approved;941478759;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CA09.0;Chronic rhinitis;1;Inactive;1346915097;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;3;Inactive;133207228/unspecified;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CA23;Asthma;4;Approved;1656445230;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CA23.31;Unspecified asthma with status asthmaticus;2;Unknown;1480952049;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CA26.Y;Other specified chronic bronchiolitis;2;Inactive;1067593741/other;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CA41.Z;Acute bronchiolitis, unspecified;3;Inactive;1310075986/unspecified;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;CB40.Y;Other specified diseases of the respiratory system;4;Approved;850824593/other;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;DA24.1;Eosinophilic oesophagitis;3;Inactive;21063503;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;DB92.1;Non-alcoholic steatohepatitis;1;Active;1884917970;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;FA20.Z;Rheumatoid arthritis, serology unspecified;3;Active;576319925/unspecified;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;GB61.Z;Chronic kidney disease, stage unspecified;3;Active;412389819/unspecified;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;KA21.4Z;Preterm newborn, unspecified;2;Unknown;1726201225/unspecified;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;KB29.0;Bronchopulmonary dysplasia originating in the perinatal period;1;Inactive;1462855296;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;MD11.C;Wheezing;3;Inactive;685476566;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;MD12;Cough;2;Unknown;2027526159;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;MG3Z;Pain, unspecified;3;Active;661232217/unspecified;30000548, 35608857, 29083616
617;montelukast;montelukast;CHEMBL787;DB00471;5281040;158966-92-8;MHM278SD3E;UCHDWCPVSPXUMX-TZIWLTJVSA-N;CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O;5862;77;957;891;0;2;5;12;41;4;Approved;1998;Small molecule;Antagonist;Q9Y271;cltr1_human;Class A (Rhodopsin);Leukotriene receptors;Lipid receptors;RA01;COVID-19;3;Active;1730556128;30000548, 35608857, 29083616
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;1G41;Sepsis with septic shock;4;Approved;1683090852;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;5A10;Type 1 diabetes mellitus;2;Active;1651053999;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;5A61.2;Gonadotropin deficiency;2;Active;1409526590;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6B8Z;Feeding or eating disorders, unspecified;2;Unknown;1412387537/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;4;Approved;1120716949/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;3;Active;111507461/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;3;Inactive;2143971168/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;3;Inactive;219731531/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C50.Z;Gambling disorder, unspecified;2;Inactive;1041487064/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DB30.Y;Other specified obstruction of large intestine;3;Inactive;320939116/other;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;EC90.Z;Pruritus, unspecified;3;Inactive;1729106757/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD11.Y;Other specified abnormalities of breathing;3;Unknown;208980208/other;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;1G41;Sepsis with septic shock;4;Approved;1683090852;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;5A10;Type 1 diabetes mellitus;2;Active;1651053999;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;5A61.2;Gonadotropin deficiency;2;Active;1409526590;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6B8Z;Feeding or eating disorders, unspecified;2;Unknown;1412387537/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;4;Approved;1120716949/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;3;Active;111507461/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;3;Inactive;2143971168/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;3;Inactive;219731531/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C50.Z;Gambling disorder, unspecified;2;Inactive;1041487064/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DB30.Y;Other specified obstruction of large intestine;3;Inactive;320939116/other;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;EC90.Z;Pruritus, unspecified;3;Inactive;1729106757/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD11.Y;Other specified abnormalities of breathing;3;Unknown;208980208/other;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;1G41;Sepsis with septic shock;4;Approved;1683090852;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;5A10;Type 1 diabetes mellitus;2;Active;1651053999;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;5A61.2;Gonadotropin deficiency;2;Active;1409526590;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6B8Z;Feeding or eating disorders, unspecified;2;Unknown;1412387537/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;4;Approved;1120716949/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;3;Active;111507461/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;3;Inactive;2143971168/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4G.4Z;Withdrawal due to unknown or unspecified psychoactive substance, unspecified;3;Inactive;219731531/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C50.Z;Gambling disorder, unspecified;2;Inactive;1041487064/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DB30.Y;Other specified obstruction of large intestine;3;Inactive;320939116/other;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;EC90.Z;Pruritus, unspecified;3;Inactive;1729106757/unspecified;30000741, 28722939, 35952141
618;naloxone;naloxone;CHEMBL80;DB01183;5284596;465-65-6;36B82AMQ7N;UZHSEJADLWPNLE-GRGSLBFTSA-N;C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;3274;21;70;594;0;2;5;2;24;4;Approved;1971;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MD11.Y;Other specified abnormalities of breathing;3;Unknown;208980208/other;30000741, 28722939, 35952141
619;brompheniramine;brompheniramine;CHEMBL811;DB00835;6834;86-22-6;H57G17P2FN;ZDIGNSYAACHWNL-UHFFFAOYSA-N;CN(C)CCC(C1=CC=C(C=C1)Br)C2=CC=CC=N2;31924;35;161;249;0;0;2;5;19;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000263, 31643407, 31319069
619;brompheniramine;brompheniramine;CHEMBL811;DB00835;6834;86-22-6;H57G17P2FN;ZDIGNSYAACHWNL-UHFFFAOYSA-N;CN(C)CCC(C1=CC=C(C=C1)Br)C2=CC=CC=N2;31924;35;161;249;0;0;2;5;19;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;30000263, 31643407, 31319069
619;brompheniramine;brompheniramine;CHEMBL811;DB00835;6834;86-22-6;H57G17P2FN;ZDIGNSYAACHWNL-UHFFFAOYSA-N;CN(C)CCC(C1=CC=C(C=C1)Br)C2=CC=CC=N2;31924;35;161;249;0;0;2;5;19;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD12;Cough;4;Approved;2027526159;30000263, 31643407, 31319069
620;eprosartan;eprosartan;CHEMBL813;DB00876;5281037;133040-01-4;2KH13Z0S0Y;OROAFUQRIXKEMV-LDADJPATSA-N;CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)C=C(CC3=CC=CS3)C(=O)O;4245;45;121;618;0;2;6;10;30;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000692, 31643826, 9585867
620;eprosartan;eprosartan;CHEMBL813;DB00876;5281037;133040-01-4;2KH13Z0S0Y;OROAFUQRIXKEMV-LDADJPATSA-N;CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)C=C(CC3=CC=CS3)C(=O)O;4245;45;121;618;0;2;6;10;30;4;Approved;1997;Small molecule;Antagonist;P30556;agtr1_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30000692, 31643826, 9585867
622;methylpromazine;methylpromazine;CHEMBL829;DB01246;5574;84-96-8;76H78MJJ52;ZZHLYYDVIOPZBE-UHFFFAOYSA-N;CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)CN(C)C;2984;47;318;311;0;0;3;4;21;4;Approved;1982;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;13470125, 13924736
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Active;897917531/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;2;Inactive;669367341/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;2;Inactive;1339785363/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Active;897917531/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;2;Inactive;669367341/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;2;Inactive;1339785363/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P21917;drd4_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Active;897917531/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;2;Inactive;669367341/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;2;Inactive;1339785363/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Active;897917531/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;2;Inactive;669367341/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;2;Inactive;1339785363/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Active;897917531/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;2;Inactive;669367341/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8E43.0Z;Neuropathic pain, unspecified;2;Inactive;1339785363/unspecified;30000069, 35952080, 31644182
623;loxapine;loxapine;CHEMBL831;DB00408;3964;1977-10-2;LER583670J;XJGVXQDUIWGIRW-UHFFFAOYSA-N;CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl;3278;31;281;450;0;0;3;1;23;4;Approved;1975;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;30000069, 35952080, 31644182
624;ticlopidine;ticlopidine;CHEMBL833;DB00208;5472;55142-85-3;OM90ZUW7M1;PHWBOXQYWZNQIN-UHFFFAOYSA-N;C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl;2638;36;315;261;0;0;2;2;17;4;Approved;1991;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;3B61.Z;Thrombophilia, unspecified;4;Approved;1733531851/unspecified;31643369, 1671474, 1675385
624;ticlopidine;ticlopidine;CHEMBL833;DB00208;5472;55142-85-3;OM90ZUW7M1;PHWBOXQYWZNQIN-UHFFFAOYSA-N;C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl;2638;36;315;261;0;0;2;2;17;4;Approved;1991;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;8B20;Stroke not known if ischaemic or haemorrhagic;4;Approved;1442995018;31643369, 1671474, 1675385
624;ticlopidine;ticlopidine;CHEMBL833;DB00208;5472;55142-85-3;OM90ZUW7M1;PHWBOXQYWZNQIN-UHFFFAOYSA-N;C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl;2638;36;315;261;0;0;2;2;17;4;Approved;1991;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BD5Z;Diseases of arteries or arterioles, unspecified;3;Inactive;1164983645/unspecified;31643369, 1671474, 1675385
624;ticlopidine;ticlopidine;CHEMBL833;DB00208;5472;55142-85-3;OM90ZUW7M1;PHWBOXQYWZNQIN-UHFFFAOYSA-N;C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl;2638;36;315;261;0;0;2;2;17;4;Approved;1991;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BD7Y;Other specified diseases of veins;4;Approved;723430526/other;31643369, 1671474, 1675385
624;ticlopidine;ticlopidine;CHEMBL833;DB00208;5472;55142-85-3;OM90ZUW7M1;PHWBOXQYWZNQIN-UHFFFAOYSA-N;C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl;2638;36;315;261;0;0;2;2;17;4;Approved;1991;Small molecule;Antagonist;Q9H244;p2y12_human;Class A (Rhodopsin);P2Y receptors;Nucleotide receptors;BE2Z;Diseases of the circulatory system, unspecified;3;Unknown;426429380/unspecified;31643369, 1671474, 1675385
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;1;Inactive;761947693/unspecified;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA90;Hyperplasia of prostate;4;Approved;978159279;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA91.Z;Inflammatory and other diseases of prostate, unspecified;2;Inactive;1594247995/unspecified;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.0Z;Calculus of kidney, unspecified;3;Unknown;389168514/unspecified;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.1;Calculus of ureter;3;Inactive;1920593940;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC01.4;Neuromuscular dysfunction of bladder, not elsewhere classified;2;Inactive;590198069;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC2Z;Diseases of the urinary system, unspecified;3;Unknown;1932345217/unspecified;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MF50.3;Retention of urine;3;Active;1775034842;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NE8Z;Injury or harm arising from surgical or medical care, not elsewhere classified, unspecified;3;Active;383104340/unspecified;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;1;Inactive;761947693/unspecified;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA90;Hyperplasia of prostate;4;Approved;978159279;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA91.Z;Inflammatory and other diseases of prostate, unspecified;2;Inactive;1594247995/unspecified;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.0Z;Calculus of kidney, unspecified;3;Unknown;389168514/unspecified;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.1;Calculus of ureter;3;Inactive;1920593940;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC01.4;Neuromuscular dysfunction of bladder, not elsewhere classified;2;Inactive;590198069;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC2Z;Diseases of the urinary system, unspecified;3;Unknown;1932345217/unspecified;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MF50.3;Retention of urine;3;Active;1775034842;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NE8Z;Injury or harm arising from surgical or medical care, not elsewhere classified, unspecified;3;Active;383104340/unspecified;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;1;Inactive;761947693/unspecified;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA90;Hyperplasia of prostate;4;Approved;978159279;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GA91.Z;Inflammatory and other diseases of prostate, unspecified;2;Inactive;1594247995/unspecified;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.0Z;Calculus of kidney, unspecified;3;Unknown;389168514/unspecified;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GB70.1;Calculus of ureter;3;Inactive;1920593940;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC01.4;Neuromuscular dysfunction of bladder, not elsewhere classified;2;Inactive;590198069;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;GC2Z;Diseases of the urinary system, unspecified;3;Unknown;1932345217/unspecified;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MF50.3;Retention of urine;3;Active;1775034842;35073027, 33108544, 31643349
625;tamsulosin;tamsulosin;CHEMBL836;DB00706;129211;106133-20-4;G3P28OML5I;DRHKJLXJIQTDTD-OAHLLOKOSA-N;CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N;4085;27;108;539;0;2;7;11;28;4;Approved;1997;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NE8Z;Injury or harm arising from surgical or medical care, not elsewhere classified, unspecified;3;Active;383104340/unspecified;35073027, 33108544, 31643349
626;carteolol;carteolol;CHEMBL839;DB00521;2583;51781-06-7;8NF31401XG;LWAFSWPYPHEXKX-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O;29237;1;706;354;0;3;4;6;21;4;Approved;1988;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000575, 17571916, 35887923
626;carteolol;carteolol;CHEMBL839;DB00521;2583;51781-06-7;8NF31401XG;LWAFSWPYPHEXKX-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O;29237;1;706;354;0;3;4;6;21;4;Approved;1988;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000575, 17571916, 35887923
626;carteolol;carteolol;CHEMBL839;DB00521;2583;51781-06-7;8NF31401XG;LWAFSWPYPHEXKX-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O;29237;1;706;354;0;3;4;6;21;4;Approved;1988;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000575, 17571916, 35887923
626;carteolol;carteolol;CHEMBL839;DB00521;2583;51781-06-7;8NF31401XG;LWAFSWPYPHEXKX-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O;29237;1;706;354;0;3;4;6;21;4;Approved;1988;Small molecule;Antagonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000575, 17571916, 35887923
626;carteolol;carteolol;CHEMBL839;DB00521;2583;51781-06-7;8NF31401XG;LWAFSWPYPHEXKX-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O;29237;1;706;354;0;3;4;6;21;4;Approved;1988;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000575, 17571916, 35887923
626;carteolol;carteolol;CHEMBL839;DB00521;2583;51781-06-7;8NF31401XG;LWAFSWPYPHEXKX-UHFFFAOYSA-N;CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O;29237;1;706;354;0;3;4;6;21;4;Approved;1988;Small molecule;Antagonist;P13945;adrb3_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;30000575, 17571916, 35887923
627;loperamide;loperamide;CHEMBL841;DB00836;3955;53179-11-6;6X9OC3H4II;RDOIQAHITMMDAJ-UHFFFAOYSA-N;CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4;477;5;438;623;0;1;3;7;34;4;Approved;1976;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;EA8Z;Dermatitis or eczema, unspecified;2;Unknown;1887882424/unspecified;21703817, 32491808, 30000356
627;loperamide;loperamide;CHEMBL841;DB00836;3955;53179-11-6;6X9OC3H4II;RDOIQAHITMMDAJ-UHFFFAOYSA-N;CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4;477;5;438;623;0;1;3;7;34;4;Approved;1976;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME05.1;Diarrhoea;4;Approved;116759077;21703817, 32491808, 30000356
627;loperamide;loperamide;CHEMBL841;DB00836;3955;53179-11-6;6X9OC3H4II;RDOIQAHITMMDAJ-UHFFFAOYSA-N;CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4;477;5;438;623;0;1;3;7;34;4;Approved;1976;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;ME07.Z;Faecal incontinence, unspecified;3;Inactive;790417430/unspecified;21703817, 32491808, 30000356
627;loperamide;loperamide;CHEMBL841;DB00836;3955;53179-11-6;6X9OC3H4II;RDOIQAHITMMDAJ-UHFFFAOYSA-N;CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4;477;5;438;623;0;1;3;7;34;4;Approved;1976;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;2;Inactive;661232217/unspecified;21703817, 32491808, 30000356
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28566;5ht1e_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28566;5ht1e_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28566;5ht1e_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P28566;5ht1e_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P41595;5ht2b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P50406;5ht6r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P50406;5ht6r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P50406;5ht6r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;P50406;5ht6r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A01.10;Huntington disease;4;Approved;2132180242;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A0Z;Movement disorders, unspecified;4;Approved;384289569/unspecified;35313032, 11520473, 35455705
628;tiapride;tiapride;CHEMBL84158;DB13025;5467;51012-32-9;LAH70H9JPH;JTVPZMFULRWINT-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC;3284;9;841;443;0;1;5;8;22;4;Approved;1981;Small molecule;Antagonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.F;Restlessness;4;Approved;496629459;35313032, 11520473, 35455705
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;1;Inactive;1580466198/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A1Y;Other specified disorders of lacrimal apparatus;3;Inactive;1628710366/other;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A78.2Z;Corneal oedema, unspecified;3;Unknown;1058326567/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9B71.0Z;Diabetic retinopathy, unspecified;2;Inactive;1006882070/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.01;Ocular hypertension;4;Approved;535283437;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9D00.3;Presbyopia;3;Active;22794400;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9E1Y;Other specified diseases of the visual system;3;Inactive;868865918/other;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ED90.0Z;Rosacea, unspecified;4;Approved;134161404/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EH76.0;Dermatoses resulting from cytotoxic or cancer chemotherapy;2;Inactive;2070891383;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME64.0;Erythema;4;Approved;800313204;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;1;Inactive;1580466198/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A1Y;Other specified disorders of lacrimal apparatus;3;Inactive;1628710366/other;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A78.2Z;Corneal oedema, unspecified;3;Unknown;1058326567/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9B71.0Z;Diabetic retinopathy, unspecified;2;Inactive;1006882070/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.01;Ocular hypertension;4;Approved;535283437;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9D00.3;Presbyopia;3;Active;22794400;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9E1Y;Other specified diseases of the visual system;3;Inactive;868865918/other;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ED90.0Z;Rosacea, unspecified;4;Approved;134161404/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EH76.0;Dermatoses resulting from cytotoxic or cancer chemotherapy;2;Inactive;2070891383;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME64.0;Erythema;4;Approved;800313204;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;1;Inactive;1580466198/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A1Y;Other specified disorders of lacrimal apparatus;3;Inactive;1628710366/other;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A60.02;Allergic conjunctivitis;4;Approved;361206059;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9A78.2Z;Corneal oedema, unspecified;3;Unknown;1058326567/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9B71.0Z;Diabetic retinopathy, unspecified;2;Inactive;1006882070/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.01;Ocular hypertension;4;Approved;535283437;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9C6Y;Other specified glaucoma or glaucoma suspect;4;Approved;551713432/other;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9D00.3;Presbyopia;3;Active;22794400;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;9E1Y;Other specified diseases of the visual system;3;Inactive;868865918/other;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ED90.0Z;Rosacea, unspecified;4;Approved;134161404/unspecified;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;EH76.0;Dermatoses resulting from cytotoxic or cancer chemotherapy;2;Inactive;2070891383;37061271, 30000738, 15989664
629;brimonidine;brimonidine;CHEMBL844;DB00484;2435;59803-98-4;E6GNX3HHTE;XYLJNLCSTIOKRM-UHFFFAOYSA-N;C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br;29213;6;622;308;0;2;3;2;17;4;Approved;1996;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;ME64.0;Erythema;4;Approved;800313204;37061271, 30000738, 15989664
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A00.Z;Disorders of intellectual development, unspecified;3;Inactive;605267007/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.0;Autism spectrum disorder without disorder of intellectual development and with mild or no impairment of functional language;3;Inactive;120443468;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;4;Approved;437815624/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A0Z;Neurodevelopmental disorders, unspecified;3;Inactive;1516623224/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A22;Schizotypal disorder;1;Inactive;18178000;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;3;Inactive;1563440232/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Active;1582741816/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Inactive;2070699808;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Inactive;2016549355/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;1;Inactive;2143971168/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;3;Inactive;719572464/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D81;Dementia due to cerebrovascular disease;3;Inactive;1365258270;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;3;Unknown;546689346/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A01.10;Huntington disease;1;Active;2132180242;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;2;Inactive;119340957;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;LD90.4;Rett syndrome;3;Inactive;201200685;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB23.0;Aggressive behaviour;4;Approved;501393848;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A00.Z;Disorders of intellectual development, unspecified;3;Inactive;605267007/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.0;Autism spectrum disorder without disorder of intellectual development and with mild or no impairment of functional language;3;Inactive;120443468;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;4;Approved;437815624/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A0Z;Neurodevelopmental disorders, unspecified;3;Inactive;1516623224/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A22;Schizotypal disorder;1;Inactive;18178000;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;3;Inactive;1563440232/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Active;1582741816/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Inactive;2070699808;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Inactive;2016549355/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;1;Inactive;2143971168/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;3;Inactive;719572464/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D81;Dementia due to cerebrovascular disease;3;Inactive;1365258270;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;3;Unknown;546689346/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A01.10;Huntington disease;1;Active;2132180242;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;2;Inactive;119340957;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;LD90.4;Rett syndrome;3;Inactive;201200685;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB23.0;Aggressive behaviour;4;Approved;501393848;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A00.Z;Disorders of intellectual development, unspecified;3;Inactive;605267007/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.0;Autism spectrum disorder without disorder of intellectual development and with mild or no impairment of functional language;3;Inactive;120443468;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A02.Z;Autism spectrum disorder, unspecified;4;Approved;437815624/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A0Z;Neurodevelopmental disorders, unspecified;3;Inactive;1516623224/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A21.Z;Schizoaffective disorder, unspecified;4;Approved;106339515/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A22;Schizotypal disorder;1;Inactive;18178000;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A70.3;Single episode depressive disorder, severe, without psychotic symptoms;3;Inactive;1669279433;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;3;Inactive;1563440232/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B20.Z;Obsessive-compulsive disorder, unspecified;2;Active;1582741816/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6B40;Post traumatic stress disorder;2;Inactive;2070699808;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C46.2Z;Stimulant dependence including amphetamines, methamphetamine or methcathinone, unspecified;2;Inactive;2016549355/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;1;Inactive;2143971168/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C91.Z;Conduct-dissocial disorder, unspecified;3;Inactive;719572464/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D81;Dementia due to cerebrovascular disease;3;Inactive;1365258270;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;3;Unknown;546689346/unspecified;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A01.10;Huntington disease;1;Active;2132180242;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A05.00;Tourette syndrome;2;Inactive;119340957;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;LD90.4;Rett syndrome;3;Inactive;201200685;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB23.0;Aggressive behaviour;4;Approved;501393848;25943458, 30000154, 29083663
630;risperidone;risperidone;CHEMBL85;DB00734;5073;106266-06-2;L6UH7ZF8HC;RAPZEAPATHNIPO-UHFFFAOYSA-N;CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F;4105;27;619;731;0;0;6;4;30;4;Approved;1993;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB24.3;Anxiety;3;Inactive;2027043655;25943458, 30000154, 29083663
631;triprolidine;triprolidine;CHEMBL855;DB00427;5282443;486-12-4;2L8T9S52QM;CBEQULMOCCWAQT-WOJGMQOQSA-N;CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC=N3;2784;39;161;336;0;0;2;4;21;4;Approved;1983;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000188, 31643493, 33768603
631;triprolidine;triprolidine;CHEMBL855;DB00427;5282443;486-12-4;2L8T9S52QM;CBEQULMOCCWAQT-WOJGMQOQSA-N;CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC=N3;2784;39;161;336;0;0;2;4;21;4;Approved;1983;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA00;Acute nasopharyngitis;4;Approved;2066255370;30000188, 31643493, 33768603
631;triprolidine;triprolidine;CHEMBL855;DB00427;5282443;486-12-4;2L8T9S52QM;CBEQULMOCCWAQT-WOJGMQOQSA-N;CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC=N3;2784;39;161;336;0;0;2;4;21;4;Approved;1983;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;30000188, 31643493, 33768603
631;triprolidine;triprolidine;CHEMBL855;DB00427;5282443;486-12-4;2L8T9S52QM;CBEQULMOCCWAQT-WOJGMQOQSA-N;CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC=N3;2784;39;161;336;0;0;2;4;21;4;Approved;1983;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;30000188, 31643493, 33768603
631;triprolidine;triprolidine;CHEMBL855;DB00427;5282443;486-12-4;2L8T9S52QM;CBEQULMOCCWAQT-WOJGMQOQSA-N;CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC=N3;2784;39;161;336;0;0;2;4;21;4;Approved;1983;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MD11.9;Nasal congestion;4;Approved;1251924794;30000188, 31643493, 33768603
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;1A40.0;Gastroenteritis or colitis without specification of origin;3;Unknown;1160271562;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;1G40;Sepsis without septic shock;3;Inactive;622600769;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;3A9Z;Anaemias or other erythrocyte disorders, unspecified;2;Unknown;224336967/unspecified;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;2;Active;1004695600;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A80.Z;Migraine, unspecified;3;Active;669367341/unspecified;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA41.00;Gastroparesis;4;Approved;598423727;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DB30.Y;Other specified obstruction of large intestine;2;Inactive;320939116/other;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DE2Z;Diseases of the digestive system, unspecified;4;Approved;1256772020/unspecified;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;JA60.0;Mild hyperemesis gravidarum;2;Inactive;1878037467;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;LB02;Gastroschisis;3;Inactive;551758329;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;MD90.1;Vomiting;4;Approved;447658033;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;2;Unknown;2044414353/unspecified;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;1A40.0;Gastroenteritis or colitis without specification of origin;3;Unknown;1160271562;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;1G40;Sepsis without septic shock;3;Inactive;622600769;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;3A9Z;Anaemias or other erythrocyte disorders, unspecified;2;Unknown;224336967/unspecified;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;2;Active;1004695600;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;3;Active;669367341/unspecified;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;DA41.00;Gastroparesis;4;Approved;598423727;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;DB30.Y;Other specified obstruction of large intestine;2;Inactive;320939116/other;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;DE2Z;Diseases of the digestive system, unspecified;4;Approved;1256772020/unspecified;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;JA60.0;Mild hyperemesis gravidarum;2;Inactive;1878037467;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;LB02;Gastroschisis;3;Inactive;551758329;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;MD90.1;Vomiting;4;Approved;447658033;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;2;Unknown;2044414353/unspecified;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;1A40.0;Gastroenteritis or colitis without specification of origin;3;Unknown;1160271562;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;1G40;Sepsis without septic shock;3;Inactive;622600769;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;3A9Z;Anaemias or other erythrocyte disorders, unspecified;2;Unknown;224336967/unspecified;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;5A41;Hypoglycaemia without associated diabetes;2;Active;1004695600;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;3;Active;669367341/unspecified;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DA41.00;Gastroparesis;4;Approved;598423727;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DB30.Y;Other specified obstruction of large intestine;2;Inactive;320939116/other;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;DE2Z;Diseases of the digestive system, unspecified;4;Approved;1256772020/unspecified;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;JA60.0;Mild hyperemesis gravidarum;2;Inactive;1878037467;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;LB02;Gastroschisis;3;Inactive;551758329;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB4D;Headache, not elsewhere classified;3;Inactive;1405405864;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD90;Nausea or vomiting;4;Approved;677319549;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MD90.1;Vomiting;4;Approved;447658033;30000411, 30137802, 35952113
632;metoclopramide;metoclopramide;CHEMBL86;DB01233;4168;364-62-5;L4YEB44I46;TTWJBBZEZQICBI-UHFFFAOYSA-N;CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl;29979;26;676;300;0;2;4;7;20;4;Approved;1979;Small molecule;Agonist;Q13639;5ht4r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;2;Unknown;2044414353/unspecified;30000411, 30137802, 35952113
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;4;Approved;821852937/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A22;Schizotypal disorder;2;Inactive;18178000;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;1;Inactive;2070699808;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C41.2Z;Cannabis dependence, unspecified;2;Active;1129015467/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Active;1699574100/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;2;Active;2143971168/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Active;897917531/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A05.00;Tourette syndrome;3;Inactive;119340957;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A20;Alzheimer disease;3;Active;1611724421;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB27.Z;Symptoms and signs of perceptual disturbance, unspecified;2;Unknown;1711901760/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Unknown;661232217/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;4;Approved;821852937/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A22;Schizotypal disorder;2;Inactive;18178000;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;1;Inactive;2070699808;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C41.2Z;Cannabis dependence, unspecified;2;Active;1129015467/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Active;1699574100/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;2;Active;2143971168/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Active;897917531/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A05.00;Tourette syndrome;3;Inactive;119340957;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A20;Alzheimer disease;3;Active;1611724421;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB27.Z;Symptoms and signs of perceptual disturbance, unspecified;2;Unknown;1711901760/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Unknown;661232217/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A05.Z;Attention deficit hyperactivity disorder, presentation unspecified;4;Approved;821852937/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6A22;Schizotypal disorder;2;Inactive;18178000;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6B40;Post traumatic stress disorder;1;Inactive;2070699808;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C40.2Z;Alcohol dependence, unspecified;2;Active;1580466198/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C41.2Z;Cannabis dependence, unspecified;2;Active;1129015467/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C45.2Z;Cocaine dependence, unspecified;2;Inactive;1691013484/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Active;1699574100/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6C4G.2Z;Unknown or unspecified psychoactive substance dependence, substance and state of remission unspecified;2;Active;2143971168/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;6D70.Z;Delirium, unspecified or unknown cause;3;Active;897917531/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A05.00;Tourette syndrome;3;Inactive;119340957;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A20;Alzheimer disease;3;Active;1611724421;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MB27.Z;Symptoms and signs of perceptual disturbance, unspecified;2;Unknown;1711901760/unspecified;30000582, 31643901, 33075480
633;guanfacine;guanfacine;CHEMBL862;DB01018;3519;29110-47-2;30OMY4G3MK;INJOMKTZOLKMBF-UHFFFAOYSA-N;C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl;24609;2;815;256;0;2;1;2;15;4;Approved;1986;Small molecule;Agonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Unknown;661232217/unspecified;30000582, 31643901, 33075480
634;procyclidine;procyclidine;CHEMBL86715;DB00387;4919;77-37-2;C6QE1Q1TKR;WYDUSKDSKCASEF-UHFFFAOYSA-N;C1CCC(CC1)C(CCN2CCCC2)(C3=CC=CC=C3)O;2874;41;235;301;0;1;2;5;21;4;Approved;1955;Small molecule;Antagonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A00.2Y;Other specified secondary parkinsonism;4;Approved;502110033/other;3814945, 2253700, 35786035
634;procyclidine;procyclidine;CHEMBL86715;DB00387;4919;77-37-2;C6QE1Q1TKR;WYDUSKDSKCASEF-UHFFFAOYSA-N;C1CCC(CC1)C(CCN2CCCC2)(C3=CC=CC=C3)O;2874;41;235;301;0;1;2;5;21;4;Approved;1955;Small molecule;Antagonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A00.2Y;Other specified secondary parkinsonism;4;Approved;502110033/other;3814945, 2253700, 35786035
634;procyclidine;procyclidine;CHEMBL86715;DB00387;4919;77-37-2;C6QE1Q1TKR;WYDUSKDSKCASEF-UHFFFAOYSA-N;C1CCC(CC1)C(CCN2CCCC2)(C3=CC=CC=C3)O;2874;41;235;301;0;1;2;5;21;4;Approved;1955;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A00.2Y;Other specified secondary parkinsonism;4;Approved;502110033/other;3814945, 2253700, 35786035
634;procyclidine;procyclidine;CHEMBL86715;DB00387;4919;77-37-2;C6QE1Q1TKR;WYDUSKDSKCASEF-UHFFFAOYSA-N;C1CCC(CC1)C(CCN2CCCC2)(C3=CC=CC=C3)O;2874;41;235;301;0;1;2;5;21;4;Approved;1955;Small molecule;Antagonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A00.2Y;Other specified secondary parkinsonism;4;Approved;502110033/other;3814945, 2253700, 35786035
635;rimiterol;rimiterol;CHEMBL88055;NA;431097;32953-89-2;NA;IYMMESGOJVNCKV-UHFFFAOYSA-N;C1CCNC(C1)C(C2=CC(=C(C=C2)O)O)O;22327;8;727;224;0;4;4;2;16;4;Approved;1977;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;CA23;Asthma;4;Approved;1656445230;19226, 2563270, 10658
636;nalbuphine;nalbuphine;CHEMBL895;DB00844;5311304;20594-83-6;L2T84IQI2K;NETZHAKZCGBWSS-CEDHKZHLSA-N;C1CC(C1)CN2CCC34C5C(CCC3(C2CC6=C4C(=C(C=C6)O)O5)O)O;3574;2;732;597;0;3;5;2;26;4;Approved;1979;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;EC90.Z;Pruritus, unspecified;3;Inactive;1729106757/unspecified;30000297, 30484997, 31661394
636;nalbuphine;nalbuphine;CHEMBL895;DB00844;5311304;20594-83-6;L2T84IQI2K;NETZHAKZCGBWSS-CEDHKZHLSA-N;C1CC(C1)CN2CCC34C5C(CCC3(C2CC6=C4C(=C(C=C6)O)O5)O)O;3574;2;732;597;0;3;5;2;26;4;Approved;1979;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MB24.F;Restlessness;3;Unknown;496629459;30000297, 30484997, 31661394
636;nalbuphine;nalbuphine;CHEMBL895;DB00844;5311304;20594-83-6;L2T84IQI2K;NETZHAKZCGBWSS-CEDHKZHLSA-N;C1CC(C1)CN2CCC34C5C(CCC3(C2CC6=C4C(=C(C=C6)O)O5)O)O;3574;2;732;597;0;3;5;2;26;4;Approved;1979;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000297, 30484997, 31661394
636;nalbuphine;nalbuphine;CHEMBL895;DB00844;5311304;20594-83-6;L2T84IQI2K;NETZHAKZCGBWSS-CEDHKZHLSA-N;C1CC(C1)CN2CCC34C5C(CCC3(C2CC6=C4C(=C(C=C6)O)O5)O)O;3574;2;732;597;0;3;5;2;26;4;Approved;1979;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;EC90.Z;Pruritus, unspecified;3;Inactive;1729106757/unspecified;30000297, 30484997, 31661394
636;nalbuphine;nalbuphine;CHEMBL895;DB00844;5311304;20594-83-6;L2T84IQI2K;NETZHAKZCGBWSS-CEDHKZHLSA-N;C1CC(C1)CN2CCC34C5C(CCC3(C2CC6=C4C(=C(C=C6)O)O5)O)O;3574;2;732;597;0;3;5;2;26;4;Approved;1979;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MB24.F;Restlessness;3;Unknown;496629459;30000297, 30484997, 31661394
636;nalbuphine;nalbuphine;CHEMBL895;DB00844;5311304;20594-83-6;L2T84IQI2K;NETZHAKZCGBWSS-CEDHKZHLSA-N;C1CC(C1)CN2CCC34C5C(CCC3(C2CC6=C4C(=C(C=C6)O)O5)O)O;3574;2;732;597;0;3;5;2;26;4;Approved;1979;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000297, 30484997, 31661394
636;nalbuphine;nalbuphine;CHEMBL895;DB00844;5311304;20594-83-6;L2T84IQI2K;NETZHAKZCGBWSS-CEDHKZHLSA-N;C1CC(C1)CN2CCC34C5C(CCC3(C2CC6=C4C(=C(C=C6)O)O5)O)O;3574;2;732;597;0;3;5;2;26;4;Approved;1979;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;EC90.Z;Pruritus, unspecified;3;Inactive;1729106757/unspecified;30000297, 30484997, 31661394
636;nalbuphine;nalbuphine;CHEMBL895;DB00844;5311304;20594-83-6;L2T84IQI2K;NETZHAKZCGBWSS-CEDHKZHLSA-N;C1CC(C1)CN2CCC34C5C(CCC3(C2CC6=C4C(=C(C=C6)O)O5)O)O;3574;2;732;597;0;3;5;2;26;4;Approved;1979;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MB24.F;Restlessness;3;Unknown;496629459;30000297, 30484997, 31661394
636;nalbuphine;nalbuphine;CHEMBL895;DB00844;5311304;20594-83-6;L2T84IQI2K;NETZHAKZCGBWSS-CEDHKZHLSA-N;C1CC(C1)CN2CCC34C5C(CCC3(C2CC6=C4C(=C(C=C6)O)O5)O)O;3574;2;732;597;0;3;5;2;26;4;Approved;1979;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;30000297, 30484997, 31661394
637;hydroxyzine;hydroxyzine;CHEMBL896;DB00557;3658;68-88-2;30S50YM8OG;ZQDWXGKKHFNSQK-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3749;37;359;376;0;1;4;8;26;4;Approved;1956;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6B0Y;Other specified anxiety or fear-related disorders;4;Approved;1336943699/other;30000044, 36843057, 31643458
637;hydroxyzine;hydroxyzine;CHEMBL896;DB00557;3658;68-88-2;30S50YM8OG;ZQDWXGKKHFNSQK-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3749;37;359;376;0;1;4;8;26;4;Approved;1956;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6B6Z;Dissociative disorders, unspecified;4;Approved;108180424/unspecified;30000044, 36843057, 31643458
637;hydroxyzine;hydroxyzine;CHEMBL896;DB00557;3658;68-88-2;30S50YM8OG;ZQDWXGKKHFNSQK-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3749;37;359;376;0;1;4;8;26;4;Approved;1956;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6D8Z;Dementia, unknown or unspecified cause;3;Unknown;546689346/unspecified;30000044, 36843057, 31643458
637;hydroxyzine;hydroxyzine;CHEMBL896;DB00557;3658;68-88-2;30S50YM8OG;ZQDWXGKKHFNSQK-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3749;37;359;376;0;1;4;8;26;4;Approved;1956;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;30000044, 36843057, 31643458
637;hydroxyzine;hydroxyzine;CHEMBL896;DB00557;3658;68-88-2;30S50YM8OG;ZQDWXGKKHFNSQK-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3749;37;359;376;0;1;4;8;26;4;Approved;1956;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;30000044, 36843057, 31643458
637;hydroxyzine;hydroxyzine;CHEMBL896;DB00557;3658;68-88-2;30S50YM8OG;ZQDWXGKKHFNSQK-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3749;37;359;376;0;1;4;8;26;4;Approved;1956;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EM0Y;Other specified diseases of the skin;4;Approved;1639304259/other;30000044, 36843057, 31643458
637;hydroxyzine;hydroxyzine;CHEMBL896;DB00557;3658;68-88-2;30S50YM8OG;ZQDWXGKKHFNSQK-UHFFFAOYSA-N;C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl;3749;37;359;376;0;1;4;8;26;4;Approved;1956;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MB24.3;Anxiety;4;Approved;2027043655;30000044, 36843057, 31643458
638;histamine;histamine;CHEMBL90;DB05381;774;51-45-6;820484N8I3;NTYJJOPFIAHURM-UHFFFAOYSA-N;C1=C(NC=N1)CCN;11115;-7;547;64;0;2;2;2;8;4;Approved;1939;Small molecule;Agonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;2B33.4;Leukaemia, unspecified;3;Inactive;1385484871;17490952, 21277530, 36931880
638;histamine;histamine;CHEMBL90;DB05381;774;51-45-6;820484N8I3;NTYJJOPFIAHURM-UHFFFAOYSA-N;C1=C(NC=N1)CCN;11115;-7;547;64;0;2;2;2;8;4;Approved;1939;Small molecule;Agonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;2C30.Z;Melanoma of skin, unspecified;3;Unknown;488336723/unspecified;17490952, 21277530, 36931880
638;histamine;histamine;CHEMBL90;DB05381;774;51-45-6;820484N8I3;NTYJJOPFIAHURM-UHFFFAOYSA-N;C1=C(NC=N1)CCN;11115;-7;547;64;0;2;2;2;8;4;Approved;1939;Small molecule;Agonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;2C90.Z;Malignant neoplasms of kidney, except renal pelvis, unspecified;2;Unknown;1048613131/unspecified;17490952, 21277530, 36931880
638;histamine;histamine;CHEMBL90;DB05381;774;51-45-6;820484N8I3;NTYJJOPFIAHURM-UHFFFAOYSA-N;C1=C(NC=N1)CCN;11115;-7;547;64;0;2;2;2;8;4;Approved;1939;Small molecule;Agonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;4;Approved;1844086508/unspecified;17490952, 21277530, 36931880
638;histamine;histamine;CHEMBL90;DB05381;774;51-45-6;820484N8I3;NTYJJOPFIAHURM-UHFFFAOYSA-N;C1=C(NC=N1)CCN;11115;-7;547;64;0;2;2;2;8;4;Approved;1939;Small molecule;Agonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;2B33.4;Leukaemia, unspecified;3;Inactive;1385484871;17490952, 21277530, 36931880
638;histamine;histamine;CHEMBL90;DB05381;774;51-45-6;820484N8I3;NTYJJOPFIAHURM-UHFFFAOYSA-N;C1=C(NC=N1)CCN;11115;-7;547;64;0;2;2;2;8;4;Approved;1939;Small molecule;Agonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;2C30.Z;Melanoma of skin, unspecified;3;Unknown;488336723/unspecified;17490952, 21277530, 36931880
638;histamine;histamine;CHEMBL90;DB05381;774;51-45-6;820484N8I3;NTYJJOPFIAHURM-UHFFFAOYSA-N;C1=C(NC=N1)CCN;11115;-7;547;64;0;2;2;2;8;4;Approved;1939;Small molecule;Agonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;2C90.Z;Malignant neoplasms of kidney, except renal pelvis, unspecified;2;Unknown;1048613131/unspecified;17490952, 21277530, 36931880
638;histamine;histamine;CHEMBL90;DB05381;774;51-45-6;820484N8I3;NTYJJOPFIAHURM-UHFFFAOYSA-N;C1=C(NC=N1)CCN;11115;-7;547;64;0;2;2;2;8;4;Approved;1939;Small molecule;Agonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;4;Approved;1844086508/unspecified;17490952, 21277530, 36931880
638;histamine;histamine;CHEMBL90;DB05381;774;51-45-6;820484N8I3;NTYJJOPFIAHURM-UHFFFAOYSA-N;C1=C(NC=N1)CCN;11115;-7;547;64;0;2;2;2;8;4;Approved;1939;Small molecule;Agonist;Q9Y5N1;hrh3_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;2B33.4;Leukaemia, unspecified;3;Inactive;1385484871;17490952, 21277530, 36931880
638;histamine;histamine;CHEMBL90;DB05381;774;51-45-6;820484N8I3;NTYJJOPFIAHURM-UHFFFAOYSA-N;C1=C(NC=N1)CCN;11115;-7;547;64;0;2;2;2;8;4;Approved;1939;Small molecule;Agonist;Q9Y5N1;hrh3_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;2C30.Z;Melanoma of skin, unspecified;3;Unknown;488336723/unspecified;17490952, 21277530, 36931880
638;histamine;histamine;CHEMBL90;DB05381;774;51-45-6;820484N8I3;NTYJJOPFIAHURM-UHFFFAOYSA-N;C1=C(NC=N1)CCN;11115;-7;547;64;0;2;2;2;8;4;Approved;1939;Small molecule;Agonist;Q9Y5N1;hrh3_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;2C90.Z;Malignant neoplasms of kidney, except renal pelvis, unspecified;2;Unknown;1048613131/unspecified;17490952, 21277530, 36931880
638;histamine;histamine;CHEMBL90;DB05381;774;51-45-6;820484N8I3;NTYJJOPFIAHURM-UHFFFAOYSA-N;C1=C(NC=N1)CCN;11115;-7;547;64;0;2;2;2;8;4;Approved;1939;Small molecule;Agonist;Q9Y5N1;hrh3_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;4;Approved;1844086508/unspecified;17490952, 21277530, 36931880
639;orphenadrine;orphenadrine;CHEMBL900;DB01173;4601;83-98-7;AL805O9OG9;QVYRGXJJSLMXQH-UHFFFAOYSA-N;CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C;2694;38;125;260;0;0;2;6;20;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;4;Approved;296066191/unspecified;33226747, 31644157, 10448460
639;orphenadrine;orphenadrine;CHEMBL900;DB01173;4601;83-98-7;AL805O9OG9;QVYRGXJJSLMXQH-UHFFFAOYSA-N;CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C;2694;38;125;260;0;0;2;6;20;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;ME84.2Z;Low back pain, unspecified;3;Unknown;1815305992/unspecified;33226747, 31644157, 10448460
639;orphenadrine;orphenadrine;CHEMBL900;DB01173;4601;83-98-7;AL805O9OG9;QVYRGXJJSLMXQH-UHFFFAOYSA-N;CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C;2694;38;125;260;0;0;2;6;20;4;Approved;1957;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;33226747, 31644157, 10448460
640;famotidine;famotidine;CHEMBL902;DB00927;;76824-35-6;5QZO15J2Z8;XUFQPHANEAPEMJ-UHFFFAOYSA-N;C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N;3375;-6;238;469;0;4;8;7;20;4;Approved;1986;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;3A51.1;Sickle cell disease without crisis;2;Active;1711513381;30000326, 30521199, 35951962
640;famotidine;famotidine;CHEMBL902;DB00927;;76824-35-6;5QZO15J2Z8;XUFQPHANEAPEMJ-UHFFFAOYSA-N;C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N;3375;-6;238;469;0;4;8;7;20;4;Approved;1986;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;2;Unknown;1683919430/unspecified;30000326, 30521199, 35951962
640;famotidine;famotidine;CHEMBL902;DB00927;;76824-35-6;5QZO15J2Z8;XUFQPHANEAPEMJ-UHFFFAOYSA-N;C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N;3375;-6;238;469;0;4;8;7;20;4;Approved;1986;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;8A02.10;Drug-induced dystonia;2;Unknown;678203506;30000326, 30521199, 35951962
640;famotidine;famotidine;CHEMBL902;DB00927;;76824-35-6;5QZO15J2Z8;XUFQPHANEAPEMJ-UHFFFAOYSA-N;C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N;3375;-6;238;469;0;4;8;7;20;4;Approved;1986;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;30000326, 30521199, 35951962
640;famotidine;famotidine;CHEMBL902;DB00927;;76824-35-6;5QZO15J2Z8;XUFQPHANEAPEMJ-UHFFFAOYSA-N;C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N;3375;-6;238;469;0;4;8;7;20;4;Approved;1986;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA24.1;Eosinophilic oesophagitis;2;Inactive;21063503;30000326, 30521199, 35951962
640;famotidine;famotidine;CHEMBL902;DB00927;;76824-35-6;5QZO15J2Z8;XUFQPHANEAPEMJ-UHFFFAOYSA-N;C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N;3375;-6;238;469;0;4;8;7;20;4;Approved;1986;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA24.Z;Oesophagitis, unspecified;4;Approved;1540965840/unspecified;30000326, 30521199, 35951962
640;famotidine;famotidine;CHEMBL902;DB00927;;76824-35-6;5QZO15J2Z8;XUFQPHANEAPEMJ-UHFFFAOYSA-N;C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N;3375;-6;238;469;0;4;8;7;20;4;Approved;1986;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA60;Gastric ulcer;4;Approved;1437411258;30000326, 30521199, 35951962
640;famotidine;famotidine;CHEMBL902;DB00927;;76824-35-6;5QZO15J2Z8;XUFQPHANEAPEMJ-UHFFFAOYSA-N;C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N;3375;-6;238;469;0;4;8;7;20;4;Approved;1986;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA60.Z;Gastric ulcer, unspecified;4;Approved;1437411258/unspecified;30000326, 30521199, 35951962
640;famotidine;famotidine;CHEMBL902;DB00927;;76824-35-6;5QZO15J2Z8;XUFQPHANEAPEMJ-UHFFFAOYSA-N;C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N;3375;-6;238;469;0;4;8;7;20;4;Approved;1986;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;30000326, 30521199, 35951962
640;famotidine;famotidine;CHEMBL902;DB00927;;76824-35-6;5QZO15J2Z8;XUFQPHANEAPEMJ-UHFFFAOYSA-N;C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N;3375;-6;238;469;0;4;8;7;20;4;Approved;1986;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA63.Z;Duodenal ulcer, unspecified;4;Approved;553678663/unspecified;30000326, 30521199, 35951962
640;famotidine;famotidine;CHEMBL902;DB00927;;76824-35-6;5QZO15J2Z8;XUFQPHANEAPEMJ-UHFFFAOYSA-N;C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N;3375;-6;238;469;0;4;8;7;20;4;Approved;1986;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA90.Z;Psoriasis of unspecified type;1;Inactive;63698555/unspecified;30000326, 30521199, 35951962
640;famotidine;famotidine;CHEMBL902;DB00927;;76824-35-6;5QZO15J2Z8;XUFQPHANEAPEMJ-UHFFFAOYSA-N;C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N;3375;-6;238;469;0;4;8;7;20;4;Approved;1986;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;FA0Z;Osteoarthritis, unspecified;4;Approved;558562409/unspecified;30000326, 30521199, 35951962
640;famotidine;famotidine;CHEMBL902;DB00927;;76824-35-6;5QZO15J2Z8;XUFQPHANEAPEMJ-UHFFFAOYSA-N;C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N;3375;-6;238;469;0;4;8;7;20;4;Approved;1986;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;FA20.Z;Rheumatoid arthritis, serology unspecified;4;Approved;576319925/unspecified;30000326, 30521199, 35951962
640;famotidine;famotidine;CHEMBL902;DB00927;;76824-35-6;5QZO15J2Z8;XUFQPHANEAPEMJ-UHFFFAOYSA-N;C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N;3375;-6;238;469;0;4;8;7;20;4;Approved;1986;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;ME24.9Z;Gastrointestinal bleeding, unspecified;3;Inactive;2044414353/unspecified;30000326, 30521199, 35951962
640;famotidine;famotidine;CHEMBL902;DB00927;;76824-35-6;5QZO15J2Z8;XUFQPHANEAPEMJ-UHFFFAOYSA-N;C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N;3375;-6;238;469;0;4;8;7;20;4;Approved;1986;Small molecule;Antagonist;P25021;hrh2_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;RA01;COVID-19;3;Active;1730556128;30000326, 30521199, 35951962
641;rizatriptan;rizatriptan;CHEMBL905;DB00953;5078;144034-80-0;51086HBW8G;ULFRLSNUDGIQQP-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3;26934;17;497;309;0;1;3;5;20;4;Approved;1998;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;3;Inactive;2048783472;30000522, 10730063, 12093318
641;rizatriptan;rizatriptan;CHEMBL905;DB00953;5078;144034-80-0;51086HBW8G;ULFRLSNUDGIQQP-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3;26934;17;497;309;0;1;3;5;20;4;Approved;1998;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;3;Inactive;525744634/unspecified;30000522, 10730063, 12093318
641;rizatriptan;rizatriptan;CHEMBL905;DB00953;5078;144034-80-0;51086HBW8G;ULFRLSNUDGIQQP-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3;26934;17;497;309;0;1;3;5;20;4;Approved;1998;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000522, 10730063, 12093318
641;rizatriptan;rizatriptan;CHEMBL905;DB00953;5078;144034-80-0;51086HBW8G;ULFRLSNUDGIQQP-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3;26934;17;497;309;0;1;3;5;20;4;Approved;1998;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;3;Inactive;2048783472;30000522, 10730063, 12093318
641;rizatriptan;rizatriptan;CHEMBL905;DB00953;5078;144034-80-0;51086HBW8G;ULFRLSNUDGIQQP-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3;26934;17;497;309;0;1;3;5;20;4;Approved;1998;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;3;Inactive;525744634/unspecified;30000522, 10730063, 12093318
641;rizatriptan;rizatriptan;CHEMBL905;DB00953;5078;144034-80-0;51086HBW8G;ULFRLSNUDGIQQP-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3;26934;17;497;309;0;1;3;5;20;4;Approved;1998;Small molecule;Agonist;P28222;5ht1b_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000522, 10730063, 12093318
641;rizatriptan;rizatriptan;CHEMBL905;DB00953;5078;144034-80-0;51086HBW8G;ULFRLSNUDGIQQP-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3;26934;17;497;309;0;1;3;5;20;4;Approved;1998;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.0;Migraine without aura;3;Inactive;2048783472;30000522, 10730063, 12093318
641;rizatriptan;rizatriptan;CHEMBL905;DB00953;5078;144034-80-0;51086HBW8G;ULFRLSNUDGIQQP-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3;26934;17;497;309;0;1;3;5;20;4;Approved;1998;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.1Z;Migraine with aura, unspecified;3;Inactive;525744634/unspecified;30000522, 10730063, 12093318
641;rizatriptan;rizatriptan;CHEMBL905;DB00953;5078;144034-80-0;51086HBW8G;ULFRLSNUDGIQQP-UHFFFAOYSA-N;CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3;26934;17;497;309;0;1;3;5;20;4;Approved;1998;Small molecule;Agonist;P30939;5ht1f_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A80.Z;Migraine, unspecified;4;Approved;669367341/unspecified;30000522, 10730063, 12093318
642;chlorprothixene;chlorprothixene;CHEMBL908;DB01239;667467;113-59-7;NA;WSPOMRSOLSGNFJ-AUWJEWJLSA-N;CN(C)CCC=C1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3159;52;285;381;0;0;2;3;21;4;Approved;1967;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;5195331, 35122399, 29945160
642;chlorprothixene;chlorprothixene;CHEMBL908;DB01239;667467;113-59-7;NA;WSPOMRSOLSGNFJ-AUWJEWJLSA-N;CN(C)CCC=C1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3159;52;285;381;0;0;2;3;21;4;Approved;1967;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;5195331, 35122399, 29945160
642;chlorprothixene;chlorprothixene;CHEMBL908;DB01239;667467;113-59-7;NA;WSPOMRSOLSGNFJ-AUWJEWJLSA-N;CN(C)CCC=C1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3159;52;285;381;0;0;2;3;21;4;Approved;1967;Small molecule;Antagonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;5195331, 35122399, 29945160
642;chlorprothixene;chlorprothixene;CHEMBL908;DB01239;667467;113-59-7;NA;WSPOMRSOLSGNFJ-AUWJEWJLSA-N;CN(C)CCC=C1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3159;52;285;381;0;0;2;3;21;4;Approved;1967;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;5195331, 35122399, 29945160
642;chlorprothixene;chlorprothixene;CHEMBL908;DB01239;667467;113-59-7;NA;WSPOMRSOLSGNFJ-AUWJEWJLSA-N;CN(C)CCC=C1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3159;52;285;381;0;0;2;3;21;4;Approved;1967;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;5195331, 35122399, 29945160
642;chlorprothixene;chlorprothixene;CHEMBL908;DB01239;667467;113-59-7;NA;WSPOMRSOLSGNFJ-AUWJEWJLSA-N;CN(C)CCC=C1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3159;52;285;381;0;0;2;3;21;4;Approved;1967;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;5195331, 35122399, 29945160
642;chlorprothixene;chlorprothixene;CHEMBL908;DB01239;667467;113-59-7;NA;WSPOMRSOLSGNFJ-AUWJEWJLSA-N;CN(C)CCC=C1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3159;52;285;381;0;0;2;3;21;4;Approved;1967;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;5195331, 35122399, 29945160
642;chlorprothixene;chlorprothixene;CHEMBL908;DB01239;667467;113-59-7;NA;WSPOMRSOLSGNFJ-AUWJEWJLSA-N;CN(C)CCC=C1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3159;52;285;381;0;0;2;3;21;4;Approved;1967;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;5195331, 35122399, 29945160
642;chlorprothixene;chlorprothixene;CHEMBL908;DB01239;667467;113-59-7;NA;WSPOMRSOLSGNFJ-AUWJEWJLSA-N;CN(C)CCC=C1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3159;52;285;381;0;0;2;3;21;4;Approved;1967;Small molecule;Antagonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;5195331, 35122399, 29945160
642;chlorprothixene;chlorprothixene;CHEMBL908;DB01239;667467;113-59-7;NA;WSPOMRSOLSGNFJ-AUWJEWJLSA-N;CN(C)CCC=C1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3159;52;285;381;0;0;2;3;21;4;Approved;1967;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A20.Z;Schizophrenia, episode unspecified;4;Approved;1683919430/unspecified;5195331, 35122399, 29945160
642;chlorprothixene;chlorprothixene;CHEMBL908;DB01239;667467;113-59-7;NA;WSPOMRSOLSGNFJ-AUWJEWJLSA-N;CN(C)CCC=C1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3159;52;285;381;0;0;2;3;21;4;Approved;1967;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;4;Approved;405565289/unspecified;5195331, 35122399, 29945160
642;chlorprothixene;chlorprothixene;CHEMBL908;DB01239;667467;113-59-7;NA;WSPOMRSOLSGNFJ-AUWJEWJLSA-N;CN(C)CCC=C1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl;3159;52;285;381;0;0;2;3;21;4;Approved;1967;Small molecule;Antagonist;P35462;drd3_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6A60.Z;Bipolar type I disorder, unspecified;4;Approved;1456478153/unspecified;5195331, 35122399, 29945160
643;rupatadine;rupatadine;CHEMBL91397;DB11614;133017;158876-82-5;2AE8M83G3E;WUZYKBABMWJHDL-UHFFFAOYSA-N;CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2;416;58;29;609;0;0;3;2;30;4;Approved;2003;Small molecule;Antagonist;P25105;ptafr_human;Class A (Rhodopsin);Platelet-activating factor receptors;Lipid receptors;2A21.Z;Mastocytosis, unspecified;2;Inactive;691643472/unspecified;23795133, 27500993, 25491409
643;rupatadine;rupatadine;CHEMBL91397;DB11614;133017;158876-82-5;2AE8M83G3E;WUZYKBABMWJHDL-UHFFFAOYSA-N;CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2;416;58;29;609;0;0;3;2;30;4;Approved;2003;Small molecule;Antagonist;P25105;ptafr_human;Class A (Rhodopsin);Platelet-activating factor receptors;Lipid receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;23795133, 27500993, 25491409
643;rupatadine;rupatadine;CHEMBL91397;DB11614;133017;158876-82-5;2AE8M83G3E;WUZYKBABMWJHDL-UHFFFAOYSA-N;CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2;416;58;29;609;0;0;3;2;30;4;Approved;2003;Small molecule;Antagonist;P25105;ptafr_human;Class A (Rhodopsin);Platelet-activating factor receptors;Lipid receptors;EB05;Urticaria of unspecified type;3;Inactive;993242399;23795133, 27500993, 25491409
643;rupatadine;rupatadine;CHEMBL91397;DB11614;133017;158876-82-5;2AE8M83G3E;WUZYKBABMWJHDL-UHFFFAOYSA-N;CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2;416;58;29;609;0;0;3;2;30;4;Approved;2003;Small molecule;Antagonist;P25105;ptafr_human;Class A (Rhodopsin);Platelet-activating factor receptors;Lipid receptors;FA20.Z;Rheumatoid arthritis, serology unspecified;3;Active;576319925/unspecified;23795133, 27500993, 25491409
643;rupatadine;rupatadine;CHEMBL91397;DB11614;133017;158876-82-5;2AE8M83G3E;WUZYKBABMWJHDL-UHFFFAOYSA-N;CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2;416;58;29;609;0;0;3;2;30;4;Approved;2003;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;2A21.Z;Mastocytosis, unspecified;2;Inactive;691643472/unspecified;23795133, 27500993, 25491409
643;rupatadine;rupatadine;CHEMBL91397;DB11614;133017;158876-82-5;2AE8M83G3E;WUZYKBABMWJHDL-UHFFFAOYSA-N;CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2;416;58;29;609;0;0;3;2;30;4;Approved;2003;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;23795133, 27500993, 25491409
643;rupatadine;rupatadine;CHEMBL91397;DB11614;133017;158876-82-5;2AE8M83G3E;WUZYKBABMWJHDL-UHFFFAOYSA-N;CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2;416;58;29;609;0;0;3;2;30;4;Approved;2003;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;3;Inactive;993242399;23795133, 27500993, 25491409
643;rupatadine;rupatadine;CHEMBL91397;DB11614;133017;158876-82-5;2AE8M83G3E;WUZYKBABMWJHDL-UHFFFAOYSA-N;CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2;416;58;29;609;0;0;3;2;30;4;Approved;2003;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;FA20.Z;Rheumatoid arthritis, serology unspecified;3;Active;576319925/unspecified;23795133, 27500993, 25491409
644;fexofenadine;fexofenadine;CHEMBL914;DB00950;3348;83799-24-0;E6582LOH6V;RWTNPBWLLIMQHL-UHFFFAOYSA-N;CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O;5017;3;81;678;0;3;5;10;37;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;32310564, 29999736, 35951967
644;fexofenadine;fexofenadine;CHEMBL914;DB00950;3348;83799-24-0;E6582LOH6V;RWTNPBWLLIMQHL-UHFFFAOYSA-N;CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O;5017;3;81;678;0;3;5;10;37;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;32310564, 29999736, 35951967
644;fexofenadine;fexofenadine;CHEMBL914;DB00950;3348;83799-24-0;E6582LOH6V;RWTNPBWLLIMQHL-UHFFFAOYSA-N;CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O;5017;3;81;678;0;3;5;10;37;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;32310564, 29999736, 35951967
644;fexofenadine;fexofenadine;CHEMBL914;DB00950;3348;83799-24-0;E6582LOH6V;RWTNPBWLLIMQHL-UHFFFAOYSA-N;CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O;5017;3;81;678;0;3;5;10;37;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA23;Asthma;3;Inactive;1656445230;32310564, 29999736, 35951967
644;fexofenadine;fexofenadine;CHEMBL914;DB00950;3348;83799-24-0;E6582LOH6V;RWTNPBWLLIMQHL-UHFFFAOYSA-N;CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O;5017;3;81;678;0;3;5;10;37;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;2;Inactive;1391387859/unspecified;32310564, 29999736, 35951967
644;fexofenadine;fexofenadine;CHEMBL914;DB00950;3348;83799-24-0;E6582LOH6V;RWTNPBWLLIMQHL-UHFFFAOYSA-N;CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O;5017;3;81;678;0;3;5;10;37;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;2;Inactive;215767047/unspecified;32310564, 29999736, 35951967
644;fexofenadine;fexofenadine;CHEMBL914;DB00950;3348;83799-24-0;E6582LOH6V;RWTNPBWLLIMQHL-UHFFFAOYSA-N;CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O;5017;3;81;678;0;3;5;10;37;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;32310564, 29999736, 35951967
644;fexofenadine;fexofenadine;CHEMBL914;DB00950;3348;83799-24-0;E6582LOH6V;RWTNPBWLLIMQHL-UHFFFAOYSA-N;CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O;5017;3;81;678;0;3;5;10;37;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;FA20.Z;Rheumatoid arthritis, serology unspecified;1;Active;576319925/unspecified;32310564, 29999736, 35951967
644;fexofenadine;fexofenadine;CHEMBL914;DB00950;3348;83799-24-0;E6582LOH6V;RWTNPBWLLIMQHL-UHFFFAOYSA-N;CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O;5017;3;81;678;0;3;5;10;37;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;GB61.Z;Chronic kidney disease, stage unspecified;3;Active;412389819/unspecified;32310564, 29999736, 35951967
644;fexofenadine;fexofenadine;CHEMBL914;DB00950;3348;83799-24-0;E6582LOH6V;RWTNPBWLLIMQHL-UHFFFAOYSA-N;CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O;5017;3;81;678;0;3;5;10;37;4;Approved;1996;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;GB70.0Z;Calculus of kidney, unspecified;2;Active;389168514/unspecified;32310564, 29999736, 35951967
645;atrasentan;atrasentan;CHEMBL9194;DB06199;159594;173937-91-2;V6D7VK2215;MOTJMGVDPWRKOC-QPVYNBJUSA-N;CCCCN(CCCC)C(=O)CN1CC(C(C1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4;5106;24;885;734;0;1;7;12;37;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2A0Z;Other and unspecified neoplasms of brain or central nervous system;1;Unknown;879154182/unspecified;30995972, 28468519, 35772861
645;atrasentan;atrasentan;CHEMBL9194;DB06199;159594;173937-91-2;V6D7VK2215;MOTJMGVDPWRKOC-QPVYNBJUSA-N;CCCCN(CCCC)C(=O)CN1CC(C(C1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4;5106;24;885;734;0;1;7;12;37;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2C51.Z;Malignant neoplasms of peritoneum, unspecified;2;Inactive;315445782/unspecified;30995972, 28468519, 35772861
645;atrasentan;atrasentan;CHEMBL9194;DB06199;159594;173937-91-2;V6D7VK2215;MOTJMGVDPWRKOC-QPVYNBJUSA-N;CCCCN(CCCC)C(=O)CN1CC(C(C1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4;5106;24;885;734;0;1;7;12;37;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2C73.Z;Malignant neoplasms of ovary, unspecified;2;Inactive;685124533/unspecified;30995972, 28468519, 35772861
645;atrasentan;atrasentan;CHEMBL9194;DB06199;159594;173937-91-2;V6D7VK2215;MOTJMGVDPWRKOC-QPVYNBJUSA-N;CCCCN(CCCC)C(=O)CN1CC(C(C1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4;5106;24;885;734;0;1;7;12;37;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2C74.Z;Malignant neoplasms of fallopian tube, unspecified;2;Inactive;459381514/unspecified;30995972, 28468519, 35772861
645;atrasentan;atrasentan;CHEMBL9194;DB06199;159594;173937-91-2;V6D7VK2215;MOTJMGVDPWRKOC-QPVYNBJUSA-N;CCCCN(CCCC)C(=O)CN1CC(C(C1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4;5106;24;885;734;0;1;7;12;37;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2C82.0;Adenocarcinoma of prostate;3;Inactive;1510677183;30995972, 28468519, 35772861
645;atrasentan;atrasentan;CHEMBL9194;DB06199;159594;173937-91-2;V6D7VK2215;MOTJMGVDPWRKOC-QPVYNBJUSA-N;CCCCN(CCCC)C(=O)CN1CC(C(C1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4;5106;24;885;734;0;1;7;12;37;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;3;Inactive;1552457716/unspecified;30995972, 28468519, 35772861
645;atrasentan;atrasentan;CHEMBL9194;DB06199;159594;173937-91-2;V6D7VK2215;MOTJMGVDPWRKOC-QPVYNBJUSA-N;CCCCN(CCCC)C(=O)CN1CC(C(C1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4;5106;24;885;734;0;1;7;12;37;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2C90.Z;Malignant neoplasms of kidney, except renal pelvis, unspecified;2;Unknown;1048613131/unspecified;30995972, 28468519, 35772861
645;atrasentan;atrasentan;CHEMBL9194;DB06199;159594;173937-91-2;V6D7VK2215;MOTJMGVDPWRKOC-QPVYNBJUSA-N;CCCCN(CCCC)C(=O)CN1CC(C(C1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4;5106;24;885;734;0;1;7;12;37;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;GB40;Nephritic syndrome;3;Active;1783829886;30995972, 28468519, 35772861
645;atrasentan;atrasentan;CHEMBL9194;DB06199;159594;173937-91-2;V6D7VK2215;MOTJMGVDPWRKOC-QPVYNBJUSA-N;CCCCN(CCCC)C(=O)CN1CC(C(C1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4;5106;24;885;734;0;1;7;12;37;3;Active;NA;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;GB61.Z;Chronic kidney disease, stage unspecified;3;Inactive;412389819/unspecified;30995972, 28468519, 35772861
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;2;Inactive;1683090852;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;2;Inactive;1164022950/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NB32.3Z;Injury of lung, unspecified;2;Inactive;359051131/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;2;Inactive;1683090852;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;2;Inactive;1164022950/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P08588;adrb1_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NB32.3Z;Injury of lung, unspecified;2;Inactive;359051131/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;2;Inactive;1683090852;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;2;Inactive;1164022950/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NB32.3Z;Injury of lung, unspecified;2;Inactive;359051131/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;2;Inactive;1683090852;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;2;Inactive;1164022950/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NB32.3Z;Injury of lung, unspecified;2;Inactive;359051131/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;1G41;Sepsis with septic shock;2;Inactive;1683090852;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BD1Z;Heart failure, unspecified;4;Approved;1458683894/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BE2Z;Diseases of the circulatory system, unspecified;4;Approved;426429380/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;MG40.Z;Shock, unspecified;2;Inactive;1164022950/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NA07.Z;Intracranial injury, unspecified;2;Unknown;277610609/unspecified;30000708, 29262042, 34347952
646;dobutamine;dobutamine;CHEMBL926;DB00841;36811;34368-04-2;3S12J47372;JRWZLRBJNMZMFE-UHFFFAOYSA-N;CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;3014;34;727;305;0;4;4;7;22;4;Approved;1978;Small molecule;Agonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;NB32.3Z;Injury of lung, unspecified;2;Inactive;359051131/unspecified;30000708, 29262042, 34347952
647;mizolastine;mizolastine;CHEMBL94454;DB12523;65906;108612-45-9;NA;PVLJETXTTWAYEW-UHFFFAOYSA-N;CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=NC=CC(=O)N5;4325;32;658;728;0;1;5;5;32;4;Approved;1998;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;11510627, 15312146, 10209699
648;azatadine;azatadine;CHEMBL946;DB00719;19861;3964-81-6;94Z39NID6C;SEBMTIQKRHYNIT-UHFFFAOYSA-N;CN1CCC(=C2C3=CC=CC=C3CCC4=C2N=CC=C4)CC1;2904;36;161;417;0;0;2;0;22;4;Approved;1977;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;30000097, 7008821, 7067923
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2C10.Y;Other specified malignant neoplasms of pancreas;1;Active;542147910/other;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2C30.Z;Melanoma of skin, unspecified;2;Inactive;488336723/unspecified;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;4A42.Z;Systemic sclerosis, unspecified;3;Inactive;1084365812/unspecified;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;9C40.40;Anterior ischemic optic neuropathy;3;Active;632323575;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;9C61.Z;Glaucoma, unspecified;1;Inactive;499924848/unspecified;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BB01.Z;Pulmonary hypertension, unspecified;4;Approved;1496633964/unspecified;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BB60.Z;Mitral valve stenosis, unspecified;1;Unknown;2115139779/unspecified;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BD10;Congestive heart failure;1;Unknown;2136808878;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;2;Unknown;133207228/unspecified;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;CA23;Asthma;2;Inactive;1656445230;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;CB03.4;Idiopathic pulmonary fibrosis;3;Inactive;1074069640;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;DA60;Gastric ulcer;3;Inactive;1437411258;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;DB99.4;Hepatopulmonary syndrome;2;Unknown;866605228;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;GB61.Z;Chronic kidney disease, stage unspecified;3;Unknown;412389819/unspecified;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;KB42;Persistent pulmonary hypertension of the newborn;3;Inactive;346808536;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;LA89.3;Hypoplastic left heart syndrome;2;Inactive;1811800027;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P24530;ednrb_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;LA8Z;Structural developmental anomaly of heart or great vessels, unspecified;3;Inactive;2004408087/unspecified;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2C10.Y;Other specified malignant neoplasms of pancreas;1;Active;542147910/other;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;2C30.Z;Melanoma of skin, unspecified;2;Inactive;488336723/unspecified;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;4A42.Z;Systemic sclerosis, unspecified;3;Inactive;1084365812/unspecified;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;9C40.40;Anterior ischemic optic neuropathy;3;Active;632323575;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;9C61.Z;Glaucoma, unspecified;1;Inactive;499924848/unspecified;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BB01.0;Pulmonary arterial hypertension;4;Approved;1931148955;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BB01.Z;Pulmonary hypertension, unspecified;4;Approved;1496633964/unspecified;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BB60.Z;Mitral valve stenosis, unspecified;1;Unknown;2115139779/unspecified;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;BD10;Congestive heart failure;1;Unknown;2136808878;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;2;Unknown;133207228/unspecified;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;CA23;Asthma;2;Inactive;1656445230;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;CB03.4;Idiopathic pulmonary fibrosis;3;Inactive;1074069640;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;DA60;Gastric ulcer;3;Inactive;1437411258;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;DB99.4;Hepatopulmonary syndrome;2;Unknown;866605228;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;GB61.Z;Chronic kidney disease, stage unspecified;3;Unknown;412389819/unspecified;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;KB42;Persistent pulmonary hypertension of the newborn;3;Inactive;346808536;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;LA89.3;Hypoplastic left heart syndrome;2;Inactive;1811800027;29999678, 31194433, 31643331
649;bosentan;bosentan;CHEMBL957;DB00559;104865;147536-97-8;XUL93R30K2;GJPICJJJRGTNOD-UHFFFAOYSA-N;CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC;5516;38;154;839;0;2;11;11;39;4;Approved;2001;Small molecule;Antagonist;P25101;ednra_human;Class A (Rhodopsin);Endothelin receptors;Peptide receptors;LA8Z;Structural developmental anomaly of heart or great vessels, unspecified;3;Inactive;2004408087/unspecified;29999678, 31194433, 31643331
650;oxymorphone;oxymorphone;CHEMBL963;DB01192;5284604;76-41-5;9VXA968E0C;UQCNKQCJZOAFTQ-ISWURRPUSA-N;CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;30134;8;70;539;0;2;5;0;22;4;Approved;1959;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;3;Inactive;1581976053/unspecified;29999720, 24481932, 16317569
650;oxymorphone;oxymorphone;CHEMBL963;DB01192;5284604;76-41-5;9VXA968E0C;UQCNKQCJZOAFTQ-ISWURRPUSA-N;CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;30134;8;70;539;0;2;5;0;22;4;Approved;1959;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;29999720, 24481932, 16317569
650;oxymorphone;oxymorphone;CHEMBL963;DB01192;5284604;76-41-5;9VXA968E0C;UQCNKQCJZOAFTQ-ISWURRPUSA-N;CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;30134;8;70;539;0;2;5;0;22;4;Approved;1959;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;3;Inactive;1581976053/unspecified;29999720, 24481932, 16317569
650;oxymorphone;oxymorphone;CHEMBL963;DB01192;5284604;76-41-5;9VXA968E0C;UQCNKQCJZOAFTQ-ISWURRPUSA-N;CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;30134;8;70;539;0;2;5;0;22;4;Approved;1959;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;29999720, 24481932, 16317569
650;oxymorphone;oxymorphone;CHEMBL963;DB01192;5284604;76-41-5;9VXA968E0C;UQCNKQCJZOAFTQ-ISWURRPUSA-N;CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;30134;8;70;539;0;2;5;0;22;4;Approved;1959;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG30.Z;Chronic pain, unspecified;3;Inactive;1581976053/unspecified;29999720, 24481932, 16317569
650;oxymorphone;oxymorphone;CHEMBL963;DB01192;5284604;76-41-5;9VXA968E0C;UQCNKQCJZOAFTQ-ISWURRPUSA-N;CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O;30134;8;70;539;0;2;5;0;22;4;Approved;1959;Small molecule;Agonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;MG3Z;Pain, unspecified;4;Approved;661232217/unspecified;29999720, 24481932, 16317569
651;carbachol;carbachol;CHEMBL965;DB00411;5831;462-58-8;54Z8M50D6Q;AIXAANGOTKPUOY-UHFFFAOYSA-N;C[N+](C)(C)CCOC(=O)N.[Cl-];18265;;523;117;0;1;3;4;11;4;Approved;1972;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000716, 5013189, 2801872
651;carbachol;carbachol;CHEMBL965;DB00411;5831;462-58-8;54Z8M50D6Q;AIXAANGOTKPUOY-UHFFFAOYSA-N;C[N+](C)(C)CCOC(=O)N.[Cl-];18265;;523;117;0;1;3;4;11;4;Approved;1972;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.3;Presbyopia;3;Active;22794400;30000716, 5013189, 2801872
651;carbachol;carbachol;CHEMBL965;DB00411;5831;462-58-8;54Z8M50D6Q;AIXAANGOTKPUOY-UHFFFAOYSA-N;C[N+](C)(C)CCOC(=O)N.[Cl-];18265;;523;117;0;1;3;4;11;4;Approved;1972;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9E1Z;Diseases of the visual system, unspecified;4;Approved;868865918/unspecified;30000716, 5013189, 2801872
651;carbachol;carbamoylcholine;CHEMBL965;DB00411;2551;462-58-8;54Z8M50D6Q;VPJXQGSRWJZDOB-UHFFFAOYSA-O;C[N+](C)(C)CCOC(=O)N;1472;-4;523;117;1;1;2;4;10;4;Approved;1972;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000716, 5013189, 2801872
651;carbachol;carbamoylcholine;CHEMBL965;DB00411;2551;462-58-8;54Z8M50D6Q;VPJXQGSRWJZDOB-UHFFFAOYSA-O;C[N+](C)(C)CCOC(=O)N;1472;-4;523;117;1;1;2;4;10;4;Approved;1972;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.3;Presbyopia;3;Active;22794400;30000716, 5013189, 2801872
651;carbachol;carbamoylcholine;CHEMBL965;DB00411;2551;462-58-8;54Z8M50D6Q;VPJXQGSRWJZDOB-UHFFFAOYSA-O;C[N+](C)(C)CCOC(=O)N;1472;-4;523;117;1;1;2;4;10;4;Approved;1972;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9E1Z;Diseases of the visual system, unspecified;4;Approved;868865918/unspecified;30000716, 5013189, 2801872
651;carbachol;carbachol;CHEMBL965;DB00411;5831;462-58-8;54Z8M50D6Q;AIXAANGOTKPUOY-UHFFFAOYSA-N;C[N+](C)(C)CCOC(=O)N.[Cl-];18265;;523;117;0;1;3;4;11;4;Approved;1972;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000716, 5013189, 2801872
651;carbachol;carbachol;CHEMBL965;DB00411;5831;462-58-8;54Z8M50D6Q;AIXAANGOTKPUOY-UHFFFAOYSA-N;C[N+](C)(C)CCOC(=O)N.[Cl-];18265;;523;117;0;1;3;4;11;4;Approved;1972;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.3;Presbyopia;3;Active;22794400;30000716, 5013189, 2801872
651;carbachol;carbachol;CHEMBL965;DB00411;5831;462-58-8;54Z8M50D6Q;AIXAANGOTKPUOY-UHFFFAOYSA-N;C[N+](C)(C)CCOC(=O)N.[Cl-];18265;;523;117;0;1;3;4;11;4;Approved;1972;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9E1Z;Diseases of the visual system, unspecified;4;Approved;868865918/unspecified;30000716, 5013189, 2801872
651;carbachol;carbamoylcholine;CHEMBL965;DB00411;2551;462-58-8;54Z8M50D6Q;VPJXQGSRWJZDOB-UHFFFAOYSA-O;C[N+](C)(C)CCOC(=O)N;1472;-4;523;117;1;1;2;4;10;4;Approved;1972;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000716, 5013189, 2801872
651;carbachol;carbamoylcholine;CHEMBL965;DB00411;2551;462-58-8;54Z8M50D6Q;VPJXQGSRWJZDOB-UHFFFAOYSA-O;C[N+](C)(C)CCOC(=O)N;1472;-4;523;117;1;1;2;4;10;4;Approved;1972;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.3;Presbyopia;3;Active;22794400;30000716, 5013189, 2801872
651;carbachol;carbamoylcholine;CHEMBL965;DB00411;2551;462-58-8;54Z8M50D6Q;VPJXQGSRWJZDOB-UHFFFAOYSA-O;C[N+](C)(C)CCOC(=O)N;1472;-4;523;117;1;1;2;4;10;4;Approved;1972;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9E1Z;Diseases of the visual system, unspecified;4;Approved;868865918/unspecified;30000716, 5013189, 2801872
651;carbachol;carbachol;CHEMBL965;DB00411;5831;462-58-8;54Z8M50D6Q;AIXAANGOTKPUOY-UHFFFAOYSA-N;C[N+](C)(C)CCOC(=O)N.[Cl-];18265;;523;117;0;1;3;4;11;4;Approved;1972;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000716, 5013189, 2801872
651;carbachol;carbachol;CHEMBL965;DB00411;5831;462-58-8;54Z8M50D6Q;AIXAANGOTKPUOY-UHFFFAOYSA-N;C[N+](C)(C)CCOC(=O)N.[Cl-];18265;;523;117;0;1;3;4;11;4;Approved;1972;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.3;Presbyopia;3;Active;22794400;30000716, 5013189, 2801872
651;carbachol;carbachol;CHEMBL965;DB00411;5831;462-58-8;54Z8M50D6Q;AIXAANGOTKPUOY-UHFFFAOYSA-N;C[N+](C)(C)CCOC(=O)N.[Cl-];18265;;523;117;0;1;3;4;11;4;Approved;1972;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9E1Z;Diseases of the visual system, unspecified;4;Approved;868865918/unspecified;30000716, 5013189, 2801872
651;carbachol;carbamoylcholine;CHEMBL965;DB00411;2551;462-58-8;54Z8M50D6Q;VPJXQGSRWJZDOB-UHFFFAOYSA-O;C[N+](C)(C)CCOC(=O)N;1472;-4;523;117;1;1;2;4;10;4;Approved;1972;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9C61.Z;Glaucoma, unspecified;4;Approved;499924848/unspecified;30000716, 5013189, 2801872
651;carbachol;carbamoylcholine;CHEMBL965;DB00411;2551;462-58-8;54Z8M50D6Q;VPJXQGSRWJZDOB-UHFFFAOYSA-O;C[N+](C)(C)CCOC(=O)N;1472;-4;523;117;1;1;2;4;10;4;Approved;1972;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9D00.3;Presbyopia;3;Active;22794400;30000716, 5013189, 2801872
651;carbachol;carbamoylcholine;CHEMBL965;DB00411;2551;462-58-8;54Z8M50D6Q;VPJXQGSRWJZDOB-UHFFFAOYSA-O;C[N+](C)(C)CCOC(=O)N;1472;-4;523;117;1;1;2;4;10;4;Approved;1972;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;9E1Z;Diseases of the visual system, unspecified;4;Approved;868865918/unspecified;30000716, 5013189, 2801872
652;methacholine;methacholine;CHEMBL978;DB06709;1993;55-92-5;03V657ZD3V;NZWOPGCLSHLLPA-UHFFFAOYSA-N;CC(C[N+](C)(C)C)OC(=O)C;16023;6;263;138;1;0;2;4;11;4;Approved;1986;Small molecule;Agonist;P08172;acm2_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;X6;Diagnostis of asthma;4;Approved;NA;31613496, 29785128, 18842907
652;methacholine;methacholine;CHEMBL978;DB06709;1993;55-92-5;03V657ZD3V;NZWOPGCLSHLLPA-UHFFFAOYSA-N;CC(C[N+](C)(C)C)OC(=O)C;16023;6;263;138;1;0;2;4;11;4;Approved;1986;Small molecule;Agonist;P20309;acm3_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;X6;Diagnostis of asthma;4;Approved;NA;31613496, 29785128, 18842907
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;4;Approved;111507461/unspecified;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C50.Z;Gambling disorder, unspecified;2;Inactive;1041487064/unspecified;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Inactive;1884917970;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;EA80.Z;Atopic eczema, unspecified;2;Inactive;215767047/unspecified;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;4;Approved;111507461/unspecified;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C50.Z;Gambling disorder, unspecified;2;Inactive;1041487064/unspecified;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Inactive;1884917970;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;EA80.Z;Atopic eczema, unspecified;2;Inactive;215767047/unspecified;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C40.2Z;Alcohol dependence, unspecified;4;Approved;1580466198/unspecified;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.Z;Disorders due to use of opioids, unspecified;4;Approved;111507461/unspecified;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C4A.2Z;Nicotine dependence, unspecified;2;Inactive;1699574100/unspecified;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C50.Z;Gambling disorder, unspecified;2;Inactive;1041487064/unspecified;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Inactive;1884917970;37603674, 31643618, 24918835
653;nalmefene;nalmefene;CHEMBL982;DB06230;5284594;55096-26-9;NA;WJBLNOPPDWQMCH-MBPVOVBZSA-N;C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O;3394;27;529;618;0;2;4;2;25;4;Approved;1995;Small molecule;Antagonist;P41145;oprk_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;EA80.Z;Atopic eczema, unspecified;2;Inactive;215767047/unspecified;37603674, 31643618, 24918835
654;pirenzepine;pirenzepine;CHEMBL9967;DB00670;4848;28797-61-7;3G0285N20N;RMHMFHUVIITRHF-UHFFFAOYSA-N;CN1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4;3514;1;688;534;0;1;5;2;26;4;Approved;1978;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA22.Z;Gastro-oesophageal reflux disease, unspecified;4;Approved;1391387859/unspecified;6688922, 34059932, 34862437
654;pirenzepine;pirenzepine;CHEMBL9967;DB00670;4848;28797-61-7;3G0285N20N;RMHMFHUVIITRHF-UHFFFAOYSA-N;CN1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4;3514;1;688;534;0;1;5;2;26;4;Approved;1978;Small molecule;Antagonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;DA61;Peptic ulcer, site unspecified;4;Approved;1145813715;6688922, 34059932, 34862437
655;loratadine;loratadine;CHEMBL998;DB00455;3957;79794-75-5;7AJO3BO7QN;JCCNYMKQOSZNPW-UHFFFAOYSA-N;CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1;3829;52;424;569;0;0;3;2;27;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;4A8Z;Allergic or hypersensitivity conditions of unspecified type;4;Approved;642618805/unspecified;35396016, 30000068, 31194418
655;loratadine;loratadine;CHEMBL998;DB00455;3957;79794-75-5;7AJO3BO7QN;JCCNYMKQOSZNPW-UHFFFAOYSA-N;CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1;3829;52;424;569;0;0;3;2;27;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.01;Allergic rhinitis due to other seasonal allergens;4;Approved;1565925107;35396016, 30000068, 31194418
655;loratadine;loratadine;CHEMBL998;DB00455;3957;79794-75-5;7AJO3BO7QN;JCCNYMKQOSZNPW-UHFFFAOYSA-N;CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1;3829;52;424;569;0;0;3;2;27;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.03;Other allergic rhinitis;4;Approved;941478759;35396016, 30000068, 31194418
655;loratadine;loratadine;CHEMBL998;DB00455;3957;79794-75-5;7AJO3BO7QN;JCCNYMKQOSZNPW-UHFFFAOYSA-N;CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1;3829;52;424;569;0;0;3;2;27;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA08.0Z;Allergic rhinitis, unspecified;4;Approved;1711769234/unspecified;35396016, 30000068, 31194418
655;loratadine;loratadine;CHEMBL998;DB00455;3957;79794-75-5;7AJO3BO7QN;JCCNYMKQOSZNPW-UHFFFAOYSA-N;CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1;3829;52;424;569;0;0;3;2;27;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CA23;Asthma;3;Inactive;1656445230;35396016, 30000068, 31194418
655;loratadine;loratadine;CHEMBL998;DB00455;3957;79794-75-5;7AJO3BO7QN;JCCNYMKQOSZNPW-UHFFFAOYSA-N;CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1;3829;52;424;569;0;0;3;2;27;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;CB07.Z;Lymphangioleiomyomatosis, unspecified;2;Active;902628446/unspecified;35396016, 30000068, 31194418
655;loratadine;loratadine;CHEMBL998;DB00455;3957;79794-75-5;7AJO3BO7QN;JCCNYMKQOSZNPW-UHFFFAOYSA-N;CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1;3829;52;424;569;0;0;3;2;27;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;DA24.1;Eosinophilic oesophagitis;2;Inactive;21063503;35396016, 30000068, 31194418
655;loratadine;loratadine;CHEMBL998;DB00455;3957;79794-75-5;7AJO3BO7QN;JCCNYMKQOSZNPW-UHFFFAOYSA-N;CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1;3829;52;424;569;0;0;3;2;27;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EA80.Z;Atopic eczema, unspecified;1;Inactive;215767047/unspecified;35396016, 30000068, 31194418
655;loratadine;loratadine;CHEMBL998;DB00455;3957;79794-75-5;7AJO3BO7QN;JCCNYMKQOSZNPW-UHFFFAOYSA-N;CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1;3829;52;424;569;0;0;3;2;27;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EB05;Urticaria of unspecified type;4;Approved;993242399;35396016, 30000068, 31194418
655;loratadine;loratadine;CHEMBL998;DB00455;3957;79794-75-5;7AJO3BO7QN;JCCNYMKQOSZNPW-UHFFFAOYSA-N;CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1;3829;52;424;569;0;0;3;2;27;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;EC90.Z;Pruritus, unspecified;4;Approved;1729106757/unspecified;35396016, 30000068, 31194418
655;loratadine;loratadine;CHEMBL998;DB00455;3957;79794-75-5;7AJO3BO7QN;JCCNYMKQOSZNPW-UHFFFAOYSA-N;CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1;3829;52;424;569;0;0;3;2;27;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;ME84.Z;Spinal pain, unspecified;2;Unknown;2051065876/unspecified;35396016, 30000068, 31194418
655;loratadine;loratadine;CHEMBL998;DB00455;3957;79794-75-5;7AJO3BO7QN;JCCNYMKQOSZNPW-UHFFFAOYSA-N;CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1;3829;52;424;569;0;0;3;2;27;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;MG3Z;Pain, unspecified;2;Unknown;661232217/unspecified;35396016, 30000068, 31194418
655;loratadine;loratadine;CHEMBL998;DB00455;3957;79794-75-5;7AJO3BO7QN;JCCNYMKQOSZNPW-UHFFFAOYSA-N;CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1;3829;52;424;569;0;0;3;2;27;4;Approved;1993;Small molecule;Antagonist;P35367;hrh1_human;Class A (Rhodopsin);Histamine receptors;Aminergic receptors;RA01;COVID-19;2;Active;1730556128;35396016, 30000068, 31194418
656;fenfluramine;fenfluramine;CHEMBL87493;DB00574;3337;458-24-2;2DS058H2CF;DBGIVFWFUFKIQN-UHFFFAOYSA-N;CCNC(C)CC1=CC(=CC=C1)C(F)(F)F;23126;34;12;203;0;1;4;4;16;4;Approved;2020;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A61.11;Dravet syndrome;4;Approved;1255654700;37316680, 37251322, 33565102
656;fenfluramine;fenfluramine;CHEMBL87493;DB00574;3337;458-24-2;2DS058H2CF;DBGIVFWFUFKIQN-UHFFFAOYSA-N;CCNC(C)CC1=CC(=CC=C1)C(F)(F)F;23126;34;12;203;0;1;4;4;16;4;Approved;2020;Small molecule;Agonist;P28221;5ht1d_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A62.1;Lennox-Gastaut syndrome;4;Approved;651135242;37316680, 37251322, 33565102
656;fenfluramine;fenfluramine;CHEMBL87493;DB00574;3337;458-24-2;2DS058H2CF;DBGIVFWFUFKIQN-UHFFFAOYSA-N;CCNC(C)CC1=CC(=CC=C1)C(F)(F)F;23126;34;12;203;0;1;4;4;16;4;Approved;2020;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A61.11;Dravet syndrome;4;Approved;1255654700;37316680, 37251322, 33565102
656;fenfluramine;fenfluramine;CHEMBL87493;DB00574;3337;458-24-2;2DS058H2CF;DBGIVFWFUFKIQN-UHFFFAOYSA-N;CCNC(C)CC1=CC(=CC=C1)C(F)(F)F;23126;34;12;203;0;1;4;4;16;4;Approved;2020;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A62.1;Lennox-Gastaut syndrome;4;Approved;651135242;37316680, 37251322, 33565102
656;fenfluramine;fenfluramine;CHEMBL87493;DB00574;3337;458-24-2;2DS058H2CF;DBGIVFWFUFKIQN-UHFFFAOYSA-N;CCNC(C)CC1=CC(=CC=C1)C(F)(F)F;23126;34;12;203;0;1;4;4;16;4;Approved;2020;Small molecule;Agonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A61.11;Dravet syndrome;4;Approved;1255654700;37316680, 37251322, 33565102
656;fenfluramine;fenfluramine;CHEMBL87493;DB00574;3337;458-24-2;2DS058H2CF;DBGIVFWFUFKIQN-UHFFFAOYSA-N;CCNC(C)CC1=CC(=CC=C1)C(F)(F)F;23126;34;12;203;0;1;4;4;16;4;Approved;2020;Small molecule;Agonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A62.1;Lennox-Gastaut syndrome;4;Approved;651135242;37316680, 37251322, 33565102
664;BGE-105;BGE-105;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Agonist;P35414;apj_human;Class A (Rhodopsin);Apelin receptors;Peptide receptors;5B81.Z;Obesity, unspecified;2;Active;149403041/unspecified;NA
733;BI 1820237;BI 1820237;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P49146;npy2r_human;Class A (Rhodopsin);Neuropeptide Y receptors;Peptide receptors;5B81.Z;Obesity, unspecified;1;Active;149403041/unspecified;NA
657;BMB-101;BMB-101;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Agonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A61.11;Dravet syndrome;1;Active;1255654700;NA
657;BMB-101;BMB-101;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Agonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;MB29.1;Binge eating;1;Active;1535148777;NA
657;BMB-101;BMB-101;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Agonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6C5Z;Disorders due to addictive behaviours, unspecified;1;Active;499894965/unspecified;NA
657;BMB-101;BMB-101;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Agonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;1;Active;405565289/unspecified;NA
657;BMB-101;BMB-101;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Agonist;P28335;5ht2c_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A6Z;Epilepsy or seizures, unspecified;2;Active;1397288146/unspecified;NA
666;CFTX-1554;CFTX-1554;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Antagonist;P50052;agtr2_human;Class A (Rhodopsin);Angiotensin receptors;Peptide receptors;MG30.51;Chronic peripheral neuropathic pain;1;Active;425464783;NA
749;CNTX-0290;CNTX-0290;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P31391;ssr4_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;MG3Z;Pain, unspecified;1;Active;661232217/unspecified;NA
668;CNTX-6016;CNTX-6016;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;8E43.0Z;Neuropathic pain, unspecified;1;Active;1339785363/unspecified;NA
669;CNTX-6970;CNTX-6970;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;P41597;ccr2_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;MG3Z;Pain, unspecified;2;Active;661232217/unspecified;NA
754;CST-103;CST-103;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;2;Active;296066191/unspecified;NA
753;CST-2032;CST-2032;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Agonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A20;Alzheimer disease;2;Active;1611724421;NA
752;CST-2140;CST-2140;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;1;Active;296066191/unspecified;NA
685;CVL-871;CVL-871;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Partial agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D86.3;Apathy in dementia;2;Active;961921436;NA
663;Petrelintide;Petrelintide;CHEMBL5314864;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Protein;Agonist;P30988;calcr_human;Class B1 (Secretin);Calcitonin receptors;Peptide receptors;5B81.Z;Obesity, unspecified;1;Active;149403041/unspecified;NA
685;CVL-871;CVL-871;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Partial agonist;P21918;drd5_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;6D86.3;Apathy in dementia;2;Active;961921436;NA
735;CVN766;CVN766;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;1;Active;405565289/unspecified;38295907
758;CYB003;CYB003;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Agonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6A7Z;Depressive disorders, unspecified;2;Active;1563440232/unspecified;NA
658;DSP-0038;DSP-0038;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P08908;5ht1a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A20;Alzheimer disease;1;Active;1611724421;NA
658;DSP-0038;DSP-0038;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;8A20;Alzheimer disease;1;Active;1611724421;NA
659;DSP-2342;DSP-2342;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Antagonist;P28223;5ht2a_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;1;Active;941859884/unspecified;NA
670;Zelnecirnon;Zelnecirnon;CHEMBL5314496;NA;139344142;2366152-15-8;Q0M1LOC2MM;ANPSFQZLPNWKHR-PRZTZBHNSA-N;CC1=C(C(=NC(=N1)N2CC(C2)C3CCCN(C3)C4CC(C4)(C)C(=O)O)NC(C)C5=C(C=C(C=C5)Cl)Cl)Cl;5669;41;816;811;0;2;7;7;37;2;Active;NA;Small molecule;Antagonist;P51679;ccr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;CA23;Asthma;2;Active;1656445230;NA
670;Zelnecirnon;Zelnecirnon;CHEMBL5314496;NA;139344142;2366152-15-8;Q0M1LOC2MM;ANPSFQZLPNWKHR-PRZTZBHNSA-N;CC1=C(C(=NC(=N1)N2CC(C2)C3CCCN(C3)C4CC(C4)(C)C(=O)O)NC(C)C5=C(C=C(C=C5)Cl)Cl)Cl;5669;41;816;811;0;2;7;7;37;2;Active;NA;Small molecule;Antagonist;P51679;ccr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;EA80.Z;Atopic eczema, unspecified;2;Active;215767047/unspecified;NA
671;Tivumecirnon;Tivumecirnon;CHEMBL5314490;DB15570;134210715;2174938-78-2;R1T69T65FJ;AKSVALRPYDVQBS-CABCVRRESA-N;CC(C1=C(C=C(C=C1)Cl)Cl)N2C3=NC(=CN=C3C(=N2)C(F)(F)F)N4CC(C4)C5CCCN(C5)CCO;5434;46;703;747;0;1;9;6;36;2;Active;NA;Small molecule;Antagonist;P51679;ccr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2C25.Y;Other specified malignant neoplasms of bronchus or lung;2;Active;316539081/other;NA
671;Tivumecirnon;Tivumecirnon;CHEMBL5314490;DB15570;134210715;2174938-78-2;R1T69T65FJ;AKSVALRPYDVQBS-CABCVRRESA-N;CC(C1=C(C=C(C=C1)Cl)Cl)N2C3=NC(=CN=C3C(=N2)C(F)(F)F)N4CC(C4)C5CCCN(C5)CCO;5434;46;703;747;0;1;9;6;36;2;Active;NA;Small molecule;Antagonist;P51679;ccr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2D60.0;Malignant neoplasm metastasis in lymph nodes of head, face or neck;2;Active;995482988;NA
671;Tivumecirnon;Tivumecirnon;CHEMBL5314490;DB15570;134210715;2174938-78-2;R1T69T65FJ;AKSVALRPYDVQBS-CABCVRRESA-N;CC(C1=C(C=C(C=C1)Cl)Cl)N2C3=NC(=CN=C3C(=N2)C(F)(F)F)N4CC(C4)C5CCCN(C5)CCO;5434;46;703;747;0;1;9;6;36;2;Active;NA;Small molecule;Antagonist;P51679;ccr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2B72.Z;Malignant neoplasms of stomach, unspecified;2;Active;1397617262/unspecified;NA
672;OB-002;OB-002;CHEMBL5314995;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Protein;Antagonist;P51681;ccr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2B91.Z;Malignant neoplasms of rectosigmoid junction, unspecified;1;Active;774170412/unspecified;33749321
659;DSP-2342;DSP-2342;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Antagonist;P34969;5ht7r_human;Class A (Rhodopsin);5-Hydroxytryptamine receptors;Aminergic receptors;6D10.Z;Personality disorder, severity unspecified;1;Active;941859884/unspecified;NA
674;BAY 3375968;BAY 3375968;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Antibody;Antagonist;P51685;ccr8_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;1;Active;1844086508/unspecified;38856863
675;BMS-986340;BMS-986340;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Antagonist;P51685;ccr8_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;2;Active;1844086508/unspecified;NA
675;BMS-986340;BMS-986340;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Antagonist;P51685;ccr8_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2D60.0;Malignant neoplasm metastasis in lymph nodes of head, face or neck;2;Active;995482988;NA
675;BMS-986340;BMS-986340;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Antagonist;P51685;ccr8_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2C30.Z;Melanoma of skin, unspecified;2;Active;488336723/unspecified;NA
675;BMS-986340;BMS-986340;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Antagonist;P51685;ccr8_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2B91.Z;Malignant neoplasms of rectosigmoid junction, unspecified;2;Active;774170412/unspecified;NA
675;BMS-986340;BMS-986340;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Antagonist;P51685;ccr8_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2B72.Z;Malignant neoplasms of stomach, unspecified;2;Active;1397617262/unspecified;NA
675;BMS-986340;BMS-986340;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Antagonist;P51685;ccr8_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2C90.Z;Malignant neoplasms of kidney, except renal pelvis, unspecified;2;Active;1048613131/unspecified;NA
675;BMS-986340;BMS-986340;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Antagonist;P51685;ccr8_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2C94.Z;Malignant neoplasms of bladder, unspecified;2;Active;1244512758/unspecified;NA
676;GS-1811;GS-1811;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Antibody;Antagonist;P51685;ccr8_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2D4Z;Unspecified malignant neoplasms of unspecified sites;1;Active;1594217552/unspecified;36352891
677;S-531011;S-531011;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Antagonist;P51685;ccr8_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;2;Active;1844086508/unspecified;37420296
678;SAR445611;SAR445611;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Antibody;Antagonist;P49238;cx3c1_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;X8;Inflammation;1;Active;NA;NA
679;Eltrekibart;Eltrekibart;CHEMBL5314628;DB19017;;2484883-56-7;WB62WIH13E;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Antagonist;P25024;cxcr1_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;ED92.0;Hidradenitis suppurativa;2;Active;1621794154;NA
679;Eltrekibart;Eltrekibart;CHEMBL5314628;DB19017;;2484883-56-7;WB62WIH13E;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Antagonist;P25025;cxcr2_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;ED92.0;Hidradenitis suppurativa;2;Active;1621794154;NA
729;DSP-3456;DSP-3456;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;NAM;Q14416;grm2_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;6A7Z;Depressive disorders, unspecified;1;Active;1563440232/unspecified;NA
681;AD-214;AD-214;CHEMBL5314974;DB18412;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Antibody;Antagonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;CB03.4;Idiopathic pulmonary fibrosis;1;Active;1074069640;NA
729;DSP-3456;DSP-3456;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;NAM;Q14832;grm3_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;6A7Z;Depressive disorders, unspecified;1;Active;1563440232/unspecified;NA
687;DT-9081;DT-9081;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Antagonist;P35408;pe2r4_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;1;Active;1844086508/unspecified;NA
683;PF-06835375;PF-06835375;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Antagonist;P32302;cxcr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;4A40.Z;Lupus erythematosus, unspecified;1;Active;1443317238/unspecified;38845046
683;PF-06835375;PF-06835375;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Antagonist;P32302;cxcr5_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;3B64.10;Immune thrombocytopenic purpura;2;Active;364346400;38845046
731;EP262;EP262;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;Q96LB1;mrgx2_human;Class A (Rhodopsin);Class A orphans;Orphan receptors;EB05;Urticaria of unspecified type;2;Active;993242399;NA
731;EP262;EP262;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;Q96LB1;mrgx2_human;Class A (Rhodopsin);Class A orphans;Orphan receptors;EA8Z;Dermatitis or eczema, unspecified;2;Active;1887882424/unspecified;NA
732;EP547;EP547;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;Q96LA9;mrgx4_human;Class A (Rhodopsin);Class A orphans;Orphan receptors;EC90.Z;Pruritus, unspecified;2;Active;1729106757/unspecified;NA
682;GPC201;GPC201;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;P07550;adrb2_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;2A83.Y;Other specified multiple myeloma and plasma cell neoplasms;2;Active;1219149360/other;NA
682;GPC201;GPC201;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;P61073;cxcr4_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;2A83.Y;Other specified multiple myeloma and plasma cell neoplasms;2;Active;1219149360/other;NA
698;GSBR-1290;GSBR-1290;NA;DB18551;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;2;Active;119724091;37364591
698;GSBR-1290;GSBR-1290;NA;DB18551;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;2;Active;149403041/unspecified;37364591
688;ONO-4578;ONO-4578;CHEMBL5314911;NA;121481566;1965316-82-8;VJ3OXN6K2H;QSRLBYGDVFRMPT-IDISGSTGSA-N;CC(C)NC(=O)C1=CC2=C(C=C1)OCCC23CC3C(=O)NC4=C(C=CC(=C4)C#N)CCCC(=O)O;4755;3;129;866;0;3;6;8;35;2;Active;NA;Small molecule;Antagonist;P35408;pe2r4_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;2B72.Z;Malignant neoplasms of stomach, unspecified;2;Active;1397617262/unspecified;36082616
688;ONO-4578;ONO-4578;CHEMBL5314911;NA;121481566;1965316-82-8;VJ3OXN6K2H;QSRLBYGDVFRMPT-IDISGSTGSA-N;CC(C)NC(=O)C1=CC2=C(C=C1)OCCC23CC3C(=O)NC4=C(C=CC(=C4)C#N)CCCC(=O)O;4755;3;129;866;0;3;6;8;35;2;Active;NA;Small molecule;Antagonist;P35408;pe2r4_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;2C10.Z;Malignant neoplasm of pancreas, unspecified;1;Active;542147910/unspecified;36082616
688;ONO-4578;ONO-4578;CHEMBL5314911;NA;121481566;1965316-82-8;VJ3OXN6K2H;QSRLBYGDVFRMPT-IDISGSTGSA-N;CC(C)NC(=O)C1=CC2=C(C=C1)OCCC23CC3C(=O)NC4=C(C=CC(=C4)C#N)CCCC(=O)O;4755;3;129;866;0;3;6;8;35;2;Active;NA;Small molecule;Antagonist;P35408;pe2r4_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;2B91.Z;Malignant neoplasms of rectosigmoid junction, unspecified;1;Active;774170412/unspecified;36082616
688;ONO-4578;ONO-4578;CHEMBL5314911;NA;121481566;1965316-82-8;VJ3OXN6K2H;QSRLBYGDVFRMPT-IDISGSTGSA-N;CC(C)NC(=O)C1=CC2=C(C=C1)OCCC23CC3C(=O)NC4=C(C=CC(=C4)C#N)CCCC(=O)O;4755;3;129;866;0;3;6;8;35;2;Active;NA;Small molecule;Antagonist;P35408;pe2r4_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;2C25.Y;Other specified malignant neoplasms of bronchus or lung;1;Active;316539081/other;36082616
688;ONO-4578;ONO-4578;CHEMBL5314911;NA;121481566;1965316-82-8;VJ3OXN6K2H;QSRLBYGDVFRMPT-IDISGSTGSA-N;CC(C)NC(=O)C1=CC2=C(C=C1)OCCC23CC3C(=O)NC4=C(C=CC(=C4)C#N)CCCC(=O)O;4755;3;129;866;0;3;6;8;35;2;Active;NA;Small molecule;Antagonist;P35408;pe2r4_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;2C6Z;Malignant neoplasms of breast, unspecified;1;Active;1047754165/unspecified;36082616
694;HRS-7535;HRS-7535;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;2;Active;119724091;38100147
694;HRS-7535;HRS-7535;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;2;Active;149403041/unspecified;38100147
690;HTL0039732;HTL0039732;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;P35408;pe2r4_human;Class A (Rhodopsin);Prostanoid receptors;Lipid receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;2;Active;1844086508/unspecified;NA
692;Retatrutide;Retatrutide;CHEMBL5095485;DB18993;171378578;2381089-83-2;NOP2Y096GV;PIHZSFXNGVXGER-QQQDAUCCSA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NCC(=O)NCC(=O)N2CCCC2C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N3CCCC3C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C)NC(=O)C(C)(C)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCCCNC(=O)C(CCCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)N)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC7=CC=C(C=C7)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C)(C)NC(=O)C(CC9=CC=C(C=C9)O)N;4860;-91;1840;11800;0;60;72;165;344;3;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;3;Active;149403041/unspecified;37366315, 37385280, 37086147
692;Retatrutide;Retatrutide;CHEMBL5095485;DB18993;171378578;2381089-83-2;NOP2Y096GV;PIHZSFXNGVXGER-QQQDAUCCSA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NCC(=O)NCC(=O)N2CCCC2C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N3CCCC3C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C)NC(=O)C(C)(C)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCCCNC(=O)C(CCCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)N)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC7=CC=C(C=C7)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C)(C)NC(=O)C(CC9=CC=C(C=C9)O)N;4860;-91;1840;11800;0;60;72;165;344;3;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A14;Diabetes mellitus, type unspecified;3;Active;1697306310;37366315, 37385280, 37086147
692;Retatrutide;Retatrutide;CHEMBL5095485;DB18993;171378578;2381089-83-2;NOP2Y096GV;PIHZSFXNGVXGER-QQQDAUCCSA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NCC(=O)NCC(=O)N2CCCC2C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N3CCCC3C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C)NC(=O)C(C)(C)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCCCNC(=O)C(CCCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)N)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC7=CC=C(C=C7)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C)(C)NC(=O)C(CC9=CC=C(C=C9)O)N;4860;-91;1840;11800;0;60;72;165;344;3;Active;NA;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;3;Active;149403041/unspecified;37366315, 37385280, 37086147
692;Retatrutide;Retatrutide;CHEMBL5095485;DB18993;171378578;2381089-83-2;NOP2Y096GV;PIHZSFXNGVXGER-QQQDAUCCSA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NCC(=O)NCC(=O)N2CCCC2C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N3CCCC3C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C)NC(=O)C(C)(C)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCCCNC(=O)C(CCCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)N)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC7=CC=C(C=C7)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C)(C)NC(=O)C(CC9=CC=C(C=C9)O)N;4860;-91;1840;11800;0;60;72;165;344;3;Active;NA;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A14;Diabetes mellitus, type unspecified;3;Active;1697306310;37366315, 37385280, 37086147
692;Retatrutide;Retatrutide;CHEMBL5095485;DB18993;171378578;2381089-83-2;NOP2Y096GV;PIHZSFXNGVXGER-QQQDAUCCSA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NCC(=O)NCC(=O)N2CCCC2C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N3CCCC3C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C)NC(=O)C(C)(C)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCCCNC(=O)C(CCCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)N)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC7=CC=C(C=C7)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C)(C)NC(=O)C(CC9=CC=C(C=C9)O)N;4860;-91;1840;11800;0;60;72;165;344;3;Active;NA;Protein;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;3;Active;149403041/unspecified;37366315, 37385280, 37086147
692;Retatrutide;Retatrutide;CHEMBL5095485;DB18993;171378578;2381089-83-2;NOP2Y096GV;PIHZSFXNGVXGER-QQQDAUCCSA-N;CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NCC(=O)NCC(=O)N2CCCC2C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N3CCCC3C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C)NC(=O)C(C)(C)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCCCNC(=O)C(CCCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)N)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC7=CC=C(C=C7)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C)(C)NC(=O)C(CC9=CC=C(C=C9)O)N;4860;-91;1840;11800;0;60;72;165;344;3;Active;NA;Protein;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A14;Diabetes mellitus, type unspecified;3;Active;1697306310;37366315, 37385280, 37086147
693;HR17031;HR17031;NA;NA;;NA;NA;NA;NA;;;;;;;;;;3;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;3;Active;119724091;NA
736;INDV-2000;INDV-2000;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;O43613;ox1r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;2;Active;1120716949/unspecified;NA
737;JZP441;JZP441;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A20.Z;Narcolepsy, unspecified;1;Active;1201727099/unspecified;NA
695;HRS9531;HRS9531;NA;NA;;NA;NA;NA;NA;;;;;;;;;;3;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;2;Active;119724091;NA
695;HRS9531;HRS9531;NA;NA;;NA;NA;NA;NA;;;;;;;;;;3;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;3;Active;149403041/unspecified;NA
695;HRS9531;HRS9531;NA;NA;;NA;NA;NA;NA;;;;;;;;;;3;Active;NA;Protein;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;2;Active;119724091;NA
695;HRS9531;HRS9531;NA;NA;;NA;NA;NA;NA;;;;;;;;;;3;Active;NA;Protein;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;3;Active;149403041/unspecified;NA
720;LTSE-2578;LTSE-2578;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Antagonist;Q92633;lpar1_human;Class A (Rhodopsin);Lysophospholipid (LPA) receptors;Lipid receptors;CB03.4;Idiopathic pulmonary fibrosis;1;Active;1074069640;NA
697;CagriSema;CagriSema;NA;NA;;NA;NA;NA;NA;;;;;;;;;;3;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;3;Active;119724091;NA
684;Lu AF28996;Lu AF28996;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P14416;drd2_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;1;Active;296066191/unspecified;NA
684;Lu AF28996;Lu AF28996;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P21728;drd1_human;Class A (Rhodopsin);Dopamine receptors;Aminergic receptors;8A00.0Z;Parkinson disease, unspecified;1;Active;296066191/unspecified;NA
699;Orforglipron;Orforglipron;CHEMBL4446782;DB18964;137319706;212020-52-3;7ZW40D021M;USUWIEBBBWHKNI-KHIFEHGGSA-N;CC1CC1(C2=NOC(=O)N2)N3C4=C(C=C(C=C4)C5CCOC(C5)(C)C)C=C3C(=O)N6CCC7=NN(C(=C7C6C)N8C=CN(C8=O)C9=C(C1=C(C=C9)N(N=C1)C)F)C1=CC(=C(C(=C1)C)F)C;883;68;144;1950;0;1;10;7;65;3;Active;NA;Small molecule;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;3;Active;149403041/unspecified;37351564, 37369232, 37264711
699;Orforglipron;Orforglipron;CHEMBL4446782;DB18964;137319706;212020-52-3;7ZW40D021M;USUWIEBBBWHKNI-KHIFEHGGSA-N;CC1CC1(C2=NOC(=O)N2)N3C4=C(C=C(C=C4)C5CCOC(C5)(C)C)C=C3C(=O)N6CCC7=NN(C(=C7C6C)N8C=CN(C8=O)C9=C(C1=C(C=C9)N(N=C1)C)F)C1=CC(=C(C(=C1)C)F)C;883;68;144;1950;0;1;10;7;65;3;Active;NA;Small molecule;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A14;Diabetes mellitus, type unspecified;3;Active;1697306310;37351564, 37369232, 37264711
700;YH25724;YH25724;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Antibody;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB9Z;Diseases of liver, unspecified;1;Active;784240230/unspecified;NA
701;Amycretin;Amycretin;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;1;Active;149403041/unspecified;NA
702;Maridebart cafraglutide;Maridebart cafraglutide;CHEMBL5314751;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;2;Active;149403041/unspecified;NA
702;Maridebart cafraglutide;Maridebart cafraglutide;CHEMBL5314751;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;2;Active;149403041/unspecified;NA
721;NBI-1117567;NBI-1117567;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;1;Active;405565289/unspecified;NA
724;NBI-1117568;NBI-1117568;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Agonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;2;Active;405565289/unspecified;NA
704;SCO-094;SCO-094;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;1;Active;119724091;NA
704;SCO-094;SCO-094;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Protein;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;1;Active;119724091;NA
705;Dapiglutide;Dapiglutide;CHEMBL5314980;DB19182;;2296814-85-0;J43GMI6IYW;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;O95838;glp2r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;2;Active;149403041/unspecified;34705281, 35580981
705;Dapiglutide;Dapiglutide;CHEMBL5314980;DB19182;;2296814-85-0;J43GMI6IYW;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;2;Active;149403041/unspecified;34705281, 35580981
723;NBI-1117569;NBI-1117569;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;1;Active;405565289/unspecified;NA
722;NBI-1117570;NBI-1117570;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;1;Active;405565289/unspecified;NA
707;Mazdutide;Mazdutide;CHEMBL5095358;DB19099;167312357;2259884-03-0;MB76Z4IBZ5;XRBYWQZGSZWYEJ-HMQIFOERSA-N;CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NCC(=O)NCC(=O)N1CCCC1C(=O)NC(CO)C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C)(C)NC(=O)C(CC8=CNC=N8)N;4476;-126;1750;10500;0;58;70;164;317;2;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;2;Active;149403041/unspecified;38092790, 36247927, 37943529
707;Mazdutide;Mazdutide;CHEMBL5095358;DB19099;167312357;2259884-03-0;MB76Z4IBZ5;XRBYWQZGSZWYEJ-HMQIFOERSA-N;CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NCC(=O)NCC(=O)N1CCCC1C(=O)NC(CO)C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C)(C)NC(=O)C(CC8=CNC=N8)N;4476;-126;1750;10500;0;58;70;164;317;2;Active;NA;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;2;Active;149403041/unspecified;38092790, 36247927, 37943529
708;Survodutide;Survodutide;CHEMBL5314776;DB18989;168429725;2805997-46-8;2ALA66NS64;MEDXQFAHWBMVIM-YIUAJOCSSA-N;CCC(C)C(C(=O)NC(CCCCNC(=O)CNC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(C)C(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C7(CCC7)NC(=O)C(CC8=CNC=N8)N;4232;-141;1760;10100;0;62;66;149;300;3;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;3;Active;149403041/unspecified;38330987, 38095657, 37330144
708;Survodutide;Survodutide;CHEMBL5314776;DB18989;168429725;2805997-46-8;2ALA66NS64;MEDXQFAHWBMVIM-YIUAJOCSSA-N;CCC(C)C(C(=O)NC(CCCCNC(=O)CNC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(C)C(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C7(CCC7)NC(=O)C(CC8=CNC=N8)N;4232;-141;1760;10100;0;62;66;149;300;3;Active;NA;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;3;Active;149403041/unspecified;38330987, 38095657, 37330144
709;CLF065;CLF065;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Protein;Agonist;O95838;glp2r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;1;Active;1158238623/unspecified;NA
710;Glepaglutide;Glepaglutide;CHEMBL4297761;DB14794;146170995;914009-86-2;4M3C1913N6;DOAUQKRTILFGHV-PDCMDPCFSA-N;CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(C)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC5=CNC=N5)N;4316;-186;1770;10200;0;63;65;152;305;3;Active;NA;Protein;Agonist;O95838;glp2r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DD91.0Z;Irritable bowel syndrome, type unspecified;3;Active;1158238623/unspecified;36323988, 36944922, 36811175
722;NBI-1117570;NBI-1117570;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P11229;acm1_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;1;Active;405565289/unspecified;NA
703;NN9541;NN9541;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;1;Active;119724091;NA
703;NN9541;NN9541;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;1;Active;119724091;NA
713;NXE0048149;NXE0048149;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;Q9Y2T5;gpr52_human;Class A (Rhodopsin);Class A orphans;Orphan receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;1;Active;405565289/unspecified;NA
747;ONO-2808;ONO-2808;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Agonist;Q9H228;s1pr5_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8D87.0Z;Multiple system atrophy, unspecified;2;Active;1890931931/unspecified;NA
751;OPC-131461;OPC-131461;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;P30518;v2r_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BD10;Congestive heart failure;2;Active;2136808878;NA
751;OPC-131461;OPC-131461;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;P37288;v1ar_human;Class A (Rhodopsin);Vasopressin and oxytocin receptors;Peptide receptors;BD10;Congestive heart failure;2;Active;2136808878;NA
714;CVN424;CVN424;CHEMBL4802203;DB18958;137359492;2254706-21-1;XO01711URG;HSWVJQBEXRKOBZ-QGZVFWFLSA-N;CC(=O)N1CCC2=C(C1)N=C(C(=N2)N3CCC(CC3)OC4=C(C=C(C=C4)F)F)NC5CCOC5;4735;24;798;698;0;1;9;5;34;3;Active;NA;Small molecule;Inverse agonist;P46095;gpr6_human;Class A (Rhodopsin);Class A orphans;Orphan receptors;8A00.0Z;Parkinson disease, unspecified;3;Active;296066191/unspecified;33795395, 35110393, 33861086
738;ORX750;ORX750;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A20.Z;Narcolepsy, unspecified;1;Active;1201727099/unspecified;NA
716;BMS-986393;BMS-986393;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Binding agent;Q9NZD1;gpc5d_human;Class C (Glutamate);Class C Orphans;Orphan receptors;2A83.Y;Other specified multiple myeloma and plasma cell neoplasms;2;Active;1219149360/other;NA
717;Forimtamig;Forimtamig;CHEMBL5314680;DB19015;;2649379-96-2;1GK8Z1OT1R;NA;NA;;;;;;;;;;1;Active;NA;Antibody;Binding agent;Q9NZD1;gpc5d_human;Class C (Glutamate);Class C Orphans;Orphan receptors;2A83.Y;Other specified multiple myeloma and plasma cell neoplasms;1;Active;1219149360/other;NA
718;AAA603;AAA603;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Protein;Antagonist;P30550;grpr_human;Class A (Rhodopsin);Bombesin receptors;Peptide receptors;2F9Z;Neoplasms of unknown behaviour of unspecified site;1;Active;1844086508/unspecified;NA
718;AAA603;AAA603;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Protein;Antagonist;P30550;grpr_human;Class A (Rhodopsin);Bombesin receptors;Peptide receptors;2C6Z;Malignant neoplasms of breast, unspecified;1;Active;1047754165/unspecified;NA
718;AAA603;AAA603;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Protein;Antagonist;P30550;grpr_human;Class A (Rhodopsin);Bombesin receptors;Peptide receptors;2A00.00;Glioblastoma of brain;1;Active;650534447;NA
719;BMS-986278;BMS-986278;CHEMBL5087506;DB18011;132232205;2170126-74-4;4UN9AOU6G8;UEUNDURNLYLSNB-HOTGVXAUSA-N;CCCN(C)C(=O)OCC1=C(N=NN1C)C2=NC(=C(C=C2)OC3CCCC(C3)C(=O)O)C;4455;21;120;638;0;1;8;9;32;3;Active;NA;Small molecule;Antagonist;Q92633;lpar1_human;Class A (Rhodopsin);Lysophospholipid (LPA) receptors;Lipid receptors;CB03.4;Idiopathic pulmonary fibrosis;3;Active;1074069640;34969771, 34709814, 35090952
386;pbf-680;pbf-680;CHEMBL3545162;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA22.Z;Chronic obstructive pulmonary disease, unspecified;2;Active;133207228/unspecified;NA
386;pbf-680;pbf-680;CHEMBL3545162;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;P30542;aa1r_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;CA23;Asthma;2;Inactive;1656445230;NA
696;PF-06954522;PF-06954522;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;1;Active;119724091;NA
673;PF-07054894;PF-07054894;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P51684;ccr6_human;Class A (Rhodopsin);Chemokine receptors;Protein receptors;DD7Z;Inflammatory bowel diseases, unspecified;1;Active;598093212/unspecified;37142443
727;PF-07258669;PF-07258669;CHEMBL5095286;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Antagonist;P32245;mc4r_human;Class A (Rhodopsin);Melanocortin receptors;Peptide receptors;5B7Z;Unspecified undernutrition;1;Active;1517885800/unspecified;36802610
397;rauwolfia serpentina;rauwolfia serpentina;CHEMBL3559672;NA;;NA;NA;NA;NA;;;;;;;;;;4;Approved;1954;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;14477647, 13113685, 13404366
725;Emraclidine;Emraclidine;CHEMBL5314557;DB18706;140830653;2170722-84-4;J241Y80EEO;DTCZNKWBDTXEBS-UHFFFAOYSA-N;CC1=CC(=NC2=C1CN(C2)C(=O)CC3CN(C3)C4=CC(=NC=C4)C(F)(F)F)C;3904;22;493;580;0;0;7;3;28;2;Active;NA;Small molecule;PAM;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;8A20;Alzheimer disease;2;Active;1611724421;36528376, 36528365, 38477292
725;Emraclidine;Emraclidine;CHEMBL5314557;DB18706;140830653;2170722-84-4;J241Y80EEO;DTCZNKWBDTXEBS-UHFFFAOYSA-N;CC1=CC(=NC2=C1CN(C2)C(=O)CC3CN(C3)C4=CC(=NC=C4)C(F)(F)F)C;3904;22;493;580;0;0;7;3;28;2;Active;NA;Small molecule;PAM;P08173;acm4_human;Class A (Rhodopsin);Acetylcholine receptors (muscarinic);Aminergic receptors;6A2Z;Schizophrenia or other primary psychotic disorders, unspecified;2;Active;405565289/unspecified;36528376, 36528365, 38477292
397;rauwolfia serpentina;rauwolfia serpentina;CHEMBL3559672;NA;;NA;NA;NA;NA;;;;;;;;;;4;Approved;1954;Small molecule;Antagonist;P08913;ada2a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;14477647, 13113685, 13404366
397;rauwolfia serpentina;rauwolfia serpentina;CHEMBL3559672;NA;;NA;NA;NA;NA;;;;;;;;;;4;Approved;1954;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;14477647, 13113685, 13404366
397;rauwolfia serpentina;rauwolfia serpentina;CHEMBL3559672;NA;;NA;NA;NA;NA;;;;;;;;;;4;Approved;1954;Small molecule;Antagonist;P18089;ada2b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;14477647, 13113685, 13404366
397;rauwolfia serpentina;rauwolfia serpentina;CHEMBL3559672;NA;;NA;NA;NA;NA;;;;;;;;;;4;Approved;1954;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;14477647, 13113685, 13404366
397;rauwolfia serpentina;rauwolfia serpentina;CHEMBL3559672;NA;;NA;NA;NA;NA;;;;;;;;;;4;Approved;1954;Small molecule;Antagonist;P18825;ada2c_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;14477647, 13113685, 13404366
397;rauwolfia serpentina;rauwolfia serpentina;CHEMBL3559672;NA;;NA;NA;NA;NA;;;;;;;;;;4;Approved;1954;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;14477647, 13113685, 13404366
397;rauwolfia serpentina;rauwolfia serpentina;CHEMBL3559672;NA;;NA;NA;NA;NA;;;;;;;;;;4;Approved;1954;Small molecule;Antagonist;P25100;ada1d_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;14477647, 13113685, 13404366
397;rauwolfia serpentina;rauwolfia serpentina;CHEMBL3559672;NA;;NA;NA;NA;NA;;;;;;;;;;4;Approved;1954;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;14477647, 13113685, 13404366
397;rauwolfia serpentina;rauwolfia serpentina;CHEMBL3559672;NA;;NA;NA;NA;NA;;;;;;;;;;4;Approved;1954;Small molecule;Antagonist;P35348;ada1a_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;14477647, 13113685, 13404366
397;rauwolfia serpentina;rauwolfia serpentina;CHEMBL3559672;NA;;NA;NA;NA;NA;;;;;;;;;;4;Approved;1954;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;7A0Z;Insomnia disorders, unspecified;4;Approved;1038292737/unspecified;14477647, 13113685, 13404366
397;rauwolfia serpentina;rauwolfia serpentina;CHEMBL3559672;NA;;NA;NA;NA;NA;;;;;;;;;;4;Approved;1954;Small molecule;Antagonist;P35368;ada1b_human;Class A (Rhodopsin);Adrenoceptors;Aminergic receptors;BA00.Z;Essential hypertension, unspecified;4;Approved;761947693/unspecified;14477647, 13113685, 13404366
750;SCO-240;SCO-240;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Antagonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;GA31.Z;Female infertility without specification whether primary or secondary;1;Active;1237004558/unspecified;38549435
750;SCO-240;SCO-240;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Antagonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;ED70.Z;Alopecia, unspecified;1;Active;1313926062/unspecified;38549435
750;SCO-240;SCO-240;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Antagonist;P35346;ssr5_human;Class A (Rhodopsin);Somatostatin receptors;Peptide receptors;5A61.3;Growth hormone deficiency;1;Active;1317547930;38549435
712;SCO-267;SCO-267;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;O14842;ffar1_human;Class A (Rhodopsin);Free fatty acid receptors;Lipid receptors;5B81.Z;Obesity, unspecified;1;Active;149403041/unspecified;34321316, 31182471, 33547250
739;TAK-925;TAK-925;CHEMBL4650341;DB16962;130310079;2114324-48-8;1QMD83K4YN;UXZAJSZFFARTEI-GUMHCPJTSA-N;COC(=O)N1CCCC(C1COC2CCC(CC2)C3=CC=CC=C3)NS(=O)(=O)C;4246;27;933;622;0;1;6;7;29;2;Active;NA;Small molecule;Agonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;7A20.Z;Narcolepsy, unspecified;2;Active;1201727099/unspecified;35614071, 38346840, 36934366
739;TAK-925;TAK-925;CHEMBL4650341;DB16962;130310079;2114324-48-8;1QMD83K4YN;UXZAJSZFFARTEI-GUMHCPJTSA-N;COC(=O)N1CCCC(C1COC2CCC(CC2)C3=CC=CC=C3)NS(=O)(=O)C;4246;27;933;622;0;1;6;7;29;2;Active;NA;Small molecule;Agonist;O43614;ox2r_human;Class A (Rhodopsin);Orexin receptors;Peptide receptors;X1;Anesthesia;2;Active;NA;35614071, 38346840, 36934366
740;MEDI0618;MEDI0618;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Antibody;Antagonist;P55085;par2_human;Class A (Rhodopsin);Proteinase-activated receptors;Peptide receptors;8A80.Z;Migraine, unspecified;2;Active;669367341/unspecified;NA
741;Eneboparatide;Eneboparatide;CHEMBL5095311;DB18207;;1349298-00-5;K6E9SY8U8D;NA;NA;;;;;;;;;;3;Active;NA;Protein;Agonist;Q03431;pth1r_human;Class B1 (Secretin);Parathyroid hormone receptors;Peptide receptors;5A50.Z;Hypoparathyroidism, unspecified;3;Active;1708733050/unspecified;38449442
742;AZD3427;AZD3427;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;Q9HBX9;rxfp1_human;Class A (Rhodopsin);Relaxin family peptide receptors;Peptide receptors;BD1Z;Heart failure, unspecified;2;Active;1458683894/unspecified;NA
712;SCO-267;SCO-267;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;O14842;ffar1_human;Class A (Rhodopsin);Free fatty acid receptors;Lipid receptors;5A14;Diabetes mellitus, type unspecified;1;Active;1697306310;34321316, 31182471, 33547250
744;Volenrelaxin;Volenrelaxin;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;Q9HBX9;rxfp1_human;Class A (Rhodopsin);Relaxin family peptide receptors;Peptide receptors;BD1Z;Heart failure, unspecified;2;Active;1458683894/unspecified;38782726
712;SCO-267;SCO-267;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;O14842;ffar1_human;Class A (Rhodopsin);Free fatty acid receptors;Lipid receptors;DB92.1;Non-alcoholic steatohepatitis;1;Active;1884917970;34321316, 31182471, 33547250
711;SHR7280;SHR7280;NA;NA;;NA;NA;NA;NA;;;;;;;;;;3;Active;NA;Small molecule;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;2E86.0;Leiomyoma of uterus;3;Active;455734276;37838623, 36506562, 37013610
746;Amiselimod;Amiselimod;CHEMBL3707375;DB17074;16129483;942399-20-4;358M5150LY;JVCPIJKPAKAIIP-UHFFFAOYSA-N;CCCCCCCOC1=C(C=C(C=C1)CCC(CO)(CO)N)C(F)(F)F;3774;38;757;376;0;3;7;12;26;2;Active;NA;Small molecule;Modulator;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;DD71.Z;Ulcerative colitis, unspecified;2;Active;784669405/unspecified;33115374, 37461948, 27714763
711;SHR7280;SHR7280;NA;NA;;NA;NA;NA;NA;;;;;;;;;;3;Active;NA;Small molecule;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA32.0;Ovarian hyperstimulation syndrome;3;Active;1216664013;37838623, 36506562, 37013610
748;Debio 4126;Debio 4126;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Protein;Antagonist;Q02643;ghrhr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A60.0;Acromegaly or pituitary gigantism;2;Active;825410563;NA
711;SHR7280;SHR7280;NA;NA;;NA;NA;NA;NA;;;;;;;;;;3;Active;NA;Small molecule;Antagonist;P30968;gnrhr_human;Class A (Rhodopsin);Gonadotrophin-releasing hormone receptors;Peptide receptors;GA10.Z;Endometriosis of unspecified site;2;Active;1838213761/unspecified;37838623, 36506562, 37013610
730;TMP-301;TMP-301;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;NAM;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;6C40.2Z;Alcohol dependence, unspecified;1;Active;1580466198/unspecified;NA
730;TMP-301;TMP-301;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;NAM;P41594;grm5_human;Class C (Glutamate);Metabotropic glutamate receptors;Amino acid receptors;6C45.2Z;Cocaine dependence, unspecified;1;Active;1691013484/unspecified;NA
745;TRV045;TRV045;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Modulator;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8E43.0Z;Neuropathic pain, unspecified;1;Active;1339785363/unspecified;NA
745;TRV045;TRV045;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Modulator;P21453;s1pr1_human;Class A (Rhodopsin);Lysophospholipid (S1P) receptors;Lipid receptors;8A6Z;Epilepsy or seizures, unspecified;1;Active;1397288146/unspecified;NA
755;TRV250;TRV250;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P41143;oprd_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;8A80.Z;Migraine, unspecified;1;Active;669367341/unspecified;32676977
757;TRV734;TRV734;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Small molecule;Agonist;P35372;oprm_human;Class A (Rhodopsin);Opioid receptors;Peptide receptors;6C43.2Z;Opioid dependence, unspecified;1;Active;1120716949/unspecified;34480428, 31286645
661;TT-702;TT-702;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2C6Z;Malignant neoplasms of breast, unspecified;2;Active;1047754165/unspecified;NA
661;TT-702;TT-702;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;P29275;aa2br_human;Class A (Rhodopsin);Adenosine receptors;Nucleotide receptors;2C82.Z;Malignant neoplasms of prostate, unspecified;2;Active;1552457716/unspecified;NA
660;TT-816;TT-816;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;2C25.Y;Other specified malignant neoplasms of bronchus or lung;2;Active;316539081/other;NA
660;TT-816;TT-816;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;2C73.Z;Malignant neoplasms of ovary, unspecified;2;Active;685124533/unspecified;NA
660;TT-816;TT-816;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Small molecule;Antagonist;P34972;cnr2_human;Class A (Rhodopsin);Cannabinoid receptors;Lipid receptors;2C90.Z;Malignant neoplasms of kidney, except renal pelvis, unspecified;2;Active;1048613131/unspecified;NA
759;Pemvidutide;Pemvidutide;CHEMBL5095142;DB18998;;2538014-94-5;A35F525WBG;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;2;Active;149403041/unspecified;39002641
759;Pemvidutide;Pemvidutide;CHEMBL5095142;DB18998;;2538014-94-5;A35F525WBG;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Active;1884917970;39002641
759;Pemvidutide;Pemvidutide;CHEMBL5095142;DB18998;;2538014-94-5;A35F525WBG;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;2;Active;149403041/unspecified;39002641
759;Pemvidutide;Pemvidutide;CHEMBL5095142;DB18998;;2538014-94-5;A35F525WBG;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Active;1884917970;39002641
760;CT388;CT388;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;1;Active;149403041/unspecified;NA
760;CT388;CT388;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;1;Active;119724091;NA
760;CT388;CT388;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Protein;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;1;Active;149403041/unspecified;NA
760;CT388;CT388;NA;NA;;NA;NA;NA;NA;;;;;;;;;;1;Active;NA;Protein;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5A11;Type 2 diabetes mellitus;1;Active;119724091;NA
761;DA-1726;DA-1726;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;2;Active;149403041/unspecified;NA
761;DA-1726;DA-1726;NA;NA;;NA;NA;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;2;Active;149403041/unspecified;NA
762;Efocipegtrutide;Efocipegtrutide;CHEMBL5095149;DB18194;;2513399-19-2;TUI1MDD9F6;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;1;Active;149403041/unspecified;NA
762;Efocipegtrutide;Efocipegtrutide;CHEMBL5095149;DB18194;;2513399-19-2;TUI1MDD9F6;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P43220;glp1r_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Active;1884917970;NA
762;Efocipegtrutide;Efocipegtrutide;CHEMBL5095149;DB18194;;2513399-19-2;TUI1MDD9F6;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;1;Active;149403041/unspecified;NA
762;Efocipegtrutide;Efocipegtrutide;CHEMBL5095149;DB18194;;2513399-19-2;TUI1MDD9F6;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P47871;glr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Active;1884917970;NA
762;Efocipegtrutide;Efocipegtrutide;CHEMBL5095149;DB18194;;2513399-19-2;TUI1MDD9F6;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;5B81.Z;Obesity, unspecified;1;Active;149403041/unspecified;NA
762;Efocipegtrutide;Efocipegtrutide;CHEMBL5095149;DB18194;;2513399-19-2;TUI1MDD9F6;NA;NA;;;;;;;;;;2;Active;NA;Protein;Agonist;P48546;gipr_human;Class B1 (Secretin);Glucagon receptor family;Peptide receptors;DB92.1;Non-alcoholic steatohepatitis;2;Active;1884917970;NA
